KR20220097470A

KR20220097470A - 항-dll3 작용제의 투여 요법

Info

Publication number: KR20220097470A
Application number: KR1020227018942A
Authority: KR
Inventors: 마리-앤 다미에타 스미트; 니레쉬 소만; 비제이 비셰시 업레티; 무쿨 미노차; 마이클 리아오; 아디티아 셰티; 사드레이 누신 하세미; 가타리 응암참난리스; 마크 앤소니 야고
Original assignee: 암젠 인크
Priority date: 2019-11-10
Filing date: 2020-11-05
Publication date: 2022-07-07
Also published as: JOP20220104A1; UY38948A; CN114746117A; AR120399A1; IL292463A; EP3819312A1; TW202128762A; EP4054636A4; JP2023501375A; US20230174643A1; WO2021092134A1; CA3156229A1; AU2020377981A1; EP4054636A1; MX2022005596A

Abstract

본 발명은 DLL3 양성 암 또는 SCLC의 치료 방법으로서, 이를 필요로 하는 대상체에게 2주마다 1회 약 0.3 mg 내지 약 100 mg 또는 약 3 mg 내지 약 200 mg의 용량의 항-DLL3 작용제를 투여하는 단계를 포함하는 방법을 제공한다. SCLC의 치료를 위한 항-DLL3 작용제의 단계 투여도 개시된다.

Description

항-DLL3 작용제의 투여 요법

관련 출원의 상호 참조

본 출원은 2019년 11월 10일에 출원된 유럽 특허 출원 번호 19208214 및 2020년 9월 14일에 출원된 미국 가출원 번호 63/078,131의 이익을 주장한다. 두 출원의 내용은 전체가 본원에 참조로 포함된다.

ASCII 텍스트 파일 형태의 서열 목록 제출

ASCII 텍스트 파일에 대한 다음의 제출 내용은 전체가 본원에 참조로 포함된다: 서열 목록의 컴퓨터 판독 가능 형식(CRF)(파일명: A-2520-WO-PCT_ST25.txt, 생성일: 2020년 10월 28일, 크기: 1,218,887 바이트).

기술분야

본 출원은 암 치료를 위한 항-DLL3 작용제의 투여량 및 투여에 관한 것이다.

소세포 폐암(small cell lung cancer, SCLC)은 불량한 예후와 제한된 치료 옵션을 갖는 폐암의 공격성 형태이며, 폐암의 약 10~15%를 나타낸다. 생존율은 수십 년 동안 낮게 유지되었고, 이러한 형태의 폐암과 싸우기 위한 새로운 치료법의 부족으로 인해, 대부분의 경우에, SCLC 환자의 5% 만이 5년 생존한다. 환자의 약 1/3은 제한 병기(limited stage) 질환을 나타낸다. 대부분의 환자는 흉부의 단지 일측에서의 종양의 존재에 의해서 정의되고, 단일 방사선장(single radiation field)에 적합한 확장 병기(extensive-stage) 질환을 나타낸다. 이들 병기는 사용 가능한 치료 요법에 영향을 주는데, 제한 병기 질환은 화학요법과 방사선으로 치료되고, 확장 병기 질환은 화학요법 단독으로 치료된다. 림프종 유사 특성을 갖는 파종성, 전이성 종양은 SCLC의 특징이다.

환자는 전형적으로 현재 에토포시드 및 시스플라틴을 포함하는 제1선 요법에 잘 반응하지만, 화학내성(chemoresistant) 질환으로 변함없이 신속하게 재발하고, 이에 대해서는 어떤 치료 옵션도 현재 사용 가능하지 않다. 재발된 불응성 환경에서의 예후는 극히 불량하고, 신속한 질환 진행 및 6개월 미만의 짧은 생존 중간값을 갖는다. 추가로, SCLC 환자는 고혈압, 심장 질환, 당뇨병 및 부종양 증후군(paraneoplastic syndrome)을 비롯한 동반이환(comorbidity)의 높은 비율을 나타낸다. 전형적으로 SCLC 환자의 고령과 커플링되어, 이들은 치료 옵션을 추가로 제한하면서, 가혹한 화학 요법을 견디는 환자의 능력에 영향을 준다.

델타 유사 3(DLL3)은 SCLC에서 차등적으로 발현되는 유형 1 막횡단 단백질 및 비정준(noncanonical) Notch 리간드이다. 면역조직화학(IHC)을 사용하여 SCLC 종양의 85%가 막 및 세포질 발현과 일치하는 패턴으로 DLL3에 대해 양성으로 염색되었다. 대조적으로, 세포질 염색 패턴이 있는 정상 뇌, 췌도 및 뇌하수체에서는 낮은 수준의 DLL3 단백질 발현이 검출되었다(문헌[Saunders et al, Sci Transl Med. 7:302ra136 (2015)]). DLL3은 SCLC에 대한 T 세포 표적 치료법 개발을 위한 신규하고 유망한 표적이다.

SCLC의 치료를 위한 치료법의 개발에 대한 충족되지 않은 의학적 요구가 있다.

본 명세서에 제공된 개시내용에 기반하여, 당업자는 본 명세서에 기재된 본 발명의 구체적 실시형태에 대한 많은 균등물을 인식하거나, 단지 일상적인 실험을 이용하여 확인할 수 있을 것이다. 이러한 균등물은 다음의 실시형태(E)에 의해 포괄하고자 한다.

E1: DLL3 양성 암을 치료하는 방법으로서, 이를 필요로 하는 대상체에게 항-DLL3 작용제를 투여하는 단계를 포함하고, 여기서 항-DLL3 작용제는 2주마다 1회 0.3 mg 내지 100 mg, 3 mg 내지 200 mg, 또는 100 mg의 용량으로 투여되는 것인 방법.

E2: DLL3 양성 암을 치료하는 방법으로서, 이를 필요로 하는 대상체에게 항-DLL3 작용제를 투여하는 단계를 포함하고, 상기 항-DLL3 작용제는 다음의 일정에 따라 투여되는 것인 방법: a) 제1일에 0.3 mg 내지 100 mg, 0.5 mg 내지 10 mg, 또는 1 mg의 제1 용량, b) 제8일에 0.3 mg 내지 100 mg, 3 내지 200 mg, 또는 100 mg의 제2 용량, 및 c) 제15일에 시작하고 그 후 2주마다 1회, 0.3 mg 내지 100 mg, 3 내지 200 mg, 또는 100 mg의 하나 이상의 후속 용량, 여기서 제2 및 후속 용량은 동일하며, 제1 용량보다 높은 용량임.

E3: DLL3 양성 암을 치료하는 방법으로서, 이를 필요로 하는 대상체에게 항-DLL3 작용제를 투여하는 단계를 포함하고, 상기 항-DLL3 작용제는 다음의 2가지 일정 중 하나에 따라 투여되는 것인 방법:

일정 I: a) 제1일에 0.5 mg 내지 10 mg 또는 1 mg의 제1 용량(준비(run-in) 용량), b) 제4일에 3 mg 내지 100 mg 또는 25 mg 내지 50 mg의 제2 용량(단계(step) 용량), c) 제8일에 3 mg 내지 200 mg 또는 100 mg의 제3 용량(단계 용량), 및 d) 제15일에 시작하고 그 후 2주마다 1회, 3 mg 내지 200 mg 또는 100 mg의 하나 이상의 후속 용량(목표 용량), 여기서 제2 용량은 제1 용량보다 높고, 제3 및 후속 용량은 동일하며 제2 용량과 동일하거나 그보다 높은 용량임; 또는

일정 II: a) 제1일에 0.5 mg 내지 10 mg 또는 1 mg의 제1 용량(준비 용량), b) 제8일에 3 mg 내지 100 mg 또는 25 mg 내지 50 mg의 제2 용량(단계 용량), c) 제15일에 3 mg 내지 200 mg 또는 100 mg의 제3 용량(단계 용량) 및 c) 제29일에 시작하고 그 후 2주마다 1회, 3 mg 내지 200 mg 또는 100 mg의 하나 이상의 후속 용량(목표 용량), 여기서 제2 용량은 제1 용량보다 높고, 제3 용량 및 후속 용량은 동일하며 제2 용량보다 높은 용량임.

E4: DLL3 양성 암을 치료하는 방법으로서, 이를 필요로 하는 대상체에게 항-DLL3 작용제를 투여하는 단계를 포함하고, 상기 항-DLL3 작용제는 다음의 일정에 따라 투여되는 것인 방법: a) 제1일에 0.5 mg 내지 10 mg 또는 1 mg의 제1 용량(준비 용량), b) 제4일에 3 mg 내지 100 mg 또는 25 mg의 제2 용량(단계 용량), c) 제8일에 3 mg 내지 100 mg 또는 50 mg의 제3 용량(단계 용량), d) 제15일에 3 mg 내지 200 mg 또는 100 mg의 제4 용량(단계 용량), 및 e) 제29일에 시작하고 그 후 2주마다 1회, 3 mg 내지 200 mg 또는 100 mg의 하나 이상의 후속 용량(목표 용량), 여기서 제2 용량은 제1 용량보다 높고, 제3 용량은 제2 용량보다 높고, 제4 용량 및 후속 용량은 동일하며 제3 용량과 동일하거나 그보다 높은 용량임.

E5: DLL3 양성 암을 치료하는 방법으로서, 이를 필요로 하는 대상체에게 항-DLL3 작용제를 투여하는 단계를 포함하고, 상기 항-DLL3 작용제는 다음의 일정에 따라 투여되는 것인 방법: a) 제1일에 0.5 mg 내지 10 mg의 제1 용량(준비 용량), b) 제4일에 3 mg 내지 200 mg의 제2 용량(단계 용량), c) 제8일에 3 mg 내지 200 mg의 제3 용량(목표 용량), 및 d) 제15일에 시작하고 그 후 2주마다 1회, 3 mg 내지 200 mg의 하나 이상의 후속 용량(목표 용량), 여기서 제2 용량은 제1 용량보다 높고, 제3 및 후속 용량은 동일하며 제2 용량과 동일한 용량임.

E6: DLL3 양성 암을 치료하는 방법으로서, 이를 필요로 하는 대상체에게 항-DLL3 작용제를 투여하는 단계를 포함하고, 상기 항-DLL3 작용제는 다음의 일정에 따라 투여되는 것인 방법: a) 제1일에 0.5 mg 내지 10 mg의 제1 용량(준비 용량), b) 제4일에 3 mg 내지 100 mg의 제2 용량(단계 용량), c) 제8일에 3 mg 내지 200 mg의 제3 용량(단계 용량), d) 제15일에 3 mg 내지 200 mg의 제4 용량(목표 용량), 및 e) 제29일에 시작하고 그 후 2주마다 1회, 3 mg 내지 200 mg 의 하나 이상의 후속 용량(목표 용량), 여기서 제2 용량은 제1 용량보다 높고, 제3 용량은 제2 용량보다 높고, 제4 용량 및 후속 용량은 동일하며 제3 용량과 동일한 용량임.

E7: E1 내지 E6 중 어느 하나에 있어서, 항-DLL3 양성 암은 소세포 폐암(SCLC)인 방법.

E8: E1 내지 E7 중 어느 하나에 있어서, 항-DLL3 양성 암은 재발성/불응성(RR) SCLC 또는 확장 질환(extensive disease, ED) SCLC인 방법.

E9: E1 내지 E8 중 어느 하나에 있어서, 항-DLL3 작용제는 2개의 결합 도메인을 포함하는 이중특이적 항체 구축물이고, 제1 도메인은 인간 DLL3에 결합하고, 제2 도메인은 인간 CD3에 결합하는 것인 방법.

E10: E9에 있어서, DLL3 결합 도메인은 서열번호 258의 아미노산 서열 내에 포함된 인간 DLL3의 에피토프에 결합하는 것인 방법.

E11: E9 또는 E10에 있어서, DLL3 결합 도메인은 (a) 다음을 포함하는 중쇄 가변 영역(VH): (i) 서열번호 31의 아미노산 서열을 포함하는 VH 상보성 결정 영역 1(CDR-H1); (ii) 서열번호 32의 아미노산 서열을 포함하는 CDR-H2; 및 (iii) 서열번호 33의 아미노산 서열을 포함하는 CDR-H3; 및 (b) 다음을 포함하는 경쇄 가변 영역(VL): (i) 서열번호 34의 아미노산 서열을 포함하는 VL 상보성 결정 영역 1(CDR-L1); (ii) 서열번호 35의 아미노산 서열을 포함하는 CDR-L2; 및 (iii) 서열번호 36의 아미노산 서열을 포함하는 CDR-L3;을 포함하는 것인 방법.

E12: E9 내지 E11 중 어느 하나에 있어서, DLL3 결합 도메인은 (1) 서열번호 37의 아미노산 서열을 포함하는 VH 및 서열번호 38의 아미노산 서열을 포함하는 VL, 또는 (2) 서열번호 435의 아미노산 서열을 포함하는 VH 및 서열번호 436의 아미노산 서열을 포함하는 VL을 포함하는 것인 방법.

E13: E9 내지 E12 중 어느 하나에 있어서, DLL3 결합 도메인의 VH 및 VL은 링커에 의해 연결되어 단일 쇄 Fv(scFv)를 형성하는 것인 방법.

E14: E13에 있어서, 링커는 서열번호 285 내지 293 중 어느 하나로부터 선택되는 서열을 포함하는 것인 방법.

E15: E13 또는 E14에 있어서, 링커는 (Gly4Ser)x(여기서, x는 1 이상의 정수(예를 들어, 1, 2, 3, 또는 4)임)를 포함하는 것인 방법.

E16: E9 내지 E15 중 어느 하나에 있어서, DLL3 결합 도메인은 서열번호 39 또는 서열번호 437의 아미노산 서열을 포함하는 것인 방법.

E17: E9 내지 E16 중 어느 하나에 있어서, CD3 결합 도메인은 (a) 다음을 포함하는 VH: 서열번호 426의 아미노산 서열을 포함하는 CDR-H1, 서열번호 427의 아미노산 서열을 포함하는 CDR-H2, 및 서열번호 428의 아미노산 서열을 포함하는 CDR-H3; 및 다음을 포함하는 VL: 서열번호 423의 아미노산 서열을 포함하는 CDR-L1, 서열번호 424의 아미노산 서열을 포함하는 CDR-L2, 및 서열번호 425의 아미노산 서열을 포함하는 CDR-L3;을 포함하는 것인 방법.

E18: E9 내지 E17 중 어느 하나에 있어서, CD3 결합 도메인은 서열번호 429의 아미노산 서열을 포함하는 VH 및 서열번호 430의 아미노산 서열을 포함하는 VL을 포함하는 것인 방법.

E19: E17 또는 E18에 있어서, CD3 결합 도메인의 VH 및 VL은 링커에 의해 연결되어 단일 쇄 Fv(scFv)를 형성하는 것인 방법.

E20: E19에 있어서, 링커는 서열번호 285 내지 293 중 어느 하나로부터 선택되는 서열을 포함하는 것인 방법.

E21: E19 또는 E20에 있어서, 링커는 (Gly4Ser)x(여기서, x는 1 이상의 정수(예를 들어, 1, 2, 3, 또는 4)임)를 포함하는 것인 방법.

E22: E17 내지 E21 중 어느 하나에 있어서, CD3 결합 도메인은 서열번호 431의 아미노산 서열을 포함하는 것인 방법.

E23: E9 내지 E22 중 어느 하나에 있어서, DLL3 결합 도메인 및 CD3 결합 도메인은 링커에 의해 연결되는 것인 방법.

E24: E23에 있어서, 링커는 서열번호 285 내지 293 중 어느 하나로부터 선택되는 서열을 포함하는 펩티드 링커인 방법.

E25: E23 또는 E24에 있어서, 링커는 (Gly4Ser)x(여기서, x는 1 이상의 정수(예를 들어, 1, 2, 3, 또는 4)임)를 포함하는 펩티드 링커인 방법.

E26: E9 내지 E25 중 어느 하나에 있어서, 항-DLL3 작용제는 DLL3 결합 도메인 및 CD3 결합 도메인을 포함하는 것인 방법. DLL3 결합 도메인은 (a) 다음을 포함하는 중쇄 가변 영역(VH): (i) 서열번호 31의 아미노산 서열을 포함하는 VH 상보성 결정 영역 1(CDR-H1); (ii) 서열번호 32의 아미노산 서열을 포함하는 CDR-H2; 및 (iii) 서열번호 33의 아미노산 서열을 포함하는 CDR-H3; 및 (b) 다음을 포함하는 경쇄 가변 영역(VL): (i) 서열번호 34의 아미노산 서열을 포함하는 VL 상보성 결정 영역 1(CDR-L1); (ii) 서열번호 35의 아미노산 서열을 포함하는 CDR-L2; 및 (iii) 서열번호 36의 아미노산 서열을 포함하는 CDR-L3;을 포함한다. CD3 결합 도메인은 (a) 다음을 포함하는 VH: (i) 서열번호 426의 아미노산 서열을 포함하는 CDR-H1, (ii) 서열번호 427의 아미노산 서열을 포함하는 CDR-H2, 및 (iii) 서열번호 428의 아미노산 서열을 포함하는 CDR-H3; 및 (b) 다음을 포함하는 VL: (i) 서열번호 423의 아미노산 서열을 포함하는 CDR-L1, (ii) 서열번호 424의 아미노산 서열을 포함하는 CDR-L2, 및 (iii) 서열번호 425의 아미노산 서열을 포함하는 CDR-L3;을 포함한다.

E27: E9 내지 E26 중 어느 하나에 있어서, DLL3 결합 도메인은 서열번호 37의 아미노산 서열을 포함하는 VH 및 서열번호 38의 아미노산 서열을 포함하는 VL을 포함하고, CD3 결합 도메인은 서열번호 429의 아미노산 서열을 포함하는 VH 및 서열번호 430의 아미노산 서열을 포함하는 VL을 포함하는 것인 방법.

E28: E9 내지 E26 중 어느 하나에 있어서, DLL3 결합 도메인은 서열번호 435의 아미노산 서열을 포함하는 VH 및 서열번호 436의 아미노산 서열을 포함하는 VL을 포함하고, CD3 결합 도메인은 서열번호 429의 아미노산 서열을 포함하는 VH 및 서열번호 430의 아미노산 서열을 포함하는 VL을 포함하는 것인 방법.

E29: E9 내지 E27 중 어느 하나에 있어서, DLL3 결합 도메인은 서열번호 39의 아미노산을 포함하고, CD3 결합 도메인은 서열번호 431의 아미노산을 포함하는 것인 방법.

E30: E9 내지 E26 또는 E28 중 어느 하나에 있어서, DLL3 결합 도메인은 서열번호 437의 아미노산을 포함하고, CD3 결합 도메인은 서열번호 431의 아미노산을 포함하는 것인 방법.

E31: E29에 있어서, 항-DLL3 작용제는 서열번호 40의 아미노산 서열을 포함하는 것인 방법.

E32: E30에 있어서, 항-DLL3 작용제는 서열번호 438의 아미노산 서열을 포함하는 것인 방법.

E33: E9 내지 E32 중 어느 하나에 있어서, 항-DLL3 작용제는 항-DLL3 작용제의 혈청 반감기를 연장하거나 증진시키는 제3 도메인을 추가로 포함하는 것인 방법.

E34: E33에 있어서, 제3 도메인은 서열번호 541 내지 548 중 어느 하나로부터 선택되는 아미노산 서열을 포함하는 것인 방법.

E35: E9 내지 E26, E28, E30, E32, E33 또는 E35 중 어느 하나에 있어서, 항-DLL3 작용제는 서열번호 520의 아미노산을 포함하는 것인 방법.

E36: E1 또는 E7 내지 E35 중 어느 하나에 있어서, 항-DLL3 작용제는 2주마다 1회 다음의 용량으로 투여되는 것인 방법: 약 0.3 mg 내지 약 90 mg, 약 0.3 mg 내지 약 80 mg, 약 0.3 mg 내지 약 70 mg, 약 0.3 mg 내지 약 60 mg, 약 0.3 mg 내지 약 50 mg, 약 0.3 mg 내지 약 40 mg, 약 0.3 mg 내지 약 30 mg, 약 0.3 mg 내지 약 20 mg, 약 0.3 mg 내지 약 10 mg, 약 0.3 mg 내지 약 3 mg, 약 0.3 mg 내지 약 1 mg, 약 1 mg 내지 약 100 mg, 약 1 mg 내지 약 90 mg, 약 1 mg 내지 약 80 mg, 약 1 mg 내지 약 70 mg, 약 1 mg 내지 약 60 mg, 약 1 mg 내지 약 50 mg, 약 1 mg 내지 약 40 mg, 약 1 mg 내지 약 30 mg, 약 1 mg 내지 약 20 mg, 약 1 mg 내지 약 10 mg, 약 1 mg 내지 약 3 mg, 약 3 mg 내지 약 100 mg, 약 3 mg 내지 약 90 mg, 약 3 mg 내지 약 80 mg, 약 3 mg 내지 약 70 mg, 약 3 mg 내지 약 60 mg, 약 3 mg 내지 약 50 mg, 약 3 mg 내지 약 40 mg, 약 3 mg 내지 약 30 mg, 약 3 mg 내지 약 20 mg, 약 3 mg 내지 약 10 mg, 약 3 mg 내지 약 12 mg, 약 3 mg 내지 약 15 mg, 약 10 mg 내지 약 100 mg, 약 10 mg 내지 약 90 mg, 약 10 mg 내지 약 80 mg, 약 10 mg 내지 약 70 mg, 약 10 mg 내지 약 60 mg, 약 10 mg 내지 약 50 mg, 약 10 mg 내지 약 40 mg, 약 10 mg 내지 약 30 mg, 약 10 mg 내지 약 20 mg, 약 10 mg 내지 약 15 mg, 약 20 mg 내지 약 100 mg, 약 20 mg 내지 약 90 mg, 약 20 mg 내지 약 80 mg, 약 20 mg 내지 약 70 mg, 약 20 mg 내지 약 60 mg, 약 20 mg 내지 약 50 mg, 약 20 mg 내지 약 40 mg, 약 20 mg 내지 약 30 mg, 약 30 mg 내지 약 100 mg, 약 30 mg 내지 약 90 mg, 약 30 mg 내지 약 80 mg, 약 30 mg 내지 약 70 mg, 약 30 mg 내지 약 60 mg, 약 30 mg 내지 약 50 mg, 또는 약 30 mg 내지 약 40 mg.

E37: E1 또는 E7 내지 E35 중 어느 하나에 있어서, 항-DLL3 작용제는 2주마다 1회 다음의 용량으로 투여되는 것인 방법: 약 3 mg 내지 약 100 mg, 약 10 내지 약 180 mg, 약 10 내지 약 150 mg, 약 30 mg 내지 약 200 mg, 약 30 mg 내지 약 180 mg, 약 30 mg 내지 약 150 mg, 약 30 mg 내지 약 120 mg, 약 50 mg 내지 약 200 mg, 약 50 mg 내지 약 180 mg, 약 50 mg 내지 약 150 mg, 약 50 mg 내지 약 120 mg, 약 70 mg 내지 약 200 mg, 약 70 mg 내지 약 180 mg, 약 70 mg 내지 약 150 mg, 약 70 mg 내지 약 120 mg, 약 90 mg 내지 약 200 mg, 약 90 mg 내지 약 180 mg, 약 90 mg 내지 약 150 mg, 약 90 mg 내지 약 120 mg, 약 100 mg 내지 약 180 mg, 약 100 mg 내지 약 150 mg, 또는 약 100 mg 내지 약 120 mg; 또는 항-DLL3 작용제는 2주마다 1회 3 mg, 10 mg, 30 mg 또는 100 mg의 용량으로 투여되는 것인 방법.

E38: E1 또는 E7 내지 E37 중 어느 하나에 있어서, 항-DLL3 작용제는 28일 주기의 제1일 및 제15일에 투여되는 것인 방법.

E39: E2 또는 E7 내지 E35 중 어느 하나에 있어서, 제2 및 하나 이상의 후속 용량은 동일하고, 제1 용량보다 적어도 1.5배, 적어도 2배, 적어도 3배, 적어도 4배, 적어도 5배, 적어도 6배, 적어도 7배, 적어도 8배, 적어도 9배, 적어도 10배, 적어도 20배, 적어도 25배, 적어도 30배, 적어도 35배, 적어도 40배, 적어도 45배, 적어도 50배, 적어도 55배, 적어도 60배, 적어도 65배, 적어도 70배, 적어도 75배, 적어도 80배, 적어도 85배, 적어도 90배, 적어도 95배, 적어도 100배, 적어도 120배, 적어도 150배, 적어도 200배 높은 것인 방법.

E40: E2, E7 내지 E35 또는 E39 중 어느 하나에 있어서, 항-DLL3 작용제의 각각의 제1 용량은 약 0.5 mg 내지 약 10 mg, 약 0.5 mg 내지 약 8 mg, 약 0.5 mg 내지 약 6 mg, 약 0.5 mg 내지 약 4 mg, 약 0.5 mg 내지 약 2 mg, 또는 약 1 mg이고, 항-DLL3 작용제의 제2 및 후속 용량은 다음 중 임의의 하나일 수 있는 것인 방법: 약 0.3 mg 내지 약 90 mg, 약 0.3 mg 내지 약 80 mg, 약 0.3 mg 내지 약 70 mg, 약 0.3 mg 내지 약 60 mg, 약 0.3 mg 내지 약 50 mg, 약 0.3 mg 내지 약 40 mg, 약 0.3 mg 내지 약 30 mg, 약 0.3 mg 내지 약 20 mg, 약 0.3 mg 내지 약 10 mg, 약 0.3 mg 내지 약 3 mg, 약 0.3 mg 내지 약 1 mg, 약 1 mg 내지 약 100 mg, 약 1 mg 내지 약 90 mg, 약 1 mg 내지 약 80 mg, 약 1 mg 내지 약 70 mg, 약 1 mg 내지 약 60 mg, 약 1 mg 내지 약 50 mg, 약 1 mg 내지 약 40 mg, 약 1 mg 내지 약 30 mg, 약 1 mg 내지 약 20 mg, 약 1 mg 내지 약 10 mg, 약 1 mg 내지 약 3 mg, 약 3 mg 내지 약 100 mg, 약 3 mg 내지 약 90 mg, 약 3 mg 내지 약 80 mg, 약 3 mg 내지 약 70 mg, 약 3 mg 내지 약 60 mg, 약 3 mg 내지 약 50 mg, 약 3 mg 내지 약 40 mg, 약 3 mg 내지 약 30 mg, 약 3 mg 내지 약 20 mg, 약 3 mg 내지 약 10 mg, 약 3 mg 내지 약 12 mg, 약 3 mg 내지 약 15 mg, 약 10 mg 내지 약 100 mg, 약 10 mg 내지 약 90 mg, 약 10 mg 내지 약 80 mg, 약 10 mg 내지 약 70 mg, 약 10 mg 내지 약 60 mg, 약 10 mg 내지 약 50 mg, 약 10 mg 내지 약 40 mg, 약 10 mg 내지 약 30 mg, 약 10 mg 내지 약 20 mg, 약 10 mg 내지 약 15 mg, 약 20 mg 내지 약 100 mg, 약 20 mg 내지 약 90 mg, 약 20 mg 내지 약 80 mg, 약 20 mg 내지 약 70 mg, 약 20 mg 내지 약 60 mg, 약 20 mg 내지 약 50 mg, 약 20 mg 내지 약 40 mg, 약 20 mg 내지 약 30 mg, 약 30 mg 내지 약 100 mg, 약 30 mg 내지 약 90 mg, 약 30 mg 내지 약 80 mg, 약 30 mg 내지 약 70 mg, 약 30 mg 내지 약 60 mg, 약 30 mg 내지 약 50 mg, 약 30 mg 내지 약 40 mg, 약 10 mg 내지 약 180 mg, 약 10 mg 내지 약 150 mg, 약 10 mg 내지 약 120 mg, 약 30 mg 내지 약 200 mg, 약 30 mg 내지 약 180 mg, 약 30 mg 내지 약 150 mg, 약 30 mg 내지 약 120 mg, 약 50 mg 내지 약 200 mg, 약 50 mg 내지 약 180 mg, 약 50 mg 내지 약 150 mg, 약 50 mg 내지 약 120 mg, 약 70 mg 내지 약 200 mg, 약 70 mg 내지 약 180 mg, 약 70 mg 내지 약 150 mg, 약 70 mg 내지 약 120 mg, 약 90 mg 내지 약 200 mg, 약 90 mg 내지 약 180 mg, 약 90 mg 내지 약 150 mg, 약 90 mg 내지 약 120 mg, 약 100 mg 내지 약 180 mg, 약 100 mg 내지 약 150 mg, 및 약 100 mg 내지 약 120 mg.

E41: E2, E7 내지 E35, E39, 또는 E40 중 어느 하나에 있어서, 항-DLL3 작용제의 제1 용량은 1 mg이고, 항-DLL3 작용제의 제2 및 후속 용량은 각각 3 mg, 10 mg, 30 mg, 또는 100 mg인 방법.

E42: E3 또는 E7 내지 E35 중 어느 하나에 있어서, 항-DLL3 작용제의 제1 용량은 약 0.5 mg 내지 약 8 mg, 약 0.5 mg 내지 약 6 mg, 약 0.5 mg 내지 약 4 mg, 약 0.5 mg 내지 약 2 mg, 또는 1 mg이고, 항-DLL3 작용제의 제2 용량은 약 3 mg 내지 약 10 mg, 약 10 mg 내지 약 100 mg, 약 10 mg 내지 약 80 mg, 약 10 mg 내지 약 60 mg, 약 20 mg 내지 약 80 mg, 약 20 mg 내지 약 60 mg, 약 25 mg 내지 약 50 mg, 약 30 mg 내지 약 80 mg, 약 30 mg 내지 약 60 mg, 약 30 mg 내지 약 40 mg, 약 40 mg 내지 약 80 mg, 또는 약 40 mg 내지 약 60 mg이고, 항-DLL3 작용제의 제3 및 후속 용량은 다음 중 임의의 하나일 수 있는 것인 방법: 약 3 mg 내지 약 100 mg, 약 10 mg 내지 약 180 mg, 약 10 mg 내지 약 150 mg, 약 10 mg 내지 약 120 mg, 약 30 mg 내지 약 200 mg, 약 30 mg 내지 약 180 mg, 약 30 mg 내지 약 150 mg, 약 30 mg 내지 약 120 mg, 약 50 mg 내지 약 200 mg, 약 50 mg 내지 약 180 mg, 약 50 mg 내지 약 150 mg, 약 70 mg 내지 약 200 mg, 약 70 mg 내지 약 180 mg, 약 70 mg 내지 약 150 mg, 약 70 mg 내지 약 120 mg, 약 90 mg 내지 약 200 mg, 약 90 mg 내지 약 180 mg, 약 90 mg 내지 약 150 mg, 약 90 mg 내지 약 120 mg, 약 100 mg 내지 약 180 mg, 약 100 mg 내지 약 150 mg, 약 100 mg 내지 약 120 mg, 또는 약 100 mg.

E43: E3, E7 내지 E35, 또는 E42 중 어느 하나에 있어서, 항-DLL3 작용제의 제1 용량은 1 mg이고, 항-DLL3 작용제의 제2 용량은 25 mg 내지 50 mg 또는 45 mg 내지 70 mg이고, 항-DLL3 작용제의 제3 및 후속 용량은 100 mg인 방법.

E44: E3, E7 내지 E35, 또는 E42 중 어느 하나에 있어서, 항-DLL3 작용제의 제1 용량은 제1일에 1 mg이고, 항-DLL3 작용제의 제2 용량은 제4일에 25 mg 또는 50 mg이고, 항-DLL3 작용제의 제3 용량은 제8일에 100 mg이고, 항-DLL3 작용제의 후속 용량은 제15일에 시작하여 그 후 2주마다 1회 100 mg인 방법.

E45: E4 또는 E7 내지 E35 중 어느 하나에 있어서, 항-DLL3 작용제의 제1 용량은 약 0.5 mg 내지 약 8 mg, 약 0.5 mg 내지 약 6 mg, 약 0.5 mg 내지 약 4 mg, 약 0.5 mg 내지 약 2 mg, 또는 1 mg이고, 항-DLL3 작용제의 제2 용량은 약 3 mg 내지 약 10 mg, 약 10 mg 내지 약 100 mg, 약 10 mg 내지 약 80 mg, 약 10 mg 내지 약 60 mg, 약 10 mg 내지 약 40 mg, 약 20 mg 내지 약 80 mg, 약 20 mg 내지 약 60 mg, 약 20 mg 내지 약 40 mg, 또는 약 25 mg이고, 항-DLL3 작용제의 제3 용량은 약 3 mg 내지 약 10 mg, 약 10 mg 내지 약 100 mg, 약 10 mg 내지 약 80 mg, 10 mg 내지 약 60 mg, 약 20 mg 내지 약 100 mg, 약 20 mg 내지 약 80 mg, 약 20 mg 내지 약 60 mg, 약 30 mg 내지 약 100 mg, 약 30 mg 내지 약 80 mg, 약 30 mg 내지 약 60 mg, 약 40 mg 내지 약 100 mg, 약 40 mg 내지 약 80 mg, 약 40 mg 내지 약 60 mg, 또는 약 50 mg이고, 항-DLL3 작용제의 제4 및 후속 용량은 다음 중 임의의 것일 수 있는 것인 방법: 약 3 mg 내지 약 100 mg, 약 10 mg 내지 약 150 mg, 약 30 mg 내지 200 mg, 약 30 mg 내지 약 150 mg, 약 30 mg 내지 약 100 mg, 약 50 mg 내지 약 200 mg, 약 50 mg 내지 약 180 mg, 약 50 mg 내지 약 150 mg, 약 50 mg 내지 약 120 mg, 약 70 mg 내지 약 200 mg, 약 70 mg 내지 약 180 mg, 약 70 mg 내지 약 120 mg, 약 90 mg 내지 약 200 mg, 약 90 mg 내지 약 180 mg, 약 90 mg 내지 약 150 mg, 약 90 mg 내지 약 120 mg, 또는 약 100 mg.

E46: E4, E7 내지 E35 또는 E45 중 어느 하나에 있어서, 항-DLL3 작용제의 제1 용량은 1 mg이고, 항-DLL3 작용제의 제2 용량은 25 mg이고, 항-DLL3 작용제의 제3 용량은 50 mg이고, 항-DLL3 작용제의 제4 및 후속 용량은 100 mg인 방법.

E47: E5 또는 E7 내지 E35 중 어느 하나에 있어서, 항-DLL3 작용제의 제1 용량은 0.5 mg 내지 8 mg, 0.5 mg 내지 6 mg, 0.5 mg 내지 4 mg, 0.5 mg 내지 2 mg, 또는 1 mg이고, 제2, 제3 용량 및 후속 용량은 각각 3 mg 내지 100 mg, 10 mg 내지 150 mg, 30 mg 내지 200 mg, 30 mg 내지 100 mg, 50 mg 내지 150 mg, 70 mg 내지 120 mg, 90 mg 내지 120 mg, 100 mg 내지 200 mg, 또는 100 mg인 방법.

E48: E6 또는 E7 내지 E35 중 어느 하나에 있어서, 제1 용량은 0.5 mg 내지 8 mg, 0.5 mg 내지 6 mg, 0.5 mg 내지 4 mg, 0.5 mg 내지 2 mg, 또는 1 mg이고, 제2 용량은 3 mg 내지 10 mg, 10 mg 내지 80 mg, 10 mg 내지 60 mg, 20 mg 내지 80 mg, 20 mg 내지 60 mg, 20 mg 내지 40 mg, 25 mg, 또는 50 mg이고, 제3, 제4 및 후속 용량은 각각 3 mg 내지 100 mg, 10 mg 내지 150 mg, 30 mg 내지 200 mg, 30 mg 내지 100 mg, 50 mg 내지 150 mg, 70 mg 내지 120 mg, 90 mg 내지 120 mg, 100 mg 내지 200 mg, 또는 100 mg인 방법.

E49: E1 내지 E48 중 어느 하나에 있어서, 대상체에게 하나 이상의 추가 치료제를 투여하는 단계를 포함하는 방법.

E50: E49에 있어서, 하나 이상의 추가 치료제는 스테로이드인 방법.

E51: E49 또는 E50에 있어서, 추가 치료제는 덱사메타손인 방법.

E52: E49 내지 E51 중 어느 하나에 있어서, 추가 치료제는 항-DLL3 작용제를 이용한 치료 전에 투여되는 것인 방법.

E53: E48 내지 E51 중 어느 하나에 있어서, 추가 치료제는 항-DLL3 작용제와 동시에 투여되는 것인 방법.

E54: E2 내지 E53 중 어느 하나에 있어서, 항-DLL3 작용제는 28일 주기로 투여되고, 항-DLL3 작용제가 투여되는 제1 주기에 대상체에게 유체(예를 들어, 식염수), 항염증제, 토실리주맙, 또는 에타너셉트를 투여하는 단계를 추가로 포함하는 방법.

E55: E54에 있어서, 준비 용량 및 단계 용량의 항-DLL3 작용제 후에 대상체에게 1 L의 식염수가 IV 주입으로 투여되는 것인 방법.

E56: E55에 있어서, 1 L의 식염수는 약 4~5시간에 걸쳐 투여되는 것인 방법.

E57: E54에 있어서, 항염증제는 코르티코스테로이드 또는 아세트아미노펜인 방법.

E58: E57에 있어서, 코르티코스테로이드는 덱사메타손인 방법.

E59: E54, E57, 또는 E58 중 어느 하나에 있어서, 항염증제 또는 토실리주맙은 준비 용량 및 단계 용량의 항-DLL3 작용제 전에 대상체에게 투여되는 것인 방법.

E60: E59에 있어서, 코르티코스테로이드는 준비 용량 및 단계 용량의 항-DLL3 작용제 약 6 내지 16시간 전에 대상체에게 투여되는 것인 방법.

E61: E59에 있어서, 토실리주맙 또는 아세트아미노펜은 준비 용량 및 단계 용량의 항-DLL3 작용제 약 1시간 전에 대상체에게 투여되는 것인 방법.

E62: E54에 있어서, 에타너셉트는 준비 용량 및 제4일의 단계 용량을 제외한 단계 용량의 항-DLL3 작용제 약 36 내지 60시간 전에 대상체에게 투여되는 것인 방법.

E63: E62에 있어서, 에타너셉트는 준비 용량 및 제4일의 단계 용량을 제외한 단계 용량의 항-DLL3 작용제 2일 전에 투여되는 것인 방법.

E64: E1 내지 E63 중 어느 하나에 있어서, 대상체는 인간인 방법.

E65: 실시형태 E1 내지 E64 중 어느 하나에 기재된 방법에서 사용하기 위한 항-DLL3 작용제.

E66: DLL3 양성 암(예를 들어, SCLC)의 치료에 사용하기 위한 항-DLL3 작용제로서, 실시형태 E1 내지 E64 중 어느 하나에 기재된 바와 같이 투여되는 항-DLL3 작용제.

E67: SCLC의 치료용 의약의 제조를 위한 항-DLL3 작용제의 용도로서, 의약은 실시형태 E1 내지 E64 중 어느 하나에 기재된 바와 같이 투여되도록 제조되는 것인 용도.

E68: DLL3 양성 암 치료용 의약의 제조에 있어서 항-DLL3 작용제의 용도로서, 항-DLL3 작용제는 실시형태 E1 내지 E64 중 어느 하나에 기재된 바와 같이 투여되는 것인 용도.

도 1은 2주마다 1회 짧은 IV 주입을 투여한 후 인간에서 단일 주기의 AMG 757의 예측된 혈청 농도-시간 프로파일을 보여준다. 점선은 AMG 757 활성(연구 123564)의 가장 민감한 마커로 확인된 AMG 757 매개 CD69 상향 조절의 50% 및 90%의 최대 효과(각각 0.61 ng/mL 및 4.6 ng/mL의 EC50 및 EC90 값)에 필요한 농도를 나타낸다.
도 2는 2주마다 1회 짧은 IV 주입을 투여한 후 인간에서 단일 주기의 AMG 757의 예측된 폐 농도-시간 프로파일을 보여준다. 점선은 SHP-77 세포에서 AMG 757 매개 세포 사멸의 50% 및 90%의 최대 효과(각각 2.8 ng/mL 및 5.7 ng/mL의 EC50 및 EC90 값)에 필요한 농도를 나타낸다.
도 3은 제1 용량 효과와 관련된 유해 사례가 0.03 mg에서 발생한다고 추정한 단계 투여 예를 보여준다.
도 4는 AMG 757로 치료한 SCLC 환자의 확인된 부분 반응(PR)을 보여준다.
도 5는 분자로 치료된 SCLC 환자의 평균 정상 상태 혈청 AMG 757 농도-시간 프로파일을 보여준다. 도 5에서 *는 단계 투여를 나타내며, 데이터는 2주 투여 간격 동안 주기 2 제15일 용량 후 제시된다. 0.1 mg군에 등록된 유일한 환자의 데이터는 해당 환자가 주기 1 동안 이탈하였기에 이용할 수 없었다.
도 6은 AMG 757로 치료한 SCLC 환자의 객관적 반응 요약을 보여준다.

본원에 개시되고 예시된 바와 같이, DLL3 및 CD3을 표적으로 하는 이중특이적 단백질(AMG 757)을 사용하여 SCLC의 치료를 위해 1상 임상 연구를 수행하였다.

AMG 757은 SCLC 치료를 위해 개발된 반감기 연장된 BiTE®(이중특이적 T 세포 관여자) 분자이다. AMG 757의 활성은 표적 세포(DLL3⁺ 세포)와 T 세포에 대한 동시 결합을 필요로 한다. AMG 757의 약리학적 효과는 이전에 프라이밍된 세포독성 CD8⁺ 또는 CD4⁺ T 림프구의 특이적 방향 변경(redirection)에 의해 매개되어 DLL3⁺ 세포를 살상한다. 최초 인간 대상(First in Human, FIH) 연구의 시작 용량 선택은 SHP-77 세포(연구 123564)에서 AMG 757 매개 CD69 상향 조절의 EC₅₀으로 확인된 최소 예상 생물학적 효과 수준(minimum anticipated biological effect level, MABEL)을 기반으로 하였다. 2주마다(Q2W) 1회 0.003 mg의 시작 용량은 인간 PK 예측을 기반으로 선택되었으며 MABEL(0.61 ng/mL)과 동등한 최대 혈청 농도를 생성할 것으로 예상된다. 이 요법은 전체 투여 간격 동안 표적 조직(예를 들어, 폐)에서 적절한 노출을 달성하는 동시에 AMG 757의 여러 치료 주기 후에 최고점 대 최저점 비율을 최소화할 것으로 예상된다. FIH 연구의 임상 경험에 기초하면, 적어도 0.3 mg Q2W의 용량이 바람직하다.

1. 정의

본원에 개시된 예시적인 이중특이적 항-DLL3 작용제 중 일부(예를 들어, BiTE® 분자)는 2개의 결합 도메인을 포함하는 재조합 단백질 구축물이며, 각각의 도메인은 전장 항체의 항원 결합 단편으로부터 유래된다. 이러한 항원 결합 단편은 (바람직하게는 실질적으로 동일한 결합 친화도로) 항원에 특이적으로 결합하는 능력을 보유한다. 항원 결합 단편의 예는 (i) Fab 단편, VL, VH, CL 및 CH1 도메인으로 구성된 1가 단편; (ii) F(ab')₂ 단편(힌지 영역에서 이황화 가교에 의해 연결된 2개의 Fab 단편을 포함하는 2가 단편); (iii) VH 및 CH1 도메인으로 구성된 Fd 단편; (iv) 항체의 단일 아암(arm)의 VL 및 VH 도메인으로 구성된 Fv 단편 및 (v) VH 도메인으로 구성된 dAb 단편(Ward et al., 1989 Nature 341:544-546)을 포함한다. 나아가, Fv 단편의 2개의 도메인인 VL 및 VH는 개별 유전자에 의해 암호화되지만, 이들은 VL 영역과 VH 영역이 (단일 쇄 Fv(scFv)로 알려진) 1가 분자를 형성하도록 짝지어지는 단일 단백질 쇄로서 생성되게 할 수 있는 합성 링커에 의해 재조합 방법을 이용하여 결합될 수 있다; 예를 들어, 문헌[Bird et al. Science 242:423-426 (1988)] 및 문헌[Huston et al., 1988, Proc. Natl. Acad. Sci. USA 85:5879-5883] 참조.

"가변 도메인"은 단독으로 또는 조합하여 항체 경쇄(VL)의 가변 영역 또는 항체 중쇄(VH)의 가변 영역을 지칭한다. 당해 분야에 공지된 바와 같이, 중쇄 및 경쇄의 가변 영역은 각각 3개의 상보성 결정 영역(CDR)에 의해 연결된 4개의 프레임워크 영역(FR)으로 구성되며, 항체의 항원 결합 부위 형성에 기여한다.

예시적인 DLL3 결합 도메인 및 CD3 결합 도메인의 "상보성 결정 영역"(CDR)이 서열 표에 제공되어 있다. CDR은 Kabat, Chothia, Kabat 및 Chothia 둘 다의 축적, AbM, 접촉, North, 및/또는 형태적 정의 또는 당해 분야에 널리 공지된 임의의 CDR 결정 방법에 따라 정의될 수 있다. 예를 들어, 문헌[Kabat et al., 1991, Sequences of Proteins of Immunological Interest, 5th ed. (과가변 영역)]; 문헌[Chothia et al., 1989, Nature 342:877-883 (구조적 루프 구조)] 참조. CDR의 AbM 정의는 Kabat과 Chothia 사이의 절충안으로, Oxford Molecular의 AbM 항체 모델링 소프트웨어(Accelrys®)를 사용한다.　CDR을 구성하는 특정 항체의 아미노산 잔기의 정체는 당해 분야에 잘 알려진 방법을 사용하여 결정할 수 있다.

"치료"라는 용어는 예방적 및/또는 치료적 처치를 포함한다. 병태의 임상적 징후가 나타나기 전에 투여되는 경우, 치료는 예방적 처치로 간주된다. 치료적 처치는 예를 들어, 질환의 중증도를 개선 또는 감소시키거나 질환의 기간을 단축시키는 것을 포함한다.

"약" 또는 "대략"은 측정 가능한 수치 변수와 관련하여 사용될 때 변수의 표시된 값과 표시된 값의 실험 오차 이내(예를 들어, 평균에 대한 95% 신뢰 간격 이내) 또는 표시된 값의 ±10% 이내(둘 중 더 큰 값)에 있는 변수의 모든 값을 지칭한다. 수치 범위는 범위를 한정하는 숫자를 포함한다.

"준비 용량(run-in dose)"은 암(예를 들어, 소세포 폐암(SCLC)) 치료를 위한 항-DLL3 작용제의 투여와 관련하여 사용될 때 제1 용량 효과(예를 들어, 사이토카인 방출 증후군(CRS))가 관찰되는 용량 이하의 항-DLL3 작용제의 초기 용량을 지칭한다. 당해 분야에 공지된 바와 같이, 준비 용량은 안전성 및 약동학 데이터의 모델링 및 시뮬레이션에 의해 결정될 수 있다. 예를 들어, 준비 용량은 CRS가 관찰되지 않거나 또는 특정 등급(예를 들어, 등급 2) 미만의 CRS가 관찰되는 항-DLL3 작용제의 최대 허용 용량(MTD)일 수 있다.

"목표 용량"은 암(예를 들어, SCLC) 치료를 위한 항-DLL3 작용제의 투여와 관련하여 사용될 때 항-DLL3 작용제의 목표 효과를 달성하는(예를 들어, SCLC의 중증도를 개선 또는 감소시키거나 SCLC의 기간을 단축시키는) 용량을 지칭한다.

"단계 용량(step dose)"은 암(예를 들어, SCLC) 치료를 위한 항-DLL3 작용제의 투여와 관련하여 사용될 때 항-DLL3 작용제가 투여되는 이전의 용량보다 높은 용량을 지칭한다. 단계 용량은 준비 용량에서부터 증가하여 목표 용량에 도달하는 하나 이상의 용량을 포함한다.

2. 항-DLL3 작용제

DLL3은 체세포 형성 동안 기능하는 배아 발달 중에 주로 발현되는 비정준 Notch 리간드이다. 세포 표면에서 발현되는 다른 Notch 리간드와 대조적으로, DLL3은 정상 조직의 골지에 축적된다(Geffers et al, J Cell Biol.178:465-476 (2007)). DLL3은 28종의 SCLC 종양 및 대규모 정상 조직 패널에서 이 표적의 차등적 발현을 분석함으로써 T 세포 기반 치료법에 대한 종양 관련 항원 및 강력한 표적으로 확인되었다(연구 123658).

인간 DLL3 단백질은 8개의 세포외 도메인을 포함한다: 신호 펩티드, N-말단, DSL, EGF1, EGF2, EGF3, EGF4, EGF5 및 EGF6. 인간 DLL3, EGF3 도메인, EGF4 도메인 및 결합된 EGF3 및 EGF4 도메인의 아미노산 서열은 각각 서열번호 252, 258, 259 및 260으로 서열 표에 제시되어 있다.

예시적인 항-DLL3 작용제는 DLL3 및 CD3에 결합하는 이중특이적 분자, 예를 들어 BiTE®(이중특이적 T 세포 관여자) 분자이다. BiTE® 분자는 2개의 유연하게 연결된 결합 도메인으로 제조된 재조합 단백질 구축물이며, 각 도메인은 항체에서 유래된다. BiTE® 분자의 하나의 결합 도메인은 종양 관련 표면 표면 항원(예컨대, DLL3)에 대해 특이적이고, 제2 결합 도메인은 T 세포 상의 T 세포 수용체 복합체의 서브유닛인 CD3에 대해 특이적이다. 이들의 설계에 의해, BiTE® 분자는 T 세포를 표적 세포와 일시적으로 연결하는 데 독특하게 적합하고, 동시에, 표적 세포에 대한 T 세포의 고유한 세포용해 가능성을 강력하게 활성화시킨다. 예를 들어, WO 99/54440, WO 2005/040220 및 WO 2008/119567 참조.

따라서, 일부 실시형태에서, 기재된 항-DLL3 작용제는 2개의 결합 도메인을 포함한다: 제1 도메인은 DLL3(바람직하게는 인간 DLL3)과 결합하고, 제2 도메인은 CD3(바람직하게는 인간 CD3)과 결합한다. 바람직하게는, 제1 도메인은 서열번호 260의 아미노산 서열 내에 포함된 DLL3의 에피토프에 결합한다. 더욱 바람직하게는, 제1 도메인은 서열번호 258의 아미노산 서열 내에 포함된 DLL3의 에피토프에 결합한다.

특정 실시형태에서, DLL3 결합 도메인은 (a) 다음을 포함하는 중쇄 가변 영역(VH): (i) 서열번호 31의 아미노산 서열을 포함하는 VH 상보성 결정 영역 1(CDR-H1); (ii) 서열번호 32의 아미노산 서열을 포함하는 CDR-H2; 및 (iii) 서열번호 33의 아미노산 서열을 포함하는 CDR-H3; 및 (b) 다음을 포함하는 경쇄 가변 영역(VL): (i) 서열번호 34의 아미노산 서열을 포함하는 VL 상보성 결정 영역 1(CDR-L1); (ii) 서열번호 35의 아미노산 서열을 포함하는 CDR-L2; 및 (iii) 서열번호 36의 아미노산 서열을 포함하는 CDR-L3;을 포함한다.

특정 실시형태에서, DLL3 결합 도메인은 서열번호 37의 아미노산 서열을 포함하는 VH 및 서열번호 38의 아미노산 서열을 포함하는 VL을 포함한다. 특정 바람직한 실시형태에서, DLL3 결합 도메인은 서열번호 435의 아미노산 서열을 포함하는 VH 및 서열번호 436의 아미노산 서열을 포함하는 VL을 포함한다.

일부 실시형태에서, VH 및 VL은 링커에 의해 연결되어 단일 쇄 Fv(scFv)를 형성한다. 일부 실시형태에서, 링커는 서열번호 285 내지 293 중 어느 하나로부터 선택되는 서열을 포함하는 펩티드 링커이다. 일부 실시형태에서, 링커는 GS 링커, 예컨대 Gly-Gly-Gly-Gly-Ser(G4S, 서열번호 286), 또는 이의 중합체, 즉, (Gly4Ser)x(여기서, x는 1 이상의 정수(예를 들어, 2 또는 3)임)(예를 들어, 서열번호 292, 293)이다.

특정 실시형태에서, DLL3 결합 도메인은 서열번호 39의 아미노산 서열을 포함한다. 특정 바람직한 실시형태에서, DLL3 결합 도메인은 서열번호 437의 아미노산 서열을 포함한다.

특정 실시형태에서, CD3 결합 도메인은 (a) 다음을 포함하는 VH: 서열번호 426의 아미노산 서열을 포함하는 CDR-H1, 서열번호 427의 아미노산 서열을 포함하는 CDR-H2, 및 서열번호 428의 아미노산 서열을 포함하는 CDR-H3; 및 다음을 포함하는 VL: 서열번호 423의 아미노산 서열을 포함하는 CDR-L1, 서열번호 424의 아미노산 서열을 포함하는 CDR-L2, 및 서열번호 425의 아미노산 서열을 포함하는 CDR-L3;을 포함한다.

특정 실시형태에서, CD3 결합 도메인은 서열번호 429의 아미노산 서열을 포함하는 VH 및 서열번호 430의 아미노산 서열을 포함하는 VL을 포함한다. 일부 실시형태에서, VH 및 VL은 링커에 의해 연결되어 단일 쇄 Fv(scFv)를 형성한다. 일부 실시형태에서, 링커는 서열번호 285 내지 293 중 어느 하나로부터 선택되는 서열을 포함하는 펩티드 링커이다. 일부 실시형태에서, 링커는 GS 링커, 예컨대 Gly-Gly-Gly-Gly-Ser(G4S, 서열번호 286), 또는 이의 중합체, 즉, (Gly4Ser)x(여기서, x는 1 이상의 정수(예를 들어, 2 또는 3)임)이다.

특정 실시형태에서, CD3 결합 도메인은 서열번호 431의 아미노산 서열을 포함한다.

특정 실시형태에서, DLL3 결합 도메인 및 CD3 결합 도메인은 링커에 의해 연결된다. 일부 실시형태에서, 링커는 서열번호 285 내지 293 중 어느 하나로부터 선택되는 서열을 포함하는 펩티드 링커이다. 일부 실시형태에서, 링커는 GS 링커, 예컨대 Gly-Gly-Gly-Gly-Ser(G4S, 서열번호 286), 또는 이의 중합체, 즉, (Gly4Ser)x(여기서, x는 1 이상의 정수(예를 들어, 2 또는 3)임)이다.

특정 실시형태에서, 본원에 개시된 항-DLL3 작용제는 2개의 도메인을 포함한다. 제1 도메인은 DLL3(바람직하게는 인간 DLL3)에 결합하고, (a) 다음을 포함하는 중쇄 가변 영역(VH): (i) 서열번호 31의 아미노산 서열을 포함하는 VH 상보성 결정 영역 1(CDR-H1); (ii) 서열번호 32의 아미노산 서열을 포함하는 CDR-H2; 및 (iii) 서열번호 33의 아미노산 서열을 포함하는 CDR-H3; 및 (b) 다음을 포함하는 경쇄 가변 영역(VL): (i) 서열번호 34의 아미노산 서열을 포함하는 VL 상보성 결정 영역 1(CDR-L1); (ii) 서열번호 35의 아미노산 서열을 포함하는 CDR-L2; 및 (iii) 서열번호 36의 아미노산 서열을 포함하는 CDR-L3;을 포함한다. 제2 도메인은 CD3(바람직하게는 인간 CD3)에 결합하고, (a) 다음을 포함하는 VH: (i) 서열번호 426의 아미노산 서열을 포함하는 CDR-H1, (ii) 서열번호 427의 아미노산 서열을 포함하는 CDR-H2, 및 (iii) 서열번호 428의 아미노산 서열을 포함하는 CDR-H3; 및 (b) 다음을 포함하는 VL: (i) 서열번호 423의 아미노산 서열을 포함하는 CDR-L1, (ii) 서열번호 424의 아미노산 서열을 포함하는 CDR-L2, 및 (iii) 서열번호 425의 아미노산 서열을 포함하는 CDR-L3;을 포함한다.

특정 실시형태에서, 본원에 기재된 항-DLL3 작용제는 2개의 도메인을 포함한다: (a) 제1 도메인은 DLL3(바람직하게는 인간 DLL3)과 결합하고, 서열번호 37의 아미노산 서열을 포함하는 VH 및 서열번호 38의 아미노산 서열을 포함하는 VL을 포함하고; (b) 제2 도메인은 CD3(바람직하게는 인간 CD3)과 결합하고, 서열번호 429의 아미노산 서열을 포함하는 VH 및 서열번호 430의 아미노산 서열을 포함하는 VL을 포함한다. 특정 바람직한 실시형태에서, 본원에 기재된 항-DLL3 작용제는 2개의 도메인을 포함한다: (a) 제1 도메인은 DLL3(바람직하게는 인간 DLL3)과 결합하고, 서열번호 435의 아미노산 서열을 포함하는 VH 및 서열번호 436의 아미노산 서열을 포함하는 VL을 포함하고; (b) 제2 도메인은 CD3(바람직하게는 인간 CD3)과 결합하고, 서열번호 429의 아미노산 서열을 포함하는 VH 및 서열번호 430의 아미노산 서열을 포함하는 VL을 포함한다.

특정 실시형태에서, 본원에 기재된 항-DLL3 작용제는 2개의 도메인을 포함한다: (a) 제1 도메인은 DLL3(바람직하게는 인간 DLL3)과 결합하고, 서열번호 39의 아미노산 서열을 포함하고; (b) 제2 도메인은 CD3(바람직하게는 인간 CD3)과 결합하고, 서열번호 431의 아미노산 서열을 포함한다. 특정 실시형태에서, 본원에 기재된 항-DLL3 작용제는 2개의 도메인을 포함한다: (a) 제1 도메인은 DLL3(바람직하게는 인간 DLL3)과 결합하고, 서열번호 437의 아미노산 서열을 포함하고; (b) 제2 도메인은 CD3(바람직하게는 인간 CD3)과 결합하고, 서열번호 431의 아미노산 서열을 포함한다.

특정 실시형태에서, 본원에 기재된 항-DLL3 작용제는 서열번호 40의 아미노산 서열을 포함한다. 특정 실시형태에서, 본원에 기재된 항-DLL3 작용제는 서열번호 438의 아미노산 서열을 포함한다.

특정 실시형태에서, 본원에 기재된 항-DLL3 작용제는 항-DLL3 작용제의 혈청 반감기를 연장하거나 증진시키는 제3 도메인을 추가로 포함한다. 특정 실시형태에서, 제3 도메인은 링커로 연결된 2개의 폴리펩티드를 포함하며, 각각의 펩티드는 인간 IgG의 힌지, CH2 및 CH3을 포함한다. 특정 실시형태에서, 제3 도메인은 N-말단에서 C-말단의 순서로 다음을 포함한다: 힌지-CH2-CH3-링커-힌지-CH2-CH3. 일부 실시형태에서, 링커는 GS 링커, 예컨대 Gly-Gly-Gly-Gly-Ser(G4S, 서열번호 286), 또는 이의 중합체, 즉, (Gly4Ser)x(여기서, x는 1 이상의 정수(예를 들어, 6)임)이다. 특정 실시형태에서, 제3 도메인은 서열번호 541 내지 548 중 어느 하나로부터 선택되는 아미노산 서열을 포함한다.

특정 실시형태에서, DLL3 결합 도메인 및 CD3 결합 도메인은 제1 링커에 의해 연결되어 펩티드를 형성하고, 펩티드는 제2 링커에 의해 제3 도메인에 연결된다. 특정 실시형태에서, 제1 링커는 서열번호 285 내지 293 중 임의의 하나로부터 선택되는 서열을 포함하는 펩티드 링커이고, 제2 링커는 서열번호 285, 286, 288, 289, 290, 292 및 293 중 임의의 하나로부터 선택되는 서열을 포함한다. 일부 실시형태에서, 제1 링커는 GS 링커, 예컨대 Gly-Gly-Gly-Gly-Ser(G4S, 서열번호 286), 또는 이의 중합체, 즉, (Gly4Ser)x(여기서, x는 1 이상의 정수(예를 들어, 2 또는 3)임)이고, 제2 링커는 서열번호 285, 286, 288, 289, 290, 292 및 293 중 임의의 하나로부터 선택되는 서열을 포함한다.

특정 실시형태에서, 본원에 기재된 항-DLL3 작용제는 3개의 도메인을 포함한다: (a) 제1 도메인은 DLL3(바람직하게는 인간 DLL3)과 결합하고, 서열번호 39의 아미노산 서열을 포함하고, (b) 제2 도메인은 CD3(바람직하게는 인간 CD3)과 결합하고, 서열번호 431의 아미노산 서열을 포함하고, (c) 제3 도메인은 서열번호 541 내지 548 중 임의의 하나로부터 선택되는 아미노산 서열을 포함한다. 특정 실시형태에서, 본원에 기재된 항-DLL3 작용제는 3개의 도메인을 포함한다: (a) 제1 도메인은 DLL3(바람직하게는 인간 DLL3)과 결합하고, 서열번호 437의 아미노산 서열을 포함하고, (b) 제2 도메인은 CD3(바람직하게는 인간 CD3)과 결합하고, 서열번호 431의 아미노산 서열을 포함하고, (c) 제3 도메인은 서열번호 541 내지 548로부터 선택되는 아미노산 서열 중 임의의 하나를 포함한다.

특정 실시형태에서, 본원에 기재된 항-DLL3 작용제는 서열번호 520의 아미노산 서열을 포함한다.

3. 항-DLL3 작용제의 투여

DLL3 양성 암을 치료하는 방법으로서, 이를 필요로 하는 대상체에게 항-DLL3 작용제를 2주마다 1회 약 0.3 mg 내지 약 100 mg, 약 3 mg 내지 약 200 mg, 또는 약 100 mg의 용량으로 투여하는 단계를 포함하는 방법이 본원에 개시된다. 특정 실시형태에서, DLL3 양성 암은 소세포 폐암(SCLC)이다. 특정 실시형태에서, SCLC는 재발성/불응성 SCLC(RR SCLC) 또는 확장 질환 SCLC(ED SCLC)이다. 특정 실시형태에서, 대상체는 SCLC, 예를 들어, RR SCLC 또는 ED SCLC를 앓는 인간이다.

특정 실시형태에서, 항-DLL3 작용제는 2주마다 1회 다음의 용량으로 투여된다: 약 0.3 mg 내지 약 100 mg, 약 0.3 mg 내지 약 90 mg, 약 0.3 mg 내지 약 80 mg, 약 0.3 mg 내지 약 70 mg, 약 0.3 mg 내지 약 60 mg, 약 0.3 mg 내지 약 50 mg, 약 0.3 mg 내지 약 40 mg, 약 0.3 mg 내지 약 30 mg, 약 0.3 mg 내지 약 20 mg, 약 0.3 mg 내지 약 10 mg, 약 0.3 mg 내지 약 3 mg, 약 0.3 mg 내지 약 1 mg, 약 1 mg 내지 약 100 mg, 약 1 mg 내지 약 90 mg, 약 1 mg 내지 약 80 mg, 약 1 mg 내지 약 70 mg, 약 1 mg 내지 약 60 mg, 약 1 mg 내지 약 50 mg, 약 1 mg 내지 약 40 mg, 약 1 mg 내지 약 30 mg, 약 1 mg 내지 약 20 mg, 약 1 mg 내지 약 10 mg, 약 1 mg 내지 약 3 mg, 약 3 mg 내지 약 100 mg, 약 3 mg 내지 약 90 mg, 약 3 mg 내지 약 80 mg, 약 3 mg 내지 약 70 mg, 약 3 mg 내지 약 60 mg, 약 3 mg 내지 약 50 mg, 약 3 mg 내지 약 40 mg, 약 3 mg 내지 약 30 mg, 약 3 mg 내지 약 20 mg, 약 3 mg 내지 약 10 mg, 약 3 mg 내지 약 12 mg, 약 3 mg 내지 약 15 mg, 약 10 mg 내지 약 100 mg, 약 10 mg 내지 약 90 mg, 약 10 mg 내지 약 80 mg, 약 10 mg 내지 약 70 mg, 약 10 mg 내지 약 60 mg, 약 10 mg 내지 약 50 mg, 약 10 mg 내지 약 40 mg, 약 10 mg 내지 약 30 mg, 약 10 mg 내지 약 20 mg, 약 10 mg 내지 약 15 mg, 약 20 mg 내지 약 100 mg, 약 20 mg 내지 약 90 mg, 약 20 mg 내지 약 80 mg, 약 20 mg 내지 약 70 mg, 약 20 mg 내지 약 60 mg, 약 20 mg 내지 약 50 mg, 약 20 mg 내지 약 40 mg, 약 20 mg 내지 약 30 mg, 약 30 mg 내지 약 100 mg, 약 30 mg 내지 약 90 mg, 약 30 mg 내지 약 80 mg, 약 30 mg 내지 약 70 mg, 약 30 mg 내지 약 60 mg, 약 30 mg 내지 약 50 mg, 또는 약 30 mg 내지 약 40 mg.

특정 실시형태에서, 항-DLL3 작용제는 2주마다 1회 다음의 용량으로 투여된다: 약 3 mg 내지 약 100 mg, 약 10 mg 내지 약 200 mg, 약 10 mg 내지 약 180 mg, 약 10 mg 내지 약 150 mg, 약 10 mg 내지 약 120 mg, 약 30 mg 내지 약 200 mg, 약 30 mg 내지 약 180 mg, 약 30 mg 내지 약 150 mg, 약 30 mg 내지 약 120 mg, 약 50 mg 내지 약 200 mg, 약 50 mg 내지 약 180 mg, 약 50 mg 내지 약 150 mg, 약 50 mg 내지 약 120 mg, 약 70 mg 내지 약 200 mg, 약 70 mg 내지 약 180 mg, 약 70 mg 내지 약 150 mg, 약 70 mg 내지 약 120 mg, 약 90 mg 내지 약 200 mg, 약 90 mg 내지 약 180 mg, 약 90 mg 내지 약 150 mg, 약 90 mg 내지 약 120 mg, 약 100 mg 내지 약 180 mg, 약 100 mg 내지 약 150 mg, 또는 약 100 mg 내지 약 120 mg.

특정 실시형태에서, 항-DLL3 작용제는 2주마다 1회 약 3 mg, 10 mg, 30 mg, 또는 100 mg의 용량으로 투여된다.

특정 실시형태에서, 항-DLL3 작용제는 28일 주기의 제1일 및 제15일에 투여된다.

실시예 2에 기재된 바와 같이, FIH 연구의 시작 용량은 SHP-77 세포(연구 123564)에서 AMG 757 매개 CD69 상향 조절의 EC₅₀으로 확인된 최소 예상 생물학적 효과 수준(MABEL)을 기반으로 하였다. 0.003 mg의 시작 용량은 인간 PK 예측을 기반으로 선택되었으며 MABEL(0.61 ng/mL)과 동등한 최대 혈청 농도를 생성할 것으로 예상된다. 1상 임상 연구에서 AMG 757의 용량은 0.003 mg 이상이며, SCLC 환자에게 2주마다(Q2W) 1회 정맥 내(IV) 주입으로 투여된다. 이 요법은 전체 투여 간격 동안 표적 조직(예를 들어, 폐)에서 적절한 노출을 달성하는 동시에 AMG 757의 여러 치료 주기 후에 최고점 대 최저점 비율을 최소화할 것으로 믿어진다.

예측된 인간 PK 매개변수는 대표적인 작용 부위로 지정되고 혈청 노출의 약 1%를 달성하는 것으로 추정된 폐에서의 AMG 757 농도를 예측하는 데 사용되었다(Vugmeyster et al, 2010). 효능의 초기 징후는 SHP-77 세포에서 세포 사멸의 평균 EC₉₀의 최저 범위(1%의 폐 노출로 추정)에 기초하여 2주마다 10 mg에서 예측되었다. 예를 들어, 실시예 2 참조.

임상 연구에서 2주마다 1회 IV 주입으로 투여된 0.3 mg(코호트 5)에서 1건의 확인된 반응이 있었다. AMG 757의 이러한 관찰된 효능은 전임상 결과에 기초하여 효능이 있을 것으로 예측된 10 mg Q2W의 용량보다 현저히 낮기 때문에 놀랍다. 추가로 확인된 반응은 고용량 코호트에서 관찰되었다. AMG 757의 효과적인 용량은 2주마다 1회 투여되는 적어도 0.3 mg(예를 들어, 약 0.3 mg 내지 약 100 mg 또는 약 3 mg 내지 약 200 mg)일 수 있는 것으로 여겨진다.

항-DLL3 작용제는 비경구, 피하, 복강 내, 폐 내, 비강 내 및/또는 병변 내 투여를 포함하는 임의의 적합한 수단에 의해 투여될 수 있다. 비경구 투여는 근육 내, 정맥 내, 동맥 내, 복강 내 또는 피하 투여를 포함한다. 일부 실시형태에서, 항-DLL3 작용제는 2주마다 1회 정맥 내(IV) 주입, 예컨대 짧은 IV 주입(대략 60분)에 의해 투여된다.

3.1 단계 투여

작용 기전으로 인해 대상체는 AMG 757의 초기 주입 후 제1 용량 효과(예를 들어, 사이토카인 방출 증후군)의 위험이 증가할 수 있다. 최적의 최대 허용 용량(MTD)은 단계 투여 접근법(예를 들어, 제1일에 초기 용량, 제8일에 단계 용량 및 제15일 이후에 시작하는 후속 용량)이 필요할 수 있다고 여겨진다. 특정 양태에서, 2개의 MTD가 추정되거나 확립될 수 있는데, 하나는 초기 투여에 대한 것(MTD1, 준비 용량)이고 다른 하나는 후속 투여에 대한 것(MTD2)이다. 특정 양태에서, 초기 준비 용량에 대한 MTD(MTD1) 및 각 단계 용량(들) 및 적용 가능한 경우 후속 용량에 대한 MTD의 다중 MTD가 추정되거나 확립될 수 있다.

대상체가 제1 용량 효과(예를 들어, 사이토카인 방출 증후군(CRS))를 경험하는 경우 CRS 사례가 관찰되는 용량을 초과하지 않는 적절한 제1 용량(MTD1)을 결정하고 실행할 수 있다. 제2 용량 및 후속 용량도 결정하고 실행할 수 있다. 또한, 제2 용량, 제3 용량, 제4 용량 및 후속 용량은 단계 투여 일정의 단계 수에 따라 결정하고 실행할 수 있다. 특정 실시형태에서, 제2 용량 및 후속 용량은 동일하고, 제1 용량보다 높다. 특정 실시형태에서, 제2 용량은 제1 용량보다 높고, 제3 및 후속 용량은 동일하고, 제2 용량보다 높다. 특정 실시형태에서, 제2 용량은 제1 용량보다 높고, 제3 용량은 제2 용량보다 높으며, 제4 및 후속 용량은 동일하고 제3 용량보다 높다. 이러한 용량 및 투여 일정은 AMG 757의 전신 노출이 단계 투여 요법의 증가된 투여 빈도 및 약물 축적 가능성으로 인해 제1 용량 효과(예를 들어, CRS)가 나타난 용량과 관련된 노출을 초과하지 않도록 하기 위해 임상 데이터(예를 들어, 약동학, 안전성 데이터 등)의 모델링 및 시뮬레이션에 의해 유도될 수 있다.

28일 주기의 항-DLL3 작용제(예를 들어, AMG 757)의 예시적인 단계 투여 일정은 아래 표에 제시되어 있으며(주기 1만 해당), 항-DLL3 작용제는 그 후 2주마다 1회 투여된다.

예시적인 단일 및 다중 단계 투여 일정(주기 1만 해당)

항-DLL3 작용제(AMG 757)	제1일	제4일	제8일	제15일
1단계	준비 용량	N/A	단계 용량 (목표 용량과 동일)	목표 용량
2단계(옵션 1)	준비 용량	단계 용량	단계 용량 (목표 용량과 동일)	목표 용량
2단계(옵션 2)	준비 용량	N/A	단계 용량	단계 용량 (목표 용량과 동일)
3단계	준비 용량	단계 용량	단계 용량	단계 용량(목표 용량과 동일)

따라서, DLL3 양성 암을 치료하는 방법으로서, 이를 필요로 하는 대상체에게 항-DLL3 작용제를 투여하는 단계를 포함하고, 항-DLL3 작용제는 1단계 투여 일정에 따라 투여되는 것인 방법이 본원에 개시된다.

특정 실시형태에서, DLL3 양성 암을 치료하는 방법으로서, 이를 필요로 하는 대상체에게 항-DLL3 작용제를 투여하는 단계를 포함하고, 항-DLL3 작용제는 다음의 일정에 따라 투여되는 것인 방법이 본원에 개시된다: a) 제1일에 0.3 mg 내지 100 mg의 제1 용량(준비 용량), b) 제8일에 0.3 mg 내지 100 mg의 제2 용량(단계 용량), 및 c) 제15일에 시작하고 그 후 2주마다 1회, 0.3 mg 내지 100 mg의 하나 이상의 후속 용량(목표 용량), 여기서 제2 및 후속 용량은 동일하며, 제1 용량보다 높은 용량임.

특정 실시형태에서, DLL3 양성 암을 치료하는 방법으로서, 이를 필요로 하는 대상체에게 항-DLL3 작용제를 투여하는 단계를 포함하고, 항-DLL3 작용제는 다음의 일정에 따라 투여되는 것인 방법이 본원에 개시된다: a) 제1일에 0.5 mg 내지 10 mg의 제1 용량(준비 용량), b) 제8일에 3 mg 내지 200 mg의 제2 용량(단계 용량) 및 c) 제15일에 시작하고 그 후 2주마다 1회, 3 mg 내지 200 mg의 하나 이상의 후속 용량(목표 용량), 여기서 제2 및 후속 용량은 동일하며 제1 용량보다 높은 용량임.

1단계 투여 일정의 특정 실시형태에서, 제2 및 후속 용량은 동일하고, 제1 용량보다 적어도 1.5배, 적어도 2배, 적어도 3배, 적어도 4배, 적어도 5배, 적어도 6배, 적어도 7배, 적어도 8배, 적어도 9배, 적어도 10배, 적어도 20배, 적어도 25배, 적어도 30배, 적어도 35배, 적어도 40배, 적어도 45배, 적어도 50배, 적어도 55배, 적어도 60배, 적어도 65배, 적어도 70배, 적어도 75배, 적어도 80배, 적어도 85배, 적어도 90배, 적어도 95배, 적어도 100배, 또는 적어도 120배, 적어도 150배, 또는 적어도 200배 높다.

1단계 투여 일정의 특정 실시형태에서, 제2 및 후속 용량은 동일하고, 제1 용량보다 적어도 1.5배, 적어도 2배, 적어도 3배, 적어도 4배, 적어도 5배, 적어도 6배, 적어도 7배, 적어도 8배, 적어도 9배, 적어도 10배, 적어도 20배, 적어도 25배, 적어도 30배, 적어도 35배, 적어도 40배, 적어도 45배, 적어도 50배, 적어도 55배, 적어도 60배, 적어도 65배, 적어도 70배, 적어도 75배, 적어도 80배, 적어도 85배, 적어도 90배, 적어도 95배, 또는 적어도 100배 높고, 항-DLL3 작용제의 제1, 제2 및 후속 용량 각각은 다음 중 임의의 하나일 수 있다: 약 0.3 mg 내지 약 100 mg, 약 0.3 mg 내지 약 90 mg, 약 0.3 mg 내지 약 80 mg, 약 0.3 mg 내지 약 70 mg, 약 0.3 mg 내지 약 60 mg, 약 0.3 mg 내지 약 50 mg, 약 0.3 mg 내지 약 40 mg, 약 0.3 mg 내지 약 30 mg, 약 0.3 mg 내지 약 20 mg, 약 0.3 mg 내지 약 10 mg, 약 0.3 mg 내지 약 3 mg, 약 0.3 mg 내지 약 1 mg, 약 1 mg 내지 약 100 mg, 약 1 mg 내지 약 90 mg, 약 1 mg 내지 약 80 mg, 약 1 mg 내지 약 70 mg, 약 1 mg 내지 약 60 mg, 약 1 mg 내지 약 50 mg, 약 1 mg 내지 약 40 mg, 약 1 mg 내지 약 30 mg, 약 1 mg 내지 약 20 mg, 약 1 mg 내지 약 10 mg, 약 1 mg 내지 약 3 mg, 약 3 mg 내지 약 100 mg, 약 3 mg 내지 약 90 mg, 약 3 mg 내지 약 80 mg, 약 3 mg 내지 약 70 mg, 약 3 mg 내지 약 60 mg, 약 3 mg 내지 약 50 mg, 약 3 mg 내지 약 40 mg, 약 3 mg 내지 약 30 mg, 약 3 mg 내지 약 20 mg, 약 3 mg 내지 약 10 mg, 약 3 mg 내지 약 12 mg, 약 3 mg 내지 약 15 mg, 약 10 mg 내지 약 100 mg, 약 10 mg 내지 약 90 mg, 약 10 mg 내지 약 80 mg, 약 10 mg 내지 약 70 mg, 약 10 mg 내지 약 60 mg, 약 10 mg 내지 약 50 mg, 약 10 mg 내지 약 40 mg, 약 10 mg 내지 약 30 mg, 약 10 mg 내지 약 20 mg, 약 10 mg 내지 약 15 mg, 약 20 mg 내지 약 100 mg, 약 20 mg 내지 약 90 mg, 약 20 mg 내지 약 80 mg, 약 20 mg 내지 약 70 mg, 약 20 mg 내지 약 60 mg, 약 20 mg 내지 약 50 mg, 약 20 mg 내지 약 40 mg, 약 20 mg 내지 약 30 mg, 약 30 mg 내지 약 100 mg, 약 30 mg 내지 약 90 mg, 약 30 mg 내지 약 80 mg, 약 30 mg 내지 약 70 mg, 약 30 mg 내지 약 60 mg, 약 30 mg 내지 약 50 mg, 및 약 30 mg 내지 약 40 mg.

1단계 투여 일정의 특정 실시형태에서, 항-DLL3 작용제의 제1 용량은 약 0.5 mg 내지 약 10 mg, 약 0.5 mg 내지 약 8 mg, 약 0.5 mg 내지 약 6 mg, 약 0.5 mg 내지 약 4 mg, 약 0.5 mg 내지 약 2 mg, 또는 약 1 mg이고; 제2 및 후속 용량은 동일하고, 제1 용량보다 적어도 3배, 적어도 5배, 적어도 10배, 적어도 20배, 적어도 30배, 적어도 40배, 적어도 50배, 적어도 60배, 적어도 70배, 적어도 80배, 적어도 90배, 적어도 100배, 적어도 120배, 적어도 150배, 또는 적어도 200배 높고, 제2 및 후속 용량 각각은 다음 중 임의의 하나일 수 있다: 약 3 mg 내지 약 200 mg, 약 3 mg 내지 약 100 mg, 약 10 mg 내지 약 180 mg, 약 10 mg 내지 약 150 mg, 약 30 mg 내지 약 200 mg, 약 30 mg 내지 약 180 mg, 약 30 mg 내지 약 150 mg, 약 30 mg 내지 약 120 mg, 약 50 mg 내지 약 200 mg, 약 50 mg 내지 약 180 mg, 약 50 mg 내지 약 150 mg, 약 50 mg 내지 약 120 mg, 약 70 mg 내지 약 200, 약 70 mg 내지 약 180, 약 70 mg 내지 약 150, 약 70 mg 내지 약 120 mg, 약 90 mg 내지 약 200, 약 90 mg 내지 약 180, 약 90 mg 내지 약 120 mg, 또는 약 100 mg.

1단계 투여 일정의 특정 실시형태에서, 항-DLL3 작용제의 제1 용량은 1 mg이고, 제2 및 후속 용량은 동일하고, 3 mg, 10 mg, 30 mg, 또는 100 mg이다.

특정 실시형태에서, DLL3 양성 암을 치료하는 방법으로서, 이를 필요로 하는 대상체에게 항-DLL3 작용제를 투여하는 단계를 포함하고, 항-DLL3 작용제는 2단계 투여 일정에 따라 투여되는 것인 방법이 본원에 개시된다.

특정 실시형태에서, DLL3 양성 암을 치료하는 방법으로서, 이를 필요로 하는 대상체에게 항-DLL3 작용제를 투여하는 단계를 포함하고, 상기 항-DLL3 작용제는 다음의 2가지 일정 중 하나에 따라 투여되는 것인 방법이 본원에 개시된다:

일정 I: a) 제1일에 0.5 mg 내지 10 mg의 제1 용량(준비 용량), b) 제4일에 3 mg 내지 100 mg의 제2 용량(단계 용량), c) 제8일에 3 mg 내지 200 mg의 제3 용량(단계 용량), 및 d) 제15일에 시작하고 그 후 2주마다 1회, 3 mg 내지 200 mg의 하나 이상의 후속 용량(목표 용량), 여기서 제2 용량은 제1 용량보다 높고, 제3 및 후속 용량은 동일하며 제2 용량보다 높은 용량임; 또는

일정 II: a) 제1일에 0.5 mg 내지 10 mg의 제1 용량(준비 용량), b) 제8일에 3 mg 내지 100 mg의 제2 용량(단계 용량), c) 제15일에 3 mg 내지 200 mg의 제3 용량(단계 용량) 및 c) 제29일에 시작하고 그 후 2주마다 1회, 3 mg 내지 200 mg의 하나 이상의 후속 용량(목표 용량), 여기서 제2 용량은 제1 용량보다 높고, 제3 용량 및 후속 용량은 동일하며 제2 용량보다 높은 용량임.

2단계 투여 일정의 특정 실시형태에서, 제2 용량은 제1 용량보다 적어도 20배, 적어도 30배, 적어도 40배, 적어도 50배, 적어도 60배, 적어도 70배, 적어도 80배, 또는 적어도 90배 높고, 제3 및 후속 용량은 동일하고 제2 용량보다 적어도 2배, 적어도 3배, 적어도 4배, 적어도 5배, 적어도 6배, 적어도 7배, 적어도 8배, 적어도 9배, 또는 적어도 10배 높다.

2단계 투여 일정의 특정 실시형태에서, 제2 용량은 제1 용량보다 약 20배 내지 약 100배, 약 20배 내지 약 90배, 약 20배 내지 약 70배, 약 20배 내지 약 50배, 약 25배 내지 약 50배, 약 30배 내지 약 100배, 약 30배 내지 약 90배, 약 30배 내지 약 70배, 또는 약 30배 내지 약 50배 높고, 제3 및 후속 용량은 동일하고 제2 용량보다 약 2배 내지 약 10배, 약 2배 내지 약 8배, 약 2배 내지 약 6배, 약 2배 내지 약 4배, 약 4배 내지 약 8배, 또는 약 4배 내지 약 6배 높다.

2단계 투여 일정의 특정 실시형태에서, 제1 용량은 약 0.5 mg 내지 약 10 mg, 약 0.5 mg 내지 약 8 mg, 약 0.5 mg 내지 약 6 mg, 약 0.5 mg 내지 약 4 mg, 약 0.5 mg 내지 약 2 mg, 또는 1 mg이고, 제2 용량은 약 3 mg 내지 약 10 mg, 약 10 mg 내지 약 100 mg, 약 10 mg 내지 약 80 mg, 약 10 mg 내지 약 60 mg, 약 20 mg 내지 약 80 mg, 약 20 mg 내지 약 60 mg, 약 25 mg 내지 약 50 mg, 약 30 mg 내지 약 80 mg, 약 30 mg 내지 약 60 mg, 약 30 mg 내지 약 40 mg, 약 40 mg 내지 약 80 mg, 또는 약 40 mg 내지 약 60 mg이고, 제3 및 후속 용량은 동일하고, 약 3 mg 내지 약 100 mg, 약 10 mg 내지 약 200 mg, 약 10 mg 내지 약 180 mg, 약 10 mg 내지 약 150 mg, 약 10 mg 내지 약 120 mg, 약 30 mg 내지 약 200 mg, 약 30 mg 내지 약 180 mg, 약 30 mg 내지 약 150 mg, 약 30 mg 내지 약 120 mg, 약 50 mg 내지 약 200 mg, 약 50 mg 내지 약 180 mg, 약 50 mg 내지 약 150 mg, 약 70 mg 내지 약 200 mg, 약 70 mg 내지 약 180 mg, 약 70 mg 내지 약 150 mg, 약 70 mg 내지 약 120 mg, 약 90 mg 내지 약 200 mg, 약 90 mg 내지 약 180 mg, 약 90 mg 내지 약 150 mg, 약 90 mg 내지 약 120 mg, 약 100 mg 내지 약 180 mg, 약 100 mg 내지 약 150 mg, 약 100 mg 내지 약 120 mg, 또는 약 100 mg이다.

2단계 투여 일정의 특정 실시형태에서, 제1 용량은 1 mg이고, 제2 용량은 약 25 mg 내지 약 50 mg이고, 제3 및 후속 용량은 동일하고, 100 mg이다. 2단계 투여 일정의 특정 실시형태에서, 제1 용량은 1 mg이고, 제2 용량은 약 45 mg 내지 약 70 mg이고, 제3 및 후속 용량은 동일하고, 100 mg이다.

2단계 투여 일정의 특정 실시형태에서, 제1 용량은 제1일에 1 mg이고, 제2 용량은 제4일에 25 mg 또는 50 mg이고, 제3 용량은 제8일에 100 mg이고, 하나 이상의 후속 용량은 제15일에 시작하고 그 후 2주마다 1회 100 mg이다.

일정 I의 특정 실시형태에서, 목표 용량은 제4일에 투여된다. 이러한 실시형태에서, 항-DLL3 작용제는 다음의 일정에 따라 투여된다: a) 제1일에 0.5 mg 내지 10 mg의 제1 용량(준비 용량), b) 제4일에 3 mg 내지 200 mg의 제2 용량(단계 용량, 목표 용량과 동일), c) 제8일에 3 mg 내지 200 mg의 제3 용량(목표 용량), 및 d) 제15일에 시작하고 그 후 2주마다 1회, 3 mg 내지 200 mg의 하나 이상의 후속 용량(목표 용량), 여기서 제2 용량은 제1 용량보다 높고, 제3 및 후속 용량은 동일하며 제2 용량과 동일한 용량임. 특정 실시형태에서, 제1 용량은 0.5 mg 내지 8 mg, 0.5 mg 내지 6 mg, 0.5 mg 내지 4 mg, 0.5 mg 내지 2 mg, 또는 1 mg이고, 제2, 제3 용량 및 후속 용량은 각각 3 mg 내지 100 mg, 10 mg 내지 150 mg, 30 mg 내지 200 mg, 30 mg 내지 100 mg, 50 mg 내지 150 mg, 70 mg 내지 120 mg, 90 mg 내지 120 mg, 100 mg 내지 200 mg, 또는 100 mg이다. 이러한 투여 일정(목표 용량이 제1 주기의 제4일, 제8일 및 제15일에 투여됨)은 항-DLL3 작용제의 원하는 혈청 수준에 신속하게 도달하는 데 도움이 된다는 점에서 유익하다고 여겨진다.

특정 실시형태에서, DLL3 양성 암을 치료하는 방법으로서, 이를 필요로 하는 대상체에게 항-DLL3 작용제를 투여하는 단계를 포함하고, 항-DLL3 작용제는 3단계 투여 일정에 따라 투여되는 것인 방법이 본원에 개시된다.

특정 실시형태에서, DLL3 양성 암을 치료하는 방법으로서, 이를 필요로 하는 대상체에게 항-DLL3 작용제를 투여하는 단계를 포함하고, 상기 항-DLL3 작용제는 다음의 일정에 따라 투여되는 것인 방법이 본원에 개시된다: a) 제1일에 0.5 mg 내지 10 mg의 제1 용량(준비 용량), b) 제4일에 3 mg 내지 100 mg의 제2 용량(단계 용량), c) 제8일에 3 mg 내지 100 mg의 제3 용량(단계 용량), d) 제15일에 3 mg 내지 200 mg의 제4 용량(단계 용량), 및 e) 제29일에 시작하고 그 후 2주마다 1회, 3 mg 내지 200 mg 의 하나 이상의 후속 용량(목표 용량), 여기서 제2 용량은 제1 용량보다 높고, 제3 용량은 제2 용량보다 높고, 제4 용량 및 후속 용량은 동일하며 제3 용량보다 높은 용량임.

3단계 투여 일정의 특정 실시형태에서, 제2 용량은 제1 용량보다 적어도 5배, 적어도 10배, 적어도 20배, 적어도 30배, 적어도 40배, 또는 적어도 50배 높고, 제3 용량은 제2 용량보다 적어도 0.5배, 적어도 1배, 적어도 2배, 적어도 3배, 또는 적어도 5배 높고, 제4 및 후속 용량은 동일하고 제3 용량보다 적어도 1배, 적어도 2배, 적어도 3배, 또는 적어도 5배 높다.

3단계 투여 일정의 특정 실시형태에서, 제2 용량은 제1 용량보다 약 5배 내지 약 70배, 약 20배 내지 약 70배, 약 20배 내지 약 60배, 약 25배 내지 약 50배 높고, 제3 용량은 제2 용량보다 약 0.5배 내지 약 4배, 약 0.5배 내지 약 2.5배, 약 1배 내지 약 4배, 또는 약 1배 내지 약 2배 높고, 제4 및 후속 용량은 동일하고 제3 용량보다 약 1배 내지 약 4배 또는 약 2배 내지 약 3배 높다.

3단계 투여 일정의 특정 실시형태에서, 제1 용량은 약 0.5 mg 내지 약 10 mg, 약 0.5 mg 내지 약 8 mg, 약 0.5 mg 내지 약 6 mg, 약 0.5 mg 내지 약 4 mg, 약 0.5 mg 내지 약 2 mg, 또는 1 mg이고, 제2 용량은 약 3 mg 내지 약 10 mg, 약 10 mg 내지 약 100 mg, 약 10 mg 내지 약 80 mg, 약 10 mg 내지 약 60 mg, 약 10 mg 내지 약 40 mg, 약 20 mg 내지 약 80 mg, 약 20 mg 내지 약 60 mg, 약 20 mg 내지 약 40 mg, 또는 약 25 mg이고, 제3 용량은 약 3 mg 내지 약 10 mg, 약 10 mg 내지 약 100 mg, 약 10 mg 내지 약 80 mg, 10 mg 내지 약 60 mg, 약 20 mg 내지 약 100 mg, 약 20 mg 내지 약 80 mg, 약 20 mg 내지 약 60 mg, 약 30 mg 내지 약 100 mg, 약 30 mg 내지 약 80 mg, 약 30 mg 내지 약 60 mg, 약 40 mg 내지 약 100 mg, 약 40 mg 내지 약 80 mg, 약 40 mg 내지 약 60 mg, 또는 약 50 mg이고, 제4 및 후속 용량은 동일하고 약 3 mg 내지 약 10 mg, 약 10 mg 내지 약 200 mg, 약 10 mg 내지 약 150 mg, 약 30 mg 내지 200 mg, 약 30 mg 내지 약 150 mg, 약 30 mg 내지 약 100 mg, 약 50 mg 내지 약 200 mg, 약 50 mg 내지 약 180 mg, 약 50 mg 내지 약 150 mg, 약 50 mg 내지 약 120 mg, 약 70 mg 내지 약 200 mg, 약 70 mg 내지 약 180 mg, 약 70 mg 내지 약 120 mg, 약 90 mg 내지 약 200 mg, 약 90 mg 내지 약 180 mg, 약 90 mg 내지 약 150 mg, 약 90 mg 내지 약 120 mg, 또는 약 100 mg이다.

3단계 투여 일정의 특정 실시형태에서, 제1 용량은 1 mg이고, 제2 용량은 25 mg이고, 제3 용량은 50 mg이고, 제4 및 후속 용량은 동일하고 100 mg이다.

3단계 투여 일정의 특정 실시형태에서, 목표 용량은 제8일에 투여된다. 이러한 실시형태에서, 항-DLL3 작용제는 다음의 일정에 따라 투여된다: a) 제1일에 0.5 mg 내지 10 mg의 제1 용량(준비 용량), b) 제4일에 3 mg 내지 100 mg의 제2 용량(단계 용량), c) 제8일에 3 mg 내지 200 mg의 제3 용량(단계 용량, 목표 용량과 동일), d) 제15일에 3 mg 내지 200 mg의 제4 용량(목표 용량), 및 e) 제29일에 시작하고 그 후 2주마다 1회, 3 mg 내지 200 mg 의 하나 이상의 후속 용량(목표 용량), 여기서 제2 용량은 제1 용량보다 높고, 제3 용량은 제2 용량보다 높고, 제4 용량 및 후속 용량은 동일하며 제3 용량과 동일한 용량임. 특정 실시형태에서, 제1 용량은 0.5 mg 내지 8 mg, 0.5 mg 내지 6 mg, 0.5 mg 내지 4 mg, 0.5 mg 내지 2 mg, 또는 1 mg이고, 제2 용량은 3 mg 내지 10 mg, 10 mg 내지 80 mg, 10 mg 내지 60 mg, 20 mg 내지 80 mg, 20 mg 내지 60 mg, 20 mg 내지 40 mg, 25 mg, 또는 50 mg이고, 제3, 제4 및 후속 용량은 각각 3 mg 내지 100 mg, 10 mg 내지 150 mg, 30 mg 내지 200 mg, 30 mg 내지 100 mg, 50 mg 내지 150 mg, 70 mg 내지 120 mg, 90 mg 내지 120 mg, 100 mg 내지 200 mg, 또는 100 mg이다. 이러한 투여 일정은 항-DLL3 작용제의 원하는 혈청 수준에 신속하게 도달하는 데 도움이 된다는 점에서 유익하다고 여겨진다.

항-DLL3 작용제는 비경구, 피하, 복강 내, 폐 내, 비강 내 및/또는 병변 내 투여를 포함하는 임의의 적합한 수단에 의해 투여될 수 있다. 비경구 투여는 근육 내, 정맥 내, 동맥 내, 복강 내 또는 피하 투여를 포함한다. 일부 실시형태에서, 항-DLL3 작용제는 정맥 내(IV) 주입에 의해 투여된다.

특정 실시형태에서, DLL3 양성 암은 소세포 폐암(SCLC)이다. 특정 실시형태에서, SCLC는 재발성/불응성 SCLC(RR SCLC) 또는 확장 질환 SCLC(ED SCLC)이다. 특정 실시형태에서, 대상체는 SCLC, 예를 들어, RR SCLC 또는 ED SCLC를 앓는 인간이다.

3.2 공동 투여

일부 실시형태에서, 본 발명의 조성물 및 방법은 하나 이상의 추가 치료제와 조합한 항-DLL3 작용제의 용도를 제공한다. 특정 실시형태에서, 하나 이상의 추가 치료제는 항-DLL3 작용제(예를 들어, AMG 757)의 CRS를 완화하는 작용제이다. 특정 실시형태에서, 하나 이상의 추가 치료제는 항염증제, 유체(예를 들어, 식염수), 항-IL6 항체(예를 들어, 토실리주맙) 또는 항-TNF 작용제(예를 들어, 에타너셉트)를 포함한다. 특정 실시형태에서, 본원에 개시된 방법은 항염증제, 유체(예를 들어, 식염수), 항-IL6 항체(예를 들어, 토실리주맙) 및 항-TNF 작용제(예를 들어, 에타너셉트) 중 하나 이상과 조합한 항-DLL3 작용제(예를 들어, AMG 757)의 투여를 포함한다.

일부 실시형태에서, 하나 이상의 추가 치료제는 (예를 들어, CRS를 예방적으로 처치하기 위한) 항염증제일 수 있다. 항염증제는 항-DLL3 작용제의 투여 전, 투여와 동시 또는 투여 후에 투여될 수 있다. 예시적인 항염증제는 아세트아미노펜, 나프록센 나트륨, 이부프로펜, 트라마돌, 아스피린, 셀레콕십, 발데콕십, 인도메타신, 또는 기타 비스테로이드성 항염증제(NSAID)를 포함한다. 기타 항염증제는 예를 들어, 베클로메타손, 하이드록시코르티손, 베타메타손, 메틸프레드니솔론, 부데소니드, 프레드니솔론, 코르티손, 프레드니손, 덱사메타손 및 트리암시놀론, 또는 기타 글루코코르티코이드를 포함한다. 특정 실시형태에서, 항염증제는 코르티코스테로이드이다. 특정 실시형태에서, 코르티코스테로이드는 덱사메타손이다. 특정 실시형태에서, 항염증제는 아세트아미노펜이다. 특정 실시형태에서, 항염증제(예를 들어, 덱사메타손 또는 아세트아미노펜과 같은 코르티코스테로이드)는 항-DLL3 작용제의 투여 전에 투여된다. 특정 실시형태에서, 덱사메타손은 예를 들어 AMG 757의 주기 1 용량 전에, 정맥 내 투여된다. 특정 실시형태에서, 덱사메타손은 경구 투여된다.

일부 실시형태에서, CRS를 완화하는 하나 이상의 추가 치료제는 유체(예를 들어, 식염수), 항-IL6 항체(예를 들어, 토실리주맙) 또는 항-TNF 작용제(예를 들어, 에타너셉트)이다. 이들 작용제 각각은 항-DLL3 작용제의 투여 전, 투여와 동시 또는 투여 후에 투여될 수 있다. 특정 실시형태에서, 식염수는 항-DLL3 작용제의 투여 후에 (예를 들어, IV 투여에 의해) 투여된다. 특정 실시형태에서, 항-IL6 항체(예를 들어, 토실리주맙) 또는 항-TNF 작용제(예를 들어, 에타너셉트)는 항-DLL3 작용제의 투여 전에 투여된다.

스테로이드(예컨대, 덱사메타손)가 사용되는 경우, 더 높은 용량의 항-DLL3 작용제가 필요할 수 있다. 따라서, 일부 양태에서, 본 발명은 SCLC 또는 DLL3 양성 암을 치료하는 방법을 제공하며, 방법은 이를 필요로 하는 대상체에게 스테로이드(예컨대, 코르티코스테로이드, 예를 들어, 덱사메타손) 및 항-DLL3 작용제를 투여하는 단계를 포함하고, 항-DLL3 작용제는 2주마다 1회 약 0.3 mg 내지 100 mg의 용량(예컨대, 2주마다 1회 약 0.3 mg 내지 약 90 mg, 약 0.3 mg 내지 약 80 mg, 약 0.3 mg 내지 약 70 mg, 약 0.3 mg 내지 약 60 mg, 약 0.3 mg 내지 약 50 mg, 약 0.3 mg 내지 약 40 mg, 약 0.3 mg 내지 약 30 mg, 약 0.3 mg 내지 약 20 mg, 약 0.3 mg 내지 약 10 mg, 약 0.3 mg 내지 약 3 mg, 약 0.3 mg 내지 약 1 mg, 약 1 mg 내지 약 30 mg, 약 1 mg 내지 약 20 mg, 약 3 mg 내지 약 15 mg, 또는 약 3 mg 내지 약 12 mg)으로 투여된다.

일부 양태에서, 본 발명은 SCLC 또는 DLL3 양성 암을 치료하는 방법을 제공하며, 방법은 이를 필요로 하는 대상체에게 스테로이드(예컨대, 코르티코스테로이드, 예를 들어, 덱사메타손) 및 항-DLL3 작용제를 투여하는 단계를 포함하고, 항-DLL3 작용제는 2주마다 1회 약 0.3 mg 내지 100 mg 또는 약 3 mg 내지 약 200 mg의 용량(예컨대, 2주마다 1회 약 3 mg 내지 약 100 mg, 약 10 mg 내지 약 180 mg, 약 10 mg 내지 약 150 mg, 약 10 mg 내지 약 120 mg, 약 30 mg 내지 약 200 mg, 약 30 mg 내지 약 180 mg, 약 30 mg 내지 약 150 mg, 약 30 mg 내지 약 120 mg, 약 50 mg 내지 약 200 mg, 약 50 mg 내지 약 180 mg, 약 50 mg 내지 약 150 mg, 약 50 mg 내지 약 120 mg, 약 70 mg 내지 약 180 mg, 약 70 mg 내지 약 150 mg, 약 70 mg 내지 약 120 mg, 약 90 mg 내지 약 180 mg, 약 90 mg 내지 약 150 mg, 약 90 mg 내지 약 120 mg, 또는 약 3 mg, 10 mg, 30 mg, 또는 100 mg)으로 투여된다. 특정 실시형태에서, 항-DLL3 작용제는 28일 주기로 투여된다. 특정 실시형태에서, 스테로이드는 항-DLL3 작용제가 투여되는 제1 주기에 투여된다.

일부 양태에서, 본 발명은 SCLC 또는 DLL3 양성 암을 치료하는 방법을 제공하며, 방법은 이를 필요로 하는 대상체에게 스테로이드(예컨대, 코르티코스테로이드, 예를 들어, 덱사메타손) 및 항-DLL3 작용제를 투여하는 단계를 포함하고, 항-DLL3 작용제는 다음의 일정에 따라 투여된다: (a) 제1일에 0.3 mg 내지 100 mg의 제1 용량(예컨대, 제1일에 약 0.3 mg 내지 약 90 mg, 약 0.3 mg 내지 약 80 mg, 약 0.3 mg 내지 약 70 mg, 약 0.3 mg 내지 약 60 mg, 약 0.3 mg 내지 약 50 mg, 약 0.3 mg 내지 약 40 mg, 약 0.3 mg 내지 약 30 mg, 약 0.3 mg 내지 약 20 mg, 약 0.3 mg 내지 약 10 mg, 약 0.3 mg 내지 약 3 mg, 약 0.3 mg 내지 약 1 mg, 약 1 mg 내지 약 30 mg, 약 1 mg 내지 약 20 mg, 약 3 mg 내지 약 15 mg, 또는 약 3 mg 내지 약 12 mg), (b) 제8일에 0.3 mg 내지 100 mg의 제2 용량(예컨대, 제8일에 약 0.3 mg 내지 약 90 mg, 약 0.3 mg 내지 약 80 mg, 약 0.3 mg 내지 약 70 mg, 약 0.3 mg 내지 약 60 mg, 약 0.3 mg 내지 약 50 mg, 약 0.3 mg 내지 약 40 mg, 약 0.3 mg 내지 약 30 mg, 약 0.3 mg 내지 약 20 mg, 약 0.3 mg 내지 약 10 mg, 약 0.3 mg 내지 약 3 mg, 약 0.3 mg 내지 약 1 mg, 약 1 mg 내지 약 30 mg, 약 1 mg 내지 약 20 mg, 약 3 mg 내지 약 15 mg, 또는 약 3 mg 내지 약 12 mg) 및 (c) 제15일에 시작하여 그 후 2주마다 1회 0.3 mg 내지 100 mg의 하나 이상의 후속 용량(예컨대, 약 0.3 mg 내지 약 90 mg, 약 0.3 mg 내지 약 80 mg, 약 0.3 mg 내지 약 70 mg, 약 0.3 mg 내지 약 60 mg, 약 0.3 mg 내지 약 50 mg, 약 0.3 mg 내지 약 40 mg, 약 0.3 mg 내지 약 30 mg, 약 0.3 mg 내지 약 20 mg, 약 0.3 mg 내지 약 10 mg, 약 0.3 mg 내지 약 3 mg, 약 0.3 mg 내지 약 1 mg, or 약 1 mg 내지 약 30 mg, 약 1 mg 내지 약 20 mg, 약 3 mg 내지 약 15 mg, 또는 약 3 mg 내지 약 12 mg), 여기서 제2 및 하나 이상의 후속 용량은 동일하고, 제1 용량보다 높은 용량임. 특정 실시형태에서, 제2 및 하나 이상의 후속 용량은 제1 용량보다 적어도 1.5배, 적어도 2배, 적어도 3배, 적어도 4배, 적어도 5배, 적어도 6배, 적어도 7배, 적어도 8배, 적어도 9배, 적어도 10배, 적어도 20배, 적어도 25배, 적어도 30배, 적어도 35배, 적어도 40배, 적어도 45배, 적어도 50배, 적어도 55배, 적어도 60배, 적어도 65배, 적어도 70배, 적어도 75배, 적어도 80배, 적어도 85배, 적어도 90배, 적어도 95배, 또는 적어도 100배 높다.

특정 실시형태에서, 항-DLL3 작용제(예를 들어, AMG 757)는 DLL3 양성 암(예를 들어, SCLC)을 앓는 대상체에게 28일의 주기로 투여되고, 여기서 항-DLL3 작용제는 제1 주기에서 항염증제, 유체(예를 들어, 식염수), 항-IL6 항체(예를 들어, 토실리주맙), 항-TNF 작용제(예를 들어, 에타너셉트), 또는 이들의 조합과 함께 투여된다. 특정 실시형태에서, 코르티코스테로이드(예를 들어, 덱사메타손)는 제1 주기에서 항-DLL3 작용제 및 항염증제, 유체(예를 들어, 식염수), 항-IL6 항체(예를 들어, 토실리주맙), 항-TNF 작용제(예를 들어, 에타너셉트), 또는 이들의 조합과 함께 추가로 투여된다. 특정 실시형태에서, 코르티코스테로이드(예를 들어, 덱사메타손)는 AMG 757 투여의 주기 1에서 IV 주입에 의해 투여된다.

특정 실시형태에서, 식염수와 같은 유체는 제1 주기에서 항-DLL3 작용제의 투여 후 IV 주입에 의해 투여된다. 특정 실시형태에서, 1리터의 식염수가 제1 주기에서 항-DLL3 작용제의 투여 후 IV 주입에 의해 투여된다. 특정 실시형태에서, 1리터의 식염수가 제1 주기에서 항-DLL3 작용제의 준비 용량 및 단계 용량(들) 후에 IV 주입에 의해 투여된다. 일부 실시형태에서, 1리터의 식염수가 항-DLL3 작용제의 투여 후 약 4~5시간에 걸쳐 IV 주입에 의해 투여된다.

특정 실시형태에서, 항염증제는 제1 주기에서 항-DLL3 작용제의 투여 전에 투여된다. 특정 실시형태에서, 항염증제는 코르티코스테로이드(예를 들어, 덱사메타손)이고, 제1 주기에서 항-DLL3 작용제의 투여 약 6 내지 약 16시간 전에 투여된다. 특정 실시형태에서, 약 8 mg의 덱사메타손이 제1 주기에서 항-DLL3 작용제의 투여 약 6 내지 약 16시간 전에 투여된다. 특정 실시형태에서, 약 8 mg의 덱사메타손이 제1 주기에서 항-DLL3 작용제의 준비 용량 및 단계 용량(들) 약 6 내지 약 16시간 전에 투여된다. 일부 실시형태에서, 덱사메타손은 경구 투여되고, 다른 실시형태에서, 덱사메타손은 정맥 내 투여된다.

특정 실시형태에서, 항염증제는 아세트아미노펜이고, 제1 주기에서 항-DLL3 작용제의 투여 약 1시간 전에 투여된다. 특정 실시형태에서, 약 650 mg의 아세트아미노펜이 제1 주기에서 항-DLL3 작용제의 투여 약 1시간 전에 투여된다. 특정 실시형태에서, 약 650 mg의 아세트아미노펜이 제1 주기에서 항-DLL3 작용제의 준비 용량 및 단계 용량(들) 약 1시간 전에 투여된다. 일부 실시형태에서, 아세트아미노펜은 경구 투여된다.

특정 실시형태에서, 항-IL6 항체는 토실리주맙이고, 제1 주기에서 항-DLL3 작용제의 투여 전에 투여된다. 특정 실시형태에서, 약 8 mg/kg의 토실리주맙이 제1 주기에서 항-DLL3 작용제의 투여 약 1시간 전에 IV 주입에 의해 대상체에게 투여된다. 특정 실시형태에서, 약 8 mg/kg의 토실리주맙이 제1 주기에서 항-DLL3 작용제의 준비 용량 및 단계 용량(들) 약 1시간 전에 IV 주입에 의해 대상체에게 투여된다.

특정 실시형태에서, 항-TNF 작용제는 에타너셉트(예를 들어, Enbrel^®)이고, 제1 주기에서 항-DLL3 작용제의 투여 전에 투여된다. 특정 실시형태에서, 에타너셉트는 제1 주기에서 항-DLL3 작용제의 투여 약 36시간 내지 약 60시간 전에 투여된다. 특정 실시형태에서, 에타너셉트는 제1 주기에서 항-DLL3 작용제의 준비 용량 및 단계 용량(들) 약 36시간 내지 약 60시간 전에 투여된다. 특정 실시형태에서, 에타너셉트는 제1 주기에서 항-DLL3 작용제의 투여 2일 전에 투여된다. 특정 실시형태에서, 약 50 mg의 에타너셉트가 제1 주기에서 항-DLL3 작용제의 투여 2일 전에 피하 투여된다. 특정 실시형태에서, 약 50 mg의 에타너셉트가 제1 주기에서, 2단계 또는 3단계 투여 일정의 제4일의 단계 용량을 제외하고, 항-DLL3 작용제의 준비 용량 및 단계 용량(들) 2일 전에 피하 투여된다.

항염증제(예를 들어, 덱사메타손 또는 아세트아미노펜), 식염수, 항-IL6 항체(예를 들어, 토실리주맙) 또는 항-TNF 작용제(예를 들어, 에타너셉트)를 이용한 항-DLL3 작용제(예를 들어, AMG757)에 대한 예시적인 CRS 완화 전략이 아래 표에 제시되어 있다. 특정 실시형태에서, 코르티코스테로이드(예를 들어, 덱사메타손)는 아래에 열거된 CRS 완화 전략에 추가하여 AMG 757 투여(예를 들어, AMG 757의 주기 1 용량 전에 투여됨)의 주기 1에서 (예를 들어, IV 주입에 의해) 추가로 투여된다.

예시적인 CRS 완화 전략(1단계 투여, 주기 1만 해당)

	제-2일 (제1일의 2일 전)	제1일	제6일	제8일	제15일
항-DLL3 작용제(AMG 757) 1단계 투여		준비 용량		단계 용량 (목표 용량과 동일)	목표 용량
IV 수화를 이용한 예방	N/A	AMG 757 직후 4~5시간에 걸쳐 1 L의 식염수	N/A	AMG 757 직후 4~5시간에 걸쳐 1 L의 식염수	N/A
경구 덱사메타손과 함께 추가 코르티코스테로이드	N/A	AMG 757 6 내지 16시간 전	N/A	AMG 757 6 내지 16시간 전	N/A
토실리주맙	N/A	AMG 757 1시간 전	N/A	AMG 757 1시간 전	N/A
에타너셉트*	제-2일	N/A	단계 용량 2일 전	N/A	N/A
아세트아미노펜	N/A	AMG 757 1시간 전	N/A	AMG 757 1시간 전	N/A

^*: 에타너셉트는 위의 표에서 예정되어 있는 용량으로부터 ± 12시간 이내에 투여될 수 있음.

예시적인 CRS 완화 전략(2단계 투여, 옵션 1, 주기 1만 해당)

	제-2일 (제1일의 2일 전)	제1일	제4일	제6일	제8일	제15일
항-DLL3 작용제(AMG 757) 2단계 투여		준비 용량	단계 용량		단계 용량 (목표 용량과 동일)	목표 용량
IV 수화를 이용한 예방	N/A	AMG 757 직후 4~5시간에 걸쳐 1 L의 식염수	AMG 757 직후 4~5시간에 걸쳐 1 L의 식염수		AMG 757 직후 4~5시간에 걸쳐 1 L의 식염수	N/A
경구 덱사메타손과 함께 추가 코르티코스테로이드	N/A	AMG 757 6 내지 16시간 전	AMG 757 6 내지 16시간 전		AMG 757 6 내지 16시간 전	N/A
토실리주맙	N/A	AMG 757 1시간 전	AMG 757 1시간 전		AMG 757 1시간 전	N/A
에타너셉트*	제-2일	N/A	N/A	단계 용량 2일 전	N/A	N/A
아세트아미노펜	N/A	AMG 757 1시간 전	AMG 757 1시간 전	N/A	AMG 757 1시간 전	N/A

^*: 에타너셉트는 위의 표에서 예정되어 있는 용량으로부터 ± 12시간 이내에 투여될 수 있음.예시적인 CRS 완화 전략(2단계 투여, 옵션 2, 주기 1만 해당)

	제-2일 (제1일의 2일 전)	제1일	제6일	제8일	제13일	제15일
항-DLL3 작용제(AMG 757) 2단계 투여		준비 용량		단계 용량		단계 용량 (목표 용량과 동일)
IV 수화를 이용한 예방	N/A	AMG 757 직후 4~5시간에 걸쳐 1 L의 식염수	N/A	AMG 757 직후 4~5시간에 걸쳐 1 L의 식염수	N/A	AMG 757 직후 4~5시간에 걸쳐 1 L의 식염수
경구 덱사메타손과 함께 추가 코르티코스테로이드	N/A	AMG 757 6 내지 16시간 전	N/A	AMG 757 6 내지 16시간 전	N/A	AMG 757 6 내지 16시간 전
토실리주맙	N/A	AMG 757 1시간 전	N/A	AMG 757 1시간 전	N/A	AMG 757 1시간 전
에타너셉트*	제-2일	N/A	단계 용량 2일 전	N/A	단계 용량 2일 전	N/A
아세트아미노펜	N/A	AMG 757 1시간 전	N/A	AMG 757 1시간 전	N/A	AMG 757 1시간 전

예시적인 CRS 완화 전략(3단계 투여, 주기 1만 해당)

	제-2일 (제1일의 2일 전)	제1일	제4일	제6일	제8일	제13일	제15일
항-DLL3 작용제(AMG 757) 3단계 투여		준비 용량	단계 용량		단계 용량		단계 용량 (목표 용량과 동일)
IV 수화를 이용한 예방	N/A	AMG 757 직후 4~5시간에 걸쳐 1 L의 식염수	AMG 757 직후 4~5시간에 걸쳐 1 L의 식염수	N/A	AMG 757 직후 4~5시간에 걸쳐 1 L의 식염수	N/A	AMG 757 직후 4~5시간에 걸쳐 1 L의 식염수
경구 덱사메타손과 함께 추가 코르티코스테로이드	N/A	AMG 757 6 내지 16시간 전	AMG 757 6 내지 16시간 전	N/A	AMG 757 6 내지 16시간 전	N/A	AMG 757 6 내지 16시간 전
토실리주맙	N/A	AMG 757 1시간 전	AMG 757 1시간 전	N/A	AMG 757 1시간 전	N/A	AMG 757 1시간 전
에타너셉트*	제-2일	N/A	N/A	단계 용량 2일 전	N/A	단계 용량 2일 전	N/A
아세트아미노펜	N/A	AMG 757 1시간 전	AMG 757 1시간 전	N/A	AMG 757 1시간 전	N/A	AMG 757 1시간 전

^*: 에타너셉트는 위의 표에서 예정되어 있는 용량으로부터 ± 12시간 이내에 투여될 수 있음.일부 양태에서, 본 발명은 SCLC 또는 DLL3 양성 암을 치료하는 방법을 제공하며, 방법은 이를 필요로 하는 대상체에게 항-DLL3 작용제 및 항염증제(예를 들어, 코르티코스테로이드, 예컨대, 덱사메타손 또는 아세트아미노펜), 식염수, 항-IL6 항체(예를 들어, 토실리주맙), 또는 항-TNF 작용제(예를 들어, 에타너셉트)를 투여하는 단계를 포함하고, 여기서 항-DLL3 작용제는 다음의 1단계 일정에 따라 28일의 주기로 투여된다: a) 제1일에 0.5 mg 내지 10 mg(예컨대, 약 0.5 mg 내지 약 8 mg, 약 0.5 mg 내지 약 6 mg, 약 0.5 mg 내지 약 4 mg, 약 0.5 mg 내지 약 2 mg, 또는 약 1 mg)의 제1 용량(준비 용량), b) 제8일에 3 mg 내지 200 mg(예컨대, 약 3 mg 내지 약 100 mg, 약 10 mg 내지 약 180 mg, 약 10 mg 내지 약 150 mg, 약 30 mg 내지 약 200 mg, 약 30 mg 내지 약 180 mg, 약 30 mg 내지 약 150 mg, 약 30 mg 내지 약 120 mg, 약 50 mg 내지 약 200 mg, 약 50 mg 내지 약 180 mg, 약 50 mg 내지 약 150 mg, 약 50 mg 내지 약 120 mg, 약 70 mg 내지 약 200, 약 70 mg 내지 약 180, 약 70 mg 내지 약 150, 약 70 mg 내지 약 120 mg, 약 90 mg 내지 약 200, 약 90 mg 내지 약 180, 약 90 mg 내지 약 150 mg, 약 90 mg 내지 약 120 mg, 또는 약 100 mg)의 제2 용량(단계 용량), 및 c) 제15일에 시작하고 그 후 2주마다 1회 3 mg 내지 200 mg(예컨대, 약 3 mg 내지 약 100 mg, 약 10 mg 내지 약 180 mg, 약 10 mg 내지 약 150 mg, 약 30 mg 내지 약 200 mg, 약 30 mg 내지 약 180 mg, 약 30 mg 내지 약 150 mg, 약 30 mg 내지 약 120 mg, 약 50 mg 내지 약 200 mg, 약 50 mg 내지 약 180 mg, 약 50 mg 내지 약 150 mg, 약 50 mg 내지 약 120 mg, 약 70 mg 내지 약 200, 약 70 mg 내지 약 180, 약 70 mg 내지 약 150, 약 70 mg 내지 약 120 mg, 약 90 mg 내지 약 200, 약 90 mg 내지 약 180, 약 90 mg 내지 약 150 mg, 약 90 mg 내지 약 120 mg, 또는 약 100 mg)의 하나 이상의 후속 용량(목표 용량), 여기서 제2 및 후속 용량은 동일하고, 제1 용량보다 높은 용량이고, 항염증제, 식염수, 항-IL6 항체 또는 항-TNF 작용제는 항-DLL3 작용제가 투여되는 제1 주기에서 투여됨. 특정 실시형태에서, 제2 및 후속 용량은 동일하고, 제1 용량보다 적어도 3배, 적어도 5배, 적어도 10배, 적어도 20배, 적어도 30배, 적어도 40배, 적어도 50배, 적어도 60배, 적어도 70배, 적어도 80배, 적어도 90배, 적어도 100배, 적어도 120배, 적어도 150배, 또는 적어도 200배 높다.

1단계 일정의 일부 실시형태에서, 방법은 항-DLL3 작용제 및 덱사메타손, 아세트아미노펜, 식염수, 토실리주맙, 또는 에타너셉트를 투여하는 단계를 포함하고, 항-DLL3 작용제의 제1 용량은 1 mg이고, 항-DLL3 작용제의 제2 용량 및 후속 용량은 동일하고, 3 mg, 10 mg, 30 mg, 또는 100 mg이고, 덱사메타손, 아세트아미노펜, 식염수, 토실리주맙, 또는 에타너셉트는 항-DLL3 작용제가 투여되는 제1 주기에서 투여된다. 이러한 1단계 일정의 일부 실시형태에서, 덱사메타손은 AMG 757 투여의 주기 1에서 IV 주입에 의해 추가로 투여된다.

일부 양태에서, 본 발명은 SCLC 또는 DLL3 양성 암을 치료하는 방법을 제공하며, 방법은 이를 필요로 하는 대상체에게 항-DLL3 작용제 및 항염증제(예를 들어, 코르티코스테로이드, 예컨대, 덱사메타손 또는 아세트아미노펜), 식염수, 항-IL6 항체(예를 들어, 토실리주맙), 또는 항-TNF 작용제(예를 들어, 에타너셉트)를 투여하는 단계를 포함하고, 여기서 항-DLL3 작용제는 다음의 2단계 일정에 따라 28일의 주기로 투여된다: 일정 I: a) 제1일에 0.5 mg 내지 10 mg(예컨대, 약 0.5 mg 내지 약 8 mg, 약 0.5 mg 내지 약 6 mg, 약 0.5 mg 내지 약 4 mg, 약 0.5 mg 내지 약 2 mg, 또는 1 mg)의 제1 용량(준비 용량), b) 제4일에 3 mg 내지 100 mg(예컨대, 약 3 mg 내지 약 10 mg, 약 10 mg 내지 약 80 mg, 약 10 mg 내지 약 60 mg, 약 20 mg 내지 약 80 mg, 약 20 mg 내지 약 60 mg, 약 25 mg 내지 약 50 mg, 약 30 mg 내지 약 80 mg, 약 30 mg 내지 약 60 mg, 약 30 mg 내지 약 40 mg, 약 40 mg 내지 약 80 mg, 또는 약 40 mg 내지 약 60 mg)의 제2 용량(단계 용량), c) 제8일에 3 mg 내지 200 mg의 제3 용량(단계 용량), 및 d) 제15일에 시작하고 그 후 2주마다 1회 3 mg 내지 200 mg의 하나 이상의 후속 용량(목표 용량), 여기서 제2 용량은 제1 용량보다 높고, 제3 및 후속 용량은 동일하고 제2 용량보다 높고, 제3 및 후속 용량은 다음 중 임의의 하나일 수 있음: 약 3 mg 내지 약 100 mg, 약 10 mg 내지 약 180 mg, 약 10 mg 내지 약 150 mg, 약 10 mg 내지 약 120 mg, 약 30 mg 내지 약 200 mg, 약 30 mg 내지 약 180 mg, 약 30 mg 내지 약 150 mg, 약 30 mg 내지 약 120 mg, 약 50 mg 내지 약 200 mg, 약 50 mg 내지 약 180 mg, 약 50 mg 내지 약 150 mg, 약 70 mg 내지 약 200 mg, 약 70 mg 내지 약 180 mg, 약 70 mg 내지 약 150 mg, 약 70 mg 내지 약 120 mg, 약 90 mg 내지 약 200 mg, 약 90 mg 내지 약 180 mg, 약 90 mg 내지 약 150 mg, 약 90 mg 내지 약 120 mg, 약 100 mg 내지 약 180 mg, 약 100 mg 내지 약 150 mg, 약 100 mg 내지 약 120 mg, 또는 약 100 mg, 여기서 항염증제, 식염수, 항-IL6 항체, 또는 항-TNF 작용제는 항-DLL3 작용제가 투여되는 제1 주기에서 투여됨. 이러한 2단계 일정의 일부 실시형태에서, 덱사메타손은 AMG 757 투여의 주기 1에서 IV 주입에 의해 추가로 투여된다.

특정 실시형태에서, 방법은 이를 필요로 하는 대상체에게 항-DLL3 작용제(예를 들어, AMG757) 및 덱사메타손, 아세트아미노펜, 식염수, 토실리주맙, 또는 에타너셉트를 투여하는 단계를 포함하고, 여기서 항-DLL3 작용제는 다음의 2단계 일정에 따라 28일의 주기로 투여된다: 제1 용량은 제1일에 1 mg이고, 제2 용량은 제4일에 25 mg 또는 50 mg이고, 제3 용량은 제8일에 100 mg이고, 하나 이상의 후속 용량은 제15일에 시작하고 그 후 2주마다 1회 100 mg이고, 여기서, 덱사메타손, 아세트아미노펜, 식염수, 토실리주맙, 또는 에타너셉트는 항-DLL3 작용제가 투여되는 제1 주기에서 투여됨. 특정 실시형태에서, 덱사메타손, 아세트아미노펜, 식염수, 토실리주맙, 또는 에타너셉트는 주기 1에서 AMG 757의 준비 및 단계 용량(들) 해당일과 동일한 날 또는 해당일 전에 투여된다. 특정 실시형태에서, 덱사메타손은 AMG 757 투여의 주기 1에서 IV 주입에 의해 추가로 투여된다.

일정 I의 특정 실시형태에서, 목표 용량은 제4일에 투여된다. 이러한 실시형태에서, 방법은 이를 필요로 하는 대상체에게 항-DLL3 작용제 및 덱사메타손, 아세트아미노펜, 식염수, 토실리주맙, 또는 에타너셉트를 투여하는 단계를 포함하고, 여기서 항-DLL3 작용제는 다음의 2단계 일정에 따라 28일의 주기로 투여된다: 일정 I: a) 제1일에 0.5 mg 내지 10 mg(예컨대, 약 0.5 mg 내지 약 8 mg, 약 0.5 mg 내지 약 6 mg, 약 0.5 mg 내지 약 4 mg, 약 0.5 mg 내지 약 2 mg, 또는 1 mg)의 제1 용량(준비 용량), b) 제4일에 3 mg 내지 200 mg의 제2 용량(단계 용량), c) 제8일에 3 mg 내지 200 mg의 제3 용량(목표 용량), 및 d) 제15일에 시작하고 그 후 2주마다 1회, 3 mg 내지 200 mg의 하나 이상의 후속 용량(목표 용량), 여기서 제2 용량은 제1 용량보다 높고, 제3 및 후속 용량은 동일하며 제2 용량과 동일한 용량이고, 제2, 제3 및 후속 용량은 다음 중 임의의 하나일 수 있음: 약 3 mg 내지 약 100 mg, 약 10 mg 내지 약 180 mg, 약 10 mg 내지 약 150 mg, 약 10 mg 내지 약 120 mg, 약 30 mg 내지 약 200 mg, 약 30 mg 내지 약 180 mg, 약 30 mg 내지 약 150 mg, 약 30 mg 내지 약 120 mg, 약 50 mg 내지 약 200 mg, 약 50 mg 내지 약 180 mg, 약 50 mg 내지 약 150 mg, 약 70 mg 내지 약 200 mg, 약 70 mg 내지 약 180 mg, 약 70 mg 내지 약 150 mg, 약 70 mg 내지 약 120 mg, 약 90 mg 내지 약 200 mg, 약 90 mg 내지 약 180 mg, 약 90 mg 내지 약 150 mg, 약 90 mg 내지 약 120 mg, 약 100 mg 내지 약 180 mg, 약 100 mg 내지 약 150 mg, 약 100 mg 내지 약 120 mg, 또는 약 100 mg, 여기서 덱사메타손, 아세트아미노펜, 식염수, 토실리주맙, 또는 에타너셉트는 항-DLL3 작용제가 투여되는 제1 주기에서 투여됨. 특정 실시형태에서, 덱사메타손, 아세트아미노펜, 식염수, 토실리주맙은 주기 1에서 AMG 757 투여의 제1일 및 제4일, 또는 제1일, 제4일 및 제8일에 투여된다. 특정 실시형태에서, 에타너셉트는 주기 1에서 AMG 757 투여의 제1일 및 제8일의 2일 전에 투여된다. 특정 실시형태에서, 에타너셉트는 주기 1에서 AMG 757 투여의 제1일의 2일 전에 투여된다. 특정 실시형태에서, 방법은 AMG 757 투여의 주기 1에서 IV 주입에 의해 덱사메타손을 투여하는 단계를 추가로 포함한다.

일부 양태에서, 본 발명은 SCLC 또는 DLL3 양성 암을 치료하는 방법을 제공하며, 방법은 이를 필요로 하는 대상체에게 항-DLL3 작용제 및 항염증제(예를 들어, 코르티코스테로이드, 예컨대, 덱사메타손 또는 아세트아미노펜), 식염수, 항-IL6 항체(예를 들어, 토실리주맙), 또는 항-TNF 작용제(예를 들어, 에타너셉트)를 투여하는 단계를 포함하고, 여기서 항-DLL3 작용제는 다음의 2단계 일정에 따라 28일의 주기로 투여된다: 일정 II: a) 제1일에 0.5 mg 내지 10 mg(예컨대, 약 0.5 mg 내지 약 8 mg, 약 0.5 mg 내지 약 6 mg, 약 0.5 mg 내지 약 4 mg, 약 0.5 mg 내지 약 2 mg, 또는 1 mg)의 제1 용량(준비 용량), b) 제8일에 3 mg 내지 100 mg(예컨대, 약 3 mg 내지 약 10 mg, 약 10 mg 내지 약 80 mg, 약 10 mg 내지 약 60 mg, 약 20 mg 내지 약 80 mg, 약 20 mg 내지 약 60 mg, 약 25 mg 내지 약 50 mg, 약 30 mg 내지 약 80 mg, 약 30 mg 내지 약 60 mg, 약 30 mg 내지 약 40 mg, 약 40 mg 내지 약 80 mg, 또는 약 40 mg 내지 약 60 mg)의 제2 용량(단계 용량), c) 제15일에 3 mg 내지 200 mg의 제3 용량(단계 용량), 및 c) 제29일에 시작하고 그 후 2주마다 1회 3 mg 내지 200 mg의 하나 이상의 후속 용량(목표 용량), 여기서 제2 용량은 제1 용량보다 높고, 제3 용량 및 후속 용량은 동일하고 제2 용량보다 높고, 제3 및 후속 용량은 다음 중 임의의 하나일 수 있음: 약 3 mg 내지 약 100 mg, 약 10 mg 내지 약 180 mg, 약 10 mg 내지 약 150 mg, 약 10 mg 내지 약 120 mg, 약 30 mg 내지 약 200 mg, 약 30 mg 내지 약 180 mg, 약 30 mg 내지 약 150 mg, 약 30 mg 내지 약 120 mg, 약 50 mg 내지 약 200 mg, 약 50 mg 내지 약 180 mg, 약 50 mg 내지 약 150 mg, 약 70 mg 내지 약 200 mg, 약 70 mg 내지 약 180 mg, 약 70 mg 내지 약 150 mg, 약 70 mg 내지 약 120 mg, 약 90 mg 내지 약 200 mg, 약 90 mg 내지 약 180 mg, 약 90 mg 내지 약 150 mg, 약 90 mg 내지 약 120 mg, 약 100 mg 내지 약 180 mg, 약 100 mg 내지 약 150 mg, 약 100 mg 내지 약 120 mg, 또는 약 100 mg, 여기서 항염증제, 식염수, 항-IL6 항체, 또는 항-TNF 작용제는 항-DLL3 작용제가 투여되는 제1 주기에서 투여됨. 이러한 2단계 일정의 일부 실시형태에서, 덱사메타손은 AMG 757 투여의 주기 1에서 IV 주입에 의해 추가로 투여된다.

2단계 투여 일정의 일부 실시형태에서, 방법은 대상체에게 항-DLL3 작용제 및 덱사메타손, 아세트아미노펜, 식염수, 토실리주맙, 또는 에타너셉트를 투여하는 단계를 포함하고, 항-DLL3 작용제의 제1 용량은 1 mg이고, 항-DLL3 작용제의 제2 용량은 약 25 mg 내지 약 50 mg이고, 항-DLL3 작용제의 제3 및 후속 용량은 동일하고 100 mg이고, 덱사메타손, 아세트아미노펜, 식염수, 토실리주맙, 또는 에타너셉트는 항-DLL3 작용제가 투여되는 제1 주기에서 투여된다.

2단계 투여 일정의 일부 실시형태에서, 방법은 대상체에게 항-DLL3 작용제 및 덱사메타손, 아세트아미노펜, 식염수, 토실리주맙, 또는 에타너셉트를 투여하는 단계를 포함하고, 항-DLL3 작용제의 제1 용량은 1 mg이고, 항-DLL3 작용제의 제2 용량은 약 45 mg 내지 약 70 mg이고, 항-DLL3 작용제의 제3 및 후속 용량은 동일하고 100 mg이고, 덱사메타손, 아세트아미노펜, 식염수, 토실리주맙, 또는 에타너셉트는 항-DLL3 작용제가 투여되는 제1 주기에서 투여된다.

2단계 투여 일정의 일부 실시형태에서, 방법은 대상체에게 항-DLL3 작용제 및 덱사메타손, 아세트아미노펜, 식염수, 토실리주맙, 또는 에타너셉트를 투여하는 단계를 포함하고, 항-DLL3 작용제의 제1 용량은 제1일에 1 mg이고, 항-DLL3 작용제의 제2 용량은 제4일에 25 mg 또는 50 mg이고, 제3 용량은 제8일에 100 mg이고, 항-DLL3 작용제의 후속 용량은 제15일에 시작하고 그 후 2주마다 1회 100 mg이고, 덱사메타손, 아세트아미노펜, 식염수, 토실리주맙, 또는 에타너셉트는 항-DLL3 작용제가 투여되는 제1 주기에서 투여된다.

일부 양태에서, 본 발명은 SCLC 또는 DLL3 양성 암을 치료하는 방법을 제공하며, 방법은 이를 필요로 하는 대상체에게 항-DLL3 작용제 및 항염증제(예를 들어, 코르티코스테로이드, 예컨대, 덱사메타손 또는 아세트아미노펜), 식염수, 항-IL6 항체(예를 들어, 토실리주맙), 또는 항-TNF 작용제(예를 들어, 에타너셉트)를 투여하는 단계를 포함하고, 여기서 항-DLL3 작용제는 다음의 3단계 일정에 따라 28일의 주기로 투여된다: a) 제1일에 0.5 mg 내지 10 mg(예컨대, 약 0.5 mg 내지 약 8 mg, 약 0.5 mg 내지 약 6 mg, 약 0.5 mg 내지 약 4 mg, 약 0.5 mg 내지 약 2 mg, 또는 1 mg)의 제1 용량(준비 용량), b) 제4일에 3 mg 내지 100 mg(예컨대, 약 3 mg 내지 약 10 mg, 약 10 mg 내지 약 100 mg, 약 10 mg 내지 약 80 mg, 약 10 mg 내지 약 60 mg, 약 10 mg 내지 약 40 mg, 약 20 mg 내지 약 80 mg, 약 20 mg 내지 약 60 mg, 약 20 mg 내지 약 40 mg, 또는 약 25 mg)의 제2 용량(단계 용량), c) 제8일에 3 mg 내지 100 mg(예컨대, 약 3 mg 내지 약 10 mg, 약 10 mg 내지 약 100 mg, 약 10 mg 내지 약 80 mg, from 10 mg 내지 약 60 mg, 약 20 mg 내지 약 100 mg, 약 20 mg 내지 약 80 mg, 약 20 mg 내지 약 60 mg, 약 30 mg 내지 약 100 mg, 약 30 mg 내지 약 80 mg, 약 30 mg 내지 약 60 mg, 약 40 mg 내지 약 100 mg, 약 40 mg 내지 약 80 mg, 약 40 mg 내지 약 60 mg, 또는 약 50 mg)의 제3 용량(단계 용량), d) 제15일에 3 mg 내지 200 mg의 제4 용량(단계 용량) 및 e) 제29일에 시작하고 그 후 2주마다 1회 3 mg 내지 200 mg의 하나 이상의 후속 용량(목표 용량), 여기서 제2 용량은 제1 용량보다 높고, 제3 용량은 제2 용량보다 높고, 제4 용량 및 후속 용량은 동일하고, 제3 용량보다 높고, 제4 및 후속 용량은 다음 중 임의의 하나일 수 있음: 약 3 mg 내지 약 100 mg, 약 10 mg 내지 약 150 mg, 약 30 mg 내지 200 mg, 약 50 mg 내지 약 200 mg, 약 50 mg 내지 약 180 mg, 약 50 mg 내지 약 150 mg, 약 50 mg 내지 약 120 mg, 약 70 mg 내지 약 200 mg, 약 70 mg 내지 약 180 mg, 약 70 mg 내지 약 120 mg, 약 90 mg 내지 약 200 mg, 약 90 mg 내지 약 180 mg, 약 90 mg 내지 약 150 mg, 약 90 mg 내지 약 120 mg, 또는 약 100 mg, 여기서 항염증제, 식염수, 항-IL6 항체, 또는 항-TNF 작용제는 항-DLL3 작용제가 투여되는 제1 주기에서 투여됨. 이러한 3단계 일정의 일부 실시형태에서, 덱사메타손은 AMG 757 투여의 주기 1에서 IV 주입에 의해 추가로 투여된다.

3단계 투여 일정의 일부 실시형태에서, 방법은 대상체에게 항-DLL3 작용제 및 덱사메타손, 아세트아미노펜, 식염수, 토실리주맙, 또는 에타너셉트를 투여하는 단계를 포함하고, 항-DLL3 작용제의 제1 용량은 1 mg이고, 항-DLL3 작용제의 제2 용량은 25 mg이고, 항-DLL3 작용제의 제3 용량은 50 mg이고, 항-DLL3 작용제의 제4 및 후속 용량은 동일하고 100 mg이고, 덱사메타손, 아세트아미노펜, 식염수, 토실리주맙, 또는 에타너셉트는 항-DLL3 작용제가 투여되는 제1 주기에서 투여된다.

3단계 투여 일정의 특정 실시형태에서, 목표 용량은 제8일에 투여된다. 이러한 실시형태에서, 방법은 이를 필요로 하는 대상체에게 항-DLL3 작용제 및 덱사메타손, 아세트아미노펜, 식염수, 토실리주맙, 또는 에타너셉트를 투여하는 단계를 포함하고, 여기서 항-DLL3 작용제는 다음의 3단계 일정에 따라 28일의 주기로 투여된다: a) 제1일에 0.5 mg 내지 10 mg(예컨대, 약 0.5 mg 내지 약 8 mg, 약 0.5 mg 내지 약 6 mg, 약 0.5 mg 내지 약 4 mg, 약 0.5 mg 내지 약 2 mg, 또는 1 mg)의 제1 용량(준비 용량), b) 제4일에 3 mg 내지 100 mg(예컨대, 3 mg 내지 10 mg, 10 mg 내지 80 mg, 10 mg 내지 60 mg, 20 mg 내지 80 mg, 20 mg 내지 60 mg, 20 mg 내지 40 mg, 25 mg, 또는 50 mg)의 제2 용량(단계 용량), c) 제8일에 3 mg 내지 200 mg의 제3 용량(단계 용량), d) 제15일에 3 mg 내지 200 mg의 제4 용량(목표 용량) 및 e) 제29일에 시작하고 그 후 2주마다 1회 3 mg 내지 200 mg의 하나 이상의 후속 용량(목표 용량), 여기서 제2 용량은 제1 용량보다 높고, 제3 용량, 제4 용량 및 후속 용량은 동일하고 제2 용량보다 높고, 제3 용량, 제4 용량 및 후속 용량 각각은 다음 중 임의의 것일 수 있음: 3 mg 내지 100 mg, 10 mg 내지 150 mg, 30 mg 내지 200 mg, 30 mg 내지 100 mg, 50 mg 내지 150 mg, 70 mg 내지 120 mg, 90 mg 내지 120 mg, 100 mg 내지 200 mg, 또는 100 mg, 여기서 덱사메타손, 아세트아미노펜, 식염수, 토실리주맙, 또는 에타너셉트는 항-DLL3 작용제가 투여되는 제1 주기에서 투여됨. 특정 실시형태에서, 덱사메타손, 아세트아미노펜, 식염수, 토실리주맙은 주기 1에서 AMG 757 투여의 제1일, 제4일 및 제8일, 또는 제1일, 제4일, 제8일 및 제15일에 투여된다. 특정 실시형태에서, 에타너셉트는 주기 1에서 AMG 757 투여의 제1일, 제8일 및 제15일의 2일 전에 투여된다. 특정 실시형태에서, 에타너셉트는 주기 1에서 AMG 757 투여의 제1일 및 제8일의 2일 전에 투여된다. 이러한 3단계 일정의 일부 실시형태에서, 덱사메타손은 AMG 757 투여의 주기 1에서 IV 주입에 의해 추가로 투여된다.

임의의 하나의 단계 투여 일정의 특정 실시형태에서, 식염수(예를 들어, 약 1리터)가 제1 주기에서 항-DLL3 작용제의 투여 후에 IV 주입에 의해 투여된다. 특정 실시형태에서, 1리터의 식염수가 제1 주기에서 항-DLL3 작용제의 준비 용량 및 단계 용량(들) 후에 IV 주입에 의해 투여된다. 일부 실시형태에서, 1리터의 식염수가 항-DLL3 작용제의 투여 후 약 4~5시간에 걸쳐 IV 주입에 의해 투여된다.

임의의 하나의 단계 투여 일정의 특정 실시형태에서, 항염증제는 코르티코스테로이드(예를 들어, 덱사메타손)이고, 제1 주기에서 항-DLL3 작용제의 투여 약 6 내지 약 16시간 전에 투여된다. 특정 실시형태에서, 약 8 mg의 덱사메타손이 제1 주기에서 항-DLL3 작용제의 투여 약 6 내지 약 16시간 전에 투여된다. 특정 실시형태에서, 8 mg의 덱사메타손이 제1 주기에서 항-DLL3 작용제의 준비 용량 및 단계 용량(들) 약 6 내지 약 16시간 전에 투여된다. 일부 실시형태에서, 덱사메타손은 경구 투여된다.

임의의 하나의 단계 투여 일정의 특정 실시형태에서, 항염증제는 아세트아미노펜이고, 제1 주기에서 항-DLL3 작용제의 투여 약 1시간 전에 투여된다. 특정 실시형태에서, 약 650 mg의 아세트아미노펜이 제1 주기에서 항-DLL3 작용제의 투여 약 1시간 전에 투여된다. 특정 실시형태에서, 약 650 mg의 아세트아미노펜이 제1 주기에서 항-DLL3 작용제의 준비 용량 및 단계 용량(들) 약 1시간 전에 투여된다. 일부 실시형태에서, 아세트아미노펜은 경구 투여된다.

임의의 하나의 단계 투여 일정의 특정 실시형태에서, 항-IL6 항체 토실리주맙은 제1 주기에서 항-DLL3 작용제의 투여 전에 투여된다. 특정 실시형태에서, 약 8 mg/kg의 토실리주맙이 제1 주기에서 항-DLL3 작용제의 투여 약 1시간 전에 IV 주입에 의해 대상체에게 투여된다. 특정 실시형태에서, 약 8 mg/kg의 토실리주맙이 제1 주기에서 항-DLL3 작용제의 준비 용량 및 단계 용량(들) 약 1시간 전에 IV 주입에 의해 대상체에게 투여된다.

임의의 하나의 단계 투여 일정의 특정 실시형태에서, 항-TNF 작용제 에타너셉트(예를 들어, Enbrel^®)는 제1 주기에서 항-DLL3 작용제의 투여 전에 투여된다. 특정 실시형태에서, 에타너셉트는 제1 주기에서 항-DLL3 작용제의 투여 약 36시간 내지 약 60시간 전에 투여된다. 특정 실시형태에서, 에타너셉트는 제1 주기에서, 2단계 또는 3단계 투여 일정의 제4일의 단계 용량을 제외하고, 항-DLL3 작용제의 준비 용량 및 단계 용량(들) 약 36시간 내지 약 60시간 전에 투여된다. 특정 실시형태에서, 약 50 mg의 에타너셉트가 제1 주기에서 항-DLL3 작용제의 투여 2일 전에 투여된다. 특정 실시형태에서, 약 50 mg의 에타너셉트가 제1 주기에서, 2단계 또는 3단계 투여 일정의 제4일의 단계 용량을 제외하고, 항-DLL3 작용제의 준비 용량 및 단계 용량(들) 2일 전에 피하 투여된다.

임의의 하나의 단계 투여 일정의 특정 실시형태에서, 대상체는 인간이다.

4. 제조 물품

제조 물품이 본원에 개시되며, 제조 물품은 (a) 항-DLL3 작용제를 포함하는 용기; 및 (b) 대상체에서 DLL3 양성 암을 치료하기 위한(또는 SCLC를 치료하기 위한) 설명서를 포함하는 포장 삽입물을 포함하고, 여기서 설명서는 약 0.3 mg 내지 약 100 mg, 약 3 mg 내지 약 200 mg, 또는 100 mg(또는 본원에 개시된 임의의 용량 범위)의 용량의 항-DLL3 작용제가 2주마다 1회, 예컨대, 28일 주기의 제1일 및 제15일에 대상체에게 투여되도록 명시한다. 설명서는 또한 항-DLL3 작용제가 다음의 일정에 따라 투여되도록 명시할 수 있다: a) 제1일에 0.3 mg 내지 100 mg(또는 본원에 개시된 임의의 용량 범위)의 제1 용량, b) 제8일에 0.3 mg 내지 100 mg(또는 본원에 개시된 임의의 용량 범위)의 제2 용량, 및 c) 제15일에 시작하고 그 후 2주마다 1회, 0.3 mg 내지 100 mg(또는 본원에 개시된 임의의 용량 범위)의 하나 이상의 후속 용량, 여기서 제2 및 하나 이상의 후속 용량은 동일하며, 제1 용량보다 높은 용량임.

설명서는 또한 항-DLL3 작용제가 다음의 일정에 따라 투여되도록 명시할 수 있다: a) 제1일에 0.5 mg 내지 10 mg(또는 본원에 개시된 임의의 용량 범위)의 제1 용량, b) 제8일에 3 mg 내지 200 mg(또는 본원에 개시된 임의의 용량 범위)의 제2 용량, 및 c) 제15일에 시작하고 그 후 2주마다 1회, 3 mg 내지 200 mg(또는 본원에 개시된 임의의 용량 범위)의 하나 이상의 후속 용량, 여기서 제2 및 하나 이상의 후속 용량은 동일하며, 제1 용량보다 높은 용량임.

특정 실시형태에서, 설명서는 항-DLL3 작용제가 다음의 2가지 일정 중 하나에 따라 투여되도록 명시한다: 일정 I: a) 제1일에 0.5 mg 내지 10 mg(또는 본원에 개시된 임의의 용량 범위)의 제1 용량(준비 용량), b) 제4일에 3 mg 내지 100 mg(또는 본원에 개시된 임의의 용량 범위)의 제2 용량(단계 용량), c) 제8일에 3 mg 내지 200 mg(또는 본원에 개시된 임의의 용량 범위)의 제3 용량(단계 용량) 및 d) 제15일에 시작하고 그 후 2주마다 1회, 3 mg 내지 200 mg(또는 본원에 개시된 임의의 용량 범위)의 하나 이상의 후속 용량(목표 용량), 여기서 제2 용량은 제1 용량보다 높고, 제3 및 후속 용량은 동일하며, 제2 용량보다 높은 용량임; 또는 일정 II: a) 제1일에 0.5 mg 내지 10 mg(또는 본원에 개시된 임의의 용량 범위)의 제1 용량(준비 용량), b) 제8일에 3 mg 내지 100 mg(또는 본원에 개시된 임의의 용량 범위)의 제2 용량(단계 용량), c) 제15일에 3 mg 내지 200 mg(또는 본원에 개시된 임의의 용량 범위)의 제3 용량(단계 용량) 및 c) 제29일에 시작하고 그 후 2주마다 1회, 3 mg 내지 200 mg(또는 본원에 개시된 임의의 용량 범위)의 하나 이상의 후속 용량(목표 용량), 여기서 제2 용량은 제1 용량보다 높고, 제3 용량 및 후속 용량은 동일하며 제2 용량보다 높은 용량임.

특정 실시형태에서, 설명서는 항-DLL3 작용제가 다음의 일정에 따라 투여되도록 명시한다: a) 제1일에 0.5 mg 내지 10 mg(또는 본원에 개시된 임의의 용량 범위)의 제1 용량(준비 용량), b) 제4일에 3 mg 내지 200 mg(또는 본원에 개시된 임의의 용량 범위)의 제2 용량(단계 용량), c) 제8일에 3 mg 내지 200 mg(또는 본원에 개시된 임의의 용량 범위)의 제3 용량(단계 용량) 및 d) 제15일에 시작하고 그 후 2주마다 1회, 3 mg 내지 200 mg(또는 본원에 개시된 임의의 용량 범위)의 하나 이상의 후속 용량(목표 용량), 여기서 제2 용량은 제1 용량보다 높고, 제3 및 후속 용량은 동일하며, 제2 용량과 동일한 용량임.

특정 실시형태에서, 설명서는 항-DLL3 작용제가 다음의 일정에 따라 투여되도록 명시한다: a) 제1일에 0.5 mg 내지 10 mg(또는 본원에 개시된 임의의 용량 범위)의 제1 용량(준비 용량), b) 제4일에 3 mg 내지 100 mg(또는 본원에 개시된 임의의 용량 범위)의 제2 용량(단계 용량), c) 제8일에 3 mg 내지 100 mg(또는 본원에 개시된 임의의 용량 범위)의 제3 용량(단계 용량), d) 제15일에 3 mg 내지 200 mg(또는 본원에 개시된 임의의 용량 범위)의 제4 용량(단계 용량) 및 e) 제29일에 시작하고 그 후 2주마다 1회, 3 mg 내지 200 mg(또는 본원에 개시된 임의의 용량 범위)의 하나 이상의 후속 용량(목표 용량), 여기서 제2 용량은 제1 용량보다 높고, 제3 용량은 제2 용량보다 높고, 제4 용량 및 후속 용량은 동일하며 제3 용량보다 높은 용량임.

특정 실시형태에서, 설명서는 항-DLL3 작용제가 다음의 일정에 따라 투여되도록 명시한다: a) 제1일에 0.5 mg 내지 10 mg(또는 본원에 개시된 임의의 용량 범위)의 제1 용량(준비 용량), b) 제4일에 3 mg 내지 100 mg(또는 본원에 개시된 임의의 용량 범위)의 제2 용량(단계 용량), c) 제8일에 3 mg 내지 200 mg(또는 본원에 개시된 임의의 용량 범위)의 제3 용량(단계 용량), d) 제15일에 3 mg 내지 200 mg(또는 본원에 개시된 임의의 용량 범위)의 제4 용량(단계 용량) 및 e) 제29일에 시작하고 그 후 2주마다 1회, 3 mg 내지 200 mg(또는 본원에 개시된 임의의 용량 범위)의 하나 이상의 후속 용량(목표 용량), 여기서 제2 용량은 제1 용량보다 높고, 제3 용량은 제2 용량보다 높고, 제4 용량 및 후속 용량은 동일하며 제3 용량과 동일한 용량임.

특정 실시형태에서, 설명서는 항염증제(예를 들어, 코르티코스테로이드, 예컨대, 덱사메타손, 또는 아세트아미노펜), 식염수, 항-IL6 항체(예를 들어, 토실리주맙) 또는 항-TNF 작용제(예를 들어, 에타너셉트)가 또한 항-DLL3 작용제가 투여되는 제1 주기에서 투여됨을 명시한다. 특정 실시형태에서, 설명서는 덱사메타손이 항-DLL3 작용제가 투여되는 제1 주기에서 (예를 들어, 항-DLL3 작용제의 주기 용량 전에 IV 투여에 의해) 추가로 투여됨을 명시한다.

실시예

실시예 1 인간 AMG 757 약동학 예측 및 최초 인간 대상 용량 선택

AMG 757의 인간 PK 매개변수는 12 ~ 4500 μg/kg 범위의 용량에서 시노몰구스 원숭이에 대한 연구에서 얻은 PK 매개변수의 알로메트릭 스케일링을 사용하여 예측하였다. 선형 제거가 있는 2구획 모델을 사용하여 통합 시노몰구스 원숭이 데이터에서 AMG 757의 약동학을 특성화했으며, 제1 용량 투여 후 항-약물 항체에 대해 양성으로 확인된 동물의 데이터를 제외하였다. 모델은 선형 청소율(CL), 중심 구획의 분포 용적(V_C), 분포 청소율(CL_D) 및 말초 분포 용적(V_T)을 사용하여 매개변수화되었다. 대비성장측정법(allometry)을 사용하여 청소율 및 용적 매개변수에 대해 각각 0.75 및 1의 지수를 사용하여 인간 AMG 757 PK를 예측하였다. 인간과 시노몰구스 원숭이의 체중을 각각 60 kg과 3 kg으로 추정하였다. 파생된 원숭이 및 예측된 인간 AMG 757 PK 매개변수가 표 1에 제공되어 있다.

[표 1]

인간 AMG 757 노출 예측에 사용된 시노몰구스 원숭이 및 예측된 인간 약동학적 매개변수

이러한 PK 예측과 함께, 확인된 시험관 내 최소 예상 생물학적 효과 수준(MABEL)을 기반으로 FIH 시작 용량을 선택하였다. 이 농도는 가장 민감한 DLL3 발현 세포주에서 AMG 757 활성의 가장 민감한 마커를 평가하여 결정하였다(연구 123564). GLP 독성 연구의 동물 노출과 관련하여, 예측된 인간 노출을 사용하여 AUC_tau(GLP 독성 연구에서 시노몰구스 원숭이의 경우 168시간, 인간의 경우 336시간) 및 FIH 연구에서 제안된 용량에 대한 C_max에 기반한 표준 비율 계산을 사용하여 노출 한계를 계산하였다.

FIH 연구는 소세포 폐암 환자에서 AMG 757의 안전성, 내약성 및 약동학을 평가한다. 전술한 예측된 인간 PK 매개변수를 사용하여 제안된 FIH 용량에서 예측된 노출을 시뮬레이션하였다(도 1). FIH 연구를 위한 AMG 757의 용량은 소세포폐암(SCLC) 환자에서 2주마다 1회 단기 IV 주입(대략 1시간)으로 투여된 0.003 mg, 0.01 mg, 0.03 mg, 0.1 mg, 0.3 mg, 1 mg, 3 mg, 10 mg, 30 mg, 100 mg 및 그 이상이다(연구 20160323). 이 요법은 AMG 757의 다수의 치료 주기 동안 피크 대 최저 비율을 최소화하면서 AMG 757 매개 세포 사멸에 대한 시험관 내 EC₉₀(5.2 ng/mL)에 대한 적절한 노출이 폐에서 달성되도록 한다.

FIH 연구를 위한 시작 용량의 선택은 시험관 내 MABEL을 기반으로 하였다. 간단히 말해서, SHP-77 종양 세포의 AMG 757 매개 세포 사멸 및 인간 말초 혈액 단핵 세포(PBMC)로부터의 T 세포 활성화 유도(CD69 및 CD25의 드 노보(de novo) 발현)의 EC₅₀ 값을 비교하였고, T 세포에서 AMG 757에 의해 유도된 CD69의 드 노보 발현이 AMG 757 활성의 가장 민감한 매개변수로 확인되었다. 12명의 서로 다른 PBMC 공여자의 개별 용량-반응 곡선 평가를 기반으로 MABEL(평균 EC₅₀)은 0.61 ng/mL(5.8 pM)로 계산되었다(연구 123564).

시험관 내 EC₅₀을 MABEL 및 FIH 시작 용량의 기초로 사용하는 것은 임상 개발에서 이전의 BiTE® 분자의 최대 권장 시작 용량을 식별하기 위한 이 전략의 이전의 안전한 실행에 의해 뒷받침된다.

실시예 2 인간에서 AMG 757의 최소 유효 노출 예측

AMG 757의 시험관 내 약리학을 평가한 연구 122717에서 생성된 시험관 내 데이터를 기반으로 AMG 757의 효과적인 노출을 예측하였다. SHP-77 세포(인간 DLL3 발현 세포주)에서 AMG 757 매개 세포 사멸의 절반 최대 효과 농도(EC₅₀) 및 90%의 최대 효과 농도(EC₉₀)를 사용하여 효능이 기대될 수 있는 농도 범위를 추정했다.

폐는 AMG 757의 대표적인 작용 부위로 사용하였으며, 유리 혈청 노출의 약 1% 노출을 달성하는 것으로 추정하였다(Vugmeyser et al., J Pharm Sci. 99:1028-1045 (2010)). 이 추정에 기초하여, SHP-77 세포에서 AMG 757 매개 세포 사멸의 EC₅₀의 최저 범위를 제공하기 위한 AMG 757의 용량은 최소한으로 효과적인 것으로 간주되었다. 효능의 초기 징후는 전체 치료 주기 동안 SHP-77 세포에서 세포 사멸의 평균 EC₉₀의 최저 범위(1%의 폐 노출로 추정)에 기초하여 2주마다 1회 10 mg IV에서 예측되었다(도 2).

실시예 3 SCLC를 앓는 대상체에서 AMG 757의 안전성, 내약성 및 약동학을 평가하는 1상 연구

배경

폐암의 10~15%를 차지하는 소세포폐암(SCLC)(Rudin et al, J Clin Oncol. 33:4106-4111(2015))은 신경내분비 분화를 나타내고, 흡연과 강하게 연관되는 공격성 폐암 하위 유형이다(Koinis et al, Transl Lung Cancer Res. 5:39-50 (2016)). 이는 높은 성장 분율, 빠른 배가 시간 및 광범위한 전이성 병변의 조기 확립을 특징으로 하는 뚜렷한 자연사를 나타낸다(Gustafsson et al, Cancer.113:5-21(2008)). 환자의 30%가 하나의 반흉곽에 국한된 질환[제한 질환(LD)]을 가지고 있는 반면, 대부분의 경우에는 하나의 방사선요법 분야에 의해 포함되지 않는 질환[확장 질환(ED)]을 가지고 있다. SCLC는 1선 화학요법(약 60%~70%의 반응률)과 방사선에 매우 민감하며, 이는 질환 재발 후 2선 요법 및 후속 요법에 대한 이후의 내성과 극명한 대조를 이룬다(Byers et al, Cancer.121:664 672(2015)). ED 환자는 진단으로부터 10~12개월 중간값에서 약물 내성이 발생하고 질환의 결과로 사망한다(Rudin et al, 2015). ED SCLC 환자의 경우, 1선 치료는 백금 기반의 화학요법이다. 미국의 대부분의 환자는 백금-에토포시드(EP) 화학요법(카보플라틴 또는 시스플라틴 사용)을 받고, 일부 환자는 특히 미국 이외의 지역에서 대안으로 백금-이리노테칸을 받는다. 2019년 3월, 아테졸리주맙은 ED-SCLC 성인 환자의 1선 치료를 위해 카보플라틴 및 에토포시드와 조합하여 미국 식품의약관리국(US FDA)의 승인을 받았다(Tecentriq® 미국 처방 정보[United States Prescribing Information, USPI], 2019년). 재발 후에는, 토포테칸이 미국 FDA에서 승인한 유일한 2선 약물이다. 그러나 이러한 상황에서 이의 적응증에도 불구하고, 토포테칸은 실망스러운 반응률을 나타냈다(Byers et al, Cancer.121:664 672(2015)).

AMG 757은 종양 특이적 항원으로서 DLL3을 표적으로 하고 T 세포의 T 세포 수용체 관련 복합 분화 클러스터 3(CD3)을 표적으로 하는 반감기 연장(half-life extended, HLE) BiTE® 분자이다. AMG 757은 SCLC 치료를 위해 개발되었으며 CD3 양성 T 세포와 DLL3 단백질을 발현하는 암 세포 사이의 면역학적 시냅스 형성에 의해 작용하는 강력한 분자이다. 이에 따른 근접성은 T 세포에 의한 DLL3 양성 표적 세포의 방향 변경된 용해를 촉발한다. AMG 757 단독요법은 피하 이식된 DLL3을 발현하는 인간 흑색종 WM266-4 세포의 성장을 유의하게 억제하였고, 동소 SHP-77-Luc 폐 종양의 관해를 유도하였다.

연구 설계

연구 20160323은 소세포 폐암 피험자에서 2주마다(예를 들어, 제8일의 단계 투여가 있거나 없음) 단기 정맥 내(IV) 주입으로 투여되는 AMG 757을 평가하는 공개 표지, 용량 증가, 다중 용량, 1상 연구이다. 이 연구에는 두 가지 적응증이 있다: A: 재발성/불응성 소세포 폐암(RR SCLC) 및 B: 확장 질환 SCLC(ED SCLC).

알려진 작용 기전으로 인해, 피험자는 AMG 757 치료를 시작하는 동안 CRS의 위험이 증가한다.

이 연구는 세 개의 파트를 포함한다:

(1) 파트 A: 재발성/불응성 소세포 폐암(RR SCLC)이 있는 피험자에서 AMG 757을 평가한다. 파트 A는 두 단계를 포함한다: (A1) AMG 757의 최대 허용 용량(MTD) 또는 권장 2상 용량(RP2D)을 결정하기 위한 용량 탐색 단계 및 (A2) 선택된 용량의 안전성 및 내약성을 확인하기 위한 용량 확장 단계.

(2) 파트 B: 확장 질환 SCLC(ED SCLC)가 있는 피험자에서 AMG 757을 평가한다. 파트 B는 파트 A에서 MTD 또는 RP2D가 확인되면 시작된다.

(3) 파트 C(추가 CRS 완화 전략 평가): 적어도 1종의 백금 기반 요법 후에 진행한 RR SCLC가 있는 피험자에 대한 AMG 757 단독요법. CRS의 위험을 완화하기 위해, 다음의 예방 조치 중 하나 이상이 실행될 수 있다(주기 1 동안에만). IV 수화, 토실리주맙 예방, 에타너셉트 예방 또는 아세트아미노펜 예방의 경구 덱사메타손 투여와 함께 추가 코르티코스테로이드 예방.

연구의 파트 A와 파트 B의 1차 목적은 AMG 757의 안전성과 내약성을 평가하고 AMG 757의 MTD 또는 RP2D를 결정하는 것이다. 연구의 파트 A와 파트 B의 2차 목적은 AMG 757의 약동학(PK)을 특성화하고 AMG 757의 예비 항종양 활성을 평가하는 것이다.

파트 A1: 용량 탐색 단계

AMG 757은 짧은 IV 주입(약 60분)으로 투여된다. 용량 증량에 사용하기 위해 미리 지정된 용량(조사를 위한 계획된 용량 수준)은 다음과 같다: 2주마다 1회 투여된 0.003 mg(코호트 1), 0.01 mg(코호트 2), 0.03 mg(코호트 3), 0.1 mg(코호트 4), 0.3 mg(코호트 5), 1 mg(코호트 6), 3 mg(코호트 7), 10 mg(코호트 8), 30 mg(코호트 9) 및 100 mg(코호트 10). 제1 주기의 투여 일정은 아래에 기재된 바와 같이 하나 이상의 단계 용량을 포함하도록 조정될 수 있다. 증량 기간 동안 강력한 임상 반응이 관찰되면, 추가 용량 증량을 중단할 수 있다. 새로운 약동학(PK), 약력학(PD) 및 안전성 데이터를 기반으로 AMG 757의 대안적인 용량 수준 또는 투여 일정(들)을 탐색할 수 있다. MTD가 계획된 용량 코호트 수준(코호트 1~10)에 도달하지 않고 안전성 및 PK/PD 데이터에 의해 뒷받침되는 경우 더 높은 용량을 탐색할 수 있다.

단계 투여: 피험자는 AMG 757의 초기 주입 후 제1 용량 효과(예를 들어, 관련 징후 및 임의의 기타 잠재적으로 발전하고 알려지지 않은 제1 용량 효과가 있는 사이토카인 방출 증후군)를 경험할 수 있다. 최적의 MTD는 단계 투여 접근법(예를 들어, 제1일의 초기 용량 및 제8일의 단계 용량)이 필요할 수 있다고 여겨진다. 2개의 MTD가 추정될 수 있는데, 하나는 초기 투여에 대한 것(MTD1)이고 다른 하나는 후속 투여에 대한 것(MTD2)이다.

연구 중 임의의 시점에서, 피험자가 처음으로 제1 용량 효과(예를 들어, 임의의 등급의 CRS 사례)를 경험할 때, 등급 2 이상의 CRS가 관찰되는 용량을 초과하지 않는, 초기 용량(MTD1)으로 실행할 적절한 용량을 결정하기 위해 안전성 데이터를 검토해야 한다. 이러한 용량 및 투여 일정은 AMG 757의 전신 노출이 제1 용량 효과가 나타난 용량과 관련된 노출을 초과하지 않도록 하기 위해 새로운 임상 데이터(예를 들어, 약동학, 안전성 데이터 등)의 모델링 및 시뮬레이션에 의해 유도된다. 단계 투여 요법의 증가된 투여 빈도와 약물 축적 가능성을 고려해야 한다.

연구 전반에 걸쳐 후속 코호트에 등록된 모든 피험자의 경우, AMG 757의 제1 주기의 제1 용량(MTD1)에 대해 일정한 용량으로 용량 증량이 계속되며, MTD2를 결정하기 위한 용량 증량에서 미리 지정된 용량에 따라 단계 용량만 증량될 것이다. 단계 투여의 예는 도 3에 제시되어 있다.

단계 투여 일정은 아래에 요약되어 있다. 투여 일정은 새로운 안전성 데이터를 기반으로 하는 DLRT 권장 사항에 따라 다음의 조치 중 하나 이상을 포함하도록 조정될 수 있다.

● 제1일에 준비 용량, 이어서 제8일에 단계 용량(목표 용량과 동일) 및 제15일 및 그 후 Q2W의 목표 용량을 포함하는 단일 단계 투여.

● 제1일에 준비 용량, 이어서 제4일에 단계 용량, 제8일에 단계 용량(목표 용량과 동일) 및 제15일 및 그 후 Q2W의 목표 용량을 포함하는 2단계 투여(옵션 1).

● 제1일에 준비 용량, 이어서 제8일에 단계 용량, 제15일에 단계 용량(목표 용량과 동일) 및 주기 2의 제1일, 그 후 Q2W의 목표 용량을 포함하는 2단계 투여(옵션 2).

● 제1일에 준비 용량, 이어서 제4일에 단계 용량, 제8일에 단계 용량, 제15일에 단계 용량(목표 용량과 동일) 및 주기 2의 제1일, 그 후 Q2W의 목표 용량을 포함하는 3단계 투여.

파트 A2: 용량 확장 단계. 용량 탐색 단계(파트 A1)를 기반으로 MTD 또는 RP2D가 선택되면 파트 A2가 시작된다.

파트 B: 파트 B는 적응증 A(파트 A1)의 예비 MTD 또는 RP2D가 확립되면 시작될 것이다.

파트 C: 새로운 안전성 데이터를 기반으로 하는 DLRT 권장 사항에 따라 아래에 요약된 하나 이상의 추가 CRS 완화 전략을 평가할 수 있다. 파트 C는 파트 A1이 진행되는 동안 시작될 것이다.

● IV 수화를 이용한 예방: 주기 1에서 준비 용량 및 단계 용량(들) 직후 4~5시간에 걸쳐 I L의 생리 식염수

● 주기 1에서 준비 용량 및 단계 용량(들) 6 내지 16시간 전에 덱사메타손 8 mg PO를 이용한 추가 코르티코스테로이드 예방

● 주기 1에서 준비 용량 및 단계 용량(들) 1시간 전에 토실리주맙 8 mg/kg IV

● 주기 1에서 제-2일 및 그 후 준비 용량 및 단계 용량(들) 2일 전에 에타너셉트 50 mg SQ(2단계 또는 3단계 투여의 제4일의 단계 용량 제외)

● 주기 1에서 준비 용량 및 단계 용량(들) 1시간 전에 아세트아미노펜 60 mg po

위의 CRS 완화 전략은 초기에 IV 덱사메타손으로 투여될 것이다. 새로운 안전성 프로파일에 기반하여, 스테로이드 예비 투약 없이 안전성 프로파일을 평가하기 위해 위의 CRS 전략 중 하나를 단독으로 계속하면서 IV 덱사메타손이 중단될 수 있다.

파트 C에 등록된 각 피험자는 전술한 AMG 757 요법 외에 위의 추가 CRS 완화 전략 중 하나만 받게 될 것이다. 피험자는 안전하고 내약성이 있다고 간주된 AMG 757의 용량으로 시작할 것이다. 새로운 안전성 데이터를 기반으로 CRS의 발생률이 감소하면, 위의 전략 중 하나 이상이 파트 A 또는 B로 실행될 수 있다.

표 2는 연구 20160323에 대한 자격 기준을 요약한 것이다.

[표 2]

주요 자격 기준

실시예 4 시험 20160323의 연구 종점

연구 20160323의 가설은 AMG 757이 안전하고 적응증 A 및 B가 있는 피험자에서 내약성이 있다는 것이다.

일차 종점: 용량 제한 독성(DLT), 치료로 인한 유해 사례(AE), 치료 관련 AE 및 활력 징후, ECG, 신체 검사 및 임상 실험실 테스트에서 임상적으로 유의한 변화.

이차 종점: 적응증 A 및 B의 경우: (1) 최대 관찰 농도(C_max), 최소 관찰 농도(C_min), 2주 투여 간격에 걸친 농도-시간 곡선 아래 면적(AUC), 다중 투여 후 축적 및 가능한 경우 반감기(t_1/2)를 포함하나 이에 한정되지 않는 정맥 내 투여 후의 AMG 757에 대한 PK 매개변수, (2) 고형 종양의 수정된 반응 평가 기준(RECIST) 1.1에 따른 객관적 반응(OR), (3) 반응의 지속기간(DOR) 및 (4) 1년 무진행 생존(PFS) 및 (5) 1년 전체 생존(OS). 적응증 B의 경우에만: 무재발 생존(Relapse Free Survival, RFS).

탐색적 종점: 적응증 A 및 B의 경우: (1) 항-AMG 757 항체 형성의 발생률, (2) 혈액 내 단백질, 핵산 및 세포 바이오마커(예를 들어, 사이토카인, 림프구 상태, CTC, sDLL3)의 변화, (3) 기준선에서 종양 조직의 세포 표면 단백질 발현(예를 들어, DLL3) 및 종양 침윤 림프구 상태. 적응증 B의 경우에만: AMG 757 치료 전 T 세포 사이토카인 생산에 대한 이전 화학요법의 효과. 파트 C의 경우에만: CRS의 발병.

실시예 5 인간에서의 효과

인간에서의 약동학: 비구획 접근법을 사용한 예비 AMG 757 PK 분석은 코호트 1에서 5까지의 피험자에 대해 수행되었다. 예비 PK 결과는 AMG 757 노출이 0.003 mg에서 0.3 mg으로 용량에 따라 증가했음을 보여준다. 추정된 최종 반감기(t_1/2)는 다수의 Q2W 투여 후 용량에 걸쳐 대략 1주일이다. 유의미한 축적은 관찰되지 않았다(< 2배).

0.3 mg IV Q2W(코호트 5)에서 1건의 확인된 반응이 있었다.

다음은 연구의 상이한 코호트에서 사용된 AMG 757 용량 및 투여 일정에 대한 요약이다.

항종양 활성은 고형 종양에서 수정된 반응 평가 기준(RECIST) 1.1을 사용하여 평가하였다; 평가는 스크리닝 시 및 AMG 757 치료 후 질환 진행, 동의 철회 또는 새로운 항암 요법 시작까지 8 ± 1주마다 수행되었다.

8개의 용량 수준(DL)에 등록된 40명의 환자(연령의 중간값 [범위], 64세 [44~80], ECOG PS: 0~1, n=39 [97.5%], 이전 선의 중간값: 2.0 [1~6]; 이전의 PD-1/PD-L1 치료: n=17 [42.5%])는 1 이상의 용량의 AMG 757을 받았다. 치료 지속기간의 중간값은 6.1주(0.1~59.4)였다. 유해 사례(AE)는 39명(97.5%)의 환자에서 발생하여 4명(10.0%)에서 중단을 초래했다. 등급 3 이상, 7명(17.5%) 및 등급 5, 1명(2.5%)(폐렴; DL5 [0.3 mg])을 포함한 32명(80.0%)은 치료와 관련되었다. 18명(45.0%)의 환자에서 사이토카인 방출 증후군(CRS)이 보고되었다. 등급 2의 CRS가 5명(12.5%)에서 보고되었고; 등급 3 이상의 CRS는 없었다. 주로 발열 ± 저혈압으로 나타난 CRS는 가역적이었고, 치료 중지나 중단으로 이어지지 않았으며, 대부분 AMG 757의 처음 2회 용량 후 24시간 이내에 발생했으며, 지지 요법, 코르티코스테로이드 및/또는 항-IL-6 치료로 관리되었다. 6명(17.6%)의 환자는 치료로 인한 항-AMG 757 결합 항체를 발달시켰다.　항-AMG 757 항체는 AE와 연관되지 않았으며 약물 노출에 명백한 영향을 미치지는 않았다. AMG 757의 평균(+SD) 정상 상태 혈청 농도-시간 프로파일은 도 5에 제시되어 있다. AMG 757은 노출에서 용량 비례 증가를 보였다(도 5).

확인된 부분 반응(PR)은 6명(15.8%)의 환자에 대해 보고되었다(DL5에서 1/12 [8.3%], DL6에서 1/8 [12.5%], DL7에서 3/7 [42.9%], 및 DL8에서 1/7 [14.3%] [도 4]). DL8에서 확인되지 않은 PR이 진행 중인 1명의 환자를 포함하여 11명(28.9%)에 대해 안정 질환이 보고되었다. PR이 확인된 환자는 이전 선의 치료법의 중간값이 2 (1~4)였고, 반응의 지속 기간이 1.9+ 내지 9.4+개월이었다. 임의의 수준에서 DLL3 발현은 31/32(96.9%) 환자 종양 샘플에서 관찰되었으며, 전체 H 점수는 40~300이었다. 광범위한 DLL3 발현에 걸쳐 종양 수축이 발생했다(H 점수, 55~300). 결과는 AMG 757이 최대 10 mg의 용량에서 허용 가능한 안전성을 가지며 SCLC 환자에서 항-종양 활성을 나타낸다는 것을 보여준다.

10종의 용량 수준(DL)에 등록된 59명의 환자는 1회 이상의 AMG 757 용량을 투여 받았다. 해당 데이터 마감일에 전체 반응률(ORR) 분석 기준을 충족한 환자의 객관적 반응 요약은 도 6에 제시되어 있다. 확인된 부분 반응(PR)은 7명(14.6%)의 환자에 대해 보고되었다(DL5에서 1/12 [8.3%], DL6에서 1/8 [12.5%], DL7에서 3/7 [42.9%], DL8에서 2/10 [20%] 및 DL 9 에서 0/7 [0%] [도 6]). 안정 질환은 코호트 9에서 2명(2/7 [28.6%])을 포함하여 12명(25%)에 대해 보고되었다. 1건의 등급 3의 CRS가 코호트 9의 한 환자에서 관찰되었으며, 지지 요법, 코르티코스테로이드 및 승압제 치료로 관리되었다. 결과는 AMG 757이 최대 30 mg의 용량에서 허용 가능한 안전성을 가지며 SCLC 환자에서 항-종양 활성을 나타낸다는 것을 보여준다.

코호트 10에 등록된 7명의 환자는 1회 이상 용량의 AMG 757을 투여 받았고 4명의 피험자는 100 mg(제8일)을 적어도 1회 투여 받았다. 이전 코호트와 비교하여 이들 환자에서 새로운 안전성 신호가 관찰되지 않았다.

본 명세서는 본 명세서 내에 인용된 참고문헌의 교시에 비추어 가장 철저하게 이해된다. 본 명세서 내의 실시형태는 본 발명의 실시형태의 예시를 제공하며, 본 발명의 범주를 제한하는 것으로 해석되어서는 안 된다. 당업자는 다수의 다른 실시형태가 본 발명에 의해 포함된다는 점을 용이하게 인식한다. 본 개시내용에 인용된 모든 간행물, 특허 및 서열은 전체가 참조로 포함된다. 참조로 포함된 자료가 본 명세서와 모순되거나 일치하지 않는 정도까지, 본 명세서는 임의의 이러한 자료를 대체할 것이다. 본 명세서의 임의의 참고문헌의 인용은 이러한 참고문헌이 본 발명에 대한 선행 기술이라는 용인은 아니다.

당업자는 본원에 기술된 본 발명의 구체적인 실시형태에 대한 많은 균등물을 인식하거나, 통상적 실험만으로도 확인할 수 있을 것이다. 이러한 균등물은 다음의 실시형태에 의해 포괄되는 것으로 의도된다.

서열 표

서열번호	DLL3 에피토프	명칭	형식/기원	아미노산 서열
1		DLL3-1	VH CDR1	dygih
2		DLL3-1	VH CDR2	visyhgsnkyyarsvkg
3		DLL3-1	VH CDR3	eipfgmdv
4		DLL3-1	VL CDR1	rssqsllhsdgynyld
5		DLL3-1	VL CDR2	lgsnras
6		DLL3-1	VL CDR3	mqalqtplt
7		DLL3-1	VH	qvqlvesgggvvqsgrslrlscaasgftfsdygihwvrqapgkglewvavisyhgsnkyyarsvkgrftvsrdnskntlylqmnslraedtavyycareipfgmdvwgqgttvtvss
8		DLL3-1	VL	divmtqtplslpvtpgepasiscrssqsllhsdgynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftltisrveaedvgvyycmqalqtpltfgggtkvdik
9	N-말단	DLL3-1	scFv	qvqlvesgggvvqsgrslrlscaasgftfsdygihwvrqapgkglewvavisyhgsnkyyarsvkgrftvsrdnskntlylqmnslraedtavyycareipfgmdvwgqgttvtvssggggsggggsggggsdivmtqtplslpvtpgepasiscrssqsllhsdgynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftltisrveaedvgvyycmqalqtpltfgggtkvdik
10		DLL3-1 xI2C	이중특이적분자	qvqlvesgggvvqsgrslrlscaasgftfsdygihwvrqapgkglewvavisyhgsnkyyarsvkgrftvsrdnskntlylqmnslraedtavyycareipfgmdvwgqgttvtvssggggsggggsggggsdivmtqtplslpvtpgepasiscrssqsllhsdgynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftltisrveaedvgvyycmqalqtpltfgggtkvdiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvl
11		DLL3-2	VH CDR1	gyymh
12		DLL3-2	VH CDR2	winpnsgdtnyaqkfqg
13		DLL3-2	VH CDR3	daniaaldafei
14		DLL3-2	VL CDR1	rasqsissyln
15		DLL3-2	VL CDR2	aasslqs
16		DLL3-2	VL CDR3	qqsystplt
17		DLL3-2	VH	qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsgdtnyaqkfqgrvtmtrdtsistaymelsrltsddtavyycardaniaaldafeiwgqgtmvtvss
18		DLL3-2	VL	diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfgggtkveik
19	N-말단	DLL3-2	scFv	qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsgdtnyaqkfqgrvtmtrdtsistaymelsrltsddtavyycardaniaaldafeiwgqgtmvtvssggggsggggsggggsdiqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfgggtkveik
20		DLL3-2 xI2C	이중특이적분자	qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsgdtnyaqkfqgrvtmtrdtsistaymelsrltsddtavyycardaniaaldafeiwgqgtmvtvssggggsggggsggggsdiqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfgggtkveiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvl
21		DLL3-3	VH CDR1	Sygmh
22		DLL3-3	VH CDR2	Visyhgrdtyyarsvkg
23		DLL3-3	VH CDR3	Dgatvtsyyysgmdv
24		DLL3-3	VL CDR1	Rasqgisnyla
25		DLL3-3	VL CDR2	Lasslqs
26		DLL3-3	VL CDR3	Qqynfypft
27		DLL3-3	VH	Qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisyhgrdtyyarsvkgrftisrdnskntlylhmnslraedtavyycardgatvtsyyysgmdvwgqgttvtvssk
28		DLL3-3	VL	Diqmtqspsslsasvgdrvtitcrasqgisnylawfqqkpgkapksliylasslqsgvpskfsgsgsgtdftltisslqpedfatyycqqynfypftfgpgtkvdik
29	EGF-1	DLL3-3	scFv	Qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisyhgrdtyyarsvkgrftisrdnskntlylhmnslraedtavyycardgatvtsyyysgmdvwgqgttvtvssggggsggggsggggsdiqmtqspsslsasvgdrvtitcrasqgisnylawfqqkpgkapksliylasslqsgvpskfsgsgsgtdftltisslqpedfatyycqqynfypftfgpgtkvdik
30		DLL3-3 xI2C	이중특이적분자	Qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisyhgrdtyyarsvkgrftisrdnskntlylhmnslraedtavyycardgatvtsyyysgmdvwgqgttvtvssggggsggggsggggsdiqmtqspsslsasvgdrvtitcrasqgisnylawfqqkpgkapksliylasslqsgvpskfsgsgsgtdftltisslqpedfatyycqqynfypftfgpgtkvdiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvl
31		DLL3-4	VH CDR1	Syyws
32		DLL3-4	VH CDR2	Yvyysgttnynpslks
33		DLL3-4	VH CDR3	Iavtgfyfdy
34		DLL3-4	VL CDR1	Rasqrvnnnyla
35		DLL3-4	VL CDR2	Gassrat
36		DLL3-4	VL CDR3	Qqydrsplt
37		DLL3-4	VH	Qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyvyysgttnynpslksrvtisvdtsknqfslklssvtaadtavyycasiavtgfyfdywgqgtlvtvss
38		DLL3-4	VL	Eivltqspgtlslspgervtlscrasqrvnnnylawyqqrpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqydrspltfgggtkleik
39	EGF-3	DLL3-4	scFv	qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyvyysgttnynpslksrvtisvdtsknqfslklssvtaadtavyycasiavtgfyfdywgqgtlvtvssggggsggggsggggseivltqspgtlslspgervtlscrasqrvnnnylawyqqrpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqydrspltfgggtkleik
40		DLL3-4 xI2C	이중특이적분자	Qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyvyysgttnynpslksrvtisvdtsknqfslklssvtaadtavyycasiavtgfyfdywgqgtlvtvssggggsggggsggggseivltqspgtlslspgervtlscrasqrvnnnylawyqqrpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqydrspltfgggtkleiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvl
41		DLL3-5	VH CDR1	Syyws
42		DLL3-5	VH CDR2	Yiyysgrtnyypslks
43		DLL3-5	VH CDR3	Iavagfffdy
44		DLL3-5	VL CDR1	Rasqsvnknyla
45		DLL3-5	VL CDR2	Gassrat
46		DLL3-5	VL CDR3	Qqydrsplt
47		DLL3-5	VH	Qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgrtnyypslksrvtisidtsknqfslklssvtaadtavyycariavagfffdywgqgtlvtvss
48		DLL3-5	VL	Eivltqspgtlslspgeratlscrasqsvnknylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqydrspltfgggtkleik
49	EGF-3	DLL3-5	scFv	qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgrtnyypslksrvtisidtsknqfslklssvtaadtavyycariavagfffdywgqgtlvtvssggggsggggsggggseivltqspgtlslspgeratlscrasqsvnknylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqydrspltfgggtkleik
50		DLL3-5 xI2C	이중특이적분자	Qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgrtnyypslksrvtisidtsknqfslklssvtaadtavyycariavagfffdywgqgtlvtvssggggsggggsggggseivltqspgtlslspgeratlscrasqsvnknylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqydrspltfgggtkleiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvl
51		DLL3-6	VH CDR1	Sfyws
52		DLL3-6	VH CDR2	Yiyysgttnynpslks
53		DLL3-6	VH CDR3	Iavagfffdy
54		DLL3-6	VL CDR1	Rasqsvnknyla
55		DLL3-6	VL CDR2	Gassrat
56		DLL3-6	VL CDR3	Qqydrsplt
57		DLL3-6	VH	Qvqlqesgpglvkpsetlsltctvsgasissfywswirqppgkglewigyiyysgttnynpslksrvtisvdtsknqfslklssvtaadtavyycariavagfffdywgqgtlvtvss
58		DLL3-6	VL	Eivltqspgtlslspgeratlscrasqsvnknylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqydrspltfgggtkveik
59	EGF-3	DLL3-6	scFv	qvqlqesgpglvkpsetlsltctvsgasissfywswirqppgkglewigyiyysgttnynpslksrvtisvdtsknqfslklssvtaadtavyycariavagfffdywgqgtlvtvssggggsggggsggggseivltqspgtlslspgeratlscrasqsvnknylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqydrspltfgggtkveik
60		DLL3-6 xI2C	이중특이적분자	Qvqlqesgpglvkpsetlsltctvsgasissfywswirqppgkglewigyiyysgttnynpslksrvtisvdtsknqfslklssvtaadtavyycariavagfffdywgqgtlvtvssggggsggggsggggseivltqspgtlslspgeratlscrasqsvnknylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqydrspltfgggtkveiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvl
61		DLL3-7	VH CDR1	Sfyws
62		DLL3-7	VH CDR2	Yiyysgttnynpslks
63		DLL3-7	VH CDR3	Iavagfffdy
64		DLL3-7	VL CDR1	Rasqsvnknyla
65		DLL3-7	VL CDR2	Gassrat
66		DLL3-7	VL CDR3	Qqydrsplt
67		DLL3-7	VH	Qvqlqesgpglvkpsqtlsltctvsgasissfywswirqppgkglewigyiyysgttnynpslksrvtisvdtsknqfslklssvtaadtavyycariavagfffdywgqgtlvtvss
68		DLL3-7	VL	Eivltqspgtlslspgeratlscrasqsvnknylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqydrspltfgggtkveik
69	EGF-3	DLL3-7	scFv	qvqlqesgpglvkpsqtlsltctvsgasissfywswirqppgkglewigyiyysgttnynpslksrvtisvdtsknqfslklssvtaadtavyycariavagfffdywgqgtlvtvssggggsggggsggggseivltqspgtlslspgeratlscrasqsvnknylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqydrspltfgggtkveik
70		DLL3-7 xI2C	이중특이적분자	Qvqlqesgpglvkpsqtlsltctvsgasissfywswirqppgkglewigyiyysgttnynpslksrvtisvdtsknqfslklssvtaadtavyycariavagfffdywgqgtlvtvssggggsggggsggggseivltqspgtlslspgeratlscrasqsvnknylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqydrspltfgggtkveiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvl
71		DLL3-8	VH CDR1	Sfyws
72		DLL3-8	VH CDR2	Yiyysgttnynpslks
73		DLL3-8	VH CDR3	Iavagfffdy
74		DLL3-8	VL CDR1	Rasqsvnknyla
75		DLL3-8	VL CDR2	Gassrat
76		DLL3-8	VL CDR3	Qqydrsplt
77		DLL3-8	VH	Qvqlqewgpglvkpsetlsltctvsgasissfywswirqppgkglewigyiyysgttnynpslksrvtisvdtsknqlslklssvtaadtavyycariavagfffdywgqgtlvtvssk
78		DLL3-8	VL	Eivltqspgtlslspgeratlscrasqsvnknylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqydrspltfgggtkvdik
79	EGF-3	DLL3-8	scFv	qvqlqewgpglvkpsetlsltctvsgasissfywswirqppgkglewigyiyysgttnynpslksrvtisvdtsknqlslklssvtaadtavyycariavagfffdywgqgtlvtvssggggsggggsggggseivltqspgtlslspgeratlscrasqsvnknylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqydrspltfgggtkvdik
80		DLL3-8 xI2C	이중특이적분자	Qvqlqewgpglvkpsetlsltctvsgasissfywswirqppgkglewigyiyysgttnynpslksrvtisvdtsknqlslklssvtaadtavyycariavagfffdywgqgtlvtvssggggsggggsggggseivltqspgtlslspgeratlscrasqsvnknylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqydrspltfgggtkvdiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvl
81		DLL3-9	VH CDR1	Sfyws
82		DLL3-9	VH CDR2	Yiyysgttnynpslks
83		DLL3-9	VH CDR3	Iavagfffdy
84		DLL3-9	VL CDR1	Rasqsvnknyla
85		DLL3-9	VL CDR2	Gassrat
86		DLL3-9	VL CDR3	Qqydrsplt
87		DLL3-9	VH	Qvqlqesgpglvkpsetlsltctvsgasissfywswirqppgkglewigyiyysgttnynpslksrvtisvdtsknqfslklssvtaadtavyycariavagfffdywgqgtlvtvss
88		DLL3-9	VL	Eivltqspgtlslspgesatlscrasqsvnknylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqydrspltfgggtrleik
89	EGF-3	DLL3-9	scFv	qvqlqesgpglvkpsetlsltctvsgasissfywswirqppgkglewigyiyysgttnynpslksrvtisvdtsknqfslklssvtaadtavyycariavagfffdywgqgtlvtvssggggsggggsggggseivltqspgtlslspgesatlscrasqsvnknylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqydrspltfgggtrleik
90		DLL3-9 xI2C	이중특이적분자	Qvqlqesgpglvkpsetlsltctvsgasissfywswirqppgkglewigyiyysgttnynpslksrvtisvdtsknqfslklssvtaadtavyycariavagfffdywgqgtlvtvssggggsggggsggggseivltqspgtlslspgesatlscrasqsvnknylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqydrspltfgggtrleiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvl
91		DLL3-10	VH CDR1	Syyws
92		DLL3-10	VH CDR2	Yifyngitnynpslks
93		DLL3-10	VH CDR3	Ihsgsfsfdy
94		DLL3-10	VL CDR1	Rasqsvsrgyla
95		DLL3-10	VL CDR2	Gassrat
96		DLL3-10	VL CDR3	Qqydtspit
97		DLL3-10	VH	Qvqlqesgpglvkpsqtlsltctvsggsissyywswirqppgkglewigyifyngitnynpslksrvtisldtsknqfslklssvtaadtakyycarihsgsfsfdywdqgtlvtvss
98		DLL3-10	VL	Eivmtqspgtlslspgeratlscrasqsvsrgylawyqqkpgqaprlliygassratdipdrfsgsgsgtdftltisrlepedfavyycqqydtspitfgqgtkveik
99	EGF-3	DLL3-10	scFv	qvqlqesgpglvkpsqtlsltctvsggsissyywswirqppgkglewigyifyngitnynpslksrvtisldtsknqfslklssvtaadtakyycarihsgsfsfdywdqgtlvtvssggggsggggsggggseivmtqspgtlslspgeratlscrasqsvsrgylawyqqkpgqaprlliygassratdipdrfsgsgsgtdftltisrlepedfavyycqqydtspitfgqgtkveik
100		DLL3-10 xI2C	이중특이적분자	Qvqlqesgpglvkpsqtlsltctvsggsissyywswirqppgkglewigyifyngitnynpslksrvtisldtsknqfslklssvtaadtakyycarihsgsfsfdywdqgtlvtvssggggsggggsggggseivmtqspgtlslspgeratlscrasqsvsrgylawyqqkpgqaprlliygassratdipdrfsgsgsgtdftltisrlepedfavyycqqydtspitfgqgtkveiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvl
101		DLL3-11	VH CDR1	nagms
102		DLL3-11	VH CDR2	riknkidggttdfaapvkg
103		DLL3-11	VH CDR3	rgwygdyfdy
104		DLL3-11	VL CDR1	rssqsllhsngynyld
105		DLL3-11	VL CDR2	lgsnras
106		DLL3-11	VL CDR3	mqalqtpft
107		DLL3-11	VH	evqlvesggglvkpggslrlscaasgfifnnagmswvrqapgkglewvgriknkidggttdfaapvkgrftisrddskntlylqmnslkaedtavyyctargwygdyfdywgqgtlvtvss
108		DLL3-11	VL	divmtqtplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgiyycmqalqtpftfgpgtkveik
109	EGF-3	DLL3-11	scFv	evqlvesggglvkpggslrlscaasgfifnnagmswvrqapgkglewvgriknkidggttdfaapvkgrftisrddskntlylqmnslkaedtavyyctargwygdyfdywgqgtlvtvssggggsggggsggggsdivmtqtplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgiyycmqalqtpftfgpgtkveik
110		DLL3-11 xI2C	이중특이적분자	evqlvesggglvkpggslrlscaasgfifnnagmswvrqapgkglewvgriknkidggttdfaapvkgrftisrddskntlylqmnslkaedtavyyctargwygdyfdywgqgtlvtvssggggsggggsggggsdivmtqtplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgiyycmqalqtpftfgpgtkveiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvl
111		DLL3-12	VH CDR1	sydih
112		DLL3-12	VH CDR2	visshgsnknyarsvkg
113		DLL3-12	VH CDR3	dgysgndpfyyyyhgmdv
114		DLL3-12	VL CDR1	rasqsissyln
115		DLL3-12	VL CDR2	aasslqs
116		DLL3-12	VL CDR3	qqsfttplt
117		DLL3-12	VH	Qvqlvesgggvvqpgrslrlscaasgfsfssydihwvrqapgkglewvavisshgsnknyarsvkgrftisrdnskntlylqmnslkaedtavyycardgysgndpfyyyyhgmdvwgqgttvtvss
118		DLL3-12	VL	diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdfsltisslqpedfatyycqqsfttpltfgggtkveik
119	EGF-3/[4]	DLL3-12	scFv	qvqlvesgggvvqpgrslrlscaasgfsfssydihwvrqapgkglewvavisshgsnknyarsvkgrftisrdnskntlylqmnslkaedtavyycardgysgndpfyyyyhgmdvwgqgttvtvssggggsggggsggggsdiqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdfsltisslqpedfatyycqqsfttpltfgggtkveik
120		DLL3-12 xI2C	이중특이적분자	qvqlvesgggvvqpgrslrlscaasgfsfssydihwvrqapgkglewvavisshgsnknyarsvkgrftisrdnskntlylqmnslkaedtavyycardgysgndpfyyyyhgmdvwgqgttvtvssggggsggggsggggsdiqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdfsltisslqpedfatyycqqsfttpltfgggtkveiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvl
121		DLL3-13	VH CDR1	syymh
122		DLL3-13	VH CDR2	iinpsdgstnyaqnfqg
123		DLL3-13	VH CDR3	ggnsafysyydmdv
124		DLL3-13	VL CDR1	Rssqslvyrdgntyls
125		DLL3-13	VL CDR2	Kvsnwqs
126		DLL3-13	VL CDR3	Mqgthwppt
127		DLL3-13	VH	Qvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinpsdgstnyaqnfqgrvtmtrdtstntvymelsslrsedtavyycarggnsafysyydmdvwgqgttvtvss
128		DLL3-13	VL	dvvmtqsplslpvtlgqpasiscrssqslvyrdgntylswfqqrpgqsprrliykvsnwqsgvpdrfsgsgsgtdftlkisrveaedvgvyfcmqgthwpptfgqgtkveik
129	EGF-4	DLL3-13	scFv	Qvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinpsdgstnyaqnfqgrvtmtrdtstntvymelsslrsedtavyycarggnsafysyydmdvwgqgttvtvssggggsggggsggggsdvvmtqsplslpvtlgqpasiscrssqslvyrdgntylswfqqrpgqsprrliykvsnwqsgvpdrfsgsgsgtdftlkisrveaedvgvyfcmqgthwpptfgqgtkveik
130		DLL3-13 xI2C	이중특이적분자	Qvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinpsdgstnyaqnfqgrvtmtrdtstntvymelsslrsedtavyycarggnsafysyydmdvwgqgttvtvssggggsggggsggggsdvvmtqsplslpvtlgqpasiscrssqslvyrdgntylswfqqrpgqsprrliykvsnwqsgvpdrfsgsgsgtdftlkisrveaedvgvyfcmqgthwpptfgqgtkveiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvl
131		DLL3-14	VH CDR1	Nyymh
132		DLL3-14	VH CDR2	Iinpsdgstsyaqkfqg
133		DLL3-14	VH CDR3	Ggnsafysyydmdv
134		DLL3-14	VL CDR1	Rssqslvyrdgntyls
135		DLL3-14	VL CDR2	Kvsnwqs
136		DLL3-14	VL CDR3	Mqgthwppt
137		DLL3-14	VH	Qvqlvqsgaevkkpgasvkvsckasgytftnyymhwvrqapglglewmgiinpsdgstsyaqkfqgrvtmtrdtstntvymdlsslrsedtavyycarggnsafysyydmdvwgqgttvtvss
138		DLL3-14	VL	Dvvmtqtplslpvtlgqpasiscrssqslvyrdgntylswfqqrpgqsprrliykvsnwqsgvpdrfsgggsgtdftlkisrveaedvgvyycmqgthwpptfgqgtkveik
139	EGF-4	DLL3-14	scFv	Qvqlvqsgaevkkpgasvkvsckasgytftnyymhwvrqapglglewmgiinpsdgstsyaqkfqgrvtmtrdtstntvymdlsslrsedtavyycarggnsafysyydmdvwgqgttvtvssggggsggggsggggsdvvmtqtplslpvtlgqpasiscrssqslvyrdgntylswfqqrpgqsprrliykvsnwqsgvpdrfsgggsgtdftlkisrveaedvgvyycmqgthwpptfgqgtkveik
140		DLL3-14 xI2C	이중특이적분자	Qvqlvqsgaevkkpgasvkvsckasgytftnyymhwvrqapglglewmgiinpsdgstsyaqkfqgrvtmtrdtstntvymdlsslrsedtavyycarggnsafysyydmdvwgqgttvtvssggggsggggsggggsdvvmtqtplslpvtlgqpasiscrssqslvyrdgntylswfqqrpgqsprrliykvsnwqsgvpdrfsgggsgtdftlkisrveaedvgvyycmqgthwpptfgqgtkveiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvl
141		DLL3-15	VH CDR1	Gyyih
142		DLL3-15	VH CDR2	Iinpsdgstsygqnfqg
143		DLL3-15	VH CDR3	Ggnsafysyydmdv
144		DLL3-15	VL CDR1	Rssqslayrdgntyls
145		DLL3-15	VL CDR2	Kvsnwqs
146		DLL3-15	VL CDR3	Mqgthwppt
147		DLL3-15	VH	Qvqlvqsgaevkkpgasvkvsckasgytftgyyihwvrqapgqglewmgiinpsdgstsygqnfqgrvtmtrdtstntvymelsslrsedtavyycarggnsafysyydmdvwgqgttvtvss
148		DLL3-15	VL	Dvvmtqsplslpvtlgqpasiscrssqslayrdgntylswfqqrpgqsprrliykvsnwqsgvpdrfsgsgsgtdftlkisrveaedvgvyfcmqgthwpptfgqgtkveik
149	EGF-4	DLL3-15	scFv	Qvqlvqsgaevkkpgasvkvsckasgytftgyyihwvrqapgqglewmgiinpsdgstsygqnfqgrvtmtrdtstntvymelsslrsedtavyycarggnsafysyydmdvwgqgttvtvssggggsggggsggggsdvvmtqsplslpvtlgqpasiscrssqslayrdgntylswfqqrpgqsprrliykvsnwqsgvpdrfsgsgsgtdftlkisrveaedvgvyfcmqgthwpptfgqgtkveik
150		DLL3-15 xI2C	이중특이적분자	Qvqlvqsgaevkkpgasvkvsckasgytftgyyihwvrqapgqglewmgiinpsdgstsygqnfqgrvtmtrdtstntvymelsslrsedtavyycarggnsafysyydmdvwgqgttvtvssggggsggggsggggsdvvmtqsplslpvtlgqpasiscrssqslayrdgntylswfqqrpgqsprrliykvsnwqsgvpdrfsgsgsgtdftlkisrveaedvgvyfcmqgthwpptfgqgtkveiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvl
151		DLL3-16	VH CDR1	ghymh
152		DLL3-16	VH CDR2	iinpsdgstnyaqkfqg
153		DLL3-16	VH CDR3	gttvvhysyydmdv
154		DLL3-16	VL CDR1	rssqslvyrdgntylt
155		DLL3-16	VL CDR2	kvsnwqs
156		DLL3-16	VL CDR3	mqgthwppt
157		DLL3-16	VH	Qvqlvqsgaevkkpgasvkvsckasgytftghymhwvrqapgqglewmgiinpsdgstnyaqkfqgrvtmtrdtststvymelrslrsedtavyyctrgttvvhysyydmdvwgqgttvtvss
158		DLL3-16	VL	dvvmtqtplslpvtlgqpasiscrssqslvyrdgntyltwfqqrpgqsprrliykvsnwqsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgthwpptfgggtkveik
159	EGF-4	DLL3-16	scFv	Qvqlvqsgaevkkpgasvkvsckasgytftghymhwvrqapgqglewmgiinpsdgstnyaqkfqgrvtmtrdtststvymelrslrsedtavyyctrgttvvhysyydmdvwgqgttvtvssggggsggggsggggsdvvmtqtplslpvtlgqpasiscrssqslvyrdgntyltwfqqrpgqsprrliykvsnwqsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgthwpptfgggtkveik
160		DLL3-16 xI2C	이중특이적분자	Qvqlvqsgaevkkpgasvkvsckasgytftghymhwvrqapgqglewmgiinpsdgstnyaqkfqgrvtmtrdtststvymelrslrsedtavyyctrgttvvhysyydmdvwgqgttvtvssggggsggggsggggsdvvmtqtplslpvtlgqpasiscrssqslvyrdgntyltwfqqrpgqsprrliykvsnwqsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgthwpptfgggtkveiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvl
161		DLL3-17	VH CDR1	nyfmh
162		DLL3-17	VH CDR2	iinpsdgstsyaqnfqg
163		DLL3-17	VH CDR3	ggnsafysyydmdv
164		DLL3-17	VL CDR1	rssqslvyrdgntyls
165		DLL3-17	VL CDR2	rvsnwqs
166		DLL3-17	VL CDR3	mqgtywppt
167		DLL3-17	VH	qvqlvqsgaevkkpgasvkvsckasgytftnyfmhwvrqapglglewmgiinpsdgstsyaqnfqgrvtmtrdtstntvymelsslrsedtavyycarggnsafysyydmdvwgqgttvtvss
168		DLL3-17	VL	dvvmtqsplslpvtlgqpasiscrssqslvyrdgntylswfqqrpgqsprrliyrvsnwqsgvpdrfsgsgsgtdftlkisrveaedvgvyfcmqgtywpptfgqgtkvdik
169	EGF-4	DLL3-17	scFv	qvqlvqsgaevkkpgasvkvsckasgytftnyfmhwvrqapglglewmgiinpsdgstsyaqnfqgrvtmtrdtstntvymelsslrsedtavyycarggnsafysyydmdvwgqgttvtvssggggsggggsggggsdvvmtqsplslpvtlgqpasiscrssqslvyrdgntylswfqqrpgqsprrliyrvsnwqsgvpdrfsgsgsgtdftlkisrveaedvgvyfcmqgtywpptfgqgtkvdik
170		DLL3-17 xI2C	이중특이적분자	qvqlvqsgaevkkpgasvkvsckasgytftnyfmhwvrqapglglewmgiinpsdgstsyaqnfqgrvtmtrdtstntvymelsslrsedtavyycarggnsafysyydmdvwgqgttvtvssggggsggggsggggsdvvmtqsplslpvtlgqpasiscrssqslvyrdgntylswfqqrpgqsprrliyrvsnwqsgvpdrfsgsgsgtdftlkisrveaedvgvyfcmqgtywpptfgqgtkvdiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvl
171		DLL3-18	VH CDR1	Nygmh
172		DLL3-18	VH CDR2	Vishhgsskyyarsvkg
173		DLL3-18	VH CDR3	Dwwelvfdy
174		DLL3-18	VL CDR1	Kssqsllhsdgktfly
175		DLL3-18	VL CDR2	Evsnrfs
176		DLL3-18	VL CDR3	Lqgihlpft
177		DLL3-18	VH	Qvqlvesgggavqpgrslrlscaasgftfsnygmhwvrqapgkglewvavishhgsskyyarsvkgrftisrdnskntlylemnslraedtavyycardwwelvfdywgqgtlvtvss
178		DLL3-18	VL	Divmtqtplslsvtpgqpasisckssqsllhsdgktflywylqkpgqppqlliyevsnrfsgvpdrfsgsgsgtdftlkisrveaedvgvyyclqgihlpftfgpgtkveik
179	EGF-5/[6]	DLL3-18	scFv	qvqlvesgggavqpgrslrlscaasgftfsnygmhwvrqapgkglewvavishhgsskyyarsvkgrftisrdnskntlylemnslraedtavyycardwwelvfdywgqgtlvtvssggggsggggsggggsdivmtqtplslsvtpgqpasisckssqsllhsdgktflywylqkpgqppqlliyevsnrfsgvpdrfsgsgsgtdftlkisrveaedvgvyyclqgihlpftfgpgtkveik
180		DLL3-18 xI2C	이중특이적분자	Qvqlvesgggavqpgrslrlscaasgftfsnygmhwvrqapgkglewvavishhgsskyyarsvkgrftisrdnskntlylemnslraedtavyycardwwelvfdywgqgtlvtvssggggsggggsggggsdivmtqtplslsvtpgqpasisckssqsllhsdgktflywylqkpgqppqlliyevsnrfsgvpdrfsgsgsgtdftlkisrveaedvgvyyclqgihlpftfgpgtkveiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvl
181		DLL3-19	VH CDR1	Nsrmgvs
182		DLL3-19	VH CDR2	Hifsndgksystslks
183		DLL3-19	VH CDR3	Ynydssgyyysffdy
184		DLL3-19	VL CDR1	Rasqsissyln
185		DLL3-19	VL CDR2	Aasslqs
186		DLL3-19	VL CDR3	Qqgysspft
187		DLL3-19	VH	Qvtlkesgpmlvkptetltltctvsgfslsnsrmgvswirqppgralewlahifsndgksystslksrltiskdtsksqvvltmtnmdpvdtatyycarynydssgyyysffdywgqgtlvtvss
188		DLL3-19	VL	Diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqgysspftfgggtkveik
189	EGF-5/[6]	DLL3-19	scFv	qvtlkesgpmlvkptetltltctvsgfslsnsrmgvswirqppgralewlahifsndgksystslksrltiskdtsksqvvltmtnmdpvdtatyycarynydssgyyysffdywgqgtlvtvssggggsggggsggggsdiqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqgysspftfgggtkveik
190		DLL3-19 xI2C	이중특이적분자	Qvtlkesgpmlvkptetltltctvsgfslsnsrmgvswirqppgralewlahifsndgksystslksrltiskdtsksqvvltmtnmdpvdtatyycarynydssgyyysffdywgqgtlvtvssggggsggggsggggsdiqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqgysspftfgggtkveiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvl
191		DLL3-20	VH CDR1	Narmgvs
192		DLL3-20	VH CDR2	Hifstdeksystslks
193		DLL3-20	VH CDR3	Yyydssgyyysffdy
194		DLL3-20	VL CDR1	Rasqsirsyln
195		DLL3-20	VL CDR2	Gasnlqs
196		DLL3-20	VL CDR3	Qqsysspft
197		DLL3-20	VH	Qvtlkesgpvlvkptetltltctvsgfslsnarmgvswlrqppgkalewlahifstdeksystslksrltiskdtsksqvvltmtnmdpvdtatyycaryyydssgyyysffdywgqgtlvtvss
198		DLL3-20	VL	Diqmtqspsslsasvgdrvtitcrasqsirsylnwyqqkpgkapklliygasnlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysspftfgggtkveik
199	EGF-5/[6]	DLL3-20	scFv	qvtlkesgpvlvkptetltltctvsgfslsnarmgvswlrqppgkalewlahifstdeksystslksrltiskdtsksqvvltmtnmdpvdtatyycaryyydssgyyysffdywgqgtlvtvssggggsggggsggggsdiqmtqspsslsasvgdrvtitcrasqsirsylnwyqqkpgkapklliygasnlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysspftfgggtkveik
200		DLL3-20 xI2C	이중특이적분자	Qvtlkesgpvlvkptetltltctvsgfslsnarmgvswlrqppgkalewlahifstdeksystslksrltiskdtsksqvvltmtnmdpvdtatyycaryyydssgyyysffdywgqgtlvtvssggggsggggsggggsdiqmtqspsslsasvgdrvtitcrasqsirsylnwyqqkpgkapklliygasnlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysspftfgggtkveiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvl
201		DLL3-21	VH CDR1	Syyih
202		DLL3-21	VH CDR2	Iinpsggsksyaqkfrg
203		DLL3-21	VH CDR3	Smstvtsdafdi
204		DLL3-21	VL CDR1	Rasqsisnyln
205		DLL3-21	VL CDR2	Aasslqs
206		DLL3-21	VL CDR3	Qqsysaplt
207		DLL3-21	VH	Qvqlvqsgaevkkpgasvkvsckasgyaftsyyihwvrqapgqglewmgiinpsggsksyaqkfrgrvtmtrdtststvymelssltsedtavyycarsmstvtsdafdiwgqgtmvtvss
208		DLL3-21	VL	Diqmtqspsslsasvgdrvtitcrasqsisnylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgteftltisslqpedfatyycqqsysapltfgggtkvdik
209	EGF-5/[6]	DLL3-21	scFv	qvqlvqsgaevkkpgasvkvsckasgyaftsyyihwvrqapgqglewmgiinpsggsksyaqkfrgrvtmtrdtststvymelssltsedtavyycarsmstvtsdafdiwgqgtmvtvssggggsggggsggggsdiqmtqspsslsasvgdrvtitcrasqsisnylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgteftltisslqpedfatyycqqsysapltfgggtkvdik
210		DLL3-21 xI2C	이중특이적분자	Qvqlvqsgaevkkpgasvkvsckasgyaftsyyihwvrqapgqglewmgiinpsggsksyaqkfrgrvtmtrdtststvymelssltsedtavyycarsmstvtsdafdiwgqgtmvtvssggggsggggsggggsdiqmtqspsslsasvgdrvtitcrasqsisnylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgteftltisslqpedfatyycqqsysapltfgggtkvdiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvl
211	EGF-3	DLL3-4 xF12Q	이중특이적분자	qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyvyysgttnynpslksrvtisvdtsknqfslklssvtaadtavyycasiavtgfyfdywgqgtlvtvssggggsggggsggggseivltqspgtlslspgervtlscrasqrvnnnylawyqqrpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqydrspltfgggtkleiksggggsEVQLVESGGGLVQPGGSLRLSCAASGFTFNSYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKGRFTISRDDSKNTAYLQMNSLKTEDTAVYYCVRHGNFGNSYVSWWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL
212	EGF-3	DLL3-5 xF12Q	이중특이적분자	qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgrtnyypslksrvtisidtsknqfslklssvtaadtavyycariavagfffdywgqgtlvtvssggggsggggsggggseivltqspgtlslspgeratlscrasqsvnknylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqydrspltfgggtkleiksggggsEVQLVESGGGLVQPGGSLRLSCAASGFTFNSYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKGRFTISRDDSKNTAYLQMNSLKTEDTAVYYCVRHGNFGNSYVSWWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL
213	EGF-3	DLL3-6 xF12Q	이중특이적분자	qvqlqesgpglvkpsetlsltctvsgasissfywswirqppgkglewigyiyysgttnynpslksrvtisvdtsknqfslklssvtaadtavyycariavagfffdywgqgtlvtvssggggsggggsggggseivltqspgtlslspgeratlscrasqsvnknylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqydrspltfgggtkveiksggggsEVQLVESGGGLVQPGGSLRLSCAASGFTFNSYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKGRFTISRDDSKNTAYLQMNSLKTEDTAVYYCVRHGNFGNSYVSWWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL
214	EGF-3	DLL3-7 xF12Q	이중특이적분자	qvqlqesgpglvkpsqtlsltctvsgasissfywswirqppgkglewigyiyysgttnynpslksrvtisvdtsknqfslklssvtaadtavyycariavagfffdywgqgtlvtvssggggsggggsggggseivltqspgtlslspgeratlscrasqsvnknylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqydrspltfgggtkveiksggggsEVQLVESGGGLVQPGGSLRLSCAASGFTFNSYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKGRFTISRDDSKNTAYLQMNSLKTEDTAVYYCVRHGNFGNSYVSWWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL
215	EGF-3	DLL3-8 xF12Q	이중특이적분자	qvqlqewgpglvkpsetlsltctvsgasissfywswirqppgkglewigyiyysgttnynpslksrvtisvdtsknqlslklssvtaadtavyycariavagfffdywgqgtlvtvssggggsggggsggggseivltqspgtlslspgeratlscrasqsvnknylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqydrspltfgggtkvdiksggggsEVQLVESGGGLVQPGGSLRLSCAASGFTFNSYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKGRFTISRDDSKNTAYLQMNSLKTEDTAVYYCVRHGNFGNSYVSWWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL
216	EGF-3	DLL3-9 xF12Q	이중특이적분자	qvqlqesgpglvkpsetlsltctvsgasissfywswirqppgkglewigyiyysgttnynpslksrvtisvdtsknqfslklssvtaadtavyycariavagfffdywgqgtlvtvssggggsggggsggggseivltqspgtlslspgesatlscrasqsvnknylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqydrspltfgggtrleiksggggsEVQLVESGGGLVQPGGSLRLSCAASGFTFNSYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKGRFTISRDDSKNTAYLQMNSLKTEDTAVYYCVRHGNFGNSYVSWWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL
217	EGF-3	DLL3-10 xF12Q	이중특이적분자	qvqlqesgpglvkpsqtlsltctvsggsissyywswirqppgkglewigyifyngitnynpslksrvtisldtsknqfslklssvtaadtakyycarihsgsfsfdywdqgtlvtvssggggsggggsggggseivmtqspgtlslspgeratlscrasqsvsrgylawyqqkpgqaprlliygassratdipdrfsgsgsgtdftltisrlepedfavyycqqydtspitfgqgtkveiksggggsEVQLVESGGGLVQPGGSLRLSCAASGFTFNSYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKGRFTISRDDSKNTAYLQMNSLKTEDTAVYYCVRHGNFGNSYVSWWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL
218	EGF-4	DLL3-13 xF12Q	이중특이적분자	QvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinpsdgstnyaqnfqgrvtmtrdtstntvymelsslrsedtavyycarggnsafysyydmdvwgqgttvtvssggggsggggsggggsdvvmtqsplslpvtlgqpasiscrssqslvyrdgntylswfqqrpgqsprrliykvsnwqsgvpdrfsgsgsgtdftlkisrveaedvgvyfcmqgthwpptfgqgtkveiksggggsEVQLVESGGGLVQPGGSLRLSCAASGFTFNSYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKGRFTISRDDSKNTAYLQMNSLKTEDTAVYYCVRHGNFGNSYVSWWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL
219	EGF-4	DLL3-14 xF12Q	이중특이적분자	QvqlvqsgaevkkpgasvkvsckasgytftnyymhwvrqapglglewmgiinpsdgstsyaqkfqgrvtmtrdtstntvymdlsslrsedtavyycarggnsafysyydmdvwgqgttvtvssggggsggggsggggsdvvmtqtplslpvtlgqpasiscrssqslvyrdgntylswfqqrpgqsprrliykvsnwqsgvpdrfsgggsgtdftlkisrveaedvgvyycmqgthwpptfgqgtkveiksggggsEVQLVESGGGLVQPGGSLRLSCAASGFTFNSYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKGRFTISRDDSKNTAYLQMNSLKTEDTAVYYCVRHGNFGNSYVSWWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL
220	EGF-4	DLL3-15 xF12Q	이중특이적분자	QvqlvqsgaevkkpgasvkvsckasgytftgyyihwvrqapgqglewmgiinpsdgstsygqnfqgrvtmtrdtstntvymelsslrsedtavyycarggnsafysyydmdvwgqgttvtvssggggsggggsggggsdvvmtqsplslpvtlgqpasiscrssqslayrdgntylswfqqrpgqsprrliykvsnwqsgvpdrfsgsgsgtdftlkisrveaedvgvyfcmqgthwpptfgqgtkveiksggggsEVQLVESGGGLVQPGGSLRLSCAASGFTFNSYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKGRFTISRDDSKNTAYLQMNSLKTEDTAVYYCVRHGNFGNSYVSWWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL
221	N-말단	DLL3-1 xI2C -HALB 변이체 1	이중특이적 분자 -HALB 변이체 1	qvqlvesgggvvqsgrslrlscaasgftfsdygihwvrqapgkglewvavisyhgsnkyyarsvkgrftvsrdnskntlylqmnslraedtavyycareipfgmdvwgqgttvtvssggggsggggsggggsdivmtqtplslpvtpgepasiscrssqsllhsdgynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftltisrveaedvgvyycmqalqtpltfgggtkvdiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvlpggggsdahksevahrfkdlgeenfkalvliafaqylqqcpfedhvklvnevtefaktcvadesaencdkslhtlfgdklctvatlretygemadccakqepernecflqhkddnpnlprlvrpevdvmctafhdneetflkkylyeiarrhpyfyapellffakrykaafteccqaadkaacllpkldelrdegkassakqrlkcaslqkfgerafkawavarlsqrfpkaefaevsklvtdltkvhtecchgdllecaddradlakyicenqdsissklkeccekpllekshciaevendempadlpslaadfveskdvcknyaeakdvflgmflyeyarrhpdysvvlllrlaktyettlekccaaadphecyakvfdefkplveepqnlikqncelfeqlgeykfqnallvrytkkvpqvstptlvevsrnlgkvgskcckhpeakrmpcaedylsvvlnqlcvlhektpvsdrvtkccteslvnrrpcfsalevdetyvpkefnagtftfhadictlsekerqikkqtalvelvkhkpkatkeqlkaamddfaafvekcckaddketcfaeegkklvaasqaalglhhhhhh
222	N-말단	DLL3-2 xI2C -HALB 변이체 1	이중특이적 분자 -HALB 변이체 1	qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsgdtnyaqkfqgrvtmtrdtsistaymelsrltsddtavyycardaniaaldafeiwgqgtmvtvssggggsggggsggggsdiqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfgggtkveiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvlpggggsdahksevahrfkdlgeenfkalvliafaqylqqcpfedhvklvnevtefaktcvadesaencdkslhtlfgdklctvatlretygemadccakqepernecflqhkddnpnlprlvrpevdvmctafhdneetflkkylyeiarrhpyfyapellffakrykaafteccqaadkaacllpkldelrdegkassakqrlkcaslqkfgerafkawavarlsqrfpkaefaevsklvtdltkvhtecchgdllecaddradlakyicenqdsissklkeccekpllekshciaevendempadlpslaadfveskdvcknyaeakdvflgmflyeyarrhpdysvvlllrlaktyettlekccaaadphecyakvfdefkplveepqnlikqncelfeqlgeykfqnallvrytkkvpqvstptlvevsrnlgkvgskcckhpeakrmpcaedylsvvlnqlcvlhektpvsdrvtkccteslvnrrpcfsalevdetyvpkefnagtftfhadictlsekerqikkqtalvelvkhkpkatkeqlkaamddfaafvekcckaddketcfaeegkklvaasqaalglhhhhhh
223	EGF-1	DLL3-3 xI2C -HALB	이중특이적 분자 -HALB	qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisyhgrdtyyarsvkgrftisrdnskntlylhmnslraedtavyycardgatvtsyyysgmdvwgqgttvtvssggggsggggsggggsdiqmtqspsslsasvgdrvtitcrasqgisnylawfqqkpgkapksliylasslqsgvpskfsgsgsgtdftltisslqpedfatyycqqynfypftfgpgtkvdiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvlpggggsdahksevahrfkdlgeenfkalvliafaqylqqcpfedhvklvnevtefaktcvadesaencdkslhtlfgdklctvatlretygemadccakqepernecflqhkddnpnlprlvrpevdvmctafhdneetflkkylyeiarrhpyfyapellffakrykaafteccqaadkaacllpkldelrdegkassakqrlkcaslqkfgerafkawavarlsqrfpkaefaevsklvtdltkvhtecchgdllecaddradlakyicenqdsissklkeccekpllekshciaevendempadlpslaadfveskdvcknyaeakdvflgmflyeyarrhpdysvvlllrlaktyettlekccaaadphecyakvfdefkplveepqnlikqncelfeqlgeykfqnallvrytkkvpqvstptlvevsrnlgkvgskcckhpeakrmpcaedylsvvlnqlcvlhektpvsdrvtkccteslvnrrpcfsalevdetyvpkefnaetftfhadictlsekerqikkqtalvelvkhkpkatkeqlkavmddfaafvekcckaddketcfaeegkklvaasqaalglhhhhhh
224	EGF-3	DLL3-4 xI2C -HALB	이중특이적 분자 -HALB	qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyvyysgttnynpslksrvtisvdtsknqfslklssvtaadtavyycasiavtgfyfdywgqgtlvtvssggggsggggsggggseivltqspgtlslspgervtlscrasqrvnnnylawyqqrpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqydrspltfgggtkleiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvlpggggsdahksevahrfkdlgeenfkalvliafaqylqqcpfedhvklvnevtefaktcvadesaencdkslhtlfgdklctvatlretygemadccakqepernecflqhkddnpnlprlvrpevdvmctafhdneetflkkylyeiarrhpyfyapellffakrykaafteccqaadkaacllpkldelrdegkassakqrlkcaslqkfgerafkawavarlsqrfpkaefaevsklvtdltkvhtecchgdllecaddradlakyicenqdsissklkeccekpllekshciaevendempadlpslaadfveskdvcknyaeakdvflgmflyeyarrhpdysvvlllrlaktyettlekccaaadphecyakvfdefkplveepqnlikqncelfeqlgeykfqnallvrytkkvpqvstptlvevsrnlgkvgskcckhpeakrmpcaedylsvvlnqlcvlhektpvsdrvtkccteslvnrrpcfsalevdetyvpkefnaetftfhadictlsekerqikkqtalvelvkhkpkatkeqlkavmddfaafvekcckaddketcfaeegkklvaasqaalglhhhhhh
225	EGF-3	DLL3-5 xI2C -HALB	이중특이적 분자 -HALB	qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgrtnyypslksrvtisidtsknqfslklssvtaadtavyycariavagfffdywgqgtlvtvssggggsggggsggggseivltqspgtlslspgeratlscrasqsvnknylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqydrspltfgggtkleiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvlpggggsdahksevahrfkdlgeenfkalvliafaqylqqcpfedhvklvnevtefaktcvadesaencdkslhtlfgdklctvatlretygemadccakqepernecflqhkddnpnlprlvrpevdvmctafhdneetflkkylyeiarrhpyfyapellffakrykaafteccqaadkaacllpkldelrdegkassakqrlkcaslqkfgerafkawavarlsqrfpkaefaevsklvtdltkvhtecchgdllecaddradlakyicenqdsissklkeccekpllekshciaevendempadlpslaadfveskdvcknyaeakdvflgmflyeyarrhpdysvvlllrlaktyettlekccaaadphecyakvfdefkplveepqnlikqncelfeqlgeykfqnallvrytkkvpqvstptlvevsrnlgkvgskcckhpeakrmpcaedylsvvlnqlcvlhektpvsdrvtkccteslvnrrpcfsalevdetyvpkefnaetftfhadictlsekerqikkqtalvelvkhkpkatkeqlkavmddfaafvekcckaddketcfaeegkklvaasqaalglhhhhhh
226	EGF-3	DLL3-6 xI2C -HALB	이중특이적 분자 -HALB	qvqlqesgpglvkpsetlsltctvsgasissfywswirqppgkglewigyiyysgttnynpslksrvtisvdtsknqfslklssvtaadtavyycariavagfffdywgqgtlvtvssggggsggggsggggseivltqspgtlslspgeratlscrasqsvnknylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqydrspltfgggtkveiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvlpggggsdahksevahrfkdlgeenfkalvliafaqylqqcpfedhvklvnevtefaktcvadesaencdkslhtlfgdklctvatlretygemadccakqepernecflqhkddnpnlprlvrpevdvmctafhdneetflkkylyeiarrhpyfyapellffakrykaafteccqaadkaacllpkldelrdegkassakqrlkcaslqkfgerafkawavarlsqrfpkaefaevsklvtdltkvhtecchgdllecaddradlakyicenqdsissklkeccekpllekshciaevendempadlpslaadfveskdvcknyaeakdvflgmflyeyarrhpdysvvlllrlaktyettlekccaaadphecyakvfdefkplveepqnlikqncelfeqlgeykfqnallvrytkkvpqvstptlvevsrnlgkvgskcckhpeakrmpcaedylsvvlnqlcvlhektpvsdrvtkccteslvnrrpcfsalevdetyvpkefnaetftfhadictlsekerqikkqtalvelvkhkpkatkeqlkavmddfaafvekcckaddketcfaeegkklvaasqaalglhhhhhh
227	EGF-3	DLL3-7 xI2C -HALB	이중특이적 분자 -HALB	qvqlqesgpglvkpsqtlsltctvsgasissfywswirqppgkglewigyiyysgttnynpslksrvtisvdtsknqfslklssvtaadtavyycariavagfffdywgqgtlvtvssggggsggggsggggseivltqspgtlslspgeratlscrasqsvnknylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqydrspltfgggtkveiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvlpggggsdahksevahrfkdlgeenfkalvliafaqylqqcpfedhvklvnevtefaktcvadesaencdkslhtlfgdklctvatlretygemadccakqepernecflqhkddnpnlprlvrpevdvmctafhdneetflkkylyeiarrhpyfyapellffakrykaafteccqaadkaacllpkldelrdegkassakqrlkcaslqkfgerafkawavarlsqrfpkaefaevsklvtdltkvhtecchgdllecaddradlakyicenqdsissklkeccekpllekshciaevendempadlpslaadfveskdvcknyaeakdvflgmflyeyarrhpdysvvlllrlaktyettlekccaaadphecyakvfdefkplveepqnlikqncelfeqlgeykfqnallvrytkkvpqvstptlvevsrnlgkvgskcckhpeakrmpcaedylsvvlnqlcvlhektpvsdrvtkccteslvnrrpcfsalevdetyvpkefnaetftfhadictlsekerqikkqtalvelvkhkpkatkeqlkavmddfaafvekcckaddketcfaeegkklvaasqaalglhhhhhh
228	EGF-3	DLL3-8 xI2C -HALB	이중특이적 분자 -HALB	qvqlqewgpglvkpsetlsltctvsgasissfywswirqppgkglewigyiyysgttnynpslksrvtisvdtsknqlslklssvtaadtavyycariavagfffdywgqgtlvtvssggggsggggsggggseivltqspgtlslspgeratlscrasqsvnknylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqydrspltfgggtkvdiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvlpggggsdahksevahrfkdlgeenfkalvliafaqylqqcpfedhvklvnevtefaktcvadesaencdkslhtlfgdklctvatlretygemadccakqepernecflqhkddnpnlprlvrpevdvmctafhdneetflkkylyeiarrhpyfyapellffakrykaafteccqaadkaacllpkldelrdegkassakqrlkcaslqkfgerafkawavarlsqrfpkaefaevsklvtdltkvhtecchgdllecaddradlakyicenqdsissklkeccekpllekshciaevendempadlpslaadfveskdvcknyaeakdvflgmflyeyarrhpdysvvlllrlaktyettlekccaaadphecyakvfdefkplveepqnlikqncelfeqlgeykfqnallvrytkkvpqvstptlvevsrnlgkvgskcckhpeakrmpcaedylsvvlnqlcvlhektpvsdrvtkccteslvnrrpcfsalevdetyvpkefnaetftfhadictlsekerqikkqtalvelvkhkpkatkeqlkavmddfaafvekcckaddketcfaeegkklvaasqaalglhhhhhh
229	EGF-3	DLL3-9 xI2C -HALB	이중특이적 분자 -HALB	qvqlqesgpglvkpsetlsltctvsgasissfywswirqppgkglewigyiyysgttnynpslksrvtisvdtsknqfslklssvtaadtavyycariavagfffdywgqgtlvtvssggggsggggsggggseivltqspgtlslspgesatlscrasqsvnknylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqydrspltfgggtrleiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvlpggggsdahksevahrfkdlgeenfkalvliafaqylqqcpfedhvklvnevtefaktcvadesaencdkslhtlfgdklctvatlretygemadccakqepernecflqhkddnpnlprlvrpevdvmctafhdneetflkkylyeiarrhpyfyapellffakrykaafteccqaadkaacllpkldelrdegkassakqrlkcaslqkfgerafkawavarlsqrfpkaefaevsklvtdltkvhtecchgdllecaddradlakyicenqdsissklkeccekpllekshciaevendempadlpslaadfveskdvcknyaeakdvflgmflyeyarrhpdysvvlllrlaktyettlekccaaadphecyakvfdefkplveepqnlikqncelfeqlgeykfqnallvrytkkvpqvstptlvevsrnlgkvgskcckhpeakrmpcaedylsvvlnqlcvlhektpvsdrvtkccteslvnrrpcfsalevdetyvpkefnaetftfhadictlsekerqikkqtalvelvkhkpkatkeqlkavmddfaafvekcckaddketcfaeegkklvaasqaalglhhhhhh
230	EGF-3	DLL3-10 xI2C -HALB	이중특이적 분자 -HALB	qvqlqesgpglvkpsqtlsltctvsggsissyywswirqppgkglewigyifyngitnynpslksrvtisldtsknqfslklssvtaadtakyycarihsgsfsfdywdqgtlvtvssggggsggggsggggseivmtqspgtlslspgeratlscrasqsvsrgylawyqqkpgqaprlliygassratdipdrfsgsgsgtdftltisrlepedfavyycqqydtspitfgqgtkveiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvlpggggsdahksevahrfkdlgeenfkalvliafaqylqqcpfedhvklvnevtefaktcvadesaencdkslhtlfgdklctvatlretygemadccakqepernecflqhkddnpnlprlvrpevdvmctafhdneetflkkylyeiarrhpyfyapellffakrykaafteccqaadkaacllpkldelrdegkassakqrlkcaslqkfgerafkawavarlsqrfpkaefaevsklvtdltkvhtecchgdllecaddradlakyicenqdsissklkeccekpllekshciaevendempadlpslaadfveskdvcknyaeakdvflgmflyeyarrhpdysvvlllrlaktyettlekccaaadphecyakvfdefkplveepqnlikqncelfeqlgeykfqnallvrytkkvpqvstptlvevsrnlgkvgskcckhpeakrmpcaedylsvvlnqlcvlhektpvsdrvtkccteslvnrrpcfsalevdetyvpkefnaetftfhadictlsekerqikkqtalvelvkhkpkatkeqlkavmddfaafvekcckaddketcfaeegkklvaasqaalglhhhhhh
231	EGF-3	DLL3-11 xI2C -HALB	이중특이적 분자 -HALB	evqlvesggglvkpggslrlscaasgfifnnagmswvrqapgkglewvgriknkidggttdfaapvkgrftisrddskntlylqmnslkaedtavyyctargwygdyfdywgqgtlvtvssggggsggggsggggsdivmtqtplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgiyycmqalqtpftfgpgtkveiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvlpggggsdahksevahrfkdlgeenfkalvliafaqylqqcpfedhvklvnevtefaktcvadesaencdkslhtlfgdklctvatlretygemadccakqepernecflqhkddnpnlprlvrpevdvmctafhdneetflkkylyeiarrhpyfyapellffakrykaafteccqaadkaacllpkldelrdegkassakqrlkcaslqkfgerafkawavarlsqrfpkaefaevsklvtdltkvhtecchgdllecaddradlakyicenqdsissklkeccekpllekshciaevendempadlpslaadfveskdvcknyaeakdvflgmflyeyarrhpdysvvlllrlaktyettlekccaaadphecyakvfdefkplveepqnlikqncelfeqlgeykfqnallvrytkkvpqvstptlvevsrnlgkvgskcckhpeakrmpcaedylsvvlnqlcvlhektpvsdrvtkccteslvnrrpcfsalevdetyvpkefnaetftfhadictlsekerqikkqtalvelvkhkpkatkeqlkavmddfaafvekcckaddketcfaeegkklvaasqaalglhhhhhh
232	EGF-3/[4]	DLL3-12 xI2C -HALB	이중특이적 분자 -HALB	qvqlvesgggvvqpgrslrlscaasgfsfssydihwvrqapgkglewvavisshgsnknyarsvkgrftisrdnskntlylqmnslkaedtavyycardgysgndpfyyyyhgmdvwgqgttvtvssggggsggggsggggsdiqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdfsltisslqpedfatyycqqsfttpltfgggtkveiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvlpggggsdahksevahrfkdlgeenfkalvliafaqylqqcpfedhvklvnevtefaktcvadesaencdkslhtlfgdklctvatlretygemadccakqepernecflqhkddnpnlprlvrpevdvmctafhdneetflkkylyeiarrhpyfyapellffakrykaafteccqaadkaacllpkldelrdegkassakqrlkcaslqkfgerafkawavarlsqrfpkaefaevsklvtdltkvhtecchgdllecaddradlakyicenqdsissklkeccekpllekshciaevendempadlpslaadfveskdvcknyaeakdvflgmflyeyarrhpdysvvlllrlaktyettlekccaaadphecyakvfdefkplveepqnlikqncelfeqlgeykfqnallvrytkkvpqvstptlvevsrnlgkvgskcckhpeakrmpcaedylsvvlnqlcvlhektpvsdrvtkccteslvnrrpcfsalevdetyvpkefnaetftfhadictlsekerqikkqtalvelvkhkpkatkeqlkavmddfaafvekcckaddketcfaeegkklvaasqaalglhhhhhh
233	EGF-4	DLL3-13 xI2C -HALB	이중특이적 분자 -HALB	qvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinpsdgstnyaqnfqgrvtmtrdtstntvymelsslrsedtavyycarggnsafysyydmdvwgqgttvtvssggggsggggsggggsdvvmtqsplslpvtlgqpasiscrssqslvyrdgntylswfqqrpgqsprrliykvsnwqsgvpdrfsgsgsgtdftlkisrveaedvgvyfcmqgthwpptfgqgtkveiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvlpggggsdahksevahrfkdlgeenfkalvliafaqylqqcpfedhvklvnevtefaktcvadesaencdkslhtlfgdklctvatlretygemadccakqepernecflqhkddnpnlprlvrpevdvmctafhdneetflkkylyeiarrhpyfyapellffakrykaafteccqaadkaacllpkldelrdegkassakqrlkcaslqkfgerafkawavarlsqrfpkaefaevsklvtdltkvhtecchgdllecaddradlakyicenqdsissklkeccekpllekshciaevendempadlpslaadfveskdvcknyaeakdvflgmflyeyarrhpdysvvlllrlaktyettlekccaaadphecyakvfdefkplveepqnlikqncelfeqlgeykfqnallvrytkkvpqvstptlvevsrnlgkvgskcckhpeakrmpcaedylsvvlnqlcvlhektpvsdrvtkccteslvnrrpcfsalevdetyvpkefnaetftfhadictlsekerqikkqtalvelvkhkpkatkeqlkavmddfaafvekcckaddketcfaeegkklvaasqaalglhhhhhh
234	EGF-4	DLL3-14 xI2C -HALB	이중특이적 분자 -HALB	qvqlvqsgaevkkpgasvkvsckasgytftnyymhwvrqapglglewmgiinpsdgstsyaqkfqgrvtmtrdtstntvymdlsslrsedtavyycarggnsafysyydmdvwgqgttvtvssggggsggggsggggsdvvmtqtplslpvtlgqpasiscrssqslvyrdgntylswfqqrpgqsprrliykvsnwqsgvpdrfsgggsgtdftlkisrveaedvgvyycmqgthwpptfgqgtkveiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvlpggggsdahksevahrfkdlgeenfkalvliafaqylqqcpfedhvklvnevtefaktcvadesaencdkslhtlfgdklctvatlretygemadccakqepernecflqhkddnpnlprlvrpevdvmctafhdneetflkkylyeiarrhpyfyapellffakrykaafteccqaadkaacllpkldelrdegkassakqrlkcaslqkfgerafkawavarlsqrfpkaefaevsklvtdltkvhtecchgdllecaddradlakyicenqdsissklkeccekpllekshciaevendempadlpslaadfveskdvcknyaeakdvflgmflyeyarrhpdysvvlllrlaktyettlekccaaadphecyakvfdefkplveepqnlikqncelfeqlgeykfqnallvrytkkvpqvstptlvevsrnlgkvgskcckhpeakrmpcaedylsvvlnqlcvlhektpvsdrvtkccteslvnrrpcfsalevdetyvpkefnaetftfhadictlsekerqikkqtalvelvkhkpkatkeqlkavmddfaafvekcckaddketcfaeegkklvaasqaalglhhhhhh
235	EGF-4	DLL3-15 xI2C -HALB	이중특이적 분자 -HALB	qvqlvqsgaevkkpgasvkvsckasgytftgyyihwvrqapgqglewmgiinpsdgstsygqnfqgrvtmtrdtstntvymelsslrsedtavyycarggnsafysyydmdvwgqgttvtvssggggsggggsggggsdvvmtqsplslpvtlgqpasiscrssqslayrdgntylswfqqrpgqsprrliykvsnwqsgvpdrfsgsgsgtdftlkisrveaedvgvyfcmqgthwpptfgqgtkveiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvlpggggsdahksevahrfkdlgeenfkalvliafaqylqqcpfedhvklvnevtefaktcvadesaencdkslhtlfgdklctvatlretygemadccakqepernecflqhkddnpnlprlvrpevdvmctafhdneetflkkylyeiarrhpyfyapellffakrykaafteccqaadkaacllpkldelrdegkassakqrlkcaslqkfgerafkawavarlsqrfpkaefaevsklvtdltkvhtecchgdllecaddradlakyicenqdsissklkeccekpllekshciaevendempadlpslaadfveskdvcknyaeakdvflgmflyeyarrhpdysvvlllrlaktyettlekccaaadphecyakvfdefkplveepqnlikqncelfeqlgeykfqnallvrytkkvpqvstptlvevsrnlgkvgskcckhpeakrmpcaedylsvvlnqlcvlhektpvsdrvtkccteslvnrrpcfsalevdetyvpkefnaetftfhadictlsekerqikkqtalvelvkhkpkatkeqlkavmddfaafvekcckaddketcfaeegkklvaasqaalglhhhhhh
236	EGF-4	DLL3-16 xI2C -HALB	이중특이적 분자 -HALB	Qvqlvqsgaevkkpgasvkvsckasgytftghymhwvrqapgqglewmgiinpsdgstnyaqkfqgrvtmtrdtststvymelrslrsedtavyyctrgttvvhysyydmdvwgqgttvtvssggggsggggsggggsdvvmtqtplslpvtlgqpasiscrssqslvyrdgntyltwfqqrpgqsprrliykvsnwqsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgthwpptfgggtkveiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvlpggggsdahksevahrfkdlgeenfkalvliafaqylqqcpfedhvklvnevtefaktcvadesaencdkslhtlfgdklctvatlretygemadccakqepernecflqhkddnpnlprlvrpevdvmctafhdneetflkkylyeiarrhpyfyapellffakrykaafteccqaadkaacllpkldelrdegkassakqrlkcaslqkfgerafkawavarlsqrfpkaefaevsklvtdltkvhtecchgdllecaddradlakyicenqdsissklkeccekpllekshciaevendempadlpslaadfveskdvcknyaeakdvflgmflyeyarrhpdysvvlllrlaktyettlekccaaadphecyakvfdefkplveepqnlikqncelfeqlgeykfqnallvrytkkvpqvstptlvevsrnlgkvgskcckhpeakrmpcaedylsvvlnqlcvlhektpvsdrvtkccteslvnrrpcfsalevdetyvpkefnaetftfhadictlsekerqikkqtalvelvkhkpkatkeqlkavmddfaafvekcckaddketcfaeegkklvaasqaalglhhhhhh
237	EGF-4	DLL3-17 xI2C -HALB	이중특이적 분자 -HALB	qvqlvqsgaevkkpgasvkvsckasgytftnyfmhwvrqapglglewmgiinpsdgstsyaqnfqgrvtmtrdtstntvymelsslrsedtavyycarggnsafysyydmdvwgqgttvtvssggggsggggsggggsdvvmtqsplslpvtlgqpasiscrssqslvyrdgntylswfqqrpgqsprrliyrvsnwqsgvpdrfsgsgsgtdftlkisrveaedvgvyfcmqgtywpptfgqgtkvdiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvlpggggsdahksevahrfkdlgeenfkalvliafaqylqqcpfedhvklvnevtefaktcvadesaencdkslhtlfgdklctvatlretygemadccakqepernecflqhkddnpnlprlvrpevdvmctafhdneetflkkylyeiarrhpyfyapellffakrykaafteccqaadkaacllpkldelrdegkassakqrlkcaslqkfgerafkawavarlsqrfpkaefaevsklvtdltkvhtecchgdllecaddradlakyicenqdsissklkeccekpllekshciaevendempadlpslaadfveskdvcknyaeakdvflgmflyeyarrhpdysvvlllrlaktyettlekccaaadphecyakvfdefkplveepqnlikqncelfeqlgeykfqnallvrytkkvpqvstptlvevsrnlgkvgskcckhpeakrmpcaedylsvvlnqlcvlhektpvsdrvtkccteslvnrrpcfsalevdetyvpkefnaetftfhadictlsekerqikkqtalvelvkhkpkatkeqlkavmddfaafvekcckaddketcfaeegkklvaasqaalglhhhhhh
238	EGF-5/[6]	DLL3-18 xI2C -HALB	이중특이적 분자 -HALB	qvqlvesgggavqpgrslrlscaasgftfsnygmhwvrqapgkglewvavishhgsskyyarsvkgrftisrdnskntlylemnslraedtavyycardwwelvfdywgqgtlvtvssggggsggggsggggsdivmtqtplslsvtpgqpasisckssqsllhsdgktflywylqkpgqppqlliyevsnrfsgvpdrfsgsgsgtdftlkisrveaedvgvyyclqgihlpftfgpgtkveiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvlpggggsdahksevahrfkdlgeenfkalvliafaqylqqcpfedhvklvnevtefaktcvadesaencdkslhtlfgdklctvatlretygemadccakqepernecflqhkddnpnlprlvrpevdvmctafhdneetflkkylyeiarrhpyfyapellffakrykaafteccqaadkaacllpkldelrdegkassakqrlkcaslqkfgerafkawavarlsqrfpkaefaevsklvtdltkvhtecchgdllecaddradlakyicenqdsissklkeccekpllekshciaevendempadlpslaadfveskdvcknyaeakdvflgmflyeyarrhpdysvvlllrlaktyettlekccaaadphecyakvfdefkplveepqnlikqncelfeqlgeykfqnallvrytkkvpqvstptlvevsrnlgkvgskcckhpeakrmpcaedylsvvlnqlcvlhektpvsdrvtkccteslvnrrpcfsalevdetyvpkefnaetftfhadictlsekerqikkqtalvelvkhkpkatkeqlkavmddfaafvekcckaddketcfaeegkklvaasqaalglhhhhhh
239	EGF-5/[6]	DLL3-19 xI2C -HALB	이중특이적 분자 -HALB	qvtlkesgpmlvkptetltltctvsgfslsnsrmgvswirqppgralewlahifsndgksystslksrltiskdtsksqvvltmtnmdpvdtatyycarynydssgyyysffdywgqgtlvtvssggggsggggsggggsdiqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqgysspftfgggtkveiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvlpggggsdahksevahrfkdlgeenfkalvliafaqylqqcpfedhvklvnevtefaktcvadesaencdkslhtlfgdklctvatlretygemadccakqepernecflqhkddnpnlprlvrpevdvmctafhdneetflkkylyeiarrhpyfyapellffakrykaafteccqaadkaacllpkldelrdegkassakqrlkcaslqkfgerafkawavarlsqrfpkaefaevsklvtdltkvhtecchgdllecaddradlakyicenqdsissklkeccekpllekshciaevendempadlpslaadfveskdvcknyaeakdvflgmflyeyarrhpdysvvlllrlaktyettlekccaaadphecyakvfdefkplveepqnlikqncelfeqlgeykfqnallvrytkkvpqvstptlvevsrnlgkvgskcckhpeakrmpcaedylsvvlnqlcvlhektpvsdrvtkccteslvnrrpcfsalevdetyvpkefnaetftfhadictlsekerqikkqtalvelvkhkpkatkeqlkavmddfaafvekcckaddketcfaeegkklvaasqaalglhhhhhh
240	EGF-5/[6]	DLL3-20 xI2C -HALB	이중특이적 분자 -HALB	qvtlkesgpvlvkptetltltctvsgfslsnarmgvswlrqppgkalewlahifstdeksystslksrltiskdtsksqvvltmtnmdpvdtatyycaryyydssgyyysffdywgqgtlvtvssggggsggggsggggsdiqmtqspsslsasvgdrvtitcrasqsirsylnwyqqkpgkapklliygasnlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysspftfgggtkveiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvlpggggsdahksevahrfkdlgeenfkalvliafaqylqqcpfedhvklvnevtefaktcvadesaencdkslhtlfgdklctvatlretygemadccakqepernecflqhkddnpnlprlvrpevdvmctafhdneetflkkylyeiarrhpyfyapellffakrykaafteccqaadkaacllpkldelrdegkassakqrlkcaslqkfgerafkawavarlsqrfpkaefaevsklvtdltkvhtecchgdllecaddradlakyicenqdsissklkeccekpllekshciaevendempadlpslaadfveskdvcknyaeakdvflgmflyeyarrhpdysvvlllrlaktyettlekccaaadphecyakvfdefkplveepqnlikqncelfeqlgeykfqnallvrytkkvpqvstptlvevsrnlgkvgskcckhpeakrmpcaedylsvvlnqlcvlhektpvsdrvtkccteslvnrrpcfsalevdetyvpkefnaetftfhadictlsekerqikkqtalvelvkhkpkatkeqlkavmddfaafvekcckaddketcfaeegkklvaasqaalglhhhhhh
241	EGF-5/[6]	DLL3-21 xI2C -HALB	이중특이적 분자 -HALB	qvqlvqsgaevkkpgasvkvsckasgyaftsyyihwvrqapgqglewmgiinpsggsksyaqkfrgrvtmtrdtststvymelssltsedtavyycarsmstvtsdafdiwgqgtmvtvssggggsggggsggggsdiqmtqspsslsasvgdrvtitcrasqsisnylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgteftltisslqpedfatyycqqsysapltfgggtkvdiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvlpggggsdahksevahrfkdlgeenfkalvliafaqylqqcpfedhvklvnevtefaktcvadesaencdkslhtlfgdklctvatlretygemadccakqepernecflqhkddnpnlprlvrpevdvmctafhdneetflkkylyeiarrhpyfyapellffakrykaafteccqaadkaacllpkldelrdegkassakqrlkcaslqkfgerafkawavarlsqrfpkaefaevsklvtdltkvhtecchgdllecaddradlakyicenqdsissklkeccekpllekshciaevendempadlpslaadfveskdvcknyaeakdvflgmflyeyarrhpdysvvlllrlaktyettlekccaaadphecyakvfdefkplveepqnlikqncelfeqlgeykfqnallvrytkkvpqvstptlvevsrnlgkvgskcckhpeakrmpcaedylsvvlnqlcvlhektpvsdrvtkccteslvnrrpcfsalevdetyvpkefnaetftfhadictlsekerqikkqtalvelvkhkpkatkeqlkavmddfaafvekcckaddketcfaeegkklvaasqaalglhhhhhh
242	EGF-3	DLL3-4 xF12Q -HALB	이중특이적 분자 -HALB	qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyvyysgttnynpslksrvtisvdtsknqfslklssvtaadtavyycasiavtgfyfdywgqgtlvtvssggggsggggsggggseivltqspgtlslspgervtlscrasqrvnnnylawyqqrpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqydrspltfgggtkleiksggggsEVQLVESGGGLVQPGGSLRLSCAASGFTFNSYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKGRFTISRDDSKNTAYLQMNSLKTEDTAVYYCVRHGNFGNSYVSWWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVLpggggsdahksevahrfkdlgeenfkalvliafaqylqqcpfedhvklvnevtefaktcvadesaencdkslhtlfgdklctvatlretygemadccakqepernecflqhkddnpnlprlvrpevdvmctafhdneetflkkylyeiarrhpyfyapellffakrykaafteccqaadkaacllpkldelrdegkassakqrlkcaslqkfgerafkawavarlsqrfpkaefaevsklvtdltkvhtecchgdllecaddradlakyicenqdsissklkeccekpllekshciaevendempadlpslaadfveskdvcknyaeakdvflgmflyeyarrhpdysvvlllrlaktyettlekccaaadphecyakvfdefkplveepqnlikqncelfeqlgeykfqnallvrytkkvpqvstptlvevsrnlgkvgskcckhpeakrmpcaedylsvvlnqlcvlhektpvsdrvtkccteslvnrrpcfsalevdetyvpkefnaetftfhadictlsekerqikkqtalvelvkhkpkatkeqlkavmddfaafvekcckaddketcfaeegkklvaasqaalglhhhhhh
243	EGF-3	DLL3-5 xF12Q -HALB	이중특이적 분자 -HALB	qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgrtnyypslksrvtisidtsknqfslklssvtaadtavyycariavagfffdywgqgtlvtvssggggsggggsggggseivltqspgtlslspgeratlscrasqsvnknylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqydrspltfgggtkleiksggggsEVQLVESGGGLVQPGGSLRLSCAASGFTFNSYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKGRFTISRDDSKNTAYLQMNSLKTEDTAVYYCVRHGNFGNSYVSWWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVLpggggsdahksevahrfkdlgeenfkalvliafaqylqqcpfedhvklvnevtefaktcvadesaencdkslhtlfgdklctvatlretygemadccakqepernecflqhkddnpnlprlvrpevdvmctafhdneetflkkylyeiarrhpyfyapellffakrykaafteccqaadkaacllpkldelrdegkassakqrlkcaslqkfgerafkawavarlsqrfpkaefaevsklvtdltkvhtecchgdllecaddradlakyicenqdsissklkeccekpllekshciaevendempadlpslaadfveskdvcknyaeakdvflgmflyeyarrhpdysvvlllrlaktyettlekccaaadphecyakvfdefkplveepqnlikqncelfeqlgeykfqnallvrytkkvpqvstptlvevsrnlgkvgskcckhpeakrmpcaedylsvvlnqlcvlhektpvsdrvtkccteslvnrrpcfsalevdetyvpkefnaetftfhadictlsekerqikkqtalvelvkhkpkatkeqlkavmddfaafvekcckaddketcfaeegkklvaasqaalglhhhhhh
244	EGF-3	DLL3-6 xF12Q -HALB	이중특이적 분자 -HALB	qvqlqesgpglvkpsetlsltctvsgasissfywswirqppgkglewigyiyysgttnynpslksrvtisvdtsknqfslklssvtaadtavyycariavagfffdywgqgtlvtvssggggsggggsggggseivltqspgtlslspgeratlscrasqsvnknylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqydrspltfgggtkveiksggggsEVQLVESGGGLVQPGGSLRLSCAASGFTFNSYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKGRFTISRDDSKNTAYLQMNSLKTEDTAVYYCVRHGNFGNSYVSWWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVLpggggsdahksevahrfkdlgeenfkalvliafaqylqqcpfedhvklvnevtefaktcvadesaencdkslhtlfgdklctvatlretygemadccakqepernecflqhkddnpnlprlvrpevdvmctafhdneetflkkylyeiarrhpyfyapellffakrykaafteccqaadkaacllpkldelrdegkassakqrlkcaslqkfgerafkawavarlsqrfpkaefaevsklvtdltkvhtecchgdllecaddradlakyicenqdsissklkeccekpllekshciaevendempadlpslaadfveskdvcknyaeakdvflgmflyeyarrhpdysvvlllrlaktyettlekccaaadphecyakvfdefkplveepqnlikqncelfeqlgeykfqnallvrytkkvpqvstptlvevsrnlgkvgskcckhpeakrmpcaedylsvvlnqlcvlhektpvsdrvtkccteslvnrrpcfsalevdetyvpkefnaetftfhadictlsekerqikkqtalvelvkhkpkatkeqlkavmddfaafvekcckaddketcfaeegkklvaasqaalglhhhhhh
245	EGF-3	DLL3-7 xF12Q -HALB	이중특이적 분자 -HALB	qvqlqesgpglvkpsqtlsltctvsgasissfywswirqppgkglewigyiyysgttnynpslksrvtisvdtsknqfslklssvtaadtavyycariavagfffdywgqgtlvtvssggggsggggsggggseivltqspgtlslspgeratlscrasqsvnknylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqydrspltfgggtkveiksggggsEVQLVESGGGLVQPGGSLRLSCAASGFTFNSYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKGRFTISRDDSKNTAYLQMNSLKTEDTAVYYCVRHGNFGNSYVSWWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVLpggggsdahksevahrfkdlgeenfkalvliafaqylqqcpfedhvklvnevtefaktcvadesaencdkslhtlfgdklctvatlretygemadccakqepernecflqhkddnpnlprlvrpevdvmctafhdneetflkkylyeiarrhpyfyapellffakrykaafteccqaadkaacllpkldelrdegkassakqrlkcaslqkfgerafkawavarlsqrfpkaefaevsklvtdltkvhtecchgdllecaddradlakyicenqdsissklkeccekpllekshciaevendempadlpslaadfveskdvcknyaeakdvflgmflyeyarrhpdysvvlllrlaktyettlekccaaadphecyakvfdefkplveepqnlikqncelfeqlgeykfqnallvrytkkvpqvstptlvevsrnlgkvgskcckhpeakrmpcaedylsvvlnqlcvlhektpvsdrvtkccteslvnrrpcfsalevdetyvpkefnaetftfhadictlsekerqikkqtalvelvkhkpkatkeqlkavmddfaafvekcckaddketcfaeegkklvaasqaalglhhhhhh
246	EGF-3	DLL3-8 xF12Q -HALB	이중특이적 분자 -HALB	qvqlqewgpglvkpsetlsltctvsgasissfywswirqppgkglewigyiyysgttnynpslksrvtisvdtsknqlslklssvtaadtavyycariavagfffdywgqgtlvtvssggggsggggsggggseivltqspgtlslspgeratlscrasqsvnknylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqydrspltfgggtkvdiksggggsEVQLVESGGGLVQPGGSLRLSCAASGFTFNSYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKGRFTISRDDSKNTAYLQMNSLKTEDTAVYYCVRHGNFGNSYVSWWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVLpggggsdahksevahrfkdlgeenfkalvliafaqylqqcpfedhvklvnevtefaktcvadesaencdkslhtlfgdklctvatlretygemadccakqepernecflqhkddnpnlprlvrpevdvmctafhdneetflkkylyeiarrhpyfyapellffakrykaafteccqaadkaacllpkldelrdegkassakqrlkcaslqkfgerafkawavarlsqrfpkaefaevsklvtdltkvhtecchgdllecaddradlakyicenqdsissklkeccekpllekshciaevendempadlpslaadfveskdvcknyaeakdvflgmflyeyarrhpdysvvlllrlaktyettlekccaaadphecyakvfdefkplveepqnlikqncelfeqlgeykfqnallvrytkkvpqvstptlvevsrnlgkvgskcckhpeakrmpcaedylsvvlnqlcvlhektpvsdrvtkccteslvnrrpcfsalevdetyvpkefnaetftfhadictlsekerqikkqtalvelvkhkpkatkeqlkavmddfaafvekcckaddketcfaeegkklvaasqaalglhhhhhh
247	EGF-3	DLL3-9 xF12Q -HALB	이중특이적 분자 -HALB	qvqlqesgpglvkpsetlsltctvsgasissfywswirqppgkglewigyiyysgttnynpslksrvtisvdtsknqfslklssvtaadtavyycariavagfffdywgqgtlvtvssggggsggggsggggseivltqspgtlslspgesatlscrasqsvnknylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqydrspltfgggtrleiksggggsEVQLVESGGGLVQPGGSLRLSCAASGFTFNSYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKGRFTISRDDSKNTAYLQMNSLKTEDTAVYYCVRHGNFGNSYVSWWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVLpggggsdahksevahrfkdlgeenfkalvliafaqylqqcpfedhvklvnevtefaktcvadesaencdkslhtlfgdklctvatlretygemadccakqepernecflqhkddnpnlprlvrpevdvmctafhdneetflkkylyeiarrhpyfyapellffakrykaafteccqaadkaacllpkldelrdegkassakqrlkcaslqkfgerafkawavarlsqrfpkaefaevsklvtdltkvhtecchgdllecaddradlakyicenqdsissklkeccekpllekshciaevendempadlpslaadfveskdvcknyaeakdvflgmflyeyarrhpdysvvlllrlaktyettlekccaaadphecyakvfdefkplveepqnlikqncelfeqlgeykfqnallvrytkkvpqvstptlvevsrnlgkvgskcckhpeakrmpcaedylsvvlnqlcvlhektpvsdrvtkccteslvnrrpcfsalevdetyvpkefnaetftfhadictlsekerqikkqtalvelvkhkpkatkeqlkavmddfaafvekcckaddketcfaeegkklvaasqaalglhhhhhh
248	EGF-3	DLL3-10 xF12Q -HALB	이중특이적 분자 -HALB	qvqlqesgpglvkpsqtlsltctvsggsissyywswirqppgkglewigyifyngitnynpslksrvtisldtsknqfslklssvtaadtakyycarihsgsfsfdywdqgtlvtvssggggsggggsggggseivmtqspgtlslspgeratlscrasqsvsrgylawyqqkpgqaprlliygassratdipdrfsgsgsgtdftltisrlepedfavyycqqydtspitfgqgtkveiksggggsEVQLVESGGGLVQPGGSLRLSCAASGFTFNSYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKGRFTISRDDSKNTAYLQMNSLKTEDTAVYYCVRHGNFGNSYVSWWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVLpggggsdahksevahrfkdlgeenfkalvliafaqylqqcpfedhvklvnevtefaktcvadesaencdkslhtlfgdklctvatlretygemadccakqepernecflqhkddnpnlprlvrpevdvmctafhdneetflkkylyeiarrhpyfyapellffakrykaafteccqaadkaacllpkldelrdegkassakqrlkcaslqkfgerafkawavarlsqrfpkaefaevsklvtdltkvhtecchgdllecaddradlakyicenqdsissklkeccekpllekshciaevendempadlpslaadfveskdvcknyaeakdvflgmflyeyarrhpdysvvlllrlaktyettlekccaaadphecyakvfdefkplveepqnlikqncelfeqlgeykfqnallvrytkkvpqvstptlvevsrnlgkvgskcckhpeakrmpcaedylsvvlnqlcvlhektpvsdrvtkccteslvnrrpcfsalevdetyvpkefnaetftfhadictlsekerqikkqtalvelvkhkpkatkeqlkavmddfaafvekcckaddketcfaeegkklvaasqaalglhhhhhh
249	EGF-4	DLL3-13 xF12Q -HALB	이중특이적 분자 -HALB	QvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinpsdgstnyaqnfqgrvtmtrdtstntvymelsslrsedtavyycarggnsafysyydmdvwgqgttvtvssggggsggggsggggsdvvmtqsplslpvtlgqpasiscrssqslvyrdgntylswfqqrpgqsprrliykvsnwqsgvpdrfsgsgsgtdftlkisrveaedvgvyfcmqgthwpptfgqgtkveiksggggsEVQLVESGGGLVQPGGSLRLSCAASGFTFNSYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKGRFTISRDDSKNTAYLQMNSLKTEDTAVYYCVRHGNFGNSYVSWWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVLpggggsdahksevahrfkdlgeenfkalvliafaqylqqcpfedhvklvnevtefaktcvadesaencdkslhtlfgdklctvatlretygemadccakqepernecflqhkddnpnlprlvrpevdvmctafhdneetflkkylyeiarrhpyfyapellffakrykaafteccqaadkaacllpkldelrdegkassakqrlkcaslqkfgerafkawavarlsqrfpkaefaevsklvtdltkvhtecchgdllecaddradlakyicenqdsissklkeccekpllekshciaevendempadlpslaadfveskdvcknyaeakdvflgmflyeyarrhpdysvvlllrlaktyettlekccaaadphecyakvfdefkplveepqnlikqncelfeqlgeykfqnallvrytkkvpqvstptlvevsrnlgkvgskcckhpeakrmpcaedylsvvlnqlcvlhektpvsdrvtkccteslvnrrpcfsalevdetyvpkefnaetftfhadictlsekerqikkqtalvelvkhkpkatkeqlkavmddfaafvekcckaddketcfaeegkklvaasqaalglhhhhhh
250	EGF-4	DLL3-14 xF12Q -HALB	이중특이적 분자 -HALB	QvqlvqsgaevkkpgasvkvsckasgytftnyymhwvrqapglglewmgiinpsdgstsyaqkfqgrvtmtrdtstntvymdlsslrsedtavyycarggnsafysyydmdvwgqgttvtvssggggsggggsggggsdvvmtqtplslpvtlgqpasiscrssqslvyrdgntylswfqqrpgqsprrliykvsnwqsgvpdrfsgggsgtdftlkisrveaedvgvyycmqgthwpptfgqgtkveiksggggsEVQLVESGGGLVQPGGSLRLSCAASGFTFNSYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKGRFTISRDDSKNTAYLQMNSLKTEDTAVYYCVRHGNFGNSYVSWWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVLpggggsdahksevahrfkdlgeenfkalvliafaqylqqcpfedhvklvnevtefaktcvadesaencdkslhtlfgdklctvatlretygemadccakqepernecflqhkddnpnlprlvrpevdvmctafhdneetflkkylyeiarrhpyfyapellffakrykaafteccqaadkaacllpkldelrdegkassakqrlkcaslqkfgerafkawavarlsqrfpkaefaevsklvtdltkvhtecchgdllecaddradlakyicenqdsissklkeccekpllekshciaevendempadlpslaadfveskdvcknyaeakdvflgmflyeyarrhpdysvvlllrlaktyettlekccaaadphecyakvfdefkplveepqnlikqncelfeqlgeykfqnallvrytkkvpqvstptlvevsrnlgkvgskcckhpeakrmpcaedylsvvlnqlcvlhektpvsdrvtkccteslvnrrpcfsalevdetyvpkefnaetftfhadictlsekerqikkqtalvelvkhkpkatkeqlkavmddfaafvekcckaddketcfaeegkklvaasqaalglhhhhhh
251	EGF-4	DLL3-15 xF12Q -HALB	이중특이적 분자 -HALB	QvqlvqsgaevkkpgasvkvsckasgytftgyyihwvrqapgqglewmgiinpsdgstsygqnfqgrvtmtrdtstntvymelsslrsedtavyycarggnsafysyydmdvwgqgttvtvssggggsggggsggggsdvvmtqsplslpvtlgqpasiscrssqslayrdgntylswfqqrpgqsprrliykvsnwqsgvpdrfsgsgsgtdftlkisrveaedvgvyfcmqgthwpptfgqgtkveiksggggsEVQLVESGGGLVQPGGSLRLSCAASGFTFNSYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKGRFTISRDDSKNTAYLQMNSLKTEDTAVYYCVRHGNFGNSYVSWWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVLpggggsdahksevahrfkdlgeenfkalvliafaqylqqcpfedhvklvnevtefaktcvadesaencdkslhtlfgdklctvatlretygemadccakqepernecflqhkddnpnlprlvrpevdvmctafhdneetflkkylyeiarrhpyfyapellffakrykaafteccqaadkaacllpkldelrdegkassakqrlkcaslqkfgerafkawavarlsqrfpkaefaevsklvtdltkvhtecchgdllecaddradlakyicenqdsissklkeccekpllekshciaevendempadlpslaadfveskdvcknyaeakdvflgmflyeyarrhpdysvvlllrlaktyettlekccaaadphecyakvfdefkplveepqnlikqncelfeqlgeykfqnallvrytkkvpqvstptlvevsrnlgkvgskcckhpeakrmpcaedylsvvlnqlcvlhektpvsdrvtkccteslvnrrpcfsalevdetyvpkefnaetftfhadictlsekerqikkqtalvelvkhkpkatkeqlkavmddfaafvekcckaddketcfaeegkklvaasqaalglhhhhhh
252	-	인간 DLL3	인간	mvsprmsgllsqtvilaliflpqtrpagvfelqihsfgpgpgpgaprspcsarlpcrlffrvclkpglseeaaespcalgaalsargpvyteqpgapapdlplpdgllqvpfrdawpgtfsfiietwreelgdqiggpawsllarvagrrrlaaggpwardiqragawelrfsyrarceppavgtactrlcrprsapsrcgpglrpcapledeceaplvcragcspehgfceqpgecrclegwtgplctvpvstssclsprgpssattgclvpgpgpcdgnpcanggscsetprsfectcprgfyglrcevsgvtcadgpcfngglcvggadpdsayichcppgfqgsncekrvdrcslqpcrngglcldlghalrcrcragfagprcehdlddcagracanggtcvegggahrcscalgfggrdcreradpcaarpcahggrcyahfsglvcacapgymgarcefpvhpdgasalpaappglrpgdpqryllppalgllvaagvagaalllvhvrrrghsqdagsrllagtpepsvhalpdalnnlrtqegsgdgpsssvdwnrpedvdpqgiyvisapsiyarevatplfpplhtgragqrqhllfpypssilsvk
253	-	인간 DLL3 ECD	인간	mvsprmsgllsqtvilaliflpqtrpagvfelqihsfgpgpgpgaprspcsarlpcrlffrvclkpglseeaaespcalgaalsargpvyteqpgapapdlplpdgllqvpfrdawpgtfsfiietwreelgdqiggpawsllarvagrrrlaaggpwardiqragawelrfsyrarceppavgtactrlcrprsapsrcgpglrpcapledeceaplvcragcspehgfceqpgecrclegwtgplctvpvstssclsprgpssattgclvpgpgpcdgnpcanggscsetprsfectcprgfyglrcevsgvtcadgpcfngglcvggadpdsayichcppgfqgsncekrvdrcslqpcrngglcldlghalrcrcragfagprcehdlddcagracanggtcvegggahrcscalgfggrdcreradpcaarpcahggrcyahfsglvcacapgymgarcefpvhpdgasalpaappglrpgdpqryl
254	-	Hu DLL3 N-말단	인간	mvsprmsgllsqtvilaliflpqtrpagvfelqihsfgpgpgpgaprspcsarlpcrlffrvclkpglseeaaespcalgaalsargpvyteqpgapapdlplpdgllqvpfrdawpgtfsfiietwreelgdqiggpawsllarvagrrrlaaggpwardiqragawelrfsyr
255	-	Hu DLL3 DSL dom	인간	arceppavgtactrlcrprsapsrcgpglrpcapledece
256	-	Hu DLL3 EGF-1	인간	aplvcragcspehgfceqpgecrclegwtgplct
257	-	Hu DLL3 EGF-2	인간	gpgpcdgnpcanggscsetprsfectcprgfyglrce
258	-	Hu DLL3 EGF-3	인간	sgvtcadgpcfngglcvggadpdsayichcppgfqgsnce
259	-	Hu DLL3 EGF-4	인간	rvdrcslqpcrngglcldlghalrcrcragfagprce
260	-	Hu DLL3 EGF-3+4	인간	sgvtcadgpcfngglcvggadpdsayichcppgfqgsncekrvdrcslqpcrngglcldlghalrcrcragfagprce
261	-	Hu DLL3 EGF-5	인간	dlddcagracanggtcvegggahrcscalgfggrdcr
262	-	Hu DLL3 EGF-6	인간	radpcaarpcahggrcyahfsglvcacapgymgarce
263	-	인간 DLL3 ECD x EpCAM	인공	mvsprmsgllsqtvilaliflpqtrpagvfelqihsfgpgpgpgaprspcsarlpcrlffrvclkpglseeaaespcalgaalsargpvyteqpgapapdlplpdgllqvpfrdawpgtfsfiietwreelgdqiggpawsllarvagrrrlaaggpwardiqragawelrfsyrarceppavgtactrlcrprsapsrcgpglrpcapledeceaplvcragcspehgfceqpgecrclegwtgplctvpvstssclsprgpssattgclvpgpgpcdgnpcanggscsetprsfectcprgfyglrcevsgvtcadgpcfngglcvggadpdsayichcppgfqgsncekrvdrcslqpcrngglcldlghalrcrcragfagprcehdlddcagracanggtcvegggahrcscalgfggrdcreradpcaarpcahggrcyahfsglvcacapgymgarcefpvhpdgasalpaappglrpgdpqrylsggggsgagviavivvvviaivagivvlvisrkkrmakyekaeikemgemhrelna
264	-	V5 x hu DLL3-DSL x EpCAM	인공	mgwsciilflvatatgvhsgkpipnpllgldstsgarceppavgtactrlcrprsapsrcgpglrpcapledeceaplvcragcspehgfceqpgecrclegwtgplctvpvstssclsprgpssattgclvpgpgpcdgnpcanggscsetprsfectcprgfyglrcevsgvtcadgpcfngglcvggadpdsayichcppgfqgsncekrvdrcslqpcrngglcldlghalrcrcragfagprcehdlddcagracanggtcvegggahrcscalgfggrdcreradpcaarpcahggrcyahfsglvcacapgymgarcefpvhpdgasalpaappglrpgdpqrylsggggsgagviavivvvviaivagivvlvisrkkrmakyekaeikemgemhrelna
265	-	V5 x hu DLL3-EGF1 x EpCAM	인공	mgwsciilflvatatgvhsgkpipnpllgldstsgaplvcragcspehgfceqpgecrclegwtgplctvpvstssclsprgpssattgclvpgpgpcdgnpcanggscsetprsfectcprgfyglrcevsgvtcadgpcfngglcvggadpdsayichcppgfqgsncekrvdrcslqpcrngglcldlghalrcrcragfagprcehdlddcagracanggtcvegggahrcscalgfggrdcreradpcaarpcahggrcyahfsglvcacapgymgarcefpvhpdgasalpaappglrpgdpqrylsggggsgagviavivvvviaivagivvlvisrkkrmakyekaeikemgemhrelna
266	-	V5 x hu DLL3-EGF2 x EpCAM	인공	mgwsciilflvatatgvhsgkpipnpllgldstsggpgpcdgnpcanggscsetprsfectcprgfyglrcevsgvtcadgpcfngglcvggadpdsayichcppgfqgsncekrvdrcslqpcrngglcldlghalrcrcragfagprcehdlddcagracanggtcvegggahrcscalgfggrdcreradpcaarpcahggrcyahfsglvcacapgymgarcefpvhpdgasalpaappglrpgdpqrylsggggsgagviavivvvviaivagivvlvisrkkrmakyekaeikemgemhrelna
267	-	V5 x hu DLL3-EGF3 x EpCAM	인공	mgwsciilflvatatgvhsgkpipnpllgldstsgsgvtcadgpcfngglcvggadpdsayichcppgfqgsncekrvdrcslqpcrngglcldlghalrcrcragfagprcehdlddcagracanggtcvegggahrcscalgfggrdcreradpcaarpcahggrcyahfsglvcacapgymgarcefpvhpdgasalpaappglrpgdpqrylsggggsgagviavivvvviaivagivvlvisrkkrmakyekaeikemgemhrelna
268	-	V5 x hu DLL3-EGF4 x EpCAM	인공	mgwsciilflvatatgvhsgkpipnpllgldstsgrvdrcslqpcrngglcldlghalrcrcragfagprcehdlddcagracanggtcvegggahrcscalgfggrdcreradpcaarpcahggrcyahfsglvcacapgymgarcefpvhpdgasalpaappglrpgdpqrylsggggsgagviavivvvviaivagivvlvisrkkrmakyekaeikemgemhrelna
269	-	V5 x hu DLL3-EGF5 x EpCAM	인공	mgwsciilflvatatgvhsgkpipnpllgldstsgdlddcagracanggtcvegggahrcscalgfggrdcreradpcaarpcahggrcyahfsglvcacapgymgarcefpvhpdgasalpaappglrpgdpqrylsggggsgagviavivvvviaivagivvlvisrkkrmakyekaeikemgemhrelna
270	-	V5 x hu DLL3-EGF6 x EpCAM	인공	mgwsciilflvatatgvhsgkpipnpllgldstsgradpcaarpcahggrcyahfsglvcacapgymgarcefpvhpdgasalpaappglrpgdpqrylsggggsgagviavivvvviaivagivvlvisrkkrmakyekaeikemgemhrelna
271	-	마카크 DLL3	시노	mvsprmsrllsqtvilalifipqarpagvfelqihsfgpgpgpgaprspcsargpcrlffrvclkpglseeaaespcalgaalsargpvyteqpeapapdlplpngllqvpfrdawpgtfsliietwreelgdqiggpawsllarvtrrrrlaaggpwardiqragawelrfsyrarcelpavgtactrlcrprsapsrcgpglrpcapledeceappvcragcslehgfceqpgecrclegwtgplcmvpastssclglrgpssattgclvpgpgpcdgnpcanggscsetpgsfectcprgfyglrcevsgvtcadgpcfngglcvggadpdsayichcppgfqgsncekrvdrcslqpcrngglcldlghalrcrcragfagprcehnlddcagracanggtcvegggahrcscalgfggrdcreradpcaarpcahggrcyahfsglvcacapgymgsrcefpvhpdgvsalpaappglrpgdpqryllppalgllvaagvagaalllvhvrrrghaqdagsrllagtpepsvhalpdalnnqrtqegpgdvpsssvdwnrpedvdsrgiyvisapsiyarea
272	-	마카크 DLL3 ECD	시노	mvsprmsrllsqtvilalifipqarpagvfelqihsfgpgpgpgaprspcsargpcrlffrvclkpglseeaaespcalgaalsargpvyteqpeapapdlplpngllqvpfrdawpgtfsliietwreelgdqiggpawsllarvtrrrrlaaggpwardiqragawelrfsyrarcelpavgtactrlcrprsapsrcgpglrpcapledeceappvcragcslehgfceqpgecrclegwtgplcmvpastssclglrgpssattgclvpgpgpcdgnpcanggscsetpgsfectcprgfyglrcevsgvtcadgpcfngglcvggadpdsayichcppgfqgsncekrvdrcslqpcrngglcldlghalrcrcragfagprcehnlddcagracanggtcvegggahrcscalgfggrdcreradpcaarpcahggrcyahfsglvcacapgymgsrcefpvhpdgvsalpaappglrpgdpqryl
273	-	Ma DLL3 N-말단	시노	mvsprmsrllsqtvilalifipqarpagvfelqihsfgpgpgpgaprspcsargpcrlffrvclkpglseeaaespcalgaalsargpvyteqpeapapdlplpngllqvpfrdawpgtfsliietwreelgdqiggpawsllarvtrrrrlaaggpwardiqragawelrfsyr
274	-	Ma DLL3 DSL dom.	시노	arcelpavgtactrlcrprsapsrcgpglrpcapledece
275	-	Ma DLL3 EGF-1	시노	appvcragcslehgfceqpgecrclegwtgplcm
276	-	Ma DLL3 EGF-2	시노	gpgpcdgnpcanggscsetpgsfectcprgfyglrce
277	-	Ma DLL3 EGF-3	시노	sgvtcadgpcfngglcvggadpdsayichcppgfqgsnce
278	-	Ma DLL3 EGF-4	시노	rvdrcslqpcrngglcldlghalrcrcragfagprce
279	-	Ma DLL3 EGF-3+4	시노	sgvtcadgpcfngglcvggadpdsayichcppgfqgsncekrvdrcslqpcrngglcldlghalrcrcragfagprce
280	-	Ma DLL3 EGF-5	시노	nlddcagracanggtcvegggahrcscalgfggrdcr
281	-	Ma DLL3 EGF-6	시노	radpcaarpcahggrcyahfsglvcacapgymgsrce
282	-	Ma DLL3 ECD x EpCAM	인공	mvsprmsrllsqtvilalifipqarpagvfelqihsfgpgpgpgaprspcsargpcrlffrvclkpglseeaaespcalgaalsargpvyteqpeapapdlplpngllqvpfrdawpgtfsliietwreelgdqiggpawsllarvtrrrrlaaggpwardiqragawelrfsyrarcelpavgtactrlcrprsapsrcgpglrpcapledeceappvcragcslehgfceqpgecrclegwtgplcmvpastssclglrgpssattgclvpgpgpcdgnpcanggscsetpgsfectcprgfyglrcevsgvtcadgpcfngglcvggadpdsayichcppgfqgsncekrvdrcslqpcrngglcldlghalrcrcragfagprcehnlddcagracanggtcvegggahrcscalgfggrdcreradpcaarpcahggrcyahfsglvcacapgymgsrcefpvhpdgvsalpaappglrpgdpqrylsggggsgagviavivvvviaivagivvlvisrkkrmakyekaeikemgemhrelna
283	-	인간 DLL1	인간	mgsrcalalavlsallcqvwssgvfelklqefvnkkgllgnrnccrggagpppcacrtffrvclkhyqasvspeppctygsavtpvlgvdsfslpdgggadsafsnpirfpfgftwpgtfsliiealhtdspddlatenperlisrlatqrhltvgeewsqdlhssgrtdlkysyrfvcdehyygegcsvfcrprddafghftcgergekvcnpgwkgpyctepiclpgcdeqhgfcdkpgeckcrvgwqgrycdecirypgclhgtcqqpwqcncqegwgglfcnqdlnycthhkpckngatctntgqgsytcscrpgytgatcelgidecdpspcknggsctdlensysctcppgfygkicelsamtcadgpcfnggrcsdspdggyscrcpvgysgfncekkidycssspcsngakcvdlgdaylcrcqagfsgrhcddnvddcasspcanggtcrdgvndfsctcppgytgrncsapvsrcehapchngatcherghryvcecargyggpncqfllpelppgpavvdlteklegqggpfpwvavcagvilvlmlllgcaavvvcvrlrlqkhrppadpcrgetetmnnlancqrekdisvsiigatqikntnkkadfhgdhsadkngfkarypavdynlvqdlkgddtavrdahskrdtkcqpqgssgeekgtpttlrggeaserkrpdsgcstskdtkyqsvyviseekdecviatev
284	-	인간 DLL4	인간	maaasrsasgwallllvalwqqraagsgvfqlqlqefinergvlasgrpcepgcrtffrvclkhfqavvspgpctfgtvstpvlgtnsfavrddssgggrnplqlpfnftwpgtfsliieawhapgddlrpealppdaliskiaiqgslavgqnwlldeqtstltrlrysyrvicsdnyygdncsrlckkrndhfghyvcqpdgnlsclpgwtgeycqqpiclsgcheqngycskpaeclcrpgwqgrlcneciphngcrhgtcstpwqctcdegwgglfcdqdlnycthhspckngatcsnsgqrsytctcrpgytgvdcelelsecdsnpcrnggsckdqedgyhclcppgyyglhcehstlscadspcfnggscrernqganyacecppnftgsncekkvdrctsnpcanggqclnrgpsrmcrcrpgftgtycelhvsdcarnpcahggtchdlenglmctcpagfsgrrcevrtsidacasspcfnratcytdlstdtfvcncpygfvgsrcefpvglppsfpwvavslgvglavllvllgmvavavrqlrlrrpddgsreamnnlsdfqkdnlipaaqlkntnqkkelevdcgldksncgkqqnhtldynlapgplgrgtmpgkfphsdkslgekaplrlhsekpecrisaicsprdsmyqsvcliseernecviatev
285	-	링커 1	인공	GGGG
286	-	링커 2	인공	GGGGS
287	-	링커 3	인공	GGGGQ
288	-	링커 4	인공	SGGGGS
289	-	링커 5	인공	PGGGGS
290	-	링커 6	인공	PGGDGS
291	-	링커 7	인공	GGGGSGGGS
292	-	링커 8	인공	GGGGSGGGGS
293		링커 9	인공	GGGGSGGGGSGGGGS
294	-	헥사-his	인공	HHHHHH
295	-	Ab156	인공	RDWDFDVFGGGTPVGG
296	-	선형 FcRn BP	인공	QRFVTGHFGGLXPANG
297	-	선형 FcRn BP-Y	인공	QRFVTGHFGGLYPANG
298	-	선형 FcRn BP-H	인공	QRFVTGHFGGLHPANG
299		코어 FcRn BP-H	인공	TGHFGGLHP
300		환식 FcRn BP-H	인공	QRFCTGHFGGLHPCNG
301	-	HALB	인간	DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGKKLVAASQAALGL
302	-	HALB 변이체 1	인공	DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAGTFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAAMDDFAAFVEKCCKADDKETCFAEEGKKLVAASQAALGL
303	-	HALB 변이체 2	인공	DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGPKLVAASQAALGL
304	-	HALB 변이체 3	인공	DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALDVDETYVPKEFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGPHLVAASKAALGL
305	-	HALB 변이체 4	인공	DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALGVDETYVPKEFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDKFAAFVEKCCKADDKETCFAEEGPKLVAASQAALGL
306	-	HALB 변이체 5	인공	DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALDVDETYVPKEFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDKFAAFVEKCCKADDKETCFAEEGPKLVAASQAALGL
307	-	HALB 변이체 6	인공	DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDKFAAFVEKCCKADDKETCFAEEGPHLVAASQAALGL
308	-	HALB 변이체 7	인공	DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGPHLVAASKAALGL
309	-	HALB 변이체 8	인공	DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDKFAAFVEKCCKADDKETCFAEEGPKLVAASKAALGL
310	-	HALB 변이체 9	인공	dahksevahrfkdlgeenfkalvliafaqylqqcpfedhvklvnevtefaktcvadesaencdkslhtlfgdklctvatlretygemadccakqepernecflqhkddnpnlprlvrpevdvmctafhdneetflkkylyeiarrhpyfyapellffakrykaafteccqaadkaacllpkldelrdegkassakqrlkcaslqkfgerafkawavarlsqrfpkaefaevsklvtdltkvhtecchgdllecaddradlakyicenqdsissklkeccekpllekshciaevendempadlpslaadfveskdvcknyaeakdvflgmflyeyarrhpdysvvlllrlaktyettlekccaaadphecyakvfdefkplveepqnlikqncelfeqlgeykfqnallvrytkkvpqvstptlvevsrnlgkvgskcckhpeakrmpcaedylsvvlnqlcvlhektpvsdrvtkccteslvnrrpcfsaldvdetyvpkefnaetftfhadictlsekerqikkqtalvelvkhkpkatkeqlkavmddfaafvekcckaddketcfaeegpklvaaskaalgl
311	-	HALB 변이체 10	인공	DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQSPFEDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGKKLVAASQAALGL
312	-	HALB 변이체 11	인공	DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQSPFEDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAGTFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAAMDDFAAFVEKCCKADDKETCFAEEGKKLVAASQAALGL
313	-	HALB 변이체 12	인공	DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQSPFEDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGPKLVAASQAALGL
314	-	HALB 변이체 13	인공	DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQSPFEDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALDVDETYVPKEFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGPHLVAASKAALGL
315	-	HALB 변이체 14	인공	DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQSPFEDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALGVDETYVPKEFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDKFAAFVEKCCKADDKETCFAEEGPKLVAASQAALGL
316	-	HALB 변이체 15	인공	DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQSPFEDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALDVDETYVPKEFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDKFAAFVEKCCKADDKETCFAEEGPKLVAASQAALGL
317	-	HALB 변이체 16	인공	DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQSPFEDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDKFAAFVEKCCKADDKETCFAEEGPHLVAASQAALGL
318	-	HALB 변이체 17	인공	DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQSPFEDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGPHLVAASKAALGL
319	-	HALB 변이체 18	인공	DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQSPFEDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDKFAAFVEKCCKADDKETCFAEEGPKLVAASKAALGL
320	-	HALB 변이체 19	인공	dahksevahrfkdlgeenfkalvliafaqylqqSpfedhvklvnevtefaktcvadesaencdkslhtlfgdklctvatlretygemadccakqepernecflqhkddnpnlprlvrpevdvmctafhdneetflkkylyeiarrhpyfyapellffakrykaafteccqaadkaacllpkldelrdegkassakqrlkcaslqkfgerafkawavarlsqrfpkaefaevsklvtdltkvhtecchgdllecaddradlakyicenqdsissklkeccekpllekshciaevendempadlpslaadfveskdvcknyaeakdvflgmflyeyarrhpdysvvlllrlaktyettlekccaaadphecyakvfdefkplveepqnlikqncelfeqlgeykfqnallvrytkkvpqvstptlvevsrnlgkvgskcckhpeakrmpcaedylsvvlnqlcvlhektpvsdrvtkccteslvnrrpcfsaldvdetyvpkefnaetftfhadictlsekerqikkqtalvelvkhkpkatkeqlkavmddfaafvekcckaddketcfaeegpklvaaskaalgl
321	-	HALB 변이체 20	인공	DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQAPFEDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGKKLVAASQAALGL
322	-	HALB 변이체 21	인공	DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQAPFEDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAGTFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAAMDDFAAFVEKCCKADDKETCFAEEGKKLVAASQAALGL
323	-	HALB 변이체 22	인공	DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQAPFEDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGPKLVAASQAALGL
324	-	HALB 변이체 23	인공	DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQAPFEDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALDVDETYVPKEFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGPHLVAASKAALGL
325	-	HALB 변이체 24	인공	DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQAPFEDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALGVDETYVPKEFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDKFAAFVEKCCKADDKETCFAEEGPKLVAASQAALGL
326	-	HALB 변이체 25	인공	DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQAPFEDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALDVDETYVPKEFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDKFAAFVEKCCKADDKETCFAEEGPKLVAASQAALGL
327	-	HALB 변이체 26	인공	DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQAPFEDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDKFAAFVEKCCKADDKETCFAEEGPHLVAASQAALGL
328	-	HALB 변이체 27	인공	DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQAPFEDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGPHLVAASKAALGL
329	-	HALB 변이체 28	인공	DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQAPFEDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDKFAAFVEKCCKADDKETCFAEEGPKLVAASKAALGL
330	-	HALB 변이체 29	인공	dahksevahrfkdlgeenfkalvliafaqylqqApfedhvklvnevtefaktcvadesaencdkslhtlfgdklctvatlretygemadccakqepernecflqhkddnpnlprlvrpevdvmctafhdneetflkkylyeiarrhpyfyapellffakrykaafteccqaadkaacllpkldelrdegkassakqrlkcaslqkfgerafkawavarlsqrfpkaefaevsklvtdltkvhtecchgdllecaddradlakyicenqdsissklkeccekpllekshciaevendempadlpslaadfveskdvcknyaeakdvflgmflyeyarrhpdysvvlllrlaktyettlekccaaadphecyakvfdefkplveepqnlikqncelfeqlgeykfqnallvrytkkvpqvstptlvevsrnlgkvgskcckhpeakrmpcaedylsvvlnqlcvlhektpvsdrvtkccteslvnrrpcfsaldvdetyvpkefnaetftfhadictlsekerqikkqtalvelvkhkpkatkeqlkavmddfaafvekcckaddketcfaeegpklvaaskaalgl
331	-	크로스 바디 1 HC	인공	ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYDTTPPVLDSDGSFFLYSDLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
332	-	크로스 바디 1 LC	인공	GQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRKEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLKSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
333	-	크로스 바디 2 HC	인공	ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVEPKSSDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYDTTPPVLDSDGSFFLYSDLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
334	-	크로스 바디 2 LC	인공	GQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECSEPKSSDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRKEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLKSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
335	-	헤테로-Fc 바인더 Fc	인공	DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRKEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLKSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
336	-	헤테로-Fc 파트너 Fc	인공	DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYDTTPPVLDSDGSFFLYSDLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
337	-	맥시-바디 1 표적 Fc	인공	EPKSSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRKEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLKSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
338	-	맥시-바디 1 CD3 Fc	인공	EPKSSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYDTTPPVLDSDGSFFLYSDLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
339	-	맥시-바디 2 표적 Fc	인공	EPKSSDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRKEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLKSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
340	-	맥시-바디 2 CD3 Fc	인공	EPKSSDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYDTTPPVLDSDGSFFLYSDLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
341	-	모노 Fc	인공	APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVTTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYDTTPPVLDSDGSFFLYSDLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
342	-	F6A의 CDR-L1	인공	GSSTGAVTSGYYPN
343		F6A의 CDR-L2	인공	GTKFLAP
344		F6A의 CDR-L3	인공	ALWYSNRWV
345		F6A의 CDR-H1	인공	IYAMN
346		F6A의 CDR-H2	인공	RIRSKYNNYATYYADSVKS
347		F6A의 CDR-H3	인공	HGNFGNSYVSFFAY
348		F6A의 VH	인공	EVQLVESggglvqpggslklscaasgftfniyamnwvrqapgkglewvarirskynnyatyyadsvksrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyvsffaywgqgtlvtvss
349		F6A의 VL	인공	QTvvtqepsltvspggtvtltcgsstgavtsgyypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycalwysnrwvfgggtkltvl
350		F6A의 VH-VL	인공	EVQLVESggglvqpggslklscaasgftfniyamnwvrqapgkglewvarirskynnyatyyadsvksrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyvsffaywgqgtlvtvssggggsggggsggggsQTvvtqepsltvspggtvtltcgsstgavtsgyypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycalwysnrwvfgggtkltvl
351		H2C의 CDR-L1	인공	GSSTGAVTSGYYPN
352		H2C의 CDR-L2	인공	GTKFLAP
353		H2C의 CDR-L3	인공	ALWYSNRWV
354		H2C의 CDR-H1	인공	KYAMN
355		H2C의 CDR-H2	인공	RIRSKYNNYATYYADSVKD
356		H2C의 CDR-H3	인공	HGNFGNSYISYWAY
357		H2C의 VH	인공	EVQLVESggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvss
358		H2C의 VL	인공	QTvvtqepsltvspggtvtltcgsstgavtsgyypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycalwysnrwvfgggtkltvl
359		H2C의 VH-VL	인공	EVQLVESggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsQTvvtqepsltvspggtvtltcgsstgavtsgyypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycalwysnrwvfgggtkltvl
360		H1E의 CDR-L1	인공	GSSTGAVTSGYYPN
361		H1E의 CDR-L2	인공	GTKFLAP
362		H1E의 CDR-L3	인공	ALWYSNRWV
363		H1E의 CDR-H1	인공	SYAMN
364		H1E의 CDR-H2	인공	RIRSKYNNYATYYADSVKG
365		H1E의 CDR-H3	인공	HGNFGNSYLSFWAY
366		H1E의 VH	인공	EVQLVESgggleqpggslklscaasgftfnsyamnwvrqapgkglewvarirskynnyatyyadsvkgrftisrddskntaylqmnnlktedtavyycvrhgnfgnsylsfwaywgqgtlvtvss
367		H1E의 VL	인공	QTvvtqepsltvspggtvtltcgsstgavtsgyypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycalwysnrwvfgggtkltvl
368		H1E의 VH-VL	인공	EVQLVESgggleqpggslklscaasgftfnsyamnwvrqapgkglewvarirskynnyatyyadsvkgrftisrddskntaylqmnnlktedtavyycvrhgnfgnsylsfwaywgqgtlvtvssggggsggggsggggsQTvvtqepsltvspggtvtltcgsstgavtsgyypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycalwysnrwvfgggtkltvl
369		G4H의 CDR-L1	인공	GSSTGAVTSGYYPN
370		G4H의 CDR-L2	인공	GTKFLAP
371		G4H의 CDR-L3	인공	ALWYSNRWV
372		G4H의 CDR-H1	인공	RYAMN
373		G4H의 CDR-H2	인공	RIRSKYNNYATYYADSVKG
374		G4H의 CDR-H3	인공	HGNFGNSYLSYFAY
375		G4H의 VH	인공	EVQLVESggglvqpggslklscaasgftfnryamnwvrqapgkglewvarirskynnyatyyadsvkgrftisrddskntaylqmnnlktedtavyycvrhgnfgnsylsyfaywgqgtlvtvss
376		G4H의 VL	인공	QTvvtqepsltvspggtvtltcgsstgavtsgyypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycalwysnrwvfgggtkltvl
377		G4H의 VH-VL	인공	EVQLVESggglvqpggslklscaasgftfnryamnwvrqapgkglewvarirskynnyatyyadsvkgrftisrddskntaylqmnnlktedtavyycvrhgnfgnsylsyfaywgqgtlvtvssggggsggggsggggsQTvvtqepsltvspggtvtltcgsstgavtsgyypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycalwysnrwvfgggtkltvl
378		A2J의 CDR-L1	인공	RSSTGAVTSGYYPN
379		A2J의 CDR-L2	인공	ATDMRPS
380		A2J의 CDR-L3	인공	ALWYSNRWV
381		A2J의 CDR-H1	인공	VYAMN
382		A2J의 CDR-H2	인공	RIRSKYNNYATYYADSVKK
383		A2J의 CDR-H3	인공	HGNFGNSYLSWWAY
384		A2J의 VH	인공	EVQLVESggglvqpggslklscaasgftfnvyamnwvrqapgkglewvarirskynnyatyyadsvkkrftisrddskntaylqmnnlktedtavyycvrhgnfgnsylswwaywgqgtlvtvss
385		A2J의 VL	인공	QTvvtqepsltvspggtvtltcrsstgavtsgyypnwvqqkpgqaprgligatdmrpsgtparfsgsllggkaaltlsgvqpedeaeyycalwysnrwvfgggtkltvl
386		A2J의 VH-VL	인공	EVQLVESggglvqpggslklscaasgftfnvyamnwvrqapgkglewvarirskynnyatyyadsvkkrftisrddskntaylqmnnlktedtavyycvrhgnfgnsylswwaywgqgtlvtvssggggsggggsggggsQTvvtqepsltvspggtvtltcrsstgavtsgyypnwvqqkpgqaprgligatdmrpsgtparfsgsllggkaaltlsgvqpedeaeyycalwysnrwvfgggtkltvl
387		E1L의 CDR-L1	인공	GSSTGAVTSGYYPN
388		E1L의 CDR-L2	인공	GTKFLAP
389		E1L의 CDR-L3	인공	ALWYSNRWV
390		E1L의 CDR-H1	인공	KYAMN
391		E1L의 CDR-H2	인공	RIRSKYNNYATYYADSVKS
392		E1L의 CDR-H3	인공	HGNFGNSYTSYYAY
393		E1L의 VH	인공	EVQLVESggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvksrftisrddskntaylqmnnlktedtavyycvrhgnfgnsytsyyaywgqgtlvtvss
394		E1L의 VL	인공	QTvvtqepsltvspggtvtltcgsstgavtsgyypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycalwysnrwvfgggtkltvl
395		E1L의 VH-VL	인공	EVQLVESggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvksrftisrddskntaylqmnnlktedtavyycvrhgnfgnsytsyyaywgqgtlvtvssggggsggggsggggsQTvvtqepsltvspggtvtltcgsstgavtsgyypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycalwysnrwvfgggtkltvl
396		E2M의 CDR-L1	인공	RSSTGAVTSGYYPN
397		E2M의 CDR-L2	인공	ATDMRPS
398		E2M의 CDR-L3	인공	ALWYSNRWV
399		E2M의 CDR-H1	인공	GYAMN
400		E2M의 CDR-H2	인공	RIRSKYNNYATYYADSVKE
401		E2M의 CDR-H3	인공	HRNFGNSYLSWFAY
402		E2M의 VH	인공	EVQLVESggglvqpggslklscaasgftfngyamnwvrqapgkglewvarirskynnyatyyadsvkerftisrddskntaylqmnnlktedtavyycvrhrnfgnsylswfaywgqgtlvtvss
403		E2M의 VL	인공	QTvvtqepsltvspggtvtltcrsstgavtsgyypnwvqqkpgqaprgligatdmrpsgtparfsgsllggkaaltlsgvqpedeaeyycalwysnrwvfgggtkltvl
404		E2M의 VH-VL	인공	EVQLVESggglvqpggslklscaasgftfngyamnwvrqapgkglewvarirskynnyatyyadsvkerftisrddskntaylqmnnlktedtavyycvrhrnfgnsylswfaywgqgtlvtvssggggsggggsggggsQTvvtqepsltvspggtvtltcrsstgavtsgyypnwvqqkpgqaprgligatdmrpsgtparfsgsllggkaaltlsgvqpedeaeyycalwysnrwvfgggtkltvl
405		F7O의 CDR-L1	인공	GSSTGAVTSGYYPN
406		F7O의 CDR-L2	인공	GTKFLAP
407		F7O의 CDR-L3	인공	ALWYSNRWV
408		F7O의 CDR-H1	인공	VYAMN
409		F7O의 CDR-H2	인공	RIRSKYNNYATYYADSVKK
410		F7O의 CDR-H3	인공	HGNFGNSYISWWAY
411		F7O의 VH	인공	EVQLVESggglvqpggslklscaasgftfnvyamnwvrqapgkglewvarirskynnyatyyadsvkkrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyiswwaywgqgtlvtvss
412		F7O의 VL	인공	QTvvtqepsltvspggtvtltcgsstgavtsgyypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycalwysnrwvfgggtkltvl
413		F7O의 VH-VL	인공	EVQLVESggglvqpggslklscaasgftfnvyamnwvrqapgkglewvarirskynnyatyyadsvkkrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyiswwaywgqgtlvtvssggggsggggsggggsQTvvtqepsltvspggtvtltcgsstgavtsgyypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycalwysnrwvfgggtkltvl
414		F12Q의 CDR-L1	인공	gsstgavtsgnypn
415		F12Q의 CDR-L2	인공	gtkflap
416		F12Q의 CDR-L3	인공	vlwysnrwv
417		F12Q의 CDR-H1	인공	syamn
418		F12Q의 CDR-H2	인공	rirskynnyatyyadsvkg
419		F12Q의 CDR-H3	인공	hgnfgnsyvswway
420		F12Q의 VH	인공	EVQLVESggglvqpggslklscaasgftfnsyamnwvrqapgkglewvarirskynnyatyyadsvkgrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyvswwaywgqgtlvtvss
421		F12Q의 VL	인공	QTvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvl
422		F12Q의 VH-VL	인공	EVQLVESggglvqpggslklscaasgftfnsyamnwvrqapgkglewvarirskynnyatyyadsvkgrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyvswwaywgqgtlvtvssggggsggggsggggsQTvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvl
423		I2C의 CDR-L1	인공	GSSTGAVTSGNYPN
424		I2C의 CDR-L2	인공	GTKFLAP
425		I2C의 CDR-L3	인공	VLWYSNRWV
426		I2C의 CDR-H1	인공	KYAMN
427		I2C의 CDR-H2	인공	RIRSKYNNYATYYADSVKD
428		I2C의 CDR-H3	인공	HGNFGNSYISYWAY
429		I2C의 VH	인공	EVQLVESggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvss
430		I2C의 VL	인공	QTvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvl
431		I2C의 VH-VL	인공	EVQLVESggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsQTvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvl
432		F12q의 VH	인공	evqlvesggglvqpggslrlscaasgftfnsyamnwvrqapgkglewvarirskynnyatyyadsvkgrftisrddskntaylqmnslktedtavyycvrhgnfgnsyvswwaywgqgtlvtvss
433		F12q의 VL	인공	QTvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvl
434		F12q의 VH-VL	인공	evqlvesggglvqpggslrlscaasgftfnsyamnwvrqapgkglewvarirskynnyatyyadsvkgrftisrddskntaylqmnslktedtavyycvrhgnfgnsyvswwaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvl

435		DLL3-4-001 (G44C)	VH	QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKCLEWIGYVYYSGTTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCASIAVTGFYFDYWGQGTLVTVSS
436		DLL3-4-001 (G234C)	VL	EIVLTQSPGTLSLSPGERVTLSCRASQRVNNNYLAWYQQRPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYDRSPLTFGCGTKLEIK
437		DLL3-4-001 (G44C-G243C)	scFv	QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKCLEWIGYVYYSGTTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCASIAVTGFYFDYWGQGTLVTVSSGGGGSGGGGSGGGGSEIVLTQSPGTLSLSPGERVTLSCRASQRVNNNYLAWYQQRPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYDRSPLTFGCGTKLEIK
438		DLL3-4-001 (CC) xI2C	이중특이적분자	QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKCLEWIGYVYYSGTTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCASIAVTGFYFDYWGQGTLVTVSSGGGGSGGGGSGGGGSEIVLTQSPGTLSLSPGERVTLSCRASQRVNNNYLAWYQQRPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYDRSPLTFGCGTKLEIKSGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL
439		DLL3-14 -D55E	VH-CDR2	IINPSEGSTSYAQKFQG
440		DLL3-14 -G56A	VH-CDR2	IINPSDASTSYAQKFQG
441		DLL3-14 -D171E	VL-CDR1	RSSQSLVYREGNTYLS
442		DLL3-14 -G172A	VL-CDR1	RSSQSLVYRDANTYLS
443		DLL3-14 -N173Q	VL-CDR1	RSSQSLVYRDGQTYLS
444		DLL3-14 -T174A	VL-CDR1	RSSQSLVYRDGNAYLS
445		DLL3-14 -L43Q	VH	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGQGLEWMGIINPSDGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGGNSAFYSYYDMDVWGQGTTVTVSS
446		DLL3-14 -D55E	VH	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGLGLEWMGIINPSEGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGGNSAFYSYYDMDVWGQGTTVTVSS
447		DLL3-14 -G56A	VH	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGLGLEWMGIINPSDASTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGGNSAFYSYYDMDVWGQGTTVTVSS
448		DLL3-14 -L43Q-D55E	VH	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGQGLEWMGIINPSEGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGGNSAFYSYYDMDVWGQGTTVTVSS
449		DLL3-14 -L43Q-G56A	VH	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGQGLEWMGIINPSDASTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGGNSAFYSYYDMDVWGQGTTVTVS
450		DLL3-14 -G44C	VH	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGLCLEWMGIINPSDGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGGNSAFYSYYDMDVWGQGTTVTVSS
451		DLL3-14 -L43Q-G44C	VH	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGQCLEWMGIINPSDGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGGNSAFYSYYDMDVWGQGTTVTVSS
452		DLL3-14 -G44C-D55E	VH	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGLCLEWMGIINPSEGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGGNSAFYSYYDMDVWGQGTTVTVSS
453		DLL3-14 -G44C-G56A	VH	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGLCLEWMGIINPSDASTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGGNSAFYSYYDMDVWGQGTTVTVSS
454		DLL3-14 -L43Q-G44C-D55E	VH	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGQCLEWMGIINPSEGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGGNSAFYSYYDMDVWGQGTTVTVSS
455		DLL3-14 -L43Q-G44C-G56A	VH	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGQCLEWMGIINPSDASTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGGNSAFYSYYDMDVWGQGTTVTVSS

456		DLL3-14 -D171E	VL	DVVMTQTPLSLPVTLGQPASISCRSSQSLVYREGNTYLSWFQQRPGQSPRRLIYKVSNWQSGVPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGQGTKVEIK
457		DLL3-14 -G172A	VL	DVVMTQTPLSLPVTLGQPASISCRSSQSLVYRDANTYLSWFQQRPGQSPRRLIYKVSNWQSGVPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGQGTKVEIK
458		DLL3-14 -N173Q	VL	DVVMTQTPLSLPVTLGQPASISCRSSQSLVYRDGQTYLSWFQQRPGQSPRRLIYKVSNWQSGVPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGQGTKVEIK
459		DLL3-14 -T174A	VL	DVVMTQTPLSLPVTLGQPASISCRSSQSLVYRDGNAYLSWFQQRPGQSPRRLIYKVSNWQSGVPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGQGTKVEIK
460		DLL3-14 -G208S	VL	DVVMTQTPLSLPVTLGQPASISCRSSQSLVYRDGNTYLSWFQQRPGQSPRRLIYKVSNWQSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGQGTKVEIK
461		DLL3-14 -D171E-G208S	VL	DVVMTQTPLSLPVTLGQPASISCRSSQSLVYREGNTYLSWFQQRPGQSPRRLIYKVSNWQSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGQGTKVEIK
462		DLL3-14 G172A-G208S	VL	DVVMTQTPLSLPVTLGQPASISCRSSQSLVYRDANTYLSWFQQRPGQSPRRLIYKVSNWQSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGQGTKVEIK
463		DLL3-14 -Q243C	VL	DVVMTQTPLSLPVTLGQPASISCRSSQSLVYRDGNTYLSWFQQRPGQSPRRLIYKVSNWQSGVPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGCGTKVEIK
464		DLL3-14 -D171E-Q243C	VL	DVVMTQTPLSLPVTLGQPASISCRSSQSLVYREGNTYLSWFQQRPGQSPRRLIYKVSNWQSGVPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGCGTKVEIK
465		DLL3-14 -G172A-Q243C	VL	DVVMTQTPLSLPVTLGQPASISCRSSQSLVYRDANTYLSWFQQRPGQSPRRLIYKVSNWQSGVPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGCGTKVEIK
466		DLL3-14 -N173Q Q243C	VL	DVVMTQTPLSLPVTLGQPASISCRSSQSLVYRDGQTYLSWFQQRPGQSPRRLIYKVSNWQSGVPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGCGTKVEIK
467		DLL3-14 -T174A-Q243C	VL	DVVMTQTPLSLPVTLGQPASISCRSSQSLVYRDGNAYLSWFQQRPGQSPRRLIYKVSNWQSGVPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGCGTKVEIK
468		DLL3-14 -G208S-Q243C	VL	DVVMTQTPLSLPVTLGQPASISCRSSQSLVYRDGNTYLSWFQQRPGQSPRRLIYKVSNWQSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGCGTKVEIK
469		DLL3-14 -D171E-G208S-Q243C	VL	DVVMTQTPLSLPVTLGQPASISCRSSQSLVYREGNTYLSWFQQRPGQSPRRLIYKVSNWQSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGCGTKVEIK
470		DLL3-14 -G172A-G208S-Q243C	VL	DVVMTQTPLSLPVTLGQPASISCRSSQSLVYRDANTYLSWFQQRPGQSPRRLIYKVSNWQSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGCGTKVEIK
471		DLL3-14 -001	scFv	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGLGLEWMGIINPSDGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGGNSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLPVTLGQPASISCRSSQSLVYREGNTYLSWFQQRPGQSPRRLIYKVSNWQSGVPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGQGTKVEIK
472		DLL3-14 -002	scFv	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGLGLEWMGIINPSDGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGGNSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLPVTLGQPASISCRSSQSLVYRDANTYLSWFQQRPGQSPRRLIYKVSNWQSGVPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGQGTKVEIK
473		DLL3-14 -003	scFv	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGLGLEWMGIINPSDGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGGNSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLPVTLGQPASISCRSSQSLVYRDGQTYLSWFQQRPGQSPRRLIYKVSNWQSGVPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGQGTKVEIK
474		DLL3-14 -004	scFv	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGLGLEWMGIINPSDGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGGNSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLPVTLGQPASISCRSSQSLVYRDGNAYLSWFQQRPGQSPRRLIYKVSNWQSGVPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGQGTKVEIK
475		DLL3-14 -005	scFv	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGLGLEWMGIINPSDGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGGNSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLPVTLGQPASISCRSSQSLVYRDGNTYLSWFQQRPGQSPRRLIYKVSNWQSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGQGTKVEIK
476		DLL3-14 -006	scFv	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGQGLEWMGIINPSDGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGGNSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLPVTLGQPASISCRSSQSLVYRDGNTYLSWFQQRPGQSPRRLIYKVSNWQSGVPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGQGTKVEIK
477		DLL3-14 -007	scFv	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGLGLEWMGIINPSEGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGGNSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLPVTLGQPASISCRSSQSLVYRDGNTYLSWFQQRPGQSPRRLIYKVSNWQSGVPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGQGTKVEIK
478		DLL3-14 -008	scFv	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGLGLEWMGIINPSDASTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGGNSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLPVTLGQPASISCRSSQSLVYRDGNTYLSWFQQRPGQSPRRLIYKVSNWQSGVPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGQGTKVEIK
479		DLL3-14 -009	scFv	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGQGLEWMGIINPSDGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGGNSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLPVTLGQPASISCRSSQSLVYRDGNTYLSWFQQRPGQSPRRLIYKVSNWQSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGQGTKVEIK
480		DLL3-14 -010	scFv	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGQGLEWMGIINPSEGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGGNSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLPVTLGQPASISCRSSQSLVYREGNTYLSWFQQRPGQSPRRLIYKVSNWQSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGQGTKVEIK
481		DLL3-14 -011	scFv	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGQGLEWMGIINPSDASTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGGNSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLPVTLGQPASISCRSSQSLVYRDANTYLSWFQQRPGQSPRRLIYKVSNWQSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGQGTKVEIK
482		DLL3-14 -012 (CC)	scFv	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGLCLEWMGIINPSDGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGGNSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLPVTLGQPASISCRSSQSLVYRDGNTYLSWFQQRPGQSPRRLIYKVSNWQSGVPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGCGTKVEIK
483		DLL3-14 -013	scFv	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGLCLEWMGIINPSDGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGGNSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLPVTLGQPASISCRSSQSLVYREGNTYLSWFQQRPGQSPRRLIYKVSNWQSGVPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGCGTKVEIK
484		DLL3-14 -014	scFv	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGLCLEWMGIINPSDGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGGNSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLPVTLGQPASISCRSSQSLVYRDANTYLSWFQQRPGQSPRRLIYKVSNWQSGVPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGCGTKVEIK
485		DLL3-14 -015	scFv	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGLCLEWMGIINPSDGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGGNSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLPVTLGQPASISCRSSQSLVYRDGQTYLSWFQQRPGQSPRRLIYKVSNWQSGVPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGCGTKVEIK
486		DLL3-14 -016	scFv	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGLCLEWMGIINPSDGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGGNSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLPVTLGQPASISCRSSQSLVYRDGNAYLSWFQQRPGQSPRRLIYKVSNWQSGVPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGCGTKVEIK
487		DLL3-14 -017	scFv	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGLCLEWMGIINPSDGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGGNSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLPVTLGQPASISCRSSQSLVYRDGNTYLSWFQQRPGQSPRRLIYKVSNWQSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGCGTKVEIK
488		DLL3-14 -018	scFv	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGQCLEWMGIINPSDGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGGNSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLPVTLGQPASISCRSSQSLVYRDGNTYLSWFQQRPGQSPRRLIYKVSNWQSGVPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGCGTKVEIK
489		DLL3-14 -019	scFv	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGLCLEWMGIINPSEGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGGNSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLPVTLGQPASISCRSSQSLVYRDGNTYLSWFQQRPGQSPRRLIYKVSNWQSGVPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGCGTKVEIK
490		DLL3-14 -020	scFv	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGLCLEWMGIINPSDASTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGGNSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLPVTLGQPASISCRSSQSLVYRDGNTYLSWFQQRPGQSPRRLIYKVSNWQSGVPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGCGTKVEIK
491		DLL3-14 -021	scFv	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGQCLEWMGIINPSDGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGGNSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLPVTLGQPASISCRSSQSLVYRDGNTYLSWFQQRPGQSPRRLIYKVSNWQSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGCGTKVEIK
492		DLL3-14 -022	scFv	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGQCLEWMGIINPSEGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGGNSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLPVTLGQPASISCRSSQSLVYREGNTYLSWFQQRPGQSPRRLIYKVSNWQSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGCGTKVEIK
493		DLL3-14 -023	scFv	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGQCLEWMGIINPSDASTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGGNSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLPVTLGQPASISCRSSQSLVYRDANTYLSWFQQRPGQSPRRLIYKVSNWQSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGCGTKVEIK

494		DLL3-14 -001 xI2C	이중특이적 분자	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGLGLEWMGIINPSDGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGGNSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLPVTLGQPASISCRSSQSLVYREGNTYLSWFQQRPGQSPRRLIYKVSNWQSGVPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGQGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL
495		DLL3-14 -002 xI2C	이중특이적 분자	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGLGLEWMGIINPSDGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGGNSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLPVTLGQPASISCRSSQSLVYRDANTYLSWFQQRPGQSPRRLIYKVSNWQSGVPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGQGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL
496		DLL3-14 -003 xI2C	이중특이적 분자	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGLGLEWMGIINPSDGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGGNSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLPVTLGQPASISCRSSQSLVYRDGQTYLSWFQQRPGQSPRRLIYKVSNWQSGVPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGQGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL
497		DLL3-14 -004 xI2C	이중특이적 분자	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGLGLEWMGIINPSDGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGGNSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLPVTLGQPASISCRSSQSLVYRDGNAYLSWFQQRPGQSPRRLIYKVSNWQSGVPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGQGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL
498		DLL3-14 -005 xI2C	이중특이적 분자	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGLGLEWMGIINPSDGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGGNSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLPVTLGQPASISCRSSQSLVYRDGNTYLSWFQQRPGQSPRRLIYKVSNWQSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGQGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL
499		DLL3-14 -006 xI2C	이중특이적 분자	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGQGLEWMGIINPSDGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGGNSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLPVTLGQPASISCRSSQSLVYRDGNTYLSWFQQRPGQSPRRLIYKVSNWQSGVPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGQGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL
500		DLL3-14 -007 xI2C	이중특이적 분자	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGLGLEWMGIINPSEGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGGNSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLPVTLGQPASISCRSSQSLVYRDGNTYLSWFQQRPGQSPRRLIYKVSNWQSGVPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGQGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL
501		DLL3-14 -008 xI2C	이중특이적 분자	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGLGLEWMGIINPSDASTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGGNSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLPVTLGQPASISCRSSQSLVYRDGNTYLSWFQQRPGQSPRRLIYKVSNWQSGVPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGQGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL
502		DLL3-14 -009 xI2C	이중특이적 분자	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGQGLEWMGIINPSDGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGGNSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLPVTLGQPASISCRSSQSLVYRDGNTYLSWFQQRPGQSPRRLIYKVSNWQSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGQGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL
503		DLL3-14 -010 xI2C	이중특이적 분자	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGQGLEWMGIINPSEGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGGNSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLPVTLGQPASISCRSSQSLVYREGNTYLSWFQQRPGQSPRRLIYKVSNWQSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGQGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL
504		DLL3-14 -011 xI2C	이중특이적 분자	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGQGLEWMGIINPSDASTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGGNSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLPVTLGQPASISCRSSQSLVYRDANTYLSWFQQRPGQSPRRLIYKVSNWQSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGQGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL
505		DLL3-14 -012 (CC) xI2C	이중특이적 분자	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGLCLEWMGIINPSDGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGGNSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLPVTLGQPASISCRSSQSLVYRDGNTYLSWFQQRPGQSPRRLIYKVSNWQSGVPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGCGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL
506		DLL3-14 -013 xI2C	이중특이적 분자	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGLCLEWMGIINPSDGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGGNSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLPVTLGQPASISCRSSQSLVYREGNTYLSWFQQRPGQSPRRLIYKVSNWQSGVPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGCGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL
507		DLL3-14 -014 xI2C	이중특이적 분자	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGLCLEWMGIINPSDGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGGNSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLPVTLGQPASISCRSSQSLVYRDANTYLSWFQQRPGQSPRRLIYKVSNWQSGVPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGCGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL
508		DLL3-14 -015 xI2C	이중특이적 분자	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGLCLEWMGIINPSDGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGGNSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLPVTLGQPASISCRSSQSLVYRDGQTYLSWFQQRPGQSPRRLIYKVSNWQSGVPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGCGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL
509		DLL3-14 -016 xI2C	이중특이적 분자	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGLCLEWMGIINPSDGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGGNSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLPVTLGQPASISCRSSQSLVYRDGNAYLSWFQQRPGQSPRRLIYKVSNWQSGVPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGCGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL
510		DLL3-14 -017 xI2C	이중특이적 분자	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGLCLEWMGIINPSDGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGGNSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLPVTLGQPASISCRSSQSLVYRDGNTYLSWFQQRPGQSPRRLIYKVSNWQSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGCGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL
511		DLL3-14 -018 xI2C	이중특이적 분자	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGQCLEWMGIINPSDGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGGNSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLPVTLGQPASISCRSSQSLVYRDGNTYLSWFQQRPGQSPRRLIYKVSNWQSGVPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGCGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL
512		DLL3-14 -019 xI2C	이중특이적 분자	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGLCLEWMGIINPSEGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGGNSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLPVTLGQPASISCRSSQSLVYRDGNTYLSWFQQRPGQSPRRLIYKVSNWQSGVPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGCGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL
513		DLL3-14 -020 xI2C	이중특이적 분자	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGLCLEWMGIINPSDASTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGGNSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLPVTLGQPASISCRSSQSLVYRDGNTYLSWFQQRPGQSPRRLIYKVSNWQSGVPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGCGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL
514		DLL3-14 -021 xI2C	이중특이적 분자	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGQCLEWMGIINPSDGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGGNSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLPVTLGQPASISCRSSQSLVYRDGNTYLSWFQQRPGQSPRRLIYKVSNWQSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGCGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL
515		DLL3-14 -022 xI2C	이중특이적 분자	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGQCLEWMGIINPSEGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGGNSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLPVTLGQPASISCRSSQSLVYREGNTYLSWFQQRPGQSPRRLIYKVSNWQSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGCGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL
516		DLL3-14 -023 xI2C	이중특이적 분자	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGQCLEWMGIINPSDASTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGGNSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLPVTLGQPASISCRSSQSLVYRDANTYLSWFQQRPGQSPRRLIYKVSNWQSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGCGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL
517		DLL3-4 xI2C -scFc	이중특이적 HLE 분자	qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyvyysgttnynpslksrvtisvdtsknqfslklssvtaadtavyycasiavtgfyfdywgqgtlvtvssggggsggggsggggseivltqspgtlslspgervtlscrasqrvnnnylawyqqrpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqydrspltfgggtkleiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvlggggdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpceeqygstyrcvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgkggggsggggsggggsggggsggggsggggsdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpceeqygstyrcvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk
518		DLL3-4 xI2C -scFc_delGK	이중특이적 HLE 분자	qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyvyysgttnynpslksrvtisvdtsknqfslklssvtaadtavyycasiavtgfyfdywgqgtlvtvssggggsggggsggggseivltqspgtlslspgervtlscrasqrvnnnylawyqqrpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqydrspltfgggtkleiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvlggggdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpceeqygstyrcvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspggggsggggsggggsggggsggggsggggsdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpceeqygstyrcvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk
519		DLL3-4-001 (CC) xI2C -scFc	이중특이적 HLE 분자	qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkclewigyvyysgttnynpslksrvtisvdtsknqfslklssvtaadtavyycasiavtgfyfdywgqgtlvtvssggggsggggsggggseivltqspgtlslspgervtlscrasqrvnnnylawyqqrpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqydrspltfgcgtkleiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvlggggdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpceeqygstyrcvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgkggggsggggsggggsggggsggggsggggsdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpceeqygstyrcvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk
520		DLL3-4-001 (CC) xI2C -scFc _delGK	이중특이적 HLE 분자	qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkclewigyvyysgttnynpslksrvtisvdtsknqfslklssvtaadtavyycasiavtgfyfdywgqgtlvtvssggggsggggsggggseivltqspgtlslspgervtlscrasqrvnnnylawyqqrpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqydrspltfgcgtkleiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvlggggdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpceeqygstyrcvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspggggsggggsggggsggggsggggsggggsdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpceeqygstyrcvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk
521		DLL3-6 xI2C -scFc	이중특이적 HLE 분자	qvqlqesgpglvkpsetlsltctvsgasissfywswirqppgkglewigyiyysgttnynpslksrvtisvdtsknqfslklssvtaadtavyycariavagfffdywgqgtlvtvssggggsggggsggggseivltqspgtlslspgeratlscrasqsvnknylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqydrspltfgggtkveiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvlggggdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpceeqygstyrcvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgkggggsggggsggggsggggsggggsggggsdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpceeqygstyrcvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk
522		DLL3-6 xI2C -scFc_delGK	이중특이적 HLE 분자	qvqlqesgpglvkpsetlsltctvsgasissfywswirqppgkglewigyiyysgttnynpslksrvtisvdtsknqfslklssvtaadtavyycariavagfffdywgqgtlvtvssggggsggggsggggseivltqspgtlslspgeratlscrasqsvnknylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqydrspltfgggtkveiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvlggggdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpceeqygstyrcvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspggggsggggsggggsggggsggggsggggsdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpceeqygstyrcvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk
523		DLL3-6-001 (CC) xI2C -scFc	이중특이적 HLE 분자	qvqlqesgpglvkpsetlsltctvsgasissfywswirqppgkclewigyiyysgttnynpslksrvtisvdtsknqfslklssvtaadtavyycariavagfffdywgqgtlvtvssggggsggggsggggseivltqspgtlslspgeratlscrasqsvnknylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqydrspltfgcgtkveiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvlggggdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpceeqygstyrcvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgkggggsggggsggggsggggsggggsggggsdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpceeqygstyrcvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk
524		DLL3-6-001 (CC) xI2C -scFc_delGK	이중특이적 HLE 분자	qvqlqesgpglvkpsetlsltctvsgasissfywswirqppgkclewigyiyysgttnynpslksrvtisvdtsknqfslklssvtaadtavyycariavagfffdywgqgtlvtvssggggsggggsggggseivltqspgtlslspgeratlscrasqsvnknylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqydrspltfgcgtkveiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvlggggdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpceeqygstyrcvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspggggsggggsggggsggggsggggsggggsdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpceeqygstyrcvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk
525		DLL3-14 xI2C -scFc	이중특이적 HLE 분자	qvqlvqsgaevkkpgasvkvsckasgytftnyymhwvrqapglglewmgiinpsdgstsyaqkfqgrvtmtrdtstntvymdlsslrsedtavyycarggnsafysyydmdvwgqgttvtvssggggsggggsggggsdvvmtqtplslpvtlgqpasiscrssqslvyrdgntylswfqqrpgqsprrliykvsnwqsgvpdrfsgggsgtdftlkisrveaedvgvyycmqgthwpptfgqgtkveiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvlggggdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpceeqygstyrcvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgkggggsggggsggggsggggsggggsggggsdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpceeqygstyrcvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk
526		DLL3-14 xI2C -scFc_delGK	이중특이적 HLE 분자	qvqlvqsgaevkkpgasvkvsckasgytftnyymhwvrqapglglewmgiinpsdgstsyaqkfqgrvtmtrdtstntvymdlsslrsedtavyycarggnsafysyydmdvwgqgttvtvssggggsggggsggggsdvvmtqtplslpvtlgqpasiscrssqslvyrdgntylswfqqrpgqsprrliykvsnwqsgvpdrfsgggsgtdftlkisrveaedvgvyycmqgthwpptfgqgtkveiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvlggggdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpceeqygstyrcvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspggggsggggsggggsggggsggggsggggsdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpceeqygstyrcvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk
527		DLL3-14 -012 (CC) xI2C -scFc	이중특이적 HLE 분자	qvqlvqsgaevkkpgasvkvsckasgytftnyymhwvrqapglclewmgiinpsdgstsyaqkfqgrvtmtrdtstntvymdlsslrsedtavyycarggnsafysyydmdvwgqgttvtvssggggsggggsggggsdvvmtqtplslpvtlgqpasiscrssqslvyrdgntylswfqqrpgqsprrliykvsnwqsgvpdrfsgggsgtdftlkisrveaedvgvyycmqgthwpptfgcgtkveiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvlggggdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpceeqygstyrcvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgkggggsggggsggggsggggsggggsggggsdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpceeqygstyrcvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk
528		DLL3-14 -012 (CC) xI2C-scFc_delGK	이중특이적 HLE 분자	qvqlvqsgaevkkpgasvkvsckasgytftnyymhwvrqapglclewmgiinpsdgstsyaqkfqgrvtmtrdtstntvymdlsslrsedtavyycarggnsafysyydmdvwgqgttvtvssggggsggggsggggsdvvmtqtplslpvtlgqpasiscrssqslvyrdgntylswfqqrpgqsprrliykvsnwqsgvpdrfsgggsgtdftlkisrveaedvgvyycmqgthwpptfgcgtkveiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvlggggdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpceeqygstyrcvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspggggsggggsggggsggggsggggsggggsdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpceeqygstyrcvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk
529		DLL3-6-001 (CC)	VH	qvqlqesgpglvkpsetlsltctvsgasissfywswirqppgkclewigyiyysgttnynpslksrvtisvdtsknqfslklssvtaadtavyycariavagfffdywgqgtlvtvss
530		DLL3-6-001 (CC)	VL	eivltqspgtlslspgeratlscrasqsvnknylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqydrspltfgcgtkveik
531		DLL3-6-001 (CC)	scFv	qvqlqesgpglvkpsetlsltctvsgasissfywswirqppgkclewigyiyysgttnynpslksrvtisvdtsknqfslklssvtaadtavyycariavagfffdywgqgtlvtvssggggsggggsggggseivltqspgtlslspgeratlscrasqsvnknylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqydrspltfgcgtkveik
532		DLL3-6-001 (CC) xI2C	이중특이적 분자	qvqlqesgpglvkpsetlsltctvsgasissfywswirqppgkclewigyiyysgttnynpslksrvtisvdtsknqfslklssvtaadtavyycariavagfffdywgqgtlvtvssggggsggggsggggseivltqspgtlslspgeratlscrasqsvnknylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqydrspltfgcgtkveiksggggsevqlvesggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynnyatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgnsyisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggtvtltcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgsllggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvl
533		Fc 단량체-1+c/-g		dkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpceeqygstyrcvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk
534		Fc 단량체-2+c/-g/ delGK		dkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpceeqygstyrcvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslsp
535		Fc 단량체-3-c/+g		dkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk
536		Fc 단량체-4-c/+g/ delGK		dkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslsp
537		Fc 단량체-5-c/-g		dkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqygstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk
538		Fc 단량체-6-c/-g/ delGK		dkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqygstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslsp
539		Fc 단량체-7+c/+g		dkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpceeqynstyrcvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk
540		Fc 단량체-8+c/+g/ delGK		dkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpceeqynstyrcvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslsp
541		scFc-1		dkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpceeqygstyrcvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgkGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpceeqygstyrcvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk
542		scFc-2		dkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpceeqygstyrcvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpceeqygstyrcvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslsp
543		scFc-3		dkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgkGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk
544		scFc-4		dkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslsp
545		scFc-5		dkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqygstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgkGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqygstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk
546		scFc-6		dkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqygstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqygstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslsp
547		scFc-7		dkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpceeqynstyrcvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgkGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpceeqynstyrcvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk
548		scFc-8		dkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpceeqynstyrcvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpceeqynstyrcvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslsp
549		(G₄S)₄ 링커		GGGGSGGGGSGGGGSGGGGS
550		(G₄S)₅ 링커		GGGGSGGGGSGGGGSGGGGSGGGGS
551		(G₄S)₆ 링커		GGGGSGGGGSGGGGSGGGGSGGGGSGGGGS
552		(G₄S)₇ 링커		GGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGS
553		(G₄S)₈ 링커		GGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGS
554		DLL3-22	이중특이적 분자	QVQLQESGPGLVKPSETLSLTCTVSGDSISSYYWTWIRQPPGKGLEWIGYIYYSGTTNYNPSLKSRVTISVDTSKSQFSLKLSSVTAADTAVYYCASIAVRGFFFDYWGQGTLVTVSSGGGGSGGGGSGGGGSEIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASTRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGTSPLTFGGGTKVEIKRSGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVLHHHHHH

SEQUENCE LISTING <110> AMGEN INC. <120> DOSING REGIMEN FOR ANTI-DLL3 AGENTS <130> A-2520-WO-PCT <150> EP 19208214 <151> 2019-11-10 <150> US 63/078,131 <151> 2020-09-14 <160> 554 <170> PatentIn version 3.5 <210> 1 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 1 Asp Tyr Gly Ile His 1 5 <210> 2 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 2 Val Ile Ser Tyr His Gly Ser Asn Lys Tyr Tyr Ala Arg Ser Val Lys 1 5 10 15 Gly <210> 3 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 3 Glu Ile Pro Phe Gly Met Asp Val 1 5 <210> 4 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 4 Arg Ser Ser Gln Ser Leu Leu His Ser Asp Gly Tyr Asn Tyr Leu Asp 1 5 10 15 <210> 5 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 5 Leu Gly Ser Asn Arg Ala Ser 1 5 <210> 6 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 6 Met Gln Ala Leu Gln Thr Pro Leu Thr 1 5 <210> 7 <211> 117 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 7 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Ser Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr 20 25 30 Gly Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Ile Ser Tyr His Gly Ser Asn Lys Tyr Tyr Ala Arg Ser Val 50 55 60 Lys Gly Arg Phe Thr Val Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Glu Ile Pro Phe Gly Met Asp Val Trp Gly Gln Gly Thr Thr 100 105 110 Val Thr Val Ser Ser 115 <210> 8 <211> 112 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 8 Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Pro Gly 1 5 10 15 Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser 20 25 30 Asp Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala 85 90 95 Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Asp Ile Lys 100 105 110 <210> 9 <211> 244 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 9 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Ser Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr 20 25 30 Gly Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Ile Ser Tyr His Gly Ser Asn Lys Tyr Tyr Ala Arg Ser Val 50 55 60 Lys Gly Arg Phe Thr Val Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Glu Ile Pro Phe Gly Met Asp Val Trp Gly Gln Gly Thr Thr 100 105 110 Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 115 120 125 Gly Gly Gly Ser Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Pro 130 135 140 Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser 145 150 155 160 Leu Leu His Ser Asp Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys 165 170 175 Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala 180 185 190 Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe 195 200 205 Thr Leu Thr Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr 210 215 220 Cys Met Gln Ala Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys 225 230 235 240 Val Asp Ile Lys <210> 10 <211> 499 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 10 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Ser Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr 20 25 30 Gly Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Ile Ser Tyr His Gly Ser Asn Lys Tyr Tyr Ala Arg Ser Val 50 55 60 Lys Gly Arg Phe Thr Val Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Glu Ile Pro Phe Gly Met Asp Val Trp Gly Gln Gly Thr Thr 100 105 110 Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 115 120 125 Gly Gly Gly Ser Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Pro 130 135 140 Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser 145 150 155 160 Leu Leu His Ser Asp Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys 165 170 175 Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala 180 185 190 Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe 195 200 205 Thr Leu Thr Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr 210 215 220 Cys Met Gln Ala Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys 225 230 235 240 Val Asp Ile Lys Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu 245 250 255 Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys 260 265 270 Ala Ala Ser Gly Phe Thr Phe Asn Lys Tyr Ala Met Asn Trp Val Arg 275 280 285 Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys 290 295 300 Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe 305 310 315 320 Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn 325 330 335 Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly 340 345 350 Asn Phe Gly Asn Ser Tyr Ile Ser Tyr Trp Ala Tyr Trp Gly Gln Gly 355 360 365 Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 370 375 380 Ser Gly Gly Gly Gly Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu 385 390 395 400 Thr Val Ser Pro Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr 405 410 415 Gly Ala Val Thr Ser Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro 420 425 430 Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro 435 440 445 Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala 450 455 460 Leu Thr Leu Ser Gly Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys 465 470 475 480 Val Leu Trp Tyr Ser Asn Arg Trp Val Phe Gly Gly Gly Thr Lys Leu 485 490 495 Thr Val Leu <210> 11 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 11 Gly Tyr Tyr Met His 1 5 <210> 12 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 12 Trp Ile Asn Pro Asn Ser Gly Asp Thr Asn Tyr Ala Gln Lys Phe Gln 1 5 10 15 Gly <210> 13 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 13 Asp Ala Asn Ile Ala Ala Leu Asp Ala Phe Glu Ile 1 5 10 <210> 14 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 14 Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn 1 5 10 <210> 15 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 15 Ala Ala Ser Ser Leu Gln Ser 1 5 <210> 16 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 16 Gln Gln Ser Tyr Ser Thr Pro Leu Thr 1 5 <210> 17 <211> 121 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 17 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Asn Pro Asn Ser Gly Asp Thr Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Arg Leu Thr Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Ala Asn Ile Ala Ala Leu Asp Ala Phe Glu Ile Trp Gly 100 105 110 Gln Gly Thr Met Val Thr Val Ser Ser 115 120 <210> 18 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 18 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu 85 90 95 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 <210> 19 <211> 243 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 19 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Asn Pro Asn Ser Gly Asp Thr Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Arg Leu Thr Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Ala Asn Ile Ala Ala Leu Asp Ala Phe Glu Ile Trp Gly 100 105 110 Gln Gly Thr Met Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly 115 120 125 Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro 130 135 140 Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg 145 150 155 160 Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro 165 170 175 Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser 180 185 190 Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr 195 200 205 Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys 210 215 220 Gln Gln Ser Tyr Ser Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val 225 230 235 240 Glu Ile Lys <210> 20 <211> 498 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 20 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Asn Pro Asn Ser Gly Asp Thr Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Arg Leu Thr Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Ala Asn Ile Ala Ala Leu Asp Ala Phe Glu Ile Trp Gly 100 105 110 Gln Gly Thr Met Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly 115 120 125 Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro 130 135 140 Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg 145 150 155 160 Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro 165 170 175 Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser 180 185 190 Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr 195 200 205 Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys 210 215 220 Gln Gln Ser Tyr Ser Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val 225 230 235 240 Glu Ile Lys Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser 245 250 255 Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala 260 265 270 Ala Ser Gly Phe Thr Phe Asn Lys Tyr Ala Met Asn Trp Val Arg Gln 275 280 285 Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr 290 295 300 Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr 305 310 315 320 Ile Ser Arg Asp Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Asn 325 330 335 Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn 340 345 350 Phe Gly Asn Ser Tyr Ile Ser Tyr Trp Ala Tyr Trp Gly Gln Gly Thr 355 360 365 Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 370 375 380 Gly Gly Gly Gly Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr 385 390 395 400 Val Ser Pro Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly 405 410 415 Ala Val Thr Ser Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly 420 425 430 Gln Ala Pro Arg Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly 435 440 445 Thr Pro Ala Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu 450 455 460 Thr Leu Ser Gly Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val 465 470 475 480 Leu Trp Tyr Ser Asn Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr 485 490 495 Val Leu <210> 21 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 21 Ser Tyr Gly Met His 1 5 <210> 22 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 22 Val Ile Ser Tyr His Gly Arg Asp Thr Tyr Tyr Ala Arg Ser Val Lys 1 5 10 15 Gly <210> 23 <211> 15 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 23 Asp Gly Ala Thr Val Thr Ser Tyr Tyr Tyr Ser Gly Met Asp Val 1 5 10 15 <210> 24 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 24 Arg Ala Ser Gln Gly Ile Ser Asn Tyr Leu Ala 1 5 10 <210> 25 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 25 Leu Ala Ser Ser Leu Gln Ser 1 5 <210> 26 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 26 Gln Gln Tyr Asn Phe Tyr Pro Phe Thr 1 5 <210> 27 <211> 125 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 27 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Ile Ser Tyr His Gly Arg Asp Thr Tyr Tyr Ala Arg Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu His Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Gly Ala Thr Val Thr Ser Tyr Tyr Tyr Ser Gly Met Asp 100 105 110 Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Lys 115 120 125 <210> 28 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 28 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Asn Tyr 20 25 30 Leu Ala Trp Phe Gln Gln Lys Pro Gly Lys Ala Pro Lys Ser Leu Ile 35 40 45 Tyr Leu Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Lys Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Phe Tyr Pro Phe 85 90 95 Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys 100 105 <210> 29 <211> 246 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 29 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Ile Ser Tyr His Gly Arg Asp Thr Tyr Tyr Ala Arg Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu His Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Gly Ala Thr Val Thr Ser Tyr Tyr Tyr Ser Gly Met Asp 100 105 110 Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly 115 120 125 Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr 130 135 140 Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile 145 150 155 160 Thr Cys Arg Ala Ser Gln Gly Ile Ser Asn Tyr Leu Ala Trp Phe Gln 165 170 175 Gln Lys Pro Gly Lys Ala Pro Lys Ser Leu Ile Tyr Leu Ala Ser Ser 180 185 190 Leu Gln Ser Gly Val Pro Ser Lys Phe Ser Gly Ser Gly Ser Gly Thr 195 200 205 Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr 210 215 220 Tyr Tyr Cys Gln Gln Tyr Asn Phe Tyr Pro Phe Thr Phe Gly Pro Gly 225 230 235 240 Thr Lys Val Asp Ile Lys 245 <210> 30 <211> 501 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 30 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Ile Ser Tyr His Gly Arg Asp Thr Tyr Tyr Ala Arg Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu His Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Gly Ala Thr Val Thr Ser Tyr Tyr Tyr Ser Gly Met Asp 100 105 110 Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly 115 120 125 Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr 130 135 140 Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile 145 150 155 160 Thr Cys Arg Ala Ser Gln Gly Ile Ser Asn Tyr Leu Ala Trp Phe Gln 165 170 175 Gln Lys Pro Gly Lys Ala Pro Lys Ser Leu Ile Tyr Leu Ala Ser Ser 180 185 190 Leu Gln Ser Gly Val Pro Ser Lys Phe Ser Gly Ser Gly Ser Gly Thr 195 200 205 Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr 210 215 220 Tyr Tyr Cys Gln Gln Tyr Asn Phe Tyr Pro Phe Thr Phe Gly Pro Gly 225 230 235 240 Thr Lys Val Asp Ile Lys Ser Gly Gly Gly Gly Ser Glu Val Gln Leu 245 250 255 Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu 260 265 270 Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys Tyr Ala Met Asn Trp 275 280 285 Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Arg Ile Arg 290 295 300 Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp 305 310 315 320 Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Ala Tyr Leu Gln 325 330 335 Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg 340 345 350 His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr Trp Ala Tyr Trp Gly 355 360 365 Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly 370 375 380 Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val Thr Gln Glu Pro 385 390 395 400 Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu Thr Cys Gly Ser 405 410 415 Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro Asn Trp Val Gln Gln 420 425 430 Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly Thr Lys Phe Leu 435 440 445 Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys 450 455 460 Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp Glu Ala Glu Tyr 465 470 475 480 Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val Phe Gly Gly Gly Thr 485 490 495 Lys Leu Thr Val Leu 500 <210> 31 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 31 Ser Tyr Tyr Trp Ser 1 5 <210> 32 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 32 Tyr Val Tyr Tyr Ser Gly Thr Thr Asn Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 33 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 33 Ile Ala Val Thr Gly Phe Tyr Phe Asp Tyr 1 5 10 <210> 34 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 34 Arg Ala Ser Gln Arg Val Asn Asn Asn Tyr Leu Ala 1 5 10 <210> 35 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 35 Gly Ala Ser Ser Arg Ala Thr 1 5 <210> 36 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 36 Gln Gln Tyr Asp Arg Ser Pro Leu Thr 1 5 <210> 37 <211> 118 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 37 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Val Tyr Tyr Ser Gly Thr Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Ser Ile Ala Val Thr Gly Phe Tyr Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser 115 <210> 38 <211> 108 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 38 Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Val Thr Leu Ser Cys Arg Ala Ser Gln Arg Val Asn Asn Asn 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Arg Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asp Arg Ser Pro 85 90 95 Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 39 <211> 241 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 39 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Val Tyr Tyr Ser Gly Thr Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Ser Ile Ala Val Thr Gly Phe Tyr Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu 130 135 140 Ser Leu Ser Pro Gly Glu Arg Val Thr Leu Ser Cys Arg Ala Ser Gln 145 150 155 160 Arg Val Asn Asn Asn Tyr Leu Ala Trp Tyr Gln Gln Arg Pro Gly Gln 165 170 175 Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile 180 185 190 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 195 200 205 Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln 210 215 220 Tyr Asp Arg Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile 225 230 235 240 Lys <210> 40 <211> 496 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 40 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Val Tyr Tyr Ser Gly Thr Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Ser Ile Ala Val Thr Gly Phe Tyr Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu 130 135 140 Ser Leu Ser Pro Gly Glu Arg Val Thr Leu Ser Cys Arg Ala Ser Gln 145 150 155 160 Arg Val Asn Asn Asn Tyr Leu Ala Trp Tyr Gln Gln Arg Pro Gly Gln 165 170 175 Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile 180 185 190 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 195 200 205 Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln 210 215 220 Tyr Asp Arg Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile 225 230 235 240 Lys Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly 245 250 255 Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser 260 265 270 Gly Phe Thr Phe Asn Lys Tyr Ala Met Asn Trp Val Arg Gln Ala Pro 275 280 285 Gly Lys Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn 290 295 300 Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser 305 310 315 320 Arg Asp Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Asn Leu Lys 325 330 335 Thr Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn Phe Gly 340 345 350 Asn Ser Tyr Ile Ser Tyr Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val 355 360 365 Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 370 375 380 Gly Gly Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser 385 390 395 400 Pro Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val 405 410 415 Thr Ser Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala 420 425 430 Pro Arg Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro 435 440 445 Ala Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu 450 455 460 Ser Gly Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp 465 470 475 480 Tyr Ser Asn Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 485 490 495 <210> 41 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 41 Ser Tyr Tyr Trp Ser 1 5 <210> 42 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 42 Tyr Ile Tyr Tyr Ser Gly Arg Thr Asn Tyr Tyr Pro Ser Leu Lys Ser 1 5 10 15 <210> 43 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 43 Ile Ala Val Ala Gly Phe Phe Phe Asp Tyr 1 5 10 <210> 44 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 44 Arg Ala Ser Gln Ser Val Asn Lys Asn Tyr Leu Ala 1 5 10 <210> 45 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 45 Gly Ala Ser Ser Arg Ala Thr 1 5 <210> 46 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 46 Gln Gln Tyr Asp Arg Ser Pro Leu Thr 1 5 <210> 47 <211> 118 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 47 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Tyr Tyr Ser Gly Arg Thr Asn Tyr Tyr Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Ile Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Ile Ala Val Ala Gly Phe Phe Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser 115 <210> 48 <211> 108 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 48 Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Asn Lys Asn 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asp Arg Ser Pro 85 90 95 Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 49 <211> 241 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 49 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Tyr Tyr Ser Gly Arg Thr Asn Tyr Tyr Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Ile Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Ile Ala Val Ala Gly Phe Phe Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu 130 135 140 Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln 145 150 155 160 Ser Val Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 165 170 175 Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile 180 185 190 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 195 200 205 Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln 210 215 220 Tyr Asp Arg Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile 225 230 235 240 Lys <210> 50 <211> 496 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 50 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Tyr Tyr Ser Gly Arg Thr Asn Tyr Tyr Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Ile Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Ile Ala Val Ala Gly Phe Phe Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu 130 135 140 Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln 145 150 155 160 Ser Val Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 165 170 175 Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile 180 185 190 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 195 200 205 Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln 210 215 220 Tyr Asp Arg Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile 225 230 235 240 Lys Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly 245 250 255 Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser 260 265 270 Gly Phe Thr Phe Asn Lys Tyr Ala Met Asn Trp Val Arg Gln Ala Pro 275 280 285 Gly Lys Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn 290 295 300 Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser 305 310 315 320 Arg Asp Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Asn Leu Lys 325 330 335 Thr Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn Phe Gly 340 345 350 Asn Ser Tyr Ile Ser Tyr Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val 355 360 365 Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 370 375 380 Gly Gly Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser 385 390 395 400 Pro Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val 405 410 415 Thr Ser Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala 420 425 430 Pro Arg Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro 435 440 445 Ala Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu 450 455 460 Ser Gly Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp 465 470 475 480 Tyr Ser Asn Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 485 490 495 <210> 51 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 51 Ser Phe Tyr Trp Ser 1 5 <210> 52 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 52 Tyr Ile Tyr Tyr Ser Gly Thr Thr Asn Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 53 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 53 Ile Ala Val Ala Gly Phe Phe Phe Asp Tyr 1 5 10 <210> 54 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 54 Arg Ala Ser Gln Ser Val Asn Lys Asn Tyr Leu Ala 1 5 10 <210> 55 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 55 Gly Ala Ser Ser Arg Ala Thr 1 5 <210> 56 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 56 Gln Gln Tyr Asp Arg Ser Pro Leu Thr 1 5 <210> 57 <211> 118 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 57 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Ala Ser Ile Ser Ser Phe 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Tyr Tyr Ser Gly Thr Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Ile Ala Val Ala Gly Phe Phe Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser 115 <210> 58 <211> 108 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 58 Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Asn Lys Asn 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asp Arg Ser Pro 85 90 95 Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 <210> 59 <211> 241 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 59 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Ala Ser Ile Ser Ser Phe 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Tyr Tyr Ser Gly Thr Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Ile Ala Val Ala Gly Phe Phe Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu 130 135 140 Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln 145 150 155 160 Ser Val Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 165 170 175 Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile 180 185 190 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 195 200 205 Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln 210 215 220 Tyr Asp Arg Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile 225 230 235 240 Lys <210> 60 <211> 496 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 60 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Ala Ser Ile Ser Ser Phe 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Tyr Tyr Ser Gly Thr Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Ile Ala Val Ala Gly Phe Phe Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu 130 135 140 Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln 145 150 155 160 Ser Val Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 165 170 175 Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile 180 185 190 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 195 200 205 Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln 210 215 220 Tyr Asp Arg Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile 225 230 235 240 Lys Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly 245 250 255 Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser 260 265 270 Gly Phe Thr Phe Asn Lys Tyr Ala Met Asn Trp Val Arg Gln Ala Pro 275 280 285 Gly Lys Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn 290 295 300 Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser 305 310 315 320 Arg Asp Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Asn Leu Lys 325 330 335 Thr Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn Phe Gly 340 345 350 Asn Ser Tyr Ile Ser Tyr Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val 355 360 365 Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 370 375 380 Gly Gly Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser 385 390 395 400 Pro Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val 405 410 415 Thr Ser Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala 420 425 430 Pro Arg Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro 435 440 445 Ala Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu 450 455 460 Ser Gly Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp 465 470 475 480 Tyr Ser Asn Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 485 490 495 <210> 61 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 61 Ser Phe Tyr Trp Ser 1 5 <210> 62 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 62 Tyr Ile Tyr Tyr Ser Gly Thr Thr Asn Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 63 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 63 Ile Ala Val Ala Gly Phe Phe Phe Asp Tyr 1 5 10 <210> 64 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 64 Arg Ala Ser Gln Ser Val Asn Lys Asn Tyr Leu Ala 1 5 10 <210> 65 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 65 Gly Ala Ser Ser Arg Ala Thr 1 5 <210> 66 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 66 Gln Gln Tyr Asp Arg Ser Pro Leu Thr 1 5 <210> 67 <211> 118 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 67 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Ala Ser Ile Ser Ser Phe 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Tyr Tyr Ser Gly Thr Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Ile Ala Val Ala Gly Phe Phe Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser 115 <210> 68 <211> 108 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 68 Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Asn Lys Asn 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asp Arg Ser Pro 85 90 95 Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 <210> 69 <211> 241 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 69 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Ala Ser Ile Ser Ser Phe 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Tyr Tyr Ser Gly Thr Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Ile Ala Val Ala Gly Phe Phe Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu 130 135 140 Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln 145 150 155 160 Ser Val Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 165 170 175 Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile 180 185 190 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 195 200 205 Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln 210 215 220 Tyr Asp Arg Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile 225 230 235 240 Lys <210> 70 <211> 496 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 70 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Ala Ser Ile Ser Ser Phe 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Tyr Tyr Ser Gly Thr Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Ile Ala Val Ala Gly Phe Phe Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu 130 135 140 Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln 145 150 155 160 Ser Val Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 165 170 175 Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile 180 185 190 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 195 200 205 Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln 210 215 220 Tyr Asp Arg Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile 225 230 235 240 Lys Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly 245 250 255 Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser 260 265 270 Gly Phe Thr Phe Asn Lys Tyr Ala Met Asn Trp Val Arg Gln Ala Pro 275 280 285 Gly Lys Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn 290 295 300 Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser 305 310 315 320 Arg Asp Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Asn Leu Lys 325 330 335 Thr Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn Phe Gly 340 345 350 Asn Ser Tyr Ile Ser Tyr Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val 355 360 365 Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 370 375 380 Gly Gly Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser 385 390 395 400 Pro Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val 405 410 415 Thr Ser Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala 420 425 430 Pro Arg Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro 435 440 445 Ala Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu 450 455 460 Ser Gly Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp 465 470 475 480 Tyr Ser Asn Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 485 490 495 <210> 71 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 71 Ser Phe Tyr Trp Ser 1 5 <210> 72 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 72 Tyr Ile Tyr Tyr Ser Gly Thr Thr Asn Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 73 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 73 Ile Ala Val Ala Gly Phe Phe Phe Asp Tyr 1 5 10 <210> 74 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 74 Arg Ala Ser Gln Ser Val Asn Lys Asn Tyr Leu Ala 1 5 10 <210> 75 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 75 Gly Ala Ser Ser Arg Ala Thr 1 5 <210> 76 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 76 Gln Gln Tyr Asp Arg Ser Pro Leu Thr 1 5 <210> 77 <211> 119 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 77 Gln Val Gln Leu Gln Glu Trp Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Ala Ser Ile Ser Ser Phe 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Tyr Tyr Ser Gly Thr Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Leu Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Ile Ala Val Ala Gly Phe Phe Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser Lys 115 <210> 78 <211> 108 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 78 Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Asn Lys Asn 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asp Arg Ser Pro 85 90 95 Leu Thr Phe Gly Gly Gly Thr Lys Val Asp Ile Lys 100 105 <210> 79 <211> 241 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 79 Gln Val Gln Leu Gln Glu Trp Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Ala Ser Ile Ser Ser Phe 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Tyr Tyr Ser Gly Thr Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Leu Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Ile Ala Val Ala Gly Phe Phe Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu 130 135 140 Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln 145 150 155 160 Ser Val Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 165 170 175 Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile 180 185 190 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 195 200 205 Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln 210 215 220 Tyr Asp Arg Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Asp Ile 225 230 235 240 Lys <210> 80 <211> 496 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 80 Gln Val Gln Leu Gln Glu Trp Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Ala Ser Ile Ser Ser Phe 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Tyr Tyr Ser Gly Thr Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Leu Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Ile Ala Val Ala Gly Phe Phe Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu 130 135 140 Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln 145 150 155 160 Ser Val Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 165 170 175 Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile 180 185 190 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 195 200 205 Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln 210 215 220 Tyr Asp Arg Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Asp Ile 225 230 235 240 Lys Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly 245 250 255 Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser 260 265 270 Gly Phe Thr Phe Asn Lys Tyr Ala Met Asn Trp Val Arg Gln Ala Pro 275 280 285 Gly Lys Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn 290 295 300 Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser 305 310 315 320 Arg Asp Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Asn Leu Lys 325 330 335 Thr Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn Phe Gly 340 345 350 Asn Ser Tyr Ile Ser Tyr Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val 355 360 365 Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 370 375 380 Gly Gly Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser 385 390 395 400 Pro Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val 405 410 415 Thr Ser Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala 420 425 430 Pro Arg Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro 435 440 445 Ala Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu 450 455 460 Ser Gly Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp 465 470 475 480 Tyr Ser Asn Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 485 490 495 <210> 81 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 81 Ser Phe Tyr Trp Ser 1 5 <210> 82 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 82 Tyr Ile Tyr Tyr Ser Gly Thr Thr Asn Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 83 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 83 Ile Ala Val Ala Gly Phe Phe Phe Asp Tyr 1 5 10 <210> 84 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 84 Arg Ala Ser Gln Ser Val Asn Lys Asn Tyr Leu Ala 1 5 10 <210> 85 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 85 Gly Ala Ser Ser Arg Ala Thr 1 5 <210> 86 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 86 Gln Gln Tyr Asp Arg Ser Pro Leu Thr 1 5 <210> 87 <211> 118 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 87 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Ala Ser Ile Ser Ser Phe 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Tyr Tyr Ser Gly Thr Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Ile Ala Val Ala Gly Phe Phe Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser 115 <210> 88 <211> 108 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 88 Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Ser Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Asn Lys Asn 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asp Arg Ser Pro 85 90 95 Leu Thr Phe Gly Gly Gly Thr Arg Leu Glu Ile Lys 100 105 <210> 89 <211> 241 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 89 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Ala Ser Ile Ser Ser Phe 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Tyr Tyr Ser Gly Thr Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Ile Ala Val Ala Gly Phe Phe Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu 130 135 140 Ser Leu Ser Pro Gly Glu Ser Ala Thr Leu Ser Cys Arg Ala Ser Gln 145 150 155 160 Ser Val Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 165 170 175 Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile 180 185 190 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 195 200 205 Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln 210 215 220 Tyr Asp Arg Ser Pro Leu Thr Phe Gly Gly Gly Thr Arg Leu Glu Ile 225 230 235 240 Lys <210> 90 <211> 496 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 90 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Ala Ser Ile Ser Ser Phe 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Tyr Tyr Ser Gly Thr Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Ile Ala Val Ala Gly Phe Phe Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu 130 135 140 Ser Leu Ser Pro Gly Glu Ser Ala Thr Leu Ser Cys Arg Ala Ser Gln 145 150 155 160 Ser Val Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 165 170 175 Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile 180 185 190 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 195 200 205 Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln 210 215 220 Tyr Asp Arg Ser Pro Leu Thr Phe Gly Gly Gly Thr Arg Leu Glu Ile 225 230 235 240 Lys Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly 245 250 255 Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser 260 265 270 Gly Phe Thr Phe Asn Lys Tyr Ala Met Asn Trp Val Arg Gln Ala Pro 275 280 285 Gly Lys Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn 290 295 300 Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser 305 310 315 320 Arg Asp Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Asn Leu Lys 325 330 335 Thr Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn Phe Gly 340 345 350 Asn Ser Tyr Ile Ser Tyr Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val 355 360 365 Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 370 375 380 Gly Gly Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser 385 390 395 400 Pro Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val 405 410 415 Thr Ser Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala 420 425 430 Pro Arg Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro 435 440 445 Ala Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu 450 455 460 Ser Gly Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp 465 470 475 480 Tyr Ser Asn Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 485 490 495 <210> 91 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 91 Ser Tyr Tyr Trp Ser 1 5 <210> 92 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 92 Tyr Ile Phe Tyr Asn Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 93 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 93 Ile His Ser Gly Ser Phe Ser Phe Asp Tyr 1 5 10 <210> 94 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 94 Arg Ala Ser Gln Ser Val Ser Arg Gly Tyr Leu Ala 1 5 10 <210> 95 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 95 Gly Ala Ser Ser Arg Ala Thr 1 5 <210> 96 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 96 Gln Gln Tyr Asp Thr Ser Pro Ile Thr 1 5 <210> 97 <211> 118 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 97 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Phe Tyr Asn Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Leu Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Lys Tyr Tyr Cys Ala 85 90 95 Arg Ile His Ser Gly Ser Phe Ser Phe Asp Tyr Trp Asp Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser 115 <210> 98 <211> 108 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 98 Glu Ile Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Arg Gly 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Asp Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asp Thr Ser Pro 85 90 95 Ile Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 <210> 99 <211> 241 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 99 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Phe Tyr Asn Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Leu Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Lys Tyr Tyr Cys Ala 85 90 95 Arg Ile His Ser Gly Ser Phe Ser Phe Asp Tyr Trp Asp Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Glu Ile Val Met Thr Gln Ser Pro Gly Thr Leu 130 135 140 Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln 145 150 155 160 Ser Val Ser Arg Gly Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 165 170 175 Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Asp Ile 180 185 190 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 195 200 205 Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln 210 215 220 Tyr Asp Thr Ser Pro Ile Thr Phe Gly Gln Gly Thr Lys Val Glu Ile 225 230 235 240 Lys <210> 100 <211> 496 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 100 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Phe Tyr Asn Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Leu Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Lys Tyr Tyr Cys Ala 85 90 95 Arg Ile His Ser Gly Ser Phe Ser Phe Asp Tyr Trp Asp Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Glu Ile Val Met Thr Gln Ser Pro Gly Thr Leu 130 135 140 Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln 145 150 155 160 Ser Val Ser Arg Gly Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 165 170 175 Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Asp Ile 180 185 190 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 195 200 205 Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln 210 215 220 Tyr Asp Thr Ser Pro Ile Thr Phe Gly Gln Gly Thr Lys Val Glu Ile 225 230 235 240 Lys Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly 245 250 255 Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser 260 265 270 Gly Phe Thr Phe Asn Lys Tyr Ala Met Asn Trp Val Arg Gln Ala Pro 275 280 285 Gly Lys Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn 290 295 300 Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser 305 310 315 320 Arg Asp Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Asn Leu Lys 325 330 335 Thr Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn Phe Gly 340 345 350 Asn Ser Tyr Ile Ser Tyr Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val 355 360 365 Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 370 375 380 Gly Gly Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser 385 390 395 400 Pro Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val 405 410 415 Thr Ser Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala 420 425 430 Pro Arg Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro 435 440 445 Ala Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu 450 455 460 Ser Gly Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp 465 470 475 480 Tyr Ser Asn Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 485 490 495 <210> 101 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 101 Asn Ala Gly Met Ser 1 5 <210> 102 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 102 Arg Ile Lys Asn Lys Ile Asp Gly Gly Thr Thr Asp Phe Ala Ala Pro 1 5 10 15 Val Lys Gly <210> 103 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 103 Arg Gly Trp Tyr Gly Asp Tyr Phe Asp Tyr 1 5 10 <210> 104 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 104 Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp 1 5 10 15 <210> 105 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 105 Leu Gly Ser Asn Arg Ala Ser 1 5 <210> 106 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 106 Met Gln Ala Leu Gln Thr Pro Phe Thr 1 5 <210> 107 <211> 121 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 107 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Phe Asn Asn Ala 20 25 30 Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Gly Arg Ile Lys Asn Lys Ile Asp Gly Gly Thr Thr Asp Phe Ala Ala 50 55 60 Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 65 70 75 80 Leu Tyr Leu Gln Met Asn Ser Leu Lys Ala Glu Asp Thr Ala Val Tyr 85 90 95 Tyr Cys Thr Ala Arg Gly Trp Tyr Gly Asp Tyr Phe Asp Tyr Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 108 <211> 112 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 108 Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Pro Gly 1 5 10 15 Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser 20 25 30 Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Ile Tyr Tyr Cys Met Gln Ala 85 90 95 Leu Gln Thr Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Glu Ile Lys 100 105 110 <210> 109 <211> 248 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 109 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Phe Asn Asn Ala 20 25 30 Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Gly Arg Ile Lys Asn Lys Ile Asp Gly Gly Thr Thr Asp Phe Ala Ala 50 55 60 Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 65 70 75 80 Leu Tyr Leu Gln Met Asn Ser Leu Lys Ala Glu Asp Thr Ala Val Tyr 85 90 95 Tyr Cys Thr Ala Arg Gly Trp Tyr Gly Asp Tyr Phe Asp Tyr Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly 115 120 125 Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Val Met Thr Gln Thr Pro 130 135 140 Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg 145 150 155 160 Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp Trp 165 170 175 Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly 180 185 190 Ser Asn Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser 195 200 205 Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val 210 215 220 Gly Ile Tyr Tyr Cys Met Gln Ala Leu Gln Thr Pro Phe Thr Phe Gly 225 230 235 240 Pro Gly Thr Lys Val Glu Ile Lys 245 <210> 110 <211> 503 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 110 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Phe Asn Asn Ala 20 25 30 Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Gly Arg Ile Lys Asn Lys Ile Asp Gly Gly Thr Thr Asp Phe Ala Ala 50 55 60 Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 65 70 75 80 Leu Tyr Leu Gln Met Asn Ser Leu Lys Ala Glu Asp Thr Ala Val Tyr 85 90 95 Tyr Cys Thr Ala Arg Gly Trp Tyr Gly Asp Tyr Phe Asp Tyr Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly 115 120 125 Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Val Met Thr Gln Thr Pro 130 135 140 Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg 145 150 155 160 Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp Trp 165 170 175 Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly 180 185 190 Ser Asn Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser 195 200 205 Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val 210 215 220 Gly Ile Tyr Tyr Cys Met Gln Ala Leu Gln Thr Pro Phe Thr Phe Gly 225 230 235 240 Pro Gly Thr Lys Val Glu Ile Lys Ser Gly Gly Gly Gly Ser Glu Val 245 250 255 Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu 260 265 270 Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys Tyr Ala Met 275 280 285 Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Arg 290 295 300 Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser Val 305 310 315 320 Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Ala Tyr 325 330 335 Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys 340 345 350 Val Arg His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr Trp Ala Tyr 355 360 365 Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser 370 375 380 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val Thr Gln 385 390 395 400 Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu Thr Cys 405 410 415 Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro Asn Trp Val 420 425 430 Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly Thr Lys 435 440 445 Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu Leu Gly 450 455 460 Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp Glu Ala 465 470 475 480 Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val Phe Gly Gly 485 490 495 Gly Thr Lys Leu Thr Val Leu 500 <210> 111 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 111 Ser Tyr Asp Ile His 1 5 <210> 112 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 112 Val Ile Ser Ser His Gly Ser Asn Lys Asn Tyr Ala Arg Ser Val Lys 1 5 10 15 Gly <210> 113 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 113 Asp Gly Tyr Ser Gly Asn Asp Pro Phe Tyr Tyr Tyr Tyr His Gly Met 1 5 10 15 Asp Val <210> 114 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 114 Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn 1 5 10 <210> 115 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 115 Ala Ala Ser Ser Leu Gln Ser 1 5 <210> 116 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 116 Gln Gln Ser Phe Thr Thr Pro Leu Thr 1 5 <210> 117 <211> 127 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 117 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Ser Tyr 20 25 30 Asp Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Ile Ser Ser His Gly Ser Asn Lys Asn Tyr Ala Arg Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Lys Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Gly Tyr Ser Gly Asn Asp Pro Phe Tyr Tyr Tyr Tyr His 100 105 110 Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 118 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 118 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Ser Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Phe Thr Thr Pro Leu 85 90 95 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 <210> 119 <211> 249 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 119 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Ser Tyr 20 25 30 Asp Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Ile Ser Ser His Gly Ser Asn Lys Asn Tyr Ala Arg Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Lys Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Gly Tyr Ser Gly Asn Asp Pro Phe Tyr Tyr Tyr Tyr His 100 105 110 Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly 115 120 125 Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile 130 135 140 Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg 145 150 155 160 Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn 165 170 175 Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala 180 185 190 Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly 195 200 205 Ser Gly Thr Asp Phe Ser Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp 210 215 220 Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Phe Thr Thr Pro Leu Thr Phe 225 230 235 240 Gly Gly Gly Thr Lys Val Glu Ile Lys 245 <210> 120 <211> 504 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 120 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Ser Tyr 20 25 30 Asp Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Ile Ser Ser His Gly Ser Asn Lys Asn Tyr Ala Arg Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Lys Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Gly Tyr Ser Gly Asn Asp Pro Phe Tyr Tyr Tyr Tyr His 100 105 110 Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly 115 120 125 Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile 130 135 140 Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg 145 150 155 160 Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn 165 170 175 Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala 180 185 190 Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly 195 200 205 Ser Gly Thr Asp Phe Ser Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp 210 215 220 Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Phe Thr Thr Pro Leu Thr Phe 225 230 235 240 Gly Gly Gly Thr Lys Val Glu Ile Lys Ser Gly Gly Gly Gly Ser Glu 245 250 255 Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser 260 265 270 Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys Tyr Ala 275 280 285 Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala 290 295 300 Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser 305 310 315 320 Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Ala 325 330 335 Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr 340 345 350 Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr Trp Ala 355 360 365 Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly 370 375 380 Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val Thr 385 390 395 400 Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu Thr 405 410 415 Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro Asn Trp 420 425 430 Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly Thr 435 440 445 Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu Leu 450 455 460 Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp Glu 465 470 475 480 Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val Phe Gly 485 490 495 Gly Gly Thr Lys Leu Thr Val Leu 500 <210> 121 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 121 Ser Tyr Tyr Met His 1 5 <210> 122 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 122 Ile Ile Asn Pro Ser Asp Gly Ser Thr Asn Tyr Ala Gln Asn Phe Gln 1 5 10 15 Gly <210> 123 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 123 Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 1 5 10 <210> 124 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 124 Arg Ser Ser Gln Ser Leu Val Tyr Arg Asp Gly Asn Thr Tyr Leu Ser 1 5 10 15 <210> 125 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 125 Lys Val Ser Asn Trp Gln Ser 1 5 <210> 126 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 126 Met Gln Gly Thr His Trp Pro Pro Thr 1 5 <210> 127 <211> 123 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 127 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Asp Gly Ser Thr Asn Tyr Ala Gln Asn Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 128 <211> 112 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 128 Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg 20 25 30 Asp Gly Asn Thr Tyr Leu Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser 35 40 45 Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Trp Gln Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Phe Cys Met Gln Gly 85 90 95 Thr His Trp Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 110 <210> 129 <211> 250 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 129 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Asp Gly Ser Thr Asn Tyr Ala Gln Asn Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln 130 135 140 Ser Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser 145 150 155 160 Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg Asp Gly Asn Thr Tyr Leu 165 170 175 Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr 180 185 190 Lys Val Ser Asn Trp Gln Ser Gly Val Pro Asp Arg Phe Ser Gly Ser 195 200 205 Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu 210 215 220 Asp Val Gly Val Tyr Phe Cys Met Gln Gly Thr His Trp Pro Pro Thr 225 230 235 240 Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 245 250 <210> 130 <211> 505 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 130 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Asp Gly Ser Thr Asn Tyr Ala Gln Asn Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln 130 135 140 Ser Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser 145 150 155 160 Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg Asp Gly Asn Thr Tyr Leu 165 170 175 Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr 180 185 190 Lys Val Ser Asn Trp Gln Ser Gly Val Pro Asp Arg Phe Ser Gly Ser 195 200 205 Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu 210 215 220 Asp Val Gly Val Tyr Phe Cys Met Gln Gly Thr His Trp Pro Pro Thr 225 230 235 240 Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Ser Gly Gly Gly Gly Ser 245 250 255 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 260 265 270 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys Tyr 275 280 285 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 290 295 300 Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 305 310 315 320 Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 325 330 335 Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr 340 345 350 Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr Trp 355 360 365 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 370 375 380 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val 385 390 395 400 Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu 405 410 415 Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro Asn 420 425 430 Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly 435 440 445 Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu 450 455 460 Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp 465 470 475 480 Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val Phe 485 490 495 Gly Gly Gly Thr Lys Leu Thr Val Leu 500 505 <210> 131 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 131 Asn Tyr Tyr Met His 1 5 <210> 132 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 132 Ile Ile Asn Pro Ser Asp Gly Ser Thr Ser Tyr Ala Gln Lys Phe Gln 1 5 10 15 Gly <210> 133 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 133 Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 1 5 10 <210> 134 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 134 Arg Ser Ser Gln Ser Leu Val Tyr Arg Asp Gly Asn Thr Tyr Leu Ser 1 5 10 15 <210> 135 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 135 Lys Val Ser Asn Trp Gln Ser 1 5 <210> 136 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 136 Met Gln Gly Thr His Trp Pro Pro Thr 1 5 <210> 137 <211> 123 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 137 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Leu Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Asp Gly Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Asp Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 138 <211> 112 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 138 Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Leu Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg 20 25 30 Asp Gly Asn Thr Tyr Leu Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser 35 40 45 Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Trp Gln Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Gly Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Gly 85 90 95 Thr His Trp Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 110 <210> 139 <211> 250 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 139 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Leu Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Asp Gly Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Asp Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln 130 135 140 Thr Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser 145 150 155 160 Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg Asp Gly Asn Thr Tyr Leu 165 170 175 Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr 180 185 190 Lys Val Ser Asn Trp Gln Ser Gly Val Pro Asp Arg Phe Ser Gly Gly 195 200 205 Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu 210 215 220 Asp Val Gly Val Tyr Tyr Cys Met Gln Gly Thr His Trp Pro Pro Thr 225 230 235 240 Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 245 250 <210> 140 <211> 505 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 140 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Leu Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Asp Gly Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Asp Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln 130 135 140 Thr Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser 145 150 155 160 Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg Asp Gly Asn Thr Tyr Leu 165 170 175 Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr 180 185 190 Lys Val Ser Asn Trp Gln Ser Gly Val Pro Asp Arg Phe Ser Gly Gly 195 200 205 Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu 210 215 220 Asp Val Gly Val Tyr Tyr Cys Met Gln Gly Thr His Trp Pro Pro Thr 225 230 235 240 Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Ser Gly Gly Gly Gly Ser 245 250 255 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 260 265 270 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys Tyr 275 280 285 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 290 295 300 Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 305 310 315 320 Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 325 330 335 Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr 340 345 350 Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr Trp 355 360 365 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 370 375 380 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val 385 390 395 400 Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu 405 410 415 Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro Asn 420 425 430 Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly 435 440 445 Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu 450 455 460 Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp 465 470 475 480 Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val Phe 485 490 495 Gly Gly Gly Thr Lys Leu Thr Val Leu 500 505 <210> 141 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 141 Gly Tyr Tyr Ile His 1 5 <210> 142 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 142 Ile Ile Asn Pro Ser Asp Gly Ser Thr Ser Tyr Gly Gln Asn Phe Gln 1 5 10 15 Gly <210> 143 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 143 Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 1 5 10 <210> 144 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 144 Arg Ser Ser Gln Ser Leu Ala Tyr Arg Asp Gly Asn Thr Tyr Leu Ser 1 5 10 15 <210> 145 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 145 Lys Val Ser Asn Trp Gln Ser 1 5 <210> 146 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 146 Met Gln Gly Thr His Trp Pro Pro Thr 1 5 <210> 147 <211> 123 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 147 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr 20 25 30 Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Asp Gly Ser Thr Ser Tyr Gly Gln Asn Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 148 <211> 112 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 148 Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Ala Tyr Arg 20 25 30 Asp Gly Asn Thr Tyr Leu Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser 35 40 45 Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Trp Gln Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Phe Cys Met Gln Gly 85 90 95 Thr His Trp Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 110 <210> 149 <211> 250 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 149 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr 20 25 30 Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Asp Gly Ser Thr Ser Tyr Gly Gln Asn Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln 130 135 140 Ser Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser 145 150 155 160 Cys Arg Ser Ser Gln Ser Leu Ala Tyr Arg Asp Gly Asn Thr Tyr Leu 165 170 175 Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr 180 185 190 Lys Val Ser Asn Trp Gln Ser Gly Val Pro Asp Arg Phe Ser Gly Ser 195 200 205 Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu 210 215 220 Asp Val Gly Val Tyr Phe Cys Met Gln Gly Thr His Trp Pro Pro Thr 225 230 235 240 Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 245 250 <210> 150 <211> 505 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 150 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr 20 25 30 Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Asp Gly Ser Thr Ser Tyr Gly Gln Asn Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln 130 135 140 Ser Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser 145 150 155 160 Cys Arg Ser Ser Gln Ser Leu Ala Tyr Arg Asp Gly Asn Thr Tyr Leu 165 170 175 Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr 180 185 190 Lys Val Ser Asn Trp Gln Ser Gly Val Pro Asp Arg Phe Ser Gly Ser 195 200 205 Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu 210 215 220 Asp Val Gly Val Tyr Phe Cys Met Gln Gly Thr His Trp Pro Pro Thr 225 230 235 240 Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Ser Gly Gly Gly Gly Ser 245 250 255 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 260 265 270 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys Tyr 275 280 285 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 290 295 300 Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 305 310 315 320 Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 325 330 335 Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr 340 345 350 Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr Trp 355 360 365 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 370 375 380 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val 385 390 395 400 Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu 405 410 415 Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro Asn 420 425 430 Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly 435 440 445 Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu 450 455 460 Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp 465 470 475 480 Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val Phe 485 490 495 Gly Gly Gly Thr Lys Leu Thr Val Leu 500 505 <210> 151 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 151 Gly His Tyr Met His 1 5 <210> 152 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 152 Ile Ile Asn Pro Ser Asp Gly Ser Thr Asn Tyr Ala Gln Lys Phe Gln 1 5 10 15 Gly <210> 153 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 153 Gly Thr Thr Val Val His Tyr Ser Tyr Tyr Asp Met Asp Val 1 5 10 <210> 154 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 154 Arg Ser Ser Gln Ser Leu Val Tyr Arg Asp Gly Asn Thr Tyr Leu Thr 1 5 10 15 <210> 155 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 155 Lys Val Ser Asn Trp Gln Ser 1 5 <210> 156 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 156 Met Gln Gly Thr His Trp Pro Pro Thr 1 5 <210> 157 <211> 123 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 157 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly His 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Asp Gly Ser Thr Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr 65 70 75 80 Met Glu Leu Arg Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Thr Arg Gly Thr Thr Val Val His Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 158 <211> 112 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 158 Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Leu Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg 20 25 30 Asp Gly Asn Thr Tyr Leu Thr Trp Phe Gln Gln Arg Pro Gly Gln Ser 35 40 45 Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Trp Gln Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Gly 85 90 95 Thr His Trp Pro Pro Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 110 <210> 159 <211> 250 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 159 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly His 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Asp Gly Ser Thr Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr 65 70 75 80 Met Glu Leu Arg Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Thr Arg Gly Thr Thr Val Val His Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln 130 135 140 Thr Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser 145 150 155 160 Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg Asp Gly Asn Thr Tyr Leu 165 170 175 Thr Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr 180 185 190 Lys Val Ser Asn Trp Gln Ser Gly Val Pro Asp Arg Phe Ser Gly Ser 195 200 205 Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu 210 215 220 Asp Val Gly Val Tyr Tyr Cys Met Gln Gly Thr His Trp Pro Pro Thr 225 230 235 240 Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 245 250 <210> 160 <211> 505 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 160 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly His 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Asp Gly Ser Thr Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr 65 70 75 80 Met Glu Leu Arg Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Thr Arg Gly Thr Thr Val Val His Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln 130 135 140 Thr Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser 145 150 155 160 Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg Asp Gly Asn Thr Tyr Leu 165 170 175 Thr Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr 180 185 190 Lys Val Ser Asn Trp Gln Ser Gly Val Pro Asp Arg Phe Ser Gly Ser 195 200 205 Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu 210 215 220 Asp Val Gly Val Tyr Tyr Cys Met Gln Gly Thr His Trp Pro Pro Thr 225 230 235 240 Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Ser Gly Gly Gly Gly Ser 245 250 255 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 260 265 270 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys Tyr 275 280 285 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 290 295 300 Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 305 310 315 320 Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 325 330 335 Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr 340 345 350 Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr Trp 355 360 365 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 370 375 380 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val 385 390 395 400 Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu 405 410 415 Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro Asn 420 425 430 Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly 435 440 445 Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu 450 455 460 Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp 465 470 475 480 Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val Phe 485 490 495 Gly Gly Gly Thr Lys Leu Thr Val Leu 500 505 <210> 161 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 161 Asn Tyr Phe Met His 1 5 <210> 162 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 162 Ile Ile Asn Pro Ser Asp Gly Ser Thr Ser Tyr Ala Gln Asn Phe Gln 1 5 10 15 Gly <210> 163 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 163 Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 1 5 10 <210> 164 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 164 Arg Ser Ser Gln Ser Leu Val Tyr Arg Asp Gly Asn Thr Tyr Leu Ser 1 5 10 15 <210> 165 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 165 Arg Val Ser Asn Trp Gln Ser 1 5 <210> 166 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 166 Met Gln Gly Thr Tyr Trp Pro Pro Thr 1 5 <210> 167 <211> 123 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 167 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Phe Met His Trp Val Arg Gln Ala Pro Gly Leu Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Asp Gly Ser Thr Ser Tyr Ala Gln Asn Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 168 <211> 112 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 168 Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg 20 25 30 Asp Gly Asn Thr Tyr Leu Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser 35 40 45 Pro Arg Arg Leu Ile Tyr Arg Val Ser Asn Trp Gln Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Phe Cys Met Gln Gly 85 90 95 Thr Tyr Trp Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Asp Ile Lys 100 105 110 <210> 169 <211> 250 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 169 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Phe Met His Trp Val Arg Gln Ala Pro Gly Leu Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Asp Gly Ser Thr Ser Tyr Ala Gln Asn Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln 130 135 140 Ser Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser 145 150 155 160 Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg Asp Gly Asn Thr Tyr Leu 165 170 175 Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr 180 185 190 Arg Val Ser Asn Trp Gln Ser Gly Val Pro Asp Arg Phe Ser Gly Ser 195 200 205 Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu 210 215 220 Asp Val Gly Val Tyr Phe Cys Met Gln Gly Thr Tyr Trp Pro Pro Thr 225 230 235 240 Phe Gly Gln Gly Thr Lys Val Asp Ile Lys 245 250 <210> 170 <211> 505 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 170 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Phe Met His Trp Val Arg Gln Ala Pro Gly Leu Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Asp Gly Ser Thr Ser Tyr Ala Gln Asn Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln 130 135 140 Ser Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser 145 150 155 160 Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg Asp Gly Asn Thr Tyr Leu 165 170 175 Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr 180 185 190 Arg Val Ser Asn Trp Gln Ser Gly Val Pro Asp Arg Phe Ser Gly Ser 195 200 205 Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu 210 215 220 Asp Val Gly Val Tyr Phe Cys Met Gln Gly Thr Tyr Trp Pro Pro Thr 225 230 235 240 Phe Gly Gln Gly Thr Lys Val Asp Ile Lys Ser Gly Gly Gly Gly Ser 245 250 255 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 260 265 270 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys Tyr 275 280 285 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 290 295 300 Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 305 310 315 320 Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 325 330 335 Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr 340 345 350 Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr Trp 355 360 365 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 370 375 380 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val 385 390 395 400 Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu 405 410 415 Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro Asn 420 425 430 Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly 435 440 445 Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu 450 455 460 Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp 465 470 475 480 Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val Phe 485 490 495 Gly Gly Gly Thr Lys Leu Thr Val Leu 500 505 <210> 171 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 171 Asn Tyr Gly Met His 1 5 <210> 172 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 172 Val Ile Ser His His Gly Ser Ser Lys Tyr Tyr Ala Arg Ser Val Lys 1 5 10 15 Gly <210> 173 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 173 Asp Trp Trp Glu Leu Val Phe Asp Tyr 1 5 <210> 174 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 174 Lys Ser Ser Gln Ser Leu Leu His Ser Asp Gly Lys Thr Phe Leu Tyr 1 5 10 15 <210> 175 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 175 Glu Val Ser Asn Arg Phe Ser 1 5 <210> 176 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 176 Leu Gln Gly Ile His Leu Pro Phe Thr 1 5 <210> 177 <211> 118 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 177 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Ala Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Ile Ser His His Gly Ser Ser Lys Tyr Tyr Ala Arg Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Glu Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Trp Trp Glu Leu Val Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser 115 <210> 178 <211> 112 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 178 Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Ser Val Thr Pro Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu His Ser 20 25 30 Asp Gly Lys Thr Phe Leu Tyr Trp Tyr Leu Gln Lys Pro Gly Gln Pro 35 40 45 Pro Gln Leu Leu Ile Tyr Glu Val Ser Asn Arg Phe Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Leu Gln Gly 85 90 95 Ile His Leu Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Glu Ile Lys 100 105 110 <210> 179 <211> 245 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 179 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Ala Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Ile Ser His His Gly Ser Ser Lys Tyr Tyr Ala Arg Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Glu Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Trp Trp Glu Leu Val Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu 130 135 140 Ser Val Thr Pro Gly Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln 145 150 155 160 Ser Leu Leu His Ser Asp Gly Lys Thr Phe Leu Tyr Trp Tyr Leu Gln 165 170 175 Lys Pro Gly Gln Pro Pro Gln Leu Leu Ile Tyr Glu Val Ser Asn Arg 180 185 190 Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp 195 200 205 Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr 210 215 220 Tyr Cys Leu Gln Gly Ile His Leu Pro Phe Thr Phe Gly Pro Gly Thr 225 230 235 240 Lys Val Glu Ile Lys 245 <210> 180 <211> 500 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 180 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Ala Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Ile Ser His His Gly Ser Ser Lys Tyr Tyr Ala Arg Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Glu Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Trp Trp Glu Leu Val Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu 130 135 140 Ser Val Thr Pro Gly Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln 145 150 155 160 Ser Leu Leu His Ser Asp Gly Lys Thr Phe Leu Tyr Trp Tyr Leu Gln 165 170 175 Lys Pro Gly Gln Pro Pro Gln Leu Leu Ile Tyr Glu Val Ser Asn Arg 180 185 190 Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp 195 200 205 Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr 210 215 220 Tyr Cys Leu Gln Gly Ile His Leu Pro Phe Thr Phe Gly Pro Gly Thr 225 230 235 240 Lys Val Glu Ile Lys Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val 245 250 255 Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser 260 265 270 Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys Tyr Ala Met Asn Trp Val 275 280 285 Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Arg Ile Arg Ser 290 295 300 Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg 305 310 315 320 Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met 325 330 335 Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg His 340 345 350 Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr Trp Ala Tyr Trp Gly Gln 355 360 365 Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly 370 375 380 Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val Thr Gln Glu Pro Ser 385 390 395 400 Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser 405 410 415 Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys 420 425 430 Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala 435 440 445 Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala 450 455 460 Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr 465 470 475 480 Cys Val Leu Trp Tyr Ser Asn Arg Trp Val Phe Gly Gly Gly Thr Lys 485 490 495 Leu Thr Val Leu 500 <210> 181 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 181 Asn Ser Arg Met Gly Val Ser 1 5 <210> 182 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 182 His Ile Phe Ser Asn Asp Gly Lys Ser Tyr Ser Thr Ser Leu Lys Ser 1 5 10 15 <210> 183 <211> 15 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 183 Tyr Asn Tyr Asp Ser Ser Gly Tyr Tyr Tyr Ser Phe Phe Asp Tyr 1 5 10 15 <210> 184 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 184 Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn 1 5 10 <210> 185 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 185 Ala Ala Ser Ser Leu Gln Ser 1 5 <210> 186 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 186 Gln Gln Gly Tyr Ser Ser Pro Phe Thr 1 5 <210> 187 <211> 125 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 187 Gln Val Thr Leu Lys Glu Ser Gly Pro Met Leu Val Lys Pro Thr Glu 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Ser Asn Ser 20 25 30 Arg Met Gly Val Ser Trp Ile Arg Gln Pro Pro Gly Arg Ala Leu Glu 35 40 45 Trp Leu Ala His Ile Phe Ser Asn Asp Gly Lys Ser Tyr Ser Thr Ser 50 55 60 Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Ser Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Tyr Asn Tyr Asp Ser Ser Gly Tyr Tyr Tyr Ser Phe Phe 100 105 110 Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 188 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 188 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Tyr Ser Ser Pro Phe 85 90 95 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 <210> 189 <211> 247 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 189 Gln Val Thr Leu Lys Glu Ser Gly Pro Met Leu Val Lys Pro Thr Glu 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Ser Asn Ser 20 25 30 Arg Met Gly Val Ser Trp Ile Arg Gln Pro Pro Gly Arg Ala Leu Glu 35 40 45 Trp Leu Ala His Ile Phe Ser Asn Asp Gly Lys Ser Tyr Ser Thr Ser 50 55 60 Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Ser Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Tyr Asn Tyr Asp Ser Ser Gly Tyr Tyr Tyr Ser Phe Phe 100 105 110 Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 115 120 125 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met 130 135 140 Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr 145 150 155 160 Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr 165 170 175 Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser 180 185 190 Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly 195 200 205 Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala 210 215 220 Thr Tyr Tyr Cys Gln Gln Gly Tyr Ser Ser Pro Phe Thr Phe Gly Gly 225 230 235 240 Gly Thr Lys Val Glu Ile Lys 245 <210> 190 <211> 502 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 190 Gln Val Thr Leu Lys Glu Ser Gly Pro Met Leu Val Lys Pro Thr Glu 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Ser Asn Ser 20 25 30 Arg Met Gly Val Ser Trp Ile Arg Gln Pro Pro Gly Arg Ala Leu Glu 35 40 45 Trp Leu Ala His Ile Phe Ser Asn Asp Gly Lys Ser Tyr Ser Thr Ser 50 55 60 Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Ser Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Tyr Asn Tyr Asp Ser Ser Gly Tyr Tyr Tyr Ser Phe Phe 100 105 110 Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 115 120 125 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met 130 135 140 Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr 145 150 155 160 Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr 165 170 175 Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser 180 185 190 Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly 195 200 205 Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala 210 215 220 Thr Tyr Tyr Cys Gln Gln Gly Tyr Ser Ser Pro Phe Thr Phe Gly Gly 225 230 235 240 Gly Thr Lys Val Glu Ile Lys Ser Gly Gly Gly Gly Ser Glu Val Gln 245 250 255 Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Lys 260 265 270 Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys Tyr Ala Met Asn 275 280 285 Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Arg Ile 290 295 300 Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys 305 310 315 320 Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Ala Tyr Leu 325 330 335 Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Val 340 345 350 Arg His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr Trp Ala Tyr Trp 355 360 365 Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly 370 375 380 Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val Thr Gln Glu 385 390 395 400 Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu Thr Cys Gly 405 410 415 Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro Asn Trp Val Gln 420 425 430 Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly Thr Lys Phe 435 440 445 Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu Leu Gly Gly 450 455 460 Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp Glu Ala Glu 465 470 475 480 Tyr Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val Phe Gly Gly Gly 485 490 495 Thr Lys Leu Thr Val Leu 500 <210> 191 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 191 Asn Ala Arg Met Gly Val Ser 1 5 <210> 192 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 192 His Ile Phe Ser Thr Asp Glu Lys Ser Tyr Ser Thr Ser Leu Lys Ser 1 5 10 15 <210> 193 <211> 15 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 193 Tyr Tyr Tyr Asp Ser Ser Gly Tyr Tyr Tyr Ser Phe Phe Asp Tyr 1 5 10 15 <210> 194 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 194 Arg Ala Ser Gln Ser Ile Arg Ser Tyr Leu Asn 1 5 10 <210> 195 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 195 Gly Ala Ser Asn Leu Gln Ser 1 5 <210> 196 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 196 Gln Gln Ser Tyr Ser Ser Pro Phe Thr 1 5 <210> 197 <211> 125 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 197 Gln Val Thr Leu Lys Glu Ser Gly Pro Val Leu Val Lys Pro Thr Glu 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Ser Asn Ala 20 25 30 Arg Met Gly Val Ser Trp Leu Arg Gln Pro Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala His Ile Phe Ser Thr Asp Glu Lys Ser Tyr Ser Thr Ser 50 55 60 Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Ser Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Tyr Tyr Tyr Asp Ser Ser Gly Tyr Tyr Tyr Ser Phe Phe 100 105 110 Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 198 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 198 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Arg Ser Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Gly Ala Ser Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Ser Pro Phe 85 90 95 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 <210> 199 <211> 247 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 199 Gln Val Thr Leu Lys Glu Ser Gly Pro Val Leu Val Lys Pro Thr Glu 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Ser Asn Ala 20 25 30 Arg Met Gly Val Ser Trp Leu Arg Gln Pro Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala His Ile Phe Ser Thr Asp Glu Lys Ser Tyr Ser Thr Ser 50 55 60 Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Ser Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Tyr Tyr Tyr Asp Ser Ser Gly Tyr Tyr Tyr Ser Phe Phe 100 105 110 Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 115 120 125 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met 130 135 140 Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr 145 150 155 160 Ile Thr Cys Arg Ala Ser Gln Ser Ile Arg Ser Tyr Leu Asn Trp Tyr 165 170 175 Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Gly Ala Ser 180 185 190 Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly 195 200 205 Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala 210 215 220 Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Ser Pro Phe Thr Phe Gly Gly 225 230 235 240 Gly Thr Lys Val Glu Ile Lys 245 <210> 200 <211> 502 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 200 Gln Val Thr Leu Lys Glu Ser Gly Pro Val Leu Val Lys Pro Thr Glu 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Ser Asn Ala 20 25 30 Arg Met Gly Val Ser Trp Leu Arg Gln Pro Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala His Ile Phe Ser Thr Asp Glu Lys Ser Tyr Ser Thr Ser 50 55 60 Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Ser Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Tyr Tyr Tyr Asp Ser Ser Gly Tyr Tyr Tyr Ser Phe Phe 100 105 110 Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 115 120 125 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met 130 135 140 Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr 145 150 155 160 Ile Thr Cys Arg Ala Ser Gln Ser Ile Arg Ser Tyr Leu Asn Trp Tyr 165 170 175 Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Gly Ala Ser 180 185 190 Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly 195 200 205 Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala 210 215 220 Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Ser Pro Phe Thr Phe Gly Gly 225 230 235 240 Gly Thr Lys Val Glu Ile Lys Ser Gly Gly Gly Gly Ser Glu Val Gln 245 250 255 Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Lys 260 265 270 Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys Tyr Ala Met Asn 275 280 285 Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Arg Ile 290 295 300 Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys 305 310 315 320 Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Ala Tyr Leu 325 330 335 Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Val 340 345 350 Arg His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr Trp Ala Tyr Trp 355 360 365 Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly 370 375 380 Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val Thr Gln Glu 385 390 395 400 Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu Thr Cys Gly 405 410 415 Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro Asn Trp Val Gln 420 425 430 Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly Thr Lys Phe 435 440 445 Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu Leu Gly Gly 450 455 460 Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp Glu Ala Glu 465 470 475 480 Tyr Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val Phe Gly Gly Gly 485 490 495 Thr Lys Leu Thr Val Leu 500 <210> 201 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 201 Ser Tyr Tyr Ile His 1 5 <210> 202 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 202 Ile Ile Asn Pro Ser Gly Gly Ser Lys Ser Tyr Ala Gln Lys Phe Arg 1 5 10 15 Gly <210> 203 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 203 Ser Met Ser Thr Val Thr Ser Asp Ala Phe Asp Ile 1 5 10 <210> 204 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 204 Arg Ala Ser Gln Ser Ile Ser Asn Tyr Leu Asn 1 5 10 <210> 205 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 205 Ala Ala Ser Ser Leu Gln Ser 1 5 <210> 206 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 206 Gln Gln Ser Tyr Ser Ala Pro Leu Thr 1 5 <210> 207 <211> 121 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 207 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Thr Ser Tyr 20 25 30 Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Gly Gly Ser Lys Ser Tyr Ala Gln Lys Phe 50 55 60 Arg Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Ser Met Ser Thr Val Thr Ser Asp Ala Phe Asp Ile Trp Gly 100 105 110 Gln Gly Thr Met Val Thr Val Ser Ser 115 120 <210> 208 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 208 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Ala Pro Leu 85 90 95 Thr Phe Gly Gly Gly Thr Lys Val Asp Ile Lys 100 105 <210> 209 <211> 243 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 209 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Thr Ser Tyr 20 25 30 Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Gly Gly Ser Lys Ser Tyr Ala Gln Lys Phe 50 55 60 Arg Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Ser Met Ser Thr Val Thr Ser Asp Ala Phe Asp Ile Trp Gly 100 105 110 Gln Gly Thr Met Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly 115 120 125 Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro 130 135 140 Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg 145 150 155 160 Ala Ser Gln Ser Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro 165 170 175 Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser 180 185 190 Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr 195 200 205 Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys 210 215 220 Gln Gln Ser Tyr Ser Ala Pro Leu Thr Phe Gly Gly Gly Thr Lys Val 225 230 235 240 Asp Ile Lys <210> 210 <211> 498 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 210 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Thr Ser Tyr 20 25 30 Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Gly Gly Ser Lys Ser Tyr Ala Gln Lys Phe 50 55 60 Arg Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Ser Met Ser Thr Val Thr Ser Asp Ala Phe Asp Ile Trp Gly 100 105 110 Gln Gly Thr Met Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly 115 120 125 Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro 130 135 140 Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg 145 150 155 160 Ala Ser Gln Ser Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro 165 170 175 Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser 180 185 190 Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr 195 200 205 Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys 210 215 220 Gln Gln Ser Tyr Ser Ala Pro Leu Thr Phe Gly Gly Gly Thr Lys Val 225 230 235 240 Asp Ile Lys Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser 245 250 255 Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala 260 265 270 Ala Ser Gly Phe Thr Phe Asn Lys Tyr Ala Met Asn Trp Val Arg Gln 275 280 285 Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr 290 295 300 Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr 305 310 315 320 Ile Ser Arg Asp Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Asn 325 330 335 Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn 340 345 350 Phe Gly Asn Ser Tyr Ile Ser Tyr Trp Ala Tyr Trp Gly Gln Gly Thr 355 360 365 Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 370 375 380 Gly Gly Gly Gly Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr 385 390 395 400 Val Ser Pro Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly 405 410 415 Ala Val Thr Ser Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly 420 425 430 Gln Ala Pro Arg Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly 435 440 445 Thr Pro Ala Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu 450 455 460 Thr Leu Ser Gly Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val 465 470 475 480 Leu Trp Tyr Ser Asn Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr 485 490 495 Val Leu <210> 211 <211> 496 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 211 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Val Tyr Tyr Ser Gly Thr Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Ser Ile Ala Val Thr Gly Phe Tyr Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu 130 135 140 Ser Leu Ser Pro Gly Glu Arg Val Thr Leu Ser Cys Arg Ala Ser Gln 145 150 155 160 Arg Val Asn Asn Asn Tyr Leu Ala Trp Tyr Gln Gln Arg Pro Gly Gln 165 170 175 Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile 180 185 190 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 195 200 205 Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln 210 215 220 Tyr Asp Arg Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile 225 230 235 240 Lys Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly 245 250 255 Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser 260 265 270 Gly Phe Thr Phe Asn Ser Tyr Ala Met Asn Trp Val Arg Gln Ala Pro 275 280 285 Gly Lys Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn 290 295 300 Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser 305 310 315 320 Arg Asp Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Ser Leu Lys 325 330 335 Thr Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn Phe Gly 340 345 350 Asn Ser Tyr Val Ser Trp Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val 355 360 365 Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 370 375 380 Gly Gly Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser 385 390 395 400 Pro Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val 405 410 415 Thr Ser Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala 420 425 430 Pro Arg Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro 435 440 445 Ala Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu 450 455 460 Ser Gly Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp 465 470 475 480 Tyr Ser Asn Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 485 490 495 <210> 212 <211> 496 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 212 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Tyr Tyr Ser Gly Arg Thr Asn Tyr Tyr Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Ile Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Ile Ala Val Ala Gly Phe Phe Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu 130 135 140 Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln 145 150 155 160 Ser Val Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 165 170 175 Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile 180 185 190 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 195 200 205 Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln 210 215 220 Tyr Asp Arg Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile 225 230 235 240 Lys Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly 245 250 255 Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser 260 265 270 Gly Phe Thr Phe Asn Ser Tyr Ala Met Asn Trp Val Arg Gln Ala Pro 275 280 285 Gly Lys Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn 290 295 300 Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser 305 310 315 320 Arg Asp Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Ser Leu Lys 325 330 335 Thr Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn Phe Gly 340 345 350 Asn Ser Tyr Val Ser Trp Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val 355 360 365 Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 370 375 380 Gly Gly Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser 385 390 395 400 Pro Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val 405 410 415 Thr Ser Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala 420 425 430 Pro Arg Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro 435 440 445 Ala Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu 450 455 460 Ser Gly Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp 465 470 475 480 Tyr Ser Asn Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 485 490 495 <210> 213 <211> 496 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 213 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Ala Ser Ile Ser Ser Phe 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Tyr Tyr Ser Gly Thr Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Ile Ala Val Ala Gly Phe Phe Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu 130 135 140 Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln 145 150 155 160 Ser Val Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 165 170 175 Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile 180 185 190 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 195 200 205 Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln 210 215 220 Tyr Asp Arg Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile 225 230 235 240 Lys Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly 245 250 255 Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser 260 265 270 Gly Phe Thr Phe Asn Ser Tyr Ala Met Asn Trp Val Arg Gln Ala Pro 275 280 285 Gly Lys Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn 290 295 300 Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser 305 310 315 320 Arg Asp Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Ser Leu Lys 325 330 335 Thr Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn Phe Gly 340 345 350 Asn Ser Tyr Val Ser Trp Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val 355 360 365 Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 370 375 380 Gly Gly Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser 385 390 395 400 Pro Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val 405 410 415 Thr Ser Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala 420 425 430 Pro Arg Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro 435 440 445 Ala Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu 450 455 460 Ser Gly Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp 465 470 475 480 Tyr Ser Asn Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 485 490 495 <210> 214 <211> 496 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 214 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Ala Ser Ile Ser Ser Phe 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Tyr Tyr Ser Gly Thr Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Ile Ala Val Ala Gly Phe Phe Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu 130 135 140 Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln 145 150 155 160 Ser Val Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 165 170 175 Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile 180 185 190 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 195 200 205 Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln 210 215 220 Tyr Asp Arg Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile 225 230 235 240 Lys Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly 245 250 255 Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser 260 265 270 Gly Phe Thr Phe Asn Ser Tyr Ala Met Asn Trp Val Arg Gln Ala Pro 275 280 285 Gly Lys Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn 290 295 300 Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser 305 310 315 320 Arg Asp Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Ser Leu Lys 325 330 335 Thr Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn Phe Gly 340 345 350 Asn Ser Tyr Val Ser Trp Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val 355 360 365 Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 370 375 380 Gly Gly Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser 385 390 395 400 Pro Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val 405 410 415 Thr Ser Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala 420 425 430 Pro Arg Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro 435 440 445 Ala Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu 450 455 460 Ser Gly Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp 465 470 475 480 Tyr Ser Asn Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 485 490 495 <210> 215 <211> 496 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 215 Gln Val Gln Leu Gln Glu Trp Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Ala Ser Ile Ser Ser Phe 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Tyr Tyr Ser Gly Thr Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Leu Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Ile Ala Val Ala Gly Phe Phe Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu 130 135 140 Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln 145 150 155 160 Ser Val Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 165 170 175 Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile 180 185 190 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 195 200 205 Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln 210 215 220 Tyr Asp Arg Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Asp Ile 225 230 235 240 Lys Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly 245 250 255 Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser 260 265 270 Gly Phe Thr Phe Asn Ser Tyr Ala Met Asn Trp Val Arg Gln Ala Pro 275 280 285 Gly Lys Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn 290 295 300 Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser 305 310 315 320 Arg Asp Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Ser Leu Lys 325 330 335 Thr Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn Phe Gly 340 345 350 Asn Ser Tyr Val Ser Trp Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val 355 360 365 Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 370 375 380 Gly Gly Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser 385 390 395 400 Pro Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val 405 410 415 Thr Ser Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala 420 425 430 Pro Arg Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro 435 440 445 Ala Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu 450 455 460 Ser Gly Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp 465 470 475 480 Tyr Ser Asn Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 485 490 495 <210> 216 <211> 496 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 216 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Ala Ser Ile Ser Ser Phe 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Tyr Tyr Ser Gly Thr Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Ile Ala Val Ala Gly Phe Phe Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu 130 135 140 Ser Leu Ser Pro Gly Glu Ser Ala Thr Leu Ser Cys Arg Ala Ser Gln 145 150 155 160 Ser Val Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 165 170 175 Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile 180 185 190 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 195 200 205 Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln 210 215 220 Tyr Asp Arg Ser Pro Leu Thr Phe Gly Gly Gly Thr Arg Leu Glu Ile 225 230 235 240 Lys Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly 245 250 255 Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser 260 265 270 Gly Phe Thr Phe Asn Ser Tyr Ala Met Asn Trp Val Arg Gln Ala Pro 275 280 285 Gly Lys Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn 290 295 300 Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser 305 310 315 320 Arg Asp Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Ser Leu Lys 325 330 335 Thr Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn Phe Gly 340 345 350 Asn Ser Tyr Val Ser Trp Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val 355 360 365 Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 370 375 380 Gly Gly Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser 385 390 395 400 Pro Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val 405 410 415 Thr Ser Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala 420 425 430 Pro Arg Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro 435 440 445 Ala Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu 450 455 460 Ser Gly Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp 465 470 475 480 Tyr Ser Asn Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 485 490 495 <210> 217 <211> 496 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 217 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Phe Tyr Asn Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Leu Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Lys Tyr Tyr Cys Ala 85 90 95 Arg Ile His Ser Gly Ser Phe Ser Phe Asp Tyr Trp Asp Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Glu Ile Val Met Thr Gln Ser Pro Gly Thr Leu 130 135 140 Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln 145 150 155 160 Ser Val Ser Arg Gly Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 165 170 175 Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Asp Ile 180 185 190 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 195 200 205 Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln 210 215 220 Tyr Asp Thr Ser Pro Ile Thr Phe Gly Gln Gly Thr Lys Val Glu Ile 225 230 235 240 Lys Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly 245 250 255 Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser 260 265 270 Gly Phe Thr Phe Asn Ser Tyr Ala Met Asn Trp Val Arg Gln Ala Pro 275 280 285 Gly Lys Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn 290 295 300 Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser 305 310 315 320 Arg Asp Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Ser Leu Lys 325 330 335 Thr Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn Phe Gly 340 345 350 Asn Ser Tyr Val Ser Trp Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val 355 360 365 Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 370 375 380 Gly Gly Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser 385 390 395 400 Pro Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val 405 410 415 Thr Ser Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala 420 425 430 Pro Arg Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro 435 440 445 Ala Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu 450 455 460 Ser Gly Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp 465 470 475 480 Tyr Ser Asn Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 485 490 495 <210> 218 <211> 505 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 218 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Asp Gly Ser Thr Asn Tyr Ala Gln Asn Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln 130 135 140 Ser Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser 145 150 155 160 Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg Asp Gly Asn Thr Tyr Leu 165 170 175 Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr 180 185 190 Lys Val Ser Asn Trp Gln Ser Gly Val Pro Asp Arg Phe Ser Gly Ser 195 200 205 Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu 210 215 220 Asp Val Gly Val Tyr Phe Cys Met Gln Gly Thr His Trp Pro Pro Thr 225 230 235 240 Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Ser Gly Gly Gly Gly Ser 245 250 255 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 260 265 270 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Ser Tyr 275 280 285 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 290 295 300 Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 305 310 315 320 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 325 330 335 Ala Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr 340 345 350 Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Val Ser Trp Trp 355 360 365 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 370 375 380 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val 385 390 395 400 Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu 405 410 415 Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro Asn 420 425 430 Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly 435 440 445 Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu 450 455 460 Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp 465 470 475 480 Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val Phe 485 490 495 Gly Gly Gly Thr Lys Leu Thr Val Leu 500 505 <210> 219 <211> 505 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 219 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Leu Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Asp Gly Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Asp Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln 130 135 140 Thr Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser 145 150 155 160 Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg Asp Gly Asn Thr Tyr Leu 165 170 175 Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr 180 185 190 Lys Val Ser Asn Trp Gln Ser Gly Val Pro Asp Arg Phe Ser Gly Gly 195 200 205 Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu 210 215 220 Asp Val Gly Val Tyr Tyr Cys Met Gln Gly Thr His Trp Pro Pro Thr 225 230 235 240 Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Ser Gly Gly Gly Gly Ser 245 250 255 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 260 265 270 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Ser Tyr 275 280 285 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 290 295 300 Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 305 310 315 320 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 325 330 335 Ala Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr 340 345 350 Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Val Ser Trp Trp 355 360 365 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 370 375 380 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val 385 390 395 400 Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu 405 410 415 Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro Asn 420 425 430 Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly 435 440 445 Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu 450 455 460 Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp 465 470 475 480 Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val Phe 485 490 495 Gly Gly Gly Thr Lys Leu Thr Val Leu 500 505 <210> 220 <211> 505 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 220 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr 20 25 30 Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Asp Gly Ser Thr Ser Tyr Gly Gln Asn Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln 130 135 140 Ser Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser 145 150 155 160 Cys Arg Ser Ser Gln Ser Leu Ala Tyr Arg Asp Gly Asn Thr Tyr Leu 165 170 175 Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr 180 185 190 Lys Val Ser Asn Trp Gln Ser Gly Val Pro Asp Arg Phe Ser Gly Ser 195 200 205 Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu 210 215 220 Asp Val Gly Val Tyr Phe Cys Met Gln Gly Thr His Trp Pro Pro Thr 225 230 235 240 Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Ser Gly Gly Gly Gly Ser 245 250 255 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 260 265 270 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Ser Tyr 275 280 285 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 290 295 300 Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 305 310 315 320 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 325 330 335 Ala Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr 340 345 350 Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Val Ser Trp Trp 355 360 365 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 370 375 380 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val 385 390 395 400 Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu 405 410 415 Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro Asn 420 425 430 Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly 435 440 445 Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu 450 455 460 Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp 465 470 475 480 Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val Phe 485 490 495 Gly Gly Gly Thr Lys Leu Thr Val Leu 500 505 <210> 221 <211> 1096 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 221 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Ser Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr 20 25 30 Gly Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Ile Ser Tyr His Gly Ser Asn Lys Tyr Tyr Ala Arg Ser Val 50 55 60 Lys Gly Arg Phe Thr Val Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Glu Ile Pro Phe Gly Met Asp Val Trp Gly Gln Gly Thr Thr 100 105 110 Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 115 120 125 Gly Gly Gly Ser Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Pro 130 135 140 Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser 145 150 155 160 Leu Leu His Ser Asp Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys 165 170 175 Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala 180 185 190 Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe 195 200 205 Thr Leu Thr Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr 210 215 220 Cys Met Gln Ala Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys 225 230 235 240 Val Asp Ile Lys Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu 245 250 255 Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys 260 265 270 Ala Ala Ser Gly Phe Thr Phe Asn Lys Tyr Ala Met Asn Trp Val Arg 275 280 285 Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys 290 295 300 Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe 305 310 315 320 Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn 325 330 335 Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly 340 345 350 Asn Phe Gly Asn Ser Tyr Ile Ser Tyr Trp Ala Tyr Trp Gly Gln Gly 355 360 365 Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 370 375 380 Ser Gly Gly Gly Gly Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu 385 390 395 400 Thr Val Ser Pro Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr 405 410 415 Gly Ala Val Thr Ser Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro 420 425 430 Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro 435 440 445 Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala 450 455 460 Leu Thr Leu Ser Gly Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys 465 470 475 480 Val Leu Trp Tyr Ser Asn Arg Trp Val Phe Gly Gly Gly Thr Lys Leu 485 490 495 Thr Val Leu Pro Gly Gly Gly Gly Ser Asp Ala His Lys Ser Glu Val 500 505 510 Ala His Arg Phe Lys Asp Leu Gly Glu Glu Asn Phe Lys Ala Leu Val 515 520 525 Leu Ile Ala Phe Ala Gln Tyr Leu Gln Gln Cys Pro Phe Glu Asp His 530 535 540 Val Lys Leu Val Asn Glu Val Thr Glu Phe Ala Lys Thr Cys Val Ala 545 550 555 560 Asp Glu Ser Ala Glu Asn Cys Asp Lys Ser Leu His Thr Leu Phe Gly 565 570 575 Asp Lys Leu Cys Thr Val Ala Thr Leu Arg Glu Thr Tyr Gly Glu Met 580 585 590 Ala Asp Cys Cys Ala Lys Gln Glu Pro Glu Arg Asn Glu Cys Phe Leu 595 600 605 Gln His Lys Asp Asp Asn Pro Asn Leu Pro Arg Leu Val Arg Pro Glu 610 615 620 Val Asp Val Met Cys Thr Ala Phe His Asp Asn Glu Glu Thr Phe Leu 625 630 635 640 Lys Lys Tyr Leu Tyr Glu Ile Ala Arg Arg His Pro Tyr Phe Tyr Ala 645 650 655 Pro Glu Leu Leu Phe Phe Ala Lys Arg Tyr Lys Ala Ala Phe Thr Glu 660 665 670 Cys Cys Gln Ala Ala Asp Lys Ala Ala Cys Leu Leu Pro Lys Leu Asp 675 680 685 Glu Leu Arg Asp Glu Gly Lys Ala Ser Ser Ala Lys Gln Arg Leu Lys 690 695 700 Cys Ala Ser Leu Gln Lys Phe Gly Glu Arg Ala Phe Lys Ala Trp Ala 705 710 715 720 Val Ala Arg Leu Ser Gln Arg Phe Pro Lys Ala Glu Phe Ala Glu Val 725 730 735 Ser Lys Leu Val Thr Asp Leu Thr Lys Val His Thr Glu Cys Cys His 740 745 750 Gly Asp Leu Leu Glu Cys Ala Asp Asp Arg Ala Asp Leu Ala Lys Tyr 755 760 765 Ile Cys Glu Asn Gln Asp Ser Ile Ser Ser Lys Leu Lys Glu Cys Cys 770 775 780 Glu Lys Pro Leu Leu Glu Lys Ser His Cys Ile Ala Glu Val Glu Asn 785 790 795 800 Asp Glu Met Pro Ala Asp Leu Pro Ser Leu Ala Ala Asp Phe Val Glu 805 810 815 Ser Lys Asp Val Cys Lys Asn Tyr Ala Glu Ala Lys Asp Val Phe Leu 820 825 830 Gly Met Phe Leu Tyr Glu Tyr Ala Arg Arg His Pro Asp Tyr Ser Val 835 840 845 Val Leu Leu Leu Arg Leu Ala Lys Thr Tyr Glu Thr Thr Leu Glu Lys 850 855 860 Cys Cys Ala Ala Ala Asp Pro His Glu Cys Tyr Ala Lys Val Phe Asp 865 870 875 880 Glu Phe Lys Pro Leu Val Glu Glu Pro Gln Asn Leu Ile Lys Gln Asn 885 890 895 Cys Glu Leu Phe Glu Gln Leu Gly Glu Tyr Lys Phe Gln Asn Ala Leu 900 905 910 Leu Val Arg Tyr Thr Lys Lys Val Pro Gln Val Ser Thr Pro Thr Leu 915 920 925 Val Glu Val Ser Arg Asn Leu Gly Lys Val Gly Ser Lys Cys Cys Lys 930 935 940 His Pro Glu Ala Lys Arg Met Pro Cys Ala Glu Asp Tyr Leu Ser Val 945 950 955 960 Val Leu Asn Gln Leu Cys Val Leu His Glu Lys Thr Pro Val Ser Asp 965 970 975 Arg Val Thr Lys Cys Cys Thr Glu Ser Leu Val Asn Arg Arg Pro Cys 980 985 990 Phe Ser Ala Leu Glu Val Asp Glu Thr Tyr Val Pro Lys Glu Phe Asn 995 1000 1005 Ala Gly Thr Phe Thr Phe His Ala Asp Ile Cys Thr Leu Ser Glu 1010 1015 1020 Lys Glu Arg Gln Ile Lys Lys Gln Thr Ala Leu Val Glu Leu Val 1025 1030 1035 Lys His Lys Pro Lys Ala Thr Lys Glu Gln Leu Lys Ala Ala Met 1040 1045 1050 Asp Asp Phe Ala Ala Phe Val Glu Lys Cys Cys Lys Ala Asp Asp 1055 1060 1065 Lys Glu Thr Cys Phe Ala Glu Glu Gly Lys Lys Leu Val Ala Ala 1070 1075 1080 Ser Gln Ala Ala Leu Gly Leu His His His His His His 1085 1090 1095 <210> 222 <211> 1095 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 222 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Asn Pro Asn Ser Gly Asp Thr Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Arg Leu Thr Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Ala Asn Ile Ala Ala Leu Asp Ala Phe Glu Ile Trp Gly 100 105 110 Gln Gly Thr Met Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly 115 120 125 Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro 130 135 140 Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg 145 150 155 160 Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro 165 170 175 Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser 180 185 190 Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr 195 200 205 Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys 210 215 220 Gln Gln Ser Tyr Ser Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val 225 230 235 240 Glu Ile Lys Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser 245 250 255 Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala 260 265 270 Ala Ser Gly Phe Thr Phe Asn Lys Tyr Ala Met Asn Trp Val Arg Gln 275 280 285 Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr 290 295 300 Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr 305 310 315 320 Ile Ser Arg Asp Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Asn 325 330 335 Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn 340 345 350 Phe Gly Asn Ser Tyr Ile Ser Tyr Trp Ala Tyr Trp Gly Gln Gly Thr 355 360 365 Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 370 375 380 Gly Gly Gly Gly Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr 385 390 395 400 Val Ser Pro Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly 405 410 415 Ala Val Thr Ser Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly 420 425 430 Gln Ala Pro Arg Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly 435 440 445 Thr Pro Ala Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu 450 455 460 Thr Leu Ser Gly Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val 465 470 475 480 Leu Trp Tyr Ser Asn Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr 485 490 495 Val Leu Pro Gly Gly Gly Gly Ser Asp Ala His Lys Ser Glu Val Ala 500 505 510 His Arg Phe Lys Asp Leu Gly Glu Glu Asn Phe Lys Ala Leu Val Leu 515 520 525 Ile Ala Phe Ala Gln Tyr Leu Gln Gln Cys Pro Phe Glu Asp His Val 530 535 540 Lys Leu Val Asn Glu Val Thr Glu Phe Ala Lys Thr Cys Val Ala Asp 545 550 555 560 Glu Ser Ala Glu Asn Cys Asp Lys Ser Leu His Thr Leu Phe Gly Asp 565 570 575 Lys Leu Cys Thr Val Ala Thr Leu Arg Glu Thr Tyr Gly Glu Met Ala 580 585 590 Asp Cys Cys Ala Lys Gln Glu Pro Glu Arg Asn Glu Cys Phe Leu Gln 595 600 605 His Lys Asp Asp Asn Pro Asn Leu Pro Arg Leu Val Arg Pro Glu Val 610 615 620 Asp Val Met Cys Thr Ala Phe His Asp Asn Glu Glu Thr Phe Leu Lys 625 630 635 640 Lys Tyr Leu Tyr Glu Ile Ala Arg Arg His Pro Tyr Phe Tyr Ala Pro 645 650 655 Glu Leu Leu Phe Phe Ala Lys Arg Tyr Lys Ala Ala Phe Thr Glu Cys 660 665 670 Cys Gln Ala Ala Asp Lys Ala Ala Cys Leu Leu Pro Lys Leu Asp Glu 675 680 685 Leu Arg Asp Glu Gly Lys Ala Ser Ser Ala Lys Gln Arg Leu Lys Cys 690 695 700 Ala Ser Leu Gln Lys Phe Gly Glu Arg Ala Phe Lys Ala Trp Ala Val 705 710 715 720 Ala Arg Leu Ser Gln Arg Phe Pro Lys Ala Glu Phe Ala Glu Val Ser 725 730 735 Lys Leu Val Thr Asp Leu Thr Lys Val His Thr Glu Cys Cys His Gly 740 745 750 Asp Leu Leu Glu Cys Ala Asp Asp Arg Ala Asp Leu Ala Lys Tyr Ile 755 760 765 Cys Glu Asn Gln Asp Ser Ile Ser Ser Lys Leu Lys Glu Cys Cys Glu 770 775 780 Lys Pro Leu Leu Glu Lys Ser His Cys Ile Ala Glu Val Glu Asn Asp 785 790 795 800 Glu Met Pro Ala Asp Leu Pro Ser Leu Ala Ala Asp Phe Val Glu Ser 805 810 815 Lys Asp Val Cys Lys Asn Tyr Ala Glu Ala Lys Asp Val Phe Leu Gly 820 825 830 Met Phe Leu Tyr Glu Tyr Ala Arg Arg His Pro Asp Tyr Ser Val Val 835 840 845 Leu Leu Leu Arg Leu Ala Lys Thr Tyr Glu Thr Thr Leu Glu Lys Cys 850 855 860 Cys Ala Ala Ala Asp Pro His Glu Cys Tyr Ala Lys Val Phe Asp Glu 865 870 875 880 Phe Lys Pro Leu Val Glu Glu Pro Gln Asn Leu Ile Lys Gln Asn Cys 885 890 895 Glu Leu Phe Glu Gln Leu Gly Glu Tyr Lys Phe Gln Asn Ala Leu Leu 900 905 910 Val Arg Tyr Thr Lys Lys Val Pro Gln Val Ser Thr Pro Thr Leu Val 915 920 925 Glu Val Ser Arg Asn Leu Gly Lys Val Gly Ser Lys Cys Cys Lys His 930 935 940 Pro Glu Ala Lys Arg Met Pro Cys Ala Glu Asp Tyr Leu Ser Val Val 945 950 955 960 Leu Asn Gln Leu Cys Val Leu His Glu Lys Thr Pro Val Ser Asp Arg 965 970 975 Val Thr Lys Cys Cys Thr Glu Ser Leu Val Asn Arg Arg Pro Cys Phe 980 985 990 Ser Ala Leu Glu Val Asp Glu Thr Tyr Val Pro Lys Glu Phe Asn Ala 995 1000 1005 Gly Thr Phe Thr Phe His Ala Asp Ile Cys Thr Leu Ser Glu Lys 1010 1015 1020 Glu Arg Gln Ile Lys Lys Gln Thr Ala Leu Val Glu Leu Val Lys 1025 1030 1035 His Lys Pro Lys Ala Thr Lys Glu Gln Leu Lys Ala Ala Met Asp 1040 1045 1050 Asp Phe Ala Ala Phe Val Glu Lys Cys Cys Lys Ala Asp Asp Lys 1055 1060 1065 Glu Thr Cys Phe Ala Glu Glu Gly Lys Lys Leu Val Ala Ala Ser 1070 1075 1080 Gln Ala Ala Leu Gly Leu His His His His His His 1085 1090 1095 <210> 223 <211> 1098 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 223 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Ile Ser Tyr His Gly Arg Asp Thr Tyr Tyr Ala Arg Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu His Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Gly Ala Thr Val Thr Ser Tyr Tyr Tyr Ser Gly Met Asp 100 105 110 Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly 115 120 125 Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr 130 135 140 Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile 145 150 155 160 Thr Cys Arg Ala Ser Gln Gly Ile Ser Asn Tyr Leu Ala Trp Phe Gln 165 170 175 Gln Lys Pro Gly Lys Ala Pro Lys Ser Leu Ile Tyr Leu Ala Ser Ser 180 185 190 Leu Gln Ser Gly Val Pro Ser Lys Phe Ser Gly Ser Gly Ser Gly Thr 195 200 205 Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr 210 215 220 Tyr Tyr Cys Gln Gln Tyr Asn Phe Tyr Pro Phe Thr Phe Gly Pro Gly 225 230 235 240 Thr Lys Val Asp Ile Lys Ser Gly Gly Gly Gly Ser Glu Val Gln Leu 245 250 255 Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu 260 265 270 Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys Tyr Ala Met Asn Trp 275 280 285 Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Arg Ile Arg 290 295 300 Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp 305 310 315 320 Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Ala Tyr Leu Gln 325 330 335 Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg 340 345 350 His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr Trp Ala Tyr Trp Gly 355 360 365 Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly 370 375 380 Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val Thr Gln Glu Pro 385 390 395 400 Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu Thr Cys Gly Ser 405 410 415 Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro Asn Trp Val Gln Gln 420 425 430 Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly Thr Lys Phe Leu 435 440 445 Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys 450 455 460 Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp Glu Ala Glu Tyr 465 470 475 480 Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val Phe Gly Gly Gly Thr 485 490 495 Lys Leu Thr Val Leu Pro Gly Gly Gly Gly Ser Asp Ala His Lys Ser 500 505 510 Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu Glu Asn Phe Lys Ala 515 520 525 Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln Gln Cys Pro Phe Glu 530 535 540 Asp His Val Lys Leu Val Asn Glu Val Thr Glu Phe Ala Lys Thr Cys 545 550 555 560 Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys Ser Leu His Thr Leu 565 570 575 Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu Arg Glu Thr Tyr Gly 580 585 590 Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro Glu Arg Asn Glu Cys 595 600 605 Phe Leu Gln His Lys Asp Asp Asn Pro Asn Leu Pro Arg Leu Val Arg 610 615 620 Pro Glu Val Asp Val Met Cys Thr Ala Phe His Asp Asn Glu Glu Thr 625 630 635 640 Phe Leu Lys Lys Tyr Leu Tyr Glu Ile Ala Arg Arg His Pro Tyr Phe 645 650 655 Tyr Ala Pro Glu Leu Leu Phe Phe Ala Lys Arg Tyr Lys Ala Ala Phe 660 665 670 Thr Glu Cys Cys Gln Ala Ala Asp Lys Ala Ala Cys Leu Leu Pro Lys 675 680 685 Leu Asp Glu Leu Arg Asp Glu Gly Lys Ala Ser Ser Ala Lys Gln Arg 690 695 700 Leu Lys Cys Ala Ser Leu Gln Lys Phe Gly Glu Arg Ala Phe Lys Ala 705 710 715 720 Trp Ala Val Ala Arg Leu Ser Gln Arg Phe Pro Lys Ala Glu Phe Ala 725 730 735 Glu Val Ser Lys Leu Val Thr Asp Leu Thr Lys Val His Thr Glu Cys 740 745 750 Cys His Gly Asp Leu Leu Glu Cys Ala Asp Asp Arg Ala Asp Leu Ala 755 760 765 Lys Tyr Ile Cys Glu Asn Gln Asp Ser Ile Ser Ser Lys Leu Lys Glu 770 775 780 Cys Cys Glu Lys Pro Leu Leu Glu Lys Ser His Cys Ile Ala Glu Val 785 790 795 800 Glu Asn Asp Glu Met Pro Ala Asp Leu Pro Ser Leu Ala Ala Asp Phe 805 810 815 Val Glu Ser Lys Asp Val Cys Lys Asn Tyr Ala Glu Ala Lys Asp Val 820 825 830 Phe Leu Gly Met Phe Leu Tyr Glu Tyr Ala Arg Arg His Pro Asp Tyr 835 840 845 Ser Val Val Leu Leu Leu Arg Leu Ala Lys Thr Tyr Glu Thr Thr Leu 850 855 860 Glu Lys Cys Cys Ala Ala Ala Asp Pro His Glu Cys Tyr Ala Lys Val 865 870 875 880 Phe Asp Glu Phe Lys Pro Leu Val Glu Glu Pro Gln Asn Leu Ile Lys 885 890 895 Gln Asn Cys Glu Leu Phe Glu Gln Leu Gly Glu Tyr Lys Phe Gln Asn 900 905 910 Ala Leu Leu Val Arg Tyr Thr Lys Lys Val Pro Gln Val Ser Thr Pro 915 920 925 Thr Leu Val Glu Val Ser Arg Asn Leu Gly Lys Val Gly Ser Lys Cys 930 935 940 Cys Lys His Pro Glu Ala Lys Arg Met Pro Cys Ala Glu Asp Tyr Leu 945 950 955 960 Ser Val Val Leu Asn Gln Leu Cys Val Leu His Glu Lys Thr Pro Val 965 970 975 Ser Asp Arg Val Thr Lys Cys Cys Thr Glu Ser Leu Val Asn Arg Arg 980 985 990 Pro Cys Phe Ser Ala Leu Glu Val Asp Glu Thr Tyr Val Pro Lys Glu 995 1000 1005 Phe Asn Ala Glu Thr Phe Thr Phe His Ala Asp Ile Cys Thr Leu 1010 1015 1020 Ser Glu Lys Glu Arg Gln Ile Lys Lys Gln Thr Ala Leu Val Glu 1025 1030 1035 Leu Val Lys His Lys Pro Lys Ala Thr Lys Glu Gln Leu Lys Ala 1040 1045 1050 Val Met Asp Asp Phe Ala Ala Phe Val Glu Lys Cys Cys Lys Ala 1055 1060 1065 Asp Asp Lys Glu Thr Cys Phe Ala Glu Glu Gly Lys Lys Leu Val 1070 1075 1080 Ala Ala Ser Gln Ala Ala Leu Gly Leu His His His His His His 1085 1090 1095 <210> 224 <211> 1093 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 224 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Val Tyr Tyr Ser Gly Thr Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Ser Ile Ala Val Thr Gly Phe Tyr Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu 130 135 140 Ser Leu Ser Pro Gly Glu Arg Val Thr Leu Ser Cys Arg Ala Ser Gln 145 150 155 160 Arg Val Asn Asn Asn Tyr Leu Ala Trp Tyr Gln Gln Arg Pro Gly Gln 165 170 175 Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile 180 185 190 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 195 200 205 Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln 210 215 220 Tyr Asp Arg Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile 225 230 235 240 Lys Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly 245 250 255 Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser 260 265 270 Gly Phe Thr Phe Asn Lys Tyr Ala Met Asn Trp Val Arg Gln Ala Pro 275 280 285 Gly Lys Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn 290 295 300 Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser 305 310 315 320 Arg Asp Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Asn Leu Lys 325 330 335 Thr Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn Phe Gly 340 345 350 Asn Ser Tyr Ile Ser Tyr Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val 355 360 365 Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 370 375 380 Gly Gly Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser 385 390 395 400 Pro Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val 405 410 415 Thr Ser Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala 420 425 430 Pro Arg Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro 435 440 445 Ala Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu 450 455 460 Ser Gly Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp 465 470 475 480 Tyr Ser Asn Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 485 490 495 Pro Gly Gly Gly Gly Ser Asp Ala His Lys Ser Glu Val Ala His Arg 500 505 510 Phe Lys Asp Leu Gly Glu Glu Asn Phe Lys Ala Leu Val Leu Ile Ala 515 520 525 Phe Ala Gln Tyr Leu Gln Gln Cys Pro Phe Glu Asp His Val Lys Leu 530 535 540 Val Asn Glu Val Thr Glu Phe Ala Lys Thr Cys Val Ala Asp Glu Ser 545 550 555 560 Ala Glu Asn Cys Asp Lys Ser Leu His Thr Leu Phe Gly Asp Lys Leu 565 570 575 Cys Thr Val Ala Thr Leu Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys 580 585 590 Cys Ala Lys Gln Glu Pro Glu Arg Asn Glu Cys Phe Leu Gln His Lys 595 600 605 Asp Asp Asn Pro Asn Leu Pro Arg Leu Val Arg Pro Glu Val Asp Val 610 615 620 Met Cys Thr Ala Phe His Asp Asn Glu Glu Thr Phe Leu Lys Lys Tyr 625 630 635 640 Leu Tyr Glu Ile Ala Arg Arg His Pro Tyr Phe Tyr Ala Pro Glu Leu 645 650 655 Leu Phe Phe Ala Lys Arg Tyr Lys Ala Ala Phe Thr Glu Cys Cys Gln 660 665 670 Ala Ala Asp Lys Ala Ala Cys Leu Leu Pro Lys Leu Asp Glu Leu Arg 675 680 685 Asp Glu Gly Lys Ala Ser Ser Ala Lys Gln Arg Leu Lys Cys Ala Ser 690 695 700 Leu Gln Lys Phe Gly Glu Arg Ala Phe Lys Ala Trp Ala Val Ala Arg 705 710 715 720 Leu Ser Gln Arg Phe Pro Lys Ala Glu Phe Ala Glu Val Ser Lys Leu 725 730 735 Val Thr Asp Leu Thr Lys Val His Thr Glu Cys Cys His Gly Asp Leu 740 745 750 Leu Glu Cys Ala Asp Asp Arg Ala Asp Leu Ala Lys Tyr Ile Cys Glu 755 760 765 Asn Gln Asp Ser Ile Ser Ser Lys Leu Lys Glu Cys Cys Glu Lys Pro 770 775 780 Leu Leu Glu Lys Ser His Cys Ile Ala Glu Val Glu Asn Asp Glu Met 785 790 795 800 Pro Ala Asp Leu Pro Ser Leu Ala Ala Asp Phe Val Glu Ser Lys Asp 805 810 815 Val Cys Lys Asn Tyr Ala Glu Ala Lys Asp Val Phe Leu Gly Met Phe 820 825 830 Leu Tyr Glu Tyr Ala Arg Arg His Pro Asp Tyr Ser Val Val Leu Leu 835 840 845 Leu Arg Leu Ala Lys Thr Tyr Glu Thr Thr Leu Glu Lys Cys Cys Ala 850 855 860 Ala Ala Asp Pro His Glu Cys Tyr Ala Lys Val Phe Asp Glu Phe Lys 865 870 875 880 Pro Leu Val Glu Glu Pro Gln Asn Leu Ile Lys Gln Asn Cys Glu Leu 885 890 895 Phe Glu Gln Leu Gly Glu Tyr Lys Phe Gln Asn Ala Leu Leu Val Arg 900 905 910 Tyr Thr Lys Lys Val Pro Gln Val Ser Thr Pro Thr Leu Val Glu Val 915 920 925 Ser Arg Asn Leu Gly Lys Val Gly Ser Lys Cys Cys Lys His Pro Glu 930 935 940 Ala Lys Arg Met Pro Cys Ala Glu Asp Tyr Leu Ser Val Val Leu Asn 945 950 955 960 Gln Leu Cys Val Leu His Glu Lys Thr Pro Val Ser Asp Arg Val Thr 965 970 975 Lys Cys Cys Thr Glu Ser Leu Val Asn Arg Arg Pro Cys Phe Ser Ala 980 985 990 Leu Glu Val Asp Glu Thr Tyr Val Pro Lys Glu Phe Asn Ala Glu Thr 995 1000 1005 Phe Thr Phe His Ala Asp Ile Cys Thr Leu Ser Glu Lys Glu Arg 1010 1015 1020 Gln Ile Lys Lys Gln Thr Ala Leu Val Glu Leu Val Lys His Lys 1025 1030 1035 Pro Lys Ala Thr Lys Glu Gln Leu Lys Ala Val Met Asp Asp Phe 1040 1045 1050 Ala Ala Phe Val Glu Lys Cys Cys Lys Ala Asp Asp Lys Glu Thr 1055 1060 1065 Cys Phe Ala Glu Glu Gly Lys Lys Leu Val Ala Ala Ser Gln Ala 1070 1075 1080 Ala Leu Gly Leu His His His His His His 1085 1090 <210> 225 <211> 1093 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 225 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Tyr Tyr Ser Gly Arg Thr Asn Tyr Tyr Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Ile Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Ile Ala Val Ala Gly Phe Phe Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu 130 135 140 Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln 145 150 155 160 Ser Val Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 165 170 175 Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile 180 185 190 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 195 200 205 Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln 210 215 220 Tyr Asp Arg Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile 225 230 235 240 Lys Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly 245 250 255 Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser 260 265 270 Gly Phe Thr Phe Asn Lys Tyr Ala Met Asn Trp Val Arg Gln Ala Pro 275 280 285 Gly Lys Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn 290 295 300 Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser 305 310 315 320 Arg Asp Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Asn Leu Lys 325 330 335 Thr Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn Phe Gly 340 345 350 Asn Ser Tyr Ile Ser Tyr Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val 355 360 365 Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 370 375 380 Gly Gly Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser 385 390 395 400 Pro Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val 405 410 415 Thr Ser Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala 420 425 430 Pro Arg Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro 435 440 445 Ala Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu 450 455 460 Ser Gly Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp 465 470 475 480 Tyr Ser Asn Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 485 490 495 Pro Gly Gly Gly Gly Ser Asp Ala His Lys Ser Glu Val Ala His Arg 500 505 510 Phe Lys Asp Leu Gly Glu Glu Asn Phe Lys Ala Leu Val Leu Ile Ala 515 520 525 Phe Ala Gln Tyr Leu Gln Gln Cys Pro Phe Glu Asp His Val Lys Leu 530 535 540 Val Asn Glu Val Thr Glu Phe Ala Lys Thr Cys Val Ala Asp Glu Ser 545 550 555 560 Ala Glu Asn Cys Asp Lys Ser Leu His Thr Leu Phe Gly Asp Lys Leu 565 570 575 Cys Thr Val Ala Thr Leu Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys 580 585 590 Cys Ala Lys Gln Glu Pro Glu Arg Asn Glu Cys Phe Leu Gln His Lys 595 600 605 Asp Asp Asn Pro Asn Leu Pro Arg Leu Val Arg Pro Glu Val Asp Val 610 615 620 Met Cys Thr Ala Phe His Asp Asn Glu Glu Thr Phe Leu Lys Lys Tyr 625 630 635 640 Leu Tyr Glu Ile Ala Arg Arg His Pro Tyr Phe Tyr Ala Pro Glu Leu 645 650 655 Leu Phe Phe Ala Lys Arg Tyr Lys Ala Ala Phe Thr Glu Cys Cys Gln 660 665 670 Ala Ala Asp Lys Ala Ala Cys Leu Leu Pro Lys Leu Asp Glu Leu Arg 675 680 685 Asp Glu Gly Lys Ala Ser Ser Ala Lys Gln Arg Leu Lys Cys Ala Ser 690 695 700 Leu Gln Lys Phe Gly Glu Arg Ala Phe Lys Ala Trp Ala Val Ala Arg 705 710 715 720 Leu Ser Gln Arg Phe Pro Lys Ala Glu Phe Ala Glu Val Ser Lys Leu 725 730 735 Val Thr Asp Leu Thr Lys Val His Thr Glu Cys Cys His Gly Asp Leu 740 745 750 Leu Glu Cys Ala Asp Asp Arg Ala Asp Leu Ala Lys Tyr Ile Cys Glu 755 760 765 Asn Gln Asp Ser Ile Ser Ser Lys Leu Lys Glu Cys Cys Glu Lys Pro 770 775 780 Leu Leu Glu Lys Ser His Cys Ile Ala Glu Val Glu Asn Asp Glu Met 785 790 795 800 Pro Ala Asp Leu Pro Ser Leu Ala Ala Asp Phe Val Glu Ser Lys Asp 805 810 815 Val Cys Lys Asn Tyr Ala Glu Ala Lys Asp Val Phe Leu Gly Met Phe 820 825 830 Leu Tyr Glu Tyr Ala Arg Arg His Pro Asp Tyr Ser Val Val Leu Leu 835 840 845 Leu Arg Leu Ala Lys Thr Tyr Glu Thr Thr Leu Glu Lys Cys Cys Ala 850 855 860 Ala Ala Asp Pro His Glu Cys Tyr Ala Lys Val Phe Asp Glu Phe Lys 865 870 875 880 Pro Leu Val Glu Glu Pro Gln Asn Leu Ile Lys Gln Asn Cys Glu Leu 885 890 895 Phe Glu Gln Leu Gly Glu Tyr Lys Phe Gln Asn Ala Leu Leu Val Arg 900 905 910 Tyr Thr Lys Lys Val Pro Gln Val Ser Thr Pro Thr Leu Val Glu Val 915 920 925 Ser Arg Asn Leu Gly Lys Val Gly Ser Lys Cys Cys Lys His Pro Glu 930 935 940 Ala Lys Arg Met Pro Cys Ala Glu Asp Tyr Leu Ser Val Val Leu Asn 945 950 955 960 Gln Leu Cys Val Leu His Glu Lys Thr Pro Val Ser Asp Arg Val Thr 965 970 975 Lys Cys Cys Thr Glu Ser Leu Val Asn Arg Arg Pro Cys Phe Ser Ala 980 985 990 Leu Glu Val Asp Glu Thr Tyr Val Pro Lys Glu Phe Asn Ala Glu Thr 995 1000 1005 Phe Thr Phe His Ala Asp Ile Cys Thr Leu Ser Glu Lys Glu Arg 1010 1015 1020 Gln Ile Lys Lys Gln Thr Ala Leu Val Glu Leu Val Lys His Lys 1025 1030 1035 Pro Lys Ala Thr Lys Glu Gln Leu Lys Ala Val Met Asp Asp Phe 1040 1045 1050 Ala Ala Phe Val Glu Lys Cys Cys Lys Ala Asp Asp Lys Glu Thr 1055 1060 1065 Cys Phe Ala Glu Glu Gly Lys Lys Leu Val Ala Ala Ser Gln Ala 1070 1075 1080 Ala Leu Gly Leu His His His His His His 1085 1090 <210> 226 <211> 1093 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 226 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Ala Ser Ile Ser Ser Phe 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Tyr Tyr Ser Gly Thr Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Ile Ala Val Ala Gly Phe Phe Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu 130 135 140 Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln 145 150 155 160 Ser Val Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 165 170 175 Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile 180 185 190 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 195 200 205 Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln 210 215 220 Tyr Asp Arg Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile 225 230 235 240 Lys Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly 245 250 255 Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser 260 265 270 Gly Phe Thr Phe Asn Lys Tyr Ala Met Asn Trp Val Arg Gln Ala Pro 275 280 285 Gly Lys Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn 290 295 300 Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser 305 310 315 320 Arg Asp Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Asn Leu Lys 325 330 335 Thr Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn Phe Gly 340 345 350 Asn Ser Tyr Ile Ser Tyr Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val 355 360 365 Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 370 375 380 Gly Gly Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser 385 390 395 400 Pro Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val 405 410 415 Thr Ser Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala 420 425 430 Pro Arg Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro 435 440 445 Ala Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu 450 455 460 Ser Gly Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp 465 470 475 480 Tyr Ser Asn Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 485 490 495 Pro Gly Gly Gly Gly Ser Asp Ala His Lys Ser Glu Val Ala His Arg 500 505 510 Phe Lys Asp Leu Gly Glu Glu Asn Phe Lys Ala Leu Val Leu Ile Ala 515 520 525 Phe Ala Gln Tyr Leu Gln Gln Cys Pro Phe Glu Asp His Val Lys Leu 530 535 540 Val Asn Glu Val Thr Glu Phe Ala Lys Thr Cys Val Ala Asp Glu Ser 545 550 555 560 Ala Glu Asn Cys Asp Lys Ser Leu His Thr Leu Phe Gly Asp Lys Leu 565 570 575 Cys Thr Val Ala Thr Leu Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys 580 585 590 Cys Ala Lys Gln Glu Pro Glu Arg Asn Glu Cys Phe Leu Gln His Lys 595 600 605 Asp Asp Asn Pro Asn Leu Pro Arg Leu Val Arg Pro Glu Val Asp Val 610 615 620 Met Cys Thr Ala Phe His Asp Asn Glu Glu Thr Phe Leu Lys Lys Tyr 625 630 635 640 Leu Tyr Glu Ile Ala Arg Arg His Pro Tyr Phe Tyr Ala Pro Glu Leu 645 650 655 Leu Phe Phe Ala Lys Arg Tyr Lys Ala Ala Phe Thr Glu Cys Cys Gln 660 665 670 Ala Ala Asp Lys Ala Ala Cys Leu Leu Pro Lys Leu Asp Glu Leu Arg 675 680 685 Asp Glu Gly Lys Ala Ser Ser Ala Lys Gln Arg Leu Lys Cys Ala Ser 690 695 700 Leu Gln Lys Phe Gly Glu Arg Ala Phe Lys Ala Trp Ala Val Ala Arg 705 710 715 720 Leu Ser Gln Arg Phe Pro Lys Ala Glu Phe Ala Glu Val Ser Lys Leu 725 730 735 Val Thr Asp Leu Thr Lys Val His Thr Glu Cys Cys His Gly Asp Leu 740 745 750 Leu Glu Cys Ala Asp Asp Arg Ala Asp Leu Ala Lys Tyr Ile Cys Glu 755 760 765 Asn Gln Asp Ser Ile Ser Ser Lys Leu Lys Glu Cys Cys Glu Lys Pro 770 775 780 Leu Leu Glu Lys Ser His Cys Ile Ala Glu Val Glu Asn Asp Glu Met 785 790 795 800 Pro Ala Asp Leu Pro Ser Leu Ala Ala Asp Phe Val Glu Ser Lys Asp 805 810 815 Val Cys Lys Asn Tyr Ala Glu Ala Lys Asp Val Phe Leu Gly Met Phe 820 825 830 Leu Tyr Glu Tyr Ala Arg Arg His Pro Asp Tyr Ser Val Val Leu Leu 835 840 845 Leu Arg Leu Ala Lys Thr Tyr Glu Thr Thr Leu Glu Lys Cys Cys Ala 850 855 860 Ala Ala Asp Pro His Glu Cys Tyr Ala Lys Val Phe Asp Glu Phe Lys 865 870 875 880 Pro Leu Val Glu Glu Pro Gln Asn Leu Ile Lys Gln Asn Cys Glu Leu 885 890 895 Phe Glu Gln Leu Gly Glu Tyr Lys Phe Gln Asn Ala Leu Leu Val Arg 900 905 910 Tyr Thr Lys Lys Val Pro Gln Val Ser Thr Pro Thr Leu Val Glu Val 915 920 925 Ser Arg Asn Leu Gly Lys Val Gly Ser Lys Cys Cys Lys His Pro Glu 930 935 940 Ala Lys Arg Met Pro Cys Ala Glu Asp Tyr Leu Ser Val Val Leu Asn 945 950 955 960 Gln Leu Cys Val Leu His Glu Lys Thr Pro Val Ser Asp Arg Val Thr 965 970 975 Lys Cys Cys Thr Glu Ser Leu Val Asn Arg Arg Pro Cys Phe Ser Ala 980 985 990 Leu Glu Val Asp Glu Thr Tyr Val Pro Lys Glu Phe Asn Ala Glu Thr 995 1000 1005 Phe Thr Phe His Ala Asp Ile Cys Thr Leu Ser Glu Lys Glu Arg 1010 1015 1020 Gln Ile Lys Lys Gln Thr Ala Leu Val Glu Leu Val Lys His Lys 1025 1030 1035 Pro Lys Ala Thr Lys Glu Gln Leu Lys Ala Val Met Asp Asp Phe 1040 1045 1050 Ala Ala Phe Val Glu Lys Cys Cys Lys Ala Asp Asp Lys Glu Thr 1055 1060 1065 Cys Phe Ala Glu Glu Gly Lys Lys Leu Val Ala Ala Ser Gln Ala 1070 1075 1080 Ala Leu Gly Leu His His His His His His 1085 1090 <210> 227 <211> 1093 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 227 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Ala Ser Ile Ser Ser Phe 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Tyr Tyr Ser Gly Thr Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Ile Ala Val Ala Gly Phe Phe Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu 130 135 140 Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln 145 150 155 160 Ser Val Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 165 170 175 Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile 180 185 190 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 195 200 205 Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln 210 215 220 Tyr Asp Arg Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile 225 230 235 240 Lys Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly 245 250 255 Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser 260 265 270 Gly Phe Thr Phe Asn Lys Tyr Ala Met Asn Trp Val Arg Gln Ala Pro 275 280 285 Gly Lys Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn 290 295 300 Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser 305 310 315 320 Arg Asp Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Asn Leu Lys 325 330 335 Thr Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn Phe Gly 340 345 350 Asn Ser Tyr Ile Ser Tyr Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val 355 360 365 Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 370 375 380 Gly Gly Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser 385 390 395 400 Pro Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val 405 410 415 Thr Ser Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala 420 425 430 Pro Arg Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro 435 440 445 Ala Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu 450 455 460 Ser Gly Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp 465 470 475 480 Tyr Ser Asn Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 485 490 495 Pro Gly Gly Gly Gly Ser Asp Ala His Lys Ser Glu Val Ala His Arg 500 505 510 Phe Lys Asp Leu Gly Glu Glu Asn Phe Lys Ala Leu Val Leu Ile Ala 515 520 525 Phe Ala Gln Tyr Leu Gln Gln Cys Pro Phe Glu Asp His Val Lys Leu 530 535 540 Val Asn Glu Val Thr Glu Phe Ala Lys Thr Cys Val Ala Asp Glu Ser 545 550 555 560 Ala Glu Asn Cys Asp Lys Ser Leu His Thr Leu Phe Gly Asp Lys Leu 565 570 575 Cys Thr Val Ala Thr Leu Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys 580 585 590 Cys Ala Lys Gln Glu Pro Glu Arg Asn Glu Cys Phe Leu Gln His Lys 595 600 605 Asp Asp Asn Pro Asn Leu Pro Arg Leu Val Arg Pro Glu Val Asp Val 610 615 620 Met Cys Thr Ala Phe His Asp Asn Glu Glu Thr Phe Leu Lys Lys Tyr 625 630 635 640 Leu Tyr Glu Ile Ala Arg Arg His Pro Tyr Phe Tyr Ala Pro Glu Leu 645 650 655 Leu Phe Phe Ala Lys Arg Tyr Lys Ala Ala Phe Thr Glu Cys Cys Gln 660 665 670 Ala Ala Asp Lys Ala Ala Cys Leu Leu Pro Lys Leu Asp Glu Leu Arg 675 680 685 Asp Glu Gly Lys Ala Ser Ser Ala Lys Gln Arg Leu Lys Cys Ala Ser 690 695 700 Leu Gln Lys Phe Gly Glu Arg Ala Phe Lys Ala Trp Ala Val Ala Arg 705 710 715 720 Leu Ser Gln Arg Phe Pro Lys Ala Glu Phe Ala Glu Val Ser Lys Leu 725 730 735 Val Thr Asp Leu Thr Lys Val His Thr Glu Cys Cys His Gly Asp Leu 740 745 750 Leu Glu Cys Ala Asp Asp Arg Ala Asp Leu Ala Lys Tyr Ile Cys Glu 755 760 765 Asn Gln Asp Ser Ile Ser Ser Lys Leu Lys Glu Cys Cys Glu Lys Pro 770 775 780 Leu Leu Glu Lys Ser His Cys Ile Ala Glu Val Glu Asn Asp Glu Met 785 790 795 800 Pro Ala Asp Leu Pro Ser Leu Ala Ala Asp Phe Val Glu Ser Lys Asp 805 810 815 Val Cys Lys Asn Tyr Ala Glu Ala Lys Asp Val Phe Leu Gly Met Phe 820 825 830 Leu Tyr Glu Tyr Ala Arg Arg His Pro Asp Tyr Ser Val Val Leu Leu 835 840 845 Leu Arg Leu Ala Lys Thr Tyr Glu Thr Thr Leu Glu Lys Cys Cys Ala 850 855 860 Ala Ala Asp Pro His Glu Cys Tyr Ala Lys Val Phe Asp Glu Phe Lys 865 870 875 880 Pro Leu Val Glu Glu Pro Gln Asn Leu Ile Lys Gln Asn Cys Glu Leu 885 890 895 Phe Glu Gln Leu Gly Glu Tyr Lys Phe Gln Asn Ala Leu Leu Val Arg 900 905 910 Tyr Thr Lys Lys Val Pro Gln Val Ser Thr Pro Thr Leu Val Glu Val 915 920 925 Ser Arg Asn Leu Gly Lys Val Gly Ser Lys Cys Cys Lys His Pro Glu 930 935 940 Ala Lys Arg Met Pro Cys Ala Glu Asp Tyr Leu Ser Val Val Leu Asn 945 950 955 960 Gln Leu Cys Val Leu His Glu Lys Thr Pro Val Ser Asp Arg Val Thr 965 970 975 Lys Cys Cys Thr Glu Ser Leu Val Asn Arg Arg Pro Cys Phe Ser Ala 980 985 990 Leu Glu Val Asp Glu Thr Tyr Val Pro Lys Glu Phe Asn Ala Glu Thr 995 1000 1005 Phe Thr Phe His Ala Asp Ile Cys Thr Leu Ser Glu Lys Glu Arg 1010 1015 1020 Gln Ile Lys Lys Gln Thr Ala Leu Val Glu Leu Val Lys His Lys 1025 1030 1035 Pro Lys Ala Thr Lys Glu Gln Leu Lys Ala Val Met Asp Asp Phe 1040 1045 1050 Ala Ala Phe Val Glu Lys Cys Cys Lys Ala Asp Asp Lys Glu Thr 1055 1060 1065 Cys Phe Ala Glu Glu Gly Lys Lys Leu Val Ala Ala Ser Gln Ala 1070 1075 1080 Ala Leu Gly Leu His His His His His His 1085 1090 <210> 228 <211> 1093 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 228 Gln Val Gln Leu Gln Glu Trp Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Ala Ser Ile Ser Ser Phe 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Tyr Tyr Ser Gly Thr Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Leu Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Ile Ala Val Ala Gly Phe Phe Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu 130 135 140 Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln 145 150 155 160 Ser Val Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 165 170 175 Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile 180 185 190 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 195 200 205 Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln 210 215 220 Tyr Asp Arg Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Asp Ile 225 230 235 240 Lys Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly 245 250 255 Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser 260 265 270 Gly Phe Thr Phe Asn Lys Tyr Ala Met Asn Trp Val Arg Gln Ala Pro 275 280 285 Gly Lys Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn 290 295 300 Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser 305 310 315 320 Arg Asp Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Asn Leu Lys 325 330 335 Thr Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn Phe Gly 340 345 350 Asn Ser Tyr Ile Ser Tyr Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val 355 360 365 Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 370 375 380 Gly Gly Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser 385 390 395 400 Pro Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val 405 410 415 Thr Ser Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala 420 425 430 Pro Arg Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro 435 440 445 Ala Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu 450 455 460 Ser Gly Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp 465 470 475 480 Tyr Ser Asn Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 485 490 495 Pro Gly Gly Gly Gly Ser Asp Ala His Lys Ser Glu Val Ala His Arg 500 505 510 Phe Lys Asp Leu Gly Glu Glu Asn Phe Lys Ala Leu Val Leu Ile Ala 515 520 525 Phe Ala Gln Tyr Leu Gln Gln Cys Pro Phe Glu Asp His Val Lys Leu 530 535 540 Val Asn Glu Val Thr Glu Phe Ala Lys Thr Cys Val Ala Asp Glu Ser 545 550 555 560 Ala Glu Asn Cys Asp Lys Ser Leu His Thr Leu Phe Gly Asp Lys Leu 565 570 575 Cys Thr Val Ala Thr Leu Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys 580 585 590 Cys Ala Lys Gln Glu Pro Glu Arg Asn Glu Cys Phe Leu Gln His Lys 595 600 605 Asp Asp Asn Pro Asn Leu Pro Arg Leu Val Arg Pro Glu Val Asp Val 610 615 620 Met Cys Thr Ala Phe His Asp Asn Glu Glu Thr Phe Leu Lys Lys Tyr 625 630 635 640 Leu Tyr Glu Ile Ala Arg Arg His Pro Tyr Phe Tyr Ala Pro Glu Leu 645 650 655 Leu Phe Phe Ala Lys Arg Tyr Lys Ala Ala Phe Thr Glu Cys Cys Gln 660 665 670 Ala Ala Asp Lys Ala Ala Cys Leu Leu Pro Lys Leu Asp Glu Leu Arg 675 680 685 Asp Glu Gly Lys Ala Ser Ser Ala Lys Gln Arg Leu Lys Cys Ala Ser 690 695 700 Leu Gln Lys Phe Gly Glu Arg Ala Phe Lys Ala Trp Ala Val Ala Arg 705 710 715 720 Leu Ser Gln Arg Phe Pro Lys Ala Glu Phe Ala Glu Val Ser Lys Leu 725 730 735 Val Thr Asp Leu Thr Lys Val His Thr Glu Cys Cys His Gly Asp Leu 740 745 750 Leu Glu Cys Ala Asp Asp Arg Ala Asp Leu Ala Lys Tyr Ile Cys Glu 755 760 765 Asn Gln Asp Ser Ile Ser Ser Lys Leu Lys Glu Cys Cys Glu Lys Pro 770 775 780 Leu Leu Glu Lys Ser His Cys Ile Ala Glu Val Glu Asn Asp Glu Met 785 790 795 800 Pro Ala Asp Leu Pro Ser Leu Ala Ala Asp Phe Val Glu Ser Lys Asp 805 810 815 Val Cys Lys Asn Tyr Ala Glu Ala Lys Asp Val Phe Leu Gly Met Phe 820 825 830 Leu Tyr Glu Tyr Ala Arg Arg His Pro Asp Tyr Ser Val Val Leu Leu 835 840 845 Leu Arg Leu Ala Lys Thr Tyr Glu Thr Thr Leu Glu Lys Cys Cys Ala 850 855 860 Ala Ala Asp Pro His Glu Cys Tyr Ala Lys Val Phe Asp Glu Phe Lys 865 870 875 880 Pro Leu Val Glu Glu Pro Gln Asn Leu Ile Lys Gln Asn Cys Glu Leu 885 890 895 Phe Glu Gln Leu Gly Glu Tyr Lys Phe Gln Asn Ala Leu Leu Val Arg 900 905 910 Tyr Thr Lys Lys Val Pro Gln Val Ser Thr Pro Thr Leu Val Glu Val 915 920 925 Ser Arg Asn Leu Gly Lys Val Gly Ser Lys Cys Cys Lys His Pro Glu 930 935 940 Ala Lys Arg Met Pro Cys Ala Glu Asp Tyr Leu Ser Val Val Leu Asn 945 950 955 960 Gln Leu Cys Val Leu His Glu Lys Thr Pro Val Ser Asp Arg Val Thr 965 970 975 Lys Cys Cys Thr Glu Ser Leu Val Asn Arg Arg Pro Cys Phe Ser Ala 980 985 990 Leu Glu Val Asp Glu Thr Tyr Val Pro Lys Glu Phe Asn Ala Glu Thr 995 1000 1005 Phe Thr Phe His Ala Asp Ile Cys Thr Leu Ser Glu Lys Glu Arg 1010 1015 1020 Gln Ile Lys Lys Gln Thr Ala Leu Val Glu Leu Val Lys His Lys 1025 1030 1035 Pro Lys Ala Thr Lys Glu Gln Leu Lys Ala Val Met Asp Asp Phe 1040 1045 1050 Ala Ala Phe Val Glu Lys Cys Cys Lys Ala Asp Asp Lys Glu Thr 1055 1060 1065 Cys Phe Ala Glu Glu Gly Lys Lys Leu Val Ala Ala Ser Gln Ala 1070 1075 1080 Ala Leu Gly Leu His His His His His His 1085 1090 <210> 229 <211> 1093 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 229 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Ala Ser Ile Ser Ser Phe 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Tyr Tyr Ser Gly Thr Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Ile Ala Val Ala Gly Phe Phe Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu 130 135 140 Ser Leu Ser Pro Gly Glu Ser Ala Thr Leu Ser Cys Arg Ala Ser Gln 145 150 155 160 Ser Val Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 165 170 175 Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile 180 185 190 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 195 200 205 Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln 210 215 220 Tyr Asp Arg Ser Pro Leu Thr Phe Gly Gly Gly Thr Arg Leu Glu Ile 225 230 235 240 Lys Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly 245 250 255 Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser 260 265 270 Gly Phe Thr Phe Asn Lys Tyr Ala Met Asn Trp Val Arg Gln Ala Pro 275 280 285 Gly Lys Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn 290 295 300 Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser 305 310 315 320 Arg Asp Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Asn Leu Lys 325 330 335 Thr Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn Phe Gly 340 345 350 Asn Ser Tyr Ile Ser Tyr Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val 355 360 365 Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 370 375 380 Gly Gly Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser 385 390 395 400 Pro Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val 405 410 415 Thr Ser Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala 420 425 430 Pro Arg Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro 435 440 445 Ala Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu 450 455 460 Ser Gly Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp 465 470 475 480 Tyr Ser Asn Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 485 490 495 Pro Gly Gly Gly Gly Ser Asp Ala His Lys Ser Glu Val Ala His Arg 500 505 510 Phe Lys Asp Leu Gly Glu Glu Asn Phe Lys Ala Leu Val Leu Ile Ala 515 520 525 Phe Ala Gln Tyr Leu Gln Gln Cys Pro Phe Glu Asp His Val Lys Leu 530 535 540 Val Asn Glu Val Thr Glu Phe Ala Lys Thr Cys Val Ala Asp Glu Ser 545 550 555 560 Ala Glu Asn Cys Asp Lys Ser Leu His Thr Leu Phe Gly Asp Lys Leu 565 570 575 Cys Thr Val Ala Thr Leu Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys 580 585 590 Cys Ala Lys Gln Glu Pro Glu Arg Asn Glu Cys Phe Leu Gln His Lys 595 600 605 Asp Asp Asn Pro Asn Leu Pro Arg Leu Val Arg Pro Glu Val Asp Val 610 615 620 Met Cys Thr Ala Phe His Asp Asn Glu Glu Thr Phe Leu Lys Lys Tyr 625 630 635 640 Leu Tyr Glu Ile Ala Arg Arg His Pro Tyr Phe Tyr Ala Pro Glu Leu 645 650 655 Leu Phe Phe Ala Lys Arg Tyr Lys Ala Ala Phe Thr Glu Cys Cys Gln 660 665 670 Ala Ala Asp Lys Ala Ala Cys Leu Leu Pro Lys Leu Asp Glu Leu Arg 675 680 685 Asp Glu Gly Lys Ala Ser Ser Ala Lys Gln Arg Leu Lys Cys Ala Ser 690 695 700 Leu Gln Lys Phe Gly Glu Arg Ala Phe Lys Ala Trp Ala Val Ala Arg 705 710 715 720 Leu Ser Gln Arg Phe Pro Lys Ala Glu Phe Ala Glu Val Ser Lys Leu 725 730 735 Val Thr Asp Leu Thr Lys Val His Thr Glu Cys Cys His Gly Asp Leu 740 745 750 Leu Glu Cys Ala Asp Asp Arg Ala Asp Leu Ala Lys Tyr Ile Cys Glu 755 760 765 Asn Gln Asp Ser Ile Ser Ser Lys Leu Lys Glu Cys Cys Glu Lys Pro 770 775 780 Leu Leu Glu Lys Ser His Cys Ile Ala Glu Val Glu Asn Asp Glu Met 785 790 795 800 Pro Ala Asp Leu Pro Ser Leu Ala Ala Asp Phe Val Glu Ser Lys Asp 805 810 815 Val Cys Lys Asn Tyr Ala Glu Ala Lys Asp Val Phe Leu Gly Met Phe 820 825 830 Leu Tyr Glu Tyr Ala Arg Arg His Pro Asp Tyr Ser Val Val Leu Leu 835 840 845 Leu Arg Leu Ala Lys Thr Tyr Glu Thr Thr Leu Glu Lys Cys Cys Ala 850 855 860 Ala Ala Asp Pro His Glu Cys Tyr Ala Lys Val Phe Asp Glu Phe Lys 865 870 875 880 Pro Leu Val Glu Glu Pro Gln Asn Leu Ile Lys Gln Asn Cys Glu Leu 885 890 895 Phe Glu Gln Leu Gly Glu Tyr Lys Phe Gln Asn Ala Leu Leu Val Arg 900 905 910 Tyr Thr Lys Lys Val Pro Gln Val Ser Thr Pro Thr Leu Val Glu Val 915 920 925 Ser Arg Asn Leu Gly Lys Val Gly Ser Lys Cys Cys Lys His Pro Glu 930 935 940 Ala Lys Arg Met Pro Cys Ala Glu Asp Tyr Leu Ser Val Val Leu Asn 945 950 955 960 Gln Leu Cys Val Leu His Glu Lys Thr Pro Val Ser Asp Arg Val Thr 965 970 975 Lys Cys Cys Thr Glu Ser Leu Val Asn Arg Arg Pro Cys Phe Ser Ala 980 985 990 Leu Glu Val Asp Glu Thr Tyr Val Pro Lys Glu Phe Asn Ala Glu Thr 995 1000 1005 Phe Thr Phe His Ala Asp Ile Cys Thr Leu Ser Glu Lys Glu Arg 1010 1015 1020 Gln Ile Lys Lys Gln Thr Ala Leu Val Glu Leu Val Lys His Lys 1025 1030 1035 Pro Lys Ala Thr Lys Glu Gln Leu Lys Ala Val Met Asp Asp Phe 1040 1045 1050 Ala Ala Phe Val Glu Lys Cys Cys Lys Ala Asp Asp Lys Glu Thr 1055 1060 1065 Cys Phe Ala Glu Glu Gly Lys Lys Leu Val Ala Ala Ser Gln Ala 1070 1075 1080 Ala Leu Gly Leu His His His His His His 1085 1090 <210> 230 <211> 1093 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 230 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Phe Tyr Asn Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Leu Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Lys Tyr Tyr Cys Ala 85 90 95 Arg Ile His Ser Gly Ser Phe Ser Phe Asp Tyr Trp Asp Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Glu Ile Val Met Thr Gln Ser Pro Gly Thr Leu 130 135 140 Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln 145 150 155 160 Ser Val Ser Arg Gly Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 165 170 175 Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Asp Ile 180 185 190 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 195 200 205 Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln 210 215 220 Tyr Asp Thr Ser Pro Ile Thr Phe Gly Gln Gly Thr Lys Val Glu Ile 225 230 235 240 Lys Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly 245 250 255 Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser 260 265 270 Gly Phe Thr Phe Asn Lys Tyr Ala Met Asn Trp Val Arg Gln Ala Pro 275 280 285 Gly Lys Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn 290 295 300 Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser 305 310 315 320 Arg Asp Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Asn Leu Lys 325 330 335 Thr Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn Phe Gly 340 345 350 Asn Ser Tyr Ile Ser Tyr Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val 355 360 365 Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 370 375 380 Gly Gly Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser 385 390 395 400 Pro Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val 405 410 415 Thr Ser Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala 420 425 430 Pro Arg Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro 435 440 445 Ala Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu 450 455 460 Ser Gly Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp 465 470 475 480 Tyr Ser Asn Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 485 490 495 Pro Gly Gly Gly Gly Ser Asp Ala His Lys Ser Glu Val Ala His Arg 500 505 510 Phe Lys Asp Leu Gly Glu Glu Asn Phe Lys Ala Leu Val Leu Ile Ala 515 520 525 Phe Ala Gln Tyr Leu Gln Gln Cys Pro Phe Glu Asp His Val Lys Leu 530 535 540 Val Asn Glu Val Thr Glu Phe Ala Lys Thr Cys Val Ala Asp Glu Ser 545 550 555 560 Ala Glu Asn Cys Asp Lys Ser Leu His Thr Leu Phe Gly Asp Lys Leu 565 570 575 Cys Thr Val Ala Thr Leu Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys 580 585 590 Cys Ala Lys Gln Glu Pro Glu Arg Asn Glu Cys Phe Leu Gln His Lys 595 600 605 Asp Asp Asn Pro Asn Leu Pro Arg Leu Val Arg Pro Glu Val Asp Val 610 615 620 Met Cys Thr Ala Phe His Asp Asn Glu Glu Thr Phe Leu Lys Lys Tyr 625 630 635 640 Leu Tyr Glu Ile Ala Arg Arg His Pro Tyr Phe Tyr Ala Pro Glu Leu 645 650 655 Leu Phe Phe Ala Lys Arg Tyr Lys Ala Ala Phe Thr Glu Cys Cys Gln 660 665 670 Ala Ala Asp Lys Ala Ala Cys Leu Leu Pro Lys Leu Asp Glu Leu Arg 675 680 685 Asp Glu Gly Lys Ala Ser Ser Ala Lys Gln Arg Leu Lys Cys Ala Ser 690 695 700 Leu Gln Lys Phe Gly Glu Arg Ala Phe Lys Ala Trp Ala Val Ala Arg 705 710 715 720 Leu Ser Gln Arg Phe Pro Lys Ala Glu Phe Ala Glu Val Ser Lys Leu 725 730 735 Val Thr Asp Leu Thr Lys Val His Thr Glu Cys Cys His Gly Asp Leu 740 745 750 Leu Glu Cys Ala Asp Asp Arg Ala Asp Leu Ala Lys Tyr Ile Cys Glu 755 760 765 Asn Gln Asp Ser Ile Ser Ser Lys Leu Lys Glu Cys Cys Glu Lys Pro 770 775 780 Leu Leu Glu Lys Ser His Cys Ile Ala Glu Val Glu Asn Asp Glu Met 785 790 795 800 Pro Ala Asp Leu Pro Ser Leu Ala Ala Asp Phe Val Glu Ser Lys Asp 805 810 815 Val Cys Lys Asn Tyr Ala Glu Ala Lys Asp Val Phe Leu Gly Met Phe 820 825 830 Leu Tyr Glu Tyr Ala Arg Arg His Pro Asp Tyr Ser Val Val Leu Leu 835 840 845 Leu Arg Leu Ala Lys Thr Tyr Glu Thr Thr Leu Glu Lys Cys Cys Ala 850 855 860 Ala Ala Asp Pro His Glu Cys Tyr Ala Lys Val Phe Asp Glu Phe Lys 865 870 875 880 Pro Leu Val Glu Glu Pro Gln Asn Leu Ile Lys Gln Asn Cys Glu Leu 885 890 895 Phe Glu Gln Leu Gly Glu Tyr Lys Phe Gln Asn Ala Leu Leu Val Arg 900 905 910 Tyr Thr Lys Lys Val Pro Gln Val Ser Thr Pro Thr Leu Val Glu Val 915 920 925 Ser Arg Asn Leu Gly Lys Val Gly Ser Lys Cys Cys Lys His Pro Glu 930 935 940 Ala Lys Arg Met Pro Cys Ala Glu Asp Tyr Leu Ser Val Val Leu Asn 945 950 955 960 Gln Leu Cys Val Leu His Glu Lys Thr Pro Val Ser Asp Arg Val Thr 965 970 975 Lys Cys Cys Thr Glu Ser Leu Val Asn Arg Arg Pro Cys Phe Ser Ala 980 985 990 Leu Glu Val Asp Glu Thr Tyr Val Pro Lys Glu Phe Asn Ala Glu Thr 995 1000 1005 Phe Thr Phe His Ala Asp Ile Cys Thr Leu Ser Glu Lys Glu Arg 1010 1015 1020 Gln Ile Lys Lys Gln Thr Ala Leu Val Glu Leu Val Lys His Lys 1025 1030 1035 Pro Lys Ala Thr Lys Glu Gln Leu Lys Ala Val Met Asp Asp Phe 1040 1045 1050 Ala Ala Phe Val Glu Lys Cys Cys Lys Ala Asp Asp Lys Glu Thr 1055 1060 1065 Cys Phe Ala Glu Glu Gly Lys Lys Leu Val Ala Ala Ser Gln Ala 1070 1075 1080 Ala Leu Gly Leu His His His His His His 1085 1090 <210> 231 <211> 1100 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 231 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Phe Asn Asn Ala 20 25 30 Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Gly Arg Ile Lys Asn Lys Ile Asp Gly Gly Thr Thr Asp Phe Ala Ala 50 55 60 Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 65 70 75 80 Leu Tyr Leu Gln Met Asn Ser Leu Lys Ala Glu Asp Thr Ala Val Tyr 85 90 95 Tyr Cys Thr Ala Arg Gly Trp Tyr Gly Asp Tyr Phe Asp Tyr Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly 115 120 125 Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Val Met Thr Gln Thr Pro 130 135 140 Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg 145 150 155 160 Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp Trp 165 170 175 Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly 180 185 190 Ser Asn Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser 195 200 205 Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val 210 215 220 Gly Ile Tyr Tyr Cys Met Gln Ala Leu Gln Thr Pro Phe Thr Phe Gly 225 230 235 240 Pro Gly Thr Lys Val Glu Ile Lys Ser Gly Gly Gly Gly Ser Glu Val 245 250 255 Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu 260 265 270 Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys Tyr Ala Met 275 280 285 Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Arg 290 295 300 Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser Val 305 310 315 320 Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Ala Tyr 325 330 335 Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys 340 345 350 Val Arg His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr Trp Ala Tyr 355 360 365 Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser 370 375 380 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val Thr Gln 385 390 395 400 Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu Thr Cys 405 410 415 Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro Asn Trp Val 420 425 430 Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly Thr Lys 435 440 445 Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu Leu Gly 450 455 460 Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp Glu Ala 465 470 475 480 Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val Phe Gly Gly 485 490 495 Gly Thr Lys Leu Thr Val Leu Pro Gly Gly Gly Gly Ser Asp Ala His 500 505 510 Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu Glu Asn Phe 515 520 525 Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln Gln Cys Pro 530 535 540 Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu Phe Ala Lys 545 550 555 560 Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys Ser Leu His 565 570 575 Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu Arg Glu Thr 580 585 590 Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro Glu Arg Asn 595 600 605 Glu Cys Phe Leu Gln His Lys Asp Asp Asn Pro Asn Leu Pro Arg Leu 610 615 620 Val Arg Pro Glu Val Asp Val Met Cys Thr Ala Phe His Asp Asn Glu 625 630 635 640 Glu Thr Phe Leu Lys Lys Tyr Leu Tyr Glu Ile Ala Arg Arg His Pro 645 650 655 Tyr Phe Tyr Ala Pro Glu Leu Leu Phe Phe Ala Lys Arg Tyr Lys Ala 660 665 670 Ala Phe Thr Glu Cys Cys Gln Ala Ala Asp Lys Ala Ala Cys Leu Leu 675 680 685 Pro Lys Leu Asp Glu Leu Arg Asp Glu Gly Lys Ala Ser Ser Ala Lys 690 695 700 Gln Arg Leu Lys Cys Ala Ser Leu Gln Lys Phe Gly Glu Arg Ala Phe 705 710 715 720 Lys Ala Trp Ala Val Ala Arg Leu Ser Gln Arg Phe Pro Lys Ala Glu 725 730 735 Phe Ala Glu Val Ser Lys Leu Val Thr Asp Leu Thr Lys Val His Thr 740 745 750 Glu Cys Cys His Gly Asp Leu Leu Glu Cys Ala Asp Asp Arg Ala Asp 755 760 765 Leu Ala Lys Tyr Ile Cys Glu Asn Gln Asp Ser Ile Ser Ser Lys Leu 770 775 780 Lys Glu Cys Cys Glu Lys Pro Leu Leu Glu Lys Ser His Cys Ile Ala 785 790 795 800 Glu Val Glu Asn Asp Glu Met Pro Ala Asp Leu Pro Ser Leu Ala Ala 805 810 815 Asp Phe Val Glu Ser Lys Asp Val Cys Lys Asn Tyr Ala Glu Ala Lys 820 825 830 Asp Val Phe Leu Gly Met Phe Leu Tyr Glu Tyr Ala Arg Arg His Pro 835 840 845 Asp Tyr Ser Val Val Leu Leu Leu Arg Leu Ala Lys Thr Tyr Glu Thr 850 855 860 Thr Leu Glu Lys Cys Cys Ala Ala Ala Asp Pro His Glu Cys Tyr Ala 865 870 875 880 Lys Val Phe Asp Glu Phe Lys Pro Leu Val Glu Glu Pro Gln Asn Leu 885 890 895 Ile Lys Gln Asn Cys Glu Leu Phe Glu Gln Leu Gly Glu Tyr Lys Phe 900 905 910 Gln Asn Ala Leu Leu Val Arg Tyr Thr Lys Lys Val Pro Gln Val Ser 915 920 925 Thr Pro Thr Leu Val Glu Val Ser Arg Asn Leu Gly Lys Val Gly Ser 930 935 940 Lys Cys Cys Lys His Pro Glu Ala Lys Arg Met Pro Cys Ala Glu Asp 945 950 955 960 Tyr Leu Ser Val Val Leu Asn Gln Leu Cys Val Leu His Glu Lys Thr 965 970 975 Pro Val Ser Asp Arg Val Thr Lys Cys Cys Thr Glu Ser Leu Val Asn 980 985 990 Arg Arg Pro Cys Phe Ser Ala Leu Glu Val Asp Glu Thr Tyr Val Pro 995 1000 1005 Lys Glu Phe Asn Ala Glu Thr Phe Thr Phe His Ala Asp Ile Cys 1010 1015 1020 Thr Leu Ser Glu Lys Glu Arg Gln Ile Lys Lys Gln Thr Ala Leu 1025 1030 1035 Val Glu Leu Val Lys His Lys Pro Lys Ala Thr Lys Glu Gln Leu 1040 1045 1050 Lys Ala Val Met Asp Asp Phe Ala Ala Phe Val Glu Lys Cys Cys 1055 1060 1065 Lys Ala Asp Asp Lys Glu Thr Cys Phe Ala Glu Glu Gly Lys Lys 1070 1075 1080 Leu Val Ala Ala Ser Gln Ala Ala Leu Gly Leu His His His His 1085 1090 1095 His His 1100 <210> 232 <211> 1101 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 232 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Ser Tyr 20 25 30 Asp Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Ile Ser Ser His Gly Ser Asn Lys Asn Tyr Ala Arg Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Lys Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Gly Tyr Ser Gly Asn Asp Pro Phe Tyr Tyr Tyr Tyr His 100 105 110 Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly 115 120 125 Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile 130 135 140 Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg 145 150 155 160 Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn 165 170 175 Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala 180 185 190 Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly 195 200 205 Ser Gly Thr Asp Phe Ser Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp 210 215 220 Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Phe Thr Thr Pro Leu Thr Phe 225 230 235 240 Gly Gly Gly Thr Lys Val Glu Ile Lys Ser Gly Gly Gly Gly Ser Glu 245 250 255 Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser 260 265 270 Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys Tyr Ala 275 280 285 Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala 290 295 300 Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser 305 310 315 320 Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Ala 325 330 335 Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr 340 345 350 Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr Trp Ala 355 360 365 Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly 370 375 380 Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val Thr 385 390 395 400 Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu Thr 405 410 415 Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro Asn Trp 420 425 430 Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly Thr 435 440 445 Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu Leu 450 455 460 Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp Glu 465 470 475 480 Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val Phe Gly 485 490 495 Gly Gly Thr Lys Leu Thr Val Leu Pro Gly Gly Gly Gly Ser Asp Ala 500 505 510 His Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu Glu Asn 515 520 525 Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln Gln Cys 530 535 540 Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu Phe Ala 545 550 555 560 Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys Ser Leu 565 570 575 His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu Arg Glu 580 585 590 Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro Glu Arg 595 600 605 Asn Glu Cys Phe Leu Gln His Lys Asp Asp Asn Pro Asn Leu Pro Arg 610 615 620 Leu Val Arg Pro Glu Val Asp Val Met Cys Thr Ala Phe His Asp Asn 625 630 635 640 Glu Glu Thr Phe Leu Lys Lys Tyr Leu Tyr Glu Ile Ala Arg Arg His 645 650 655 Pro Tyr Phe Tyr Ala Pro Glu Leu Leu Phe Phe Ala Lys Arg Tyr Lys 660 665 670 Ala Ala Phe Thr Glu Cys Cys Gln Ala Ala Asp Lys Ala Ala Cys Leu 675 680 685 Leu Pro Lys Leu Asp Glu Leu Arg Asp Glu Gly Lys Ala Ser Ser Ala 690 695 700 Lys Gln Arg Leu Lys Cys Ala Ser Leu Gln Lys Phe Gly Glu Arg Ala 705 710 715 720 Phe Lys Ala Trp Ala Val Ala Arg Leu Ser Gln Arg Phe Pro Lys Ala 725 730 735 Glu Phe Ala Glu Val Ser Lys Leu Val Thr Asp Leu Thr Lys Val His 740 745 750 Thr Glu Cys Cys His Gly Asp Leu Leu Glu Cys Ala Asp Asp Arg Ala 755 760 765 Asp Leu Ala Lys Tyr Ile Cys Glu Asn Gln Asp Ser Ile Ser Ser Lys 770 775 780 Leu Lys Glu Cys Cys Glu Lys Pro Leu Leu Glu Lys Ser His Cys Ile 785 790 795 800 Ala Glu Val Glu Asn Asp Glu Met Pro Ala Asp Leu Pro Ser Leu Ala 805 810 815 Ala Asp Phe Val Glu Ser Lys Asp Val Cys Lys Asn Tyr Ala Glu Ala 820 825 830 Lys Asp Val Phe Leu Gly Met Phe Leu Tyr Glu Tyr Ala Arg Arg His 835 840 845 Pro Asp Tyr Ser Val Val Leu Leu Leu Arg Leu Ala Lys Thr Tyr Glu 850 855 860 Thr Thr Leu Glu Lys Cys Cys Ala Ala Ala Asp Pro His Glu Cys Tyr 865 870 875 880 Ala Lys Val Phe Asp Glu Phe Lys Pro Leu Val Glu Glu Pro Gln Asn 885 890 895 Leu Ile Lys Gln Asn Cys Glu Leu Phe Glu Gln Leu Gly Glu Tyr Lys 900 905 910 Phe Gln Asn Ala Leu Leu Val Arg Tyr Thr Lys Lys Val Pro Gln Val 915 920 925 Ser Thr Pro Thr Leu Val Glu Val Ser Arg Asn Leu Gly Lys Val Gly 930 935 940 Ser Lys Cys Cys Lys His Pro Glu Ala Lys Arg Met Pro Cys Ala Glu 945 950 955 960 Asp Tyr Leu Ser Val Val Leu Asn Gln Leu Cys Val Leu His Glu Lys 965 970 975 Thr Pro Val Ser Asp Arg Val Thr Lys Cys Cys Thr Glu Ser Leu Val 980 985 990 Asn Arg Arg Pro Cys Phe Ser Ala Leu Glu Val Asp Glu Thr Tyr Val 995 1000 1005 Pro Lys Glu Phe Asn Ala Glu Thr Phe Thr Phe His Ala Asp Ile 1010 1015 1020 Cys Thr Leu Ser Glu Lys Glu Arg Gln Ile Lys Lys Gln Thr Ala 1025 1030 1035 Leu Val Glu Leu Val Lys His Lys Pro Lys Ala Thr Lys Glu Gln 1040 1045 1050 Leu Lys Ala Val Met Asp Asp Phe Ala Ala Phe Val Glu Lys Cys 1055 1060 1065 Cys Lys Ala Asp Asp Lys Glu Thr Cys Phe Ala Glu Glu Gly Lys 1070 1075 1080 Lys Leu Val Ala Ala Ser Gln Ala Ala Leu Gly Leu His His His 1085 1090 1095 His His His 1100 <210> 233 <211> 1102 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 233 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Asp Gly Ser Thr Asn Tyr Ala Gln Asn Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln 130 135 140 Ser Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser 145 150 155 160 Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg Asp Gly Asn Thr Tyr Leu 165 170 175 Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr 180 185 190 Lys Val Ser Asn Trp Gln Ser Gly Val Pro Asp Arg Phe Ser Gly Ser 195 200 205 Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu 210 215 220 Asp Val Gly Val Tyr Phe Cys Met Gln Gly Thr His Trp Pro Pro Thr 225 230 235 240 Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Ser Gly Gly Gly Gly Ser 245 250 255 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 260 265 270 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys Tyr 275 280 285 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 290 295 300 Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 305 310 315 320 Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 325 330 335 Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr 340 345 350 Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr Trp 355 360 365 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 370 375 380 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val 385 390 395 400 Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu 405 410 415 Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro Asn 420 425 430 Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly 435 440 445 Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu 450 455 460 Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp 465 470 475 480 Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val Phe 485 490 495 Gly Gly Gly Thr Lys Leu Thr Val Leu Pro Gly Gly Gly Gly Ser Asp 500 505 510 Ala His Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu Glu 515 520 525 Asn Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln Gln 530 535 540 Cys Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu Phe 545 550 555 560 Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys Ser 565 570 575 Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu Arg 580 585 590 Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro Glu 595 600 605 Arg Asn Glu Cys Phe Leu Gln His Lys Asp Asp Asn Pro Asn Leu Pro 610 615 620 Arg Leu Val Arg Pro Glu Val Asp Val Met Cys Thr Ala Phe His Asp 625 630 635 640 Asn Glu Glu Thr Phe Leu Lys Lys Tyr Leu Tyr Glu Ile Ala Arg Arg 645 650 655 His Pro Tyr Phe Tyr Ala Pro Glu Leu Leu Phe Phe Ala Lys Arg Tyr 660 665 670 Lys Ala Ala Phe Thr Glu Cys Cys Gln Ala Ala Asp Lys Ala Ala Cys 675 680 685 Leu Leu Pro Lys Leu Asp Glu Leu Arg Asp Glu Gly Lys Ala Ser Ser 690 695 700 Ala Lys Gln Arg Leu Lys Cys Ala Ser Leu Gln Lys Phe Gly Glu Arg 705 710 715 720 Ala Phe Lys Ala Trp Ala Val Ala Arg Leu Ser Gln Arg Phe Pro Lys 725 730 735 Ala Glu Phe Ala Glu Val Ser Lys Leu Val Thr Asp Leu Thr Lys Val 740 745 750 His Thr Glu Cys Cys His Gly Asp Leu Leu Glu Cys Ala Asp Asp Arg 755 760 765 Ala Asp Leu Ala Lys Tyr Ile Cys Glu Asn Gln Asp Ser Ile Ser Ser 770 775 780 Lys Leu Lys Glu Cys Cys Glu Lys Pro Leu Leu Glu Lys Ser His Cys 785 790 795 800 Ile Ala Glu Val Glu Asn Asp Glu Met Pro Ala Asp Leu Pro Ser Leu 805 810 815 Ala Ala Asp Phe Val Glu Ser Lys Asp Val Cys Lys Asn Tyr Ala Glu 820 825 830 Ala Lys Asp Val Phe Leu Gly Met Phe Leu Tyr Glu Tyr Ala Arg Arg 835 840 845 His Pro Asp Tyr Ser Val Val Leu Leu Leu Arg Leu Ala Lys Thr Tyr 850 855 860 Glu Thr Thr Leu Glu Lys Cys Cys Ala Ala Ala Asp Pro His Glu Cys 865 870 875 880 Tyr Ala Lys Val Phe Asp Glu Phe Lys Pro Leu Val Glu Glu Pro Gln 885 890 895 Asn Leu Ile Lys Gln Asn Cys Glu Leu Phe Glu Gln Leu Gly Glu Tyr 900 905 910 Lys Phe Gln Asn Ala Leu Leu Val Arg Tyr Thr Lys Lys Val Pro Gln 915 920 925 Val Ser Thr Pro Thr Leu Val Glu Val Ser Arg Asn Leu Gly Lys Val 930 935 940 Gly Ser Lys Cys Cys Lys His Pro Glu Ala Lys Arg Met Pro Cys Ala 945 950 955 960 Glu Asp Tyr Leu Ser Val Val Leu Asn Gln Leu Cys Val Leu His Glu 965 970 975 Lys Thr Pro Val Ser Asp Arg Val Thr Lys Cys Cys Thr Glu Ser Leu 980 985 990 Val Asn Arg Arg Pro Cys Phe Ser Ala Leu Glu Val Asp Glu Thr Tyr 995 1000 1005 Val Pro Lys Glu Phe Asn Ala Glu Thr Phe Thr Phe His Ala Asp 1010 1015 1020 Ile Cys Thr Leu Ser Glu Lys Glu Arg Gln Ile Lys Lys Gln Thr 1025 1030 1035 Ala Leu Val Glu Leu Val Lys His Lys Pro Lys Ala Thr Lys Glu 1040 1045 1050 Gln Leu Lys Ala Val Met Asp Asp Phe Ala Ala Phe Val Glu Lys 1055 1060 1065 Cys Cys Lys Ala Asp Asp Lys Glu Thr Cys Phe Ala Glu Glu Gly 1070 1075 1080 Lys Lys Leu Val Ala Ala Ser Gln Ala Ala Leu Gly Leu His His 1085 1090 1095 His His His His 1100 <210> 234 <211> 1102 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 234 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Leu Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Asp Gly Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Asp Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln 130 135 140 Thr Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser 145 150 155 160 Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg Asp Gly Asn Thr Tyr Leu 165 170 175 Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr 180 185 190 Lys Val Ser Asn Trp Gln Ser Gly Val Pro Asp Arg Phe Ser Gly Gly 195 200 205 Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu 210 215 220 Asp Val Gly Val Tyr Tyr Cys Met Gln Gly Thr His Trp Pro Pro Thr 225 230 235 240 Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Ser Gly Gly Gly Gly Ser 245 250 255 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 260 265 270 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys Tyr 275 280 285 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 290 295 300 Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 305 310 315 320 Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 325 330 335 Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr 340 345 350 Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr Trp 355 360 365 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 370 375 380 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val 385 390 395 400 Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu 405 410 415 Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro Asn 420 425 430 Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly 435 440 445 Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu 450 455 460 Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp 465 470 475 480 Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val Phe 485 490 495 Gly Gly Gly Thr Lys Leu Thr Val Leu Pro Gly Gly Gly Gly Ser Asp 500 505 510 Ala His Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu Glu 515 520 525 Asn Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln Gln 530 535 540 Cys Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu Phe 545 550 555 560 Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys Ser 565 570 575 Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu Arg 580 585 590 Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro Glu 595 600 605 Arg Asn Glu Cys Phe Leu Gln His Lys Asp Asp Asn Pro Asn Leu Pro 610 615 620 Arg Leu Val Arg Pro Glu Val Asp Val Met Cys Thr Ala Phe His Asp 625 630 635 640 Asn Glu Glu Thr Phe Leu Lys Lys Tyr Leu Tyr Glu Ile Ala Arg Arg 645 650 655 His Pro Tyr Phe Tyr Ala Pro Glu Leu Leu Phe Phe Ala Lys Arg Tyr 660 665 670 Lys Ala Ala Phe Thr Glu Cys Cys Gln Ala Ala Asp Lys Ala Ala Cys 675 680 685 Leu Leu Pro Lys Leu Asp Glu Leu Arg Asp Glu Gly Lys Ala Ser Ser 690 695 700 Ala Lys Gln Arg Leu Lys Cys Ala Ser Leu Gln Lys Phe Gly Glu Arg 705 710 715 720 Ala Phe Lys Ala Trp Ala Val Ala Arg Leu Ser Gln Arg Phe Pro Lys 725 730 735 Ala Glu Phe Ala Glu Val Ser Lys Leu Val Thr Asp Leu Thr Lys Val 740 745 750 His Thr Glu Cys Cys His Gly Asp Leu Leu Glu Cys Ala Asp Asp Arg 755 760 765 Ala Asp Leu Ala Lys Tyr Ile Cys Glu Asn Gln Asp Ser Ile Ser Ser 770 775 780 Lys Leu Lys Glu Cys Cys Glu Lys Pro Leu Leu Glu Lys Ser His Cys 785 790 795 800 Ile Ala Glu Val Glu Asn Asp Glu Met Pro Ala Asp Leu Pro Ser Leu 805 810 815 Ala Ala Asp Phe Val Glu Ser Lys Asp Val Cys Lys Asn Tyr Ala Glu 820 825 830 Ala Lys Asp Val Phe Leu Gly Met Phe Leu Tyr Glu Tyr Ala Arg Arg 835 840 845 His Pro Asp Tyr Ser Val Val Leu Leu Leu Arg Leu Ala Lys Thr Tyr 850 855 860 Glu Thr Thr Leu Glu Lys Cys Cys Ala Ala Ala Asp Pro His Glu Cys 865 870 875 880 Tyr Ala Lys Val Phe Asp Glu Phe Lys Pro Leu Val Glu Glu Pro Gln 885 890 895 Asn Leu Ile Lys Gln Asn Cys Glu Leu Phe Glu Gln Leu Gly Glu Tyr 900 905 910 Lys Phe Gln Asn Ala Leu Leu Val Arg Tyr Thr Lys Lys Val Pro Gln 915 920 925 Val Ser Thr Pro Thr Leu Val Glu Val Ser Arg Asn Leu Gly Lys Val 930 935 940 Gly Ser Lys Cys Cys Lys His Pro Glu Ala Lys Arg Met Pro Cys Ala 945 950 955 960 Glu Asp Tyr Leu Ser Val Val Leu Asn Gln Leu Cys Val Leu His Glu 965 970 975 Lys Thr Pro Val Ser Asp Arg Val Thr Lys Cys Cys Thr Glu Ser Leu 980 985 990 Val Asn Arg Arg Pro Cys Phe Ser Ala Leu Glu Val Asp Glu Thr Tyr 995 1000 1005 Val Pro Lys Glu Phe Asn Ala Glu Thr Phe Thr Phe His Ala Asp 1010 1015 1020 Ile Cys Thr Leu Ser Glu Lys Glu Arg Gln Ile Lys Lys Gln Thr 1025 1030 1035 Ala Leu Val Glu Leu Val Lys His Lys Pro Lys Ala Thr Lys Glu 1040 1045 1050 Gln Leu Lys Ala Val Met Asp Asp Phe Ala Ala Phe Val Glu Lys 1055 1060 1065 Cys Cys Lys Ala Asp Asp Lys Glu Thr Cys Phe Ala Glu Glu Gly 1070 1075 1080 Lys Lys Leu Val Ala Ala Ser Gln Ala Ala Leu Gly Leu His His 1085 1090 1095 His His His His 1100 <210> 235 <211> 1102 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 235 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr 20 25 30 Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Asp Gly Ser Thr Ser Tyr Gly Gln Asn Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln 130 135 140 Ser Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser 145 150 155 160 Cys Arg Ser Ser Gln Ser Leu Ala Tyr Arg Asp Gly Asn Thr Tyr Leu 165 170 175 Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr 180 185 190 Lys Val Ser Asn Trp Gln Ser Gly Val Pro Asp Arg Phe Ser Gly Ser 195 200 205 Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu 210 215 220 Asp Val Gly Val Tyr Phe Cys Met Gln Gly Thr His Trp Pro Pro Thr 225 230 235 240 Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Ser Gly Gly Gly Gly Ser 245 250 255 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 260 265 270 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys Tyr 275 280 285 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 290 295 300 Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 305 310 315 320 Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 325 330 335 Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr 340 345 350 Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr Trp 355 360 365 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 370 375 380 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val 385 390 395 400 Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu 405 410 415 Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro Asn 420 425 430 Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly 435 440 445 Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu 450 455 460 Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp 465 470 475 480 Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val Phe 485 490 495 Gly Gly Gly Thr Lys Leu Thr Val Leu Pro Gly Gly Gly Gly Ser Asp 500 505 510 Ala His Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu Glu 515 520 525 Asn Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln Gln 530 535 540 Cys Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu Phe 545 550 555 560 Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys Ser 565 570 575 Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu Arg 580 585 590 Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro Glu 595 600 605 Arg Asn Glu Cys Phe Leu Gln His Lys Asp Asp Asn Pro Asn Leu Pro 610 615 620 Arg Leu Val Arg Pro Glu Val Asp Val Met Cys Thr Ala Phe His Asp 625 630 635 640 Asn Glu Glu Thr Phe Leu Lys Lys Tyr Leu Tyr Glu Ile Ala Arg Arg 645 650 655 His Pro Tyr Phe Tyr Ala Pro Glu Leu Leu Phe Phe Ala Lys Arg Tyr 660 665 670 Lys Ala Ala Phe Thr Glu Cys Cys Gln Ala Ala Asp Lys Ala Ala Cys 675 680 685 Leu Leu Pro Lys Leu Asp Glu Leu Arg Asp Glu Gly Lys Ala Ser Ser 690 695 700 Ala Lys Gln Arg Leu Lys Cys Ala Ser Leu Gln Lys Phe Gly Glu Arg 705 710 715 720 Ala Phe Lys Ala Trp Ala Val Ala Arg Leu Ser Gln Arg Phe Pro Lys 725 730 735 Ala Glu Phe Ala Glu Val Ser Lys Leu Val Thr Asp Leu Thr Lys Val 740 745 750 His Thr Glu Cys Cys His Gly Asp Leu Leu Glu Cys Ala Asp Asp Arg 755 760 765 Ala Asp Leu Ala Lys Tyr Ile Cys Glu Asn Gln Asp Ser Ile Ser Ser 770 775 780 Lys Leu Lys Glu Cys Cys Glu Lys Pro Leu Leu Glu Lys Ser His Cys 785 790 795 800 Ile Ala Glu Val Glu Asn Asp Glu Met Pro Ala Asp Leu Pro Ser Leu 805 810 815 Ala Ala Asp Phe Val Glu Ser Lys Asp Val Cys Lys Asn Tyr Ala Glu 820 825 830 Ala Lys Asp Val Phe Leu Gly Met Phe Leu Tyr Glu Tyr Ala Arg Arg 835 840 845 His Pro Asp Tyr Ser Val Val Leu Leu Leu Arg Leu Ala Lys Thr Tyr 850 855 860 Glu Thr Thr Leu Glu Lys Cys Cys Ala Ala Ala Asp Pro His Glu Cys 865 870 875 880 Tyr Ala Lys Val Phe Asp Glu Phe Lys Pro Leu Val Glu Glu Pro Gln 885 890 895 Asn Leu Ile Lys Gln Asn Cys Glu Leu Phe Glu Gln Leu Gly Glu Tyr 900 905 910 Lys Phe Gln Asn Ala Leu Leu Val Arg Tyr Thr Lys Lys Val Pro Gln 915 920 925 Val Ser Thr Pro Thr Leu Val Glu Val Ser Arg Asn Leu Gly Lys Val 930 935 940 Gly Ser Lys Cys Cys Lys His Pro Glu Ala Lys Arg Met Pro Cys Ala 945 950 955 960 Glu Asp Tyr Leu Ser Val Val Leu Asn Gln Leu Cys Val Leu His Glu 965 970 975 Lys Thr Pro Val Ser Asp Arg Val Thr Lys Cys Cys Thr Glu Ser Leu 980 985 990 Val Asn Arg Arg Pro Cys Phe Ser Ala Leu Glu Val Asp Glu Thr Tyr 995 1000 1005 Val Pro Lys Glu Phe Asn Ala Glu Thr Phe Thr Phe His Ala Asp 1010 1015 1020 Ile Cys Thr Leu Ser Glu Lys Glu Arg Gln Ile Lys Lys Gln Thr 1025 1030 1035 Ala Leu Val Glu Leu Val Lys His Lys Pro Lys Ala Thr Lys Glu 1040 1045 1050 Gln Leu Lys Ala Val Met Asp Asp Phe Ala Ala Phe Val Glu Lys 1055 1060 1065 Cys Cys Lys Ala Asp Asp Lys Glu Thr Cys Phe Ala Glu Glu Gly 1070 1075 1080 Lys Lys Leu Val Ala Ala Ser Gln Ala Ala Leu Gly Leu His His 1085 1090 1095 His His His His 1100 <210> 236 <211> 1102 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 236 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly His 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Asp Gly Ser Thr Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr 65 70 75 80 Met Glu Leu Arg Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Thr Arg Gly Thr Thr Val Val His Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln 130 135 140 Thr Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser 145 150 155 160 Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg Asp Gly Asn Thr Tyr Leu 165 170 175 Thr Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr 180 185 190 Lys Val Ser Asn Trp Gln Ser Gly Val Pro Asp Arg Phe Ser Gly Ser 195 200 205 Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu 210 215 220 Asp Val Gly Val Tyr Tyr Cys Met Gln Gly Thr His Trp Pro Pro Thr 225 230 235 240 Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Ser Gly Gly Gly Gly Ser 245 250 255 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 260 265 270 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys Tyr 275 280 285 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 290 295 300 Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 305 310 315 320 Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 325 330 335 Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr 340 345 350 Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr Trp 355 360 365 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 370 375 380 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val 385 390 395 400 Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu 405 410 415 Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro Asn 420 425 430 Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly 435 440 445 Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu 450 455 460 Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp 465 470 475 480 Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val Phe 485 490 495 Gly Gly Gly Thr Lys Leu Thr Val Leu Pro Gly Gly Gly Gly Ser Asp 500 505 510 Ala His Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu Glu 515 520 525 Asn Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln Gln 530 535 540 Cys Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu Phe 545 550 555 560 Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys Ser 565 570 575 Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu Arg 580 585 590 Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro Glu 595 600 605 Arg Asn Glu Cys Phe Leu Gln His Lys Asp Asp Asn Pro Asn Leu Pro 610 615 620 Arg Leu Val Arg Pro Glu Val Asp Val Met Cys Thr Ala Phe His Asp 625 630 635 640 Asn Glu Glu Thr Phe Leu Lys Lys Tyr Leu Tyr Glu Ile Ala Arg Arg 645 650 655 His Pro Tyr Phe Tyr Ala Pro Glu Leu Leu Phe Phe Ala Lys Arg Tyr 660 665 670 Lys Ala Ala Phe Thr Glu Cys Cys Gln Ala Ala Asp Lys Ala Ala Cys 675 680 685 Leu Leu Pro Lys Leu Asp Glu Leu Arg Asp Glu Gly Lys Ala Ser Ser 690 695 700 Ala Lys Gln Arg Leu Lys Cys Ala Ser Leu Gln Lys Phe Gly Glu Arg 705 710 715 720 Ala Phe Lys Ala Trp Ala Val Ala Arg Leu Ser Gln Arg Phe Pro Lys 725 730 735 Ala Glu Phe Ala Glu Val Ser Lys Leu Val Thr Asp Leu Thr Lys Val 740 745 750 His Thr Glu Cys Cys His Gly Asp Leu Leu Glu Cys Ala Asp Asp Arg 755 760 765 Ala Asp Leu Ala Lys Tyr Ile Cys Glu Asn Gln Asp Ser Ile Ser Ser 770 775 780 Lys Leu Lys Glu Cys Cys Glu Lys Pro Leu Leu Glu Lys Ser His Cys 785 790 795 800 Ile Ala Glu Val Glu Asn Asp Glu Met Pro Ala Asp Leu Pro Ser Leu 805 810 815 Ala Ala Asp Phe Val Glu Ser Lys Asp Val Cys Lys Asn Tyr Ala Glu 820 825 830 Ala Lys Asp Val Phe Leu Gly Met Phe Leu Tyr Glu Tyr Ala Arg Arg 835 840 845 His Pro Asp Tyr Ser Val Val Leu Leu Leu Arg Leu Ala Lys Thr Tyr 850 855 860 Glu Thr Thr Leu Glu Lys Cys Cys Ala Ala Ala Asp Pro His Glu Cys 865 870 875 880 Tyr Ala Lys Val Phe Asp Glu Phe Lys Pro Leu Val Glu Glu Pro Gln 885 890 895 Asn Leu Ile Lys Gln Asn Cys Glu Leu Phe Glu Gln Leu Gly Glu Tyr 900 905 910 Lys Phe Gln Asn Ala Leu Leu Val Arg Tyr Thr Lys Lys Val Pro Gln 915 920 925 Val Ser Thr Pro Thr Leu Val Glu Val Ser Arg Asn Leu Gly Lys Val 930 935 940 Gly Ser Lys Cys Cys Lys His Pro Glu Ala Lys Arg Met Pro Cys Ala 945 950 955 960 Glu Asp Tyr Leu Ser Val Val Leu Asn Gln Leu Cys Val Leu His Glu 965 970 975 Lys Thr Pro Val Ser Asp Arg Val Thr Lys Cys Cys Thr Glu Ser Leu 980 985 990 Val Asn Arg Arg Pro Cys Phe Ser Ala Leu Glu Val Asp Glu Thr Tyr 995 1000 1005 Val Pro Lys Glu Phe Asn Ala Glu Thr Phe Thr Phe His Ala Asp 1010 1015 1020 Ile Cys Thr Leu Ser Glu Lys Glu Arg Gln Ile Lys Lys Gln Thr 1025 1030 1035 Ala Leu Val Glu Leu Val Lys His Lys Pro Lys Ala Thr Lys Glu 1040 1045 1050 Gln Leu Lys Ala Val Met Asp Asp Phe Ala Ala Phe Val Glu Lys 1055 1060 1065 Cys Cys Lys Ala Asp Asp Lys Glu Thr Cys Phe Ala Glu Glu Gly 1070 1075 1080 Lys Lys Leu Val Ala Ala Ser Gln Ala Ala Leu Gly Leu His His 1085 1090 1095 His His His His 1100 <210> 237 <211> 1102 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 237 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Phe Met His Trp Val Arg Gln Ala Pro Gly Leu Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Asp Gly Ser Thr Ser Tyr Ala Gln Asn Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln 130 135 140 Ser Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser 145 150 155 160 Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg Asp Gly Asn Thr Tyr Leu 165 170 175 Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr 180 185 190 Arg Val Ser Asn Trp Gln Ser Gly Val Pro Asp Arg Phe Ser Gly Ser 195 200 205 Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu 210 215 220 Asp Val Gly Val Tyr Phe Cys Met Gln Gly Thr Tyr Trp Pro Pro Thr 225 230 235 240 Phe Gly Gln Gly Thr Lys Val Asp Ile Lys Ser Gly Gly Gly Gly Ser 245 250 255 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 260 265 270 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys Tyr 275 280 285 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 290 295 300 Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 305 310 315 320 Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 325 330 335 Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr 340 345 350 Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr Trp 355 360 365 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 370 375 380 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val 385 390 395 400 Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu 405 410 415 Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro Asn 420 425 430 Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly 435 440 445 Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu 450 455 460 Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp 465 470 475 480 Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val Phe 485 490 495 Gly Gly Gly Thr Lys Leu Thr Val Leu Pro Gly Gly Gly Gly Ser Asp 500 505 510 Ala His Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu Glu 515 520 525 Asn Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln Gln 530 535 540 Cys Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu Phe 545 550 555 560 Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys Ser 565 570 575 Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu Arg 580 585 590 Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro Glu 595 600 605 Arg Asn Glu Cys Phe Leu Gln His Lys Asp Asp Asn Pro Asn Leu Pro 610 615 620 Arg Leu Val Arg Pro Glu Val Asp Val Met Cys Thr Ala Phe His Asp 625 630 635 640 Asn Glu Glu Thr Phe Leu Lys Lys Tyr Leu Tyr Glu Ile Ala Arg Arg 645 650 655 His Pro Tyr Phe Tyr Ala Pro Glu Leu Leu Phe Phe Ala Lys Arg Tyr 660 665 670 Lys Ala Ala Phe Thr Glu Cys Cys Gln Ala Ala Asp Lys Ala Ala Cys 675 680 685 Leu Leu Pro Lys Leu Asp Glu Leu Arg Asp Glu Gly Lys Ala Ser Ser 690 695 700 Ala Lys Gln Arg Leu Lys Cys Ala Ser Leu Gln Lys Phe Gly Glu Arg 705 710 715 720 Ala Phe Lys Ala Trp Ala Val Ala Arg Leu Ser Gln Arg Phe Pro Lys 725 730 735 Ala Glu Phe Ala Glu Val Ser Lys Leu Val Thr Asp Leu Thr Lys Val 740 745 750 His Thr Glu Cys Cys His Gly Asp Leu Leu Glu Cys Ala Asp Asp Arg 755 760 765 Ala Asp Leu Ala Lys Tyr Ile Cys Glu Asn Gln Asp Ser Ile Ser Ser 770 775 780 Lys Leu Lys Glu Cys Cys Glu Lys Pro Leu Leu Glu Lys Ser His Cys 785 790 795 800 Ile Ala Glu Val Glu Asn Asp Glu Met Pro Ala Asp Leu Pro Ser Leu 805 810 815 Ala Ala Asp Phe Val Glu Ser Lys Asp Val Cys Lys Asn Tyr Ala Glu 820 825 830 Ala Lys Asp Val Phe Leu Gly Met Phe Leu Tyr Glu Tyr Ala Arg Arg 835 840 845 His Pro Asp Tyr Ser Val Val Leu Leu Leu Arg Leu Ala Lys Thr Tyr 850 855 860 Glu Thr Thr Leu Glu Lys Cys Cys Ala Ala Ala Asp Pro His Glu Cys 865 870 875 880 Tyr Ala Lys Val Phe Asp Glu Phe Lys Pro Leu Val Glu Glu Pro Gln 885 890 895 Asn Leu Ile Lys Gln Asn Cys Glu Leu Phe Glu Gln Leu Gly Glu Tyr 900 905 910 Lys Phe Gln Asn Ala Leu Leu Val Arg Tyr Thr Lys Lys Val Pro Gln 915 920 925 Val Ser Thr Pro Thr Leu Val Glu Val Ser Arg Asn Leu Gly Lys Val 930 935 940 Gly Ser Lys Cys Cys Lys His Pro Glu Ala Lys Arg Met Pro Cys Ala 945 950 955 960 Glu Asp Tyr Leu Ser Val Val Leu Asn Gln Leu Cys Val Leu His Glu 965 970 975 Lys Thr Pro Val Ser Asp Arg Val Thr Lys Cys Cys Thr Glu Ser Leu 980 985 990 Val Asn Arg Arg Pro Cys Phe Ser Ala Leu Glu Val Asp Glu Thr Tyr 995 1000 1005 Val Pro Lys Glu Phe Asn Ala Glu Thr Phe Thr Phe His Ala Asp 1010 1015 1020 Ile Cys Thr Leu Ser Glu Lys Glu Arg Gln Ile Lys Lys Gln Thr 1025 1030 1035 Ala Leu Val Glu Leu Val Lys His Lys Pro Lys Ala Thr Lys Glu 1040 1045 1050 Gln Leu Lys Ala Val Met Asp Asp Phe Ala Ala Phe Val Glu Lys 1055 1060 1065 Cys Cys Lys Ala Asp Asp Lys Glu Thr Cys Phe Ala Glu Glu Gly 1070 1075 1080 Lys Lys Leu Val Ala Ala Ser Gln Ala Ala Leu Gly Leu His His 1085 1090 1095 His His His His 1100 <210> 238 <211> 1097 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 238 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Ala Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Ile Ser His His Gly Ser Ser Lys Tyr Tyr Ala Arg Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Glu Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Trp Trp Glu Leu Val Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu 130 135 140 Ser Val Thr Pro Gly Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln 145 150 155 160 Ser Leu Leu His Ser Asp Gly Lys Thr Phe Leu Tyr Trp Tyr Leu Gln 165 170 175 Lys Pro Gly Gln Pro Pro Gln Leu Leu Ile Tyr Glu Val Ser Asn Arg 180 185 190 Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp 195 200 205 Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr 210 215 220 Tyr Cys Leu Gln Gly Ile His Leu Pro Phe Thr Phe Gly Pro Gly Thr 225 230 235 240 Lys Val Glu Ile Lys Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val 245 250 255 Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser 260 265 270 Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys Tyr Ala Met Asn Trp Val 275 280 285 Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Arg Ile Arg Ser 290 295 300 Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg 305 310 315 320 Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met 325 330 335 Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg His 340 345 350 Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr Trp Ala Tyr Trp Gly Gln 355 360 365 Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly 370 375 380 Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val Thr Gln Glu Pro Ser 385 390 395 400 Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser 405 410 415 Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys 420 425 430 Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala 435 440 445 Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala 450 455 460 Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr 465 470 475 480 Cys Val Leu Trp Tyr Ser Asn Arg Trp Val Phe Gly Gly Gly Thr Lys 485 490 495 Leu Thr Val Leu Pro Gly Gly Gly Gly Ser Asp Ala His Lys Ser Glu 500 505 510 Val Ala His Arg Phe Lys Asp Leu Gly Glu Glu Asn Phe Lys Ala Leu 515 520 525 Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln Gln Cys Pro Phe Glu Asp 530 535 540 His Val Lys Leu Val Asn Glu Val Thr Glu Phe Ala Lys Thr Cys Val 545 550 555 560 Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys Ser Leu His Thr Leu Phe 565 570 575 Gly Asp Lys Leu Cys Thr Val Ala Thr Leu Arg Glu Thr Tyr Gly Glu 580 585 590 Met Ala Asp Cys Cys Ala Lys Gln Glu Pro Glu Arg Asn Glu Cys Phe 595 600 605 Leu Gln His Lys Asp Asp Asn Pro Asn Leu Pro Arg Leu Val Arg Pro 610 615 620 Glu Val Asp Val Met Cys Thr Ala Phe His Asp Asn Glu Glu Thr Phe 625 630 635 640 Leu Lys Lys Tyr Leu Tyr Glu Ile Ala Arg Arg His Pro Tyr Phe Tyr 645 650 655 Ala Pro Glu Leu Leu Phe Phe Ala Lys Arg Tyr Lys Ala Ala Phe Thr 660 665 670 Glu Cys Cys Gln Ala Ala Asp Lys Ala Ala Cys Leu Leu Pro Lys Leu 675 680 685 Asp Glu Leu Arg Asp Glu Gly Lys Ala Ser Ser Ala Lys Gln Arg Leu 690 695 700 Lys Cys Ala Ser Leu Gln Lys Phe Gly Glu Arg Ala Phe Lys Ala Trp 705 710 715 720 Ala Val Ala Arg Leu Ser Gln Arg Phe Pro Lys Ala Glu Phe Ala Glu 725 730 735 Val Ser Lys Leu Val Thr Asp Leu Thr Lys Val His Thr Glu Cys Cys 740 745 750 His Gly Asp Leu Leu Glu Cys Ala Asp Asp Arg Ala Asp Leu Ala Lys 755 760 765 Tyr Ile Cys Glu Asn Gln Asp Ser Ile Ser Ser Lys Leu Lys Glu Cys 770 775 780 Cys Glu Lys Pro Leu Leu Glu Lys Ser His Cys Ile Ala Glu Val Glu 785 790 795 800 Asn Asp Glu Met Pro Ala Asp Leu Pro Ser Leu Ala Ala Asp Phe Val 805 810 815 Glu Ser Lys Asp Val Cys Lys Asn Tyr Ala Glu Ala Lys Asp Val Phe 820 825 830 Leu Gly Met Phe Leu Tyr Glu Tyr Ala Arg Arg His Pro Asp Tyr Ser 835 840 845 Val Val Leu Leu Leu Arg Leu Ala Lys Thr Tyr Glu Thr Thr Leu Glu 850 855 860 Lys Cys Cys Ala Ala Ala Asp Pro His Glu Cys Tyr Ala Lys Val Phe 865 870 875 880 Asp Glu Phe Lys Pro Leu Val Glu Glu Pro Gln Asn Leu Ile Lys Gln 885 890 895 Asn Cys Glu Leu Phe Glu Gln Leu Gly Glu Tyr Lys Phe Gln Asn Ala 900 905 910 Leu Leu Val Arg Tyr Thr Lys Lys Val Pro Gln Val Ser Thr Pro Thr 915 920 925 Leu Val Glu Val Ser Arg Asn Leu Gly Lys Val Gly Ser Lys Cys Cys 930 935 940 Lys His Pro Glu Ala Lys Arg Met Pro Cys Ala Glu Asp Tyr Leu Ser 945 950 955 960 Val Val Leu Asn Gln Leu Cys Val Leu His Glu Lys Thr Pro Val Ser 965 970 975 Asp Arg Val Thr Lys Cys Cys Thr Glu Ser Leu Val Asn Arg Arg Pro 980 985 990 Cys Phe Ser Ala Leu Glu Val Asp Glu Thr Tyr Val Pro Lys Glu Phe 995 1000 1005 Asn Ala Glu Thr Phe Thr Phe His Ala Asp Ile Cys Thr Leu Ser 1010 1015 1020 Glu Lys Glu Arg Gln Ile Lys Lys Gln Thr Ala Leu Val Glu Leu 1025 1030 1035 Val Lys His Lys Pro Lys Ala Thr Lys Glu Gln Leu Lys Ala Val 1040 1045 1050 Met Asp Asp Phe Ala Ala Phe Val Glu Lys Cys Cys Lys Ala Asp 1055 1060 1065 Asp Lys Glu Thr Cys Phe Ala Glu Glu Gly Lys Lys Leu Val Ala 1070 1075 1080 Ala Ser Gln Ala Ala Leu Gly Leu His His His His His His 1085 1090 1095 <210> 239 <211> 1099 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 239 Gln Val Thr Leu Lys Glu Ser Gly Pro Met Leu Val Lys Pro Thr Glu 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Ser Asn Ser 20 25 30 Arg Met Gly Val Ser Trp Ile Arg Gln Pro Pro Gly Arg Ala Leu Glu 35 40 45 Trp Leu Ala His Ile Phe Ser Asn Asp Gly Lys Ser Tyr Ser Thr Ser 50 55 60 Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Ser Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Tyr Asn Tyr Asp Ser Ser Gly Tyr Tyr Tyr Ser Phe Phe 100 105 110 Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 115 120 125 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met 130 135 140 Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr 145 150 155 160 Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr 165 170 175 Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser 180 185 190 Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly 195 200 205 Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala 210 215 220 Thr Tyr Tyr Cys Gln Gln Gly Tyr Ser Ser Pro Phe Thr Phe Gly Gly 225 230 235 240 Gly Thr Lys Val Glu Ile Lys Ser Gly Gly Gly Gly Ser Glu Val Gln 245 250 255 Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Lys 260 265 270 Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys Tyr Ala Met Asn 275 280 285 Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Arg Ile 290 295 300 Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys 305 310 315 320 Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Ala Tyr Leu 325 330 335 Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Val 340 345 350 Arg His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr Trp Ala Tyr Trp 355 360 365 Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly 370 375 380 Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val Thr Gln Glu 385 390 395 400 Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu Thr Cys Gly 405 410 415 Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro Asn Trp Val Gln 420 425 430 Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly Thr Lys Phe 435 440 445 Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu Leu Gly Gly 450 455 460 Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp Glu Ala Glu 465 470 475 480 Tyr Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val Phe Gly Gly Gly 485 490 495 Thr Lys Leu Thr Val Leu Pro Gly Gly Gly Gly Ser Asp Ala His Lys 500 505 510 Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu Glu Asn Phe Lys 515 520 525 Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln Gln Cys Pro Phe 530 535 540 Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu Phe Ala Lys Thr 545 550 555 560 Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys Ser Leu His Thr 565 570 575 Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu Arg Glu Thr Tyr 580 585 590 Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro Glu Arg Asn Glu 595 600 605 Cys Phe Leu Gln His Lys Asp Asp Asn Pro Asn Leu Pro Arg Leu Val 610 615 620 Arg Pro Glu Val Asp Val Met Cys Thr Ala Phe His Asp Asn Glu Glu 625 630 635 640 Thr Phe Leu Lys Lys Tyr Leu Tyr Glu Ile Ala Arg Arg His Pro Tyr 645 650 655 Phe Tyr Ala Pro Glu Leu Leu Phe Phe Ala Lys Arg Tyr Lys Ala Ala 660 665 670 Phe Thr Glu Cys Cys Gln Ala Ala Asp Lys Ala Ala Cys Leu Leu Pro 675 680 685 Lys Leu Asp Glu Leu Arg Asp Glu Gly Lys Ala Ser Ser Ala Lys Gln 690 695 700 Arg Leu Lys Cys Ala Ser Leu Gln Lys Phe Gly Glu Arg Ala Phe Lys 705 710 715 720 Ala Trp Ala Val Ala Arg Leu Ser Gln Arg Phe Pro Lys Ala Glu Phe 725 730 735 Ala Glu Val Ser Lys Leu Val Thr Asp Leu Thr Lys Val His Thr Glu 740 745 750 Cys Cys His Gly Asp Leu Leu Glu Cys Ala Asp Asp Arg Ala Asp Leu 755 760 765 Ala Lys Tyr Ile Cys Glu Asn Gln Asp Ser Ile Ser Ser Lys Leu Lys 770 775 780 Glu Cys Cys Glu Lys Pro Leu Leu Glu Lys Ser His Cys Ile Ala Glu 785 790 795 800 Val Glu Asn Asp Glu Met Pro Ala Asp Leu Pro Ser Leu Ala Ala Asp 805 810 815 Phe Val Glu Ser Lys Asp Val Cys Lys Asn Tyr Ala Glu Ala Lys Asp 820 825 830 Val Phe Leu Gly Met Phe Leu Tyr Glu Tyr Ala Arg Arg His Pro Asp 835 840 845 Tyr Ser Val Val Leu Leu Leu Arg Leu Ala Lys Thr Tyr Glu Thr Thr 850 855 860 Leu Glu Lys Cys Cys Ala Ala Ala Asp Pro His Glu Cys Tyr Ala Lys 865 870 875 880 Val Phe Asp Glu Phe Lys Pro Leu Val Glu Glu Pro Gln Asn Leu Ile 885 890 895 Lys Gln Asn Cys Glu Leu Phe Glu Gln Leu Gly Glu Tyr Lys Phe Gln 900 905 910 Asn Ala Leu Leu Val Arg Tyr Thr Lys Lys Val Pro Gln Val Ser Thr 915 920 925 Pro Thr Leu Val Glu Val Ser Arg Asn Leu Gly Lys Val Gly Ser Lys 930 935 940 Cys Cys Lys His Pro Glu Ala Lys Arg Met Pro Cys Ala Glu Asp Tyr 945 950 955 960 Leu Ser Val Val Leu Asn Gln Leu Cys Val Leu His Glu Lys Thr Pro 965 970 975 Val Ser Asp Arg Val Thr Lys Cys Cys Thr Glu Ser Leu Val Asn Arg 980 985 990 Arg Pro Cys Phe Ser Ala Leu Glu Val Asp Glu Thr Tyr Val Pro Lys 995 1000 1005 Glu Phe Asn Ala Glu Thr Phe Thr Phe His Ala Asp Ile Cys Thr 1010 1015 1020 Leu Ser Glu Lys Glu Arg Gln Ile Lys Lys Gln Thr Ala Leu Val 1025 1030 1035 Glu Leu Val Lys His Lys Pro Lys Ala Thr Lys Glu Gln Leu Lys 1040 1045 1050 Ala Val Met Asp Asp Phe Ala Ala Phe Val Glu Lys Cys Cys Lys 1055 1060 1065 Ala Asp Asp Lys Glu Thr Cys Phe Ala Glu Glu Gly Lys Lys Leu 1070 1075 1080 Val Ala Ala Ser Gln Ala Ala Leu Gly Leu His His His His His 1085 1090 1095 His <210> 240 <211> 1099 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 240 Gln Val Thr Leu Lys Glu Ser Gly Pro Val Leu Val Lys Pro Thr Glu 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Ser Asn Ala 20 25 30 Arg Met Gly Val Ser Trp Leu Arg Gln Pro Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala His Ile Phe Ser Thr Asp Glu Lys Ser Tyr Ser Thr Ser 50 55 60 Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Ser Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Tyr Tyr Tyr Asp Ser Ser Gly Tyr Tyr Tyr Ser Phe Phe 100 105 110 Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 115 120 125 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met 130 135 140 Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr 145 150 155 160 Ile Thr Cys Arg Ala Ser Gln Ser Ile Arg Ser Tyr Leu Asn Trp Tyr 165 170 175 Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Gly Ala Ser 180 185 190 Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly 195 200 205 Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala 210 215 220 Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Ser Pro Phe Thr Phe Gly Gly 225 230 235 240 Gly Thr Lys Val Glu Ile Lys Ser Gly Gly Gly Gly Ser Glu Val Gln 245 250 255 Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Lys 260 265 270 Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys Tyr Ala Met Asn 275 280 285 Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Arg Ile 290 295 300 Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys 305 310 315 320 Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Ala Tyr Leu 325 330 335 Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Val 340 345 350 Arg His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr Trp Ala Tyr Trp 355 360 365 Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly 370 375 380 Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val Thr Gln Glu 385 390 395 400 Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu Thr Cys Gly 405 410 415 Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro Asn Trp Val Gln 420 425 430 Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly Thr Lys Phe 435 440 445 Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu Leu Gly Gly 450 455 460 Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp Glu Ala Glu 465 470 475 480 Tyr Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val Phe Gly Gly Gly 485 490 495 Thr Lys Leu Thr Val Leu Pro Gly Gly Gly Gly Ser Asp Ala His Lys 500 505 510 Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu Glu Asn Phe Lys 515 520 525 Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln Gln Cys Pro Phe 530 535 540 Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu Phe Ala Lys Thr 545 550 555 560 Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys Ser Leu His Thr 565 570 575 Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu Arg Glu Thr Tyr 580 585 590 Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro Glu Arg Asn Glu 595 600 605 Cys Phe Leu Gln His Lys Asp Asp Asn Pro Asn Leu Pro Arg Leu Val 610 615 620 Arg Pro Glu Val Asp Val Met Cys Thr Ala Phe His Asp Asn Glu Glu 625 630 635 640 Thr Phe Leu Lys Lys Tyr Leu Tyr Glu Ile Ala Arg Arg His Pro Tyr 645 650 655 Phe Tyr Ala Pro Glu Leu Leu Phe Phe Ala Lys Arg Tyr Lys Ala Ala 660 665 670 Phe Thr Glu Cys Cys Gln Ala Ala Asp Lys Ala Ala Cys Leu Leu Pro 675 680 685 Lys Leu Asp Glu Leu Arg Asp Glu Gly Lys Ala Ser Ser Ala Lys Gln 690 695 700 Arg Leu Lys Cys Ala Ser Leu Gln Lys Phe Gly Glu Arg Ala Phe Lys 705 710 715 720 Ala Trp Ala Val Ala Arg Leu Ser Gln Arg Phe Pro Lys Ala Glu Phe 725 730 735 Ala Glu Val Ser Lys Leu Val Thr Asp Leu Thr Lys Val His Thr Glu 740 745 750 Cys Cys His Gly Asp Leu Leu Glu Cys Ala Asp Asp Arg Ala Asp Leu 755 760 765 Ala Lys Tyr Ile Cys Glu Asn Gln Asp Ser Ile Ser Ser Lys Leu Lys 770 775 780 Glu Cys Cys Glu Lys Pro Leu Leu Glu Lys Ser His Cys Ile Ala Glu 785 790 795 800 Val Glu Asn Asp Glu Met Pro Ala Asp Leu Pro Ser Leu Ala Ala Asp 805 810 815 Phe Val Glu Ser Lys Asp Val Cys Lys Asn Tyr Ala Glu Ala Lys Asp 820 825 830 Val Phe Leu Gly Met Phe Leu Tyr Glu Tyr Ala Arg Arg His Pro Asp 835 840 845 Tyr Ser Val Val Leu Leu Leu Arg Leu Ala Lys Thr Tyr Glu Thr Thr 850 855 860 Leu Glu Lys Cys Cys Ala Ala Ala Asp Pro His Glu Cys Tyr Ala Lys 865 870 875 880 Val Phe Asp Glu Phe Lys Pro Leu Val Glu Glu Pro Gln Asn Leu Ile 885 890 895 Lys Gln Asn Cys Glu Leu Phe Glu Gln Leu Gly Glu Tyr Lys Phe Gln 900 905 910 Asn Ala Leu Leu Val Arg Tyr Thr Lys Lys Val Pro Gln Val Ser Thr 915 920 925 Pro Thr Leu Val Glu Val Ser Arg Asn Leu Gly Lys Val Gly Ser Lys 930 935 940 Cys Cys Lys His Pro Glu Ala Lys Arg Met Pro Cys Ala Glu Asp Tyr 945 950 955 960 Leu Ser Val Val Leu Asn Gln Leu Cys Val Leu His Glu Lys Thr Pro 965 970 975 Val Ser Asp Arg Val Thr Lys Cys Cys Thr Glu Ser Leu Val Asn Arg 980 985 990 Arg Pro Cys Phe Ser Ala Leu Glu Val Asp Glu Thr Tyr Val Pro Lys 995 1000 1005 Glu Phe Asn Ala Glu Thr Phe Thr Phe His Ala Asp Ile Cys Thr 1010 1015 1020 Leu Ser Glu Lys Glu Arg Gln Ile Lys Lys Gln Thr Ala Leu Val 1025 1030 1035 Glu Leu Val Lys His Lys Pro Lys Ala Thr Lys Glu Gln Leu Lys 1040 1045 1050 Ala Val Met Asp Asp Phe Ala Ala Phe Val Glu Lys Cys Cys Lys 1055 1060 1065 Ala Asp Asp Lys Glu Thr Cys Phe Ala Glu Glu Gly Lys Lys Leu 1070 1075 1080 Val Ala Ala Ser Gln Ala Ala Leu Gly Leu His His His His His 1085 1090 1095 His <210> 241 <211> 1095 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 241 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Thr Ser Tyr 20 25 30 Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Gly Gly Ser Lys Ser Tyr Ala Gln Lys Phe 50 55 60 Arg Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Ser Met Ser Thr Val Thr Ser Asp Ala Phe Asp Ile Trp Gly 100 105 110 Gln Gly Thr Met Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly 115 120 125 Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro 130 135 140 Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg 145 150 155 160 Ala Ser Gln Ser Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro 165 170 175 Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser 180 185 190 Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr 195 200 205 Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys 210 215 220 Gln Gln Ser Tyr Ser Ala Pro Leu Thr Phe Gly Gly Gly Thr Lys Val 225 230 235 240 Asp Ile Lys Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser 245 250 255 Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala 260 265 270 Ala Ser Gly Phe Thr Phe Asn Lys Tyr Ala Met Asn Trp Val Arg Gln 275 280 285 Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr 290 295 300 Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr 305 310 315 320 Ile Ser Arg Asp Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Asn 325 330 335 Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn 340 345 350 Phe Gly Asn Ser Tyr Ile Ser Tyr Trp Ala Tyr Trp Gly Gln Gly Thr 355 360 365 Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 370 375 380 Gly Gly Gly Gly Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr 385 390 395 400 Val Ser Pro Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly 405 410 415 Ala Val Thr Ser Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly 420 425 430 Gln Ala Pro Arg Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly 435 440 445 Thr Pro Ala Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu 450 455 460 Thr Leu Ser Gly Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val 465 470 475 480 Leu Trp Tyr Ser Asn Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr 485 490 495 Val Leu Pro Gly Gly Gly Gly Ser Asp Ala His Lys Ser Glu Val Ala 500 505 510 His Arg Phe Lys Asp Leu Gly Glu Glu Asn Phe Lys Ala Leu Val Leu 515 520 525 Ile Ala Phe Ala Gln Tyr Leu Gln Gln Cys Pro Phe Glu Asp His Val 530 535 540 Lys Leu Val Asn Glu Val Thr Glu Phe Ala Lys Thr Cys Val Ala Asp 545 550 555 560 Glu Ser Ala Glu Asn Cys Asp Lys Ser Leu His Thr Leu Phe Gly Asp 565 570 575 Lys Leu Cys Thr Val Ala Thr Leu Arg Glu Thr Tyr Gly Glu Met Ala 580 585 590 Asp Cys Cys Ala Lys Gln Glu Pro Glu Arg Asn Glu Cys Phe Leu Gln 595 600 605 His Lys Asp Asp Asn Pro Asn Leu Pro Arg Leu Val Arg Pro Glu Val 610 615 620 Asp Val Met Cys Thr Ala Phe His Asp Asn Glu Glu Thr Phe Leu Lys 625 630 635 640 Lys Tyr Leu Tyr Glu Ile Ala Arg Arg His Pro Tyr Phe Tyr Ala Pro 645 650 655 Glu Leu Leu Phe Phe Ala Lys Arg Tyr Lys Ala Ala Phe Thr Glu Cys 660 665 670 Cys Gln Ala Ala Asp Lys Ala Ala Cys Leu Leu Pro Lys Leu Asp Glu 675 680 685 Leu Arg Asp Glu Gly Lys Ala Ser Ser Ala Lys Gln Arg Leu Lys Cys 690 695 700 Ala Ser Leu Gln Lys Phe Gly Glu Arg Ala Phe Lys Ala Trp Ala Val 705 710 715 720 Ala Arg Leu Ser Gln Arg Phe Pro Lys Ala Glu Phe Ala Glu Val Ser 725 730 735 Lys Leu Val Thr Asp Leu Thr Lys Val His Thr Glu Cys Cys His Gly 740 745 750 Asp Leu Leu Glu Cys Ala Asp Asp Arg Ala Asp Leu Ala Lys Tyr Ile 755 760 765 Cys Glu Asn Gln Asp Ser Ile Ser Ser Lys Leu Lys Glu Cys Cys Glu 770 775 780 Lys Pro Leu Leu Glu Lys Ser His Cys Ile Ala Glu Val Glu Asn Asp 785 790 795 800 Glu Met Pro Ala Asp Leu Pro Ser Leu Ala Ala Asp Phe Val Glu Ser 805 810 815 Lys Asp Val Cys Lys Asn Tyr Ala Glu Ala Lys Asp Val Phe Leu Gly 820 825 830 Met Phe Leu Tyr Glu Tyr Ala Arg Arg His Pro Asp Tyr Ser Val Val 835 840 845 Leu Leu Leu Arg Leu Ala Lys Thr Tyr Glu Thr Thr Leu Glu Lys Cys 850 855 860 Cys Ala Ala Ala Asp Pro His Glu Cys Tyr Ala Lys Val Phe Asp Glu 865 870 875 880 Phe Lys Pro Leu Val Glu Glu Pro Gln Asn Leu Ile Lys Gln Asn Cys 885 890 895 Glu Leu Phe Glu Gln Leu Gly Glu Tyr Lys Phe Gln Asn Ala Leu Leu 900 905 910 Val Arg Tyr Thr Lys Lys Val Pro Gln Val Ser Thr Pro Thr Leu Val 915 920 925 Glu Val Ser Arg Asn Leu Gly Lys Val Gly Ser Lys Cys Cys Lys His 930 935 940 Pro Glu Ala Lys Arg Met Pro Cys Ala Glu Asp Tyr Leu Ser Val Val 945 950 955 960 Leu Asn Gln Leu Cys Val Leu His Glu Lys Thr Pro Val Ser Asp Arg 965 970 975 Val Thr Lys Cys Cys Thr Glu Ser Leu Val Asn Arg Arg Pro Cys Phe 980 985 990 Ser Ala Leu Glu Val Asp Glu Thr Tyr Val Pro Lys Glu Phe Asn Ala 995 1000 1005 Glu Thr Phe Thr Phe His Ala Asp Ile Cys Thr Leu Ser Glu Lys 1010 1015 1020 Glu Arg Gln Ile Lys Lys Gln Thr Ala Leu Val Glu Leu Val Lys 1025 1030 1035 His Lys Pro Lys Ala Thr Lys Glu Gln Leu Lys Ala Val Met Asp 1040 1045 1050 Asp Phe Ala Ala Phe Val Glu Lys Cys Cys Lys Ala Asp Asp Lys 1055 1060 1065 Glu Thr Cys Phe Ala Glu Glu Gly Lys Lys Leu Val Ala Ala Ser 1070 1075 1080 Gln Ala Ala Leu Gly Leu His His His His His His 1085 1090 1095 <210> 242 <211> 1093 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 242 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Val Tyr Tyr Ser Gly Thr Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Ser Ile Ala Val Thr Gly Phe Tyr Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu 130 135 140 Ser Leu Ser Pro Gly Glu Arg Val Thr Leu Ser Cys Arg Ala Ser Gln 145 150 155 160 Arg Val Asn Asn Asn Tyr Leu Ala Trp Tyr Gln Gln Arg Pro Gly Gln 165 170 175 Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile 180 185 190 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 195 200 205 Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln 210 215 220 Tyr Asp Arg Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile 225 230 235 240 Lys Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly 245 250 255 Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser 260 265 270 Gly Phe Thr Phe Asn Ser Tyr Ala Met Asn Trp Val Arg Gln Ala Pro 275 280 285 Gly Lys Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn 290 295 300 Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser 305 310 315 320 Arg Asp Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Ser Leu Lys 325 330 335 Thr Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn Phe Gly 340 345 350 Asn Ser Tyr Val Ser Trp Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val 355 360 365 Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 370 375 380 Gly Gly Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser 385 390 395 400 Pro Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val 405 410 415 Thr Ser Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala 420 425 430 Pro Arg Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro 435 440 445 Ala Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu 450 455 460 Ser Gly Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp 465 470 475 480 Tyr Ser Asn Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 485 490 495 Pro Gly Gly Gly Gly Ser Asp Ala His Lys Ser Glu Val Ala His Arg 500 505 510 Phe Lys Asp Leu Gly Glu Glu Asn Phe Lys Ala Leu Val Leu Ile Ala 515 520 525 Phe Ala Gln Tyr Leu Gln Gln Cys Pro Phe Glu Asp His Val Lys Leu 530 535 540 Val Asn Glu Val Thr Glu Phe Ala Lys Thr Cys Val Ala Asp Glu Ser 545 550 555 560 Ala Glu Asn Cys Asp Lys Ser Leu His Thr Leu Phe Gly Asp Lys Leu 565 570 575 Cys Thr Val Ala Thr Leu Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys 580 585 590 Cys Ala Lys Gln Glu Pro Glu Arg Asn Glu Cys Phe Leu Gln His Lys 595 600 605 Asp Asp Asn Pro Asn Leu Pro Arg Leu Val Arg Pro Glu Val Asp Val 610 615 620 Met Cys Thr Ala Phe His Asp Asn Glu Glu Thr Phe Leu Lys Lys Tyr 625 630 635 640 Leu Tyr Glu Ile Ala Arg Arg His Pro Tyr Phe Tyr Ala Pro Glu Leu 645 650 655 Leu Phe Phe Ala Lys Arg Tyr Lys Ala Ala Phe Thr Glu Cys Cys Gln 660 665 670 Ala Ala Asp Lys Ala Ala Cys Leu Leu Pro Lys Leu Asp Glu Leu Arg 675 680 685 Asp Glu Gly Lys Ala Ser Ser Ala Lys Gln Arg Leu Lys Cys Ala Ser 690 695 700 Leu Gln Lys Phe Gly Glu Arg Ala Phe Lys Ala Trp Ala Val Ala Arg 705 710 715 720 Leu Ser Gln Arg Phe Pro Lys Ala Glu Phe Ala Glu Val Ser Lys Leu 725 730 735 Val Thr Asp Leu Thr Lys Val His Thr Glu Cys Cys His Gly Asp Leu 740 745 750 Leu Glu Cys Ala Asp Asp Arg Ala Asp Leu Ala Lys Tyr Ile Cys Glu 755 760 765 Asn Gln Asp Ser Ile Ser Ser Lys Leu Lys Glu Cys Cys Glu Lys Pro 770 775 780 Leu Leu Glu Lys Ser His Cys Ile Ala Glu Val Glu Asn Asp Glu Met 785 790 795 800 Pro Ala Asp Leu Pro Ser Leu Ala Ala Asp Phe Val Glu Ser Lys Asp 805 810 815 Val Cys Lys Asn Tyr Ala Glu Ala Lys Asp Val Phe Leu Gly Met Phe 820 825 830 Leu Tyr Glu Tyr Ala Arg Arg His Pro Asp Tyr Ser Val Val Leu Leu 835 840 845 Leu Arg Leu Ala Lys Thr Tyr Glu Thr Thr Leu Glu Lys Cys Cys Ala 850 855 860 Ala Ala Asp Pro His Glu Cys Tyr Ala Lys Val Phe Asp Glu Phe Lys 865 870 875 880 Pro Leu Val Glu Glu Pro Gln Asn Leu Ile Lys Gln Asn Cys Glu Leu 885 890 895 Phe Glu Gln Leu Gly Glu Tyr Lys Phe Gln Asn Ala Leu Leu Val Arg 900 905 910 Tyr Thr Lys Lys Val Pro Gln Val Ser Thr Pro Thr Leu Val Glu Val 915 920 925 Ser Arg Asn Leu Gly Lys Val Gly Ser Lys Cys Cys Lys His Pro Glu 930 935 940 Ala Lys Arg Met Pro Cys Ala Glu Asp Tyr Leu Ser Val Val Leu Asn 945 950 955 960 Gln Leu Cys Val Leu His Glu Lys Thr Pro Val Ser Asp Arg Val Thr 965 970 975 Lys Cys Cys Thr Glu Ser Leu Val Asn Arg Arg Pro Cys Phe Ser Ala 980 985 990 Leu Glu Val Asp Glu Thr Tyr Val Pro Lys Glu Phe Asn Ala Glu Thr 995 1000 1005 Phe Thr Phe His Ala Asp Ile Cys Thr Leu Ser Glu Lys Glu Arg 1010 1015 1020 Gln Ile Lys Lys Gln Thr Ala Leu Val Glu Leu Val Lys His Lys 1025 1030 1035 Pro Lys Ala Thr Lys Glu Gln Leu Lys Ala Val Met Asp Asp Phe 1040 1045 1050 Ala Ala Phe Val Glu Lys Cys Cys Lys Ala Asp Asp Lys Glu Thr 1055 1060 1065 Cys Phe Ala Glu Glu Gly Lys Lys Leu Val Ala Ala Ser Gln Ala 1070 1075 1080 Ala Leu Gly Leu His His His His His His 1085 1090 <210> 243 <211> 1093 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 243 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Tyr Tyr Ser Gly Arg Thr Asn Tyr Tyr Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Ile Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Ile Ala Val Ala Gly Phe Phe Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu 130 135 140 Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln 145 150 155 160 Ser Val Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 165 170 175 Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile 180 185 190 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 195 200 205 Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln 210 215 220 Tyr Asp Arg Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile 225 230 235 240 Lys Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly 245 250 255 Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser 260 265 270 Gly Phe Thr Phe Asn Ser Tyr Ala Met Asn Trp Val Arg Gln Ala Pro 275 280 285 Gly Lys Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn 290 295 300 Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser 305 310 315 320 Arg Asp Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Ser Leu Lys 325 330 335 Thr Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn Phe Gly 340 345 350 Asn Ser Tyr Val Ser Trp Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val 355 360 365 Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 370 375 380 Gly Gly Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser 385 390 395 400 Pro Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val 405 410 415 Thr Ser Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala 420 425 430 Pro Arg Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro 435 440 445 Ala Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu 450 455 460 Ser Gly Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp 465 470 475 480 Tyr Ser Asn Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 485 490 495 Pro Gly Gly Gly Gly Ser Asp Ala His Lys Ser Glu Val Ala His Arg 500 505 510 Phe Lys Asp Leu Gly Glu Glu Asn Phe Lys Ala Leu Val Leu Ile Ala 515 520 525 Phe Ala Gln Tyr Leu Gln Gln Cys Pro Phe Glu Asp His Val Lys Leu 530 535 540 Val Asn Glu Val Thr Glu Phe Ala Lys Thr Cys Val Ala Asp Glu Ser 545 550 555 560 Ala Glu Asn Cys Asp Lys Ser Leu His Thr Leu Phe Gly Asp Lys Leu 565 570 575 Cys Thr Val Ala Thr Leu Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys 580 585 590 Cys Ala Lys Gln Glu Pro Glu Arg Asn Glu Cys Phe Leu Gln His Lys 595 600 605 Asp Asp Asn Pro Asn Leu Pro Arg Leu Val Arg Pro Glu Val Asp Val 610 615 620 Met Cys Thr Ala Phe His Asp Asn Glu Glu Thr Phe Leu Lys Lys Tyr 625 630 635 640 Leu Tyr Glu Ile Ala Arg Arg His Pro Tyr Phe Tyr Ala Pro Glu Leu 645 650 655 Leu Phe Phe Ala Lys Arg Tyr Lys Ala Ala Phe Thr Glu Cys Cys Gln 660 665 670 Ala Ala Asp Lys Ala Ala Cys Leu Leu Pro Lys Leu Asp Glu Leu Arg 675 680 685 Asp Glu Gly Lys Ala Ser Ser Ala Lys Gln Arg Leu Lys Cys Ala Ser 690 695 700 Leu Gln Lys Phe Gly Glu Arg Ala Phe Lys Ala Trp Ala Val Ala Arg 705 710 715 720 Leu Ser Gln Arg Phe Pro Lys Ala Glu Phe Ala Glu Val Ser Lys Leu 725 730 735 Val Thr Asp Leu Thr Lys Val His Thr Glu Cys Cys His Gly Asp Leu 740 745 750 Leu Glu Cys Ala Asp Asp Arg Ala Asp Leu Ala Lys Tyr Ile Cys Glu 755 760 765 Asn Gln Asp Ser Ile Ser Ser Lys Leu Lys Glu Cys Cys Glu Lys Pro 770 775 780 Leu Leu Glu Lys Ser His Cys Ile Ala Glu Val Glu Asn Asp Glu Met 785 790 795 800 Pro Ala Asp Leu Pro Ser Leu Ala Ala Asp Phe Val Glu Ser Lys Asp 805 810 815 Val Cys Lys Asn Tyr Ala Glu Ala Lys Asp Val Phe Leu Gly Met Phe 820 825 830 Leu Tyr Glu Tyr Ala Arg Arg His Pro Asp Tyr Ser Val Val Leu Leu 835 840 845 Leu Arg Leu Ala Lys Thr Tyr Glu Thr Thr Leu Glu Lys Cys Cys Ala 850 855 860 Ala Ala Asp Pro His Glu Cys Tyr Ala Lys Val Phe Asp Glu Phe Lys 865 870 875 880 Pro Leu Val Glu Glu Pro Gln Asn Leu Ile Lys Gln Asn Cys Glu Leu 885 890 895 Phe Glu Gln Leu Gly Glu Tyr Lys Phe Gln Asn Ala Leu Leu Val Arg 900 905 910 Tyr Thr Lys Lys Val Pro Gln Val Ser Thr Pro Thr Leu Val Glu Val 915 920 925 Ser Arg Asn Leu Gly Lys Val Gly Ser Lys Cys Cys Lys His Pro Glu 930 935 940 Ala Lys Arg Met Pro Cys Ala Glu Asp Tyr Leu Ser Val Val Leu Asn 945 950 955 960 Gln Leu Cys Val Leu His Glu Lys Thr Pro Val Ser Asp Arg Val Thr 965 970 975 Lys Cys Cys Thr Glu Ser Leu Val Asn Arg Arg Pro Cys Phe Ser Ala 980 985 990 Leu Glu Val Asp Glu Thr Tyr Val Pro Lys Glu Phe Asn Ala Glu Thr 995 1000 1005 Phe Thr Phe His Ala Asp Ile Cys Thr Leu Ser Glu Lys Glu Arg 1010 1015 1020 Gln Ile Lys Lys Gln Thr Ala Leu Val Glu Leu Val Lys His Lys 1025 1030 1035 Pro Lys Ala Thr Lys Glu Gln Leu Lys Ala Val Met Asp Asp Phe 1040 1045 1050 Ala Ala Phe Val Glu Lys Cys Cys Lys Ala Asp Asp Lys Glu Thr 1055 1060 1065 Cys Phe Ala Glu Glu Gly Lys Lys Leu Val Ala Ala Ser Gln Ala 1070 1075 1080 Ala Leu Gly Leu His His His His His His 1085 1090 <210> 244 <211> 1093 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 244 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Ala Ser Ile Ser Ser Phe 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Tyr Tyr Ser Gly Thr Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Ile Ala Val Ala Gly Phe Phe Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu 130 135 140 Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln 145 150 155 160 Ser Val Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 165 170 175 Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile 180 185 190 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 195 200 205 Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln 210 215 220 Tyr Asp Arg Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile 225 230 235 240 Lys Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly 245 250 255 Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser 260 265 270 Gly Phe Thr Phe Asn Ser Tyr Ala Met Asn Trp Val Arg Gln Ala Pro 275 280 285 Gly Lys Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn 290 295 300 Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser 305 310 315 320 Arg Asp Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Ser Leu Lys 325 330 335 Thr Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn Phe Gly 340 345 350 Asn Ser Tyr Val Ser Trp Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val 355 360 365 Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 370 375 380 Gly Gly Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser 385 390 395 400 Pro Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val 405 410 415 Thr Ser Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala 420 425 430 Pro Arg Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro 435 440 445 Ala Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu 450 455 460 Ser Gly Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp 465 470 475 480 Tyr Ser Asn Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 485 490 495 Pro Gly Gly Gly Gly Ser Asp Ala His Lys Ser Glu Val Ala His Arg 500 505 510 Phe Lys Asp Leu Gly Glu Glu Asn Phe Lys Ala Leu Val Leu Ile Ala 515 520 525 Phe Ala Gln Tyr Leu Gln Gln Cys Pro Phe Glu Asp His Val Lys Leu 530 535 540 Val Asn Glu Val Thr Glu Phe Ala Lys Thr Cys Val Ala Asp Glu Ser 545 550 555 560 Ala Glu Asn Cys Asp Lys Ser Leu His Thr Leu Phe Gly Asp Lys Leu 565 570 575 Cys Thr Val Ala Thr Leu Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys 580 585 590 Cys Ala Lys Gln Glu Pro Glu Arg Asn Glu Cys Phe Leu Gln His Lys 595 600 605 Asp Asp Asn Pro Asn Leu Pro Arg Leu Val Arg Pro Glu Val Asp Val 610 615 620 Met Cys Thr Ala Phe His Asp Asn Glu Glu Thr Phe Leu Lys Lys Tyr 625 630 635 640 Leu Tyr Glu Ile Ala Arg Arg His Pro Tyr Phe Tyr Ala Pro Glu Leu 645 650 655 Leu Phe Phe Ala Lys Arg Tyr Lys Ala Ala Phe Thr Glu Cys Cys Gln 660 665 670 Ala Ala Asp Lys Ala Ala Cys Leu Leu Pro Lys Leu Asp Glu Leu Arg 675 680 685 Asp Glu Gly Lys Ala Ser Ser Ala Lys Gln Arg Leu Lys Cys Ala Ser 690 695 700 Leu Gln Lys Phe Gly Glu Arg Ala Phe Lys Ala Trp Ala Val Ala Arg 705 710 715 720 Leu Ser Gln Arg Phe Pro Lys Ala Glu Phe Ala Glu Val Ser Lys Leu 725 730 735 Val Thr Asp Leu Thr Lys Val His Thr Glu Cys Cys His Gly Asp Leu 740 745 750 Leu Glu Cys Ala Asp Asp Arg Ala Asp Leu Ala Lys Tyr Ile Cys Glu 755 760 765 Asn Gln Asp Ser Ile Ser Ser Lys Leu Lys Glu Cys Cys Glu Lys Pro 770 775 780 Leu Leu Glu Lys Ser His Cys Ile Ala Glu Val Glu Asn Asp Glu Met 785 790 795 800 Pro Ala Asp Leu Pro Ser Leu Ala Ala Asp Phe Val Glu Ser Lys Asp 805 810 815 Val Cys Lys Asn Tyr Ala Glu Ala Lys Asp Val Phe Leu Gly Met Phe 820 825 830 Leu Tyr Glu Tyr Ala Arg Arg His Pro Asp Tyr Ser Val Val Leu Leu 835 840 845 Leu Arg Leu Ala Lys Thr Tyr Glu Thr Thr Leu Glu Lys Cys Cys Ala 850 855 860 Ala Ala Asp Pro His Glu Cys Tyr Ala Lys Val Phe Asp Glu Phe Lys 865 870 875 880 Pro Leu Val Glu Glu Pro Gln Asn Leu Ile Lys Gln Asn Cys Glu Leu 885 890 895 Phe Glu Gln Leu Gly Glu Tyr Lys Phe Gln Asn Ala Leu Leu Val Arg 900 905 910 Tyr Thr Lys Lys Val Pro Gln Val Ser Thr Pro Thr Leu Val Glu Val 915 920 925 Ser Arg Asn Leu Gly Lys Val Gly Ser Lys Cys Cys Lys His Pro Glu 930 935 940 Ala Lys Arg Met Pro Cys Ala Glu Asp Tyr Leu Ser Val Val Leu Asn 945 950 955 960 Gln Leu Cys Val Leu His Glu Lys Thr Pro Val Ser Asp Arg Val Thr 965 970 975 Lys Cys Cys Thr Glu Ser Leu Val Asn Arg Arg Pro Cys Phe Ser Ala 980 985 990 Leu Glu Val Asp Glu Thr Tyr Val Pro Lys Glu Phe Asn Ala Glu Thr 995 1000 1005 Phe Thr Phe His Ala Asp Ile Cys Thr Leu Ser Glu Lys Glu Arg 1010 1015 1020 Gln Ile Lys Lys Gln Thr Ala Leu Val Glu Leu Val Lys His Lys 1025 1030 1035 Pro Lys Ala Thr Lys Glu Gln Leu Lys Ala Val Met Asp Asp Phe 1040 1045 1050 Ala Ala Phe Val Glu Lys Cys Cys Lys Ala Asp Asp Lys Glu Thr 1055 1060 1065 Cys Phe Ala Glu Glu Gly Lys Lys Leu Val Ala Ala Ser Gln Ala 1070 1075 1080 Ala Leu Gly Leu His His His His His His 1085 1090 <210> 245 <211> 1093 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 245 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Ala Ser Ile Ser Ser Phe 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Tyr Tyr Ser Gly Thr Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Ile Ala Val Ala Gly Phe Phe Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu 130 135 140 Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln 145 150 155 160 Ser Val Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 165 170 175 Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile 180 185 190 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 195 200 205 Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln 210 215 220 Tyr Asp Arg Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile 225 230 235 240 Lys Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly 245 250 255 Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser 260 265 270 Gly Phe Thr Phe Asn Ser Tyr Ala Met Asn Trp Val Arg Gln Ala Pro 275 280 285 Gly Lys Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn 290 295 300 Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser 305 310 315 320 Arg Asp Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Ser Leu Lys 325 330 335 Thr Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn Phe Gly 340 345 350 Asn Ser Tyr Val Ser Trp Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val 355 360 365 Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 370 375 380 Gly Gly Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser 385 390 395 400 Pro Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val 405 410 415 Thr Ser Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala 420 425 430 Pro Arg Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro 435 440 445 Ala Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu 450 455 460 Ser Gly Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp 465 470 475 480 Tyr Ser Asn Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 485 490 495 Pro Gly Gly Gly Gly Ser Asp Ala His Lys Ser Glu Val Ala His Arg 500 505 510 Phe Lys Asp Leu Gly Glu Glu Asn Phe Lys Ala Leu Val Leu Ile Ala 515 520 525 Phe Ala Gln Tyr Leu Gln Gln Cys Pro Phe Glu Asp His Val Lys Leu 530 535 540 Val Asn Glu Val Thr Glu Phe Ala Lys Thr Cys Val Ala Asp Glu Ser 545 550 555 560 Ala Glu Asn Cys Asp Lys Ser Leu His Thr Leu Phe Gly Asp Lys Leu 565 570 575 Cys Thr Val Ala Thr Leu Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys 580 585 590 Cys Ala Lys Gln Glu Pro Glu Arg Asn Glu Cys Phe Leu Gln His Lys 595 600 605 Asp Asp Asn Pro Asn Leu Pro Arg Leu Val Arg Pro Glu Val Asp Val 610 615 620 Met Cys Thr Ala Phe His Asp Asn Glu Glu Thr Phe Leu Lys Lys Tyr 625 630 635 640 Leu Tyr Glu Ile Ala Arg Arg His Pro Tyr Phe Tyr Ala Pro Glu Leu 645 650 655 Leu Phe Phe Ala Lys Arg Tyr Lys Ala Ala Phe Thr Glu Cys Cys Gln 660 665 670 Ala Ala Asp Lys Ala Ala Cys Leu Leu Pro Lys Leu Asp Glu Leu Arg 675 680 685 Asp Glu Gly Lys Ala Ser Ser Ala Lys Gln Arg Leu Lys Cys Ala Ser 690 695 700 Leu Gln Lys Phe Gly Glu Arg Ala Phe Lys Ala Trp Ala Val Ala Arg 705 710 715 720 Leu Ser Gln Arg Phe Pro Lys Ala Glu Phe Ala Glu Val Ser Lys Leu 725 730 735 Val Thr Asp Leu Thr Lys Val His Thr Glu Cys Cys His Gly Asp Leu 740 745 750 Leu Glu Cys Ala Asp Asp Arg Ala Asp Leu Ala Lys Tyr Ile Cys Glu 755 760 765 Asn Gln Asp Ser Ile Ser Ser Lys Leu Lys Glu Cys Cys Glu Lys Pro 770 775 780 Leu Leu Glu Lys Ser His Cys Ile Ala Glu Val Glu Asn Asp Glu Met 785 790 795 800 Pro Ala Asp Leu Pro Ser Leu Ala Ala Asp Phe Val Glu Ser Lys Asp 805 810 815 Val Cys Lys Asn Tyr Ala Glu Ala Lys Asp Val Phe Leu Gly Met Phe 820 825 830 Leu Tyr Glu Tyr Ala Arg Arg His Pro Asp Tyr Ser Val Val Leu Leu 835 840 845 Leu Arg Leu Ala Lys Thr Tyr Glu Thr Thr Leu Glu Lys Cys Cys Ala 850 855 860 Ala Ala Asp Pro His Glu Cys Tyr Ala Lys Val Phe Asp Glu Phe Lys 865 870 875 880 Pro Leu Val Glu Glu Pro Gln Asn Leu Ile Lys Gln Asn Cys Glu Leu 885 890 895 Phe Glu Gln Leu Gly Glu Tyr Lys Phe Gln Asn Ala Leu Leu Val Arg 900 905 910 Tyr Thr Lys Lys Val Pro Gln Val Ser Thr Pro Thr Leu Val Glu Val 915 920 925 Ser Arg Asn Leu Gly Lys Val Gly Ser Lys Cys Cys Lys His Pro Glu 930 935 940 Ala Lys Arg Met Pro Cys Ala Glu Asp Tyr Leu Ser Val Val Leu Asn 945 950 955 960 Gln Leu Cys Val Leu His Glu Lys Thr Pro Val Ser Asp Arg Val Thr 965 970 975 Lys Cys Cys Thr Glu Ser Leu Val Asn Arg Arg Pro Cys Phe Ser Ala 980 985 990 Leu Glu Val Asp Glu Thr Tyr Val Pro Lys Glu Phe Asn Ala Glu Thr 995 1000 1005 Phe Thr Phe His Ala Asp Ile Cys Thr Leu Ser Glu Lys Glu Arg 1010 1015 1020 Gln Ile Lys Lys Gln Thr Ala Leu Val Glu Leu Val Lys His Lys 1025 1030 1035 Pro Lys Ala Thr Lys Glu Gln Leu Lys Ala Val Met Asp Asp Phe 1040 1045 1050 Ala Ala Phe Val Glu Lys Cys Cys Lys Ala Asp Asp Lys Glu Thr 1055 1060 1065 Cys Phe Ala Glu Glu Gly Lys Lys Leu Val Ala Ala Ser Gln Ala 1070 1075 1080 Ala Leu Gly Leu His His His His His His 1085 1090 <210> 246 <211> 1093 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 246 Gln Val Gln Leu Gln Glu Trp Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Ala Ser Ile Ser Ser Phe 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Tyr Tyr Ser Gly Thr Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Leu Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Ile Ala Val Ala Gly Phe Phe Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu 130 135 140 Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln 145 150 155 160 Ser Val Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 165 170 175 Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile 180 185 190 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 195 200 205 Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln 210 215 220 Tyr Asp Arg Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Asp Ile 225 230 235 240 Lys Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly 245 250 255 Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser 260 265 270 Gly Phe Thr Phe Asn Ser Tyr Ala Met Asn Trp Val Arg Gln Ala Pro 275 280 285 Gly Lys Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn 290 295 300 Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser 305 310 315 320 Arg Asp Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Ser Leu Lys 325 330 335 Thr Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn Phe Gly 340 345 350 Asn Ser Tyr Val Ser Trp Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val 355 360 365 Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 370 375 380 Gly Gly Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser 385 390 395 400 Pro Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val 405 410 415 Thr Ser Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala 420 425 430 Pro Arg Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro 435 440 445 Ala Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu 450 455 460 Ser Gly Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp 465 470 475 480 Tyr Ser Asn Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 485 490 495 Pro Gly Gly Gly Gly Ser Asp Ala His Lys Ser Glu Val Ala His Arg 500 505 510 Phe Lys Asp Leu Gly Glu Glu Asn Phe Lys Ala Leu Val Leu Ile Ala 515 520 525 Phe Ala Gln Tyr Leu Gln Gln Cys Pro Phe Glu Asp His Val Lys Leu 530 535 540 Val Asn Glu Val Thr Glu Phe Ala Lys Thr Cys Val Ala Asp Glu Ser 545 550 555 560 Ala Glu Asn Cys Asp Lys Ser Leu His Thr Leu Phe Gly Asp Lys Leu 565 570 575 Cys Thr Val Ala Thr Leu Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys 580 585 590 Cys Ala Lys Gln Glu Pro Glu Arg Asn Glu Cys Phe Leu Gln His Lys 595 600 605 Asp Asp Asn Pro Asn Leu Pro Arg Leu Val Arg Pro Glu Val Asp Val 610 615 620 Met Cys Thr Ala Phe His Asp Asn Glu Glu Thr Phe Leu Lys Lys Tyr 625 630 635 640 Leu Tyr Glu Ile Ala Arg Arg His Pro Tyr Phe Tyr Ala Pro Glu Leu 645 650 655 Leu Phe Phe Ala Lys Arg Tyr Lys Ala Ala Phe Thr Glu Cys Cys Gln 660 665 670 Ala Ala Asp Lys Ala Ala Cys Leu Leu Pro Lys Leu Asp Glu Leu Arg 675 680 685 Asp Glu Gly Lys Ala Ser Ser Ala Lys Gln Arg Leu Lys Cys Ala Ser 690 695 700 Leu Gln Lys Phe Gly Glu Arg Ala Phe Lys Ala Trp Ala Val Ala Arg 705 710 715 720 Leu Ser Gln Arg Phe Pro Lys Ala Glu Phe Ala Glu Val Ser Lys Leu 725 730 735 Val Thr Asp Leu Thr Lys Val His Thr Glu Cys Cys His Gly Asp Leu 740 745 750 Leu Glu Cys Ala Asp Asp Arg Ala Asp Leu Ala Lys Tyr Ile Cys Glu 755 760 765 Asn Gln Asp Ser Ile Ser Ser Lys Leu Lys Glu Cys Cys Glu Lys Pro 770 775 780 Leu Leu Glu Lys Ser His Cys Ile Ala Glu Val Glu Asn Asp Glu Met 785 790 795 800 Pro Ala Asp Leu Pro Ser Leu Ala Ala Asp Phe Val Glu Ser Lys Asp 805 810 815 Val Cys Lys Asn Tyr Ala Glu Ala Lys Asp Val Phe Leu Gly Met Phe 820 825 830 Leu Tyr Glu Tyr Ala Arg Arg His Pro Asp Tyr Ser Val Val Leu Leu 835 840 845 Leu Arg Leu Ala Lys Thr Tyr Glu Thr Thr Leu Glu Lys Cys Cys Ala 850 855 860 Ala Ala Asp Pro His Glu Cys Tyr Ala Lys Val Phe Asp Glu Phe Lys 865 870 875 880 Pro Leu Val Glu Glu Pro Gln Asn Leu Ile Lys Gln Asn Cys Glu Leu 885 890 895 Phe Glu Gln Leu Gly Glu Tyr Lys Phe Gln Asn Ala Leu Leu Val Arg 900 905 910 Tyr Thr Lys Lys Val Pro Gln Val Ser Thr Pro Thr Leu Val Glu Val 915 920 925 Ser Arg Asn Leu Gly Lys Val Gly Ser Lys Cys Cys Lys His Pro Glu 930 935 940 Ala Lys Arg Met Pro Cys Ala Glu Asp Tyr Leu Ser Val Val Leu Asn 945 950 955 960 Gln Leu Cys Val Leu His Glu Lys Thr Pro Val Ser Asp Arg Val Thr 965 970 975 Lys Cys Cys Thr Glu Ser Leu Val Asn Arg Arg Pro Cys Phe Ser Ala 980 985 990 Leu Glu Val Asp Glu Thr Tyr Val Pro Lys Glu Phe Asn Ala Glu Thr 995 1000 1005 Phe Thr Phe His Ala Asp Ile Cys Thr Leu Ser Glu Lys Glu Arg 1010 1015 1020 Gln Ile Lys Lys Gln Thr Ala Leu Val Glu Leu Val Lys His Lys 1025 1030 1035 Pro Lys Ala Thr Lys Glu Gln Leu Lys Ala Val Met Asp Asp Phe 1040 1045 1050 Ala Ala Phe Val Glu Lys Cys Cys Lys Ala Asp Asp Lys Glu Thr 1055 1060 1065 Cys Phe Ala Glu Glu Gly Lys Lys Leu Val Ala Ala Ser Gln Ala 1070 1075 1080 Ala Leu Gly Leu His His His His His His 1085 1090 <210> 247 <211> 1093 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 247 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Ala Ser Ile Ser Ser Phe 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Tyr Tyr Ser Gly Thr Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Ile Ala Val Ala Gly Phe Phe Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu 130 135 140 Ser Leu Ser Pro Gly Glu Ser Ala Thr Leu Ser Cys Arg Ala Ser Gln 145 150 155 160 Ser Val Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 165 170 175 Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile 180 185 190 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 195 200 205 Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln 210 215 220 Tyr Asp Arg Ser Pro Leu Thr Phe Gly Gly Gly Thr Arg Leu Glu Ile 225 230 235 240 Lys Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly 245 250 255 Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser 260 265 270 Gly Phe Thr Phe Asn Ser Tyr Ala Met Asn Trp Val Arg Gln Ala Pro 275 280 285 Gly Lys Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn 290 295 300 Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser 305 310 315 320 Arg Asp Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Ser Leu Lys 325 330 335 Thr Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn Phe Gly 340 345 350 Asn Ser Tyr Val Ser Trp Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val 355 360 365 Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 370 375 380 Gly Gly Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser 385 390 395 400 Pro Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val 405 410 415 Thr Ser Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala 420 425 430 Pro Arg Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro 435 440 445 Ala Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu 450 455 460 Ser Gly Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp 465 470 475 480 Tyr Ser Asn Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 485 490 495 Pro Gly Gly Gly Gly Ser Asp Ala His Lys Ser Glu Val Ala His Arg 500 505 510 Phe Lys Asp Leu Gly Glu Glu Asn Phe Lys Ala Leu Val Leu Ile Ala 515 520 525 Phe Ala Gln Tyr Leu Gln Gln Cys Pro Phe Glu Asp His Val Lys Leu 530 535 540 Val Asn Glu Val Thr Glu Phe Ala Lys Thr Cys Val Ala Asp Glu Ser 545 550 555 560 Ala Glu Asn Cys Asp Lys Ser Leu His Thr Leu Phe Gly Asp Lys Leu 565 570 575 Cys Thr Val Ala Thr Leu Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys 580 585 590 Cys Ala Lys Gln Glu Pro Glu Arg Asn Glu Cys Phe Leu Gln His Lys 595 600 605 Asp Asp Asn Pro Asn Leu Pro Arg Leu Val Arg Pro Glu Val Asp Val 610 615 620 Met Cys Thr Ala Phe His Asp Asn Glu Glu Thr Phe Leu Lys Lys Tyr 625 630 635 640 Leu Tyr Glu Ile Ala Arg Arg His Pro Tyr Phe Tyr Ala Pro Glu Leu 645 650 655 Leu Phe Phe Ala Lys Arg Tyr Lys Ala Ala Phe Thr Glu Cys Cys Gln 660 665 670 Ala Ala Asp Lys Ala Ala Cys Leu Leu Pro Lys Leu Asp Glu Leu Arg 675 680 685 Asp Glu Gly Lys Ala Ser Ser Ala Lys Gln Arg Leu Lys Cys Ala Ser 690 695 700 Leu Gln Lys Phe Gly Glu Arg Ala Phe Lys Ala Trp Ala Val Ala Arg 705 710 715 720 Leu Ser Gln Arg Phe Pro Lys Ala Glu Phe Ala Glu Val Ser Lys Leu 725 730 735 Val Thr Asp Leu Thr Lys Val His Thr Glu Cys Cys His Gly Asp Leu 740 745 750 Leu Glu Cys Ala Asp Asp Arg Ala Asp Leu Ala Lys Tyr Ile Cys Glu 755 760 765 Asn Gln Asp Ser Ile Ser Ser Lys Leu Lys Glu Cys Cys Glu Lys Pro 770 775 780 Leu Leu Glu Lys Ser His Cys Ile Ala Glu Val Glu Asn Asp Glu Met 785 790 795 800 Pro Ala Asp Leu Pro Ser Leu Ala Ala Asp Phe Val Glu Ser Lys Asp 805 810 815 Val Cys Lys Asn Tyr Ala Glu Ala Lys Asp Val Phe Leu Gly Met Phe 820 825 830 Leu Tyr Glu Tyr Ala Arg Arg His Pro Asp Tyr Ser Val Val Leu Leu 835 840 845 Leu Arg Leu Ala Lys Thr Tyr Glu Thr Thr Leu Glu Lys Cys Cys Ala 850 855 860 Ala Ala Asp Pro His Glu Cys Tyr Ala Lys Val Phe Asp Glu Phe Lys 865 870 875 880 Pro Leu Val Glu Glu Pro Gln Asn Leu Ile Lys Gln Asn Cys Glu Leu 885 890 895 Phe Glu Gln Leu Gly Glu Tyr Lys Phe Gln Asn Ala Leu Leu Val Arg 900 905 910 Tyr Thr Lys Lys Val Pro Gln Val Ser Thr Pro Thr Leu Val Glu Val 915 920 925 Ser Arg Asn Leu Gly Lys Val Gly Ser Lys Cys Cys Lys His Pro Glu 930 935 940 Ala Lys Arg Met Pro Cys Ala Glu Asp Tyr Leu Ser Val Val Leu Asn 945 950 955 960 Gln Leu Cys Val Leu His Glu Lys Thr Pro Val Ser Asp Arg Val Thr 965 970 975 Lys Cys Cys Thr Glu Ser Leu Val Asn Arg Arg Pro Cys Phe Ser Ala 980 985 990 Leu Glu Val Asp Glu Thr Tyr Val Pro Lys Glu Phe Asn Ala Glu Thr 995 1000 1005 Phe Thr Phe His Ala Asp Ile Cys Thr Leu Ser Glu Lys Glu Arg 1010 1015 1020 Gln Ile Lys Lys Gln Thr Ala Leu Val Glu Leu Val Lys His Lys 1025 1030 1035 Pro Lys Ala Thr Lys Glu Gln Leu Lys Ala Val Met Asp Asp Phe 1040 1045 1050 Ala Ala Phe Val Glu Lys Cys Cys Lys Ala Asp Asp Lys Glu Thr 1055 1060 1065 Cys Phe Ala Glu Glu Gly Lys Lys Leu Val Ala Ala Ser Gln Ala 1070 1075 1080 Ala Leu Gly Leu His His His His His His 1085 1090 <210> 248 <211> 1093 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 248 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Phe Tyr Asn Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Leu Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Lys Tyr Tyr Cys Ala 85 90 95 Arg Ile His Ser Gly Ser Phe Ser Phe Asp Tyr Trp Asp Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Glu Ile Val Met Thr Gln Ser Pro Gly Thr Leu 130 135 140 Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln 145 150 155 160 Ser Val Ser Arg Gly Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 165 170 175 Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Asp Ile 180 185 190 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 195 200 205 Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln 210 215 220 Tyr Asp Thr Ser Pro Ile Thr Phe Gly Gln Gly Thr Lys Val Glu Ile 225 230 235 240 Lys Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly 245 250 255 Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser 260 265 270 Gly Phe Thr Phe Asn Ser Tyr Ala Met Asn Trp Val Arg Gln Ala Pro 275 280 285 Gly Lys Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn 290 295 300 Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser 305 310 315 320 Arg Asp Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Ser Leu Lys 325 330 335 Thr Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn Phe Gly 340 345 350 Asn Ser Tyr Val Ser Trp Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val 355 360 365 Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 370 375 380 Gly Gly Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser 385 390 395 400 Pro Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val 405 410 415 Thr Ser Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala 420 425 430 Pro Arg Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro 435 440 445 Ala Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu 450 455 460 Ser Gly Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp 465 470 475 480 Tyr Ser Asn Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 485 490 495 Pro Gly Gly Gly Gly Ser Asp Ala His Lys Ser Glu Val Ala His Arg 500 505 510 Phe Lys Asp Leu Gly Glu Glu Asn Phe Lys Ala Leu Val Leu Ile Ala 515 520 525 Phe Ala Gln Tyr Leu Gln Gln Cys Pro Phe Glu Asp His Val Lys Leu 530 535 540 Val Asn Glu Val Thr Glu Phe Ala Lys Thr Cys Val Ala Asp Glu Ser 545 550 555 560 Ala Glu Asn Cys Asp Lys Ser Leu His Thr Leu Phe Gly Asp Lys Leu 565 570 575 Cys Thr Val Ala Thr Leu Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys 580 585 590 Cys Ala Lys Gln Glu Pro Glu Arg Asn Glu Cys Phe Leu Gln His Lys 595 600 605 Asp Asp Asn Pro Asn Leu Pro Arg Leu Val Arg Pro Glu Val Asp Val 610 615 620 Met Cys Thr Ala Phe His Asp Asn Glu Glu Thr Phe Leu Lys Lys Tyr 625 630 635 640 Leu Tyr Glu Ile Ala Arg Arg His Pro Tyr Phe Tyr Ala Pro Glu Leu 645 650 655 Leu Phe Phe Ala Lys Arg Tyr Lys Ala Ala Phe Thr Glu Cys Cys Gln 660 665 670 Ala Ala Asp Lys Ala Ala Cys Leu Leu Pro Lys Leu Asp Glu Leu Arg 675 680 685 Asp Glu Gly Lys Ala Ser Ser Ala Lys Gln Arg Leu Lys Cys Ala Ser 690 695 700 Leu Gln Lys Phe Gly Glu Arg Ala Phe Lys Ala Trp Ala Val Ala Arg 705 710 715 720 Leu Ser Gln Arg Phe Pro Lys Ala Glu Phe Ala Glu Val Ser Lys Leu 725 730 735 Val Thr Asp Leu Thr Lys Val His Thr Glu Cys Cys His Gly Asp Leu 740 745 750 Leu Glu Cys Ala Asp Asp Arg Ala Asp Leu Ala Lys Tyr Ile Cys Glu 755 760 765 Asn Gln Asp Ser Ile Ser Ser Lys Leu Lys Glu Cys Cys Glu Lys Pro 770 775 780 Leu Leu Glu Lys Ser His Cys Ile Ala Glu Val Glu Asn Asp Glu Met 785 790 795 800 Pro Ala Asp Leu Pro Ser Leu Ala Ala Asp Phe Val Glu Ser Lys Asp 805 810 815 Val Cys Lys Asn Tyr Ala Glu Ala Lys Asp Val Phe Leu Gly Met Phe 820 825 830 Leu Tyr Glu Tyr Ala Arg Arg His Pro Asp Tyr Ser Val Val Leu Leu 835 840 845 Leu Arg Leu Ala Lys Thr Tyr Glu Thr Thr Leu Glu Lys Cys Cys Ala 850 855 860 Ala Ala Asp Pro His Glu Cys Tyr Ala Lys Val Phe Asp Glu Phe Lys 865 870 875 880 Pro Leu Val Glu Glu Pro Gln Asn Leu Ile Lys Gln Asn Cys Glu Leu 885 890 895 Phe Glu Gln Leu Gly Glu Tyr Lys Phe Gln Asn Ala Leu Leu Val Arg 900 905 910 Tyr Thr Lys Lys Val Pro Gln Val Ser Thr Pro Thr Leu Val Glu Val 915 920 925 Ser Arg Asn Leu Gly Lys Val Gly Ser Lys Cys Cys Lys His Pro Glu 930 935 940 Ala Lys Arg Met Pro Cys Ala Glu Asp Tyr Leu Ser Val Val Leu Asn 945 950 955 960 Gln Leu Cys Val Leu His Glu Lys Thr Pro Val Ser Asp Arg Val Thr 965 970 975 Lys Cys Cys Thr Glu Ser Leu Val Asn Arg Arg Pro Cys Phe Ser Ala 980 985 990 Leu Glu Val Asp Glu Thr Tyr Val Pro Lys Glu Phe Asn Ala Glu Thr 995 1000 1005 Phe Thr Phe His Ala Asp Ile Cys Thr Leu Ser Glu Lys Glu Arg 1010 1015 1020 Gln Ile Lys Lys Gln Thr Ala Leu Val Glu Leu Val Lys His Lys 1025 1030 1035 Pro Lys Ala Thr Lys Glu Gln Leu Lys Ala Val Met Asp Asp Phe 1040 1045 1050 Ala Ala Phe Val Glu Lys Cys Cys Lys Ala Asp Asp Lys Glu Thr 1055 1060 1065 Cys Phe Ala Glu Glu Gly Lys Lys Leu Val Ala Ala Ser Gln Ala 1070 1075 1080 Ala Leu Gly Leu His His His His His His 1085 1090 <210> 249 <211> 1102 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 249 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Asp Gly Ser Thr Asn Tyr Ala Gln Asn Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln 130 135 140 Ser Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser 145 150 155 160 Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg Asp Gly Asn Thr Tyr Leu 165 170 175 Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr 180 185 190 Lys Val Ser Asn Trp Gln Ser Gly Val Pro Asp Arg Phe Ser Gly Ser 195 200 205 Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu 210 215 220 Asp Val Gly Val Tyr Phe Cys Met Gln Gly Thr His Trp Pro Pro Thr 225 230 235 240 Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Ser Gly Gly Gly Gly Ser 245 250 255 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 260 265 270 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Ser Tyr 275 280 285 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 290 295 300 Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 305 310 315 320 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 325 330 335 Ala Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr 340 345 350 Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Val Ser Trp Trp 355 360 365 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 370 375 380 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val 385 390 395 400 Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu 405 410 415 Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro Asn 420 425 430 Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly 435 440 445 Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu 450 455 460 Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp 465 470 475 480 Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val Phe 485 490 495 Gly Gly Gly Thr Lys Leu Thr Val Leu Pro Gly Gly Gly Gly Ser Asp 500 505 510 Ala His Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu Glu 515 520 525 Asn Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln Gln 530 535 540 Cys Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu Phe 545 550 555 560 Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys Ser 565 570 575 Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu Arg 580 585 590 Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro Glu 595 600 605 Arg Asn Glu Cys Phe Leu Gln His Lys Asp Asp Asn Pro Asn Leu Pro 610 615 620 Arg Leu Val Arg Pro Glu Val Asp Val Met Cys Thr Ala Phe His Asp 625 630 635 640 Asn Glu Glu Thr Phe Leu Lys Lys Tyr Leu Tyr Glu Ile Ala Arg Arg 645 650 655 His Pro Tyr Phe Tyr Ala Pro Glu Leu Leu Phe Phe Ala Lys Arg Tyr 660 665 670 Lys Ala Ala Phe Thr Glu Cys Cys Gln Ala Ala Asp Lys Ala Ala Cys 675 680 685 Leu Leu Pro Lys Leu Asp Glu Leu Arg Asp Glu Gly Lys Ala Ser Ser 690 695 700 Ala Lys Gln Arg Leu Lys Cys Ala Ser Leu Gln Lys Phe Gly Glu Arg 705 710 715 720 Ala Phe Lys Ala Trp Ala Val Ala Arg Leu Ser Gln Arg Phe Pro Lys 725 730 735 Ala Glu Phe Ala Glu Val Ser Lys Leu Val Thr Asp Leu Thr Lys Val 740 745 750 His Thr Glu Cys Cys His Gly Asp Leu Leu Glu Cys Ala Asp Asp Arg 755 760 765 Ala Asp Leu Ala Lys Tyr Ile Cys Glu Asn Gln Asp Ser Ile Ser Ser 770 775 780 Lys Leu Lys Glu Cys Cys Glu Lys Pro Leu Leu Glu Lys Ser His Cys 785 790 795 800 Ile Ala Glu Val Glu Asn Asp Glu Met Pro Ala Asp Leu Pro Ser Leu 805 810 815 Ala Ala Asp Phe Val Glu Ser Lys Asp Val Cys Lys Asn Tyr Ala Glu 820 825 830 Ala Lys Asp Val Phe Leu Gly Met Phe Leu Tyr Glu Tyr Ala Arg Arg 835 840 845 His Pro Asp Tyr Ser Val Val Leu Leu Leu Arg Leu Ala Lys Thr Tyr 850 855 860 Glu Thr Thr Leu Glu Lys Cys Cys Ala Ala Ala Asp Pro His Glu Cys 865 870 875 880 Tyr Ala Lys Val Phe Asp Glu Phe Lys Pro Leu Val Glu Glu Pro Gln 885 890 895 Asn Leu Ile Lys Gln Asn Cys Glu Leu Phe Glu Gln Leu Gly Glu Tyr 900 905 910 Lys Phe Gln Asn Ala Leu Leu Val Arg Tyr Thr Lys Lys Val Pro Gln 915 920 925 Val Ser Thr Pro Thr Leu Val Glu Val Ser Arg Asn Leu Gly Lys Val 930 935 940 Gly Ser Lys Cys Cys Lys His Pro Glu Ala Lys Arg Met Pro Cys Ala 945 950 955 960 Glu Asp Tyr Leu Ser Val Val Leu Asn Gln Leu Cys Val Leu His Glu 965 970 975 Lys Thr Pro Val Ser Asp Arg Val Thr Lys Cys Cys Thr Glu Ser Leu 980 985 990 Val Asn Arg Arg Pro Cys Phe Ser Ala Leu Glu Val Asp Glu Thr Tyr 995 1000 1005 Val Pro Lys Glu Phe Asn Ala Glu Thr Phe Thr Phe His Ala Asp 1010 1015 1020 Ile Cys Thr Leu Ser Glu Lys Glu Arg Gln Ile Lys Lys Gln Thr 1025 1030 1035 Ala Leu Val Glu Leu Val Lys His Lys Pro Lys Ala Thr Lys Glu 1040 1045 1050 Gln Leu Lys Ala Val Met Asp Asp Phe Ala Ala Phe Val Glu Lys 1055 1060 1065 Cys Cys Lys Ala Asp Asp Lys Glu Thr Cys Phe Ala Glu Glu Gly 1070 1075 1080 Lys Lys Leu Val Ala Ala Ser Gln Ala Ala Leu Gly Leu His His 1085 1090 1095 His His His His 1100 <210> 250 <211> 1102 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 250 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Leu Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Asp Gly Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Asp Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln 130 135 140 Thr Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser 145 150 155 160 Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg Asp Gly Asn Thr Tyr Leu 165 170 175 Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr 180 185 190 Lys Val Ser Asn Trp Gln Ser Gly Val Pro Asp Arg Phe Ser Gly Gly 195 200 205 Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu 210 215 220 Asp Val Gly Val Tyr Tyr Cys Met Gln Gly Thr His Trp Pro Pro Thr 225 230 235 240 Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Ser Gly Gly Gly Gly Ser 245 250 255 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 260 265 270 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Ser Tyr 275 280 285 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 290 295 300 Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 305 310 315 320 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 325 330 335 Ala Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr 340 345 350 Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Val Ser Trp Trp 355 360 365 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 370 375 380 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val 385 390 395 400 Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu 405 410 415 Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro Asn 420 425 430 Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly 435 440 445 Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu 450 455 460 Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp 465 470 475 480 Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val Phe 485 490 495 Gly Gly Gly Thr Lys Leu Thr Val Leu Pro Gly Gly Gly Gly Ser Asp 500 505 510 Ala His Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu Glu 515 520 525 Asn Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln Gln 530 535 540 Cys Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu Phe 545 550 555 560 Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys Ser 565 570 575 Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu Arg 580 585 590 Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro Glu 595 600 605 Arg Asn Glu Cys Phe Leu Gln His Lys Asp Asp Asn Pro Asn Leu Pro 610 615 620 Arg Leu Val Arg Pro Glu Val Asp Val Met Cys Thr Ala Phe His Asp 625 630 635 640 Asn Glu Glu Thr Phe Leu Lys Lys Tyr Leu Tyr Glu Ile Ala Arg Arg 645 650 655 His Pro Tyr Phe Tyr Ala Pro Glu Leu Leu Phe Phe Ala Lys Arg Tyr 660 665 670 Lys Ala Ala Phe Thr Glu Cys Cys Gln Ala Ala Asp Lys Ala Ala Cys 675 680 685 Leu Leu Pro Lys Leu Asp Glu Leu Arg Asp Glu Gly Lys Ala Ser Ser 690 695 700 Ala Lys Gln Arg Leu Lys Cys Ala Ser Leu Gln Lys Phe Gly Glu Arg 705 710 715 720 Ala Phe Lys Ala Trp Ala Val Ala Arg Leu Ser Gln Arg Phe Pro Lys 725 730 735 Ala Glu Phe Ala Glu Val Ser Lys Leu Val Thr Asp Leu Thr Lys Val 740 745 750 His Thr Glu Cys Cys His Gly Asp Leu Leu Glu Cys Ala Asp Asp Arg 755 760 765 Ala Asp Leu Ala Lys Tyr Ile Cys Glu Asn Gln Asp Ser Ile Ser Ser 770 775 780 Lys Leu Lys Glu Cys Cys Glu Lys Pro Leu Leu Glu Lys Ser His Cys 785 790 795 800 Ile Ala Glu Val Glu Asn Asp Glu Met Pro Ala Asp Leu Pro Ser Leu 805 810 815 Ala Ala Asp Phe Val Glu Ser Lys Asp Val Cys Lys Asn Tyr Ala Glu 820 825 830 Ala Lys Asp Val Phe Leu Gly Met Phe Leu Tyr Glu Tyr Ala Arg Arg 835 840 845 His Pro Asp Tyr Ser Val Val Leu Leu Leu Arg Leu Ala Lys Thr Tyr 850 855 860 Glu Thr Thr Leu Glu Lys Cys Cys Ala Ala Ala Asp Pro His Glu Cys 865 870 875 880 Tyr Ala Lys Val Phe Asp Glu Phe Lys Pro Leu Val Glu Glu Pro Gln 885 890 895 Asn Leu Ile Lys Gln Asn Cys Glu Leu Phe Glu Gln Leu Gly Glu Tyr 900 905 910 Lys Phe Gln Asn Ala Leu Leu Val Arg Tyr Thr Lys Lys Val Pro Gln 915 920 925 Val Ser Thr Pro Thr Leu Val Glu Val Ser Arg Asn Leu Gly Lys Val 930 935 940 Gly Ser Lys Cys Cys Lys His Pro Glu Ala Lys Arg Met Pro Cys Ala 945 950 955 960 Glu Asp Tyr Leu Ser Val Val Leu Asn Gln Leu Cys Val Leu His Glu 965 970 975 Lys Thr Pro Val Ser Asp Arg Val Thr Lys Cys Cys Thr Glu Ser Leu 980 985 990 Val Asn Arg Arg Pro Cys Phe Ser Ala Leu Glu Val Asp Glu Thr Tyr 995 1000 1005 Val Pro Lys Glu Phe Asn Ala Glu Thr Phe Thr Phe His Ala Asp 1010 1015 1020 Ile Cys Thr Leu Ser Glu Lys Glu Arg Gln Ile Lys Lys Gln Thr 1025 1030 1035 Ala Leu Val Glu Leu Val Lys His Lys Pro Lys Ala Thr Lys Glu 1040 1045 1050 Gln Leu Lys Ala Val Met Asp Asp Phe Ala Ala Phe Val Glu Lys 1055 1060 1065 Cys Cys Lys Ala Asp Asp Lys Glu Thr Cys Phe Ala Glu Glu Gly 1070 1075 1080 Lys Lys Leu Val Ala Ala Ser Gln Ala Ala Leu Gly Leu His His 1085 1090 1095 His His His His 1100 <210> 251 <211> 1102 <212> PRT <213> Homo sapiens <400> 251 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr 20 25 30 Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Asp Gly Ser Thr Ser Tyr Gly Gln Asn Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln 130 135 140 Ser Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser 145 150 155 160 Cys Arg Ser Ser Gln Ser Leu Ala Tyr Arg Asp Gly Asn Thr Tyr Leu 165 170 175 Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr 180 185 190 Lys Val Ser Asn Trp Gln Ser Gly Val Pro Asp Arg Phe Ser Gly Ser 195 200 205 Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu 210 215 220 Asp Val Gly Val Tyr Phe Cys Met Gln Gly Thr His Trp Pro Pro Thr 225 230 235 240 Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Ser Gly Gly Gly Gly Ser 245 250 255 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 260 265 270 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Ser Tyr 275 280 285 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 290 295 300 Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 305 310 315 320 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 325 330 335 Ala Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr 340 345 350 Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Val Ser Trp Trp 355 360 365 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 370 375 380 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val 385 390 395 400 Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu 405 410 415 Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro Asn 420 425 430 Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly 435 440 445 Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu 450 455 460 Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp 465 470 475 480 Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val Phe 485 490 495 Gly Gly Gly Thr Lys Leu Thr Val Leu Pro Gly Gly Gly Gly Ser Asp 500 505 510 Ala His Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu Glu 515 520 525 Asn Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln Gln 530 535 540 Cys Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu Phe 545 550 555 560 Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys Ser 565 570 575 Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu Arg 580 585 590 Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro Glu 595 600 605 Arg Asn Glu Cys Phe Leu Gln His Lys Asp Asp Asn Pro Asn Leu Pro 610 615 620 Arg Leu Val Arg Pro Glu Val Asp Val Met Cys Thr Ala Phe His Asp 625 630 635 640 Asn Glu Glu Thr Phe Leu Lys Lys Tyr Leu Tyr Glu Ile Ala Arg Arg 645 650 655 His Pro Tyr Phe Tyr Ala Pro Glu Leu Leu Phe Phe Ala Lys Arg Tyr 660 665 670 Lys Ala Ala Phe Thr Glu Cys Cys Gln Ala Ala Asp Lys Ala Ala Cys 675 680 685 Leu Leu Pro Lys Leu Asp Glu Leu Arg Asp Glu Gly Lys Ala Ser Ser 690 695 700 Ala Lys Gln Arg Leu Lys Cys Ala Ser Leu Gln Lys Phe Gly Glu Arg 705 710 715 720 Ala Phe Lys Ala Trp Ala Val Ala Arg Leu Ser Gln Arg Phe Pro Lys 725 730 735 Ala Glu Phe Ala Glu Val Ser Lys Leu Val Thr Asp Leu Thr Lys Val 740 745 750 His Thr Glu Cys Cys His Gly Asp Leu Leu Glu Cys Ala Asp Asp Arg 755 760 765 Ala Asp Leu Ala Lys Tyr Ile Cys Glu Asn Gln Asp Ser Ile Ser Ser 770 775 780 Lys Leu Lys Glu Cys Cys Glu Lys Pro Leu Leu Glu Lys Ser His Cys 785 790 795 800 Ile Ala Glu Val Glu Asn Asp Glu Met Pro Ala Asp Leu Pro Ser Leu 805 810 815 Ala Ala Asp Phe Val Glu Ser Lys Asp Val Cys Lys Asn Tyr Ala Glu 820 825 830 Ala Lys Asp Val Phe Leu Gly Met Phe Leu Tyr Glu Tyr Ala Arg Arg 835 840 845 His Pro Asp Tyr Ser Val Val Leu Leu Leu Arg Leu Ala Lys Thr Tyr 850 855 860 Glu Thr Thr Leu Glu Lys Cys Cys Ala Ala Ala Asp Pro His Glu Cys 865 870 875 880 Tyr Ala Lys Val Phe Asp Glu Phe Lys Pro Leu Val Glu Glu Pro Gln 885 890 895 Asn Leu Ile Lys Gln Asn Cys Glu Leu Phe Glu Gln Leu Gly Glu Tyr 900 905 910 Lys Phe Gln Asn Ala Leu Leu Val Arg Tyr Thr Lys Lys Val Pro Gln 915 920 925 Val Ser Thr Pro Thr Leu Val Glu Val Ser Arg Asn Leu Gly Lys Val 930 935 940 Gly Ser Lys Cys Cys Lys His Pro Glu Ala Lys Arg Met Pro Cys Ala 945 950 955 960 Glu Asp Tyr Leu Ser Val Val Leu Asn Gln Leu Cys Val Leu His Glu 965 970 975 Lys Thr Pro Val Ser Asp Arg Val Thr Lys Cys Cys Thr Glu Ser Leu 980 985 990 Val Asn Arg Arg Pro Cys Phe Ser Ala Leu Glu Val Asp Glu Thr Tyr 995 1000 1005 Val Pro Lys Glu Phe Asn Ala Glu Thr Phe Thr Phe His Ala Asp 1010 1015 1020 Ile Cys Thr Leu Ser Glu Lys Glu Arg Gln Ile Lys Lys Gln Thr 1025 1030 1035 Ala Leu Val Glu Leu Val Lys His Lys Pro Lys Ala Thr Lys Glu 1040 1045 1050 Gln Leu Lys Ala Val Met Asp Asp Phe Ala Ala Phe Val Glu Lys 1055 1060 1065 Cys Cys Lys Ala Asp Asp Lys Glu Thr Cys Phe Ala Glu Glu Gly 1070 1075 1080 Lys Lys Leu Val Ala Ala Ser Gln Ala Ala Leu Gly Leu His His 1085 1090 1095 His His His His 1100 <210> 252 <211> 618 <212> PRT <213> Homo sapiens <400> 252 Met Val Ser Pro Arg Met Ser Gly Leu Leu Ser Gln Thr Val Ile Leu 1 5 10 15 Ala Leu Ile Phe Leu Pro Gln Thr Arg Pro Ala Gly Val Phe Glu Leu 20 25 30 Gln Ile His Ser Phe Gly Pro Gly Pro Gly Pro Gly Ala Pro Arg Ser 35 40 45 Pro Cys Ser Ala Arg Leu Pro Cys Arg Leu Phe Phe Arg Val Cys Leu 50 55 60 Lys Pro Gly Leu Ser Glu Glu Ala Ala Glu Ser Pro Cys Ala Leu Gly 65 70 75 80 Ala Ala Leu Ser Ala Arg Gly Pro Val Tyr Thr Glu Gln Pro Gly Ala 85 90 95 Pro Ala Pro Asp Leu Pro Leu Pro Asp Gly Leu Leu Gln Val Pro Phe 100 105 110 Arg Asp Ala Trp Pro Gly Thr Phe Ser Phe Ile Ile Glu Thr Trp Arg 115 120 125 Glu Glu Leu Gly Asp Gln Ile Gly Gly Pro Ala Trp Ser Leu Leu Ala 130 135 140 Arg Val Ala Gly Arg Arg Arg Leu Ala Ala Gly Gly Pro Trp Ala Arg 145 150 155 160 Asp Ile Gln Arg Ala Gly Ala Trp Glu Leu Arg Phe Ser Tyr Arg Ala 165 170 175 Arg Cys Glu Pro Pro Ala Val Gly Thr Ala Cys Thr Arg Leu Cys Arg 180 185 190 Pro Arg Ser Ala Pro Ser Arg Cys Gly Pro Gly Leu Arg Pro Cys Ala 195 200 205 Pro Leu Glu Asp Glu Cys Glu Ala Pro Leu Val Cys Arg Ala Gly Cys 210 215 220 Ser Pro Glu His Gly Phe Cys Glu Gln Pro Gly Glu Cys Arg Cys Leu 225 230 235 240 Glu Gly Trp Thr Gly Pro Leu Cys Thr Val Pro Val Ser Thr Ser Ser 245 250 255 Cys Leu Ser Pro Arg Gly Pro Ser Ser Ala Thr Thr Gly Cys Leu Val 260 265 270 Pro Gly Pro Gly Pro Cys Asp Gly Asn Pro Cys Ala Asn Gly Gly Ser 275 280 285 Cys Ser Glu Thr Pro Arg Ser Phe Glu Cys Thr Cys Pro Arg Gly Phe 290 295 300 Tyr Gly Leu Arg Cys Glu Val Ser Gly Val Thr Cys Ala Asp Gly Pro 305 310 315 320 Cys Phe Asn Gly Gly Leu Cys Val Gly Gly Ala Asp Pro Asp Ser Ala 325 330 335 Tyr Ile Cys His Cys Pro Pro Gly Phe Gln Gly Ser Asn Cys Glu Lys 340 345 350 Arg Val Asp Arg Cys Ser Leu Gln Pro Cys Arg Asn Gly Gly Leu Cys 355 360 365 Leu Asp Leu Gly His Ala Leu Arg Cys Arg Cys Arg Ala Gly Phe Ala 370 375 380 Gly Pro Arg Cys Glu His Asp Leu Asp Asp Cys Ala Gly Arg Ala Cys 385 390 395 400 Ala Asn Gly Gly Thr Cys Val Glu Gly Gly Gly Ala His Arg Cys Ser 405 410 415 Cys Ala Leu Gly Phe Gly Gly Arg Asp Cys Arg Glu Arg Ala Asp Pro 420 425 430 Cys Ala Ala Arg Pro Cys Ala His Gly Gly Arg Cys Tyr Ala His Phe 435 440 445 Ser Gly Leu Val Cys Ala Cys Ala Pro Gly Tyr Met Gly Ala Arg Cys 450 455 460 Glu Phe Pro Val His Pro Asp Gly Ala Ser Ala Leu Pro Ala Ala Pro 465 470 475 480 Pro Gly Leu Arg Pro Gly Asp Pro Gln Arg Tyr Leu Leu Pro Pro Ala 485 490 495 Leu Gly Leu Leu Val Ala Ala Gly Val Ala Gly Ala Ala Leu Leu Leu 500 505 510 Val His Val Arg Arg Arg Gly His Ser Gln Asp Ala Gly Ser Arg Leu 515 520 525 Leu Ala Gly Thr Pro Glu Pro Ser Val His Ala Leu Pro Asp Ala Leu 530 535 540 Asn Asn Leu Arg Thr Gln Glu Gly Ser Gly Asp Gly Pro Ser Ser Ser 545 550 555 560 Val Asp Trp Asn Arg Pro Glu Asp Val Asp Pro Gln Gly Ile Tyr Val 565 570 575 Ile Ser Ala Pro Ser Ile Tyr Ala Arg Glu Val Ala Thr Pro Leu Phe 580 585 590 Pro Pro Leu His Thr Gly Arg Ala Gly Gln Arg Gln His Leu Leu Phe 595 600 605 Pro Tyr Pro Ser Ser Ile Leu Ser Val Lys 610 615 <210> 253 <211> 492 <212> PRT <213> Homo sapiens <400> 253 Met Val Ser Pro Arg Met Ser Gly Leu Leu Ser Gln Thr Val Ile Leu 1 5 10 15 Ala Leu Ile Phe Leu Pro Gln Thr Arg Pro Ala Gly Val Phe Glu Leu 20 25 30 Gln Ile His Ser Phe Gly Pro Gly Pro Gly Pro Gly Ala Pro Arg Ser 35 40 45 Pro Cys Ser Ala Arg Leu Pro Cys Arg Leu Phe Phe Arg Val Cys Leu 50 55 60 Lys Pro Gly Leu Ser Glu Glu Ala Ala Glu Ser Pro Cys Ala Leu Gly 65 70 75 80 Ala Ala Leu Ser Ala Arg Gly Pro Val Tyr Thr Glu Gln Pro Gly Ala 85 90 95 Pro Ala Pro Asp Leu Pro Leu Pro Asp Gly Leu Leu Gln Val Pro Phe 100 105 110 Arg Asp Ala Trp Pro Gly Thr Phe Ser Phe Ile Ile Glu Thr Trp Arg 115 120 125 Glu Glu Leu Gly Asp Gln Ile Gly Gly Pro Ala Trp Ser Leu Leu Ala 130 135 140 Arg Val Ala Gly Arg Arg Arg Leu Ala Ala Gly Gly Pro Trp Ala Arg 145 150 155 160 Asp Ile Gln Arg Ala Gly Ala Trp Glu Leu Arg Phe Ser Tyr Arg Ala 165 170 175 Arg Cys Glu Pro Pro Ala Val Gly Thr Ala Cys Thr Arg Leu Cys Arg 180 185 190 Pro Arg Ser Ala Pro Ser Arg Cys Gly Pro Gly Leu Arg Pro Cys Ala 195 200 205 Pro Leu Glu Asp Glu Cys Glu Ala Pro Leu Val Cys Arg Ala Gly Cys 210 215 220 Ser Pro Glu His Gly Phe Cys Glu Gln Pro Gly Glu Cys Arg Cys Leu 225 230 235 240 Glu Gly Trp Thr Gly Pro Leu Cys Thr Val Pro Val Ser Thr Ser Ser 245 250 255 Cys Leu Ser Pro Arg Gly Pro Ser Ser Ala Thr Thr Gly Cys Leu Val 260 265 270 Pro Gly Pro Gly Pro Cys Asp Gly Asn Pro Cys Ala Asn Gly Gly Ser 275 280 285 Cys Ser Glu Thr Pro Arg Ser Phe Glu Cys Thr Cys Pro Arg Gly Phe 290 295 300 Tyr Gly Leu Arg Cys Glu Val Ser Gly Val Thr Cys Ala Asp Gly Pro 305 310 315 320 Cys Phe Asn Gly Gly Leu Cys Val Gly Gly Ala Asp Pro Asp Ser Ala 325 330 335 Tyr Ile Cys His Cys Pro Pro Gly Phe Gln Gly Ser Asn Cys Glu Lys 340 345 350 Arg Val Asp Arg Cys Ser Leu Gln Pro Cys Arg Asn Gly Gly Leu Cys 355 360 365 Leu Asp Leu Gly His Ala Leu Arg Cys Arg Cys Arg Ala Gly Phe Ala 370 375 380 Gly Pro Arg Cys Glu His Asp Leu Asp Asp Cys Ala Gly Arg Ala Cys 385 390 395 400 Ala Asn Gly Gly Thr Cys Val Glu Gly Gly Gly Ala His Arg Cys Ser 405 410 415 Cys Ala Leu Gly Phe Gly Gly Arg Asp Cys Arg Glu Arg Ala Asp Pro 420 425 430 Cys Ala Ala Arg Pro Cys Ala His Gly Gly Arg Cys Tyr Ala His Phe 435 440 445 Ser Gly Leu Val Cys Ala Cys Ala Pro Gly Tyr Met Gly Ala Arg Cys 450 455 460 Glu Phe Pro Val His Pro Asp Gly Ala Ser Ala Leu Pro Ala Ala Pro 465 470 475 480 Pro Gly Leu Arg Pro Gly Asp Pro Gln Arg Tyr Leu 485 490 <210> 254 <211> 175 <212> PRT <213> Homo sapiens <400> 254 Met Val Ser Pro Arg Met Ser Gly Leu Leu Ser Gln Thr Val Ile Leu 1 5 10 15 Ala Leu Ile Phe Leu Pro Gln Thr Arg Pro Ala Gly Val Phe Glu Leu 20 25 30 Gln Ile His Ser Phe Gly Pro Gly Pro Gly Pro Gly Ala Pro Arg Ser 35 40 45 Pro Cys Ser Ala Arg Leu Pro Cys Arg Leu Phe Phe Arg Val Cys Leu 50 55 60 Lys Pro Gly Leu Ser Glu Glu Ala Ala Glu Ser Pro Cys Ala Leu Gly 65 70 75 80 Ala Ala Leu Ser Ala Arg Gly Pro Val Tyr Thr Glu Gln Pro Gly Ala 85 90 95 Pro Ala Pro Asp Leu Pro Leu Pro Asp Gly Leu Leu Gln Val Pro Phe 100 105 110 Arg Asp Ala Trp Pro Gly Thr Phe Ser Phe Ile Ile Glu Thr Trp Arg 115 120 125 Glu Glu Leu Gly Asp Gln Ile Gly Gly Pro Ala Trp Ser Leu Leu Ala 130 135 140 Arg Val Ala Gly Arg Arg Arg Leu Ala Ala Gly Gly Pro Trp Ala Arg 145 150 155 160 Asp Ile Gln Arg Ala Gly Ala Trp Glu Leu Arg Phe Ser Tyr Arg 165 170 175 <210> 255 <211> 40 <212> PRT <213> Homo sapiens <400> 255 Ala Arg Cys Glu Pro Pro Ala Val Gly Thr Ala Cys Thr Arg Leu Cys 1 5 10 15 Arg Pro Arg Ser Ala Pro Ser Arg Cys Gly Pro Gly Leu Arg Pro Cys 20 25 30 Ala Pro Leu Glu Asp Glu Cys Glu 35 40 <210> 256 <211> 34 <212> PRT <213> Homo sapiens <400> 256 Ala Pro Leu Val Cys Arg Ala Gly Cys Ser Pro Glu His Gly Phe Cys 1 5 10 15 Glu Gln Pro Gly Glu Cys Arg Cys Leu Glu Gly Trp Thr Gly Pro Leu 20 25 30 Cys Thr <210> 257 <211> 37 <212> PRT <213> Homo sapiens <400> 257 Gly Pro Gly Pro Cys Asp Gly Asn Pro Cys Ala Asn Gly Gly Ser Cys 1 5 10 15 Ser Glu Thr Pro Arg Ser Phe Glu Cys Thr Cys Pro Arg Gly Phe Tyr 20 25 30 Gly Leu Arg Cys Glu 35 <210> 258 <211> 40 <212> PRT <213> Homo sapiens <400> 258 Ser Gly Val Thr Cys Ala Asp Gly Pro Cys Phe Asn Gly Gly Leu Cys 1 5 10 15 Val Gly Gly Ala Asp Pro Asp Ser Ala Tyr Ile Cys His Cys Pro Pro 20 25 30 Gly Phe Gln Gly Ser Asn Cys Glu 35 40 <210> 259 <211> 37 <212> PRT <213> Homo sapiens <400> 259 Arg Val Asp Arg Cys Ser Leu Gln Pro Cys Arg Asn Gly Gly Leu Cys 1 5 10 15 Leu Asp Leu Gly His Ala Leu Arg Cys Arg Cys Arg Ala Gly Phe Ala 20 25 30 Gly Pro Arg Cys Glu 35 <210> 260 <211> 78 <212> PRT <213> Homo sapiens <400> 260 Ser Gly Val Thr Cys Ala Asp Gly Pro Cys Phe Asn Gly Gly Leu Cys 1 5 10 15 Val Gly Gly Ala Asp Pro Asp Ser Ala Tyr Ile Cys His Cys Pro Pro 20 25 30 Gly Phe Gln Gly Ser Asn Cys Glu Lys Arg Val Asp Arg Cys Ser Leu 35 40 45 Gln Pro Cys Arg Asn Gly Gly Leu Cys Leu Asp Leu Gly His Ala Leu 50 55 60 Arg Cys Arg Cys Arg Ala Gly Phe Ala Gly Pro Arg Cys Glu 65 70 75 <210> 261 <211> 37 <212> PRT <213> Homo sapiens <400> 261 Asp Leu Asp Asp Cys Ala Gly Arg Ala Cys Ala Asn Gly Gly Thr Cys 1 5 10 15 Val Glu Gly Gly Gly Ala His Arg Cys Ser Cys Ala Leu Gly Phe Gly 20 25 30 Gly Arg Asp Cys Arg 35 <210> 262 <211> 37 <212> PRT <213> Homo sapiens <400> 262 Arg Ala Asp Pro Cys Ala Ala Arg Pro Cys Ala His Gly Gly Arg Cys 1 5 10 15 Tyr Ala His Phe Ser Gly Leu Val Cys Ala Cys Ala Pro Gly Tyr Met 20 25 30 Gly Ala Arg Cys Glu 35 <210> 263 <211> 548 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 263 Met Val Ser Pro Arg Met Ser Gly Leu Leu Ser Gln Thr Val Ile Leu 1 5 10 15 Ala Leu Ile Phe Leu Pro Gln Thr Arg Pro Ala Gly Val Phe Glu Leu 20 25 30 Gln Ile His Ser Phe Gly Pro Gly Pro Gly Pro Gly Ala Pro Arg Ser 35 40 45 Pro Cys Ser Ala Arg Leu Pro Cys Arg Leu Phe Phe Arg Val Cys Leu 50 55 60 Lys Pro Gly Leu Ser Glu Glu Ala Ala Glu Ser Pro Cys Ala Leu Gly 65 70 75 80 Ala Ala Leu Ser Ala Arg Gly Pro Val Tyr Thr Glu Gln Pro Gly Ala 85 90 95 Pro Ala Pro Asp Leu Pro Leu Pro Asp Gly Leu Leu Gln Val Pro Phe 100 105 110 Arg Asp Ala Trp Pro Gly Thr Phe Ser Phe Ile Ile Glu Thr Trp Arg 115 120 125 Glu Glu Leu Gly Asp Gln Ile Gly Gly Pro Ala Trp Ser Leu Leu Ala 130 135 140 Arg Val Ala Gly Arg Arg Arg Leu Ala Ala Gly Gly Pro Trp Ala Arg 145 150 155 160 Asp Ile Gln Arg Ala Gly Ala Trp Glu Leu Arg Phe Ser Tyr Arg Ala 165 170 175 Arg Cys Glu Pro Pro Ala Val Gly Thr Ala Cys Thr Arg Leu Cys Arg 180 185 190 Pro Arg Ser Ala Pro Ser Arg Cys Gly Pro Gly Leu Arg Pro Cys Ala 195 200 205 Pro Leu Glu Asp Glu Cys Glu Ala Pro Leu Val Cys Arg Ala Gly Cys 210 215 220 Ser Pro Glu His Gly Phe Cys Glu Gln Pro Gly Glu Cys Arg Cys Leu 225 230 235 240 Glu Gly Trp Thr Gly Pro Leu Cys Thr Val Pro Val Ser Thr Ser Ser 245 250 255 Cys Leu Ser Pro Arg Gly Pro Ser Ser Ala Thr Thr Gly Cys Leu Val 260 265 270 Pro Gly Pro Gly Pro Cys Asp Gly Asn Pro Cys Ala Asn Gly Gly Ser 275 280 285 Cys Ser Glu Thr Pro Arg Ser Phe Glu Cys Thr Cys Pro Arg Gly Phe 290 295 300 Tyr Gly Leu Arg Cys Glu Val Ser Gly Val Thr Cys Ala Asp Gly Pro 305 310 315 320 Cys Phe Asn Gly Gly Leu Cys Val Gly Gly Ala Asp Pro Asp Ser Ala 325 330 335 Tyr Ile Cys His Cys Pro Pro Gly Phe Gln Gly Ser Asn Cys Glu Lys 340 345 350 Arg Val Asp Arg Cys Ser Leu Gln Pro Cys Arg Asn Gly Gly Leu Cys 355 360 365 Leu Asp Leu Gly His Ala Leu Arg Cys Arg Cys Arg Ala Gly Phe Ala 370 375 380 Gly Pro Arg Cys Glu His Asp Leu Asp Asp Cys Ala Gly Arg Ala Cys 385 390 395 400 Ala Asn Gly Gly Thr Cys Val Glu Gly Gly Gly Ala His Arg Cys Ser 405 410 415 Cys Ala Leu Gly Phe Gly Gly Arg Asp Cys Arg Glu Arg Ala Asp Pro 420 425 430 Cys Ala Ala Arg Pro Cys Ala His Gly Gly Arg Cys Tyr Ala His Phe 435 440 445 Ser Gly Leu Val Cys Ala Cys Ala Pro Gly Tyr Met Gly Ala Arg Cys 450 455 460 Glu Phe Pro Val His Pro Asp Gly Ala Ser Ala Leu Pro Ala Ala Pro 465 470 475 480 Pro Gly Leu Arg Pro Gly Asp Pro Gln Arg Tyr Leu Ser Gly Gly Gly 485 490 495 Gly Ser Gly Ala Gly Val Ile Ala Val Ile Val Val Val Val Ile Ala 500 505 510 Ile Val Ala Gly Ile Val Val Leu Val Ile Ser Arg Lys Lys Arg Met 515 520 525 Ala Lys Tyr Glu Lys Ala Glu Ile Lys Glu Met Gly Glu Met His Arg 530 535 540 Glu Leu Asn Ala 545 <210> 264 <211> 408 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 264 Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly 1 5 10 15 Val His Ser Gly Lys Pro Ile Pro Asn Pro Leu Leu Gly Leu Asp Ser 20 25 30 Thr Ser Gly Ala Arg Cys Glu Pro Pro Ala Val Gly Thr Ala Cys Thr 35 40 45 Arg Leu Cys Arg Pro Arg Ser Ala Pro Ser Arg Cys Gly Pro Gly Leu 50 55 60 Arg Pro Cys Ala Pro Leu Glu Asp Glu Cys Glu Ala Pro Leu Val Cys 65 70 75 80 Arg Ala Gly Cys Ser Pro Glu His Gly Phe Cys Glu Gln Pro Gly Glu 85 90 95 Cys Arg Cys Leu Glu Gly Trp Thr Gly Pro Leu Cys Thr Val Pro Val 100 105 110 Ser Thr Ser Ser Cys Leu Ser Pro Arg Gly Pro Ser Ser Ala Thr Thr 115 120 125 Gly Cys Leu Val Pro Gly Pro Gly Pro Cys Asp Gly Asn Pro Cys Ala 130 135 140 Asn Gly Gly Ser Cys Ser Glu Thr Pro Arg Ser Phe Glu Cys Thr Cys 145 150 155 160 Pro Arg Gly Phe Tyr Gly Leu Arg Cys Glu Val Ser Gly Val Thr Cys 165 170 175 Ala Asp Gly Pro Cys Phe Asn Gly Gly Leu Cys Val Gly Gly Ala Asp 180 185 190 Pro Asp Ser Ala Tyr Ile Cys His Cys Pro Pro Gly Phe Gln Gly Ser 195 200 205 Asn Cys Glu Lys Arg Val Asp Arg Cys Ser Leu Gln Pro Cys Arg Asn 210 215 220 Gly Gly Leu Cys Leu Asp Leu Gly His Ala Leu Arg Cys Arg Cys Arg 225 230 235 240 Ala Gly Phe Ala Gly Pro Arg Cys Glu His Asp Leu Asp Asp Cys Ala 245 250 255 Gly Arg Ala Cys Ala Asn Gly Gly Thr Cys Val Glu Gly Gly Gly Ala 260 265 270 His Arg Cys Ser Cys Ala Leu Gly Phe Gly Gly Arg Asp Cys Arg Glu 275 280 285 Arg Ala Asp Pro Cys Ala Ala Arg Pro Cys Ala His Gly Gly Arg Cys 290 295 300 Tyr Ala His Phe Ser Gly Leu Val Cys Ala Cys Ala Pro Gly Tyr Met 305 310 315 320 Gly Ala Arg Cys Glu Phe Pro Val His Pro Asp Gly Ala Ser Ala Leu 325 330 335 Pro Ala Ala Pro Pro Gly Leu Arg Pro Gly Asp Pro Gln Arg Tyr Leu 340 345 350 Ser Gly Gly Gly Gly Ser Gly Ala Gly Val Ile Ala Val Ile Val Val 355 360 365 Val Val Ile Ala Ile Val Ala Gly Ile Val Val Leu Val Ile Ser Arg 370 375 380 Lys Lys Arg Met Ala Lys Tyr Glu Lys Ala Glu Ile Lys Glu Met Gly 385 390 395 400 Glu Met His Arg Glu Leu Asn Ala 405 <210> 265 <211> 368 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 265 Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly 1 5 10 15 Val His Ser Gly Lys Pro Ile Pro Asn Pro Leu Leu Gly Leu Asp Ser 20 25 30 Thr Ser Gly Ala Pro Leu Val Cys Arg Ala Gly Cys Ser Pro Glu His 35 40 45 Gly Phe Cys Glu Gln Pro Gly Glu Cys Arg Cys Leu Glu Gly Trp Thr 50 55 60 Gly Pro Leu Cys Thr Val Pro Val Ser Thr Ser Ser Cys Leu Ser Pro 65 70 75 80 Arg Gly Pro Ser Ser Ala Thr Thr Gly Cys Leu Val Pro Gly Pro Gly 85 90 95 Pro Cys Asp Gly Asn Pro Cys Ala Asn Gly Gly Ser Cys Ser Glu Thr 100 105 110 Pro Arg Ser Phe Glu Cys Thr Cys Pro Arg Gly Phe Tyr Gly Leu Arg 115 120 125 Cys Glu Val Ser Gly Val Thr Cys Ala Asp Gly Pro Cys Phe Asn Gly 130 135 140 Gly Leu Cys Val Gly Gly Ala Asp Pro Asp Ser Ala Tyr Ile Cys His 145 150 155 160 Cys Pro Pro Gly Phe Gln Gly Ser Asn Cys Glu Lys Arg Val Asp Arg 165 170 175 Cys Ser Leu Gln Pro Cys Arg Asn Gly Gly Leu Cys Leu Asp Leu Gly 180 185 190 His Ala Leu Arg Cys Arg Cys Arg Ala Gly Phe Ala Gly Pro Arg Cys 195 200 205 Glu His Asp Leu Asp Asp Cys Ala Gly Arg Ala Cys Ala Asn Gly Gly 210 215 220 Thr Cys Val Glu Gly Gly Gly Ala His Arg Cys Ser Cys Ala Leu Gly 225 230 235 240 Phe Gly Gly Arg Asp Cys Arg Glu Arg Ala Asp Pro Cys Ala Ala Arg 245 250 255 Pro Cys Ala His Gly Gly Arg Cys Tyr Ala His Phe Ser Gly Leu Val 260 265 270 Cys Ala Cys Ala Pro Gly Tyr Met Gly Ala Arg Cys Glu Phe Pro Val 275 280 285 His Pro Asp Gly Ala Ser Ala Leu Pro Ala Ala Pro Pro Gly Leu Arg 290 295 300 Pro Gly Asp Pro Gln Arg Tyr Leu Ser Gly Gly Gly Gly Ser Gly Ala 305 310 315 320 Gly Val Ile Ala Val Ile Val Val Val Val Ile Ala Ile Val Ala Gly 325 330 335 Ile Val Val Leu Val Ile Ser Arg Lys Lys Arg Met Ala Lys Tyr Glu 340 345 350 Lys Ala Glu Ile Lys Glu Met Gly Glu Met His Arg Glu Leu Asn Ala 355 360 365 <210> 266 <211> 310 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 266 Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly 1 5 10 15 Val His Ser Gly Lys Pro Ile Pro Asn Pro Leu Leu Gly Leu Asp Ser 20 25 30 Thr Ser Gly Gly Pro Gly Pro Cys Asp Gly Asn Pro Cys Ala Asn Gly 35 40 45 Gly Ser Cys Ser Glu Thr Pro Arg Ser Phe Glu Cys Thr Cys Pro Arg 50 55 60 Gly Phe Tyr Gly Leu Arg Cys Glu Val Ser Gly Val Thr Cys Ala Asp 65 70 75 80 Gly Pro Cys Phe Asn Gly Gly Leu Cys Val Gly Gly Ala Asp Pro Asp 85 90 95 Ser Ala Tyr Ile Cys His Cys Pro Pro Gly Phe Gln Gly Ser Asn Cys 100 105 110 Glu Lys Arg Val Asp Arg Cys Ser Leu Gln Pro Cys Arg Asn Gly Gly 115 120 125 Leu Cys Leu Asp Leu Gly His Ala Leu Arg Cys Arg Cys Arg Ala Gly 130 135 140 Phe Ala Gly Pro Arg Cys Glu His Asp Leu Asp Asp Cys Ala Gly Arg 145 150 155 160 Ala Cys Ala Asn Gly Gly Thr Cys Val Glu Gly Gly Gly Ala His Arg 165 170 175 Cys Ser Cys Ala Leu Gly Phe Gly Gly Arg Asp Cys Arg Glu Arg Ala 180 185 190 Asp Pro Cys Ala Ala Arg Pro Cys Ala His Gly Gly Arg Cys Tyr Ala 195 200 205 His Phe Ser Gly Leu Val Cys Ala Cys Ala Pro Gly Tyr Met Gly Ala 210 215 220 Arg Cys Glu Phe Pro Val His Pro Asp Gly Ala Ser Ala Leu Pro Ala 225 230 235 240 Ala Pro Pro Gly Leu Arg Pro Gly Asp Pro Gln Arg Tyr Leu Ser Gly 245 250 255 Gly Gly Gly Ser Gly Ala Gly Val Ile Ala Val Ile Val Val Val Val 260 265 270 Ile Ala Ile Val Ala Gly Ile Val Val Leu Val Ile Ser Arg Lys Lys 275 280 285 Arg Met Ala Lys Tyr Glu Lys Ala Glu Ile Lys Glu Met Gly Glu Met 290 295 300 His Arg Glu Leu Asn Ala 305 310 <210> 267 <211> 272 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 267 Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly 1 5 10 15 Val His Ser Gly Lys Pro Ile Pro Asn Pro Leu Leu Gly Leu Asp Ser 20 25 30 Thr Ser Gly Ser Gly Val Thr Cys Ala Asp Gly Pro Cys Phe Asn Gly 35 40 45 Gly Leu Cys Val Gly Gly Ala Asp Pro Asp Ser Ala Tyr Ile Cys His 50 55 60 Cys Pro Pro Gly Phe Gln Gly Ser Asn Cys Glu Lys Arg Val Asp Arg 65 70 75 80 Cys Ser Leu Gln Pro Cys Arg Asn Gly Gly Leu Cys Leu Asp Leu Gly 85 90 95 His Ala Leu Arg Cys Arg Cys Arg Ala Gly Phe Ala Gly Pro Arg Cys 100 105 110 Glu His Asp Leu Asp Asp Cys Ala Gly Arg Ala Cys Ala Asn Gly Gly 115 120 125 Thr Cys Val Glu Gly Gly Gly Ala His Arg Cys Ser Cys Ala Leu Gly 130 135 140 Phe Gly Gly Arg Asp Cys Arg Glu Arg Ala Asp Pro Cys Ala Ala Arg 145 150 155 160 Pro Cys Ala His Gly Gly Arg Cys Tyr Ala His Phe Ser Gly Leu Val 165 170 175 Cys Ala Cys Ala Pro Gly Tyr Met Gly Ala Arg Cys Glu Phe Pro Val 180 185 190 His Pro Asp Gly Ala Ser Ala Leu Pro Ala Ala Pro Pro Gly Leu Arg 195 200 205 Pro Gly Asp Pro Gln Arg Tyr Leu Ser Gly Gly Gly Gly Ser Gly Ala 210 215 220 Gly Val Ile Ala Val Ile Val Val Val Val Ile Ala Ile Val Ala Gly 225 230 235 240 Ile Val Val Leu Val Ile Ser Arg Lys Lys Arg Met Ala Lys Tyr Glu 245 250 255 Lys Ala Glu Ile Lys Glu Met Gly Glu Met His Arg Glu Leu Asn Ala 260 265 270 <210> 268 <211> 231 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 268 Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly 1 5 10 15 Val His Ser Gly Lys Pro Ile Pro Asn Pro Leu Leu Gly Leu Asp Ser 20 25 30 Thr Ser Gly Arg Val Asp Arg Cys Ser Leu Gln Pro Cys Arg Asn Gly 35 40 45 Gly Leu Cys Leu Asp Leu Gly His Ala Leu Arg Cys Arg Cys Arg Ala 50 55 60 Gly Phe Ala Gly Pro Arg Cys Glu His Asp Leu Asp Asp Cys Ala Gly 65 70 75 80 Arg Ala Cys Ala Asn Gly Gly Thr Cys Val Glu Gly Gly Gly Ala His 85 90 95 Arg Cys Ser Cys Ala Leu Gly Phe Gly Gly Arg Asp Cys Arg Glu Arg 100 105 110 Ala Asp Pro Cys Ala Ala Arg Pro Cys Ala His Gly Gly Arg Cys Tyr 115 120 125 Ala His Phe Ser Gly Leu Val Cys Ala Cys Ala Pro Gly Tyr Met Gly 130 135 140 Ala Arg Cys Glu Phe Pro Val His Pro Asp Gly Ala Ser Ala Leu Pro 145 150 155 160 Ala Ala Pro Pro Gly Leu Arg Pro Gly Asp Pro Gln Arg Tyr Leu Ser 165 170 175 Gly Gly Gly Gly Ser Gly Ala Gly Val Ile Ala Val Ile Val Val Val 180 185 190 Val Ile Ala Ile Val Ala Gly Ile Val Val Leu Val Ile Ser Arg Lys 195 200 205 Lys Arg Met Ala Lys Tyr Glu Lys Ala Glu Ile Lys Glu Met Gly Glu 210 215 220 Met His Arg Glu Leu Asn Ala 225 230 <210> 269 <211> 193 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 269 Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly 1 5 10 15 Val His Ser Gly Lys Pro Ile Pro Asn Pro Leu Leu Gly Leu Asp Ser 20 25 30 Thr Ser Gly Asp Leu Asp Asp Cys Ala Gly Arg Ala Cys Ala Asn Gly 35 40 45 Gly Thr Cys Val Glu Gly Gly Gly Ala His Arg Cys Ser Cys Ala Leu 50 55 60 Gly Phe Gly Gly Arg Asp Cys Arg Glu Arg Ala Asp Pro Cys Ala Ala 65 70 75 80 Arg Pro Cys Ala His Gly Gly Arg Cys Tyr Ala His Phe Ser Gly Leu 85 90 95 Val Cys Ala Cys Ala Pro Gly Tyr Met Gly Ala Arg Cys Glu Phe Pro 100 105 110 Val His Pro Asp Gly Ala Ser Ala Leu Pro Ala Ala Pro Pro Gly Leu 115 120 125 Arg Pro Gly Asp Pro Gln Arg Tyr Leu Ser Gly Gly Gly Gly Ser Gly 130 135 140 Ala Gly Val Ile Ala Val Ile Val Val Val Val Ile Ala Ile Val Ala 145 150 155 160 Gly Ile Val Val Leu Val Ile Ser Arg Lys Lys Arg Met Ala Lys Tyr 165 170 175 Glu Lys Ala Glu Ile Lys Glu Met Gly Glu Met His Arg Glu Leu Asn 180 185 190 Ala <210> 270 <211> 155 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 270 Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly 1 5 10 15 Val His Ser Gly Lys Pro Ile Pro Asn Pro Leu Leu Gly Leu Asp Ser 20 25 30 Thr Ser Gly Arg Ala Asp Pro Cys Ala Ala Arg Pro Cys Ala His Gly 35 40 45 Gly Arg Cys Tyr Ala His Phe Ser Gly Leu Val Cys Ala Cys Ala Pro 50 55 60 Gly Tyr Met Gly Ala Arg Cys Glu Phe Pro Val His Pro Asp Gly Ala 65 70 75 80 Ser Ala Leu Pro Ala Ala Pro Pro Gly Leu Arg Pro Gly Asp Pro Gln 85 90 95 Arg Tyr Leu Ser Gly Gly Gly Gly Ser Gly Ala Gly Val Ile Ala Val 100 105 110 Ile Val Val Val Val Ile Ala Ile Val Ala Gly Ile Val Val Leu Val 115 120 125 Ile Ser Arg Lys Lys Arg Met Ala Lys Tyr Glu Lys Ala Glu Ile Lys 130 135 140 Glu Met Gly Glu Met His Arg Glu Leu Asn Ala 145 150 155 <210> 271 <211> 587 <212> PRT <213> Macaca fascicularis <400> 271 Met Val Ser Pro Arg Met Ser Arg Leu Leu Ser Gln Thr Val Ile Leu 1 5 10 15 Ala Leu Ile Phe Ile Pro Gln Ala Arg Pro Ala Gly Val Phe Glu Leu 20 25 30 Gln Ile His Ser Phe Gly Pro Gly Pro Gly Pro Gly Ala Pro Arg Ser 35 40 45 Pro Cys Ser Ala Arg Gly Pro Cys Arg Leu Phe Phe Arg Val Cys Leu 50 55 60 Lys Pro Gly Leu Ser Glu Glu Ala Ala Glu Ser Pro Cys Ala Leu Gly 65 70 75 80 Ala Ala Leu Ser Ala Arg Gly Pro Val Tyr Thr Glu Gln Pro Glu Ala 85 90 95 Pro Ala Pro Asp Leu Pro Leu Pro Asn Gly Leu Leu Gln Val Pro Phe 100 105 110 Arg Asp Ala Trp Pro Gly Thr Phe Ser Leu Ile Ile Glu Thr Trp Arg 115 120 125 Glu Glu Leu Gly Asp Gln Ile Gly Gly Pro Ala Trp Ser Leu Leu Ala 130 135 140 Arg Val Thr Arg Arg Arg Arg Leu Ala Ala Gly Gly Pro Trp Ala Arg 145 150 155 160 Asp Ile Gln Arg Ala Gly Ala Trp Glu Leu Arg Phe Ser Tyr Arg Ala 165 170 175 Arg Cys Glu Leu Pro Ala Val Gly Thr Ala Cys Thr Arg Leu Cys Arg 180 185 190 Pro Arg Ser Ala Pro Ser Arg Cys Gly Pro Gly Leu Arg Pro Cys Ala 195 200 205 Pro Leu Glu Asp Glu Cys Glu Ala Pro Pro Val Cys Arg Ala Gly Cys 210 215 220 Ser Leu Glu His Gly Phe Cys Glu Gln Pro Gly Glu Cys Arg Cys Leu 225 230 235 240 Glu Gly Trp Thr Gly Pro Leu Cys Met Val Pro Ala Ser Thr Ser Ser 245 250 255 Cys Leu Gly Leu Arg Gly Pro Ser Ser Ala Thr Thr Gly Cys Leu Val 260 265 270 Pro Gly Pro Gly Pro Cys Asp Gly Asn Pro Cys Ala Asn Gly Gly Ser 275 280 285 Cys Ser Glu Thr Pro Gly Ser Phe Glu Cys Thr Cys Pro Arg Gly Phe 290 295 300 Tyr Gly Leu Arg Cys Glu Val Ser Gly Val Thr Cys Ala Asp Gly Pro 305 310 315 320 Cys Phe Asn Gly Gly Leu Cys Val Gly Gly Ala Asp Pro Asp Ser Ala 325 330 335 Tyr Ile Cys His Cys Pro Pro Gly Phe Gln Gly Ser Asn Cys Glu Lys 340 345 350 Arg Val Asp Arg Cys Ser Leu Gln Pro Cys Arg Asn Gly Gly Leu Cys 355 360 365 Leu Asp Leu Gly His Ala Leu Arg Cys Arg Cys Arg Ala Gly Phe Ala 370 375 380 Gly Pro Arg Cys Glu His Asn Leu Asp Asp Cys Ala Gly Arg Ala Cys 385 390 395 400 Ala Asn Gly Gly Thr Cys Val Glu Gly Gly Gly Ala His Arg Cys Ser 405 410 415 Cys Ala Leu Gly Phe Gly Gly Arg Asp Cys Arg Glu Arg Ala Asp Pro 420 425 430 Cys Ala Ala Arg Pro Cys Ala His Gly Gly Arg Cys Tyr Ala His Phe 435 440 445 Ser Gly Leu Val Cys Ala Cys Ala Pro Gly Tyr Met Gly Ser Arg Cys 450 455 460 Glu Phe Pro Val His Pro Asp Gly Val Ser Ala Leu Pro Ala Ala Pro 465 470 475 480 Pro Gly Leu Arg Pro Gly Asp Pro Gln Arg Tyr Leu Leu Pro Pro Ala 485 490 495 Leu Gly Leu Leu Val Ala Ala Gly Val Ala Gly Ala Ala Leu Leu Leu 500 505 510 Val His Val Arg Arg Arg Gly His Ala Gln Asp Ala Gly Ser Arg Leu 515 520 525 Leu Ala Gly Thr Pro Glu Pro Ser Val His Ala Leu Pro Asp Ala Leu 530 535 540 Asn Asn Gln Arg Thr Gln Glu Gly Pro Gly Asp Val Pro Ser Ser Ser 545 550 555 560 Val Asp Trp Asn Arg Pro Glu Asp Val Asp Ser Arg Gly Ile Tyr Val 565 570 575 Ile Ser Ala Pro Ser Ile Tyr Ala Arg Glu Ala 580 585 <210> 272 <211> 492 <212> PRT <213> Macaca fascicularis <400> 272 Met Val Ser Pro Arg Met Ser Arg Leu Leu Ser Gln Thr Val Ile Leu 1 5 10 15 Ala Leu Ile Phe Ile Pro Gln Ala Arg Pro Ala Gly Val Phe Glu Leu 20 25 30 Gln Ile His Ser Phe Gly Pro Gly Pro Gly Pro Gly Ala Pro Arg Ser 35 40 45 Pro Cys Ser Ala Arg Gly Pro Cys Arg Leu Phe Phe Arg Val Cys Leu 50 55 60 Lys Pro Gly Leu Ser Glu Glu Ala Ala Glu Ser Pro Cys Ala Leu Gly 65 70 75 80 Ala Ala Leu Ser Ala Arg Gly Pro Val Tyr Thr Glu Gln Pro Glu Ala 85 90 95 Pro Ala Pro Asp Leu Pro Leu Pro Asn Gly Leu Leu Gln Val Pro Phe 100 105 110 Arg Asp Ala Trp Pro Gly Thr Phe Ser Leu Ile Ile Glu Thr Trp Arg 115 120 125 Glu Glu Leu Gly Asp Gln Ile Gly Gly Pro Ala Trp Ser Leu Leu Ala 130 135 140 Arg Val Thr Arg Arg Arg Arg Leu Ala Ala Gly Gly Pro Trp Ala Arg 145 150 155 160 Asp Ile Gln Arg Ala Gly Ala Trp Glu Leu Arg Phe Ser Tyr Arg Ala 165 170 175 Arg Cys Glu Leu Pro Ala Val Gly Thr Ala Cys Thr Arg Leu Cys Arg 180 185 190 Pro Arg Ser Ala Pro Ser Arg Cys Gly Pro Gly Leu Arg Pro Cys Ala 195 200 205 Pro Leu Glu Asp Glu Cys Glu Ala Pro Pro Val Cys Arg Ala Gly Cys 210 215 220 Ser Leu Glu His Gly Phe Cys Glu Gln Pro Gly Glu Cys Arg Cys Leu 225 230 235 240 Glu Gly Trp Thr Gly Pro Leu Cys Met Val Pro Ala Ser Thr Ser Ser 245 250 255 Cys Leu Gly Leu Arg Gly Pro Ser Ser Ala Thr Thr Gly Cys Leu Val 260 265 270 Pro Gly Pro Gly Pro Cys Asp Gly Asn Pro Cys Ala Asn Gly Gly Ser 275 280 285 Cys Ser Glu Thr Pro Gly Ser Phe Glu Cys Thr Cys Pro Arg Gly Phe 290 295 300 Tyr Gly Leu Arg Cys Glu Val Ser Gly Val Thr Cys Ala Asp Gly Pro 305 310 315 320 Cys Phe Asn Gly Gly Leu Cys Val Gly Gly Ala Asp Pro Asp Ser Ala 325 330 335 Tyr Ile Cys His Cys Pro Pro Gly Phe Gln Gly Ser Asn Cys Glu Lys 340 345 350 Arg Val Asp Arg Cys Ser Leu Gln Pro Cys Arg Asn Gly Gly Leu Cys 355 360 365 Leu Asp Leu Gly His Ala Leu Arg Cys Arg Cys Arg Ala Gly Phe Ala 370 375 380 Gly Pro Arg Cys Glu His Asn Leu Asp Asp Cys Ala Gly Arg Ala Cys 385 390 395 400 Ala Asn Gly Gly Thr Cys Val Glu Gly Gly Gly Ala His Arg Cys Ser 405 410 415 Cys Ala Leu Gly Phe Gly Gly Arg Asp Cys Arg Glu Arg Ala Asp Pro 420 425 430 Cys Ala Ala Arg Pro Cys Ala His Gly Gly Arg Cys Tyr Ala His Phe 435 440 445 Ser Gly Leu Val Cys Ala Cys Ala Pro Gly Tyr Met Gly Ser Arg Cys 450 455 460 Glu Phe Pro Val His Pro Asp Gly Val Ser Ala Leu Pro Ala Ala Pro 465 470 475 480 Pro Gly Leu Arg Pro Gly Asp Pro Gln Arg Tyr Leu 485 490 <210> 273 <211> 175 <212> PRT <213> Macaca fascicularis <400> 273 Met Val Ser Pro Arg Met Ser Arg Leu Leu Ser Gln Thr Val Ile Leu 1 5 10 15 Ala Leu Ile Phe Ile Pro Gln Ala Arg Pro Ala Gly Val Phe Glu Leu 20 25 30 Gln Ile His Ser Phe Gly Pro Gly Pro Gly Pro Gly Ala Pro Arg Ser 35 40 45 Pro Cys Ser Ala Arg Gly Pro Cys Arg Leu Phe Phe Arg Val Cys Leu 50 55 60 Lys Pro Gly Leu Ser Glu Glu Ala Ala Glu Ser Pro Cys Ala Leu Gly 65 70 75 80 Ala Ala Leu Ser Ala Arg Gly Pro Val Tyr Thr Glu Gln Pro Glu Ala 85 90 95 Pro Ala Pro Asp Leu Pro Leu Pro Asn Gly Leu Leu Gln Val Pro Phe 100 105 110 Arg Asp Ala Trp Pro Gly Thr Phe Ser Leu Ile Ile Glu Thr Trp Arg 115 120 125 Glu Glu Leu Gly Asp Gln Ile Gly Gly Pro Ala Trp Ser Leu Leu Ala 130 135 140 Arg Val Thr Arg Arg Arg Arg Leu Ala Ala Gly Gly Pro Trp Ala Arg 145 150 155 160 Asp Ile Gln Arg Ala Gly Ala Trp Glu Leu Arg Phe Ser Tyr Arg 165 170 175 <210> 274 <211> 40 <212> PRT <213> Macaca fascicularis <400> 274 Ala Arg Cys Glu Leu Pro Ala Val Gly Thr Ala Cys Thr Arg Leu Cys 1 5 10 15 Arg Pro Arg Ser Ala Pro Ser Arg Cys Gly Pro Gly Leu Arg Pro Cys 20 25 30 Ala Pro Leu Glu Asp Glu Cys Glu 35 40 <210> 275 <211> 34 <212> PRT <213> Macaca fascicularis <400> 275 Ala Pro Pro Val Cys Arg Ala Gly Cys Ser Leu Glu His Gly Phe Cys 1 5 10 15 Glu Gln Pro Gly Glu Cys Arg Cys Leu Glu Gly Trp Thr Gly Pro Leu 20 25 30 Cys Met <210> 276 <211> 37 <212> PRT <213> Macaca fascicularis <400> 276 Gly Pro Gly Pro Cys Asp Gly Asn Pro Cys Ala Asn Gly Gly Ser Cys 1 5 10 15 Ser Glu Thr Pro Gly Ser Phe Glu Cys Thr Cys Pro Arg Gly Phe Tyr 20 25 30 Gly Leu Arg Cys Glu 35 <210> 277 <211> 40 <212> PRT <213> Macaca fascicularis <400> 277 Ser Gly Val Thr Cys Ala Asp Gly Pro Cys Phe Asn Gly Gly Leu Cys 1 5 10 15 Val Gly Gly Ala Asp Pro Asp Ser Ala Tyr Ile Cys His Cys Pro Pro 20 25 30 Gly Phe Gln Gly Ser Asn Cys Glu 35 40 <210> 278 <211> 37 <212> PRT <213> Macaca fascicularis <400> 278 Arg Val Asp Arg Cys Ser Leu Gln Pro Cys Arg Asn Gly Gly Leu Cys 1 5 10 15 Leu Asp Leu Gly His Ala Leu Arg Cys Arg Cys Arg Ala Gly Phe Ala 20 25 30 Gly Pro Arg Cys Glu 35 <210> 279 <211> 78 <212> PRT <213> Macaca fascicularis <400> 279 Ser Gly Val Thr Cys Ala Asp Gly Pro Cys Phe Asn Gly Gly Leu Cys 1 5 10 15 Val Gly Gly Ala Asp Pro Asp Ser Ala Tyr Ile Cys His Cys Pro Pro 20 25 30 Gly Phe Gln Gly Ser Asn Cys Glu Lys Arg Val Asp Arg Cys Ser Leu 35 40 45 Gln Pro Cys Arg Asn Gly Gly Leu Cys Leu Asp Leu Gly His Ala Leu 50 55 60 Arg Cys Arg Cys Arg Ala Gly Phe Ala Gly Pro Arg Cys Glu 65 70 75 <210> 280 <211> 37 <212> PRT <213> Macaca fascicularis <400> 280 Asn Leu Asp Asp Cys Ala Gly Arg Ala Cys Ala Asn Gly Gly Thr Cys 1 5 10 15 Val Glu Gly Gly Gly Ala His Arg Cys Ser Cys Ala Leu Gly Phe Gly 20 25 30 Gly Arg Asp Cys Arg 35 <210> 281 <211> 37 <212> PRT <213> Macaca fascicularis <400> 281 Arg Ala Asp Pro Cys Ala Ala Arg Pro Cys Ala His Gly Gly Arg Cys 1 5 10 15 Tyr Ala His Phe Ser Gly Leu Val Cys Ala Cys Ala Pro Gly Tyr Met 20 25 30 Gly Ser Arg Cys Glu 35 <210> 282 <211> 548 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 282 Met Val Ser Pro Arg Met Ser Arg Leu Leu Ser Gln Thr Val Ile Leu 1 5 10 15 Ala Leu Ile Phe Ile Pro Gln Ala Arg Pro Ala Gly Val Phe Glu Leu 20 25 30 Gln Ile His Ser Phe Gly Pro Gly Pro Gly Pro Gly Ala Pro Arg Ser 35 40 45 Pro Cys Ser Ala Arg Gly Pro Cys Arg Leu Phe Phe Arg Val Cys Leu 50 55 60 Lys Pro Gly Leu Ser Glu Glu Ala Ala Glu Ser Pro Cys Ala Leu Gly 65 70 75 80 Ala Ala Leu Ser Ala Arg Gly Pro Val Tyr Thr Glu Gln Pro Glu Ala 85 90 95 Pro Ala Pro Asp Leu Pro Leu Pro Asn Gly Leu Leu Gln Val Pro Phe 100 105 110 Arg Asp Ala Trp Pro Gly Thr Phe Ser Leu Ile Ile Glu Thr Trp Arg 115 120 125 Glu Glu Leu Gly Asp Gln Ile Gly Gly Pro Ala Trp Ser Leu Leu Ala 130 135 140 Arg Val Thr Arg Arg Arg Arg Leu Ala Ala Gly Gly Pro Trp Ala Arg 145 150 155 160 Asp Ile Gln Arg Ala Gly Ala Trp Glu Leu Arg Phe Ser Tyr Arg Ala 165 170 175 Arg Cys Glu Leu Pro Ala Val Gly Thr Ala Cys Thr Arg Leu Cys Arg 180 185 190 Pro Arg Ser Ala Pro Ser Arg Cys Gly Pro Gly Leu Arg Pro Cys Ala 195 200 205 Pro Leu Glu Asp Glu Cys Glu Ala Pro Pro Val Cys Arg Ala Gly Cys 210 215 220 Ser Leu Glu His Gly Phe Cys Glu Gln Pro Gly Glu Cys Arg Cys Leu 225 230 235 240 Glu Gly Trp Thr Gly Pro Leu Cys Met Val Pro Ala Ser Thr Ser Ser 245 250 255 Cys Leu Gly Leu Arg Gly Pro Ser Ser Ala Thr Thr Gly Cys Leu Val 260 265 270 Pro Gly Pro Gly Pro Cys Asp Gly Asn Pro Cys Ala Asn Gly Gly Ser 275 280 285 Cys Ser Glu Thr Pro Gly Ser Phe Glu Cys Thr Cys Pro Arg Gly Phe 290 295 300 Tyr Gly Leu Arg Cys Glu Val Ser Gly Val Thr Cys Ala Asp Gly Pro 305 310 315 320 Cys Phe Asn Gly Gly Leu Cys Val Gly Gly Ala Asp Pro Asp Ser Ala 325 330 335 Tyr Ile Cys His Cys Pro Pro Gly Phe Gln Gly Ser Asn Cys Glu Lys 340 345 350 Arg Val Asp Arg Cys Ser Leu Gln Pro Cys Arg Asn Gly Gly Leu Cys 355 360 365 Leu Asp Leu Gly His Ala Leu Arg Cys Arg Cys Arg Ala Gly Phe Ala 370 375 380 Gly Pro Arg Cys Glu His Asn Leu Asp Asp Cys Ala Gly Arg Ala Cys 385 390 395 400 Ala Asn Gly Gly Thr Cys Val Glu Gly Gly Gly Ala His Arg Cys Ser 405 410 415 Cys Ala Leu Gly Phe Gly Gly Arg Asp Cys Arg Glu Arg Ala Asp Pro 420 425 430 Cys Ala Ala Arg Pro Cys Ala His Gly Gly Arg Cys Tyr Ala His Phe 435 440 445 Ser Gly Leu Val Cys Ala Cys Ala Pro Gly Tyr Met Gly Ser Arg Cys 450 455 460 Glu Phe Pro Val His Pro Asp Gly Val Ser Ala Leu Pro Ala Ala Pro 465 470 475 480 Pro Gly Leu Arg Pro Gly Asp Pro Gln Arg Tyr Leu Ser Gly Gly Gly 485 490 495 Gly Ser Gly Ala Gly Val Ile Ala Val Ile Val Val Val Val Ile Ala 500 505 510 Ile Val Ala Gly Ile Val Val Leu Val Ile Ser Arg Lys Lys Arg Met 515 520 525 Ala Lys Tyr Glu Lys Ala Glu Ile Lys Glu Met Gly Glu Met His Arg 530 535 540 Glu Leu Asn Ala 545 <210> 283 <211> 723 <212> PRT <213> Homo sapiens <400> 283 Met Gly Ser Arg Cys Ala Leu Ala Leu Ala Val Leu Ser Ala Leu Leu 1 5 10 15 Cys Gln Val Trp Ser Ser Gly Val Phe Glu Leu Lys Leu Gln Glu Phe 20 25 30 Val Asn Lys Lys Gly Leu Leu Gly Asn Arg Asn Cys Cys Arg Gly Gly 35 40 45 Ala Gly Pro Pro Pro Cys Ala Cys Arg Thr Phe Phe Arg Val Cys Leu 50 55 60 Lys His Tyr Gln Ala Ser Val Ser Pro Glu Pro Pro Cys Thr Tyr Gly 65 70 75 80 Ser Ala Val Thr Pro Val Leu Gly Val Asp Ser Phe Ser Leu Pro Asp 85 90 95 Gly Gly Gly Ala Asp Ser Ala Phe Ser Asn Pro Ile Arg Phe Pro Phe 100 105 110 Gly Phe Thr Trp Pro Gly Thr Phe Ser Leu Ile Ile Glu Ala Leu His 115 120 125 Thr Asp Ser Pro Asp Asp Leu Ala Thr Glu Asn Pro Glu Arg Leu Ile 130 135 140 Ser Arg Leu Ala Thr Gln Arg His Leu Thr Val Gly Glu Glu Trp Ser 145 150 155 160 Gln Asp Leu His Ser Ser Gly Arg Thr Asp Leu Lys Tyr Ser Tyr Arg 165 170 175 Phe Val Cys Asp Glu His Tyr Tyr Gly Glu Gly Cys Ser Val Phe Cys 180 185 190 Arg Pro Arg Asp Asp Ala Phe Gly His Phe Thr Cys Gly Glu Arg Gly 195 200 205 Glu Lys Val Cys Asn Pro Gly Trp Lys Gly Pro Tyr Cys Thr Glu Pro 210 215 220 Ile Cys Leu Pro Gly Cys Asp Glu Gln His Gly Phe Cys Asp Lys Pro 225 230 235 240 Gly Glu Cys Lys Cys Arg Val Gly Trp Gln Gly Arg Tyr Cys Asp Glu 245 250 255 Cys Ile Arg Tyr Pro Gly Cys Leu His Gly Thr Cys Gln Gln Pro Trp 260 265 270 Gln Cys Asn Cys Gln Glu Gly Trp Gly Gly Leu Phe Cys Asn Gln Asp 275 280 285 Leu Asn Tyr Cys Thr His His Lys Pro Cys Lys Asn Gly Ala Thr Cys 290 295 300 Thr Asn Thr Gly Gln Gly Ser Tyr Thr Cys Ser Cys Arg Pro Gly Tyr 305 310 315 320 Thr Gly Ala Thr Cys Glu Leu Gly Ile Asp Glu Cys Asp Pro Ser Pro 325 330 335 Cys Lys Asn Gly Gly Ser Cys Thr Asp Leu Glu Asn Ser Tyr Ser Cys 340 345 350 Thr Cys Pro Pro Gly Phe Tyr Gly Lys Ile Cys Glu Leu Ser Ala Met 355 360 365 Thr Cys Ala Asp Gly Pro Cys Phe Asn Gly Gly Arg Cys Ser Asp Ser 370 375 380 Pro Asp Gly Gly Tyr Ser Cys Arg Cys Pro Val Gly Tyr Ser Gly Phe 385 390 395 400 Asn Cys Glu Lys Lys Ile Asp Tyr Cys Ser Ser Ser Pro Cys Ser Asn 405 410 415 Gly Ala Lys Cys Val Asp Leu Gly Asp Ala Tyr Leu Cys Arg Cys Gln 420 425 430 Ala Gly Phe Ser Gly Arg His Cys Asp Asp Asn Val Asp Asp Cys Ala 435 440 445 Ser Ser Pro Cys Ala Asn Gly Gly Thr Cys Arg Asp Gly Val Asn Asp 450 455 460 Phe Ser Cys Thr Cys Pro Pro Gly Tyr Thr Gly Arg Asn Cys Ser Ala 465 470 475 480 Pro Val Ser Arg Cys Glu His Ala Pro Cys His Asn Gly Ala Thr Cys 485 490 495 His Glu Arg Gly His Arg Tyr Val Cys Glu Cys Ala Arg Gly Tyr Gly 500 505 510 Gly Pro Asn Cys Gln Phe Leu Leu Pro Glu Leu Pro Pro Gly Pro Ala 515 520 525 Val Val Asp Leu Thr Glu Lys Leu Glu Gly Gln Gly Gly Pro Phe Pro 530 535 540 Trp Val Ala Val Cys Ala Gly Val Ile Leu Val Leu Met Leu Leu Leu 545 550 555 560 Gly Cys Ala Ala Val Val Val Cys Val Arg Leu Arg Leu Gln Lys His 565 570 575 Arg Pro Pro Ala Asp Pro Cys Arg Gly Glu Thr Glu Thr Met Asn Asn 580 585 590 Leu Ala Asn Cys Gln Arg Glu Lys Asp Ile Ser Val Ser Ile Ile Gly 595 600 605 Ala Thr Gln Ile Lys Asn Thr Asn Lys Lys Ala Asp Phe His Gly Asp 610 615 620 His Ser Ala Asp Lys Asn Gly Phe Lys Ala Arg Tyr Pro Ala Val Asp 625 630 635 640 Tyr Asn Leu Val Gln Asp Leu Lys Gly Asp Asp Thr Ala Val Arg Asp 645 650 655 Ala His Ser Lys Arg Asp Thr Lys Cys Gln Pro Gln Gly Ser Ser Gly 660 665 670 Glu Glu Lys Gly Thr Pro Thr Thr Leu Arg Gly Gly Glu Ala Ser Glu 675 680 685 Arg Lys Arg Pro Asp Ser Gly Cys Ser Thr Ser Lys Asp Thr Lys Tyr 690 695 700 Gln Ser Val Tyr Val Ile Ser Glu Glu Lys Asp Glu Cys Val Ile Ala 705 710 715 720 Thr Glu Val <210> 284 <211> 685 <212> PRT <213> Homo sapiens <400> 284 Met Ala Ala Ala Ser Arg Ser Ala Ser Gly Trp Ala Leu Leu Leu Leu 1 5 10 15 Val Ala Leu Trp Gln Gln Arg Ala Ala Gly Ser Gly Val Phe Gln Leu 20 25 30 Gln Leu Gln Glu Phe Ile Asn Glu Arg Gly Val Leu Ala Ser Gly Arg 35 40 45 Pro Cys Glu Pro Gly Cys Arg Thr Phe Phe Arg Val Cys Leu Lys His 50 55 60 Phe Gln Ala Val Val Ser Pro Gly Pro Cys Thr Phe Gly Thr Val Ser 65 70 75 80 Thr Pro Val Leu Gly Thr Asn Ser Phe Ala Val Arg Asp Asp Ser Ser 85 90 95 Gly Gly Gly Arg Asn Pro Leu Gln Leu Pro Phe Asn Phe Thr Trp Pro 100 105 110 Gly Thr Phe Ser Leu Ile Ile Glu Ala Trp His Ala Pro Gly Asp Asp 115 120 125 Leu Arg Pro Glu Ala Leu Pro Pro Asp Ala Leu Ile Ser Lys Ile Ala 130 135 140 Ile Gln Gly Ser Leu Ala Val Gly Gln Asn Trp Leu Leu Asp Glu Gln 145 150 155 160 Thr Ser Thr Leu Thr Arg Leu Arg Tyr Ser Tyr Arg Val Ile Cys Ser 165 170 175 Asp Asn Tyr Tyr Gly Asp Asn Cys Ser Arg Leu Cys Lys Lys Arg Asn 180 185 190 Asp His Phe Gly His Tyr Val Cys Gln Pro Asp Gly Asn Leu Ser Cys 195 200 205 Leu Pro Gly Trp Thr Gly Glu Tyr Cys Gln Gln Pro Ile Cys Leu Ser 210 215 220 Gly Cys His Glu Gln Asn Gly Tyr Cys Ser Lys Pro Ala Glu Cys Leu 225 230 235 240 Cys Arg Pro Gly Trp Gln Gly Arg Leu Cys Asn Glu Cys Ile Pro His 245 250 255 Asn Gly Cys Arg His Gly Thr Cys Ser Thr Pro Trp Gln Cys Thr Cys 260 265 270 Asp Glu Gly Trp Gly Gly Leu Phe Cys Asp Gln Asp Leu Asn Tyr Cys 275 280 285 Thr His His Ser Pro Cys Lys Asn Gly Ala Thr Cys Ser Asn Ser Gly 290 295 300 Gln Arg Ser Tyr Thr Cys Thr Cys Arg Pro Gly Tyr Thr Gly Val Asp 305 310 315 320 Cys Glu Leu Glu Leu Ser Glu Cys Asp Ser Asn Pro Cys Arg Asn Gly 325 330 335 Gly Ser Cys Lys Asp Gln Glu Asp Gly Tyr His Cys Leu Cys Pro Pro 340 345 350 Gly Tyr Tyr Gly Leu His Cys Glu His Ser Thr Leu Ser Cys Ala Asp 355 360 365 Ser Pro Cys Phe Asn Gly Gly Ser Cys Arg Glu Arg Asn Gln Gly Ala 370 375 380 Asn Tyr Ala Cys Glu Cys Pro Pro Asn Phe Thr Gly Ser Asn Cys Glu 385 390 395 400 Lys Lys Val Asp Arg Cys Thr Ser Asn Pro Cys Ala Asn Gly Gly Gln 405 410 415 Cys Leu Asn Arg Gly Pro Ser Arg Met Cys Arg Cys Arg Pro Gly Phe 420 425 430 Thr Gly Thr Tyr Cys Glu Leu His Val Ser Asp Cys Ala Arg Asn Pro 435 440 445 Cys Ala His Gly Gly Thr Cys His Asp Leu Glu Asn Gly Leu Met Cys 450 455 460 Thr Cys Pro Ala Gly Phe Ser Gly Arg Arg Cys Glu Val Arg Thr Ser 465 470 475 480 Ile Asp Ala Cys Ala Ser Ser Pro Cys Phe Asn Arg Ala Thr Cys Tyr 485 490 495 Thr Asp Leu Ser Thr Asp Thr Phe Val Cys Asn Cys Pro Tyr Gly Phe 500 505 510 Val Gly Ser Arg Cys Glu Phe Pro Val Gly Leu Pro Pro Ser Phe Pro 515 520 525 Trp Val Ala Val Ser Leu Gly Val Gly Leu Ala Val Leu Leu Val Leu 530 535 540 Leu Gly Met Val Ala Val Ala Val Arg Gln Leu Arg Leu Arg Arg Pro 545 550 555 560 Asp Asp Gly Ser Arg Glu Ala Met Asn Asn Leu Ser Asp Phe Gln Lys 565 570 575 Asp Asn Leu Ile Pro Ala Ala Gln Leu Lys Asn Thr Asn Gln Lys Lys 580 585 590 Glu Leu Glu Val Asp Cys Gly Leu Asp Lys Ser Asn Cys Gly Lys Gln 595 600 605 Gln Asn His Thr Leu Asp Tyr Asn Leu Ala Pro Gly Pro Leu Gly Arg 610 615 620 Gly Thr Met Pro Gly Lys Phe Pro His Ser Asp Lys Ser Leu Gly Glu 625 630 635 640 Lys Ala Pro Leu Arg Leu His Ser Glu Lys Pro Glu Cys Arg Ile Ser 645 650 655 Ala Ile Cys Ser Pro Arg Asp Ser Met Tyr Gln Ser Val Cys Leu Ile 660 665 670 Ser Glu Glu Arg Asn Glu Cys Val Ile Ala Thr Glu Val 675 680 685 <210> 285 <211> 4 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 285 Gly Gly Gly Gly 1 <210> 286 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 286 Gly Gly Gly Gly Ser 1 5 <210> 287 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 287 Gly Gly Gly Gly Gln 1 5 <210> 288 <211> 6 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 288 Ser Gly Gly Gly Gly Ser 1 5 <210> 289 <211> 6 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 289 Pro Gly Gly Gly Gly Ser 1 5 <210> 290 <211> 6 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 290 Pro Gly Gly Asp Gly Ser 1 5 <210> 291 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 291 Gly Gly Gly Gly Ser Gly Gly Gly Ser 1 5 <210> 292 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 292 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 1 5 10 <210> 293 <211> 15 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 293 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 1 5 10 15 <210> 294 <211> 6 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 294 His His His His His His 1 5 <210> 295 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 295 Arg Asp Trp Asp Phe Asp Val Phe Gly Gly Gly Thr Pro Val Gly Gly 1 5 10 15 <210> 296 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> misc_feature <222> (12)..(12) <223> Xaa can be any naturally occurring amino acid <400> 296 Gln Arg Phe Val Thr Gly His Phe Gly Gly Leu Xaa Pro Ala Asn Gly 1 5 10 15 <210> 297 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 297 Gln Arg Phe Val Thr Gly His Phe Gly Gly Leu Tyr Pro Ala Asn Gly 1 5 10 15 <210> 298 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 298 Gln Arg Phe Val Thr Gly His Phe Gly Gly Leu His Pro Ala Asn Gly 1 5 10 15 <210> 299 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 299 Thr Gly His Phe Gly Gly Leu His Pro 1 5 <210> 300 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 300 Gln Arg Phe Cys Thr Gly His Phe Gly Gly Leu His Pro Cys Asn Gly 1 5 10 15 <210> 301 <211> 585 <212> PRT <213> Homo sapiens <400> 301 Asp Ala His Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu 1 5 10 15 Glu Asn Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln 20 25 30 Gln Cys Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu 35 40 45 Phe Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys 50 55 60 Ser Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu 65 70 75 80 Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro 85 90 95 Glu Arg Asn Glu Cys Phe Leu Gln His Lys Asp Asp Asn Pro Asn Leu 100 105 110 Pro Arg Leu Val Arg Pro Glu Val Asp Val Met Cys Thr Ala Phe His 115 120 125 Asp Asn Glu Glu Thr Phe Leu Lys Lys Tyr Leu Tyr Glu Ile Ala Arg 130 135 140 Arg His Pro Tyr Phe Tyr Ala Pro Glu Leu Leu Phe Phe Ala Lys Arg 145 150 155 160 Tyr Lys Ala Ala Phe Thr Glu Cys Cys Gln Ala Ala Asp Lys Ala Ala 165 170 175 Cys Leu Leu Pro Lys Leu Asp Glu Leu Arg Asp Glu Gly Lys Ala Ser 180 185 190 Ser Ala Lys Gln Arg Leu Lys Cys Ala Ser Leu Gln Lys Phe Gly Glu 195 200 205 Arg Ala Phe Lys Ala Trp Ala Val Ala Arg Leu Ser Gln Arg Phe Pro 210 215 220 Lys Ala Glu Phe Ala Glu Val Ser Lys Leu Val Thr Asp Leu Thr Lys 225 230 235 240 Val His Thr Glu Cys Cys His Gly Asp Leu Leu Glu Cys Ala Asp Asp 245 250 255 Arg Ala Asp Leu Ala Lys Tyr Ile Cys Glu Asn Gln Asp Ser Ile Ser 260 265 270 Ser Lys Leu Lys Glu Cys Cys Glu Lys Pro Leu Leu Glu Lys Ser His 275 280 285 Cys Ile Ala Glu Val Glu Asn Asp Glu Met Pro Ala Asp Leu Pro Ser 290 295 300 Leu Ala Ala Asp Phe Val Glu Ser Lys Asp Val Cys Lys Asn Tyr Ala 305 310 315 320 Glu Ala Lys Asp Val Phe Leu Gly Met Phe Leu Tyr Glu Tyr Ala Arg 325 330 335 Arg His Pro Asp Tyr Ser Val Val Leu Leu Leu Arg Leu Ala Lys Thr 340 345 350 Tyr Glu Thr Thr Leu Glu Lys Cys Cys Ala Ala Ala Asp Pro His Glu 355 360 365 Cys Tyr Ala Lys Val Phe Asp Glu Phe Lys Pro Leu Val Glu Glu Pro 370 375 380 Gln Asn Leu Ile Lys Gln Asn Cys Glu Leu Phe Glu Gln Leu Gly Glu 385 390 395 400 Tyr Lys Phe Gln Asn Ala Leu Leu Val Arg Tyr Thr Lys Lys Val Pro 405 410 415 Gln Val Ser Thr Pro Thr Leu Val Glu Val Ser Arg Asn Leu Gly Lys 420 425 430 Val Gly Ser Lys Cys Cys Lys His Pro Glu Ala Lys Arg Met Pro Cys 435 440 445 Ala Glu Asp Tyr Leu Ser Val Val Leu Asn Gln Leu Cys Val Leu His 450 455 460 Glu Lys Thr Pro Val Ser Asp Arg Val Thr Lys Cys Cys Thr Glu Ser 465 470 475 480 Leu Val Asn Arg Arg Pro Cys Phe Ser Ala Leu Glu Val Asp Glu Thr 485 490 495 Tyr Val Pro Lys Glu Phe Asn Ala Glu Thr Phe Thr Phe His Ala Asp 500 505 510 Ile Cys Thr Leu Ser Glu Lys Glu Arg Gln Ile Lys Lys Gln Thr Ala 515 520 525 Leu Val Glu Leu Val Lys His Lys Pro Lys Ala Thr Lys Glu Gln Leu 530 535 540 Lys Ala Val Met Asp Asp Phe Ala Ala Phe Val Glu Lys Cys Cys Lys 545 550 555 560 Ala Asp Asp Lys Glu Thr Cys Phe Ala Glu Glu Gly Lys Lys Leu Val 565 570 575 Ala Ala Ser Gln Ala Ala Leu Gly Leu 580 585 <210> 302 <211> 585 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 302 Asp Ala His Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu 1 5 10 15 Glu Asn Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln 20 25 30 Gln Cys Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu 35 40 45 Phe Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys 50 55 60 Ser Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu 65 70 75 80 Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro 85 90 95 Glu Arg Asn Glu Cys Phe Leu Gln His Lys Asp Asp Asn Pro Asn Leu 100 105 110 Pro Arg Leu Val Arg Pro Glu Val Asp Val Met Cys Thr Ala Phe His 115 120 125 Asp Asn Glu Glu Thr Phe Leu Lys Lys Tyr Leu Tyr Glu Ile Ala Arg 130 135 140 Arg His Pro Tyr Phe Tyr Ala Pro Glu Leu Leu Phe Phe Ala Lys Arg 145 150 155 160 Tyr Lys Ala Ala Phe Thr Glu Cys Cys Gln Ala Ala Asp Lys Ala Ala 165 170 175 Cys Leu Leu Pro Lys Leu Asp Glu Leu Arg Asp Glu Gly Lys Ala Ser 180 185 190 Ser Ala Lys Gln Arg Leu Lys Cys Ala Ser Leu Gln Lys Phe Gly Glu 195 200 205 Arg Ala Phe Lys Ala Trp Ala Val Ala Arg Leu Ser Gln Arg Phe Pro 210 215 220 Lys Ala Glu Phe Ala Glu Val Ser Lys Leu Val Thr Asp Leu Thr Lys 225 230 235 240 Val His Thr Glu Cys Cys His Gly Asp Leu Leu Glu Cys Ala Asp Asp 245 250 255 Arg Ala Asp Leu Ala Lys Tyr Ile Cys Glu Asn Gln Asp Ser Ile Ser 260 265 270 Ser Lys Leu Lys Glu Cys Cys Glu Lys Pro Leu Leu Glu Lys Ser His 275 280 285 Cys Ile Ala Glu Val Glu Asn Asp Glu Met Pro Ala Asp Leu Pro Ser 290 295 300 Leu Ala Ala Asp Phe Val Glu Ser Lys Asp Val Cys Lys Asn Tyr Ala 305 310 315 320 Glu Ala Lys Asp Val Phe Leu Gly Met Phe Leu Tyr Glu Tyr Ala Arg 325 330 335 Arg His Pro Asp Tyr Ser Val Val Leu Leu Leu Arg Leu Ala Lys Thr 340 345 350 Tyr Glu Thr Thr Leu Glu Lys Cys Cys Ala Ala Ala Asp Pro His Glu 355 360 365 Cys Tyr Ala Lys Val Phe Asp Glu Phe Lys Pro Leu Val Glu Glu Pro 370 375 380 Gln Asn Leu Ile Lys Gln Asn Cys Glu Leu Phe Glu Gln Leu Gly Glu 385 390 395 400 Tyr Lys Phe Gln Asn Ala Leu Leu Val Arg Tyr Thr Lys Lys Val Pro 405 410 415 Gln Val Ser Thr Pro Thr Leu Val Glu Val Ser Arg Asn Leu Gly Lys 420 425 430 Val Gly Ser Lys Cys Cys Lys His Pro Glu Ala Lys Arg Met Pro Cys 435 440 445 Ala Glu Asp Tyr Leu Ser Val Val Leu Asn Gln Leu Cys Val Leu His 450 455 460 Glu Lys Thr Pro Val Ser Asp Arg Val Thr Lys Cys Cys Thr Glu Ser 465 470 475 480 Leu Val Asn Arg Arg Pro Cys Phe Ser Ala Leu Glu Val Asp Glu Thr 485 490 495 Tyr Val Pro Lys Glu Phe Asn Ala Gly Thr Phe Thr Phe His Ala Asp 500 505 510 Ile Cys Thr Leu Ser Glu Lys Glu Arg Gln Ile Lys Lys Gln Thr Ala 515 520 525 Leu Val Glu Leu Val Lys His Lys Pro Lys Ala Thr Lys Glu Gln Leu 530 535 540 Lys Ala Ala Met Asp Asp Phe Ala Ala Phe Val Glu Lys Cys Cys Lys 545 550 555 560 Ala Asp Asp Lys Glu Thr Cys Phe Ala Glu Glu Gly Lys Lys Leu Val 565 570 575 Ala Ala Ser Gln Ala Ala Leu Gly Leu 580 585 <210> 303 <211> 585 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 303 Asp Ala His Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu 1 5 10 15 Glu Asn Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln 20 25 30 Gln Cys Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu 35 40 45 Phe Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys 50 55 60 Ser Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu 65 70 75 80 Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro 85 90 95 Glu Arg Asn Glu Cys Phe Leu Gln His Lys Asp Asp Asn Pro Asn Leu 100 105 110 Pro Arg Leu Val Arg Pro Glu Val Asp Val Met Cys Thr Ala Phe His 115 120 125 Asp Asn Glu Glu Thr Phe Leu Lys Lys Tyr Leu Tyr Glu Ile Ala Arg 130 135 140 Arg His Pro Tyr Phe Tyr Ala Pro Glu Leu Leu Phe Phe Ala Lys Arg 145 150 155 160 Tyr Lys Ala Ala Phe Thr Glu Cys Cys Gln Ala Ala Asp Lys Ala Ala 165 170 175 Cys Leu Leu Pro Lys Leu Asp Glu Leu Arg Asp Glu Gly Lys Ala Ser 180 185 190 Ser Ala Lys Gln Arg Leu Lys Cys Ala Ser Leu Gln Lys Phe Gly Glu 195 200 205 Arg Ala Phe Lys Ala Trp Ala Val Ala Arg Leu Ser Gln Arg Phe Pro 210 215 220 Lys Ala Glu Phe Ala Glu Val Ser Lys Leu Val Thr Asp Leu Thr Lys 225 230 235 240 Val His Thr Glu Cys Cys His Gly Asp Leu Leu Glu Cys Ala Asp Asp 245 250 255 Arg Ala Asp Leu Ala Lys Tyr Ile Cys Glu Asn Gln Asp Ser Ile Ser 260 265 270 Ser Lys Leu Lys Glu Cys Cys Glu Lys Pro Leu Leu Glu Lys Ser His 275 280 285 Cys Ile Ala Glu Val Glu Asn Asp Glu Met Pro Ala Asp Leu Pro Ser 290 295 300 Leu Ala Ala Asp Phe Val Glu Ser Lys Asp Val Cys Lys Asn Tyr Ala 305 310 315 320 Glu Ala Lys Asp Val Phe Leu Gly Met Phe Leu Tyr Glu Tyr Ala Arg 325 330 335 Arg His Pro Asp Tyr Ser Val Val Leu Leu Leu Arg Leu Ala Lys Thr 340 345 350 Tyr Glu Thr Thr Leu Glu Lys Cys Cys Ala Ala Ala Asp Pro His Glu 355 360 365 Cys Tyr Ala Lys Val Phe Asp Glu Phe Lys Pro Leu Val Glu Glu Pro 370 375 380 Gln Asn Leu Ile Lys Gln Asn Cys Glu Leu Phe Glu Gln Leu Gly Glu 385 390 395 400 Tyr Lys Phe Gln Asn Ala Leu Leu Val Arg Tyr Thr Lys Lys Val Pro 405 410 415 Gln Val Ser Thr Pro Thr Leu Val Glu Val Ser Arg Asn Leu Gly Lys 420 425 430 Val Gly Ser Lys Cys Cys Lys His Pro Glu Ala Lys Arg Met Pro Cys 435 440 445 Ala Glu Asp Tyr Leu Ser Val Val Leu Asn Gln Leu Cys Val Leu His 450 455 460 Glu Lys Thr Pro Val Ser Asp Arg Val Thr Lys Cys Cys Thr Glu Ser 465 470 475 480 Leu Val Asn Arg Arg Pro Cys Phe Ser Ala Leu Glu Val Asp Glu Thr 485 490 495 Tyr Val Pro Lys Glu Phe Asn Ala Glu Thr Phe Thr Phe His Ala Asp 500 505 510 Ile Cys Thr Leu Ser Glu Lys Glu Arg Gln Ile Lys Lys Gln Thr Ala 515 520 525 Leu Val Glu Leu Val Lys His Lys Pro Lys Ala Thr Lys Glu Gln Leu 530 535 540 Lys Ala Val Met Asp Asp Phe Ala Ala Phe Val Glu Lys Cys Cys Lys 545 550 555 560 Ala Asp Asp Lys Glu Thr Cys Phe Ala Glu Glu Gly Pro Lys Leu Val 565 570 575 Ala Ala Ser Gln Ala Ala Leu Gly Leu 580 585 <210> 304 <211> 585 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 304 Asp Ala His Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu 1 5 10 15 Glu Asn Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln 20 25 30 Gln Cys Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu 35 40 45 Phe Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys 50 55 60 Ser Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu 65 70 75 80 Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro 85 90 95 Glu Arg Asn Glu Cys Phe Leu Gln His Lys Asp Asp Asn Pro Asn Leu 100 105 110 Pro Arg Leu Val Arg Pro Glu Val Asp Val Met Cys Thr Ala Phe His 115 120 125 Asp Asn Glu Glu Thr Phe Leu Lys Lys Tyr Leu Tyr Glu Ile Ala Arg 130 135 140 Arg His Pro Tyr Phe Tyr Ala Pro Glu Leu Leu Phe Phe Ala Lys Arg 145 150 155 160 Tyr Lys Ala Ala Phe Thr Glu Cys Cys Gln Ala Ala Asp Lys Ala Ala 165 170 175 Cys Leu Leu Pro Lys Leu Asp Glu Leu Arg Asp Glu Gly Lys Ala Ser 180 185 190 Ser Ala Lys Gln Arg Leu Lys Cys Ala Ser Leu Gln Lys Phe Gly Glu 195 200 205 Arg Ala Phe Lys Ala Trp Ala Val Ala Arg Leu Ser Gln Arg Phe Pro 210 215 220 Lys Ala Glu Phe Ala Glu Val Ser Lys Leu Val Thr Asp Leu Thr Lys 225 230 235 240 Val His Thr Glu Cys Cys His Gly Asp Leu Leu Glu Cys Ala Asp Asp 245 250 255 Arg Ala Asp Leu Ala Lys Tyr Ile Cys Glu Asn Gln Asp Ser Ile Ser 260 265 270 Ser Lys Leu Lys Glu Cys Cys Glu Lys Pro Leu Leu Glu Lys Ser His 275 280 285 Cys Ile Ala Glu Val Glu Asn Asp Glu Met Pro Ala Asp Leu Pro Ser 290 295 300 Leu Ala Ala Asp Phe Val Glu Ser Lys Asp Val Cys Lys Asn Tyr Ala 305 310 315 320 Glu Ala Lys Asp Val Phe Leu Gly Met Phe Leu Tyr Glu Tyr Ala Arg 325 330 335 Arg His Pro Asp Tyr Ser Val Val Leu Leu Leu Arg Leu Ala Lys Thr 340 345 350 Tyr Glu Thr Thr Leu Glu Lys Cys Cys Ala Ala Ala Asp Pro His Glu 355 360 365 Cys Tyr Ala Lys Val Phe Asp Glu Phe Lys Pro Leu Val Glu Glu Pro 370 375 380 Gln Asn Leu Ile Lys Gln Asn Cys Glu Leu Phe Glu Gln Leu Gly Glu 385 390 395 400 Tyr Lys Phe Gln Asn Ala Leu Leu Val Arg Tyr Thr Lys Lys Val Pro 405 410 415 Gln Val Ser Thr Pro Thr Leu Val Glu Val Ser Arg Asn Leu Gly Lys 420 425 430 Val Gly Ser Lys Cys Cys Lys His Pro Glu Ala Lys Arg Met Pro Cys 435 440 445 Ala Glu Asp Tyr Leu Ser Val Val Leu Asn Gln Leu Cys Val Leu His 450 455 460 Glu Lys Thr Pro Val Ser Asp Arg Val Thr Lys Cys Cys Thr Glu Ser 465 470 475 480 Leu Val Asn Arg Arg Pro Cys Phe Ser Ala Leu Asp Val Asp Glu Thr 485 490 495 Tyr Val Pro Lys Glu Phe Asn Ala Glu Thr Phe Thr Phe His Ala Asp 500 505 510 Ile Cys Thr Leu Ser Glu Lys Glu Arg Gln Ile Lys Lys Gln Thr Ala 515 520 525 Leu Val Glu Leu Val Lys His Lys Pro Lys Ala Thr Lys Glu Gln Leu 530 535 540 Lys Ala Val Met Asp Asp Phe Ala Ala Phe Val Glu Lys Cys Cys Lys 545 550 555 560 Ala Asp Asp Lys Glu Thr Cys Phe Ala Glu Glu Gly Pro His Leu Val 565 570 575 Ala Ala Ser Lys Ala Ala Leu Gly Leu 580 585 <210> 305 <211> 585 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 305 Asp Ala His Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu 1 5 10 15 Glu Asn Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln 20 25 30 Gln Cys Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu 35 40 45 Phe Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys 50 55 60 Ser Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu 65 70 75 80 Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro 85 90 95 Glu Arg Asn Glu Cys Phe Leu Gln His Lys Asp Asp Asn Pro Asn Leu 100 105 110 Pro Arg Leu Val Arg Pro Glu Val Asp Val Met Cys Thr Ala Phe His 115 120 125 Asp Asn Glu Glu Thr Phe Leu Lys Lys Tyr Leu Tyr Glu Ile Ala Arg 130 135 140 Arg His Pro Tyr Phe Tyr Ala Pro Glu Leu Leu Phe Phe Ala Lys Arg 145 150 155 160 Tyr Lys Ala Ala Phe Thr Glu Cys Cys Gln Ala Ala Asp Lys Ala Ala 165 170 175 Cys Leu Leu Pro Lys Leu Asp Glu Leu Arg Asp Glu Gly Lys Ala Ser 180 185 190 Ser Ala Lys Gln Arg Leu Lys Cys Ala Ser Leu Gln Lys Phe Gly Glu 195 200 205 Arg Ala Phe Lys Ala Trp Ala Val Ala Arg Leu Ser Gln Arg Phe Pro 210 215 220 Lys Ala Glu Phe Ala Glu Val Ser Lys Leu Val Thr Asp Leu Thr Lys 225 230 235 240 Val His Thr Glu Cys Cys His Gly Asp Leu Leu Glu Cys Ala Asp Asp 245 250 255 Arg Ala Asp Leu Ala Lys Tyr Ile Cys Glu Asn Gln Asp Ser Ile Ser 260 265 270 Ser Lys Leu Lys Glu Cys Cys Glu Lys Pro Leu Leu Glu Lys Ser His 275 280 285 Cys Ile Ala Glu Val Glu Asn Asp Glu Met Pro Ala Asp Leu Pro Ser 290 295 300 Leu Ala Ala Asp Phe Val Glu Ser Lys Asp Val Cys Lys Asn Tyr Ala 305 310 315 320 Glu Ala Lys Asp Val Phe Leu Gly Met Phe Leu Tyr Glu Tyr Ala Arg 325 330 335 Arg His Pro Asp Tyr Ser Val Val Leu Leu Leu Arg Leu Ala Lys Thr 340 345 350 Tyr Glu Thr Thr Leu Glu Lys Cys Cys Ala Ala Ala Asp Pro His Glu 355 360 365 Cys Tyr Ala Lys Val Phe Asp Glu Phe Lys Pro Leu Val Glu Glu Pro 370 375 380 Gln Asn Leu Ile Lys Gln Asn Cys Glu Leu Phe Glu Gln Leu Gly Glu 385 390 395 400 Tyr Lys Phe Gln Asn Ala Leu Leu Val Arg Tyr Thr Lys Lys Val Pro 405 410 415 Gln Val Ser Thr Pro Thr Leu Val Glu Val Ser Arg Asn Leu Gly Lys 420 425 430 Val Gly Ser Lys Cys Cys Lys His Pro Glu Ala Lys Arg Met Pro Cys 435 440 445 Ala Glu Asp Tyr Leu Ser Val Val Leu Asn Gln Leu Cys Val Leu His 450 455 460 Glu Lys Thr Pro Val Ser Asp Arg Val Thr Lys Cys Cys Thr Glu Ser 465 470 475 480 Leu Val Asn Arg Arg Pro Cys Phe Ser Ala Leu Gly Val Asp Glu Thr 485 490 495 Tyr Val Pro Lys Glu Phe Asn Ala Glu Thr Phe Thr Phe His Ala Asp 500 505 510 Ile Cys Thr Leu Ser Glu Lys Glu Arg Gln Ile Lys Lys Gln Thr Ala 515 520 525 Leu Val Glu Leu Val Lys His Lys Pro Lys Ala Thr Lys Glu Gln Leu 530 535 540 Lys Ala Val Met Asp Lys Phe Ala Ala Phe Val Glu Lys Cys Cys Lys 545 550 555 560 Ala Asp Asp Lys Glu Thr Cys Phe Ala Glu Glu Gly Pro Lys Leu Val 565 570 575 Ala Ala Ser Gln Ala Ala Leu Gly Leu 580 585 <210> 306 <211> 585 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 306 Asp Ala His Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu 1 5 10 15 Glu Asn Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln 20 25 30 Gln Cys Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu 35 40 45 Phe Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys 50 55 60 Ser Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu 65 70 75 80 Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro 85 90 95 Glu Arg Asn Glu Cys Phe Leu Gln His Lys Asp Asp Asn Pro Asn Leu 100 105 110 Pro Arg Leu Val Arg Pro Glu Val Asp Val Met Cys Thr Ala Phe His 115 120 125 Asp Asn Glu Glu Thr Phe Leu Lys Lys Tyr Leu Tyr Glu Ile Ala Arg 130 135 140 Arg His Pro Tyr Phe Tyr Ala Pro Glu Leu Leu Phe Phe Ala Lys Arg 145 150 155 160 Tyr Lys Ala Ala Phe Thr Glu Cys Cys Gln Ala Ala Asp Lys Ala Ala 165 170 175 Cys Leu Leu Pro Lys Leu Asp Glu Leu Arg Asp Glu Gly Lys Ala Ser 180 185 190 Ser Ala Lys Gln Arg Leu Lys Cys Ala Ser Leu Gln Lys Phe Gly Glu 195 200 205 Arg Ala Phe Lys Ala Trp Ala Val Ala Arg Leu Ser Gln Arg Phe Pro 210 215 220 Lys Ala Glu Phe Ala Glu Val Ser Lys Leu Val Thr Asp Leu Thr Lys 225 230 235 240 Val His Thr Glu Cys Cys His Gly Asp Leu Leu Glu Cys Ala Asp Asp 245 250 255 Arg Ala Asp Leu Ala Lys Tyr Ile Cys Glu Asn Gln Asp Ser Ile Ser 260 265 270 Ser Lys Leu Lys Glu Cys Cys Glu Lys Pro Leu Leu Glu Lys Ser His 275 280 285 Cys Ile Ala Glu Val Glu Asn Asp Glu Met Pro Ala Asp Leu Pro Ser 290 295 300 Leu Ala Ala Asp Phe Val Glu Ser Lys Asp Val Cys Lys Asn Tyr Ala 305 310 315 320 Glu Ala Lys Asp Val Phe Leu Gly Met Phe Leu Tyr Glu Tyr Ala Arg 325 330 335 Arg His Pro Asp Tyr Ser Val Val Leu Leu Leu Arg Leu Ala Lys Thr 340 345 350 Tyr Glu Thr Thr Leu Glu Lys Cys Cys Ala Ala Ala Asp Pro His Glu 355 360 365 Cys Tyr Ala Lys Val Phe Asp Glu Phe Lys Pro Leu Val Glu Glu Pro 370 375 380 Gln Asn Leu Ile Lys Gln Asn Cys Glu Leu Phe Glu Gln Leu Gly Glu 385 390 395 400 Tyr Lys Phe Gln Asn Ala Leu Leu Val Arg Tyr Thr Lys Lys Val Pro 405 410 415 Gln Val Ser Thr Pro Thr Leu Val Glu Val Ser Arg Asn Leu Gly Lys 420 425 430 Val Gly Ser Lys Cys Cys Lys His Pro Glu Ala Lys Arg Met Pro Cys 435 440 445 Ala Glu Asp Tyr Leu Ser Val Val Leu Asn Gln Leu Cys Val Leu His 450 455 460 Glu Lys Thr Pro Val Ser Asp Arg Val Thr Lys Cys Cys Thr Glu Ser 465 470 475 480 Leu Val Asn Arg Arg Pro Cys Phe Ser Ala Leu Asp Val Asp Glu Thr 485 490 495 Tyr Val Pro Lys Glu Phe Asn Ala Glu Thr Phe Thr Phe His Ala Asp 500 505 510 Ile Cys Thr Leu Ser Glu Lys Glu Arg Gln Ile Lys Lys Gln Thr Ala 515 520 525 Leu Val Glu Leu Val Lys His Lys Pro Lys Ala Thr Lys Glu Gln Leu 530 535 540 Lys Ala Val Met Asp Lys Phe Ala Ala Phe Val Glu Lys Cys Cys Lys 545 550 555 560 Ala Asp Asp Lys Glu Thr Cys Phe Ala Glu Glu Gly Pro Lys Leu Val 565 570 575 Ala Ala Ser Gln Ala Ala Leu Gly Leu 580 585 <210> 307 <211> 585 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 307 Asp Ala His Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu 1 5 10 15 Glu Asn Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln 20 25 30 Gln Cys Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu 35 40 45 Phe Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys 50 55 60 Ser Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu 65 70 75 80 Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro 85 90 95 Glu Arg Asn Glu Cys Phe Leu Gln His Lys Asp Asp Asn Pro Asn Leu 100 105 110 Pro Arg Leu Val Arg Pro Glu Val Asp Val Met Cys Thr Ala Phe His 115 120 125 Asp Asn Glu Glu Thr Phe Leu Lys Lys Tyr Leu Tyr Glu Ile Ala Arg 130 135 140 Arg His Pro Tyr Phe Tyr Ala Pro Glu Leu Leu Phe Phe Ala Lys Arg 145 150 155 160 Tyr Lys Ala Ala Phe Thr Glu Cys Cys Gln Ala Ala Asp Lys Ala Ala 165 170 175 Cys Leu Leu Pro Lys Leu Asp Glu Leu Arg Asp Glu Gly Lys Ala Ser 180 185 190 Ser Ala Lys Gln Arg Leu Lys Cys Ala Ser Leu Gln Lys Phe Gly Glu 195 200 205 Arg Ala Phe Lys Ala Trp Ala Val Ala Arg Leu Ser Gln Arg Phe Pro 210 215 220 Lys Ala Glu Phe Ala Glu Val Ser Lys Leu Val Thr Asp Leu Thr Lys 225 230 235 240 Val His Thr Glu Cys Cys His Gly Asp Leu Leu Glu Cys Ala Asp Asp 245 250 255 Arg Ala Asp Leu Ala Lys Tyr Ile Cys Glu Asn Gln Asp Ser Ile Ser 260 265 270 Ser Lys Leu Lys Glu Cys Cys Glu Lys Pro Leu Leu Glu Lys Ser His 275 280 285 Cys Ile Ala Glu Val Glu Asn Asp Glu Met Pro Ala Asp Leu Pro Ser 290 295 300 Leu Ala Ala Asp Phe Val Glu Ser Lys Asp Val Cys Lys Asn Tyr Ala 305 310 315 320 Glu Ala Lys Asp Val Phe Leu Gly Met Phe Leu Tyr Glu Tyr Ala Arg 325 330 335 Arg His Pro Asp Tyr Ser Val Val Leu Leu Leu Arg Leu Ala Lys Thr 340 345 350 Tyr Glu Thr Thr Leu Glu Lys Cys Cys Ala Ala Ala Asp Pro His Glu 355 360 365 Cys Tyr Ala Lys Val Phe Asp Glu Phe Lys Pro Leu Val Glu Glu Pro 370 375 380 Gln Asn Leu Ile Lys Gln Asn Cys Glu Leu Phe Glu Gln Leu Gly Glu 385 390 395 400 Tyr Lys Phe Gln Asn Ala Leu Leu Val Arg Tyr Thr Lys Lys Val Pro 405 410 415 Gln Val Ser Thr Pro Thr Leu Val Glu Val Ser Arg Asn Leu Gly Lys 420 425 430 Val Gly Ser Lys Cys Cys Lys His Pro Glu Ala Lys Arg Met Pro Cys 435 440 445 Ala Glu Asp Tyr Leu Ser Val Val Leu Asn Gln Leu Cys Val Leu His 450 455 460 Glu Lys Thr Pro Val Ser Asp Arg Val Thr Lys Cys Cys Thr Glu Ser 465 470 475 480 Leu Val Asn Arg Arg Pro Cys Phe Ser Ala Leu Glu Val Asp Glu Thr 485 490 495 Tyr Val Pro Lys Glu Phe Asn Ala Glu Thr Phe Thr Phe His Ala Asp 500 505 510 Ile Cys Thr Leu Ser Glu Lys Glu Arg Gln Ile Lys Lys Gln Thr Ala 515 520 525 Leu Val Glu Leu Val Lys His Lys Pro Lys Ala Thr Lys Glu Gln Leu 530 535 540 Lys Ala Val Met Asp Lys Phe Ala Ala Phe Val Glu Lys Cys Cys Lys 545 550 555 560 Ala Asp Asp Lys Glu Thr Cys Phe Ala Glu Glu Gly Pro His Leu Val 565 570 575 Ala Ala Ser Gln Ala Ala Leu Gly Leu 580 585 <210> 308 <211> 585 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 308 Asp Ala His Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu 1 5 10 15 Glu Asn Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln 20 25 30 Gln Cys Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu 35 40 45 Phe Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys 50 55 60 Ser Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu 65 70 75 80 Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro 85 90 95 Glu Arg Asn Glu Cys Phe Leu Gln His Lys Asp Asp Asn Pro Asn Leu 100 105 110 Pro Arg Leu Val Arg Pro Glu Val Asp Val Met Cys Thr Ala Phe His 115 120 125 Asp Asn Glu Glu Thr Phe Leu Lys Lys Tyr Leu Tyr Glu Ile Ala Arg 130 135 140 Arg His Pro Tyr Phe Tyr Ala Pro Glu Leu Leu Phe Phe Ala Lys Arg 145 150 155 160 Tyr Lys Ala Ala Phe Thr Glu Cys Cys Gln Ala Ala Asp Lys Ala Ala 165 170 175 Cys Leu Leu Pro Lys Leu Asp Glu Leu Arg Asp Glu Gly Lys Ala Ser 180 185 190 Ser Ala Lys Gln Arg Leu Lys Cys Ala Ser Leu Gln Lys Phe Gly Glu 195 200 205 Arg Ala Phe Lys Ala Trp Ala Val Ala Arg Leu Ser Gln Arg Phe Pro 210 215 220 Lys Ala Glu Phe Ala Glu Val Ser Lys Leu Val Thr Asp Leu Thr Lys 225 230 235 240 Val His Thr Glu Cys Cys His Gly Asp Leu Leu Glu Cys Ala Asp Asp 245 250 255 Arg Ala Asp Leu Ala Lys Tyr Ile Cys Glu Asn Gln Asp Ser Ile Ser 260 265 270 Ser Lys Leu Lys Glu Cys Cys Glu Lys Pro Leu Leu Glu Lys Ser His 275 280 285 Cys Ile Ala Glu Val Glu Asn Asp Glu Met Pro Ala Asp Leu Pro Ser 290 295 300 Leu Ala Ala Asp Phe Val Glu Ser Lys Asp Val Cys Lys Asn Tyr Ala 305 310 315 320 Glu Ala Lys Asp Val Phe Leu Gly Met Phe Leu Tyr Glu Tyr Ala Arg 325 330 335 Arg His Pro Asp Tyr Ser Val Val Leu Leu Leu Arg Leu Ala Lys Thr 340 345 350 Tyr Glu Thr Thr Leu Glu Lys Cys Cys Ala Ala Ala Asp Pro His Glu 355 360 365 Cys Tyr Ala Lys Val Phe Asp Glu Phe Lys Pro Leu Val Glu Glu Pro 370 375 380 Gln Asn Leu Ile Lys Gln Asn Cys Glu Leu Phe Glu Gln Leu Gly Glu 385 390 395 400 Tyr Lys Phe Gln Asn Ala Leu Leu Val Arg Tyr Thr Lys Lys Val Pro 405 410 415 Gln Val Ser Thr Pro Thr Leu Val Glu Val Ser Arg Asn Leu Gly Lys 420 425 430 Val Gly Ser Lys Cys Cys Lys His Pro Glu Ala Lys Arg Met Pro Cys 435 440 445 Ala Glu Asp Tyr Leu Ser Val Val Leu Asn Gln Leu Cys Val Leu His 450 455 460 Glu Lys Thr Pro Val Ser Asp Arg Val Thr Lys Cys Cys Thr Glu Ser 465 470 475 480 Leu Val Asn Arg Arg Pro Cys Phe Ser Ala Leu Glu Val Asp Glu Thr 485 490 495 Tyr Val Pro Lys Glu Phe Asn Ala Glu Thr Phe Thr Phe His Ala Asp 500 505 510 Ile Cys Thr Leu Ser Glu Lys Glu Arg Gln Ile Lys Lys Gln Thr Ala 515 520 525 Leu Val Glu Leu Val Lys His Lys Pro Lys Ala Thr Lys Glu Gln Leu 530 535 540 Lys Ala Val Met Asp Asp Phe Ala Ala Phe Val Glu Lys Cys Cys Lys 545 550 555 560 Ala Asp Asp Lys Glu Thr Cys Phe Ala Glu Glu Gly Pro His Leu Val 565 570 575 Ala Ala Ser Lys Ala Ala Leu Gly Leu 580 585 <210> 309 <211> 585 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 309 Asp Ala His Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu 1 5 10 15 Glu Asn Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln 20 25 30 Gln Cys Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu 35 40 45 Phe Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys 50 55 60 Ser Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu 65 70 75 80 Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro 85 90 95 Glu Arg Asn Glu Cys Phe Leu Gln His Lys Asp Asp Asn Pro Asn Leu 100 105 110 Pro Arg Leu Val Arg Pro Glu Val Asp Val Met Cys Thr Ala Phe His 115 120 125 Asp Asn Glu Glu Thr Phe Leu Lys Lys Tyr Leu Tyr Glu Ile Ala Arg 130 135 140 Arg His Pro Tyr Phe Tyr Ala Pro Glu Leu Leu Phe Phe Ala Lys Arg 145 150 155 160 Tyr Lys Ala Ala Phe Thr Glu Cys Cys Gln Ala Ala Asp Lys Ala Ala 165 170 175 Cys Leu Leu Pro Lys Leu Asp Glu Leu Arg Asp Glu Gly Lys Ala Ser 180 185 190 Ser Ala Lys Gln Arg Leu Lys Cys Ala Ser Leu Gln Lys Phe Gly Glu 195 200 205 Arg Ala Phe Lys Ala Trp Ala Val Ala Arg Leu Ser Gln Arg Phe Pro 210 215 220 Lys Ala Glu Phe Ala Glu Val Ser Lys Leu Val Thr Asp Leu Thr Lys 225 230 235 240 Val His Thr Glu Cys Cys His Gly Asp Leu Leu Glu Cys Ala Asp Asp 245 250 255 Arg Ala Asp Leu Ala Lys Tyr Ile Cys Glu Asn Gln Asp Ser Ile Ser 260 265 270 Ser Lys Leu Lys Glu Cys Cys Glu Lys Pro Leu Leu Glu Lys Ser His 275 280 285 Cys Ile Ala Glu Val Glu Asn Asp Glu Met Pro Ala Asp Leu Pro Ser 290 295 300 Leu Ala Ala Asp Phe Val Glu Ser Lys Asp Val Cys Lys Asn Tyr Ala 305 310 315 320 Glu Ala Lys Asp Val Phe Leu Gly Met Phe Leu Tyr Glu Tyr Ala Arg 325 330 335 Arg His Pro Asp Tyr Ser Val Val Leu Leu Leu Arg Leu Ala Lys Thr 340 345 350 Tyr Glu Thr Thr Leu Glu Lys Cys Cys Ala Ala Ala Asp Pro His Glu 355 360 365 Cys Tyr Ala Lys Val Phe Asp Glu Phe Lys Pro Leu Val Glu Glu Pro 370 375 380 Gln Asn Leu Ile Lys Gln Asn Cys Glu Leu Phe Glu Gln Leu Gly Glu 385 390 395 400 Tyr Lys Phe Gln Asn Ala Leu Leu Val Arg Tyr Thr Lys Lys Val Pro 405 410 415 Gln Val Ser Thr Pro Thr Leu Val Glu Val Ser Arg Asn Leu Gly Lys 420 425 430 Val Gly Ser Lys Cys Cys Lys His Pro Glu Ala Lys Arg Met Pro Cys 435 440 445 Ala Glu Asp Tyr Leu Ser Val Val Leu Asn Gln Leu Cys Val Leu His 450 455 460 Glu Lys Thr Pro Val Ser Asp Arg Val Thr Lys Cys Cys Thr Glu Ser 465 470 475 480 Leu Val Asn Arg Arg Pro Cys Phe Ser Ala Leu Glu Val Asp Glu Thr 485 490 495 Tyr Val Pro Lys Glu Phe Asn Ala Glu Thr Phe Thr Phe His Ala Asp 500 505 510 Ile Cys Thr Leu Ser Glu Lys Glu Arg Gln Ile Lys Lys Gln Thr Ala 515 520 525 Leu Val Glu Leu Val Lys His Lys Pro Lys Ala Thr Lys Glu Gln Leu 530 535 540 Lys Ala Val Met Asp Lys Phe Ala Ala Phe Val Glu Lys Cys Cys Lys 545 550 555 560 Ala Asp Asp Lys Glu Thr Cys Phe Ala Glu Glu Gly Pro Lys Leu Val 565 570 575 Ala Ala Ser Lys Ala Ala Leu Gly Leu 580 585 <210> 310 <211> 585 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 310 Asp Ala His Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu 1 5 10 15 Glu Asn Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln 20 25 30 Gln Cys Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu 35 40 45 Phe Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys 50 55 60 Ser Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu 65 70 75 80 Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro 85 90 95 Glu Arg Asn Glu Cys Phe Leu Gln His Lys Asp Asp Asn Pro Asn Leu 100 105 110 Pro Arg Leu Val Arg Pro Glu Val Asp Val Met Cys Thr Ala Phe His 115 120 125 Asp Asn Glu Glu Thr Phe Leu Lys Lys Tyr Leu Tyr Glu Ile Ala Arg 130 135 140 Arg His Pro Tyr Phe Tyr Ala Pro Glu Leu Leu Phe Phe Ala Lys Arg 145 150 155 160 Tyr Lys Ala Ala Phe Thr Glu Cys Cys Gln Ala Ala Asp Lys Ala Ala 165 170 175 Cys Leu Leu Pro Lys Leu Asp Glu Leu Arg Asp Glu Gly Lys Ala Ser 180 185 190 Ser Ala Lys Gln Arg Leu Lys Cys Ala Ser Leu Gln Lys Phe Gly Glu 195 200 205 Arg Ala Phe Lys Ala Trp Ala Val Ala Arg Leu Ser Gln Arg Phe Pro 210 215 220 Lys Ala Glu Phe Ala Glu Val Ser Lys Leu Val Thr Asp Leu Thr Lys 225 230 235 240 Val His Thr Glu Cys Cys His Gly Asp Leu Leu Glu Cys Ala Asp Asp 245 250 255 Arg Ala Asp Leu Ala Lys Tyr Ile Cys Glu Asn Gln Asp Ser Ile Ser 260 265 270 Ser Lys Leu Lys Glu Cys Cys Glu Lys Pro Leu Leu Glu Lys Ser His 275 280 285 Cys Ile Ala Glu Val Glu Asn Asp Glu Met Pro Ala Asp Leu Pro Ser 290 295 300 Leu Ala Ala Asp Phe Val Glu Ser Lys Asp Val Cys Lys Asn Tyr Ala 305 310 315 320 Glu Ala Lys Asp Val Phe Leu Gly Met Phe Leu Tyr Glu Tyr Ala Arg 325 330 335 Arg His Pro Asp Tyr Ser Val Val Leu Leu Leu Arg Leu Ala Lys Thr 340 345 350 Tyr Glu Thr Thr Leu Glu Lys Cys Cys Ala Ala Ala Asp Pro His Glu 355 360 365 Cys Tyr Ala Lys Val Phe Asp Glu Phe Lys Pro Leu Val Glu Glu Pro 370 375 380 Gln Asn Leu Ile Lys Gln Asn Cys Glu Leu Phe Glu Gln Leu Gly Glu 385 390 395 400 Tyr Lys Phe Gln Asn Ala Leu Leu Val Arg Tyr Thr Lys Lys Val Pro 405 410 415 Gln Val Ser Thr Pro Thr Leu Val Glu Val Ser Arg Asn Leu Gly Lys 420 425 430 Val Gly Ser Lys Cys Cys Lys His Pro Glu Ala Lys Arg Met Pro Cys 435 440 445 Ala Glu Asp Tyr Leu Ser Val Val Leu Asn Gln Leu Cys Val Leu His 450 455 460 Glu Lys Thr Pro Val Ser Asp Arg Val Thr Lys Cys Cys Thr Glu Ser 465 470 475 480 Leu Val Asn Arg Arg Pro Cys Phe Ser Ala Leu Asp Val Asp Glu Thr 485 490 495 Tyr Val Pro Lys Glu Phe Asn Ala Glu Thr Phe Thr Phe His Ala Asp 500 505 510 Ile Cys Thr Leu Ser Glu Lys Glu Arg Gln Ile Lys Lys Gln Thr Ala 515 520 525 Leu Val Glu Leu Val Lys His Lys Pro Lys Ala Thr Lys Glu Gln Leu 530 535 540 Lys Ala Val Met Asp Asp Phe Ala Ala Phe Val Glu Lys Cys Cys Lys 545 550 555 560 Ala Asp Asp Lys Glu Thr Cys Phe Ala Glu Glu Gly Pro Lys Leu Val 565 570 575 Ala Ala Ser Lys Ala Ala Leu Gly Leu 580 585 <210> 311 <211> 585 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 311 Asp Ala His Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu 1 5 10 15 Glu Asn Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln 20 25 30 Gln Ser Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu 35 40 45 Phe Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys 50 55 60 Ser Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu 65 70 75 80 Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro 85 90 95 Glu Arg Asn Glu Cys Phe Leu Gln His Lys Asp Asp Asn Pro Asn Leu 100 105 110 Pro Arg Leu Val Arg Pro Glu Val Asp Val Met Cys Thr Ala Phe His 115 120 125 Asp Asn Glu Glu Thr Phe Leu Lys Lys Tyr Leu Tyr Glu Ile Ala Arg 130 135 140 Arg His Pro Tyr Phe Tyr Ala Pro Glu Leu Leu Phe Phe Ala Lys Arg 145 150 155 160 Tyr Lys Ala Ala Phe Thr Glu Cys Cys Gln Ala Ala Asp Lys Ala Ala 165 170 175 Cys Leu Leu Pro Lys Leu Asp Glu Leu Arg Asp Glu Gly Lys Ala Ser 180 185 190 Ser Ala Lys Gln Arg Leu Lys Cys Ala Ser Leu Gln Lys Phe Gly Glu 195 200 205 Arg Ala Phe Lys Ala Trp Ala Val Ala Arg Leu Ser Gln Arg Phe Pro 210 215 220 Lys Ala Glu Phe Ala Glu Val Ser Lys Leu Val Thr Asp Leu Thr Lys 225 230 235 240 Val His Thr Glu Cys Cys His Gly Asp Leu Leu Glu Cys Ala Asp Asp 245 250 255 Arg Ala Asp Leu Ala Lys Tyr Ile Cys Glu Asn Gln Asp Ser Ile Ser 260 265 270 Ser Lys Leu Lys Glu Cys Cys Glu Lys Pro Leu Leu Glu Lys Ser His 275 280 285 Cys Ile Ala Glu Val Glu Asn Asp Glu Met Pro Ala Asp Leu Pro Ser 290 295 300 Leu Ala Ala Asp Phe Val Glu Ser Lys Asp Val Cys Lys Asn Tyr Ala 305 310 315 320 Glu Ala Lys Asp Val Phe Leu Gly Met Phe Leu Tyr Glu Tyr Ala Arg 325 330 335 Arg His Pro Asp Tyr Ser Val Val Leu Leu Leu Arg Leu Ala Lys Thr 340 345 350 Tyr Glu Thr Thr Leu Glu Lys Cys Cys Ala Ala Ala Asp Pro His Glu 355 360 365 Cys Tyr Ala Lys Val Phe Asp Glu Phe Lys Pro Leu Val Glu Glu Pro 370 375 380 Gln Asn Leu Ile Lys Gln Asn Cys Glu Leu Phe Glu Gln Leu Gly Glu 385 390 395 400 Tyr Lys Phe Gln Asn Ala Leu Leu Val Arg Tyr Thr Lys Lys Val Pro 405 410 415 Gln Val Ser Thr Pro Thr Leu Val Glu Val Ser Arg Asn Leu Gly Lys 420 425 430 Val Gly Ser Lys Cys Cys Lys His Pro Glu Ala Lys Arg Met Pro Cys 435 440 445 Ala Glu Asp Tyr Leu Ser Val Val Leu Asn Gln Leu Cys Val Leu His 450 455 460 Glu Lys Thr Pro Val Ser Asp Arg Val Thr Lys Cys Cys Thr Glu Ser 465 470 475 480 Leu Val Asn Arg Arg Pro Cys Phe Ser Ala Leu Glu Val Asp Glu Thr 485 490 495 Tyr Val Pro Lys Glu Phe Asn Ala Glu Thr Phe Thr Phe His Ala Asp 500 505 510 Ile Cys Thr Leu Ser Glu Lys Glu Arg Gln Ile Lys Lys Gln Thr Ala 515 520 525 Leu Val Glu Leu Val Lys His Lys Pro Lys Ala Thr Lys Glu Gln Leu 530 535 540 Lys Ala Val Met Asp Asp Phe Ala Ala Phe Val Glu Lys Cys Cys Lys 545 550 555 560 Ala Asp Asp Lys Glu Thr Cys Phe Ala Glu Glu Gly Lys Lys Leu Val 565 570 575 Ala Ala Ser Gln Ala Ala Leu Gly Leu 580 585 <210> 312 <211> 585 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 312 Asp Ala His Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu 1 5 10 15 Glu Asn Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln 20 25 30 Gln Ser Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu 35 40 45 Phe Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys 50 55 60 Ser Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu 65 70 75 80 Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro 85 90 95 Glu Arg Asn Glu Cys Phe Leu Gln His Lys Asp Asp Asn Pro Asn Leu 100 105 110 Pro Arg Leu Val Arg Pro Glu Val Asp Val Met Cys Thr Ala Phe His 115 120 125 Asp Asn Glu Glu Thr Phe Leu Lys Lys Tyr Leu Tyr Glu Ile Ala Arg 130 135 140 Arg His Pro Tyr Phe Tyr Ala Pro Glu Leu Leu Phe Phe Ala Lys Arg 145 150 155 160 Tyr Lys Ala Ala Phe Thr Glu Cys Cys Gln Ala Ala Asp Lys Ala Ala 165 170 175 Cys Leu Leu Pro Lys Leu Asp Glu Leu Arg Asp Glu Gly Lys Ala Ser 180 185 190 Ser Ala Lys Gln Arg Leu Lys Cys Ala Ser Leu Gln Lys Phe Gly Glu 195 200 205 Arg Ala Phe Lys Ala Trp Ala Val Ala Arg Leu Ser Gln Arg Phe Pro 210 215 220 Lys Ala Glu Phe Ala Glu Val Ser Lys Leu Val Thr Asp Leu Thr Lys 225 230 235 240 Val His Thr Glu Cys Cys His Gly Asp Leu Leu Glu Cys Ala Asp Asp 245 250 255 Arg Ala Asp Leu Ala Lys Tyr Ile Cys Glu Asn Gln Asp Ser Ile Ser 260 265 270 Ser Lys Leu Lys Glu Cys Cys Glu Lys Pro Leu Leu Glu Lys Ser His 275 280 285 Cys Ile Ala Glu Val Glu Asn Asp Glu Met Pro Ala Asp Leu Pro Ser 290 295 300 Leu Ala Ala Asp Phe Val Glu Ser Lys Asp Val Cys Lys Asn Tyr Ala 305 310 315 320 Glu Ala Lys Asp Val Phe Leu Gly Met Phe Leu Tyr Glu Tyr Ala Arg 325 330 335 Arg His Pro Asp Tyr Ser Val Val Leu Leu Leu Arg Leu Ala Lys Thr 340 345 350 Tyr Glu Thr Thr Leu Glu Lys Cys Cys Ala Ala Ala Asp Pro His Glu 355 360 365 Cys Tyr Ala Lys Val Phe Asp Glu Phe Lys Pro Leu Val Glu Glu Pro 370 375 380 Gln Asn Leu Ile Lys Gln Asn Cys Glu Leu Phe Glu Gln Leu Gly Glu 385 390 395 400 Tyr Lys Phe Gln Asn Ala Leu Leu Val Arg Tyr Thr Lys Lys Val Pro 405 410 415 Gln Val Ser Thr Pro Thr Leu Val Glu Val Ser Arg Asn Leu Gly Lys 420 425 430 Val Gly Ser Lys Cys Cys Lys His Pro Glu Ala Lys Arg Met Pro Cys 435 440 445 Ala Glu Asp Tyr Leu Ser Val Val Leu Asn Gln Leu Cys Val Leu His 450 455 460 Glu Lys Thr Pro Val Ser Asp Arg Val Thr Lys Cys Cys Thr Glu Ser 465 470 475 480 Leu Val Asn Arg Arg Pro Cys Phe Ser Ala Leu Glu Val Asp Glu Thr 485 490 495 Tyr Val Pro Lys Glu Phe Asn Ala Gly Thr Phe Thr Phe His Ala Asp 500 505 510 Ile Cys Thr Leu Ser Glu Lys Glu Arg Gln Ile Lys Lys Gln Thr Ala 515 520 525 Leu Val Glu Leu Val Lys His Lys Pro Lys Ala Thr Lys Glu Gln Leu 530 535 540 Lys Ala Ala Met Asp Asp Phe Ala Ala Phe Val Glu Lys Cys Cys Lys 545 550 555 560 Ala Asp Asp Lys Glu Thr Cys Phe Ala Glu Glu Gly Lys Lys Leu Val 565 570 575 Ala Ala Ser Gln Ala Ala Leu Gly Leu 580 585 <210> 313 <211> 585 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 313 Asp Ala His Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu 1 5 10 15 Glu Asn Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln 20 25 30 Gln Ser Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu 35 40 45 Phe Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys 50 55 60 Ser Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu 65 70 75 80 Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro 85 90 95 Glu Arg Asn Glu Cys Phe Leu Gln His Lys Asp Asp Asn Pro Asn Leu 100 105 110 Pro Arg Leu Val Arg Pro Glu Val Asp Val Met Cys Thr Ala Phe His 115 120 125 Asp Asn Glu Glu Thr Phe Leu Lys Lys Tyr Leu Tyr Glu Ile Ala Arg 130 135 140 Arg His Pro Tyr Phe Tyr Ala Pro Glu Leu Leu Phe Phe Ala Lys Arg 145 150 155 160 Tyr Lys Ala Ala Phe Thr Glu Cys Cys Gln Ala Ala Asp Lys Ala Ala 165 170 175 Cys Leu Leu Pro Lys Leu Asp Glu Leu Arg Asp Glu Gly Lys Ala Ser 180 185 190 Ser Ala Lys Gln Arg Leu Lys Cys Ala Ser Leu Gln Lys Phe Gly Glu 195 200 205 Arg Ala Phe Lys Ala Trp Ala Val Ala Arg Leu Ser Gln Arg Phe Pro 210 215 220 Lys Ala Glu Phe Ala Glu Val Ser Lys Leu Val Thr Asp Leu Thr Lys 225 230 235 240 Val His Thr Glu Cys Cys His Gly Asp Leu Leu Glu Cys Ala Asp Asp 245 250 255 Arg Ala Asp Leu Ala Lys Tyr Ile Cys Glu Asn Gln Asp Ser Ile Ser 260 265 270 Ser Lys Leu Lys Glu Cys Cys Glu Lys Pro Leu Leu Glu Lys Ser His 275 280 285 Cys Ile Ala Glu Val Glu Asn Asp Glu Met Pro Ala Asp Leu Pro Ser 290 295 300 Leu Ala Ala Asp Phe Val Glu Ser Lys Asp Val Cys Lys Asn Tyr Ala 305 310 315 320 Glu Ala Lys Asp Val Phe Leu Gly Met Phe Leu Tyr Glu Tyr Ala Arg 325 330 335 Arg His Pro Asp Tyr Ser Val Val Leu Leu Leu Arg Leu Ala Lys Thr 340 345 350 Tyr Glu Thr Thr Leu Glu Lys Cys Cys Ala Ala Ala Asp Pro His Glu 355 360 365 Cys Tyr Ala Lys Val Phe Asp Glu Phe Lys Pro Leu Val Glu Glu Pro 370 375 380 Gln Asn Leu Ile Lys Gln Asn Cys Glu Leu Phe Glu Gln Leu Gly Glu 385 390 395 400 Tyr Lys Phe Gln Asn Ala Leu Leu Val Arg Tyr Thr Lys Lys Val Pro 405 410 415 Gln Val Ser Thr Pro Thr Leu Val Glu Val Ser Arg Asn Leu Gly Lys 420 425 430 Val Gly Ser Lys Cys Cys Lys His Pro Glu Ala Lys Arg Met Pro Cys 435 440 445 Ala Glu Asp Tyr Leu Ser Val Val Leu Asn Gln Leu Cys Val Leu His 450 455 460 Glu Lys Thr Pro Val Ser Asp Arg Val Thr Lys Cys Cys Thr Glu Ser 465 470 475 480 Leu Val Asn Arg Arg Pro Cys Phe Ser Ala Leu Glu Val Asp Glu Thr 485 490 495 Tyr Val Pro Lys Glu Phe Asn Ala Glu Thr Phe Thr Phe His Ala Asp 500 505 510 Ile Cys Thr Leu Ser Glu Lys Glu Arg Gln Ile Lys Lys Gln Thr Ala 515 520 525 Leu Val Glu Leu Val Lys His Lys Pro Lys Ala Thr Lys Glu Gln Leu 530 535 540 Lys Ala Val Met Asp Asp Phe Ala Ala Phe Val Glu Lys Cys Cys Lys 545 550 555 560 Ala Asp Asp Lys Glu Thr Cys Phe Ala Glu Glu Gly Pro Lys Leu Val 565 570 575 Ala Ala Ser Gln Ala Ala Leu Gly Leu 580 585 <210> 314 <211> 585 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 314 Asp Ala His Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu 1 5 10 15 Glu Asn Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln 20 25 30 Gln Ser Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu 35 40 45 Phe Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys 50 55 60 Ser Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu 65 70 75 80 Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro 85 90 95 Glu Arg Asn Glu Cys Phe Leu Gln His Lys Asp Asp Asn Pro Asn Leu 100 105 110 Pro Arg Leu Val Arg Pro Glu Val Asp Val Met Cys Thr Ala Phe His 115 120 125 Asp Asn Glu Glu Thr Phe Leu Lys Lys Tyr Leu Tyr Glu Ile Ala Arg 130 135 140 Arg His Pro Tyr Phe Tyr Ala Pro Glu Leu Leu Phe Phe Ala Lys Arg 145 150 155 160 Tyr Lys Ala Ala Phe Thr Glu Cys Cys Gln Ala Ala Asp Lys Ala Ala 165 170 175 Cys Leu Leu Pro Lys Leu Asp Glu Leu Arg Asp Glu Gly Lys Ala Ser 180 185 190 Ser Ala Lys Gln Arg Leu Lys Cys Ala Ser Leu Gln Lys Phe Gly Glu 195 200 205 Arg Ala Phe Lys Ala Trp Ala Val Ala Arg Leu Ser Gln Arg Phe Pro 210 215 220 Lys Ala Glu Phe Ala Glu Val Ser Lys Leu Val Thr Asp Leu Thr Lys 225 230 235 240 Val His Thr Glu Cys Cys His Gly Asp Leu Leu Glu Cys Ala Asp Asp 245 250 255 Arg Ala Asp Leu Ala Lys Tyr Ile Cys Glu Asn Gln Asp Ser Ile Ser 260 265 270 Ser Lys Leu Lys Glu Cys Cys Glu Lys Pro Leu Leu Glu Lys Ser His 275 280 285 Cys Ile Ala Glu Val Glu Asn Asp Glu Met Pro Ala Asp Leu Pro Ser 290 295 300 Leu Ala Ala Asp Phe Val Glu Ser Lys Asp Val Cys Lys Asn Tyr Ala 305 310 315 320 Glu Ala Lys Asp Val Phe Leu Gly Met Phe Leu Tyr Glu Tyr Ala Arg 325 330 335 Arg His Pro Asp Tyr Ser Val Val Leu Leu Leu Arg Leu Ala Lys Thr 340 345 350 Tyr Glu Thr Thr Leu Glu Lys Cys Cys Ala Ala Ala Asp Pro His Glu 355 360 365 Cys Tyr Ala Lys Val Phe Asp Glu Phe Lys Pro Leu Val Glu Glu Pro 370 375 380 Gln Asn Leu Ile Lys Gln Asn Cys Glu Leu Phe Glu Gln Leu Gly Glu 385 390 395 400 Tyr Lys Phe Gln Asn Ala Leu Leu Val Arg Tyr Thr Lys Lys Val Pro 405 410 415 Gln Val Ser Thr Pro Thr Leu Val Glu Val Ser Arg Asn Leu Gly Lys 420 425 430 Val Gly Ser Lys Cys Cys Lys His Pro Glu Ala Lys Arg Met Pro Cys 435 440 445 Ala Glu Asp Tyr Leu Ser Val Val Leu Asn Gln Leu Cys Val Leu His 450 455 460 Glu Lys Thr Pro Val Ser Asp Arg Val Thr Lys Cys Cys Thr Glu Ser 465 470 475 480 Leu Val Asn Arg Arg Pro Cys Phe Ser Ala Leu Asp Val Asp Glu Thr 485 490 495 Tyr Val Pro Lys Glu Phe Asn Ala Glu Thr Phe Thr Phe His Ala Asp 500 505 510 Ile Cys Thr Leu Ser Glu Lys Glu Arg Gln Ile Lys Lys Gln Thr Ala 515 520 525 Leu Val Glu Leu Val Lys His Lys Pro Lys Ala Thr Lys Glu Gln Leu 530 535 540 Lys Ala Val Met Asp Asp Phe Ala Ala Phe Val Glu Lys Cys Cys Lys 545 550 555 560 Ala Asp Asp Lys Glu Thr Cys Phe Ala Glu Glu Gly Pro His Leu Val 565 570 575 Ala Ala Ser Lys Ala Ala Leu Gly Leu 580 585 <210> 315 <211> 585 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 315 Asp Ala His Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu 1 5 10 15 Glu Asn Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln 20 25 30 Gln Ser Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu 35 40 45 Phe Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys 50 55 60 Ser Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu 65 70 75 80 Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro 85 90 95 Glu Arg Asn Glu Cys Phe Leu Gln His Lys Asp Asp Asn Pro Asn Leu 100 105 110 Pro Arg Leu Val Arg Pro Glu Val Asp Val Met Cys Thr Ala Phe His 115 120 125 Asp Asn Glu Glu Thr Phe Leu Lys Lys Tyr Leu Tyr Glu Ile Ala Arg 130 135 140 Arg His Pro Tyr Phe Tyr Ala Pro Glu Leu Leu Phe Phe Ala Lys Arg 145 150 155 160 Tyr Lys Ala Ala Phe Thr Glu Cys Cys Gln Ala Ala Asp Lys Ala Ala 165 170 175 Cys Leu Leu Pro Lys Leu Asp Glu Leu Arg Asp Glu Gly Lys Ala Ser 180 185 190 Ser Ala Lys Gln Arg Leu Lys Cys Ala Ser Leu Gln Lys Phe Gly Glu 195 200 205 Arg Ala Phe Lys Ala Trp Ala Val Ala Arg Leu Ser Gln Arg Phe Pro 210 215 220 Lys Ala Glu Phe Ala Glu Val Ser Lys Leu Val Thr Asp Leu Thr Lys 225 230 235 240 Val His Thr Glu Cys Cys His Gly Asp Leu Leu Glu Cys Ala Asp Asp 245 250 255 Arg Ala Asp Leu Ala Lys Tyr Ile Cys Glu Asn Gln Asp Ser Ile Ser 260 265 270 Ser Lys Leu Lys Glu Cys Cys Glu Lys Pro Leu Leu Glu Lys Ser His 275 280 285 Cys Ile Ala Glu Val Glu Asn Asp Glu Met Pro Ala Asp Leu Pro Ser 290 295 300 Leu Ala Ala Asp Phe Val Glu Ser Lys Asp Val Cys Lys Asn Tyr Ala 305 310 315 320 Glu Ala Lys Asp Val Phe Leu Gly Met Phe Leu Tyr Glu Tyr Ala Arg 325 330 335 Arg His Pro Asp Tyr Ser Val Val Leu Leu Leu Arg Leu Ala Lys Thr 340 345 350 Tyr Glu Thr Thr Leu Glu Lys Cys Cys Ala Ala Ala Asp Pro His Glu 355 360 365 Cys Tyr Ala Lys Val Phe Asp Glu Phe Lys Pro Leu Val Glu Glu Pro 370 375 380 Gln Asn Leu Ile Lys Gln Asn Cys Glu Leu Phe Glu Gln Leu Gly Glu 385 390 395 400 Tyr Lys Phe Gln Asn Ala Leu Leu Val Arg Tyr Thr Lys Lys Val Pro 405 410 415 Gln Val Ser Thr Pro Thr Leu Val Glu Val Ser Arg Asn Leu Gly Lys 420 425 430 Val Gly Ser Lys Cys Cys Lys His Pro Glu Ala Lys Arg Met Pro Cys 435 440 445 Ala Glu Asp Tyr Leu Ser Val Val Leu Asn Gln Leu Cys Val Leu His 450 455 460 Glu Lys Thr Pro Val Ser Asp Arg Val Thr Lys Cys Cys Thr Glu Ser 465 470 475 480 Leu Val Asn Arg Arg Pro Cys Phe Ser Ala Leu Gly Val Asp Glu Thr 485 490 495 Tyr Val Pro Lys Glu Phe Asn Ala Glu Thr Phe Thr Phe His Ala Asp 500 505 510 Ile Cys Thr Leu Ser Glu Lys Glu Arg Gln Ile Lys Lys Gln Thr Ala 515 520 525 Leu Val Glu Leu Val Lys His Lys Pro Lys Ala Thr Lys Glu Gln Leu 530 535 540 Lys Ala Val Met Asp Lys Phe Ala Ala Phe Val Glu Lys Cys Cys Lys 545 550 555 560 Ala Asp Asp Lys Glu Thr Cys Phe Ala Glu Glu Gly Pro Lys Leu Val 565 570 575 Ala Ala Ser Gln Ala Ala Leu Gly Leu 580 585 <210> 316 <211> 585 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 316 Asp Ala His Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu 1 5 10 15 Glu Asn Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln 20 25 30 Gln Ser Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu 35 40 45 Phe Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys 50 55 60 Ser Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu 65 70 75 80 Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro 85 90 95 Glu Arg Asn Glu Cys Phe Leu Gln His Lys Asp Asp Asn Pro Asn Leu 100 105 110 Pro Arg Leu Val Arg Pro Glu Val Asp Val Met Cys Thr Ala Phe His 115 120 125 Asp Asn Glu Glu Thr Phe Leu Lys Lys Tyr Leu Tyr Glu Ile Ala Arg 130 135 140 Arg His Pro Tyr Phe Tyr Ala Pro Glu Leu Leu Phe Phe Ala Lys Arg 145 150 155 160 Tyr Lys Ala Ala Phe Thr Glu Cys Cys Gln Ala Ala Asp Lys Ala Ala 165 170 175 Cys Leu Leu Pro Lys Leu Asp Glu Leu Arg Asp Glu Gly Lys Ala Ser 180 185 190 Ser Ala Lys Gln Arg Leu Lys Cys Ala Ser Leu Gln Lys Phe Gly Glu 195 200 205 Arg Ala Phe Lys Ala Trp Ala Val Ala Arg Leu Ser Gln Arg Phe Pro 210 215 220 Lys Ala Glu Phe Ala Glu Val Ser Lys Leu Val Thr Asp Leu Thr Lys 225 230 235 240 Val His Thr Glu Cys Cys His Gly Asp Leu Leu Glu Cys Ala Asp Asp 245 250 255 Arg Ala Asp Leu Ala Lys Tyr Ile Cys Glu Asn Gln Asp Ser Ile Ser 260 265 270 Ser Lys Leu Lys Glu Cys Cys Glu Lys Pro Leu Leu Glu Lys Ser His 275 280 285 Cys Ile Ala Glu Val Glu Asn Asp Glu Met Pro Ala Asp Leu Pro Ser 290 295 300 Leu Ala Ala Asp Phe Val Glu Ser Lys Asp Val Cys Lys Asn Tyr Ala 305 310 315 320 Glu Ala Lys Asp Val Phe Leu Gly Met Phe Leu Tyr Glu Tyr Ala Arg 325 330 335 Arg His Pro Asp Tyr Ser Val Val Leu Leu Leu Arg Leu Ala Lys Thr 340 345 350 Tyr Glu Thr Thr Leu Glu Lys Cys Cys Ala Ala Ala Asp Pro His Glu 355 360 365 Cys Tyr Ala Lys Val Phe Asp Glu Phe Lys Pro Leu Val Glu Glu Pro 370 375 380 Gln Asn Leu Ile Lys Gln Asn Cys Glu Leu Phe Glu Gln Leu Gly Glu 385 390 395 400 Tyr Lys Phe Gln Asn Ala Leu Leu Val Arg Tyr Thr Lys Lys Val Pro 405 410 415 Gln Val Ser Thr Pro Thr Leu Val Glu Val Ser Arg Asn Leu Gly Lys 420 425 430 Val Gly Ser Lys Cys Cys Lys His Pro Glu Ala Lys Arg Met Pro Cys 435 440 445 Ala Glu Asp Tyr Leu Ser Val Val Leu Asn Gln Leu Cys Val Leu His 450 455 460 Glu Lys Thr Pro Val Ser Asp Arg Val Thr Lys Cys Cys Thr Glu Ser 465 470 475 480 Leu Val Asn Arg Arg Pro Cys Phe Ser Ala Leu Asp Val Asp Glu Thr 485 490 495 Tyr Val Pro Lys Glu Phe Asn Ala Glu Thr Phe Thr Phe His Ala Asp 500 505 510 Ile Cys Thr Leu Ser Glu Lys Glu Arg Gln Ile Lys Lys Gln Thr Ala 515 520 525 Leu Val Glu Leu Val Lys His Lys Pro Lys Ala Thr Lys Glu Gln Leu 530 535 540 Lys Ala Val Met Asp Lys Phe Ala Ala Phe Val Glu Lys Cys Cys Lys 545 550 555 560 Ala Asp Asp Lys Glu Thr Cys Phe Ala Glu Glu Gly Pro Lys Leu Val 565 570 575 Ala Ala Ser Gln Ala Ala Leu Gly Leu 580 585 <210> 317 <211> 585 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 317 Asp Ala His Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu 1 5 10 15 Glu Asn Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln 20 25 30 Gln Ser Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu 35 40 45 Phe Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys 50 55 60 Ser Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu 65 70 75 80 Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro 85 90 95 Glu Arg Asn Glu Cys Phe Leu Gln His Lys Asp Asp Asn Pro Asn Leu 100 105 110 Pro Arg Leu Val Arg Pro Glu Val Asp Val Met Cys Thr Ala Phe His 115 120 125 Asp Asn Glu Glu Thr Phe Leu Lys Lys Tyr Leu Tyr Glu Ile Ala Arg 130 135 140 Arg His Pro Tyr Phe Tyr Ala Pro Glu Leu Leu Phe Phe Ala Lys Arg 145 150 155 160 Tyr Lys Ala Ala Phe Thr Glu Cys Cys Gln Ala Ala Asp Lys Ala Ala 165 170 175 Cys Leu Leu Pro Lys Leu Asp Glu Leu Arg Asp Glu Gly Lys Ala Ser 180 185 190 Ser Ala Lys Gln Arg Leu Lys Cys Ala Ser Leu Gln Lys Phe Gly Glu 195 200 205 Arg Ala Phe Lys Ala Trp Ala Val Ala Arg Leu Ser Gln Arg Phe Pro 210 215 220 Lys Ala Glu Phe Ala Glu Val Ser Lys Leu Val Thr Asp Leu Thr Lys 225 230 235 240 Val His Thr Glu Cys Cys His Gly Asp Leu Leu Glu Cys Ala Asp Asp 245 250 255 Arg Ala Asp Leu Ala Lys Tyr Ile Cys Glu Asn Gln Asp Ser Ile Ser 260 265 270 Ser Lys Leu Lys Glu Cys Cys Glu Lys Pro Leu Leu Glu Lys Ser His 275 280 285 Cys Ile Ala Glu Val Glu Asn Asp Glu Met Pro Ala Asp Leu Pro Ser 290 295 300 Leu Ala Ala Asp Phe Val Glu Ser Lys Asp Val Cys Lys Asn Tyr Ala 305 310 315 320 Glu Ala Lys Asp Val Phe Leu Gly Met Phe Leu Tyr Glu Tyr Ala Arg 325 330 335 Arg His Pro Asp Tyr Ser Val Val Leu Leu Leu Arg Leu Ala Lys Thr 340 345 350 Tyr Glu Thr Thr Leu Glu Lys Cys Cys Ala Ala Ala Asp Pro His Glu 355 360 365 Cys Tyr Ala Lys Val Phe Asp Glu Phe Lys Pro Leu Val Glu Glu Pro 370 375 380 Gln Asn Leu Ile Lys Gln Asn Cys Glu Leu Phe Glu Gln Leu Gly Glu 385 390 395 400 Tyr Lys Phe Gln Asn Ala Leu Leu Val Arg Tyr Thr Lys Lys Val Pro 405 410 415 Gln Val Ser Thr Pro Thr Leu Val Glu Val Ser Arg Asn Leu Gly Lys 420 425 430 Val Gly Ser Lys Cys Cys Lys His Pro Glu Ala Lys Arg Met Pro Cys 435 440 445 Ala Glu Asp Tyr Leu Ser Val Val Leu Asn Gln Leu Cys Val Leu His 450 455 460 Glu Lys Thr Pro Val Ser Asp Arg Val Thr Lys Cys Cys Thr Glu Ser 465 470 475 480 Leu Val Asn Arg Arg Pro Cys Phe Ser Ala Leu Glu Val Asp Glu Thr 485 490 495 Tyr Val Pro Lys Glu Phe Asn Ala Glu Thr Phe Thr Phe His Ala Asp 500 505 510 Ile Cys Thr Leu Ser Glu Lys Glu Arg Gln Ile Lys Lys Gln Thr Ala 515 520 525 Leu Val Glu Leu Val Lys His Lys Pro Lys Ala Thr Lys Glu Gln Leu 530 535 540 Lys Ala Val Met Asp Lys Phe Ala Ala Phe Val Glu Lys Cys Cys Lys 545 550 555 560 Ala Asp Asp Lys Glu Thr Cys Phe Ala Glu Glu Gly Pro His Leu Val 565 570 575 Ala Ala Ser Gln Ala Ala Leu Gly Leu 580 585 <210> 318 <211> 585 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 318 Asp Ala His Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu 1 5 10 15 Glu Asn Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln 20 25 30 Gln Ser Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu 35 40 45 Phe Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys 50 55 60 Ser Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu 65 70 75 80 Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro 85 90 95 Glu Arg Asn Glu Cys Phe Leu Gln His Lys Asp Asp Asn Pro Asn Leu 100 105 110 Pro Arg Leu Val Arg Pro Glu Val Asp Val Met Cys Thr Ala Phe His 115 120 125 Asp Asn Glu Glu Thr Phe Leu Lys Lys Tyr Leu Tyr Glu Ile Ala Arg 130 135 140 Arg His Pro Tyr Phe Tyr Ala Pro Glu Leu Leu Phe Phe Ala Lys Arg 145 150 155 160 Tyr Lys Ala Ala Phe Thr Glu Cys Cys Gln Ala Ala Asp Lys Ala Ala 165 170 175 Cys Leu Leu Pro Lys Leu Asp Glu Leu Arg Asp Glu Gly Lys Ala Ser 180 185 190 Ser Ala Lys Gln Arg Leu Lys Cys Ala Ser Leu Gln Lys Phe Gly Glu 195 200 205 Arg Ala Phe Lys Ala Trp Ala Val Ala Arg Leu Ser Gln Arg Phe Pro 210 215 220 Lys Ala Glu Phe Ala Glu Val Ser Lys Leu Val Thr Asp Leu Thr Lys 225 230 235 240 Val His Thr Glu Cys Cys His Gly Asp Leu Leu Glu Cys Ala Asp Asp 245 250 255 Arg Ala Asp Leu Ala Lys Tyr Ile Cys Glu Asn Gln Asp Ser Ile Ser 260 265 270 Ser Lys Leu Lys Glu Cys Cys Glu Lys Pro Leu Leu Glu Lys Ser His 275 280 285 Cys Ile Ala Glu Val Glu Asn Asp Glu Met Pro Ala Asp Leu Pro Ser 290 295 300 Leu Ala Ala Asp Phe Val Glu Ser Lys Asp Val Cys Lys Asn Tyr Ala 305 310 315 320 Glu Ala Lys Asp Val Phe Leu Gly Met Phe Leu Tyr Glu Tyr Ala Arg 325 330 335 Arg His Pro Asp Tyr Ser Val Val Leu Leu Leu Arg Leu Ala Lys Thr 340 345 350 Tyr Glu Thr Thr Leu Glu Lys Cys Cys Ala Ala Ala Asp Pro His Glu 355 360 365 Cys Tyr Ala Lys Val Phe Asp Glu Phe Lys Pro Leu Val Glu Glu Pro 370 375 380 Gln Asn Leu Ile Lys Gln Asn Cys Glu Leu Phe Glu Gln Leu Gly Glu 385 390 395 400 Tyr Lys Phe Gln Asn Ala Leu Leu Val Arg Tyr Thr Lys Lys Val Pro 405 410 415 Gln Val Ser Thr Pro Thr Leu Val Glu Val Ser Arg Asn Leu Gly Lys 420 425 430 Val Gly Ser Lys Cys Cys Lys His Pro Glu Ala Lys Arg Met Pro Cys 435 440 445 Ala Glu Asp Tyr Leu Ser Val Val Leu Asn Gln Leu Cys Val Leu His 450 455 460 Glu Lys Thr Pro Val Ser Asp Arg Val Thr Lys Cys Cys Thr Glu Ser 465 470 475 480 Leu Val Asn Arg Arg Pro Cys Phe Ser Ala Leu Glu Val Asp Glu Thr 485 490 495 Tyr Val Pro Lys Glu Phe Asn Ala Glu Thr Phe Thr Phe His Ala Asp 500 505 510 Ile Cys Thr Leu Ser Glu Lys Glu Arg Gln Ile Lys Lys Gln Thr Ala 515 520 525 Leu Val Glu Leu Val Lys His Lys Pro Lys Ala Thr Lys Glu Gln Leu 530 535 540 Lys Ala Val Met Asp Asp Phe Ala Ala Phe Val Glu Lys Cys Cys Lys 545 550 555 560 Ala Asp Asp Lys Glu Thr Cys Phe Ala Glu Glu Gly Pro His Leu Val 565 570 575 Ala Ala Ser Lys Ala Ala Leu Gly Leu 580 585 <210> 319 <211> 585 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 319 Asp Ala His Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu 1 5 10 15 Glu Asn Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln 20 25 30 Gln Ser Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu 35 40 45 Phe Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys 50 55 60 Ser Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu 65 70 75 80 Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro 85 90 95 Glu Arg Asn Glu Cys Phe Leu Gln His Lys Asp Asp Asn Pro Asn Leu 100 105 110 Pro Arg Leu Val Arg Pro Glu Val Asp Val Met Cys Thr Ala Phe His 115 120 125 Asp Asn Glu Glu Thr Phe Leu Lys Lys Tyr Leu Tyr Glu Ile Ala Arg 130 135 140 Arg His Pro Tyr Phe Tyr Ala Pro Glu Leu Leu Phe Phe Ala Lys Arg 145 150 155 160 Tyr Lys Ala Ala Phe Thr Glu Cys Cys Gln Ala Ala Asp Lys Ala Ala 165 170 175 Cys Leu Leu Pro Lys Leu Asp Glu Leu Arg Asp Glu Gly Lys Ala Ser 180 185 190 Ser Ala Lys Gln Arg Leu Lys Cys Ala Ser Leu Gln Lys Phe Gly Glu 195 200 205 Arg Ala Phe Lys Ala Trp Ala Val Ala Arg Leu Ser Gln Arg Phe Pro 210 215 220 Lys Ala Glu Phe Ala Glu Val Ser Lys Leu Val Thr Asp Leu Thr Lys 225 230 235 240 Val His Thr Glu Cys Cys His Gly Asp Leu Leu Glu Cys Ala Asp Asp 245 250 255 Arg Ala Asp Leu Ala Lys Tyr Ile Cys Glu Asn Gln Asp Ser Ile Ser 260 265 270 Ser Lys Leu Lys Glu Cys Cys Glu Lys Pro Leu Leu Glu Lys Ser His 275 280 285 Cys Ile Ala Glu Val Glu Asn Asp Glu Met Pro Ala Asp Leu Pro Ser 290 295 300 Leu Ala Ala Asp Phe Val Glu Ser Lys Asp Val Cys Lys Asn Tyr Ala 305 310 315 320 Glu Ala Lys Asp Val Phe Leu Gly Met Phe Leu Tyr Glu Tyr Ala Arg 325 330 335 Arg His Pro Asp Tyr Ser Val Val Leu Leu Leu Arg Leu Ala Lys Thr 340 345 350 Tyr Glu Thr Thr Leu Glu Lys Cys Cys Ala Ala Ala Asp Pro His Glu 355 360 365 Cys Tyr Ala Lys Val Phe Asp Glu Phe Lys Pro Leu Val Glu Glu Pro 370 375 380 Gln Asn Leu Ile Lys Gln Asn Cys Glu Leu Phe Glu Gln Leu Gly Glu 385 390 395 400 Tyr Lys Phe Gln Asn Ala Leu Leu Val Arg Tyr Thr Lys Lys Val Pro 405 410 415 Gln Val Ser Thr Pro Thr Leu Val Glu Val Ser Arg Asn Leu Gly Lys 420 425 430 Val Gly Ser Lys Cys Cys Lys His Pro Glu Ala Lys Arg Met Pro Cys 435 440 445 Ala Glu Asp Tyr Leu Ser Val Val Leu Asn Gln Leu Cys Val Leu His 450 455 460 Glu Lys Thr Pro Val Ser Asp Arg Val Thr Lys Cys Cys Thr Glu Ser 465 470 475 480 Leu Val Asn Arg Arg Pro Cys Phe Ser Ala Leu Glu Val Asp Glu Thr 485 490 495 Tyr Val Pro Lys Glu Phe Asn Ala Glu Thr Phe Thr Phe His Ala Asp 500 505 510 Ile Cys Thr Leu Ser Glu Lys Glu Arg Gln Ile Lys Lys Gln Thr Ala 515 520 525 Leu Val Glu Leu Val Lys His Lys Pro Lys Ala Thr Lys Glu Gln Leu 530 535 540 Lys Ala Val Met Asp Lys Phe Ala Ala Phe Val Glu Lys Cys Cys Lys 545 550 555 560 Ala Asp Asp Lys Glu Thr Cys Phe Ala Glu Glu Gly Pro Lys Leu Val 565 570 575 Ala Ala Ser Lys Ala Ala Leu Gly Leu 580 585 <210> 320 <211> 585 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 320 Asp Ala His Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu 1 5 10 15 Glu Asn Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln 20 25 30 Gln Ser Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu 35 40 45 Phe Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys 50 55 60 Ser Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu 65 70 75 80 Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro 85 90 95 Glu Arg Asn Glu Cys Phe Leu Gln His Lys Asp Asp Asn Pro Asn Leu 100 105 110 Pro Arg Leu Val Arg Pro Glu Val Asp Val Met Cys Thr Ala Phe His 115 120 125 Asp Asn Glu Glu Thr Phe Leu Lys Lys Tyr Leu Tyr Glu Ile Ala Arg 130 135 140 Arg His Pro Tyr Phe Tyr Ala Pro Glu Leu Leu Phe Phe Ala Lys Arg 145 150 155 160 Tyr Lys Ala Ala Phe Thr Glu Cys Cys Gln Ala Ala Asp Lys Ala Ala 165 170 175 Cys Leu Leu Pro Lys Leu Asp Glu Leu Arg Asp Glu Gly Lys Ala Ser 180 185 190 Ser Ala Lys Gln Arg Leu Lys Cys Ala Ser Leu Gln Lys Phe Gly Glu 195 200 205 Arg Ala Phe Lys Ala Trp Ala Val Ala Arg Leu Ser Gln Arg Phe Pro 210 215 220 Lys Ala Glu Phe Ala Glu Val Ser Lys Leu Val Thr Asp Leu Thr Lys 225 230 235 240 Val His Thr Glu Cys Cys His Gly Asp Leu Leu Glu Cys Ala Asp Asp 245 250 255 Arg Ala Asp Leu Ala Lys Tyr Ile Cys Glu Asn Gln Asp Ser Ile Ser 260 265 270 Ser Lys Leu Lys Glu Cys Cys Glu Lys Pro Leu Leu Glu Lys Ser His 275 280 285 Cys Ile Ala Glu Val Glu Asn Asp Glu Met Pro Ala Asp Leu Pro Ser 290 295 300 Leu Ala Ala Asp Phe Val Glu Ser Lys Asp Val Cys Lys Asn Tyr Ala 305 310 315 320 Glu Ala Lys Asp Val Phe Leu Gly Met Phe Leu Tyr Glu Tyr Ala Arg 325 330 335 Arg His Pro Asp Tyr Ser Val Val Leu Leu Leu Arg Leu Ala Lys Thr 340 345 350 Tyr Glu Thr Thr Leu Glu Lys Cys Cys Ala Ala Ala Asp Pro His Glu 355 360 365 Cys Tyr Ala Lys Val Phe Asp Glu Phe Lys Pro Leu Val Glu Glu Pro 370 375 380 Gln Asn Leu Ile Lys Gln Asn Cys Glu Leu Phe Glu Gln Leu Gly Glu 385 390 395 400 Tyr Lys Phe Gln Asn Ala Leu Leu Val Arg Tyr Thr Lys Lys Val Pro 405 410 415 Gln Val Ser Thr Pro Thr Leu Val Glu Val Ser Arg Asn Leu Gly Lys 420 425 430 Val Gly Ser Lys Cys Cys Lys His Pro Glu Ala Lys Arg Met Pro Cys 435 440 445 Ala Glu Asp Tyr Leu Ser Val Val Leu Asn Gln Leu Cys Val Leu His 450 455 460 Glu Lys Thr Pro Val Ser Asp Arg Val Thr Lys Cys Cys Thr Glu Ser 465 470 475 480 Leu Val Asn Arg Arg Pro Cys Phe Ser Ala Leu Asp Val Asp Glu Thr 485 490 495 Tyr Val Pro Lys Glu Phe Asn Ala Glu Thr Phe Thr Phe His Ala Asp 500 505 510 Ile Cys Thr Leu Ser Glu Lys Glu Arg Gln Ile Lys Lys Gln Thr Ala 515 520 525 Leu Val Glu Leu Val Lys His Lys Pro Lys Ala Thr Lys Glu Gln Leu 530 535 540 Lys Ala Val Met Asp Asp Phe Ala Ala Phe Val Glu Lys Cys Cys Lys 545 550 555 560 Ala Asp Asp Lys Glu Thr Cys Phe Ala Glu Glu Gly Pro Lys Leu Val 565 570 575 Ala Ala Ser Lys Ala Ala Leu Gly Leu 580 585 <210> 321 <211> 585 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 321 Asp Ala His Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu 1 5 10 15 Glu Asn Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln 20 25 30 Gln Ala Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu 35 40 45 Phe Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys 50 55 60 Ser Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu 65 70 75 80 Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro 85 90 95 Glu Arg Asn Glu Cys Phe Leu Gln His Lys Asp Asp Asn Pro Asn Leu 100 105 110 Pro Arg Leu Val Arg Pro Glu Val Asp Val Met Cys Thr Ala Phe His 115 120 125 Asp Asn Glu Glu Thr Phe Leu Lys Lys Tyr Leu Tyr Glu Ile Ala Arg 130 135 140 Arg His Pro Tyr Phe Tyr Ala Pro Glu Leu Leu Phe Phe Ala Lys Arg 145 150 155 160 Tyr Lys Ala Ala Phe Thr Glu Cys Cys Gln Ala Ala Asp Lys Ala Ala 165 170 175 Cys Leu Leu Pro Lys Leu Asp Glu Leu Arg Asp Glu Gly Lys Ala Ser 180 185 190 Ser Ala Lys Gln Arg Leu Lys Cys Ala Ser Leu Gln Lys Phe Gly Glu 195 200 205 Arg Ala Phe Lys Ala Trp Ala Val Ala Arg Leu Ser Gln Arg Phe Pro 210 215 220 Lys Ala Glu Phe Ala Glu Val Ser Lys Leu Val Thr Asp Leu Thr Lys 225 230 235 240 Val His Thr Glu Cys Cys His Gly Asp Leu Leu Glu Cys Ala Asp Asp 245 250 255 Arg Ala Asp Leu Ala Lys Tyr Ile Cys Glu Asn Gln Asp Ser Ile Ser 260 265 270 Ser Lys Leu Lys Glu Cys Cys Glu Lys Pro Leu Leu Glu Lys Ser His 275 280 285 Cys Ile Ala Glu Val Glu Asn Asp Glu Met Pro Ala Asp Leu Pro Ser 290 295 300 Leu Ala Ala Asp Phe Val Glu Ser Lys Asp Val Cys Lys Asn Tyr Ala 305 310 315 320 Glu Ala Lys Asp Val Phe Leu Gly Met Phe Leu Tyr Glu Tyr Ala Arg 325 330 335 Arg His Pro Asp Tyr Ser Val Val Leu Leu Leu Arg Leu Ala Lys Thr 340 345 350 Tyr Glu Thr Thr Leu Glu Lys Cys Cys Ala Ala Ala Asp Pro His Glu 355 360 365 Cys Tyr Ala Lys Val Phe Asp Glu Phe Lys Pro Leu Val Glu Glu Pro 370 375 380 Gln Asn Leu Ile Lys Gln Asn Cys Glu Leu Phe Glu Gln Leu Gly Glu 385 390 395 400 Tyr Lys Phe Gln Asn Ala Leu Leu Val Arg Tyr Thr Lys Lys Val Pro 405 410 415 Gln Val Ser Thr Pro Thr Leu Val Glu Val Ser Arg Asn Leu Gly Lys 420 425 430 Val Gly Ser Lys Cys Cys Lys His Pro Glu Ala Lys Arg Met Pro Cys 435 440 445 Ala Glu Asp Tyr Leu Ser Val Val Leu Asn Gln Leu Cys Val Leu His 450 455 460 Glu Lys Thr Pro Val Ser Asp Arg Val Thr Lys Cys Cys Thr Glu Ser 465 470 475 480 Leu Val Asn Arg Arg Pro Cys Phe Ser Ala Leu Glu Val Asp Glu Thr 485 490 495 Tyr Val Pro Lys Glu Phe Asn Ala Glu Thr Phe Thr Phe His Ala Asp 500 505 510 Ile Cys Thr Leu Ser Glu Lys Glu Arg Gln Ile Lys Lys Gln Thr Ala 515 520 525 Leu Val Glu Leu Val Lys His Lys Pro Lys Ala Thr Lys Glu Gln Leu 530 535 540 Lys Ala Val Met Asp Asp Phe Ala Ala Phe Val Glu Lys Cys Cys Lys 545 550 555 560 Ala Asp Asp Lys Glu Thr Cys Phe Ala Glu Glu Gly Lys Lys Leu Val 565 570 575 Ala Ala Ser Gln Ala Ala Leu Gly Leu 580 585 <210> 322 <211> 585 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 322 Asp Ala His Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu 1 5 10 15 Glu Asn Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln 20 25 30 Gln Ala Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu 35 40 45 Phe Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys 50 55 60 Ser Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu 65 70 75 80 Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro 85 90 95 Glu Arg Asn Glu Cys Phe Leu Gln His Lys Asp Asp Asn Pro Asn Leu 100 105 110 Pro Arg Leu Val Arg Pro Glu Val Asp Val Met Cys Thr Ala Phe His 115 120 125 Asp Asn Glu Glu Thr Phe Leu Lys Lys Tyr Leu Tyr Glu Ile Ala Arg 130 135 140 Arg His Pro Tyr Phe Tyr Ala Pro Glu Leu Leu Phe Phe Ala Lys Arg 145 150 155 160 Tyr Lys Ala Ala Phe Thr Glu Cys Cys Gln Ala Ala Asp Lys Ala Ala 165 170 175 Cys Leu Leu Pro Lys Leu Asp Glu Leu Arg Asp Glu Gly Lys Ala Ser 180 185 190 Ser Ala Lys Gln Arg Leu Lys Cys Ala Ser Leu Gln Lys Phe Gly Glu 195 200 205 Arg Ala Phe Lys Ala Trp Ala Val Ala Arg Leu Ser Gln Arg Phe Pro 210 215 220 Lys Ala Glu Phe Ala Glu Val Ser Lys Leu Val Thr Asp Leu Thr Lys 225 230 235 240 Val His Thr Glu Cys Cys His Gly Asp Leu Leu Glu Cys Ala Asp Asp 245 250 255 Arg Ala Asp Leu Ala Lys Tyr Ile Cys Glu Asn Gln Asp Ser Ile Ser 260 265 270 Ser Lys Leu Lys Glu Cys Cys Glu Lys Pro Leu Leu Glu Lys Ser His 275 280 285 Cys Ile Ala Glu Val Glu Asn Asp Glu Met Pro Ala Asp Leu Pro Ser 290 295 300 Leu Ala Ala Asp Phe Val Glu Ser Lys Asp Val Cys Lys Asn Tyr Ala 305 310 315 320 Glu Ala Lys Asp Val Phe Leu Gly Met Phe Leu Tyr Glu Tyr Ala Arg 325 330 335 Arg His Pro Asp Tyr Ser Val Val Leu Leu Leu Arg Leu Ala Lys Thr 340 345 350 Tyr Glu Thr Thr Leu Glu Lys Cys Cys Ala Ala Ala Asp Pro His Glu 355 360 365 Cys Tyr Ala Lys Val Phe Asp Glu Phe Lys Pro Leu Val Glu Glu Pro 370 375 380 Gln Asn Leu Ile Lys Gln Asn Cys Glu Leu Phe Glu Gln Leu Gly Glu 385 390 395 400 Tyr Lys Phe Gln Asn Ala Leu Leu Val Arg Tyr Thr Lys Lys Val Pro 405 410 415 Gln Val Ser Thr Pro Thr Leu Val Glu Val Ser Arg Asn Leu Gly Lys 420 425 430 Val Gly Ser Lys Cys Cys Lys His Pro Glu Ala Lys Arg Met Pro Cys 435 440 445 Ala Glu Asp Tyr Leu Ser Val Val Leu Asn Gln Leu Cys Val Leu His 450 455 460 Glu Lys Thr Pro Val Ser Asp Arg Val Thr Lys Cys Cys Thr Glu Ser 465 470 475 480 Leu Val Asn Arg Arg Pro Cys Phe Ser Ala Leu Glu Val Asp Glu Thr 485 490 495 Tyr Val Pro Lys Glu Phe Asn Ala Gly Thr Phe Thr Phe His Ala Asp 500 505 510 Ile Cys Thr Leu Ser Glu Lys Glu Arg Gln Ile Lys Lys Gln Thr Ala 515 520 525 Leu Val Glu Leu Val Lys His Lys Pro Lys Ala Thr Lys Glu Gln Leu 530 535 540 Lys Ala Ala Met Asp Asp Phe Ala Ala Phe Val Glu Lys Cys Cys Lys 545 550 555 560 Ala Asp Asp Lys Glu Thr Cys Phe Ala Glu Glu Gly Lys Lys Leu Val 565 570 575 Ala Ala Ser Gln Ala Ala Leu Gly Leu 580 585 <210> 323 <211> 585 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 323 Asp Ala His Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu 1 5 10 15 Glu Asn Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln 20 25 30 Gln Ala Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu 35 40 45 Phe Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys 50 55 60 Ser Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu 65 70 75 80 Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro 85 90 95 Glu Arg Asn Glu Cys Phe Leu Gln His Lys Asp Asp Asn Pro Asn Leu 100 105 110 Pro Arg Leu Val Arg Pro Glu Val Asp Val Met Cys Thr Ala Phe His 115 120 125 Asp Asn Glu Glu Thr Phe Leu Lys Lys Tyr Leu Tyr Glu Ile Ala Arg 130 135 140 Arg His Pro Tyr Phe Tyr Ala Pro Glu Leu Leu Phe Phe Ala Lys Arg 145 150 155 160 Tyr Lys Ala Ala Phe Thr Glu Cys Cys Gln Ala Ala Asp Lys Ala Ala 165 170 175 Cys Leu Leu Pro Lys Leu Asp Glu Leu Arg Asp Glu Gly Lys Ala Ser 180 185 190 Ser Ala Lys Gln Arg Leu Lys Cys Ala Ser Leu Gln Lys Phe Gly Glu 195 200 205 Arg Ala Phe Lys Ala Trp Ala Val Ala Arg Leu Ser Gln Arg Phe Pro 210 215 220 Lys Ala Glu Phe Ala Glu Val Ser Lys Leu Val Thr Asp Leu Thr Lys 225 230 235 240 Val His Thr Glu Cys Cys His Gly Asp Leu Leu Glu Cys Ala Asp Asp 245 250 255 Arg Ala Asp Leu Ala Lys Tyr Ile Cys Glu Asn Gln Asp Ser Ile Ser 260 265 270 Ser Lys Leu Lys Glu Cys Cys Glu Lys Pro Leu Leu Glu Lys Ser His 275 280 285 Cys Ile Ala Glu Val Glu Asn Asp Glu Met Pro Ala Asp Leu Pro Ser 290 295 300 Leu Ala Ala Asp Phe Val Glu Ser Lys Asp Val Cys Lys Asn Tyr Ala 305 310 315 320 Glu Ala Lys Asp Val Phe Leu Gly Met Phe Leu Tyr Glu Tyr Ala Arg 325 330 335 Arg His Pro Asp Tyr Ser Val Val Leu Leu Leu Arg Leu Ala Lys Thr 340 345 350 Tyr Glu Thr Thr Leu Glu Lys Cys Cys Ala Ala Ala Asp Pro His Glu 355 360 365 Cys Tyr Ala Lys Val Phe Asp Glu Phe Lys Pro Leu Val Glu Glu Pro 370 375 380 Gln Asn Leu Ile Lys Gln Asn Cys Glu Leu Phe Glu Gln Leu Gly Glu 385 390 395 400 Tyr Lys Phe Gln Asn Ala Leu Leu Val Arg Tyr Thr Lys Lys Val Pro 405 410 415 Gln Val Ser Thr Pro Thr Leu Val Glu Val Ser Arg Asn Leu Gly Lys 420 425 430 Val Gly Ser Lys Cys Cys Lys His Pro Glu Ala Lys Arg Met Pro Cys 435 440 445 Ala Glu Asp Tyr Leu Ser Val Val Leu Asn Gln Leu Cys Val Leu His 450 455 460 Glu Lys Thr Pro Val Ser Asp Arg Val Thr Lys Cys Cys Thr Glu Ser 465 470 475 480 Leu Val Asn Arg Arg Pro Cys Phe Ser Ala Leu Glu Val Asp Glu Thr 485 490 495 Tyr Val Pro Lys Glu Phe Asn Ala Glu Thr Phe Thr Phe His Ala Asp 500 505 510 Ile Cys Thr Leu Ser Glu Lys Glu Arg Gln Ile Lys Lys Gln Thr Ala 515 520 525 Leu Val Glu Leu Val Lys His Lys Pro Lys Ala Thr Lys Glu Gln Leu 530 535 540 Lys Ala Val Met Asp Asp Phe Ala Ala Phe Val Glu Lys Cys Cys Lys 545 550 555 560 Ala Asp Asp Lys Glu Thr Cys Phe Ala Glu Glu Gly Pro Lys Leu Val 565 570 575 Ala Ala Ser Gln Ala Ala Leu Gly Leu 580 585 <210> 324 <211> 585 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 324 Asp Ala His Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu 1 5 10 15 Glu Asn Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln 20 25 30 Gln Ala Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu 35 40 45 Phe Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys 50 55 60 Ser Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu 65 70 75 80 Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro 85 90 95 Glu Arg Asn Glu Cys Phe Leu Gln His Lys Asp Asp Asn Pro Asn Leu 100 105 110 Pro Arg Leu Val Arg Pro Glu Val Asp Val Met Cys Thr Ala Phe His 115 120 125 Asp Asn Glu Glu Thr Phe Leu Lys Lys Tyr Leu Tyr Glu Ile Ala Arg 130 135 140 Arg His Pro Tyr Phe Tyr Ala Pro Glu Leu Leu Phe Phe Ala Lys Arg 145 150 155 160 Tyr Lys Ala Ala Phe Thr Glu Cys Cys Gln Ala Ala Asp Lys Ala Ala 165 170 175 Cys Leu Leu Pro Lys Leu Asp Glu Leu Arg Asp Glu Gly Lys Ala Ser 180 185 190 Ser Ala Lys Gln Arg Leu Lys Cys Ala Ser Leu Gln Lys Phe Gly Glu 195 200 205 Arg Ala Phe Lys Ala Trp Ala Val Ala Arg Leu Ser Gln Arg Phe Pro 210 215 220 Lys Ala Glu Phe Ala Glu Val Ser Lys Leu Val Thr Asp Leu Thr Lys 225 230 235 240 Val His Thr Glu Cys Cys His Gly Asp Leu Leu Glu Cys Ala Asp Asp 245 250 255 Arg Ala Asp Leu Ala Lys Tyr Ile Cys Glu Asn Gln Asp Ser Ile Ser 260 265 270 Ser Lys Leu Lys Glu Cys Cys Glu Lys Pro Leu Leu Glu Lys Ser His 275 280 285 Cys Ile Ala Glu Val Glu Asn Asp Glu Met Pro Ala Asp Leu Pro Ser 290 295 300 Leu Ala Ala Asp Phe Val Glu Ser Lys Asp Val Cys Lys Asn Tyr Ala 305 310 315 320 Glu Ala Lys Asp Val Phe Leu Gly Met Phe Leu Tyr Glu Tyr Ala Arg 325 330 335 Arg His Pro Asp Tyr Ser Val Val Leu Leu Leu Arg Leu Ala Lys Thr 340 345 350 Tyr Glu Thr Thr Leu Glu Lys Cys Cys Ala Ala Ala Asp Pro His Glu 355 360 365 Cys Tyr Ala Lys Val Phe Asp Glu Phe Lys Pro Leu Val Glu Glu Pro 370 375 380 Gln Asn Leu Ile Lys Gln Asn Cys Glu Leu Phe Glu Gln Leu Gly Glu 385 390 395 400 Tyr Lys Phe Gln Asn Ala Leu Leu Val Arg Tyr Thr Lys Lys Val Pro 405 410 415 Gln Val Ser Thr Pro Thr Leu Val Glu Val Ser Arg Asn Leu Gly Lys 420 425 430 Val Gly Ser Lys Cys Cys Lys His Pro Glu Ala Lys Arg Met Pro Cys 435 440 445 Ala Glu Asp Tyr Leu Ser Val Val Leu Asn Gln Leu Cys Val Leu His 450 455 460 Glu Lys Thr Pro Val Ser Asp Arg Val Thr Lys Cys Cys Thr Glu Ser 465 470 475 480 Leu Val Asn Arg Arg Pro Cys Phe Ser Ala Leu Asp Val Asp Glu Thr 485 490 495 Tyr Val Pro Lys Glu Phe Asn Ala Glu Thr Phe Thr Phe His Ala Asp 500 505 510 Ile Cys Thr Leu Ser Glu Lys Glu Arg Gln Ile Lys Lys Gln Thr Ala 515 520 525 Leu Val Glu Leu Val Lys His Lys Pro Lys Ala Thr Lys Glu Gln Leu 530 535 540 Lys Ala Val Met Asp Asp Phe Ala Ala Phe Val Glu Lys Cys Cys Lys 545 550 555 560 Ala Asp Asp Lys Glu Thr Cys Phe Ala Glu Glu Gly Pro His Leu Val 565 570 575 Ala Ala Ser Lys Ala Ala Leu Gly Leu 580 585 <210> 325 <211> 585 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 325 Asp Ala His Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu 1 5 10 15 Glu Asn Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln 20 25 30 Gln Ala Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu 35 40 45 Phe Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys 50 55 60 Ser Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu 65 70 75 80 Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro 85 90 95 Glu Arg Asn Glu Cys Phe Leu Gln His Lys Asp Asp Asn Pro Asn Leu 100 105 110 Pro Arg Leu Val Arg Pro Glu Val Asp Val Met Cys Thr Ala Phe His 115 120 125 Asp Asn Glu Glu Thr Phe Leu Lys Lys Tyr Leu Tyr Glu Ile Ala Arg 130 135 140 Arg His Pro Tyr Phe Tyr Ala Pro Glu Leu Leu Phe Phe Ala Lys Arg 145 150 155 160 Tyr Lys Ala Ala Phe Thr Glu Cys Cys Gln Ala Ala Asp Lys Ala Ala 165 170 175 Cys Leu Leu Pro Lys Leu Asp Glu Leu Arg Asp Glu Gly Lys Ala Ser 180 185 190 Ser Ala Lys Gln Arg Leu Lys Cys Ala Ser Leu Gln Lys Phe Gly Glu 195 200 205 Arg Ala Phe Lys Ala Trp Ala Val Ala Arg Leu Ser Gln Arg Phe Pro 210 215 220 Lys Ala Glu Phe Ala Glu Val Ser Lys Leu Val Thr Asp Leu Thr Lys 225 230 235 240 Val His Thr Glu Cys Cys His Gly Asp Leu Leu Glu Cys Ala Asp Asp 245 250 255 Arg Ala Asp Leu Ala Lys Tyr Ile Cys Glu Asn Gln Asp Ser Ile Ser 260 265 270 Ser Lys Leu Lys Glu Cys Cys Glu Lys Pro Leu Leu Glu Lys Ser His 275 280 285 Cys Ile Ala Glu Val Glu Asn Asp Glu Met Pro Ala Asp Leu Pro Ser 290 295 300 Leu Ala Ala Asp Phe Val Glu Ser Lys Asp Val Cys Lys Asn Tyr Ala 305 310 315 320 Glu Ala Lys Asp Val Phe Leu Gly Met Phe Leu Tyr Glu Tyr Ala Arg 325 330 335 Arg His Pro Asp Tyr Ser Val Val Leu Leu Leu Arg Leu Ala Lys Thr 340 345 350 Tyr Glu Thr Thr Leu Glu Lys Cys Cys Ala Ala Ala Asp Pro His Glu 355 360 365 Cys Tyr Ala Lys Val Phe Asp Glu Phe Lys Pro Leu Val Glu Glu Pro 370 375 380 Gln Asn Leu Ile Lys Gln Asn Cys Glu Leu Phe Glu Gln Leu Gly Glu 385 390 395 400 Tyr Lys Phe Gln Asn Ala Leu Leu Val Arg Tyr Thr Lys Lys Val Pro 405 410 415 Gln Val Ser Thr Pro Thr Leu Val Glu Val Ser Arg Asn Leu Gly Lys 420 425 430 Val Gly Ser Lys Cys Cys Lys His Pro Glu Ala Lys Arg Met Pro Cys 435 440 445 Ala Glu Asp Tyr Leu Ser Val Val Leu Asn Gln Leu Cys Val Leu His 450 455 460 Glu Lys Thr Pro Val Ser Asp Arg Val Thr Lys Cys Cys Thr Glu Ser 465 470 475 480 Leu Val Asn Arg Arg Pro Cys Phe Ser Ala Leu Gly Val Asp Glu Thr 485 490 495 Tyr Val Pro Lys Glu Phe Asn Ala Glu Thr Phe Thr Phe His Ala Asp 500 505 510 Ile Cys Thr Leu Ser Glu Lys Glu Arg Gln Ile Lys Lys Gln Thr Ala 515 520 525 Leu Val Glu Leu Val Lys His Lys Pro Lys Ala Thr Lys Glu Gln Leu 530 535 540 Lys Ala Val Met Asp Lys Phe Ala Ala Phe Val Glu Lys Cys Cys Lys 545 550 555 560 Ala Asp Asp Lys Glu Thr Cys Phe Ala Glu Glu Gly Pro Lys Leu Val 565 570 575 Ala Ala Ser Gln Ala Ala Leu Gly Leu 580 585 <210> 326 <211> 585 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 326 Asp Ala His Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu 1 5 10 15 Glu Asn Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln 20 25 30 Gln Ala Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu 35 40 45 Phe Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys 50 55 60 Ser Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu 65 70 75 80 Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro 85 90 95 Glu Arg Asn Glu Cys Phe Leu Gln His Lys Asp Asp Asn Pro Asn Leu 100 105 110 Pro Arg Leu Val Arg Pro Glu Val Asp Val Met Cys Thr Ala Phe His 115 120 125 Asp Asn Glu Glu Thr Phe Leu Lys Lys Tyr Leu Tyr Glu Ile Ala Arg 130 135 140 Arg His Pro Tyr Phe Tyr Ala Pro Glu Leu Leu Phe Phe Ala Lys Arg 145 150 155 160 Tyr Lys Ala Ala Phe Thr Glu Cys Cys Gln Ala Ala Asp Lys Ala Ala 165 170 175 Cys Leu Leu Pro Lys Leu Asp Glu Leu Arg Asp Glu Gly Lys Ala Ser 180 185 190 Ser Ala Lys Gln Arg Leu Lys Cys Ala Ser Leu Gln Lys Phe Gly Glu 195 200 205 Arg Ala Phe Lys Ala Trp Ala Val Ala Arg Leu Ser Gln Arg Phe Pro 210 215 220 Lys Ala Glu Phe Ala Glu Val Ser Lys Leu Val Thr Asp Leu Thr Lys 225 230 235 240 Val His Thr Glu Cys Cys His Gly Asp Leu Leu Glu Cys Ala Asp Asp 245 250 255 Arg Ala Asp Leu Ala Lys Tyr Ile Cys Glu Asn Gln Asp Ser Ile Ser 260 265 270 Ser Lys Leu Lys Glu Cys Cys Glu Lys Pro Leu Leu Glu Lys Ser His 275 280 285 Cys Ile Ala Glu Val Glu Asn Asp Glu Met Pro Ala Asp Leu Pro Ser 290 295 300 Leu Ala Ala Asp Phe Val Glu Ser Lys Asp Val Cys Lys Asn Tyr Ala 305 310 315 320 Glu Ala Lys Asp Val Phe Leu Gly Met Phe Leu Tyr Glu Tyr Ala Arg 325 330 335 Arg His Pro Asp Tyr Ser Val Val Leu Leu Leu Arg Leu Ala Lys Thr 340 345 350 Tyr Glu Thr Thr Leu Glu Lys Cys Cys Ala Ala Ala Asp Pro His Glu 355 360 365 Cys Tyr Ala Lys Val Phe Asp Glu Phe Lys Pro Leu Val Glu Glu Pro 370 375 380 Gln Asn Leu Ile Lys Gln Asn Cys Glu Leu Phe Glu Gln Leu Gly Glu 385 390 395 400 Tyr Lys Phe Gln Asn Ala Leu Leu Val Arg Tyr Thr Lys Lys Val Pro 405 410 415 Gln Val Ser Thr Pro Thr Leu Val Glu Val Ser Arg Asn Leu Gly Lys 420 425 430 Val Gly Ser Lys Cys Cys Lys His Pro Glu Ala Lys Arg Met Pro Cys 435 440 445 Ala Glu Asp Tyr Leu Ser Val Val Leu Asn Gln Leu Cys Val Leu His 450 455 460 Glu Lys Thr Pro Val Ser Asp Arg Val Thr Lys Cys Cys Thr Glu Ser 465 470 475 480 Leu Val Asn Arg Arg Pro Cys Phe Ser Ala Leu Asp Val Asp Glu Thr 485 490 495 Tyr Val Pro Lys Glu Phe Asn Ala Glu Thr Phe Thr Phe His Ala Asp 500 505 510 Ile Cys Thr Leu Ser Glu Lys Glu Arg Gln Ile Lys Lys Gln Thr Ala 515 520 525 Leu Val Glu Leu Val Lys His Lys Pro Lys Ala Thr Lys Glu Gln Leu 530 535 540 Lys Ala Val Met Asp Lys Phe Ala Ala Phe Val Glu Lys Cys Cys Lys 545 550 555 560 Ala Asp Asp Lys Glu Thr Cys Phe Ala Glu Glu Gly Pro Lys Leu Val 565 570 575 Ala Ala Ser Gln Ala Ala Leu Gly Leu 580 585 <210> 327 <211> 585 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 327 Asp Ala His Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu 1 5 10 15 Glu Asn Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln 20 25 30 Gln Ala Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu 35 40 45 Phe Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys 50 55 60 Ser Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu 65 70 75 80 Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro 85 90 95 Glu Arg Asn Glu Cys Phe Leu Gln His Lys Asp Asp Asn Pro Asn Leu 100 105 110 Pro Arg Leu Val Arg Pro Glu Val Asp Val Met Cys Thr Ala Phe His 115 120 125 Asp Asn Glu Glu Thr Phe Leu Lys Lys Tyr Leu Tyr Glu Ile Ala Arg 130 135 140 Arg His Pro Tyr Phe Tyr Ala Pro Glu Leu Leu Phe Phe Ala Lys Arg 145 150 155 160 Tyr Lys Ala Ala Phe Thr Glu Cys Cys Gln Ala Ala Asp Lys Ala Ala 165 170 175 Cys Leu Leu Pro Lys Leu Asp Glu Leu Arg Asp Glu Gly Lys Ala Ser 180 185 190 Ser Ala Lys Gln Arg Leu Lys Cys Ala Ser Leu Gln Lys Phe Gly Glu 195 200 205 Arg Ala Phe Lys Ala Trp Ala Val Ala Arg Leu Ser Gln Arg Phe Pro 210 215 220 Lys Ala Glu Phe Ala Glu Val Ser Lys Leu Val Thr Asp Leu Thr Lys 225 230 235 240 Val His Thr Glu Cys Cys His Gly Asp Leu Leu Glu Cys Ala Asp Asp 245 250 255 Arg Ala Asp Leu Ala Lys Tyr Ile Cys Glu Asn Gln Asp Ser Ile Ser 260 265 270 Ser Lys Leu Lys Glu Cys Cys Glu Lys Pro Leu Leu Glu Lys Ser His 275 280 285 Cys Ile Ala Glu Val Glu Asn Asp Glu Met Pro Ala Asp Leu Pro Ser 290 295 300 Leu Ala Ala Asp Phe Val Glu Ser Lys Asp Val Cys Lys Asn Tyr Ala 305 310 315 320 Glu Ala Lys Asp Val Phe Leu Gly Met Phe Leu Tyr Glu Tyr Ala Arg 325 330 335 Arg His Pro Asp Tyr Ser Val Val Leu Leu Leu Arg Leu Ala Lys Thr 340 345 350 Tyr Glu Thr Thr Leu Glu Lys Cys Cys Ala Ala Ala Asp Pro His Glu 355 360 365 Cys Tyr Ala Lys Val Phe Asp Glu Phe Lys Pro Leu Val Glu Glu Pro 370 375 380 Gln Asn Leu Ile Lys Gln Asn Cys Glu Leu Phe Glu Gln Leu Gly Glu 385 390 395 400 Tyr Lys Phe Gln Asn Ala Leu Leu Val Arg Tyr Thr Lys Lys Val Pro 405 410 415 Gln Val Ser Thr Pro Thr Leu Val Glu Val Ser Arg Asn Leu Gly Lys 420 425 430 Val Gly Ser Lys Cys Cys Lys His Pro Glu Ala Lys Arg Met Pro Cys 435 440 445 Ala Glu Asp Tyr Leu Ser Val Val Leu Asn Gln Leu Cys Val Leu His 450 455 460 Glu Lys Thr Pro Val Ser Asp Arg Val Thr Lys Cys Cys Thr Glu Ser 465 470 475 480 Leu Val Asn Arg Arg Pro Cys Phe Ser Ala Leu Glu Val Asp Glu Thr 485 490 495 Tyr Val Pro Lys Glu Phe Asn Ala Glu Thr Phe Thr Phe His Ala Asp 500 505 510 Ile Cys Thr Leu Ser Glu Lys Glu Arg Gln Ile Lys Lys Gln Thr Ala 515 520 525 Leu Val Glu Leu Val Lys His Lys Pro Lys Ala Thr Lys Glu Gln Leu 530 535 540 Lys Ala Val Met Asp Lys Phe Ala Ala Phe Val Glu Lys Cys Cys Lys 545 550 555 560 Ala Asp Asp Lys Glu Thr Cys Phe Ala Glu Glu Gly Pro His Leu Val 565 570 575 Ala Ala Ser Gln Ala Ala Leu Gly Leu 580 585 <210> 328 <211> 585 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 328 Asp Ala His Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu 1 5 10 15 Glu Asn Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln 20 25 30 Gln Ala Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu 35 40 45 Phe Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys 50 55 60 Ser Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu 65 70 75 80 Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro 85 90 95 Glu Arg Asn Glu Cys Phe Leu Gln His Lys Asp Asp Asn Pro Asn Leu 100 105 110 Pro Arg Leu Val Arg Pro Glu Val Asp Val Met Cys Thr Ala Phe His 115 120 125 Asp Asn Glu Glu Thr Phe Leu Lys Lys Tyr Leu Tyr Glu Ile Ala Arg 130 135 140 Arg His Pro Tyr Phe Tyr Ala Pro Glu Leu Leu Phe Phe Ala Lys Arg 145 150 155 160 Tyr Lys Ala Ala Phe Thr Glu Cys Cys Gln Ala Ala Asp Lys Ala Ala 165 170 175 Cys Leu Leu Pro Lys Leu Asp Glu Leu Arg Asp Glu Gly Lys Ala Ser 180 185 190 Ser Ala Lys Gln Arg Leu Lys Cys Ala Ser Leu Gln Lys Phe Gly Glu 195 200 205 Arg Ala Phe Lys Ala Trp Ala Val Ala Arg Leu Ser Gln Arg Phe Pro 210 215 220 Lys Ala Glu Phe Ala Glu Val Ser Lys Leu Val Thr Asp Leu Thr Lys 225 230 235 240 Val His Thr Glu Cys Cys His Gly Asp Leu Leu Glu Cys Ala Asp Asp 245 250 255 Arg Ala Asp Leu Ala Lys Tyr Ile Cys Glu Asn Gln Asp Ser Ile Ser 260 265 270 Ser Lys Leu Lys Glu Cys Cys Glu Lys Pro Leu Leu Glu Lys Ser His 275 280 285 Cys Ile Ala Glu Val Glu Asn Asp Glu Met Pro Ala Asp Leu Pro Ser 290 295 300 Leu Ala Ala Asp Phe Val Glu Ser Lys Asp Val Cys Lys Asn Tyr Ala 305 310 315 320 Glu Ala Lys Asp Val Phe Leu Gly Met Phe Leu Tyr Glu Tyr Ala Arg 325 330 335 Arg His Pro Asp Tyr Ser Val Val Leu Leu Leu Arg Leu Ala Lys Thr 340 345 350 Tyr Glu Thr Thr Leu Glu Lys Cys Cys Ala Ala Ala Asp Pro His Glu 355 360 365 Cys Tyr Ala Lys Val Phe Asp Glu Phe Lys Pro Leu Val Glu Glu Pro 370 375 380 Gln Asn Leu Ile Lys Gln Asn Cys Glu Leu Phe Glu Gln Leu Gly Glu 385 390 395 400 Tyr Lys Phe Gln Asn Ala Leu Leu Val Arg Tyr Thr Lys Lys Val Pro 405 410 415 Gln Val Ser Thr Pro Thr Leu Val Glu Val Ser Arg Asn Leu Gly Lys 420 425 430 Val Gly Ser Lys Cys Cys Lys His Pro Glu Ala Lys Arg Met Pro Cys 435 440 445 Ala Glu Asp Tyr Leu Ser Val Val Leu Asn Gln Leu Cys Val Leu His 450 455 460 Glu Lys Thr Pro Val Ser Asp Arg Val Thr Lys Cys Cys Thr Glu Ser 465 470 475 480 Leu Val Asn Arg Arg Pro Cys Phe Ser Ala Leu Glu Val Asp Glu Thr 485 490 495 Tyr Val Pro Lys Glu Phe Asn Ala Glu Thr Phe Thr Phe His Ala Asp 500 505 510 Ile Cys Thr Leu Ser Glu Lys Glu Arg Gln Ile Lys Lys Gln Thr Ala 515 520 525 Leu Val Glu Leu Val Lys His Lys Pro Lys Ala Thr Lys Glu Gln Leu 530 535 540 Lys Ala Val Met Asp Asp Phe Ala Ala Phe Val Glu Lys Cys Cys Lys 545 550 555 560 Ala Asp Asp Lys Glu Thr Cys Phe Ala Glu Glu Gly Pro His Leu Val 565 570 575 Ala Ala Ser Lys Ala Ala Leu Gly Leu 580 585 <210> 329 <211> 585 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 329 Asp Ala His Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu 1 5 10 15 Glu Asn Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln 20 25 30 Gln Ala Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu 35 40 45 Phe Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys 50 55 60 Ser Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu 65 70 75 80 Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro 85 90 95 Glu Arg Asn Glu Cys Phe Leu Gln His Lys Asp Asp Asn Pro Asn Leu 100 105 110 Pro Arg Leu Val Arg Pro Glu Val Asp Val Met Cys Thr Ala Phe His 115 120 125 Asp Asn Glu Glu Thr Phe Leu Lys Lys Tyr Leu Tyr Glu Ile Ala Arg 130 135 140 Arg His Pro Tyr Phe Tyr Ala Pro Glu Leu Leu Phe Phe Ala Lys Arg 145 150 155 160 Tyr Lys Ala Ala Phe Thr Glu Cys Cys Gln Ala Ala Asp Lys Ala Ala 165 170 175 Cys Leu Leu Pro Lys Leu Asp Glu Leu Arg Asp Glu Gly Lys Ala Ser 180 185 190 Ser Ala Lys Gln Arg Leu Lys Cys Ala Ser Leu Gln Lys Phe Gly Glu 195 200 205 Arg Ala Phe Lys Ala Trp Ala Val Ala Arg Leu Ser Gln Arg Phe Pro 210 215 220 Lys Ala Glu Phe Ala Glu Val Ser Lys Leu Val Thr Asp Leu Thr Lys 225 230 235 240 Val His Thr Glu Cys Cys His Gly Asp Leu Leu Glu Cys Ala Asp Asp 245 250 255 Arg Ala Asp Leu Ala Lys Tyr Ile Cys Glu Asn Gln Asp Ser Ile Ser 260 265 270 Ser Lys Leu Lys Glu Cys Cys Glu Lys Pro Leu Leu Glu Lys Ser His 275 280 285 Cys Ile Ala Glu Val Glu Asn Asp Glu Met Pro Ala Asp Leu Pro Ser 290 295 300 Leu Ala Ala Asp Phe Val Glu Ser Lys Asp Val Cys Lys Asn Tyr Ala 305 310 315 320 Glu Ala Lys Asp Val Phe Leu Gly Met Phe Leu Tyr Glu Tyr Ala Arg 325 330 335 Arg His Pro Asp Tyr Ser Val Val Leu Leu Leu Arg Leu Ala Lys Thr 340 345 350 Tyr Glu Thr Thr Leu Glu Lys Cys Cys Ala Ala Ala Asp Pro His Glu 355 360 365 Cys Tyr Ala Lys Val Phe Asp Glu Phe Lys Pro Leu Val Glu Glu Pro 370 375 380 Gln Asn Leu Ile Lys Gln Asn Cys Glu Leu Phe Glu Gln Leu Gly Glu 385 390 395 400 Tyr Lys Phe Gln Asn Ala Leu Leu Val Arg Tyr Thr Lys Lys Val Pro 405 410 415 Gln Val Ser Thr Pro Thr Leu Val Glu Val Ser Arg Asn Leu Gly Lys 420 425 430 Val Gly Ser Lys Cys Cys Lys His Pro Glu Ala Lys Arg Met Pro Cys 435 440 445 Ala Glu Asp Tyr Leu Ser Val Val Leu Asn Gln Leu Cys Val Leu His 450 455 460 Glu Lys Thr Pro Val Ser Asp Arg Val Thr Lys Cys Cys Thr Glu Ser 465 470 475 480 Leu Val Asn Arg Arg Pro Cys Phe Ser Ala Leu Glu Val Asp Glu Thr 485 490 495 Tyr Val Pro Lys Glu Phe Asn Ala Glu Thr Phe Thr Phe His Ala Asp 500 505 510 Ile Cys Thr Leu Ser Glu Lys Glu Arg Gln Ile Lys Lys Gln Thr Ala 515 520 525 Leu Val Glu Leu Val Lys His Lys Pro Lys Ala Thr Lys Glu Gln Leu 530 535 540 Lys Ala Val Met Asp Lys Phe Ala Ala Phe Val Glu Lys Cys Cys Lys 545 550 555 560 Ala Asp Asp Lys Glu Thr Cys Phe Ala Glu Glu Gly Pro Lys Leu Val 565 570 575 Ala Ala Ser Lys Ala Ala Leu Gly Leu 580 585 <210> 330 <211> 585 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 330 Asp Ala His Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu 1 5 10 15 Glu Asn Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln 20 25 30 Gln Ala Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu 35 40 45 Phe Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys 50 55 60 Ser Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu 65 70 75 80 Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro 85 90 95 Glu Arg Asn Glu Cys Phe Leu Gln His Lys Asp Asp Asn Pro Asn Leu 100 105 110 Pro Arg Leu Val Arg Pro Glu Val Asp Val Met Cys Thr Ala Phe His 115 120 125 Asp Asn Glu Glu Thr Phe Leu Lys Lys Tyr Leu Tyr Glu Ile Ala Arg 130 135 140 Arg His Pro Tyr Phe Tyr Ala Pro Glu Leu Leu Phe Phe Ala Lys Arg 145 150 155 160 Tyr Lys Ala Ala Phe Thr Glu Cys Cys Gln Ala Ala Asp Lys Ala Ala 165 170 175 Cys Leu Leu Pro Lys Leu Asp Glu Leu Arg Asp Glu Gly Lys Ala Ser 180 185 190 Ser Ala Lys Gln Arg Leu Lys Cys Ala Ser Leu Gln Lys Phe Gly Glu 195 200 205 Arg Ala Phe Lys Ala Trp Ala Val Ala Arg Leu Ser Gln Arg Phe Pro 210 215 220 Lys Ala Glu Phe Ala Glu Val Ser Lys Leu Val Thr Asp Leu Thr Lys 225 230 235 240 Val His Thr Glu Cys Cys His Gly Asp Leu Leu Glu Cys Ala Asp Asp 245 250 255 Arg Ala Asp Leu Ala Lys Tyr Ile Cys Glu Asn Gln Asp Ser Ile Ser 260 265 270 Ser Lys Leu Lys Glu Cys Cys Glu Lys Pro Leu Leu Glu Lys Ser His 275 280 285 Cys Ile Ala Glu Val Glu Asn Asp Glu Met Pro Ala Asp Leu Pro Ser 290 295 300 Leu Ala Ala Asp Phe Val Glu Ser Lys Asp Val Cys Lys Asn Tyr Ala 305 310 315 320 Glu Ala Lys Asp Val Phe Leu Gly Met Phe Leu Tyr Glu Tyr Ala Arg 325 330 335 Arg His Pro Asp Tyr Ser Val Val Leu Leu Leu Arg Leu Ala Lys Thr 340 345 350 Tyr Glu Thr Thr Leu Glu Lys Cys Cys Ala Ala Ala Asp Pro His Glu 355 360 365 Cys Tyr Ala Lys Val Phe Asp Glu Phe Lys Pro Leu Val Glu Glu Pro 370 375 380 Gln Asn Leu Ile Lys Gln Asn Cys Glu Leu Phe Glu Gln Leu Gly Glu 385 390 395 400 Tyr Lys Phe Gln Asn Ala Leu Leu Val Arg Tyr Thr Lys Lys Val Pro 405 410 415 Gln Val Ser Thr Pro Thr Leu Val Glu Val Ser Arg Asn Leu Gly Lys 420 425 430 Val Gly Ser Lys Cys Cys Lys His Pro Glu Ala Lys Arg Met Pro Cys 435 440 445 Ala Glu Asp Tyr Leu Ser Val Val Leu Asn Gln Leu Cys Val Leu His 450 455 460 Glu Lys Thr Pro Val Ser Asp Arg Val Thr Lys Cys Cys Thr Glu Ser 465 470 475 480 Leu Val Asn Arg Arg Pro Cys Phe Ser Ala Leu Asp Val Asp Glu Thr 485 490 495 Tyr Val Pro Lys Glu Phe Asn Ala Glu Thr Phe Thr Phe His Ala Asp 500 505 510 Ile Cys Thr Leu Ser Glu Lys Glu Arg Gln Ile Lys Lys Gln Thr Ala 515 520 525 Leu Val Glu Leu Val Lys His Lys Pro Lys Ala Thr Lys Glu Gln Leu 530 535 540 Lys Ala Val Met Asp Asp Phe Ala Ala Phe Val Glu Lys Cys Cys Lys 545 550 555 560 Ala Asp Asp Lys Glu Thr Cys Phe Ala Glu Glu Gly Pro Lys Leu Val 565 570 575 Ala Ala Ser Lys Ala Ala Leu Gly Leu 580 585 <210> 331 <211> 330 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 331 Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys 1 5 10 15 Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 20 25 30 Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 35 40 45 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 50 55 60 Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 65 70 75 80 Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 85 90 95 Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys 100 105 110 Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro 115 120 125 Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys 130 135 140 Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp 145 150 155 160 Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Cys Glu 165 170 175 Glu Gln Tyr Gly Ser Thr Tyr Arg Cys Val Ser Val Leu Thr Val Leu 180 185 190 His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 195 200 205 Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly 210 215 220 Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu 225 230 235 240 Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr 245 250 255 Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn 260 265 270 Asn Tyr Asp Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe 275 280 285 Leu Tyr Ser Asp Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 290 295 300 Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr 305 310 315 320 Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 325 330 <210> 332 <211> 333 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 332 Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser 1 5 10 15 Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp 20 25 30 Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro 35 40 45 Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn 50 55 60 Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys 65 70 75 80 Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val 85 90 95 Glu Lys Thr Val Ala Pro Thr Glu Cys Ser Asp Lys Thr His Thr Cys 100 105 110 Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu 115 120 125 Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu 130 135 140 Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys 145 150 155 160 Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys 165 170 175 Pro Cys Glu Glu Gln Tyr Gly Ser Thr Tyr Arg Cys Val Ser Val Leu 180 185 190 Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys 195 200 205 Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys 210 215 220 Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser 225 230 235 240 Arg Lys Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys 245 250 255 Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln 260 265 270 Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Lys Ser Asp Gly 275 280 285 Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln 290 295 300 Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn 305 310 315 320 His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 325 330 <210> 333 <211> 330 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 333 Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg 1 5 10 15 Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 20 25 30 Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 35 40 45 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 50 55 60 Leu Ser Ser Val Val Thr Val Pro Ser Ser Asn Phe Gly Thr Gln Thr 65 70 75 80 Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys 85 90 95 Thr Val Glu Pro Lys Ser Ser Asp Lys Thr His Thr Cys Pro Pro Cys 100 105 110 Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro 115 120 125 Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys 130 135 140 Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp 145 150 155 160 Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 165 170 175 Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 180 185 190 His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 195 200 205 Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly 210 215 220 Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu 225 230 235 240 Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr 245 250 255 Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn 260 265 270 Asn Tyr Asp Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe 275 280 285 Leu Tyr Ser Asp Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 290 295 300 Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr 305 310 315 320 Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 325 330 <210> 334 <211> 338 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 334 Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser 1 5 10 15 Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp 20 25 30 Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro 35 40 45 Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn 50 55 60 Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys 65 70 75 80 Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val 85 90 95 Glu Lys Thr Val Ala Pro Thr Glu Cys Ser Glu Pro Lys Ser Ser Asp 100 105 110 Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly 115 120 125 Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 130 135 140 Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 145 150 155 160 Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 165 170 175 Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg 180 185 190 Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys 195 200 205 Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 210 215 220 Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 225 230 235 240 Thr Leu Pro Pro Ser Arg Lys Glu Met Thr Lys Asn Gln Val Ser Leu 245 250 255 Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 260 265 270 Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 275 280 285 Leu Lys Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 290 295 300 Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His 305 310 315 320 Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro 325 330 335 Gly Lys <210> 335 <211> 227 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 335 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 1 5 10 15 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 20 25 30 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 35 40 45 Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 50 55 60 His Asn Ala Lys Thr Lys Pro Cys Glu Glu Gln Tyr Gly Ser Thr Tyr 65 70 75 80 Arg Cys Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 85 90 95 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 100 105 110 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 115 120 125 Tyr Thr Leu Pro Pro Ser Arg Lys Glu Met Thr Lys Asn Gln Val Ser 130 135 140 Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 145 150 155 160 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 165 170 175 Val Leu Lys Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 180 185 190 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 195 200 205 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 210 215 220 Pro Gly Lys 225 <210> 336 <211> 227 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 336 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 1 5 10 15 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 20 25 30 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 35 40 45 Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 50 55 60 His Asn Ala Lys Thr Lys Pro Cys Glu Glu Gln Tyr Gly Ser Thr Tyr 65 70 75 80 Arg Cys Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 85 90 95 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 100 105 110 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 115 120 125 Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser 130 135 140 Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 145 150 155 160 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Asp Thr Thr Pro Pro 165 170 175 Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Asp Leu Thr Val 180 185 190 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 195 200 205 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 210 215 220 Pro Gly Lys 225 <210> 337 <211> 232 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 337 Glu Pro Lys Ser Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala 1 5 10 15 Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro 20 25 30 Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val 35 40 45 Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val 50 55 60 Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Cys Glu Glu Gln 65 70 75 80 Tyr Gly Ser Thr Tyr Arg Cys Val Ser Val Leu Thr Val Leu His Gln 85 90 95 Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala 100 105 110 Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro 115 120 125 Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Lys Glu Met Thr 130 135 140 Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser 145 150 155 160 Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr 165 170 175 Lys Thr Thr Pro Pro Val Leu Lys Ser Asp Gly Ser Phe Phe Leu Tyr 180 185 190 Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe 195 200 205 Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys 210 215 220 Ser Leu Ser Leu Ser Pro Gly Lys 225 230 <210> 338 <211> 232 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 338 Glu Pro Lys Ser Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala 1 5 10 15 Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro 20 25 30 Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val 35 40 45 Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val 50 55 60 Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Cys Glu Glu Gln 65 70 75 80 Tyr Gly Ser Thr Tyr Arg Cys Val Ser Val Leu Thr Val Leu His Gln 85 90 95 Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala 100 105 110 Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro 115 120 125 Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr 130 135 140 Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser 145 150 155 160 Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr 165 170 175 Asp Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr 180 185 190 Ser Asp Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe 195 200 205 Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys 210 215 220 Ser Leu Ser Leu Ser Pro Gly Lys 225 230 <210> 339 <211> 232 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 339 Glu Pro Lys Ser Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala 1 5 10 15 Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro 20 25 30 Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val 35 40 45 Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val 50 55 60 Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln 65 70 75 80 Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln 85 90 95 Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala 100 105 110 Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro 115 120 125 Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Lys Glu Met Thr 130 135 140 Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser 145 150 155 160 Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr 165 170 175 Lys Thr Thr Pro Pro Val Leu Lys Ser Asp Gly Ser Phe Phe Leu Tyr 180 185 190 Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe 195 200 205 Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys 210 215 220 Ser Leu Ser Leu Ser Pro Gly Lys 225 230 <210> 340 <211> 232 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 340 Glu Pro Lys Ser Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala 1 5 10 15 Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro 20 25 30 Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val 35 40 45 Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val 50 55 60 Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln 65 70 75 80 Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln 85 90 95 Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala 100 105 110 Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro 115 120 125 Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr 130 135 140 Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser 145 150 155 160 Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr 165 170 175 Asp Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr 180 185 190 Ser Asp Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe 195 200 205 Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys 210 215 220 Ser Leu Ser Leu Ser Pro Gly Lys 225 230 <210> 341 <211> 217 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 341 Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys 1 5 10 15 Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val 20 25 30 Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr 35 40 45 Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu 50 55 60 Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His 65 70 75 80 Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys 85 90 95 Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln 100 105 110 Pro Arg Glu Pro Gln Val Thr Thr Leu Pro Pro Ser Arg Glu Glu Met 115 120 125 Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro 130 135 140 Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn 145 150 155 160 Tyr Asp Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu 165 170 175 Tyr Ser Asp Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val 180 185 190 Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln 195 200 205 Lys Ser Leu Ser Leu Ser Pro Gly Lys 210 215 <210> 342 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 342 Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Tyr Tyr Pro Asn 1 5 10 <210> 343 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 343 Gly Thr Lys Phe Leu Ala Pro 1 5 <210> 344 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 344 Ala Leu Trp Tyr Ser Asn Arg Trp Val 1 5 <210> 345 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 345 Ile Tyr Ala Met Asn 1 5 <210> 346 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 346 Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser 1 5 10 15 Val Lys Ser <210> 347 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 347 His Gly Asn Phe Gly Asn Ser Tyr Val Ser Phe Phe Ala Tyr 1 5 10 <210> 348 <211> 125 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 348 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Ile Tyr 20 25 30 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 50 55 60 Ser Val Lys Ser Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 65 70 75 80 Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr 85 90 95 Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Val Ser Phe Phe 100 105 110 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 349 <211> 109 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 349 Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly 1 5 10 15 Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly 20 25 30 Tyr Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly 35 40 45 Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe 50 55 60 Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val 65 70 75 80 Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Ala Leu Trp Tyr Ser Asn 85 90 95 Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 350 <211> 249 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 350 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Ile Tyr 20 25 30 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 50 55 60 Ser Val Lys Ser Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 65 70 75 80 Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr 85 90 95 Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Val Ser Phe Phe 100 105 110 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 115 120 125 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val 130 135 140 Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu 145 150 155 160 Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Tyr Tyr Pro Asn 165 170 175 Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly 180 185 190 Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu 195 200 205 Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp 210 215 220 Glu Ala Glu Tyr Tyr Cys Ala Leu Trp Tyr Ser Asn Arg Trp Val Phe 225 230 235 240 Gly Gly Gly Thr Lys Leu Thr Val Leu 245 <210> 351 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 351 Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Tyr Tyr Pro Asn 1 5 10 <210> 352 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 352 Gly Thr Lys Phe Leu Ala Pro 1 5 <210> 353 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 353 Ala Leu Trp Tyr Ser Asn Arg Trp Val 1 5 <210> 354 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 354 Lys Tyr Ala Met Asn 1 5 <210> 355 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 355 Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser 1 5 10 15 Val Lys Asp <210> 356 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 356 His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr Trp Ala Tyr 1 5 10 <210> 357 <211> 125 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 357 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys Tyr 20 25 30 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 50 55 60 Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 65 70 75 80 Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr 85 90 95 Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr Trp 100 105 110 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 358 <211> 109 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 358 Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly 1 5 10 15 Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly 20 25 30 Tyr Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly 35 40 45 Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe 50 55 60 Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val 65 70 75 80 Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Ala Leu Trp Tyr Ser Asn 85 90 95 Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 359 <211> 249 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 359 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys Tyr 20 25 30 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 50 55 60 Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 65 70 75 80 Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr 85 90 95 Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr Trp 100 105 110 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 115 120 125 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val 130 135 140 Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu 145 150 155 160 Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Tyr Tyr Pro Asn 165 170 175 Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly 180 185 190 Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu 195 200 205 Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp 210 215 220 Glu Ala Glu Tyr Tyr Cys Ala Leu Trp Tyr Ser Asn Arg Trp Val Phe 225 230 235 240 Gly Gly Gly Thr Lys Leu Thr Val Leu 245 <210> 360 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 360 Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Tyr Tyr Pro Asn 1 5 10 <210> 361 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 361 Gly Thr Lys Phe Leu Ala Pro 1 5 <210> 362 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 362 Ala Leu Trp Tyr Ser Asn Arg Trp Val 1 5 <210> 363 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 363 Ser Tyr Ala Met Asn 1 5 <210> 364 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 364 Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser 1 5 10 15 Val Lys Gly <210> 365 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 365 His Gly Asn Phe Gly Asn Ser Tyr Leu Ser Phe Trp Ala Tyr 1 5 10 <210> 366 <211> 125 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 366 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Glu Gln Pro Gly Gly 1 5 10 15 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Ser Tyr 20 25 30 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 65 70 75 80 Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr 85 90 95 Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Leu Ser Phe Trp 100 105 110 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 367 <211> 109 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 367 Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly 1 5 10 15 Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly 20 25 30 Tyr Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly 35 40 45 Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe 50 55 60 Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val 65 70 75 80 Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Ala Leu Trp Tyr Ser Asn 85 90 95 Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 368 <211> 249 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 368 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Glu Gln Pro Gly Gly 1 5 10 15 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Ser Tyr 20 25 30 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 65 70 75 80 Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr 85 90 95 Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Leu Ser Phe Trp 100 105 110 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 115 120 125 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val 130 135 140 Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu 145 150 155 160 Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Tyr Tyr Pro Asn 165 170 175 Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly 180 185 190 Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu 195 200 205 Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp 210 215 220 Glu Ala Glu Tyr Tyr Cys Ala Leu Trp Tyr Ser Asn Arg Trp Val Phe 225 230 235 240 Gly Gly Gly Thr Lys Leu Thr Val Leu 245 <210> 369 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 369 Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Tyr Tyr Pro Asn 1 5 10 <210> 370 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 370 Gly Thr Lys Phe Leu Ala Pro 1 5 <210> 371 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 371 Ala Leu Trp Tyr Ser Asn Arg Trp Val 1 5 <210> 372 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 372 Arg Tyr Ala Met Asn 1 5 <210> 373 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 373 Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser 1 5 10 15 Val Lys Gly <210> 374 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 374 His Gly Asn Phe Gly Asn Ser Tyr Leu Ser Tyr Phe Ala Tyr 1 5 10 <210> 375 <211> 125 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 375 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Arg Tyr 20 25 30 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 65 70 75 80 Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr 85 90 95 Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Leu Ser Tyr Phe 100 105 110 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 376 <211> 109 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 376 Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly 1 5 10 15 Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly 20 25 30 Tyr Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly 35 40 45 Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe 50 55 60 Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val 65 70 75 80 Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Ala Leu Trp Tyr Ser Asn 85 90 95 Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 377 <211> 249 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 377 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Arg Tyr 20 25 30 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 65 70 75 80 Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr 85 90 95 Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Leu Ser Tyr Phe 100 105 110 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 115 120 125 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val 130 135 140 Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu 145 150 155 160 Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Tyr Tyr Pro Asn 165 170 175 Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly 180 185 190 Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu 195 200 205 Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp 210 215 220 Glu Ala Glu Tyr Tyr Cys Ala Leu Trp Tyr Ser Asn Arg Trp Val Phe 225 230 235 240 Gly Gly Gly Thr Lys Leu Thr Val Leu 245 <210> 378 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 378 Arg Ser Ser Thr Gly Ala Val Thr Ser Gly Tyr Tyr Pro Asn 1 5 10 <210> 379 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 379 Ala Thr Asp Met Arg Pro Ser 1 5 <210> 380 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 380 Ala Leu Trp Tyr Ser Asn Arg Trp Val 1 5 <210> 381 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 381 Val Tyr Ala Met Asn 1 5 <210> 382 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 382 Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser 1 5 10 15 Val Lys Lys <210> 383 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 383 His Gly Asn Phe Gly Asn Ser Tyr Leu Ser Trp Trp Ala Tyr 1 5 10 <210> 384 <211> 125 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 384 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Val Tyr 20 25 30 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 50 55 60 Ser Val Lys Lys Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 65 70 75 80 Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr 85 90 95 Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Leu Ser Trp Trp 100 105 110 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 385 <211> 109 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 385 Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly 1 5 10 15 Thr Val Thr Leu Thr Cys Arg Ser Ser Thr Gly Ala Val Thr Ser Gly 20 25 30 Tyr Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly 35 40 45 Leu Ile Gly Ala Thr Asp Met Arg Pro Ser Gly Thr Pro Ala Arg Phe 50 55 60 Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val 65 70 75 80 Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Ala Leu Trp Tyr Ser Asn 85 90 95 Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 386 <211> 249 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 386 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Val Tyr 20 25 30 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 50 55 60 Ser Val Lys Lys Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 65 70 75 80 Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr 85 90 95 Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Leu Ser Trp Trp 100 105 110 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 115 120 125 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val 130 135 140 Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu 145 150 155 160 Thr Cys Arg Ser Ser Thr Gly Ala Val Thr Ser Gly Tyr Tyr Pro Asn 165 170 175 Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Ala 180 185 190 Thr Asp Met Arg Pro Ser Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu 195 200 205 Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp 210 215 220 Glu Ala Glu Tyr Tyr Cys Ala Leu Trp Tyr Ser Asn Arg Trp Val Phe 225 230 235 240 Gly Gly Gly Thr Lys Leu Thr Val Leu 245 <210> 387 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 387 Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Tyr Tyr Pro Asn 1 5 10 <210> 388 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 388 Gly Thr Lys Phe Leu Ala Pro 1 5 <210> 389 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 389 Ala Leu Trp Tyr Ser Asn Arg Trp Val 1 5 <210> 390 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 390 Lys Tyr Ala Met Asn 1 5 <210> 391 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 391 Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser 1 5 10 15 Val Lys Ser <210> 392 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 392 His Gly Asn Phe Gly Asn Ser Tyr Thr Ser Tyr Tyr Ala Tyr 1 5 10 <210> 393 <211> 125 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 393 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys Tyr 20 25 30 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 50 55 60 Ser Val Lys Ser Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 65 70 75 80 Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr 85 90 95 Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Thr Ser Tyr Tyr 100 105 110 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 394 <211> 109 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 394 Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly 1 5 10 15 Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly 20 25 30 Tyr Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly 35 40 45 Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe 50 55 60 Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val 65 70 75 80 Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Ala Leu Trp Tyr Ser Asn 85 90 95 Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 395 <211> 249 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 395 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys Tyr 20 25 30 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 50 55 60 Ser Val Lys Ser Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 65 70 75 80 Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr 85 90 95 Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Thr Ser Tyr Tyr 100 105 110 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 115 120 125 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val 130 135 140 Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu 145 150 155 160 Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Tyr Tyr Pro Asn 165 170 175 Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly 180 185 190 Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu 195 200 205 Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp 210 215 220 Glu Ala Glu Tyr Tyr Cys Ala Leu Trp Tyr Ser Asn Arg Trp Val Phe 225 230 235 240 Gly Gly Gly Thr Lys Leu Thr Val Leu 245 <210> 396 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 396 Arg Ser Ser Thr Gly Ala Val Thr Ser Gly Tyr Tyr Pro Asn 1 5 10 <210> 397 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 397 Ala Thr Asp Met Arg Pro Ser 1 5 <210> 398 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 398 Ala Leu Trp Tyr Ser Asn Arg Trp Val 1 5 <210> 399 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 399 Gly Tyr Ala Met Asn 1 5 <210> 400 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 400 Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser 1 5 10 15 Val Lys Glu <210> 401 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 401 His Arg Asn Phe Gly Asn Ser Tyr Leu Ser Trp Phe Ala Tyr 1 5 10 <210> 402 <211> 125 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 402 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Gly Tyr 20 25 30 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 50 55 60 Ser Val Lys Glu Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 65 70 75 80 Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr 85 90 95 Tyr Cys Val Arg His Arg Asn Phe Gly Asn Ser Tyr Leu Ser Trp Phe 100 105 110 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 403 <211> 109 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 403 Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly 1 5 10 15 Thr Val Thr Leu Thr Cys Arg Ser Ser Thr Gly Ala Val Thr Ser Gly 20 25 30 Tyr Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly 35 40 45 Leu Ile Gly Ala Thr Asp Met Arg Pro Ser Gly Thr Pro Ala Arg Phe 50 55 60 Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val 65 70 75 80 Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Ala Leu Trp Tyr Ser Asn 85 90 95 Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 404 <211> 249 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 404 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Gly Tyr 20 25 30 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 50 55 60 Ser Val Lys Glu Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 65 70 75 80 Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr 85 90 95 Tyr Cys Val Arg His Arg Asn Phe Gly Asn Ser Tyr Leu Ser Trp Phe 100 105 110 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 115 120 125 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val 130 135 140 Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu 145 150 155 160 Thr Cys Arg Ser Ser Thr Gly Ala Val Thr Ser Gly Tyr Tyr Pro Asn 165 170 175 Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Ala 180 185 190 Thr Asp Met Arg Pro Ser Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu 195 200 205 Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp 210 215 220 Glu Ala Glu Tyr Tyr Cys Ala Leu Trp Tyr Ser Asn Arg Trp Val Phe 225 230 235 240 Gly Gly Gly Thr Lys Leu Thr Val Leu 245 <210> 405 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 405 Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Tyr Tyr Pro Asn 1 5 10 <210> 406 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 406 Gly Thr Lys Phe Leu Ala Pro 1 5 <210> 407 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 407 Ala Leu Trp Tyr Ser Asn Arg Trp Val 1 5 <210> 408 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 408 Val Tyr Ala Met Asn 1 5 <210> 409 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 409 Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser 1 5 10 15 Val Lys Lys <210> 410 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 410 His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Trp Trp Ala Tyr 1 5 10 <210> 411 <211> 125 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 411 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Val Tyr 20 25 30 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 50 55 60 Ser Val Lys Lys Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 65 70 75 80 Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr 85 90 95 Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Trp Trp 100 105 110 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 412 <211> 109 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 412 Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly 1 5 10 15 Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly 20 25 30 Tyr Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly 35 40 45 Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe 50 55 60 Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val 65 70 75 80 Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Ala Leu Trp Tyr Ser Asn 85 90 95 Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 413 <211> 249 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 413 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Val Tyr 20 25 30 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 50 55 60 Ser Val Lys Lys Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 65 70 75 80 Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr 85 90 95 Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Trp Trp 100 105 110 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 115 120 125 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val 130 135 140 Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu 145 150 155 160 Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Tyr Tyr Pro Asn 165 170 175 Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly 180 185 190 Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu 195 200 205 Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp 210 215 220 Glu Ala Glu Tyr Tyr Cys Ala Leu Trp Tyr Ser Asn Arg Trp Val Phe 225 230 235 240 Gly Gly Gly Thr Lys Leu Thr Val Leu 245 <210> 414 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 414 Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro Asn 1 5 10 <210> 415 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 415 Gly Thr Lys Phe Leu Ala Pro 1 5 <210> 416 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 416 Val Leu Trp Tyr Ser Asn Arg Trp Val 1 5 <210> 417 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 417 Ser Tyr Ala Met Asn 1 5 <210> 418 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 418 Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser 1 5 10 15 Val Lys Gly <210> 419 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 419 His Gly Asn Phe Gly Asn Ser Tyr Val Ser Trp Trp Ala Tyr 1 5 10 <210> 420 <211> 125 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 420 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Ser Tyr 20 25 30 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 65 70 75 80 Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr 85 90 95 Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Val Ser Trp Trp 100 105 110 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 421 <211> 109 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 421 Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly 1 5 10 15 Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly 20 25 30 Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly 35 40 45 Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe 50 55 60 Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val 65 70 75 80 Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn 85 90 95 Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 422 <211> 249 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 422 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Ser Tyr 20 25 30 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 65 70 75 80 Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr 85 90 95 Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Val Ser Trp Trp 100 105 110 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 115 120 125 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val 130 135 140 Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu 145 150 155 160 Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro Asn 165 170 175 Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly 180 185 190 Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu 195 200 205 Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp 210 215 220 Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val Phe 225 230 235 240 Gly Gly Gly Thr Lys Leu Thr Val Leu 245 <210> 423 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 423 Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro Asn 1 5 10 <210> 424 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 424 Gly Thr Lys Phe Leu Ala Pro 1 5 <210> 425 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 425 Val Leu Trp Tyr Ser Asn Arg Trp Val 1 5 <210> 426 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 426 Lys Tyr Ala Met Asn 1 5 <210> 427 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 427 Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser 1 5 10 15 Val Lys Asp <210> 428 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 428 His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr Trp Ala Tyr 1 5 10 <210> 429 <211> 125 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 429 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys Tyr 20 25 30 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 50 55 60 Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 65 70 75 80 Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr 85 90 95 Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr Trp 100 105 110 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 430 <211> 109 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 430 Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly 1 5 10 15 Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly 20 25 30 Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly 35 40 45 Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe 50 55 60 Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val 65 70 75 80 Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn 85 90 95 Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 431 <211> 249 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 431 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys Tyr 20 25 30 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 50 55 60 Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 65 70 75 80 Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr 85 90 95 Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr Trp 100 105 110 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 115 120 125 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val 130 135 140 Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu 145 150 155 160 Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro Asn 165 170 175 Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly 180 185 190 Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu 195 200 205 Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp 210 215 220 Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val Phe 225 230 235 240 Gly Gly Gly Thr Lys Leu Thr Val Leu 245 <210> 432 <211> 125 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 432 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Ser Tyr 20 25 30 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 65 70 75 80 Ala Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr 85 90 95 Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Val Ser Trp Trp 100 105 110 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 433 <211> 109 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 433 Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly 1 5 10 15 Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly 20 25 30 Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly 35 40 45 Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe 50 55 60 Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val 65 70 75 80 Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn 85 90 95 Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 434 <211> 249 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 434 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Ser Tyr 20 25 30 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 65 70 75 80 Ala Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr 85 90 95 Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Val Ser Trp Trp 100 105 110 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 115 120 125 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val 130 135 140 Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu 145 150 155 160 Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro Asn 165 170 175 Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly 180 185 190 Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu 195 200 205 Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp 210 215 220 Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val Phe 225 230 235 240 Gly Gly Gly Thr Lys Leu Thr Val Leu 245 <210> 435 <211> 118 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 435 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Cys Leu Glu Trp Ile 35 40 45 Gly Tyr Val Tyr Tyr Ser Gly Thr Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Ser Ile Ala Val Thr Gly Phe Tyr Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser 115 <210> 436 <211> 108 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 436 Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Val Thr Leu Ser Cys Arg Ala Ser Gln Arg Val Asn Asn Asn 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Arg Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asp Arg Ser Pro 85 90 95 Leu Thr Phe Gly Cys Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 437 <211> 241 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 437 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Cys Leu Glu Trp Ile 35 40 45 Gly Tyr Val Tyr Tyr Ser Gly Thr Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Ser Ile Ala Val Thr Gly Phe Tyr Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu 130 135 140 Ser Leu Ser Pro Gly Glu Arg Val Thr Leu Ser Cys Arg Ala Ser Gln 145 150 155 160 Arg Val Asn Asn Asn Tyr Leu Ala Trp Tyr Gln Gln Arg Pro Gly Gln 165 170 175 Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile 180 185 190 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 195 200 205 Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln 210 215 220 Tyr Asp Arg Ser Pro Leu Thr Phe Gly Cys Gly Thr Lys Leu Glu Ile 225 230 235 240 Lys <210> 438 <211> 496 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 438 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Cys Leu Glu Trp Ile 35 40 45 Gly Tyr Val Tyr Tyr Ser Gly Thr Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Ser Ile Ala Val Thr Gly Phe Tyr Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu 130 135 140 Ser Leu Ser Pro Gly Glu Arg Val Thr Leu Ser Cys Arg Ala Ser Gln 145 150 155 160 Arg Val Asn Asn Asn Tyr Leu Ala Trp Tyr Gln Gln Arg Pro Gly Gln 165 170 175 Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile 180 185 190 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 195 200 205 Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln 210 215 220 Tyr Asp Arg Ser Pro Leu Thr Phe Gly Cys Gly Thr Lys Leu Glu Ile 225 230 235 240 Lys Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly 245 250 255 Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser 260 265 270 Gly Phe Thr Phe Asn Lys Tyr Ala Met Asn Trp Val Arg Gln Ala Pro 275 280 285 Gly Lys Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn 290 295 300 Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser 305 310 315 320 Arg Asp Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Asn Leu Lys 325 330 335 Thr Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn Phe Gly 340 345 350 Asn Ser Tyr Ile Ser Tyr Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val 355 360 365 Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 370 375 380 Gly Gly Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser 385 390 395 400 Pro Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val 405 410 415 Thr Ser Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala 420 425 430 Pro Arg Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro 435 440 445 Ala Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu 450 455 460 Ser Gly Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp 465 470 475 480 Tyr Ser Asn Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 485 490 495 <210> 439 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 439 Ile Ile Asn Pro Ser Glu Gly Ser Thr Ser Tyr Ala Gln Lys Phe Gln 1 5 10 15 Gly <210> 440 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 440 Ile Ile Asn Pro Ser Asp Ala Ser Thr Ser Tyr Ala Gln Lys Phe Gln 1 5 10 15 Gly <210> 441 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 441 Arg Ser Ser Gln Ser Leu Val Tyr Arg Glu Gly Asn Thr Tyr Leu Ser 1 5 10 15 <210> 442 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 442 Arg Ser Ser Gln Ser Leu Val Tyr Arg Asp Ala Asn Thr Tyr Leu Ser 1 5 10 15 <210> 443 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 443 Arg Ser Ser Gln Ser Leu Val Tyr Arg Asp Gly Gln Thr Tyr Leu Ser 1 5 10 15 <210> 444 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 444 Arg Ser Ser Gln Ser Leu Val Tyr Arg Asp Gly Asn Ala Tyr Leu Ser 1 5 10 15 <210> 445 <211> 123 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 445 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Asp Gly Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Asp Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 446 <211> 123 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 446 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Leu Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Glu Gly Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Asp Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 447 <211> 123 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 447 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Leu Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Asp Ala Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Asp Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 448 <211> 123 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 448 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Glu Gly Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Asp Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 449 <211> 122 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 449 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Asp Ala Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Asp Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser 115 120 <210> 450 <211> 123 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 450 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Leu Cys Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Asp Gly Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Asp Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 451 <211> 123 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 451 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Cys Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Asp Gly Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Asp Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 452 <211> 123 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 452 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Leu Cys Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Glu Gly Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Asp Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 453 <211> 123 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 453 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Leu Cys Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Asp Ala Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Asp Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 454 <211> 123 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 454 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Cys Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Glu Gly Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Asp Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 455 <211> 123 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 455 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Cys Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Asp Ala Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Asp Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 456 <211> 112 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 456 Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Leu Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg 20 25 30 Glu Gly Asn Thr Tyr Leu Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser 35 40 45 Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Trp Gln Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Gly Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Gly 85 90 95 Thr His Trp Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 110 <210> 457 <211> 112 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 457 Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Leu Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg 20 25 30 Asp Ala Asn Thr Tyr Leu Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser 35 40 45 Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Trp Gln Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Gly Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Gly 85 90 95 Thr His Trp Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 110 <210> 458 <211> 112 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 458 Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Leu Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg 20 25 30 Asp Gly Gln Thr Tyr Leu Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser 35 40 45 Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Trp Gln Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Gly Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Gly 85 90 95 Thr His Trp Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 110 <210> 459 <211> 112 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 459 Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Leu Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg 20 25 30 Asp Gly Asn Ala Tyr Leu Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser 35 40 45 Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Trp Gln Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Gly Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Gly 85 90 95 Thr His Trp Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 110 <210> 460 <211> 112 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 460 Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Leu Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg 20 25 30 Asp Gly Asn Thr Tyr Leu Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser 35 40 45 Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Trp Gln Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Gly 85 90 95 Thr His Trp Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 110 <210> 461 <211> 112 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 461 Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Leu Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg 20 25 30 Glu Gly Asn Thr Tyr Leu Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser 35 40 45 Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Trp Gln Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Gly 85 90 95 Thr His Trp Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 110 <210> 462 <211> 112 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 462 Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Leu Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg 20 25 30 Asp Ala Asn Thr Tyr Leu Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser 35 40 45 Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Trp Gln Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Gly 85 90 95 Thr His Trp Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 110 <210> 463 <211> 112 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 463 Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Leu Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg 20 25 30 Asp Gly Asn Thr Tyr Leu Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser 35 40 45 Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Trp Gln Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Gly Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Gly 85 90 95 Thr His Trp Pro Pro Thr Phe Gly Cys Gly Thr Lys Val Glu Ile Lys 100 105 110 <210> 464 <211> 112 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 464 Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Leu Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg 20 25 30 Glu Gly Asn Thr Tyr Leu Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser 35 40 45 Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Trp Gln Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Gly Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Gly 85 90 95 Thr His Trp Pro Pro Thr Phe Gly Cys Gly Thr Lys Val Glu Ile Lys 100 105 110 <210> 465 <211> 112 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 465 Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Leu Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg 20 25 30 Asp Ala Asn Thr Tyr Leu Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser 35 40 45 Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Trp Gln Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Gly Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Gly 85 90 95 Thr His Trp Pro Pro Thr Phe Gly Cys Gly Thr Lys Val Glu Ile Lys 100 105 110 <210> 466 <211> 112 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 466 Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Leu Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg 20 25 30 Asp Gly Gln Thr Tyr Leu Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser 35 40 45 Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Trp Gln Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Gly Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Gly 85 90 95 Thr His Trp Pro Pro Thr Phe Gly Cys Gly Thr Lys Val Glu Ile Lys 100 105 110 <210> 467 <211> 112 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 467 Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Leu Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg 20 25 30 Asp Gly Asn Ala Tyr Leu Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser 35 40 45 Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Trp Gln Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Gly Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Gly 85 90 95 Thr His Trp Pro Pro Thr Phe Gly Cys Gly Thr Lys Val Glu Ile Lys 100 105 110 <210> 468 <211> 112 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 468 Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Leu Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg 20 25 30 Asp Gly Asn Thr Tyr Leu Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser 35 40 45 Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Trp Gln Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Gly 85 90 95 Thr His Trp Pro Pro Thr Phe Gly Cys Gly Thr Lys Val Glu Ile Lys 100 105 110 <210> 469 <211> 112 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 469 Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Leu Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg 20 25 30 Glu Gly Asn Thr Tyr Leu Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser 35 40 45 Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Trp Gln Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Gly 85 90 95 Thr His Trp Pro Pro Thr Phe Gly Cys Gly Thr Lys Val Glu Ile Lys 100 105 110 <210> 470 <211> 112 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 470 Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Leu Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg 20 25 30 Asp Ala Asn Thr Tyr Leu Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser 35 40 45 Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Trp Gln Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Gly 85 90 95 Thr His Trp Pro Pro Thr Phe Gly Cys Gly Thr Lys Val Glu Ile Lys 100 105 110 <210> 471 <211> 250 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 471 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Leu Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Asp Gly Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Asp Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln 130 135 140 Thr Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser 145 150 155 160 Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg Glu Gly Asn Thr Tyr Leu 165 170 175 Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr 180 185 190 Lys Val Ser Asn Trp Gln Ser Gly Val Pro Asp Arg Phe Ser Gly Gly 195 200 205 Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu 210 215 220 Asp Val Gly Val Tyr Tyr Cys Met Gln Gly Thr His Trp Pro Pro Thr 225 230 235 240 Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 245 250 <210> 472 <211> 250 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 472 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Leu Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Asp Gly Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Asp Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln 130 135 140 Thr Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser 145 150 155 160 Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg Asp Ala Asn Thr Tyr Leu 165 170 175 Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr 180 185 190 Lys Val Ser Asn Trp Gln Ser Gly Val Pro Asp Arg Phe Ser Gly Gly 195 200 205 Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu 210 215 220 Asp Val Gly Val Tyr Tyr Cys Met Gln Gly Thr His Trp Pro Pro Thr 225 230 235 240 Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 245 250 <210> 473 <211> 250 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 473 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Leu Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Asp Gly Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Asp Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln 130 135 140 Thr Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser 145 150 155 160 Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg Asp Gly Gln Thr Tyr Leu 165 170 175 Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr 180 185 190 Lys Val Ser Asn Trp Gln Ser Gly Val Pro Asp Arg Phe Ser Gly Gly 195 200 205 Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu 210 215 220 Asp Val Gly Val Tyr Tyr Cys Met Gln Gly Thr His Trp Pro Pro Thr 225 230 235 240 Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 245 250 <210> 474 <211> 250 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 474 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Leu Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Asp Gly Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Asp Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln 130 135 140 Thr Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser 145 150 155 160 Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg Asp Gly Asn Ala Tyr Leu 165 170 175 Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr 180 185 190 Lys Val Ser Asn Trp Gln Ser Gly Val Pro Asp Arg Phe Ser Gly Gly 195 200 205 Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu 210 215 220 Asp Val Gly Val Tyr Tyr Cys Met Gln Gly Thr His Trp Pro Pro Thr 225 230 235 240 Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 245 250 <210> 475 <211> 250 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 475 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Leu Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Asp Gly Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Asp Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln 130 135 140 Thr Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser 145 150 155 160 Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg Asp Gly Asn Thr Tyr Leu 165 170 175 Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr 180 185 190 Lys Val Ser Asn Trp Gln Ser Gly Val Pro Asp Arg Phe Ser Gly Ser 195 200 205 Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu 210 215 220 Asp Val Gly Val Tyr Tyr Cys Met Gln Gly Thr His Trp Pro Pro Thr 225 230 235 240 Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 245 250 <210> 476 <211> 250 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 476 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Asp Gly Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Asp Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln 130 135 140 Thr Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser 145 150 155 160 Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg Asp Gly Asn Thr Tyr Leu 165 170 175 Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr 180 185 190 Lys Val Ser Asn Trp Gln Ser Gly Val Pro Asp Arg Phe Ser Gly Gly 195 200 205 Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu 210 215 220 Asp Val Gly Val Tyr Tyr Cys Met Gln Gly Thr His Trp Pro Pro Thr 225 230 235 240 Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 245 250 <210> 477 <211> 250 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 477 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Leu Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Glu Gly Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Asp Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln 130 135 140 Thr Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser 145 150 155 160 Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg Asp Gly Asn Thr Tyr Leu 165 170 175 Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr 180 185 190 Lys Val Ser Asn Trp Gln Ser Gly Val Pro Asp Arg Phe Ser Gly Gly 195 200 205 Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu 210 215 220 Asp Val Gly Val Tyr Tyr Cys Met Gln Gly Thr His Trp Pro Pro Thr 225 230 235 240 Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 245 250 <210> 478 <211> 250 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 478 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Leu Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Asp Ala Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Asp Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln 130 135 140 Thr Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser 145 150 155 160 Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg Asp Gly Asn Thr Tyr Leu 165 170 175 Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr 180 185 190 Lys Val Ser Asn Trp Gln Ser Gly Val Pro Asp Arg Phe Ser Gly Gly 195 200 205 Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu 210 215 220 Asp Val Gly Val Tyr Tyr Cys Met Gln Gly Thr His Trp Pro Pro Thr 225 230 235 240 Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 245 250 <210> 479 <211> 250 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 479 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Asp Gly Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Asp Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln 130 135 140 Thr Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser 145 150 155 160 Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg Asp Gly Asn Thr Tyr Leu 165 170 175 Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr 180 185 190 Lys Val Ser Asn Trp Gln Ser Gly Val Pro Asp Arg Phe Ser Gly Ser 195 200 205 Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu 210 215 220 Asp Val Gly Val Tyr Tyr Cys Met Gln Gly Thr His Trp Pro Pro Thr 225 230 235 240 Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 245 250 <210> 480 <211> 250 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 480 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Glu Gly Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Asp Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln 130 135 140 Thr Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser 145 150 155 160 Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg Glu Gly Asn Thr Tyr Leu 165 170 175 Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr 180 185 190 Lys Val Ser Asn Trp Gln Ser Gly Val Pro Asp Arg Phe Ser Gly Ser 195 200 205 Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu 210 215 220 Asp Val Gly Val Tyr Tyr Cys Met Gln Gly Thr His Trp Pro Pro Thr 225 230 235 240 Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 245 250 <210> 481 <211> 250 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 481 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Asp Ala Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Asp Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln 130 135 140 Thr Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser 145 150 155 160 Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg Asp Ala Asn Thr Tyr Leu 165 170 175 Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr 180 185 190 Lys Val Ser Asn Trp Gln Ser Gly Val Pro Asp Arg Phe Ser Gly Ser 195 200 205 Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu 210 215 220 Asp Val Gly Val Tyr Tyr Cys Met Gln Gly Thr His Trp Pro Pro Thr 225 230 235 240 Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 245 250 <210> 482 <211> 250 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 482 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Leu Cys Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Asp Gly Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Asp Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln 130 135 140 Thr Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser 145 150 155 160 Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg Asp Gly Asn Thr Tyr Leu 165 170 175 Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr 180 185 190 Lys Val Ser Asn Trp Gln Ser Gly Val Pro Asp Arg Phe Ser Gly Gly 195 200 205 Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu 210 215 220 Asp Val Gly Val Tyr Tyr Cys Met Gln Gly Thr His Trp Pro Pro Thr 225 230 235 240 Phe Gly Cys Gly Thr Lys Val Glu Ile Lys 245 250 <210> 483 <211> 250 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 483 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Leu Cys Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Asp Gly Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Asp Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln 130 135 140 Thr Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser 145 150 155 160 Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg Glu Gly Asn Thr Tyr Leu 165 170 175 Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr 180 185 190 Lys Val Ser Asn Trp Gln Ser Gly Val Pro Asp Arg Phe Ser Gly Gly 195 200 205 Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu 210 215 220 Asp Val Gly Val Tyr Tyr Cys Met Gln Gly Thr His Trp Pro Pro Thr 225 230 235 240 Phe Gly Cys Gly Thr Lys Val Glu Ile Lys 245 250 <210> 484 <211> 250 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 484 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Leu Cys Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Asp Gly Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Asp Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln 130 135 140 Thr Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser 145 150 155 160 Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg Asp Ala Asn Thr Tyr Leu 165 170 175 Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr 180 185 190 Lys Val Ser Asn Trp Gln Ser Gly Val Pro Asp Arg Phe Ser Gly Gly 195 200 205 Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu 210 215 220 Asp Val Gly Val Tyr Tyr Cys Met Gln Gly Thr His Trp Pro Pro Thr 225 230 235 240 Phe Gly Cys Gly Thr Lys Val Glu Ile Lys 245 250 <210> 485 <211> 250 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 485 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Leu Cys Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Asp Gly Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Asp Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln 130 135 140 Thr Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser 145 150 155 160 Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg Asp Gly Gln Thr Tyr Leu 165 170 175 Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr 180 185 190 Lys Val Ser Asn Trp Gln Ser Gly Val Pro Asp Arg Phe Ser Gly Gly 195 200 205 Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu 210 215 220 Asp Val Gly Val Tyr Tyr Cys Met Gln Gly Thr His Trp Pro Pro Thr 225 230 235 240 Phe Gly Cys Gly Thr Lys Val Glu Ile Lys 245 250 <210> 486 <211> 250 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 486 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Leu Cys Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Asp Gly Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Asp Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln 130 135 140 Thr Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser 145 150 155 160 Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg Asp Gly Asn Ala Tyr Leu 165 170 175 Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr 180 185 190 Lys Val Ser Asn Trp Gln Ser Gly Val Pro Asp Arg Phe Ser Gly Gly 195 200 205 Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu 210 215 220 Asp Val Gly Val Tyr Tyr Cys Met Gln Gly Thr His Trp Pro Pro Thr 225 230 235 240 Phe Gly Cys Gly Thr Lys Val Glu Ile Lys 245 250 <210> 487 <211> 250 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 487 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Leu Cys Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Asp Gly Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Asp Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln 130 135 140 Thr Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser 145 150 155 160 Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg Asp Gly Asn Thr Tyr Leu 165 170 175 Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr 180 185 190 Lys Val Ser Asn Trp Gln Ser Gly Val Pro Asp Arg Phe Ser Gly Ser 195 200 205 Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu 210 215 220 Asp Val Gly Val Tyr Tyr Cys Met Gln Gly Thr His Trp Pro Pro Thr 225 230 235 240 Phe Gly Cys Gly Thr Lys Val Glu Ile Lys 245 250 <210> 488 <211> 250 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 488 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Cys Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Asp Gly Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Asp Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln 130 135 140 Thr Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser 145 150 155 160 Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg Asp Gly Asn Thr Tyr Leu 165 170 175 Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr 180 185 190 Lys Val Ser Asn Trp Gln Ser Gly Val Pro Asp Arg Phe Ser Gly Gly 195 200 205 Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu 210 215 220 Asp Val Gly Val Tyr Tyr Cys Met Gln Gly Thr His Trp Pro Pro Thr 225 230 235 240 Phe Gly Cys Gly Thr Lys Val Glu Ile Lys 245 250 <210> 489 <211> 250 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 489 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Leu Cys Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Glu Gly Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Asp Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln 130 135 140 Thr Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser 145 150 155 160 Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg Asp Gly Asn Thr Tyr Leu 165 170 175 Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr 180 185 190 Lys Val Ser Asn Trp Gln Ser Gly Val Pro Asp Arg Phe Ser Gly Gly 195 200 205 Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu 210 215 220 Asp Val Gly Val Tyr Tyr Cys Met Gln Gly Thr His Trp Pro Pro Thr 225 230 235 240 Phe Gly Cys Gly Thr Lys Val Glu Ile Lys 245 250 <210> 490 <211> 250 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 490 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Leu Cys Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Asp Ala Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Asp Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln 130 135 140 Thr Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser 145 150 155 160 Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg Asp Gly Asn Thr Tyr Leu 165 170 175 Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr 180 185 190 Lys Val Ser Asn Trp Gln Ser Gly Val Pro Asp Arg Phe Ser Gly Gly 195 200 205 Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu 210 215 220 Asp Val Gly Val Tyr Tyr Cys Met Gln Gly Thr His Trp Pro Pro Thr 225 230 235 240 Phe Gly Cys Gly Thr Lys Val Glu Ile Lys 245 250 <210> 491 <211> 250 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 491 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Cys Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Asp Gly Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Asp Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln 130 135 140 Thr Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser 145 150 155 160 Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg Asp Gly Asn Thr Tyr Leu 165 170 175 Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr 180 185 190 Lys Val Ser Asn Trp Gln Ser Gly Val Pro Asp Arg Phe Ser Gly Ser 195 200 205 Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu 210 215 220 Asp Val Gly Val Tyr Tyr Cys Met Gln Gly Thr His Trp Pro Pro Thr 225 230 235 240 Phe Gly Cys Gly Thr Lys Val Glu Ile Lys 245 250 <210> 492 <211> 250 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 492 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Cys Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Glu Gly Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Asp Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln 130 135 140 Thr Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser 145 150 155 160 Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg Glu Gly Asn Thr Tyr Leu 165 170 175 Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr 180 185 190 Lys Val Ser Asn Trp Gln Ser Gly Val Pro Asp Arg Phe Ser Gly Ser 195 200 205 Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu 210 215 220 Asp Val Gly Val Tyr Tyr Cys Met Gln Gly Thr His Trp Pro Pro Thr 225 230 235 240 Phe Gly Cys Gly Thr Lys Val Glu Ile Lys 245 250 <210> 493 <211> 250 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 493 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Cys Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Asp Ala Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Asp Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln 130 135 140 Thr Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser 145 150 155 160 Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg Asp Ala Asn Thr Tyr Leu 165 170 175 Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr 180 185 190 Lys Val Ser Asn Trp Gln Ser Gly Val Pro Asp Arg Phe Ser Gly Ser 195 200 205 Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu 210 215 220 Asp Val Gly Val Tyr Tyr Cys Met Gln Gly Thr His Trp Pro Pro Thr 225 230 235 240 Phe Gly Cys Gly Thr Lys Val Glu Ile Lys 245 250 <210> 494 <211> 505 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 494 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Leu Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Asp Gly Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Asp Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln 130 135 140 Thr Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser 145 150 155 160 Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg Glu Gly Asn Thr Tyr Leu 165 170 175 Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr 180 185 190 Lys Val Ser Asn Trp Gln Ser Gly Val Pro Asp Arg Phe Ser Gly Gly 195 200 205 Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu 210 215 220 Asp Val Gly Val Tyr Tyr Cys Met Gln Gly Thr His Trp Pro Pro Thr 225 230 235 240 Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Ser Gly Gly Gly Gly Ser 245 250 255 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 260 265 270 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys Tyr 275 280 285 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 290 295 300 Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 305 310 315 320 Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 325 330 335 Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr 340 345 350 Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr Trp 355 360 365 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 370 375 380 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val 385 390 395 400 Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu 405 410 415 Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro Asn 420 425 430 Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly 435 440 445 Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu 450 455 460 Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp 465 470 475 480 Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val Phe 485 490 495 Gly Gly Gly Thr Lys Leu Thr Val Leu 500 505 <210> 495 <211> 505 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 495 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Leu Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Asp Gly Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Asp Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln 130 135 140 Thr Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser 145 150 155 160 Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg Asp Ala Asn Thr Tyr Leu 165 170 175 Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr 180 185 190 Lys Val Ser Asn Trp Gln Ser Gly Val Pro Asp Arg Phe Ser Gly Gly 195 200 205 Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu 210 215 220 Asp Val Gly Val Tyr Tyr Cys Met Gln Gly Thr His Trp Pro Pro Thr 225 230 235 240 Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Ser Gly Gly Gly Gly Ser 245 250 255 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 260 265 270 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys Tyr 275 280 285 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 290 295 300 Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 305 310 315 320 Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 325 330 335 Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr 340 345 350 Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr Trp 355 360 365 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 370 375 380 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val 385 390 395 400 Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu 405 410 415 Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro Asn 420 425 430 Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly 435 440 445 Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu 450 455 460 Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp 465 470 475 480 Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val Phe 485 490 495 Gly Gly Gly Thr Lys Leu Thr Val Leu 500 505 <210> 496 <211> 505 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 496 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Leu Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Asp Gly Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Asp Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln 130 135 140 Thr Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser 145 150 155 160 Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg Asp Gly Gln Thr Tyr Leu 165 170 175 Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr 180 185 190 Lys Val Ser Asn Trp Gln Ser Gly Val Pro Asp Arg Phe Ser Gly Gly 195 200 205 Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu 210 215 220 Asp Val Gly Val Tyr Tyr Cys Met Gln Gly Thr His Trp Pro Pro Thr 225 230 235 240 Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Ser Gly Gly Gly Gly Ser 245 250 255 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 260 265 270 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys Tyr 275 280 285 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 290 295 300 Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 305 310 315 320 Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 325 330 335 Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr 340 345 350 Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr Trp 355 360 365 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 370 375 380 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val 385 390 395 400 Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu 405 410 415 Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro Asn 420 425 430 Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly 435 440 445 Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu 450 455 460 Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp 465 470 475 480 Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val Phe 485 490 495 Gly Gly Gly Thr Lys Leu Thr Val Leu 500 505 <210> 497 <211> 505 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 497 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Leu Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Asp Gly Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Asp Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln 130 135 140 Thr Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser 145 150 155 160 Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg Asp Gly Asn Ala Tyr Leu 165 170 175 Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr 180 185 190 Lys Val Ser Asn Trp Gln Ser Gly Val Pro Asp Arg Phe Ser Gly Gly 195 200 205 Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu 210 215 220 Asp Val Gly Val Tyr Tyr Cys Met Gln Gly Thr His Trp Pro Pro Thr 225 230 235 240 Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Ser Gly Gly Gly Gly Ser 245 250 255 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 260 265 270 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys Tyr 275 280 285 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 290 295 300 Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 305 310 315 320 Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 325 330 335 Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr 340 345 350 Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr Trp 355 360 365 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 370 375 380 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val 385 390 395 400 Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu 405 410 415 Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro Asn 420 425 430 Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly 435 440 445 Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu 450 455 460 Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp 465 470 475 480 Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val Phe 485 490 495 Gly Gly Gly Thr Lys Leu Thr Val Leu 500 505 <210> 498 <211> 505 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 498 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Leu Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Asp Gly Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Asp Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln 130 135 140 Thr Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser 145 150 155 160 Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg Asp Gly Asn Thr Tyr Leu 165 170 175 Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr 180 185 190 Lys Val Ser Asn Trp Gln Ser Gly Val Pro Asp Arg Phe Ser Gly Ser 195 200 205 Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu 210 215 220 Asp Val Gly Val Tyr Tyr Cys Met Gln Gly Thr His Trp Pro Pro Thr 225 230 235 240 Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Ser Gly Gly Gly Gly Ser 245 250 255 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 260 265 270 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys Tyr 275 280 285 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 290 295 300 Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 305 310 315 320 Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 325 330 335 Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr 340 345 350 Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr Trp 355 360 365 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 370 375 380 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val 385 390 395 400 Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu 405 410 415 Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro Asn 420 425 430 Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly 435 440 445 Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu 450 455 460 Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp 465 470 475 480 Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val Phe 485 490 495 Gly Gly Gly Thr Lys Leu Thr Val Leu 500 505 <210> 499 <211> 505 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 499 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Asp Gly Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Asp Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln 130 135 140 Thr Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser 145 150 155 160 Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg Asp Gly Asn Thr Tyr Leu 165 170 175 Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr 180 185 190 Lys Val Ser Asn Trp Gln Ser Gly Val Pro Asp Arg Phe Ser Gly Gly 195 200 205 Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu 210 215 220 Asp Val Gly Val Tyr Tyr Cys Met Gln Gly Thr His Trp Pro Pro Thr 225 230 235 240 Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Ser Gly Gly Gly Gly Ser 245 250 255 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 260 265 270 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys Tyr 275 280 285 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 290 295 300 Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 305 310 315 320 Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 325 330 335 Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr 340 345 350 Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr Trp 355 360 365 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 370 375 380 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val 385 390 395 400 Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu 405 410 415 Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro Asn 420 425 430 Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly 435 440 445 Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu 450 455 460 Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp 465 470 475 480 Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val Phe 485 490 495 Gly Gly Gly Thr Lys Leu Thr Val Leu 500 505 <210> 500 <211> 505 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 500 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Leu Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Glu Gly Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Asp Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln 130 135 140 Thr Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser 145 150 155 160 Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg Asp Gly Asn Thr Tyr Leu 165 170 175 Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr 180 185 190 Lys Val Ser Asn Trp Gln Ser Gly Val Pro Asp Arg Phe Ser Gly Gly 195 200 205 Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu 210 215 220 Asp Val Gly Val Tyr Tyr Cys Met Gln Gly Thr His Trp Pro Pro Thr 225 230 235 240 Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Ser Gly Gly Gly Gly Ser 245 250 255 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 260 265 270 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys Tyr 275 280 285 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 290 295 300 Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 305 310 315 320 Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 325 330 335 Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr 340 345 350 Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr Trp 355 360 365 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 370 375 380 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val 385 390 395 400 Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu 405 410 415 Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro Asn 420 425 430 Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly 435 440 445 Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu 450 455 460 Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp 465 470 475 480 Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val Phe 485 490 495 Gly Gly Gly Thr Lys Leu Thr Val Leu 500 505 <210> 501 <211> 505 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 501 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Leu Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Asp Ala Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Asp Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln 130 135 140 Thr Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser 145 150 155 160 Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg Asp Gly Asn Thr Tyr Leu 165 170 175 Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr 180 185 190 Lys Val Ser Asn Trp Gln Ser Gly Val Pro Asp Arg Phe Ser Gly Gly 195 200 205 Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu 210 215 220 Asp Val Gly Val Tyr Tyr Cys Met Gln Gly Thr His Trp Pro Pro Thr 225 230 235 240 Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Ser Gly Gly Gly Gly Ser 245 250 255 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 260 265 270 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys Tyr 275 280 285 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 290 295 300 Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 305 310 315 320 Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 325 330 335 Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr 340 345 350 Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr Trp 355 360 365 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 370 375 380 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val 385 390 395 400 Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu 405 410 415 Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro Asn 420 425 430 Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly 435 440 445 Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu 450 455 460 Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp 465 470 475 480 Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val Phe 485 490 495 Gly Gly Gly Thr Lys Leu Thr Val Leu 500 505 <210> 502 <211> 505 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 502 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Asp Gly Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Asp Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln 130 135 140 Thr Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser 145 150 155 160 Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg Asp Gly Asn Thr Tyr Leu 165 170 175 Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr 180 185 190 Lys Val Ser Asn Trp Gln Ser Gly Val Pro Asp Arg Phe Ser Gly Ser 195 200 205 Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu 210 215 220 Asp Val Gly Val Tyr Tyr Cys Met Gln Gly Thr His Trp Pro Pro Thr 225 230 235 240 Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Ser Gly Gly Gly Gly Ser 245 250 255 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 260 265 270 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys Tyr 275 280 285 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 290 295 300 Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 305 310 315 320 Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 325 330 335 Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr 340 345 350 Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr Trp 355 360 365 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 370 375 380 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val 385 390 395 400 Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu 405 410 415 Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro Asn 420 425 430 Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly 435 440 445 Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu 450 455 460 Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp 465 470 475 480 Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val Phe 485 490 495 Gly Gly Gly Thr Lys Leu Thr Val Leu 500 505 <210> 503 <211> 505 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 503 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Glu Gly Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Asp Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln 130 135 140 Thr Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser 145 150 155 160 Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg Glu Gly Asn Thr Tyr Leu 165 170 175 Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr 180 185 190 Lys Val Ser Asn Trp Gln Ser Gly Val Pro Asp Arg Phe Ser Gly Ser 195 200 205 Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu 210 215 220 Asp Val Gly Val Tyr Tyr Cys Met Gln Gly Thr His Trp Pro Pro Thr 225 230 235 240 Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Ser Gly Gly Gly Gly Ser 245 250 255 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 260 265 270 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys Tyr 275 280 285 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 290 295 300 Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 305 310 315 320 Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 325 330 335 Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr 340 345 350 Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr Trp 355 360 365 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 370 375 380 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val 385 390 395 400 Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu 405 410 415 Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro Asn 420 425 430 Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly 435 440 445 Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu 450 455 460 Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp 465 470 475 480 Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val Phe 485 490 495 Gly Gly Gly Thr Lys Leu Thr Val Leu 500 505 <210> 504 <211> 505 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 504 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Asp Ala Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Asp Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln 130 135 140 Thr Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser 145 150 155 160 Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg Asp Ala Asn Thr Tyr Leu 165 170 175 Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr 180 185 190 Lys Val Ser Asn Trp Gln Ser Gly Val Pro Asp Arg Phe Ser Gly Ser 195 200 205 Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu 210 215 220 Asp Val Gly Val Tyr Tyr Cys Met Gln Gly Thr His Trp Pro Pro Thr 225 230 235 240 Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Ser Gly Gly Gly Gly Ser 245 250 255 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 260 265 270 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys Tyr 275 280 285 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 290 295 300 Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 305 310 315 320 Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 325 330 335 Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr 340 345 350 Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr Trp 355 360 365 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 370 375 380 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val 385 390 395 400 Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu 405 410 415 Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro Asn 420 425 430 Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly 435 440 445 Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu 450 455 460 Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp 465 470 475 480 Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val Phe 485 490 495 Gly Gly Gly Thr Lys Leu Thr Val Leu 500 505 <210> 505 <211> 505 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 505 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Leu Cys Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Asp Gly Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Asp Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln 130 135 140 Thr Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser 145 150 155 160 Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg Asp Gly Asn Thr Tyr Leu 165 170 175 Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr 180 185 190 Lys Val Ser Asn Trp Gln Ser Gly Val Pro Asp Arg Phe Ser Gly Gly 195 200 205 Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu 210 215 220 Asp Val Gly Val Tyr Tyr Cys Met Gln Gly Thr His Trp Pro Pro Thr 225 230 235 240 Phe Gly Cys Gly Thr Lys Val Glu Ile Lys Ser Gly Gly Gly Gly Ser 245 250 255 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 260 265 270 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys Tyr 275 280 285 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 290 295 300 Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 305 310 315 320 Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 325 330 335 Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr 340 345 350 Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr Trp 355 360 365 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 370 375 380 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val 385 390 395 400 Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu 405 410 415 Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro Asn 420 425 430 Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly 435 440 445 Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu 450 455 460 Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp 465 470 475 480 Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val Phe 485 490 495 Gly Gly Gly Thr Lys Leu Thr Val Leu 500 505 <210> 506 <211> 505 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 506 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Leu Cys Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Asp Gly Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Asp Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln 130 135 140 Thr Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser 145 150 155 160 Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg Glu Gly Asn Thr Tyr Leu 165 170 175 Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr 180 185 190 Lys Val Ser Asn Trp Gln Ser Gly Val Pro Asp Arg Phe Ser Gly Gly 195 200 205 Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu 210 215 220 Asp Val Gly Val Tyr Tyr Cys Met Gln Gly Thr His Trp Pro Pro Thr 225 230 235 240 Phe Gly Cys Gly Thr Lys Val Glu Ile Lys Ser Gly Gly Gly Gly Ser 245 250 255 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 260 265 270 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys Tyr 275 280 285 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 290 295 300 Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 305 310 315 320 Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 325 330 335 Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr 340 345 350 Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr Trp 355 360 365 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 370 375 380 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val 385 390 395 400 Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu 405 410 415 Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro Asn 420 425 430 Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly 435 440 445 Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu 450 455 460 Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp 465 470 475 480 Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val Phe 485 490 495 Gly Gly Gly Thr Lys Leu Thr Val Leu 500 505 <210> 507 <211> 505 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 507 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Leu Cys Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Asp Gly Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Asp Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln 130 135 140 Thr Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser 145 150 155 160 Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg Asp Ala Asn Thr Tyr Leu 165 170 175 Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr 180 185 190 Lys Val Ser Asn Trp Gln Ser Gly Val Pro Asp Arg Phe Ser Gly Gly 195 200 205 Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu 210 215 220 Asp Val Gly Val Tyr Tyr Cys Met Gln Gly Thr His Trp Pro Pro Thr 225 230 235 240 Phe Gly Cys Gly Thr Lys Val Glu Ile Lys Ser Gly Gly Gly Gly Ser 245 250 255 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 260 265 270 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys Tyr 275 280 285 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 290 295 300 Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 305 310 315 320 Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 325 330 335 Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr 340 345 350 Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr Trp 355 360 365 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 370 375 380 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val 385 390 395 400 Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu 405 410 415 Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro Asn 420 425 430 Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly 435 440 445 Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu 450 455 460 Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp 465 470 475 480 Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val Phe 485 490 495 Gly Gly Gly Thr Lys Leu Thr Val Leu 500 505 <210> 508 <211> 505 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 508 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Leu Cys Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Asp Gly Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Asp Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln 130 135 140 Thr Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser 145 150 155 160 Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg Asp Gly Gln Thr Tyr Leu 165 170 175 Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr 180 185 190 Lys Val Ser Asn Trp Gln Ser Gly Val Pro Asp Arg Phe Ser Gly Gly 195 200 205 Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu 210 215 220 Asp Val Gly Val Tyr Tyr Cys Met Gln Gly Thr His Trp Pro Pro Thr 225 230 235 240 Phe Gly Cys Gly Thr Lys Val Glu Ile Lys Ser Gly Gly Gly Gly Ser 245 250 255 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 260 265 270 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys Tyr 275 280 285 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 290 295 300 Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 305 310 315 320 Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 325 330 335 Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr 340 345 350 Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr Trp 355 360 365 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 370 375 380 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val 385 390 395 400 Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu 405 410 415 Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro Asn 420 425 430 Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly 435 440 445 Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu 450 455 460 Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp 465 470 475 480 Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val Phe 485 490 495 Gly Gly Gly Thr Lys Leu Thr Val Leu 500 505 <210> 509 <211> 505 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 509 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Leu Cys Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Asp Gly Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Asp Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln 130 135 140 Thr Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser 145 150 155 160 Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg Asp Gly Asn Ala Tyr Leu 165 170 175 Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr 180 185 190 Lys Val Ser Asn Trp Gln Ser Gly Val Pro Asp Arg Phe Ser Gly Gly 195 200 205 Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu 210 215 220 Asp Val Gly Val Tyr Tyr Cys Met Gln Gly Thr His Trp Pro Pro Thr 225 230 235 240 Phe Gly Cys Gly Thr Lys Val Glu Ile Lys Ser Gly Gly Gly Gly Ser 245 250 255 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 260 265 270 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys Tyr 275 280 285 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 290 295 300 Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 305 310 315 320 Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 325 330 335 Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr 340 345 350 Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr Trp 355 360 365 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 370 375 380 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val 385 390 395 400 Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu 405 410 415 Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro Asn 420 425 430 Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly 435 440 445 Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu 450 455 460 Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp 465 470 475 480 Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val Phe 485 490 495 Gly Gly Gly Thr Lys Leu Thr Val Leu 500 505 <210> 510 <211> 505 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 510 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Leu Cys Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Asp Gly Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Asp Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln 130 135 140 Thr Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser 145 150 155 160 Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg Asp Gly Asn Thr Tyr Leu 165 170 175 Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr 180 185 190 Lys Val Ser Asn Trp Gln Ser Gly Val Pro Asp Arg Phe Ser Gly Ser 195 200 205 Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu 210 215 220 Asp Val Gly Val Tyr Tyr Cys Met Gln Gly Thr His Trp Pro Pro Thr 225 230 235 240 Phe Gly Cys Gly Thr Lys Val Glu Ile Lys Ser Gly Gly Gly Gly Ser 245 250 255 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 260 265 270 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys Tyr 275 280 285 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 290 295 300 Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 305 310 315 320 Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 325 330 335 Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr 340 345 350 Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr Trp 355 360 365 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 370 375 380 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val 385 390 395 400 Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu 405 410 415 Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro Asn 420 425 430 Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly 435 440 445 Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu 450 455 460 Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp 465 470 475 480 Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val Phe 485 490 495 Gly Gly Gly Thr Lys Leu Thr Val Leu 500 505 <210> 511 <211> 505 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 511 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Cys Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Asp Gly Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Asp Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln 130 135 140 Thr Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser 145 150 155 160 Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg Asp Gly Asn Thr Tyr Leu 165 170 175 Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr 180 185 190 Lys Val Ser Asn Trp Gln Ser Gly Val Pro Asp Arg Phe Ser Gly Gly 195 200 205 Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu 210 215 220 Asp Val Gly Val Tyr Tyr Cys Met Gln Gly Thr His Trp Pro Pro Thr 225 230 235 240 Phe Gly Cys Gly Thr Lys Val Glu Ile Lys Ser Gly Gly Gly Gly Ser 245 250 255 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 260 265 270 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys Tyr 275 280 285 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 290 295 300 Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 305 310 315 320 Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 325 330 335 Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr 340 345 350 Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr Trp 355 360 365 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 370 375 380 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val 385 390 395 400 Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu 405 410 415 Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro Asn 420 425 430 Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly 435 440 445 Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu 450 455 460 Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp 465 470 475 480 Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val Phe 485 490 495 Gly Gly Gly Thr Lys Leu Thr Val Leu 500 505 <210> 512 <211> 505 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 512 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Leu Cys Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Glu Gly Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Asp Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln 130 135 140 Thr Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser 145 150 155 160 Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg Asp Gly Asn Thr Tyr Leu 165 170 175 Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr 180 185 190 Lys Val Ser Asn Trp Gln Ser Gly Val Pro Asp Arg Phe Ser Gly Gly 195 200 205 Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu 210 215 220 Asp Val Gly Val Tyr Tyr Cys Met Gln Gly Thr His Trp Pro Pro Thr 225 230 235 240 Phe Gly Cys Gly Thr Lys Val Glu Ile Lys Ser Gly Gly Gly Gly Ser 245 250 255 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 260 265 270 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys Tyr 275 280 285 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 290 295 300 Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 305 310 315 320 Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 325 330 335 Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr 340 345 350 Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr Trp 355 360 365 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 370 375 380 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val 385 390 395 400 Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu 405 410 415 Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro Asn 420 425 430 Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly 435 440 445 Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu 450 455 460 Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp 465 470 475 480 Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val Phe 485 490 495 Gly Gly Gly Thr Lys Leu Thr Val Leu 500 505 <210> 513 <211> 505 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 513 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Leu Cys Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Asp Ala Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Asp Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln 130 135 140 Thr Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser 145 150 155 160 Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg Asp Gly Asn Thr Tyr Leu 165 170 175 Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr 180 185 190 Lys Val Ser Asn Trp Gln Ser Gly Val Pro Asp Arg Phe Ser Gly Gly 195 200 205 Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu 210 215 220 Asp Val Gly Val Tyr Tyr Cys Met Gln Gly Thr His Trp Pro Pro Thr 225 230 235 240 Phe Gly Cys Gly Thr Lys Val Glu Ile Lys Ser Gly Gly Gly Gly Ser 245 250 255 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 260 265 270 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys Tyr 275 280 285 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 290 295 300 Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 305 310 315 320 Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 325 330 335 Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr 340 345 350 Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr Trp 355 360 365 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 370 375 380 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val 385 390 395 400 Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu 405 410 415 Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro Asn 420 425 430 Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly 435 440 445 Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu 450 455 460 Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp 465 470 475 480 Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val Phe 485 490 495 Gly Gly Gly Thr Lys Leu Thr Val Leu 500 505 <210> 514 <211> 505 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 514 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Cys Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Asp Gly Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Asp Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln 130 135 140 Thr Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser 145 150 155 160 Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg Asp Gly Asn Thr Tyr Leu 165 170 175 Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr 180 185 190 Lys Val Ser Asn Trp Gln Ser Gly Val Pro Asp Arg Phe Ser Gly Ser 195 200 205 Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu 210 215 220 Asp Val Gly Val Tyr Tyr Cys Met Gln Gly Thr His Trp Pro Pro Thr 225 230 235 240 Phe Gly Cys Gly Thr Lys Val Glu Ile Lys Ser Gly Gly Gly Gly Ser 245 250 255 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 260 265 270 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys Tyr 275 280 285 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 290 295 300 Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 305 310 315 320 Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 325 330 335 Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr 340 345 350 Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr Trp 355 360 365 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 370 375 380 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val 385 390 395 400 Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu 405 410 415 Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro Asn 420 425 430 Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly 435 440 445 Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu 450 455 460 Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp 465 470 475 480 Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val Phe 485 490 495 Gly Gly Gly Thr Lys Leu Thr Val Leu 500 505 <210> 515 <211> 505 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 515 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Cys Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Glu Gly Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Asp Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln 130 135 140 Thr Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser 145 150 155 160 Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg Glu Gly Asn Thr Tyr Leu 165 170 175 Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr 180 185 190 Lys Val Ser Asn Trp Gln Ser Gly Val Pro Asp Arg Phe Ser Gly Ser 195 200 205 Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu 210 215 220 Asp Val Gly Val Tyr Tyr Cys Met Gln Gly Thr His Trp Pro Pro Thr 225 230 235 240 Phe Gly Cys Gly Thr Lys Val Glu Ile Lys Ser Gly Gly Gly Gly Ser 245 250 255 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 260 265 270 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys Tyr 275 280 285 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 290 295 300 Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 305 310 315 320 Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 325 330 335 Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr 340 345 350 Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr Trp 355 360 365 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 370 375 380 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val 385 390 395 400 Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu 405 410 415 Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro Asn 420 425 430 Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly 435 440 445 Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu 450 455 460 Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp 465 470 475 480 Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val Phe 485 490 495 Gly Gly Gly Thr Lys Leu Thr Val Leu 500 505 <210> 516 <211> 505 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 516 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Cys Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Asp Ala Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Asp Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln 130 135 140 Thr Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser 145 150 155 160 Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg Asp Ala Asn Thr Tyr Leu 165 170 175 Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr 180 185 190 Lys Val Ser Asn Trp Gln Ser Gly Val Pro Asp Arg Phe Ser Gly Ser 195 200 205 Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu 210 215 220 Asp Val Gly Val Tyr Tyr Cys Met Gln Gly Thr His Trp Pro Pro Thr 225 230 235 240 Phe Gly Cys Gly Thr Lys Val Glu Ile Lys Ser Gly Gly Gly Gly Ser 245 250 255 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 260 265 270 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys Tyr 275 280 285 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 290 295 300 Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 305 310 315 320 Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 325 330 335 Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr 340 345 350 Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr Trp 355 360 365 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 370 375 380 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val 385 390 395 400 Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu 405 410 415 Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro Asn 420 425 430 Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly 435 440 445 Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu 450 455 460 Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp 465 470 475 480 Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val Phe 485 490 495 Gly Gly Gly Thr Lys Leu Thr Val Leu 500 505 <210> 517 <211> 984 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 517 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Val Tyr Tyr Ser Gly Thr Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Ser Ile Ala Val Thr Gly Phe Tyr Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu 130 135 140 Ser Leu Ser Pro Gly Glu Arg Val Thr Leu Ser Cys Arg Ala Ser Gln 145 150 155 160 Arg Val Asn Asn Asn Tyr Leu Ala Trp Tyr Gln Gln Arg Pro Gly Gln 165 170 175 Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile 180 185 190 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 195 200 205 Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln 210 215 220 Tyr Asp Arg Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile 225 230 235 240 Lys Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly 245 250 255 Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser 260 265 270 Gly Phe Thr Phe Asn Lys Tyr Ala Met Asn Trp Val Arg Gln Ala Pro 275 280 285 Gly Lys Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn 290 295 300 Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser 305 310 315 320 Arg Asp Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Asn Leu Lys 325 330 335 Thr Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn Phe Gly 340 345 350 Asn Ser Tyr Ile Ser Tyr Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val 355 360 365 Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 370 375 380 Gly Gly Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser 385 390 395 400 Pro Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val 405 410 415 Thr Ser Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala 420 425 430 Pro Arg Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro 435 440 445 Ala Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu 450 455 460 Ser Gly Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp 465 470 475 480 Tyr Ser Asn Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 485 490 495 Gly Gly Gly Gly Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro 500 505 510 Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys 515 520 525 Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val 530 535 540 Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp 545 550 555 560 Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Cys Glu Glu Gln Tyr 565 570 575 Gly Ser Thr Tyr Arg Cys Val Ser Val Leu Thr Val Leu His Gln Asp 580 585 590 Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu 595 600 605 Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg 610 615 620 Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys 625 630 635 640 Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp 645 650 655 Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys 660 665 670 Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser 675 680 685 Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser 690 695 700 Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser 705 710 715 720 Leu Ser Leu Ser Pro Gly Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly 725 730 735 Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 740 745 750 Gly Gly Gly Gly Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala 755 760 765 Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro 770 775 780 Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val 785 790 795 800 Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val 805 810 815 Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Cys Glu Glu Gln 820 825 830 Tyr Gly Ser Thr Tyr Arg Cys Val Ser Val Leu Thr Val Leu His Gln 835 840 845 Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala 850 855 860 Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro 865 870 875 880 Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr 885 890 895 Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser 900 905 910 Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr 915 920 925 Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr 930 935 940 Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe 945 950 955 960 Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys 965 970 975 Ser Leu Ser Leu Ser Pro Gly Lys 980 <210> 518 <211> 982 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 518 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Val Tyr Tyr Ser Gly Thr Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Ser Ile Ala Val Thr Gly Phe Tyr Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu 130 135 140 Ser Leu Ser Pro Gly Glu Arg Val Thr Leu Ser Cys Arg Ala Ser Gln 145 150 155 160 Arg Val Asn Asn Asn Tyr Leu Ala Trp Tyr Gln Gln Arg Pro Gly Gln 165 170 175 Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile 180 185 190 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 195 200 205 Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln 210 215 220 Tyr Asp Arg Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile 225 230 235 240 Lys Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly 245 250 255 Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser 260 265 270 Gly Phe Thr Phe Asn Lys Tyr Ala Met Asn Trp Val Arg Gln Ala Pro 275 280 285 Gly Lys Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn 290 295 300 Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser 305 310 315 320 Arg Asp Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Asn Leu Lys 325 330 335 Thr Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn Phe Gly 340 345 350 Asn Ser Tyr Ile Ser Tyr Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val 355 360 365 Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 370 375 380 Gly Gly Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser 385 390 395 400 Pro Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val 405 410 415 Thr Ser Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala 420 425 430 Pro Arg Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro 435 440 445 Ala Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu 450 455 460 Ser Gly Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp 465 470 475 480 Tyr Ser Asn Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 485 490 495 Gly Gly Gly Gly Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro 500 505 510 Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys 515 520 525 Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val 530 535 540 Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp 545 550 555 560 Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Cys Glu Glu Gln Tyr 565 570 575 Gly Ser Thr Tyr Arg Cys Val Ser Val Leu Thr Val Leu His Gln Asp 580 585 590 Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu 595 600 605 Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg 610 615 620 Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys 625 630 635 640 Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp 645 650 655 Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys 660 665 670 Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser 675 680 685 Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser 690 695 700 Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser 705 710 715 720 Leu Ser Leu Ser Pro Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 725 730 735 Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 740 745 750 Gly Gly Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu 755 760 765 Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp 770 775 780 Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp 785 790 795 800 Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly 805 810 815 Val Glu Val His Asn Ala Lys Thr Lys Pro Cys Glu Glu Gln Tyr Gly 820 825 830 Ser Thr Tyr Arg Cys Val Ser Val Leu Thr Val Leu His Gln Asp Trp 835 840 845 Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro 850 855 860 Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu 865 870 875 880 Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn 885 890 895 Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile 900 905 910 Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr 915 920 925 Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys 930 935 940 Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys 945 950 955 960 Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu 965 970 975 Ser Leu Ser Pro Gly Lys 980 <210> 519 <211> 984 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 519 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Cys Leu Glu Trp Ile 35 40 45 Gly Tyr Val Tyr Tyr Ser Gly Thr Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Ser Ile Ala Val Thr Gly Phe Tyr Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu 130 135 140 Ser Leu Ser Pro Gly Glu Arg Val Thr Leu Ser Cys Arg Ala Ser Gln 145 150 155 160 Arg Val Asn Asn Asn Tyr Leu Ala Trp Tyr Gln Gln Arg Pro Gly Gln 165 170 175 Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile 180 185 190 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 195 200 205 Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln 210 215 220 Tyr Asp Arg Ser Pro Leu Thr Phe Gly Cys Gly Thr Lys Leu Glu Ile 225 230 235 240 Lys Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly 245 250 255 Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser 260 265 270 Gly Phe Thr Phe Asn Lys Tyr Ala Met Asn Trp Val Arg Gln Ala Pro 275 280 285 Gly Lys Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn 290 295 300 Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser 305 310 315 320 Arg Asp Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Asn Leu Lys 325 330 335 Thr Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn Phe Gly 340 345 350 Asn Ser Tyr Ile Ser Tyr Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val 355 360 365 Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 370 375 380 Gly Gly Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser 385 390 395 400 Pro Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val 405 410 415 Thr Ser Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala 420 425 430 Pro Arg Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro 435 440 445 Ala Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu 450 455 460 Ser Gly Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp 465 470 475 480 Tyr Ser Asn Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 485 490 495 Gly Gly Gly Gly Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro 500 505 510 Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys 515 520 525 Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val 530 535 540 Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp 545 550 555 560 Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Cys Glu Glu Gln Tyr 565 570 575 Gly Ser Thr Tyr Arg Cys Val Ser Val Leu Thr Val Leu His Gln Asp 580 585 590 Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu 595 600 605 Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg 610 615 620 Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys 625 630 635 640 Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp 645 650 655 Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys 660 665 670 Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser 675 680 685 Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser 690 695 700 Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser 705 710 715 720 Leu Ser Leu Ser Pro Gly Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly 725 730 735 Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 740 745 750 Gly Gly Gly Gly Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala 755 760 765 Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro 770 775 780 Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val 785 790 795 800 Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val 805 810 815 Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Cys Glu Glu Gln 820 825 830 Tyr Gly Ser Thr Tyr Arg Cys Val Ser Val Leu Thr Val Leu His Gln 835 840 845 Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala 850 855 860 Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro 865 870 875 880 Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr 885 890 895 Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser 900 905 910 Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr 915 920 925 Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr 930 935 940 Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe 945 950 955 960 Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys 965 970 975 Ser Leu Ser Leu Ser Pro Gly Lys 980 <210> 520 <211> 982 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 520 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Cys Leu Glu Trp Ile 35 40 45 Gly Tyr Val Tyr Tyr Ser Gly Thr Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Ser Ile Ala Val Thr Gly Phe Tyr Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu 130 135 140 Ser Leu Ser Pro Gly Glu Arg Val Thr Leu Ser Cys Arg Ala Ser Gln 145 150 155 160 Arg Val Asn Asn Asn Tyr Leu Ala Trp Tyr Gln Gln Arg Pro Gly Gln 165 170 175 Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile 180 185 190 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 195 200 205 Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln 210 215 220 Tyr Asp Arg Ser Pro Leu Thr Phe Gly Cys Gly Thr Lys Leu Glu Ile 225 230 235 240 Lys Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly 245 250 255 Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser 260 265 270 Gly Phe Thr Phe Asn Lys Tyr Ala Met Asn Trp Val Arg Gln Ala Pro 275 280 285 Gly Lys Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn 290 295 300 Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser 305 310 315 320 Arg Asp Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Asn Leu Lys 325 330 335 Thr Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn Phe Gly 340 345 350 Asn Ser Tyr Ile Ser Tyr Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val 355 360 365 Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 370 375 380 Gly Gly Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser 385 390 395 400 Pro Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val 405 410 415 Thr Ser Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala 420 425 430 Pro Arg Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro 435 440 445 Ala Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu 450 455 460 Ser Gly Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp 465 470 475 480 Tyr Ser Asn Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 485 490 495 Gly Gly Gly Gly Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro 500 505 510 Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys 515 520 525 Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val 530 535 540 Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp 545 550 555 560 Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Cys Glu Glu Gln Tyr 565 570 575 Gly Ser Thr Tyr Arg Cys Val Ser Val Leu Thr Val Leu His Gln Asp 580 585 590 Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu 595 600 605 Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg 610 615 620 Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys 625 630 635 640 Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp 645 650 655 Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys 660 665 670 Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser 675 680 685 Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser 690 695 700 Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser 705 710 715 720 Leu Ser Leu Ser Pro Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 725 730 735 Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 740 745 750 Gly Gly Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu 755 760 765 Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp 770 775 780 Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp 785 790 795 800 Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly 805 810 815 Val Glu Val His Asn Ala Lys Thr Lys Pro Cys Glu Glu Gln Tyr Gly 820 825 830 Ser Thr Tyr Arg Cys Val Ser Val Leu Thr Val Leu His Gln Asp Trp 835 840 845 Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro 850 855 860 Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu 865 870 875 880 Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn 885 890 895 Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile 900 905 910 Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr 915 920 925 Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys 930 935 940 Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys 945 950 955 960 Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu 965 970 975 Ser Leu Ser Pro Gly Lys 980 <210> 521 <211> 984 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 521 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Ala Ser Ile Ser Ser Phe 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Tyr Tyr Ser Gly Thr Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Ile Ala Val Ala Gly Phe Phe Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu 130 135 140 Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln 145 150 155 160 Ser Val Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 165 170 175 Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile 180 185 190 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 195 200 205 Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln 210 215 220 Tyr Asp Arg Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile 225 230 235 240 Lys Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly 245 250 255 Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser 260 265 270 Gly Phe Thr Phe Asn Lys Tyr Ala Met Asn Trp Val Arg Gln Ala Pro 275 280 285 Gly Lys Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn 290 295 300 Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser 305 310 315 320 Arg Asp Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Asn Leu Lys 325 330 335 Thr Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn Phe Gly 340 345 350 Asn Ser Tyr Ile Ser Tyr Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val 355 360 365 Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 370 375 380 Gly Gly Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser 385 390 395 400 Pro Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val 405 410 415 Thr Ser Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala 420 425 430 Pro Arg Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro 435 440 445 Ala Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu 450 455 460 Ser Gly Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp 465 470 475 480 Tyr Ser Asn Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 485 490 495 Gly Gly Gly Gly Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro 500 505 510 Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys 515 520 525 Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val 530 535 540 Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp 545 550 555 560 Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Cys Glu Glu Gln Tyr 565 570 575 Gly Ser Thr Tyr Arg Cys Val Ser Val Leu Thr Val Leu His Gln Asp 580 585 590 Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu 595 600 605 Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg 610 615 620 Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys 625 630 635 640 Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp 645 650 655 Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys 660 665 670 Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser 675 680 685 Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser 690 695 700 Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser 705 710 715 720 Leu Ser Leu Ser Pro Gly Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly 725 730 735 Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 740 745 750 Gly Gly Gly Gly Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala 755 760 765 Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro 770 775 780 Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val 785 790 795 800 Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val 805 810 815 Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Cys Glu Glu Gln 820 825 830 Tyr Gly Ser Thr Tyr Arg Cys Val Ser Val Leu Thr Val Leu His Gln 835 840 845 Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala 850 855 860 Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro 865 870 875 880 Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr 885 890 895 Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser 900 905 910 Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr 915 920 925 Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr 930 935 940 Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe 945 950 955 960 Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys 965 970 975 Ser Leu Ser Leu Ser Pro Gly Lys 980 <210> 522 <211> 982 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 522 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Ala Ser Ile Ser Ser Phe 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Tyr Tyr Ser Gly Thr Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Ile Ala Val Ala Gly Phe Phe Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu 130 135 140 Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln 145 150 155 160 Ser Val Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 165 170 175 Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile 180 185 190 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 195 200 205 Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln 210 215 220 Tyr Asp Arg Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile 225 230 235 240 Lys Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly 245 250 255 Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser 260 265 270 Gly Phe Thr Phe Asn Lys Tyr Ala Met Asn Trp Val Arg Gln Ala Pro 275 280 285 Gly Lys Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn 290 295 300 Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser 305 310 315 320 Arg Asp Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Asn Leu Lys 325 330 335 Thr Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn Phe Gly 340 345 350 Asn Ser Tyr Ile Ser Tyr Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val 355 360 365 Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 370 375 380 Gly Gly Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser 385 390 395 400 Pro Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val 405 410 415 Thr Ser Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala 420 425 430 Pro Arg Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro 435 440 445 Ala Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu 450 455 460 Ser Gly Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp 465 470 475 480 Tyr Ser Asn Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 485 490 495 Gly Gly Gly Gly Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro 500 505 510 Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys 515 520 525 Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val 530 535 540 Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp 545 550 555 560 Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Cys Glu Glu Gln Tyr 565 570 575 Gly Ser Thr Tyr Arg Cys Val Ser Val Leu Thr Val Leu His Gln Asp 580 585 590 Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu 595 600 605 Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg 610 615 620 Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys 625 630 635 640 Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp 645 650 655 Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys 660 665 670 Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser 675 680 685 Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser 690 695 700 Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser 705 710 715 720 Leu Ser Leu Ser Pro Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 725 730 735 Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 740 745 750 Gly Gly Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu 755 760 765 Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp 770 775 780 Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp 785 790 795 800 Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly 805 810 815 Val Glu Val His Asn Ala Lys Thr Lys Pro Cys Glu Glu Gln Tyr Gly 820 825 830 Ser Thr Tyr Arg Cys Val Ser Val Leu Thr Val Leu His Gln Asp Trp 835 840 845 Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro 850 855 860 Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu 865 870 875 880 Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn 885 890 895 Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile 900 905 910 Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr 915 920 925 Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys 930 935 940 Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys 945 950 955 960 Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu 965 970 975 Ser Leu Ser Pro Gly Lys 980 <210> 523 <211> 984 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 523 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Ala Ser Ile Ser Ser Phe 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Cys Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Tyr Tyr Ser Gly Thr Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Ile Ala Val Ala Gly Phe Phe Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu 130 135 140 Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln 145 150 155 160 Ser Val Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 165 170 175 Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile 180 185 190 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 195 200 205 Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln 210 215 220 Tyr Asp Arg Ser Pro Leu Thr Phe Gly Cys Gly Thr Lys Val Glu Ile 225 230 235 240 Lys Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly 245 250 255 Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser 260 265 270 Gly Phe Thr Phe Asn Lys Tyr Ala Met Asn Trp Val Arg Gln Ala Pro 275 280 285 Gly Lys Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn 290 295 300 Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser 305 310 315 320 Arg Asp Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Asn Leu Lys 325 330 335 Thr Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn Phe Gly 340 345 350 Asn Ser Tyr Ile Ser Tyr Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val 355 360 365 Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 370 375 380 Gly Gly Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser 385 390 395 400 Pro Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val 405 410 415 Thr Ser Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala 420 425 430 Pro Arg Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro 435 440 445 Ala Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu 450 455 460 Ser Gly Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp 465 470 475 480 Tyr Ser Asn Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 485 490 495 Gly Gly Gly Gly Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro 500 505 510 Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys 515 520 525 Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val 530 535 540 Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp 545 550 555 560 Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Cys Glu Glu Gln Tyr 565 570 575 Gly Ser Thr Tyr Arg Cys Val Ser Val Leu Thr Val Leu His Gln Asp 580 585 590 Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu 595 600 605 Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg 610 615 620 Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys 625 630 635 640 Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp 645 650 655 Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys 660 665 670 Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser 675 680 685 Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser 690 695 700 Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser 705 710 715 720 Leu Ser Leu Ser Pro Gly Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly 725 730 735 Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 740 745 750 Gly Gly Gly Gly Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala 755 760 765 Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro 770 775 780 Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val 785 790 795 800 Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val 805 810 815 Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Cys Glu Glu Gln 820 825 830 Tyr Gly Ser Thr Tyr Arg Cys Val Ser Val Leu Thr Val Leu His Gln 835 840 845 Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala 850 855 860 Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro 865 870 875 880 Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr 885 890 895 Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser 900 905 910 Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr 915 920 925 Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr 930 935 940 Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe 945 950 955 960 Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys 965 970 975 Ser Leu Ser Leu Ser Pro Gly Lys 980 <210> 524 <211> 982 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 524 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Ala Ser Ile Ser Ser Phe 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Cys Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Tyr Tyr Ser Gly Thr Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Ile Ala Val Ala Gly Phe Phe Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu 130 135 140 Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln 145 150 155 160 Ser Val Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 165 170 175 Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile 180 185 190 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 195 200 205 Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln 210 215 220 Tyr Asp Arg Ser Pro Leu Thr Phe Gly Cys Gly Thr Lys Val Glu Ile 225 230 235 240 Lys Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly 245 250 255 Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser 260 265 270 Gly Phe Thr Phe Asn Lys Tyr Ala Met Asn Trp Val Arg Gln Ala Pro 275 280 285 Gly Lys Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn 290 295 300 Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser 305 310 315 320 Arg Asp Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Asn Leu Lys 325 330 335 Thr Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn Phe Gly 340 345 350 Asn Ser Tyr Ile Ser Tyr Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val 355 360 365 Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 370 375 380 Gly Gly Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser 385 390 395 400 Pro Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val 405 410 415 Thr Ser Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala 420 425 430 Pro Arg Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro 435 440 445 Ala Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu 450 455 460 Ser Gly Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp 465 470 475 480 Tyr Ser Asn Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 485 490 495 Gly Gly Gly Gly Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro 500 505 510 Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys 515 520 525 Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val 530 535 540 Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp 545 550 555 560 Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Cys Glu Glu Gln Tyr 565 570 575 Gly Ser Thr Tyr Arg Cys Val Ser Val Leu Thr Val Leu His Gln Asp 580 585 590 Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu 595 600 605 Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg 610 615 620 Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys 625 630 635 640 Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp 645 650 655 Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys 660 665 670 Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser 675 680 685 Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser 690 695 700 Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser 705 710 715 720 Leu Ser Leu Ser Pro Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 725 730 735 Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 740 745 750 Gly Gly Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu 755 760 765 Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp 770 775 780 Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp 785 790 795 800 Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly 805 810 815 Val Glu Val His Asn Ala Lys Thr Lys Pro Cys Glu Glu Gln Tyr Gly 820 825 830 Ser Thr Tyr Arg Cys Val Ser Val Leu Thr Val Leu His Gln Asp Trp 835 840 845 Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro 850 855 860 Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu 865 870 875 880 Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn 885 890 895 Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile 900 905 910 Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr 915 920 925 Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys 930 935 940 Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys 945 950 955 960 Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu 965 970 975 Ser Leu Ser Pro Gly Lys 980 <210> 525 <211> 993 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 525 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Leu Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Asp Gly Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Asp Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln 130 135 140 Thr Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser 145 150 155 160 Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg Asp Gly Asn Thr Tyr Leu 165 170 175 Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr 180 185 190 Lys Val Ser Asn Trp Gln Ser Gly Val Pro Asp Arg Phe Ser Gly Gly 195 200 205 Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu 210 215 220 Asp Val Gly Val Tyr Tyr Cys Met Gln Gly Thr His Trp Pro Pro Thr 225 230 235 240 Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Ser Gly Gly Gly Gly Ser 245 250 255 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 260 265 270 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys Tyr 275 280 285 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 290 295 300 Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 305 310 315 320 Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 325 330 335 Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr 340 345 350 Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr Trp 355 360 365 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 370 375 380 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val 385 390 395 400 Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu 405 410 415 Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro Asn 420 425 430 Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly 435 440 445 Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu 450 455 460 Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp 465 470 475 480 Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val Phe 485 490 495 Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gly Gly Gly Asp Lys Thr 500 505 510 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 515 520 525 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 530 535 540 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 545 550 555 560 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 565 570 575 Lys Thr Lys Pro Cys Glu Glu Gln Tyr Gly Ser Thr Tyr Arg Cys Val 580 585 590 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 595 600 605 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 610 615 620 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 625 630 635 640 Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys 645 650 655 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 660 665 670 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 675 680 685 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 690 695 700 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 705 710 715 720 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 725 730 735 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 740 745 750 Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Lys 755 760 765 Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro 770 775 780 Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser 785 790 795 800 Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp 805 810 815 Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn 820 825 830 Ala Lys Thr Lys Pro Cys Glu Glu Gln Tyr Gly Ser Thr Tyr Arg Cys 835 840 845 Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu 850 855 860 Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys 865 870 875 880 Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr 885 890 895 Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr 900 905 910 Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu 915 920 925 Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu 930 935 940 Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys 945 950 955 960 Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu 965 970 975 Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 980 985 990 Lys <210> 526 <211> 991 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 526 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Leu Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Asp Gly Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Asp Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln 130 135 140 Thr Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser 145 150 155 160 Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg Asp Gly Asn Thr Tyr Leu 165 170 175 Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr 180 185 190 Lys Val Ser Asn Trp Gln Ser Gly Val Pro Asp Arg Phe Ser Gly Gly 195 200 205 Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu 210 215 220 Asp Val Gly Val Tyr Tyr Cys Met Gln Gly Thr His Trp Pro Pro Thr 225 230 235 240 Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Ser Gly Gly Gly Gly Ser 245 250 255 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 260 265 270 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys Tyr 275 280 285 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 290 295 300 Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 305 310 315 320 Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 325 330 335 Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr 340 345 350 Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr Trp 355 360 365 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 370 375 380 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val 385 390 395 400 Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu 405 410 415 Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro Asn 420 425 430 Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly 435 440 445 Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu 450 455 460 Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp 465 470 475 480 Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val Phe 485 490 495 Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gly Gly Gly Asp Lys Thr 500 505 510 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 515 520 525 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 530 535 540 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 545 550 555 560 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 565 570 575 Lys Thr Lys Pro Cys Glu Glu Gln Tyr Gly Ser Thr Tyr Arg Cys Val 580 585 590 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 595 600 605 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 610 615 620 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 625 630 635 640 Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys 645 650 655 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 660 665 670 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 675 680 685 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 690 695 700 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 705 710 715 720 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Gly 725 730 735 Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly 740 745 750 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Lys Thr His 755 760 765 Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val 770 775 780 Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr 785 790 795 800 Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu 805 810 815 Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys 820 825 830 Thr Lys Pro Cys Glu Glu Gln Tyr Gly Ser Thr Tyr Arg Cys Val Ser 835 840 845 Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys 850 855 860 Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile 865 870 875 880 Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro 885 890 895 Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu 900 905 910 Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn 915 920 925 Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser 930 935 940 Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg 945 950 955 960 Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu 965 970 975 His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 980 985 990 <210> 527 <211> 993 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 527 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Leu Cys Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Asp Gly Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Asp Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln 130 135 140 Thr Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser 145 150 155 160 Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg Asp Gly Asn Thr Tyr Leu 165 170 175 Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr 180 185 190 Lys Val Ser Asn Trp Gln Ser Gly Val Pro Asp Arg Phe Ser Gly Gly 195 200 205 Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu 210 215 220 Asp Val Gly Val Tyr Tyr Cys Met Gln Gly Thr His Trp Pro Pro Thr 225 230 235 240 Phe Gly Cys Gly Thr Lys Val Glu Ile Lys Ser Gly Gly Gly Gly Ser 245 250 255 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 260 265 270 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys Tyr 275 280 285 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 290 295 300 Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 305 310 315 320 Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 325 330 335 Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr 340 345 350 Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr Trp 355 360 365 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 370 375 380 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val 385 390 395 400 Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu 405 410 415 Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro Asn 420 425 430 Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly 435 440 445 Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu 450 455 460 Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp 465 470 475 480 Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val Phe 485 490 495 Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gly Gly Gly Asp Lys Thr 500 505 510 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 515 520 525 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 530 535 540 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 545 550 555 560 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 565 570 575 Lys Thr Lys Pro Cys Glu Glu Gln Tyr Gly Ser Thr Tyr Arg Cys Val 580 585 590 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 595 600 605 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 610 615 620 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 625 630 635 640 Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys 645 650 655 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 660 665 670 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 675 680 685 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 690 695 700 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 705 710 715 720 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 725 730 735 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 740 745 750 Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Lys 755 760 765 Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro 770 775 780 Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser 785 790 795 800 Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp 805 810 815 Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn 820 825 830 Ala Lys Thr Lys Pro Cys Glu Glu Gln Tyr Gly Ser Thr Tyr Arg Cys 835 840 845 Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu 850 855 860 Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys 865 870 875 880 Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr 885 890 895 Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr 900 905 910 Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu 915 920 925 Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu 930 935 940 Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys 945 950 955 960 Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu 965 970 975 Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 980 985 990 Lys <210> 528 <211> 991 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 528 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Leu Cys Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Asp Gly Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Asp Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Asn Ser Ala Phe Tyr Ser Tyr Tyr Asp Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln 130 135 140 Thr Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser 145 150 155 160 Cys Arg Ser Ser Gln Ser Leu Val Tyr Arg Asp Gly Asn Thr Tyr Leu 165 170 175 Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr 180 185 190 Lys Val Ser Asn Trp Gln Ser Gly Val Pro Asp Arg Phe Ser Gly Gly 195 200 205 Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu 210 215 220 Asp Val Gly Val Tyr Tyr Cys Met Gln Gly Thr His Trp Pro Pro Thr 225 230 235 240 Phe Gly Cys Gly Thr Lys Val Glu Ile Lys Ser Gly Gly Gly Gly Ser 245 250 255 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 260 265 270 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Lys Tyr 275 280 285 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 290 295 300 Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 305 310 315 320 Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 325 330 335 Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr 340 345 350 Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr Trp 355 360 365 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 370 375 380 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Thr Val Val 385 390 395 400 Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu 405 410 415 Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Asn Tyr Pro Asn 420 425 430 Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly 435 440 445 Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu 450 455 460 Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp 465 470 475 480 Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn Arg Trp Val Phe 485 490 495 Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gly Gly Gly Asp Lys Thr 500 505 510 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 515 520 525 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 530 535 540 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 545 550 555 560 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 565 570 575 Lys Thr Lys Pro Cys Glu Glu Gln Tyr Gly Ser Thr Tyr Arg Cys Val 580 585 590 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 595 600 605 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 610 615 620 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 625 630 635 640 Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys 645 650 655 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 660 665 670 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 675 680 685 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 690 695 700 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 705 710 715 720 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Gly 725 730 735 Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly 740 745 750 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Lys Thr His 755 760 765 Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val 770 775 780 Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr 785 790 795 800 Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu 805 810 815 Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys 820 825 830 Thr Lys Pro Cys Glu Glu Gln Tyr Gly Ser Thr Tyr Arg Cys Val Ser 835 840 845 Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys 850 855 860 Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile 865 870 875 880 Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro 885 890 895 Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu 900 905 910 Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn 915 920 925 Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser 930 935 940 Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg 945 950 955 960 Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu 965 970 975 His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 980 985 990 <210> 529 <211> 118 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 529 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Ala Ser Ile Ser Ser Phe 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Cys Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Tyr Tyr Ser Gly Thr Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Ile Ala Val Ala Gly Phe Phe Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser 115 <210> 530 <211> 108 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 530 Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Asn Lys Asn 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asp Arg Ser Pro 85 90 95 Leu Thr Phe Gly Cys Gly Thr Lys Val Glu Ile Lys 100 105 <210> 531 <211> 241 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 531 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Ala Ser Ile Ser Ser Phe 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Cys Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Tyr Tyr Ser Gly Thr Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Ile Ala Val Ala Gly Phe Phe Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu 130 135 140 Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln 145 150 155 160 Ser Val Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 165 170 175 Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile 180 185 190 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 195 200 205 Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln 210 215 220 Tyr Asp Arg Ser Pro Leu Thr Phe Gly Cys Gly Thr Lys Val Glu Ile 225 230 235 240 Lys <210> 532 <211> 496 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 532 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Ala Ser Ile Ser Ser Phe 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Cys Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Tyr Tyr Ser Gly Thr Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Ile Ala Val Ala Gly Phe Phe Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu 130 135 140 Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln 145 150 155 160 Ser Val Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 165 170 175 Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile 180 185 190 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 195 200 205 Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln 210 215 220 Tyr Asp Arg Ser Pro Leu Thr Phe Gly Cys Gly Thr Lys Val Glu Ile 225 230 235 240 Lys Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly 245 250 255 Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser 260 265 270 Gly Phe Thr Phe Asn Lys Tyr Ala Met Asn Trp Val Arg Gln Ala Pro 275 280 285 Gly Lys Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn 290 295 300 Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser 305 310 315 320 Arg Asp Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Asn Leu Lys 325 330 335 Thr Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn Phe Gly 340 345 350 Asn Ser Tyr Ile Ser Tyr Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val 355 360 365 Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 370 375 380 Gly Gly Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser 385 390 395 400 Pro Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val 405 410 415 Thr Ser Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala 420 425 430 Pro Arg Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro 435 440 445 Ala Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu 450 455 460 Ser Gly Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp 465 470 475 480 Tyr Ser Asn Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 485 490 495 <210> 533 <211> 227 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 533 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 1 5 10 15 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 20 25 30 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 35 40 45 Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 50 55 60 His Asn Ala Lys Thr Lys Pro Cys Glu Glu Gln Tyr Gly Ser Thr Tyr 65 70 75 80 Arg Cys Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 85 90 95 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 100 105 110 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 115 120 125 Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser 130 135 140 Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 145 150 155 160 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 165 170 175 Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 180 185 190 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 195 200 205 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 210 215 220 Pro Gly Lys 225 <210> 534 <211> 225 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 534 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 1 5 10 15 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 20 25 30 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 35 40 45 Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 50 55 60 His Asn Ala Lys Thr Lys Pro Cys Glu Glu Gln Tyr Gly Ser Thr Tyr 65 70 75 80 Arg Cys Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 85 90 95 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 100 105 110 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 115 120 125 Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser 130 135 140 Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 145 150 155 160 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 165 170 175 Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 180 185 190 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 195 200 205 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 210 215 220 Pro 225 <210> 535 <211> 227 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 535 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 1 5 10 15 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 20 25 30 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 35 40 45 Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 50 55 60 His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 65 70 75 80 Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 85 90 95 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 100 105 110 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 115 120 125 Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser 130 135 140 Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 145 150 155 160 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 165 170 175 Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 180 185 190 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 195 200 205 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 210 215 220 Pro Gly Lys 225 <210> 536 <211> 225 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 536 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 1 5 10 15 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 20 25 30 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 35 40 45 Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 50 55 60 His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 65 70 75 80 Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 85 90 95 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 100 105 110 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 115 120 125 Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser 130 135 140 Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 145 150 155 160 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 165 170 175 Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 180 185 190 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 195 200 205 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 210 215 220 Pro 225 <210> 537 <211> 227 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 537 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 1 5 10 15 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 20 25 30 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 35 40 45 Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 50 55 60 His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Gly Ser Thr Tyr 65 70 75 80 Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 85 90 95 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 100 105 110 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 115 120 125 Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser 130 135 140 Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 145 150 155 160 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 165 170 175 Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 180 185 190 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 195 200 205 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 210 215 220 Pro Gly Lys 225 <210> 538 <211> 225 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 538 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 1 5 10 15 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 20 25 30 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 35 40 45 Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 50 55 60 His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Gly Ser Thr Tyr 65 70 75 80 Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 85 90 95 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 100 105 110 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 115 120 125 Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser 130 135 140 Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 145 150 155 160 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 165 170 175 Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 180 185 190 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 195 200 205 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 210 215 220 Pro 225 <210> 539 <211> 227 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 539 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 1 5 10 15 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 20 25 30 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 35 40 45 Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 50 55 60 His Asn Ala Lys Thr Lys Pro Cys Glu Glu Gln Tyr Asn Ser Thr Tyr 65 70 75 80 Arg Cys Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 85 90 95 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 100 105 110 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 115 120 125 Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser 130 135 140 Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 145 150 155 160 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 165 170 175 Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 180 185 190 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 195 200 205 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 210 215 220 Pro Gly Lys 225 <210> 540 <211> 225 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 540 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 1 5 10 15 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 20 25 30 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 35 40 45 Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 50 55 60 His Asn Ala Lys Thr Lys Pro Cys Glu Glu Gln Tyr Asn Ser Thr Tyr 65 70 75 80 Arg Cys Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 85 90 95 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 100 105 110 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 115 120 125 Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser 130 135 140 Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 145 150 155 160 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 165 170 175 Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 180 185 190 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 195 200 205 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 210 215 220 Pro 225 <210> 541 <211> 484 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 541 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 1 5 10 15 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 20 25 30 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 35 40 45 Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 50 55 60 His Asn Ala Lys Thr Lys Pro Cys Glu Glu Gln Tyr Gly Ser Thr Tyr 65 70 75 80 Arg Cys Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 85 90 95 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 100 105 110 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 115 120 125 Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser 130 135 140 Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 145 150 155 160 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 165 170 175 Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 180 185 190 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 195 200 205 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 210 215 220 Pro Gly Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly 225 230 235 240 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 245 250 255 Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu 260 265 270 Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu 275 280 285 Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser 290 295 300 His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu 305 310 315 320 Val His Asn Ala Lys Thr Lys Pro Cys Glu Glu Gln Tyr Gly Ser Thr 325 330 335 Tyr Arg Cys Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn 340 345 350 Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro 355 360 365 Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln 370 375 380 Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val 385 390 395 400 Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val 405 410 415 Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro 420 425 430 Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr 435 440 445 Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val 450 455 460 Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu 465 470 475 480 Ser Pro Gly Lys <210> 542 <211> 480 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 542 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 1 5 10 15 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 20 25 30 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 35 40 45 Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 50 55 60 His Asn Ala Lys Thr Lys Pro Cys Glu Glu Gln Tyr Gly Ser Thr Tyr 65 70 75 80 Arg Cys Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 85 90 95 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 100 105 110 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 115 120 125 Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser 130 135 140 Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 145 150 155 160 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 165 170 175 Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 180 185 190 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 195 200 205 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 210 215 220 Pro Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 225 230 235 240 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp 245 250 255 Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 260 265 270 Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 275 280 285 Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 290 295 300 Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 305 310 315 320 Asn Ala Lys Thr Lys Pro Cys Glu Glu Gln Tyr Gly Ser Thr Tyr Arg 325 330 335 Cys Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys 340 345 350 Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 355 360 365 Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 370 375 380 Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu 385 390 395 400 Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 405 410 415 Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 420 425 430 Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 435 440 445 Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His 450 455 460 Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro 465 470 475 480 <210> 543 <211> 484 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 543 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 1 5 10 15 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 20 25 30 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 35 40 45 Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 50 55 60 His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 65 70 75 80 Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 85 90 95 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 100 105 110 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 115 120 125 Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser 130 135 140 Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 145 150 155 160 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 165 170 175 Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 180 185 190 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 195 200 205 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 210 215 220 Pro Gly Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly 225 230 235 240 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 245 250 255 Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu 260 265 270 Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu 275 280 285 Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser 290 295 300 His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu 305 310 315 320 Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr 325 330 335 Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn 340 345 350 Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro 355 360 365 Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln 370 375 380 Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val 385 390 395 400 Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val 405 410 415 Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro 420 425 430 Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr 435 440 445 Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val 450 455 460 Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu 465 470 475 480 Ser Pro Gly Lys <210> 544 <211> 480 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 544 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 1 5 10 15 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 20 25 30 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 35 40 45 Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 50 55 60 His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 65 70 75 80 Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 85 90 95 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 100 105 110 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 115 120 125 Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser 130 135 140 Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 145 150 155 160 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 165 170 175 Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 180 185 190 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 195 200 205 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 210 215 220 Pro Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 225 230 235 240 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp 245 250 255 Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 260 265 270 Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 275 280 285 Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 290 295 300 Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 305 310 315 320 Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg 325 330 335 Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys 340 345 350 Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 355 360 365 Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 370 375 380 Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu 385 390 395 400 Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 405 410 415 Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 420 425 430 Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 435 440 445 Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His 450 455 460 Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro 465 470 475 480 <210> 545 <211> 484 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 545 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 1 5 10 15 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 20 25 30 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 35 40 45 Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 50 55 60 His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Gly Ser Thr Tyr 65 70 75 80 Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 85 90 95 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 100 105 110 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 115 120 125 Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser 130 135 140 Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 145 150 155 160 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 165 170 175 Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 180 185 190 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 195 200 205 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 210 215 220 Pro Gly Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly 225 230 235 240 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 245 250 255 Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu 260 265 270 Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu 275 280 285 Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser 290 295 300 His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu 305 310 315 320 Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Gly Ser Thr 325 330 335 Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn 340 345 350 Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro 355 360 365 Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln 370 375 380 Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val 385 390 395 400 Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val 405 410 415 Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro 420 425 430 Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr 435 440 445 Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val 450 455 460 Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu 465 470 475 480 Ser Pro Gly Lys <210> 546 <211> 480 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 546 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 1 5 10 15 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 20 25 30 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 35 40 45 Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 50 55 60 His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Gly Ser Thr Tyr 65 70 75 80 Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 85 90 95 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 100 105 110 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 115 120 125 Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser 130 135 140 Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 145 150 155 160 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 165 170 175 Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 180 185 190 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 195 200 205 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 210 215 220 Pro Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 225 230 235 240 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp 245 250 255 Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 260 265 270 Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 275 280 285 Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 290 295 300 Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 305 310 315 320 Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Gly Ser Thr Tyr Arg 325 330 335 Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys 340 345 350 Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 355 360 365 Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 370 375 380 Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu 385 390 395 400 Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 405 410 415 Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 420 425 430 Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 435 440 445 Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His 450 455 460 Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro 465 470 475 480 <210> 547 <211> 484 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 547 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 1 5 10 15 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 20 25 30 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 35 40 45 Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 50 55 60 His Asn Ala Lys Thr Lys Pro Cys Glu Glu Gln Tyr Asn Ser Thr Tyr 65 70 75 80 Arg Cys Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 85 90 95 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 100 105 110 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 115 120 125 Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser 130 135 140 Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 145 150 155 160 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 165 170 175 Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 180 185 190 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 195 200 205 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 210 215 220 Pro Gly Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly 225 230 235 240 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 245 250 255 Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu 260 265 270 Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu 275 280 285 Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser 290 295 300 His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu 305 310 315 320 Val His Asn Ala Lys Thr Lys Pro Cys Glu Glu Gln Tyr Asn Ser Thr 325 330 335 Tyr Arg Cys Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn 340 345 350 Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro 355 360 365 Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln 370 375 380 Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val 385 390 395 400 Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val 405 410 415 Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro 420 425 430 Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr 435 440 445 Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val 450 455 460 Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu 465 470 475 480 Ser Pro Gly Lys <210> 548 <211> 480 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 548 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 1 5 10 15 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 20 25 30 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 35 40 45 Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 50 55 60 His Asn Ala Lys Thr Lys Pro Cys Glu Glu Gln Tyr Asn Ser Thr Tyr 65 70 75 80 Arg Cys Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 85 90 95 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 100 105 110 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 115 120 125 Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser 130 135 140 Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 145 150 155 160 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 165 170 175 Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 180 185 190 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 195 200 205 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 210 215 220 Pro Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 225 230 235 240 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp 245 250 255 Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 260 265 270 Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 275 280 285 Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 290 295 300 Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 305 310 315 320 Asn Ala Lys Thr Lys Pro Cys Glu Glu Gln Tyr Asn Ser Thr Tyr Arg 325 330 335 Cys Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys 340 345 350 Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 355 360 365 Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 370 375 380 Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu 385 390 395 400 Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 405 410 415 Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 420 425 430 Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 435 440 445 Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His 450 455 460 Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro 465 470 475 480 <210> 549 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 549 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 1 5 10 15 Gly Gly Gly Ser 20 <210> 550 <211> 25 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 550 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 1 5 10 15 Gly Gly Gly Ser Gly Gly Gly Gly Ser 20 25 <210> 551 <211> 30 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 551 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 1 5 10 15 Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 20 25 30 <210> 552 <211> 35 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 552 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 1 5 10 15 Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 20 25 30 Gly Gly Ser 35 <210> 553 <211> 40 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 553 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 1 5 10 15 Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 20 25 30 Gly Gly Ser Gly Gly Gly Gly Ser 35 40 <210> 554 <211> 503 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 554 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Tyr 20 25 30 Tyr Trp Thr Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Tyr Tyr Ser Gly Thr Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Ser Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Ser Ile Ala Val Arg Gly Phe Phe Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu 130 135 140 Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln 145 150 155 160 Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 165 170 175 Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile 180 185 190 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 195 200 205 Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln 210 215 220 Tyr Gly Thr Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile 225 230 235 240 Lys Arg Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly 245 250 255 Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala 260 265 270 Ser Gly Phe Thr Phe Asn Lys Tyr Ala Met Asn Trp Val Arg Gln Ala 275 280 285 Pro Gly Lys Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr Asn 290 295 300 Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile 305 310 315 320 Ser Arg Asp Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Asn Leu 325 330 335 Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn Phe 340 345 350 Gly Asn Ser Tyr Ile Ser Tyr Trp Ala Tyr Trp Gly Gln Gly Thr Leu 355 360 365 Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 370 375 380 Gly Gly Gly Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val 385 390 395 400 Ser Pro Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala 405 410 415 Val Thr Ser Gly Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln 420 425 430 Ala Pro Arg Gly Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr 435 440 445 Pro Ala Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr 450 455 460 Leu Ser Gly Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu 465 470 475 480 Trp Tyr Ser Asn Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val 485 490 495 Leu His His His His His His 500

Claims

DLL3 양성 암을 치료하는 방법으로서, 이를 필요로 하는 대상체에게 서열번호 437 및 431의 아미노산 서열을 포함하는 항-DLL3 작용제를 투여하는 단계를 포함하고, 항-DLL3 작용제는 2주마다 1회 3 mg 내지 200 mg의 용량으로 투여되는 것인 방법.
제1항에 있어서, 항-DLL3 작용제는 2주마다 1회 3 mg 내지 100, 10 mg 내지 150 mg, 30 mg 내지 200 mg, 30 mg 내지 100 mg, 50 mg 내지 150 mg, 70 mg 내지 120 mg, 90 mg 내지 120 mg, 또는 100 mg 내지 200 mg의 용량으로 투여되는 것인 방법.
제1항에 있어서, 항-DLL3 작용제는 2주마다 1회 3 mg, 10 mg, 30 mg, 또는 100 mg의 용량으로 투여되는 것인 방법.
제1항 내지 제3항 중 어느 한 항에 있어서, 항-DLL3 작용제는 28일 주기의 제1일 및 제15일에 투여되는 것인 방법.
DLL3 양성 암을 치료하는 방법으로서, 이를 필요로 하는 대상체에게 서열번호 437 및 431의 아미노산 서열을 포함하는 항-DLL3 작용제를 투여하는 단계를 포함하고, 상기 항-DLL3 작용제는 다음의 일정에 따라 투여되는 것인 방법: a) 제1일에 0.5 mg 내지 10 mg의 제1 용량(준비 용량), b) 제8일에 3 mg 내지 200 mg의 제2 용량(단계 용량) 및 c) 제15일에 시작하고 그 후 2주마다 1회, 3 mg 내지 200 mg의 하나 이상의 후속 용량(목표 용량), 여기서 제2 및 후속 용량은 동일하며 제1 용량보다 높은 용량임.
제5항에 있어서, 제2 및 후속 용량은 제1 용량보다 적어도 3 배, 적어도 5배, 적어도 10배, 적어도 20배, 적어도 30배, 적어도 40배, 적어도 50배, 적어도 60배, 적어도 70배, 적어도 80배, 적어도 90배, 적어도 100배, 적어도 120배, 적어도 150배, 또는 적어도 200배 높은 용량인 방법.
제5항 또는 제6항에 있어서, 제1 용량은 0.5 mg 내지 8 mg, 0.5 mg 내지 6 mg, 0.5 mg 내지 4 mg, 0.5 mg 내지 2 mg, 또는 1 mg이고;
제2 용량 또는 후속 용량은 3 mg 내지 100 mg, 10 mg 내지 150 mg, 30 mg 내지 200 mg, 30 mg 내지 100 mg, 50 mg 내지 150 mg, 70 mg 내지 120 mg, 90 mg 내지 120 mg, 또는 100 mg 내지 200 mg인 방법.
제5항 내지 제7항 중 어느 한 항에 있어서, 제1 용량은 1 mg이고, 제2 용량 및 후속 용량은 각각 3 mg, 10 mg, 30 mg, 또는 100 mg인 방법.
DLL3 양성 암을 치료하는 방법으로서, 이를 필요로 하는 대상체에게 서열번호 437 및 431의 아미노산 서열을 포함하는 항-DLL3 작용제를 투여하는 단계를 포함하고, 상기 항-DLL3 작용제는 다음의 2가지 일정 중 하나에 따라 투여되는 것인 방법:
일정 I: a) 제1일에 0.5 mg 내지 10 mg의 제1 용량(준비 용량), b) 제4일에 3 mg 내지 100 mg의 제2 용량(단계 용량), c) 제8일에 3 mg 내지 200 mg의 제3 용량(단계 용량), 및 d) 제15일에 시작하고 그 후 2주마다 1회, 3 mg 내지 200 mg의 하나 이상의 후속 용량(목표 용량), 여기서 제2 용량은 제1 용량보다 높고, 제3 및 후속 용량은 동일하며 제2 용량보다 높은 용량임; 또는
일정 II: a) 제1일에 0.5 mg 내지 10 mg의 제1 용량(준비 용량), b) 제8일에 3 mg 내지 100 mg의 제2 용량(단계 용량), c) 제15일에 3 mg 내지 200 mg의 제3 용량(단계 용량) 및 c) 제29일에 시작하고 그 후 2주마다 1회, 3 mg 내지 200 mg의 하나 이상의 후속 용량(목표 용량), 여기서 제2 용량은 제1 용량보다 높고, 제3 용량 및 후속 용량은 동일하며 제2 용량보다 높은 용량임.
제9항에 있어서, 각 일정의 제1 용량은 0.5 mg 내지 8 mg, 0.5 mg 내지 6 mg, 0.5 mg 내지 4 mg, 0.5 mg 내지 2 mg, 또는 1 mg이고;
각 일정의 제2 용량은 3 mg 내지 10 mg, 10 mg 내지 80 mg, 10 mg 내지 60 mg, 20 mg 내지 80 mg, 20 mg 내지 60 mg, 25 mg 내지 50 mg, 30 mg 내지 80 mg, 40 mg 내지 60 mg, 25 mg, 또는 50 mg이고;
각 일정의 제3 용량 및 후속 용량은 3 mg 내지 100 mg, 10 mg 내지 150 mg, 30 mg 내지 200 mg, 30 mg 내지 100 mg, 50 mg 내지 150 mg, 70 mg 내지 120 mg, 90 mg 내지 120 mg, 100 mg 내지 200 mg, 또는 100 mg인 방법.
제9항에 있어서, 제2 용량은 제1 용량보다 20배 내지 90배, 20배 내지 70배, 또는 25배 내지 50배 높고, 제3 및 후속 용량은 제2 용량보다 2배 내지 10배 높은 용량인 방법.
DLL3 양성 암을 치료하는 방법으로서, 이를 필요로 하는 대상체에게 서열번호 437 및 431의 아미노산 서열을 포함하는 항-DLL3 작용제를 투여하는 단계를 포함하고, 상기 항-DLL3 작용제는 다음의 일정에 따라 투여되는 것인 방법: a) 제1일에 0.5 mg 내지 10 mg의 제1 용량(준비 용량), b) 제4일에 3 mg 내지 100 mg의 제2 용량(단계 용량), c) 제8일에 3 mg 내지 100 mg의 제3 용량(단계 용량), d) 제15일에 3 mg 내지 200 mg의 제4 용량(단계 용량), 및 e) 제29일에 시작하고 그 후 2주마다 1회, 3 mg 내지 200 mg 의 하나 이상의 후속 용량(목표 용량), 여기서 제2 용량은 제1 용량보다 높고, 제3 용량은 제2 용량보다 높고, 제4 용량 및 후속 용량은 동일하며 제3 용량보다 높은 용량임.
제12항에 있어서, 제1 용량은 0.5 mg 내지 8 mg, 0.5 mg 내지 6 mg, 0.5 mg 내지 4 mg, 0.5 mg 내지 2 mg, 또는 1 mg이고;
제2 용량은 3 mg 내지 10 mg, 10 mg 내지 80 mg, 10 mg 내지 60 mg, 20 mg 내지 80 mg, 20 mg 내지 60 mg, 20 mg 내지 40 mg, 또는 25 mg이고;
제3 용량은 3 mg 내지 10 mg, 10 mg 내지 80 mg, 10 mg 내지 60 mg, 20 mg 내지 80 mg, 20 mg 내지 60 mg, 30 mg 내지 80 mg, 30 mg 내지 60 mg, 40 mg 내지 80 mg, 40 mg 내지 60 mg, 또는 50 mg이고;
제4 용량 및 후속 용량은 3 mg 내지 100 mg, 10 mg 내지 150 mg, 30 mg 내지 200 mg, 30 mg 내지 100 mg, 50 mg 내지 150 mg, 70 mg 내지 120 mg, 90 mg 내지 120 mg, 100 mg 내지 200 mg, 또는 100 mg인 방법.
제12항에 있어서, 제2 용량은 제1 용량보다 5배 내지 30배, 20배 내지 70배, 또는 25배 내지 50배 높고, 제3 용량은 제2 용량보다 0.5배 내지 3배 높고, 제4 용량 및 후속 용량은 제3 용량보다 2배 내지 4배 높은 용량인 방법.
제1항 내지 제14항 중 어느 한 항에 있어서, 항-DLL3 작용제는 서열번호 438 또는 520의 아미노산 서열을 포함하는 것인 방법.
제1항 내지 제15항 중 어느 하나에 있어서, 항-DLL3 작용제는 28일 주기로 투여되고, 항-DLL3 작용제가 투여되는 제1 주기에 대상체에게 식염수, 항염증제, 토실리주맙, 또는 에타너셉트를 투여하는 단계를 추가로 포함하는 방법.
제16항에 있어서, 준비 용량 및 단계 용량의 항-DLL3 작용제 후에 대상체에게 1 L의 식염수가 IV 주입으로 투여되는 것인 방법.
제16항에 있어서, 항염증제는 코르티코스테로이드 또는 아세트아미노펜인 방법.
제18항에 있어서, 코르티코스테로이드는 덱사메타손인 방법.
제16항, 제18항 또는 제19항 중 어느 한 항에 있어서, 항염증제 또는 토실리주맙은 준비 용량 및 단계 용량의 항-DLL3 작용제 전에 대상체에게 투여되는 것인 방법.
제20항에 있어서, 코르티코스테로이드는 준비 용량 및 단계 용량의 항-DLL3 작용제 6 내지 16시간 전에 대상체에게 투여되는 것인 방법.
제20항에 있어서, 아세트아미노펜 또는 토실리주맙은 준비 용량 및 단계 용량의 항-DLL3 작용제 1시간 전에 대상체에게 투여되는 것인 방법.
제16항에 있어서, 에타너셉트는 준비 용량 및 제4일의 단계 용량을 제외한 단계 용량의 항-DLL3 작용제 36 내지 60시간 전에 투여되는 것인 방법.
제23항에 있어서, 에타너셉트는 준비 용량 및 제4일의 단계 용량을 제외한 단계 용량의 항-DLL3 작용제 2일 전에 투여되는 것인 방법.
DLL3 양성 암을 치료하는 방법으로서, 이를 필요로 하는 대상체에게 서열번호 437 및 431의 아미노산 서열을 포함하는 항-DLL3 작용제를 투여하는 단계를 포함하고, 상기 항-DLL3 작용제는 다음의 일정에 따라 투여되는 것인 방법: a) 제1일에 0.5 mg 내지 10 mg의 제1 용량(준비 용량), b) 제4일에 3 mg 내지 200 mg의 제2 용량(단계 용량), c) 제8일에 3 mg 내지 200 mg의 제3 용량(목표 용량), 및 d) 제15일에 시작하고 그 후 2주마다 1회, 3 mg 내지 200 mg의 하나 이상의 후속 용량(목표 용량), 여기서 제2 용량은 제1 용량보다 높고, 제3 및 후속 용량은 동일하며 제2 용량과 동일한 용량임.
제25항에 있어서, 제1 용량은 0.5 mg 내지 8 mg, 0.5 mg 내지 6 mg, 0.5 mg 내지 4 mg, 0.5 mg 내지 2 mg, 또는 1 mg이고, 제2, 제3 용량 및 후속 용량은 각각 3 mg 내지 100 mg, 10 mg 내지 150 mg, 30 mg 내지 200 mg, 30 mg 내지 100 mg, 50 mg 내지 150 mg, 70 mg 내지 120 mg, 90 mg 내지 120 mg, 100 mg 내지 200 mg, 또는 100 mg인 방법.
DLL3 양성 암을 치료하는 방법으로서, 이를 필요로 하는 대상체에게 서열번호 437 및 431의 아미노산 서열을 포함하는 항-DLL3 작용제를 투여하는 단계를 포함하고, 상기 항-DLL3 작용제는 다음의 일정에 따라 투여되는 것인 방법: a) 제1일에 0.5 mg 내지 10 mg의 제1 용량(준비 용량), b) 제4일에 3 mg 내지 100 mg의 제2 용량(단계 용량), c) 제8일에 3 mg 내지 200 mg의 제3 용량(단계 용량), d) 제15일에 3 mg 내지 200 mg의 제4 용량(목표 용량), 및 e) 제29일에 시작하고 그 후 2주마다 1회, 3 mg 내지 200 mg 의 하나 이상의 후속 용량(목표 용량), 여기서 제2 용량은 제1 용량보다 높고, 제3 용량은 제2 용량보다 높고, 제4 용량 및 후속 용량은 동일하며 제3 용량과 동일한 용량임.
제27항에 있어서, 제1 용량은 0.5 mg 내지 8 mg, 0.5 mg 내지 6 mg, 0.5 mg 내지 4 mg, 0.5 mg 내지 2 mg, 또는 1 mg이고, 제2 용량은 3 mg 내지 10 mg, 10 mg 내지 80 mg, 10 mg 내지 60 mg, 20 mg 내지 80 mg, 20 mg 내지 60 mg, 20 mg 내지 40 mg, 25 mg, 또는 50 mg이고, 제3, 제4 및 후속 용량은 각각 3 mg 내지 100 mg, 10 mg 내지 150 mg, 30 mg 내지 200 mg, 30 mg 내지 100 mg, 50 mg 내지 150 mg, 70 mg 내지 120 mg, 90 mg 내지 120 mg, 100 mg 내지 200 mg, 또는 100 mg인 방법.
제25항 내지 제28항 중 어느 한 항에 있어서, 항-DLL3 작용제는 서열번호 438 또는 520의 아미노산 서열을 포함하는 것인 방법.
제25항 내지 제29항 중 어느 하나에 있어서, 항-DLL3 작용제는 28일 주기로 투여되고, 항-DLL3 작용제가 투여되는 제1 주기에 대상체에게 식염수, 아세트아미노펜, 덱사메타손, 토실리주맙, 또는 에타너셉트를 투여하는 단계를 추가로 포함하는 방법.
제25항 또는 제26항에 있어서, 식염수, 아세트아미노펜, 덱사메타손, 또는 토실리주맙은 항-DLL3 작용제가 투여되는 제1 주기의 제1일 및 제4일, 또는 제1일, 제4일 및 제8일에 대상체에게 투여되는 것인 방법.
제25항 또는 제26항에 있어서, 에타너셉트는 항-DLL3 작용제가 투여되는 제1 주기의 제1일의 2일 전 및 제8일의 2일 전, 또는 제1일의 2일 전에 대상체에게 투여되는 것인 방법.
제27항 또는 제28항에 있어서, 식염수, 아세트아미노펜, 덱사메타손, 또는 토실리주맙은 항-DLL3 작용제가 투여되는 제1 주기의 제1일, 제4일 및 제8일, 또는 제1일, 제4일, 제8일 및 제15일에 대상체에게 투여되는 것인 방법.
제27항 또는 제28항에 있어서, 에타너셉트는 항-DLL3 작용제가 투여되는 제1 주기의 제1일, 제8일 및 제15일의 2일 전, 또는 제1일 및 제8일의 2일 전에 대상체에게 투여되는 것인 방법.
제1항 내지 제34항 중 어느 한 항에 있어서, 제1 주기에서 항-DLL3 작용제를 투여하는 단계 전에 코르티코스테로이드를 투여하는 단계를 추가로 포함하는 방법.
제35항에 있어서, 코르티코스테로이드는 IV 주입에 의해 투여되는 덱사메타손인 방법.
제1항 내지 제36항 중 어느 한 항에 있어서, 암은 소세포 폐암(SCLC)인 방법.
제1항 내지 제37항 중 어느 한 항에 있어서, 암은 재발성/불응성 SCLC(RR SCLC) 또는 확장 질환 SCLC(ED SCLC)인 방법.
제1항 내지 제38항 중 어느 한 항에 있어서, 항-DLL3 작용제는 IV 주입에 의해 투여되는 것인 방법.
제1항 내지 제39항 중 어느 한 항에 있어서, 대상체는 인간인 방법.